<SEC-DOCUMENT>0001047469-16-014777.txt : 20160808
<SEC-HEADER>0001047469-16-014777.hdr.sgml : 20160808
<ACCEPTANCE-DATETIME>20160808140056
ACCESSION NUMBER:		0001047469-16-014777
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		18
FILED AS OF DATE:		20160808
DATE AS OF CHANGE:		20160808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Gemphire Therapeutics Inc.
		CENTRAL INDEX KEY:			0001638287
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				472389984
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-210815
		FILM NUMBER:		161813651

	BUSINESS ADDRESS:	
		STREET 1:		43334 7 MILE ROAD
		STREET 2:		SUITE 1000
		CITY:			NORTHVILLE
		STATE:			MI
		ZIP:			48167
		BUSINESS PHONE:		248-980-6538

	MAIL ADDRESS:	
		STREET 1:		43334 7 MILE ROAD
		STREET 2:		SUITE 1000
		CITY:			NORTHVILLE
		STATE:			MI
		ZIP:			48167
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>a2229387z424b4.htm
<DESCRIPTION>424B4
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg40101_table_of_contents">  TABLE OF CONTENTS</A> <BR>
<A HREF="#fc40101_index_to_the_financial_statements">  Index to The Financial Statements</A><BR></font>
</P>

<P style="font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Filed Pursuant to Rule&nbsp;424(b)(4)<BR>
Registration No.: 333-210815  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> PROSPECTUS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>3,000,000 Shares  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>
<IMG SRC="g342833.jpg" ALT="GRAPHIC" WIDTH="180" HEIGHT="103">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=5><B>Gemphire Therapeutics&nbsp;Inc.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>Common Stock  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are offering 3,000,000&nbsp;shares of our common stock. This is our initial public offering and no public market currently exists for our common stock. The
initial public offering price of our common stock is $10.00 per share. Our common stock has been approved for listing on the NASDAQ Global Market under the symbol "GEMP". </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
are an emerging growth company as that term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, have elected to comply with certain reduced public company reporting
requirements for this prospectus and future filings. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>Investing in our common stock involves a high degree of risk. See "Risk Factors" beginning on page&nbsp;12 of this prospectus.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or determined if this
prospectus is truthful or complete. Any representation to the contrary is a criminal offense.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


 </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:20%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="8pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="59pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="8pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="82pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>PER SHARE </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>TOTAL </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B> </B></FONT><FONT SIZE=2>Public Offering Price</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>10.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>30,000,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Underwriting Discounts and Commissions<SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.70</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2,100,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds to Gemphire, before expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>9.30</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>27,900,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">We
have agreed to reimburse the underwriters for certain expenses. See "Underwriting." </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>Certain of our existing security holders and their affiliated entities, and other entities and individuals associated with us and them have indicated an interest
in purchasing approximately $10&nbsp;million of shares (or 1,000,000 shares) in the aggregate of our common stock in this offering at the initial public offering price. The underwriters will receive
the same underwriting discount on any shares purchased by these entities as they will on any other shares sold to the public in this offering. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have granted the underwriters an option for a period of 30&nbsp;days to purchase up to an additional 450,000&nbsp;shares of common stock. If the underwriters exercise the option in full, the
total underwriting discounts and commissions payable by us will be $2.4&nbsp;million, and the total proceeds to us, before expenses will be $32.1&nbsp;million. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
underwriters expect to deliver the shares of common stock to purchasers on or about August&nbsp;10, 2016. </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><I>Joint Book-Running Managers  </I></FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="48%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=4><B>Jefferies</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=4><B>RBC Capital Markets</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><I>Co-Lead Manager  </I></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B>Canaccord Genuity  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><I>Co-Managers  </I></FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="48%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=3><B>Laidlaw &amp; Company (UK) Ltd.</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=3>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=3><B>LifeSci Capital</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>Prospectus
dated August&nbsp;4, 2016 </FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=197467,FOLIO='blank',FILE='DISK112:[15ZCH1.15ZCH40101]BC40101A.;61',USER='CHE105948',CD=';5-AUG-2016;22:07' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_bg40101_1_1"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="BG40101A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="bg40101_table_of_contents"> </A>
<BR></FONT><FONT SIZE=2><B>  TABLE OF CONTENTS    <BR>    </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<A NAME="BG40101_TOC"></A> </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>PAGE </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#ca40101_prospectus_summary"><p style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prospectus Summary</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ca40101_prospectus_summary"><FONT SIZE=2> 1</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#ck40101_risk_factors"><p style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk Factors</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ck40101_risk_factors"><FONT SIZE=2> 12</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#da40101_special_note_regarding_forward-looking_statements"><p style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Special Note Regarding Forward-Looking Statements</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#da40101_special_note_regarding_forward-looking_statements"><FONT SIZE=2> 55</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#da40101_statistical_data_and_market_information"><p style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Statistical Data and Market Information</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#da40101_statistical_data_and_market_information"><FONT SIZE=2> 57</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#dc40101_use_of_proceeds"><p style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Use of Proceeds</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#dc40101_use_of_proceeds"><FONT SIZE=2> 58</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#dc40101_dividend_policy"><p style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dividend Policy</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#dc40101_dividend_policy"><FONT SIZE=2> 59</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#de40101_capitalization"><p style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Capitalization</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#de40101_capitalization"><FONT SIZE=2> 60</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#dg40101_dilution"><p style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dilution</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#dg40101_dilution"><FONT SIZE=2> 63</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#di40101_selected_financial_data"><p style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Selected Financial Data</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#di40101_selected_financial_data"><FONT SIZE=2> 65</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#dk40101_management_s_discussion_and_an__man03466"><p style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Management's Discussion and Analysis of Financial Condition and Results of
Operations</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#dk40101_management_s_discussion_and_an__man03466"><FONT SIZE=2> 68</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#dq40101_business"><p style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Business</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#dq40101_business"><FONT SIZE=2> 85</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#ei40101_management"><p style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Management</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ei40101_management"><FONT SIZE=2> 132</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#ek40101_executive_officer_and_director_compensation"><p style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Executive Officer and Director Compensation</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ek40101_executive_officer_and_director_compensation"><FONT SIZE=2> 139</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#eo40101_certain_relationships_and_related_party_transactions"><p style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Certain Relationships and Related Party Transactions</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#eo40101_certain_relationships_and_related_party_transactions"><FONT SIZE=2> 152</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#eq40101_principal_stockholders"><p style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Principal Stockholders</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#eq40101_principal_stockholders"><FONT SIZE=2> 157</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#es40101_description_of_capital_stock"><p style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Description of Capital Stock</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#es40101_description_of_capital_stock"><FONT SIZE=2> 160</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#eu40101_shares_eligible_for_future_sale"><p style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shares Eligible for Future Sale</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#eu40101_shares_eligible_for_future_sale"><FONT SIZE=2> 165</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#ew40101_material_u.s._federal_income_t__mat03201"><p style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Material U.S. Federal Income Tax Consequences to Non-U.S. Holders of Our Common
Stock</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ew40101_material_u.s._federal_income_t__mat03201"><FONT SIZE=2> 167</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#ey40101_underwriting"><p style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Underwriting</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ey40101_underwriting"><FONT SIZE=2> 171</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#ez40101_legal_matters"><p style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal Matters</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ez40101_legal_matters"><FONT SIZE=2> 180</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#ez40101_experts"><p style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Experts</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ez40101_experts"><FONT SIZE=2> 180</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#ez40101_where_you_can_find_additional_information"><p style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Where You Can Find Additional Information</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ez40101_where_you_can_find_additional_information"><FONT SIZE=2> 180</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#fc40101_index_to_the_financial_statements"><p style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Index to the Financial Statements</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#fc40101_index_to_the_financial_statements"><FONT SIZE=2> F-1</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<P style="font-family:arial;"><FONT SIZE=2>We
have not authorized anyone to provide you with information that is different from that contained in this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we
have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We and the underwriters are offering to sell
our common stock, and seeking offers to buy our common stock, only in jurisdictions where such offers and sales are permitted. You should assume that the information in this prospectus is accurate
only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of our common stock. Our business, financial condition, results of operations and prospects
may have changed since that date. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For
investors outside the United States: We have not and the underwriters have not done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction
where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any
restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside the United States. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>Through and including August&nbsp;29, 2016 (25&nbsp;days after the date of this prospectus), all dealers effecting transactions in these securities, whether or not
participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the obligation of dealers to deliver a prospectus when acting as underwriters and
with respect to their unsold allotments or subscriptions.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>i</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=468029,FOLIO='i',FILE='DISK112:[15ZCH1.15ZCH40101]BG40101A.;33',USER='CHE108053',CD=';5-AUG-2016;02:19' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ca40101_1_1"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ca40101_prospectus_summary"> </A>
<A NAME="toc_ca40101_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROSPECTUS SUMMARY    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>This summary highlights information contained in other parts of this prospectus. Because it is only a summary, it does not
contain all of the information that you should consider before investing in shares of our common stock and it is qualified in its entirety by, and should be read in conjunction with, the more detailed
information appearing elsewhere in this prospectus. You should read the entire prospectus carefully, especially "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results
of
Operations" and our financial statements, related notes and other financial information elsewhere in this prospectus, before deciding to buy shares of our common stock. Unless the context requires
otherwise, references in this prospectus to "we," "us," "the Company" and "our" refer to Gemphire Therapeutics&nbsp;Inc.  </I></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Overview  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious
medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad
cholesterol, triglycerides, or fat in the blood, or both. We are developing our product candidate gemcabene (CI-1027), a novel, once-daily, oral therapy, for patients who are unable to achieve normal
levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy. Gemcabene's mechanism of action is designed to enhance the clearance of very low-density lipoproteins
(VLDLs) in the plasma and inhibit the production of fatty acids and cholesterol in the liver. Gemcabene is liver-directed and inhibits apolipoprotein C-III (apoC-III) protein in the liver and may
inhibit acetyl-CoA carboxylase (ACC) in the liver. Gemcabene has been tested as monotherapy and in combination with statins and other drugs in 895&nbsp;subjects, which we define as healthy
volunteers and patients, across 18 Phase&nbsp;1 and Phase&nbsp;2 clinical trials and has demonstrated promising evidence of efficacy, safety and tolerability. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Cardiovascular
disease is a major health concern, causing more deaths globally than any other disease. Dyslipidemia is generally viewed as an important predictor of cardiovascular events including
heart attack and stroke, and a cause of cardiovascular disease. It comprises one of the largest therapeutic areas with annual worldwide drug sales of approximately $22&nbsp;billion in 2013. We
estimate more than 40% of Americans have LDL-C or triglycerides, or both, above a normal range. Statins, such as Lipitor, marketed by Pfizer&nbsp;Inc. (Pfizer), and Crestor, marketed by AstraZeneca
Pharmaceuticals LP (AstraZeneca), among others, are standard of care for LDL-C lowering, while fibrates, prescription fish oils and niacin are standard of care for triglyceride lowering. Although
these drugs are highly prescribed and capable of reducing LDL-C and triglyceride levels, many patients are unable to effectively manage their dyslipidemia with currently approved therapies and are in
need of better treatment alternatives. For example, approximately 40% of patients on statins are unable to meet their LDL-C lowering goal, and doubling a statin dose has shown to incrementally lower
LDL-C levels by a nominal percentage (approximately 6% based on historical evidence), while increasing safety and tolerability concerns. An even higher percentage of patients with severe
hypertriglyceridemia do not achieve triglyceride levels low enough to reduce the risk of developing co-morbidities such as pancreatitis. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
believe gemcabene possesses a differentiated product profile compared to other therapies in the market and in clinical development. Key attributes of our product candidate include the
following: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B> Cost-effective,
once-daily, oral therapy.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Gemcabene is a small molecule formulated as a tablet and is cost effective to manufacture. As a once-daily,
oral therapy, gemcabene, if approved, would be more convenient than other non-statin therapies, many of which require frequent injections or multiple daily doses. We expect to take a value-based
approach to pricing across the target indications.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B> Promising safety
and tolerability.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Gemcabene was observed to be well tolerated in 895&nbsp;subjects across 18 Phase&nbsp;1 and Phase&nbsp;2 trials
both as monotherapy and in combination with statins. No subjects died and no subjects experienced a serious adverse event (SAE) that was considered to be related to gemcabene. Adverse events (AEs)
reported were generally mild to moderate in intensity. </FONT></DD></DL>
</UL>
 <p style="font-family:arial;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=290023,FOLIO='1',FILE='DISK112:[15ZCH1.15ZCH40101]CA40101A.;75',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_ca40101_1_2"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">

<UL>
<UL>

<P style="font-family:arial;"><FONT SIZE=2>Gemcabene
did not appear to increase the reporting of myalgia (muscle pain) when added to statin therapy and no treatment related events of myalgia were reported in any gemcabene monotherapy arm in
the dyslipidemia trials.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B> Significant
lipid-lowering of LDL-C, high-sensitivity C-reactive protein (hsCRP) and triglycerides.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;In Phase&nbsp;2 trials, patients with
hypercholesterolemia treated with gemcabene as monotherapy were observed to have significantly lowered LDL-C by approximately 30% from baseline and significantly lowered hsCRP by approximately 40%
from baseline. In addition, patients with hypertriglyceridemia (<FONT FACE="SYMBOL">&#179;</FONT>200&nbsp;mg/dL) were observed to have significantly lowered triglycerides by approximately
40%, and based on post-hoc analysis, gemcabene was observed to lower triglycerides by up to 60% in patients with severe triglyceride levels
(<FONT FACE="SYMBOL">&#179;</FONT>500&nbsp;mg/dL). Our product candidate's ability to meaningfully lower levels of multiple key lipids attributable to cardiovascular disease may expand
its use across multiple indications within the dyslipidemia market.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B> Additive effect
in combination with statins.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;In a Phase&nbsp;2 trial in patients with uncontrolled hypercholesterolemia while on stable statin therapy,
gemcabene was observed to significantly lower LDL-C by an additional 25% to 31% from baseline. This data indicates that gemcabene may better treat a large population of patients who are unable to
reach their lipid goal with statins and other currently prescribed therapies.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B> No drug-drug
interactions when combined with high-intensity statin doses.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;In two Phase&nbsp;1 trials, gemcabene was tested in combination with
high-intensity statin doses, 80&nbsp;mg simvastatin and 80&nbsp;mg atorvastatin. No clinically relevant drug-drug interactions were observed. In addition, gemcabene has been formulated as a
fixed-dose combination tablet with various atorvastatin doses, which may offer additional convenience and compliance to patients. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>We
are initially pursuing gemcabene in the following four indications (representing approximately 14&nbsp;million addressable patients in the United States) as a treatment in addition to maximally
tolerated statin therapy (the maximum dose tolerated by each patient) for patients who are unable to reach their lipid-lowering goals:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  homozygous familial hypercholesterolemia (HoFH), a rare genetic lipid disorder
which results in elevated LDL-C usually due to mutations in both alleles, a pair of genes on a chromosome responsible for a specific trait, of the LDL-receptor gene; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  heterozygous familial hypercholesterolemia (HeFH), a more prevalent genetic
lipid condition which results in elevated LDL-C usually due to a mutation in one allele of the LDL-receptor gene; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  atherosclerotic cardiovascular disease (ASCVD), patients with
hypercholesterolemia, or patients with elevated LDL-C who have had or are at risk for a cardiovascular event, such as heart attack or stroke; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> severe hypertriglyceridemia (SHTG), in which patients with elevated
triglycerides are at an increased risk of developing co-morbidities such as pancreatitis. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>We
are pursuing HoFH given that gemcabene has recently received orphan drug designation for this indication. We believe we can design an efficient development plan to provide a new treatment
alternative for those patients. Furthermore, we believe that gemcabene's potential ability to treat patients in the most severe segment of the dyslipidemia market, HoFH, will enhance brand awareness
among key thought leaders and physicians. We are developing gemcabene for HeFH, ASCVD and SHTG given gemcabene's: (1)&nbsp;promising clinical data in these indications; (2)&nbsp;cost-effective
manufacturing process; (3)&nbsp;convenient oral dosing; (4)&nbsp;viability as adjunct combination therapy; and (5)&nbsp;large commercial potential. By the end of 2016, we expect to initiate
three late stage clinical trials for gemcabene in HoFH, hypercholesterolemia, including HeFH and ASCVD patients on maximally tolerated statins, and SHTG. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
believe it is unlikely the FDA will require us to initiate a cardiovascular outcomes trial for our target indications. The FDA has not required the initiation or completion of cardiovascular
outcomes trials for </FONT></P>
 <p style="font-family:arial;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=4,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=357764,FOLIO='2',FILE='DISK112:[15ZCH1.15ZCH40101]CA40101A.;75',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_ca40101_1_3"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">
 <P style="font-family:arial;"><FONT SIZE=2>recent
approvals of certain dyslipidemia therapies, including non-statin therapies targeting LDL-C for the treatment of HoFH, HeFH and ASCVD and triglyceride lowering for treatment of SHTG. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ca40101_gemcabene_pipeline_indications"> </A>
<A NAME="toc_ca40101_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Gemcabene Pipeline Indications    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g433713.jpg" ALT="GRAPHIC" WIDTH="679" HEIGHT="297">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
company was co-founded by former Pfizer employees, Dr.&nbsp;Charles Bisgaier and David Lowenschuss, who were responsible for licensing exclusive worldwide rights to gemcabene from Pfizer in
April 2011. Prior to co-founding the original Esperion Therapeutics, Inc. (Esperion) in 1998, which was acquired by Pfizer in 2004, Dr.&nbsp;Bisgaier worked at Parke-Davis, a division of
Warner-Lambert Company from 1990 to 1998, and was instrumental in the discovery and development of gemcabene, as well as the development of Lipitor and Lopid. Many of our employees and
consultants have been involved in the historical development of gemcabene and other innovative dyslipidemia product candidates in development, including ETC-216, a synthetic high-density lipoprotein
mimetic based on ApoAI-Milano (developed by the original Esperion, Pfizer and currently The Medicines Company), ACP-501 (developed by AlphaCore Pharma, later acquired by AstraZeneca) and ETC-1002
(developed by the original Esperion, Pfizer and the current Esperion). We have organized a medical advisory board including Drs. John Kastelein, Evan Stein, Robert Hegele and Dirk Blom who combined
have been involved in numerous dyslipidemia and cardiovascular disease clinical trials (e.g. statins from their earliest trials, fibrates, ezetimibe, cholesteryl ester transfer protein (CETP)
inhibitors, extended release niacin, antisense oligonucleotides (mipomersen) and monoclonal antibodies including PCSK9 inhibitors) and published numerous research papers. The management team, led by
our CEO Mina Sooch, collectively has significant experience in operating and financing biopharmaceutical companies and discovering, developing and commercializing treatments in the cardiovascular and
orphan markets. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our Strategy  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our goal is to become a leading cardio-metabolic biopharmaceutical company that develops and commercializes best-in-class therapies for patients, and
provides attractive solutions for physicians and payors. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
core elements of our strategy to achieve our goal are the following: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I> Advance the
late-stage clinical development of gemcabene across multiple target indications.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;We are focused on a broad spectrum of indications for
dyslipidemia patients ranging from the orphan indication HoFH to more prevalent conditions, such as HeFH, ASCVD and SHTG. We believe that these indications present favorable regulatory pathways and
the highest likelihood of commercial </FONT></DD></DL>
</UL>
 <p style="font-family:arial;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=5,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=653635,FOLIO='3',FILE='DISK112:[15ZCH1.15ZCH40101]CA40101A.;75',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_ca40101_1_4"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">
 <UL>
<UL>

<P style="font-family:arial;"><FONT SIZE=2>success
compared to other potential indications for gemcabene. By the end of 2016, we plan to initiate three late stage clinical trials with early results expected starting at the end of 2016
continuing through the second half of 2017.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I> Expand the
breadth of indications beyond dyslipidemia for gemcabene.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;We are also exploring the utility of gemcabene in Nonalcoholic Steatohepatitis
(NASH) and/or Nonalcoholic Fatty Liver Disease (NAFLD) given its mechanism of action that decreases the production of the apoC-III protein and may inhibit ACC, which has been observed to result in the
lowering of triglycerides in the plasma and may reduce liver fat. We plan to test gemcabene in an established NASH preclinical model for further proof of concept. We will organize the appropriate
mid-stage clinical studies.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I> Pursue oral
combination opportunities for gemcabene.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;Oral combination therapy is the current paradigm for the treatment of dyslipidemia, as patients
typically require multiple drugs to address their dyslipidemia as well as other co-morbidities. As part of our development strategy, we plan to formulate and manufacture gemcabene in fixed-dose
combination with statins and other lipid-lowering agents.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I> Continue to
build out our patent portfolio for gemcabene.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;We believe our patents and patent applications provide us with a significant competitive
advantage. As of May&nbsp;2, 2016 we had 27&nbsp;issued patents and 23 pending patent applications for gemcabene in the United States and internationally directed to formulations, compositions,
methods of use and methods of manufacturing. We intend to aggressively prosecute and defend our patent portfolio and pursue new patents in order to ensure the long term commercial success of
gemcabene.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I> Maximize the
global commercial value of gemcabene.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;We have retained all commercial and manufacturing rights to gemcabene. We believe we could
independently commercialize gemcabene for the treatment of patients with HoFH in the United States with a targeted sales force and would seek commercial partners outside of the United States. For
larger indications, such as HeFH, ASCVD and SHTG, we would assess partnership opportunities for Phase&nbsp;3 development and the worldwide commercialization of gemcabene.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I> Leverage the
expertise and experience of our management team to evaluate future in-licensing and acquisition opportunities.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;Across our leadership
team, we have discovered and/or developed Lipitor, Lopid, ETC-1002, ETC-216, ACP-501, CER-209, CER-001 and PNT-2258, and commercialized many lipid regulating and orphan drugs including Crestor,
Myalept and Lynparza. Our team is well-qualified to identify and in-license or acquire clinical-stage cardio-metabolic assets, and we intend to evaluate these opportunities to diversify our pipeline
and generate long-term growth. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks Associated With Our Business  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our business is subject to numerous risks and uncertainties, including those highlighted in the section entitled "Risk Factors" immediately following
this prospectus summary. These risks include, but are not limited to, the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We have incurred only losses since inception and have not generated any revenue,
and we expect to incur losses for the foreseeable future and may never achieve or maintain profitability. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We currently depend entirely on the success of gemcabene, our only product
candidate. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The results of previous clinical trials may not be predictive of future results,
and the results of our current and planned clinical trials may not satisfy the requirements of the FDA or non-U.S. regulatory authorities. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We may fail to demonstrate safety and efficacy for gemcabene or see undesirable
side effects that were not previously identified. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We may experience difficulties in clinical development, such as the enrollment
of patients in clinical trials, which could result in increased costs to us and could delay our development timeline. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We may never receive marketing approval for, or successfully commercialize,
gemcabene for any indication. </FONT></DD></DL>
</UL>
 <p style="font-family:arial;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=6,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=149605,FOLIO='4',FILE='DISK112:[15ZCH1.15ZCH40101]CA40101A.;75',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_ca40101_1_5"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">
<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  Gemcabene is subject to a partial clinical hold with respect to clinical trials
of longer than six months in duration until ongoing preclinical toxicology studies are complete, which may lead to significant delays or the failure of gemcabene to obtain marketing approval. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Changes in regulatory requirements or U.S. Food and Drug Administration (FDA)
guidance, or unanticipated events during our clinical trials, may result in changes to clinical trial protocols or additional clinical trial requirements, such as the initiation or completion of a
cardiovascular outcomes trial. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We rely on third-party clinical research organizations, suppliers and
manufacturers, and we are not able to directly control all aspects of our preclinical studies, clinical trials and drug manufacturing. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We depend on intellectual property licensed from Pfizer for gemcabene, and the
termination of this license would harm our business. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> If we are unable to adequately protect our proprietary technology or maintain
issued patents sufficient to protect gemcabene or any future product candidate, others could compete against us more directly. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We need to establish sales and marketing capabilities or enter into agreements
with third parties to sell and market gemcabene, if approved, for successful commercialization. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We face substantial competition, which may result in others discovering,
developing or commercializing products before or more successfully than we do. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Our future success depends on our ability to attract and retain our executives
and key personnel. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Our recurring operating losses have raised substantial doubt regarding our
ability to continue as a going concern. We will need substantial additional capital in the future. If additional capital is not available, we will have to delay, reduce or cease operations. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Corporate Information  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We were formed in Michigan as Michigan Life Therapeutics,&nbsp;LLC (MLT) in November 2008. In October 2014, we incorporated a new entity under the
name Gemphire Therapeutics&nbsp;Inc. in Delaware. MLT then merged with and into Gemphire, with Gemphire as the surviving entity. The purpose of the merger was to change the jurisdiction of our
incorporation from Michigan to Delaware and to convert from a limited liability company to a corporation. Our principal executive offices are located at 43334 Seven Mile Road, Suite&nbsp;1000,
Northville, Michigan 48167, and our telephone number is (248)&nbsp;681-9815. Our corporate website address is www.gemphire.com. Information contained on or accessible through our website is not a
part of this prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference only. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This
prospectus contains references to trademarks belonging to us and other entities. Solely for convenience, trademarks and trade names referred to in this prospectus, including logos, artwork and
other visual displays, may appear without the &reg; or &#153; symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under
applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other companies' trade names or trademarks to imply a
relationship with, or endorsement or sponsorship of us by, any other companies. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Implications of Being an Emerging Growth Company  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As a company with less than $1.0&nbsp;billion in revenue during our last fiscal year, we qualify as an "emerging growth company," as defined in the
Jumpstart Our Business Startups Act (JOBS Act) enacted in April 2012. As an "emerging growth company" we are:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  permitted to present only two years of audited financial statements and only
two years of related Management's Discussion and Analysis of Financial Condition and Results of Operations in this prospectus; </FONT></DD></DL>
</UL>
 <p style="font-family:arial;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=7,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=587124,FOLIO='5',FILE='DISK112:[15ZCH1.15ZCH40101]CA40101A.;75',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_ca40101_1_6"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">
 <UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> not being required to comply with the auditor attestation requirements of
Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, as amended; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  permitted to take advantage of reduced disclosure obligations regarding
executive compensation in our periodic reports, proxy statements and registration statements; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  permitted to take advantage of exemptions from the requirements of holding a
nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>We
may use these provisions until the last day of our fiscal year following the fifth anniversary of the closing of this offering. However, if certain events occur prior to the end of such five-year
period, including if we become a "large accelerated filer," our annual gross revenue exceeds $1.0&nbsp;billion or we issue more than $1.0&nbsp;billion of non-convertible debt in any three-year
period, we will cease to be an emerging growth company prior to the end of such five-year period. We have elected to take advantage of certain of the reduced disclosure obligations in the registration
statement of which this prospectus is a part and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to our stockholders
may be different than you might receive from other public reporting companies in which you hold equity interests. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. We have irrevocably elected not to
avail ourselves of this exemption and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. </FONT></P>
 <p style="font-family:arial;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=8,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=768190,FOLIO='6',FILE='DISK112:[15ZCH1.15ZCH40101]CA40101A.;75',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_cc40101_1_7"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="cc40101_the_offering"> </A>
<A NAME="toc_cc40101_1"> </A>
<BR></FONT><FONT SIZE=2><B>  The Offering    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="48%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common stock offered by us</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> 3,000,000&nbsp;shares</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Option to purchase additional shares</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> We have granted to the underwriters the option, exercisable for 30&nbsp;days from the date of this prospectus, to purchase
up to 450,000 additional shares of common stock.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common&nbsp;stock&nbsp;to&nbsp;be&nbsp;outstanding&nbsp;after&nbsp;this&nbsp;offering</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> 8,431,615&nbsp;shares (8,881,615&nbsp;shares if the underwriters exercise their option to purchase additional shares in
full)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Use of proceeds</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> We estimate that we will receive net proceeds of approximately $25.6&nbsp;million (or approximately $29.8&nbsp;million if
the underwriters exercise their option to purchase additional shares in full) from the sale of the shares of common stock offered by us in this offering, after deducting the underwriting discounts and commissions and estimated offering expenses
payable by us. We intend to use the net proceeds from this offering, together with cash and cash equivalents, to fund: development costs associated with three late stage clinical trials of gemcabene for our target indications, our planned end of
Phase&nbsp;2 meetings with the FDA, manufacturing related activities, preclinical studies and related activities for gemcabene and the balance for general corporate purposes. See "Use of Proceeds."</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk factors</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> You should read the "Risk Factors" section of this prospectus for a discussion of certain of the factors to consider
carefully before deciding to purchase any shares of our common stock.</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proposed NASDAQ Global Market symbol</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> "GEMP"</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Potential insider participation</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Certain of our existing security holders and their affiliated entities, and other entities and individuals associated with
us and them have indicated an interest in purchasing approximately $10&nbsp;million of shares (or 1,000,000 shares) in the aggregate of our common stock in this offering at the initial public offering price. The underwriters will receive the same
underwriting discount on any shares purchased by these entities as they will on any other shares sold to the public in this offering.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<p style="font-family:arial;"><font  style="font-size:8pt;line-height:9pt;"></FONT><FONT SIZE=2>
</font></p><p style="font-family:arial;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=9,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=310362,FOLIO='7',FILE='DISK112:[15ZCH1.15ZCH40101]CC40101A.;59',USER='CHE107256',CD=';5-AUG-2016;17:36' -->
<A NAME="page_cc40101_1_8"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="48%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Directed share program</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> At our request, the underwriters have reserved up to 10% of the shares of our common stock offered by this prospectus for sale, at the
initial public offering price, to our directors, officers, employees and other individuals associated with us and members of their respective families. We do not know if these persons will choose to purchase all or any portion of these reserved
shares, but any purchases they do make will reduce the number of shares available to the general public. The underwriters will receive the same underwriting discount on any shares purchased by these investors as they will on any other shares sold to
the public in this offering. Any shares purchased by such investors will be subject to the lock-up restrictions described in the section titled "Underwriting."</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>The
number of shares of our common stock to be outstanding after this offering is based on 5,431,615&nbsp;shares of common stock outstanding as of March&nbsp;31, 2016, which
excludes:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  302,842&nbsp;shares of common stock issuable upon the exercise of stock
options outstanding as of March&nbsp;31, 2016 at a weighted-average exercise price of $2.428 per share; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  1,825,200&nbsp;shares of common stock issuable upon the exercise of stock
options with a per share exercise price equal to the initial public offering price to be granted to certain officers, directors, employees and consultants in connection with this offering; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  269,522&nbsp;shares of common stock reserved for future issuance under our
2015 Equity Incentive Plan (the 2015 Plan), which was amended and restated in connection with this offering, and 150,000&nbsp;shares of common stock reserved for future issuance under our 2016
Employee Stock Purchase Plan, which became effective in connection with this offering, as well as any automatic increases in the number of shares of common stock reserved for future issuance under
these plans; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> shares of common stock issuable upon conversion of our convertible notes issued
after March&nbsp;31, 2016, which notes and accrued and unpaid interest thereon will automatically convert immediately prior to the closing of this offering into 765,052 shares, based on an expected
closing date of August&nbsp;10, 2016; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 24,257 shares of common stock issuable upon the automatic conversion of the
accrued and unpaid interest that accrued after March&nbsp;31, 2016 and through the expected closing date of August&nbsp;10, 2016 on our convertible notes issued prior to March&nbsp;31, 2016; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 21,576 shares of common stock issued immediately prior to the closing of the
offering pursuant to the Accrued Dividends described elsewhere in this prospectus in the section titled "Dividend Policy" that accrued after March&nbsp;31, 2016 and through the expected closing date
of August&nbsp;10, 2016. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Unless
otherwise indicated, all information contained in this prospectus assumes the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the conversion of all of our convertible preferred stock outstanding as of
March&nbsp;31, 2016 into 745,637&nbsp;shares of common stock immediately prior to the closing of this offering; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a 1-for-3.119 reverse split of our common stock and preferred stock, which
became effective on April&nbsp;27, 2016; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the issuance of 59,992&nbsp;shares of common stock pursuant to the Accrued
Dividends described elsewhere in this prospectus in the section titled "Dividend Policy" immediately prior to the closing of the offering (assuming the closing of the offering occurred on
March&nbsp;31, 2016); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the automatic conversion of the principal and accrued and unpaid interest
outstanding as of March&nbsp;31, 2016 on our convertible notes issued prior to March&nbsp;31, 2016 into 867,498&nbsp;shares of common stock immediately prior to the closing of the offering; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> no exercise by the underwriters of their option to purchase up to an additional
450,000&nbsp;shares of our common stock; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the filing of our amended and restated certificate of incorporation and the
adoption of our amended and restated bylaws immediately prior to the closing of this offering. </FONT></DD></DL>
</UL>
 <p style="font-family:arial;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=10,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=994232,FOLIO='8',FILE='DISK112:[15ZCH1.15ZCH40101]CC40101A.;59',USER='CHE107256',CD=';5-AUG-2016;17:36' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ce40101_1_9"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ce40101_summary_financial_data"> </A>
<A NAME="toc_ce40101_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Summary Financial Data    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following summary financial data should be read together with our financial statements and related notes, "Capitalization," "Selected Financial
Data" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" appearing elsewhere in this prospectus. The summary financial data in this section are not intended to
replace our financial statements and the related notes. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
derived the summary statements of operations data for the years ended December&nbsp;31, 2014 and 2015 and the summary balance sheet data as of December&nbsp;31, 2015 from our audited financial
statements and related notes appearing elsewhere in this prospectus. We derived the summary statements of operations data for the three months ended March&nbsp;31, 2015 and 2016 and the summary
balance sheet data as of March&nbsp;31, 2016 from our unaudited interim financial statements appearing elsewhere in this prospectus. The unaudited interim financial statements have been prepared on
the same basis as our audited financial statements and include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the financial information set
forth in those statements. Our historical results for any prior period are not necessarily indicative of results expected in any future period, and our interim results are not necessarily indicative
of results for a full year or any other period. </FONT></P>
 <p style="font-family:arial;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=11,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=509249,FOLIO='9',FILE='DISK112:[15ZCH1.15ZCH40101]CE40101A.;74',USER='CHE105948',CD=';5-AUG-2016;22:06' -->
<A NAME="page_ce40101_1_10"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">
<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="70pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="70pt" style="font-family:arial;"></TD>
<TD WIDTH="14pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="70pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="70pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Three Months Ended<BR>
March&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2015 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2015 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2016 </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(unaudited)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands, except share and per&nbsp;share&nbsp;amounts)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Statements of Operations Data:</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating expenses:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>214</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3,177</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>475</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,050</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 52</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 3,991</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 206</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 1,176</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Acquired in-process research and development</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> &#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 908</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 908</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> &#151; </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 266</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 8,076</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 1,589</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 2,226 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss from operations</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (266</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (8,076</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (1,589</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (2,226</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:11pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest (expense) income</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
(55</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
(762</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
(690</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
127</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss on convertible note extinguishment</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> &#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (198</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> &#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> &#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income (expense)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 7</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> &#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (4</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (320</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (9,029</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (2,279</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (2,103</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adjustment to redemption value on Series&nbsp;A convertible preferred stock</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> &#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (2,968</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (2,517</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (149</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Premium upon substantial modification of convertible notes with certain stockholders</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> &#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (1,047</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> &#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> &#151; </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss attributable to common stockholders</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(320</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(13,044</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,796</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2,252</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss per share attributable to common stockholders, basic and diluted<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(0.21</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4.54</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2.27</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(0.65</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 1,521,703</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 2,875,053</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 2,110,097</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 3,468,764 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma net loss per share attributable to common stockholders, basic and diluted (unaudited)<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2.95</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(0.42</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted-average shares used in computing pro forma net loss per share attributable to common stockholders, basic and diluted (unaudited)<SUP>(1)
</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 4,305,100</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 5,301,705 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">See
notes 2 and&nbsp;10 to our financial statements appearing elsewhere in this prospectus for further details on the calculation of net
loss per share attributable to common stockholders, basic and diluted, and pro forma net loss per share attributable to common stockholders, basic and diluted, and the weighted-average number of
shares used in computation of the per share amounts. On April&nbsp;22, 2016, our board of directors approved a 1-for-3.119 reverse stock split of our common stock and preferred stock, which became
effective on April&nbsp;27, 2016. All share and per share data in this table have been adjusted to reflect the reverse stock split. </FONT></DD></DL>
 <p style="font-family:arial;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=12,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=718197,FOLIO='10',FILE='DISK112:[15ZCH1.15ZCH40101]CE40101A.;74',USER='CHE105948',CD=';5-AUG-2016;22:06' -->
<A NAME="page_ce40101_1_11"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="83pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="83pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="83pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>March&nbsp;31, 2016 </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Actual </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Pro&nbsp;Forma<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font> </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Pro Forma<BR>
As&nbsp;Adjusted<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font> </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(unaudited)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Balance Sheet Information:</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,629</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,629</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>27,229</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Working capital</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (599</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (599</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 25,006</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total assets</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 2,637</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 1,658</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 27,258</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Convertible notes (including premium conversion derivative)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 6,792</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> &#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> &#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total liabilities</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 9,044</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 2,252</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 2,252</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;A convertible preferred stock</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 8,102</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> &#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> &#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated deficit</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (14,521</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (14,535</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (14,535</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stockholders' (deficit) equity</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (14,509</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (594</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 25,006</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Pro
forma balance sheet data reflects (i)&nbsp;the automatic conversion of all outstanding shares of our convertible preferred stock into
745,637 shares of common stock immediately prior to the closing of this offering, (ii)&nbsp;the issuance of 59,992&nbsp;shares of common stock immediately prior to the closing of the offering
pursuant to the Accrued Dividends described elsewhere in this prospectus in the section titled "Dividend Policy" (assuming the closing of the offering occurred on March&nbsp;31 2016),
(iii)&nbsp;the issuance of 867,498 shares of common stock pursuant to the automatic conversion of the principal and accrued and unpaid interest outstanding on March&nbsp;31, 2016 on our
convertible notes issued prior to March&nbsp;31, 2016, immediately prior to the closing of this offering, (iv)&nbsp;the accelerated vesting of 162,945&nbsp;shares of restricted stock unvested as
of March&nbsp;31, 2016 valued at approximately $14,000 held by certain employees upon the closing of this offering and (v)&nbsp;the filing of our amended and restated certificate of incorporation
immediately prior to the closing of this offering.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Pro
forma as adjusted balance sheet data reflects (i)&nbsp;the pro forma adjustments set forth above in footnote&nbsp;(1) and
(ii)&nbsp;the issuance and sale of 3,000,000&nbsp;shares of common stock in this offering at the initial public offering price of $10.00 per share, after deducting the underwriting discounts and
commissions and estimated offering expenses payable by us.  </FONT>
<BR>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
pro forma and pro forma as adjusted balance sheet data does not reflect: (i)&nbsp;our convertible notes that were issued after March&nbsp;31, 2016, which notes and accrued and unpaid interest
thereon will automatically convert immediately prior to the closing of this offering into 765,052 shares of common stock, based on an expected closing date of August&nbsp;10, 2016;
(ii)&nbsp;24,257 shares of common stock issuable upon the automatic conversion of the accrued and unpaid interest that accrued after March&nbsp;31, 2016 and through the expected closing date of
August&nbsp;10, 2016 on our convertible notes issued prior to March&nbsp;31, 2016; or (iii)&nbsp;21,576 shares of common stock issued immediately prior to the closing of the offering pursuant to
the Accrued Dividends described elsewhere in this prospectus in the section titled "Dividend Policy" that accrued after March&nbsp;31, 2016 and through the expected closing date of August&nbsp;10,
2016. </FONT></P>

</DD></DL>
 <p style="font-family:arial;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=13,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=855482,FOLIO='11',FILE='DISK112:[15ZCH1.15ZCH40101]CE40101A.;74',USER='CHE105948',CD=';5-AUG-2016;22:06' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ck40101_1_12"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ck40101_risk_factors"> </A>
<A NAME="toc_ck40101_1"> </A>
<BR></FONT><FONT SIZE=2><B>  RISK FACTORS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well
as the other information in this prospectus, including our financial statements, related notes and other financial information appearing elsewhere in this prospectus and "Management's Discussion and
Analysis of Financial Condition and Results of Operations," before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could harm our
business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline and you may lose all or part of your investment.
Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.  </I></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks Related to the Development of Gemcabene or any Future Product Candidate  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We currently depend entirely on the success of gemcabene, our only product candidate. We may never
receive marketing approval for, or successfully commercialize, gemcabene for any indication.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We currently have only one product candidate, gemcabene, in clinical development, and our business depends on its successful clinical development,
regulatory approval and commercialization. The research, testing, manufacturing, labeling, approval, sale, marketing and distribution of a drug product are subject to extensive regulation by the FDA
and other regulatory authorities in the United States and other countries, where regulations differ from country to country. We are not permitted to market gemcabene in the United States until we
receive approval of a new drug application (NDA) from the FDA or in any foreign countries until we receive the requisite approval from such countries. We have not submitted an NDA to the FDA or
comparable applications to other regulatory authorities or received marketing approval for gemcabene. Before obtaining regulatory approval for the commercial sale of gemcabene for a particular
indication, we must demonstrate through preclinical testing and clinical trials that gemcabene is safe and effective for use in that target indication. This process can take many years and may be
followed by post-marketing studies and surveillance, which will require the expenditure of substantial resources beyond the proceeds we raise in this offering. Of the large number of drugs in
development in the United States, only a small percentage of drugs successfully complete the FDA regulatory approval process and are commercialized. Accordingly, even if we are able to complete
development of gemcabene, we cannot assure you that gemcabene will be approved or commercialized. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Obtaining
approval of an NDA is an extensive, lengthy, expensive and uncertain process, and the FDA may delay, limit or deny approval of gemcabene for many reasons,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the data collected from preclinical studies and clinical trials of gemcabene may
not be sufficient to support the submission of an NDA; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we may not be able to demonstrate to the satisfaction of the FDA that gemcabene
is safe and effective for any indication; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the results of clinical trials may not meet the level of statistical
significance or clinical significance required by the FDA for approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the FDA may disagree with the number, design, size, conduct or implementation of
our clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the FDA may not find the data from preclinical studies and clinical trials
sufficient to demonstrate that gemcabene's clinical and other benefits outweigh its safety risks; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the FDA may disagree with our interpretation of data from preclinical studies or
clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the FDA may not accept data generated at our clinical trial sites; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the FDA may have difficulties scheduling an advisory committee meeting in a
timely manner or the advisory committee may recommend against approval of our application or may recommend that the FDA require, as a condition of approval, additional preclinical studies or clinical
trials, limitations on approved labeling or distribution and use restrictions; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=14,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=471507,FOLIO='12',FILE='DISK112:[15ZCH1.15ZCH40101]CK40101A.;27',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_ck40101_1_13"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the FDA may require development of a risk evaluation and mitigation strategy
(REMS) as a condition of approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the FDA may identify deficiencies in the manufacturing processes or facilities
of third party manufacturers with which we enter into agreements for clinical and commercial supplies; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the FDA may change its approval policies or adopt new regulations. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The results of previous clinical trials may not be predictive of future results, and the results of
our current and planned clinical trials may not satisfy the requirements of the FDA or non-U.S. regulatory authorities.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The results from the prior preclinical studies and clinical trials for gemcabene discussed elsewhere in this prospectus may not necessarily be
predictive of the results of future preclinical studies or clinical trials. Even if we are able to complete our planned clinical trials of gemcabene according to our current development timeline, the
results from our prior clinical trials of gemcabene may not be replicated in these future trials. Many companies in the pharmaceutical and biotechnology industries (including those with greater
resources and experience than us) have suffered significant setbacks in late-stage clinical trials after achieving positive results in early stage development, and we cannot be certain that we will
not face similar setbacks. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway or safety or efficacy observations made in clinical
trials, including previously unreported AEs. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that believed their product
candidates performed satisfactorily in preclinical studies and clinical trials nonetheless have failed to obtain FDA approval. If we fail to produce positive results in our clinical trials of
gemcabene, the development timeline and regulatory approval and commercialization prospects for gemcabene and our business and financial prospects, would be adversely affected. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Further,
gemcabene may not be approved even if it achieves its primary endpoint in Phase&nbsp;3 registration trials. The FDA or non-U.S. regulatory authorities may disagree with our trial design and
our interpretation of data from preclinical studies and clinical trials. In addition, any of these regulatory authorities may change requirements for the approval of a product candidate even after
reviewing and providing comments or advice on a protocol for a pivotal clinical trial that has the potential to result in approval by the FDA or another regulatory authority. Furthermore, any of these
regulatory authorities may also approve our product candidate for fewer or more limited indications than we request or may grant approval contingent on the performance of costly post-marketing
clinical trials. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
plan to commence three late stage clinical trials by the end of 2016. If successful, we plan to eventually seek regulatory approvals of gemcabene initially in the United States, Canada and Europe,
and we may seek approvals in other geographies. Before obtaining regulatory approvals for the commercial sale of any product candidate for any target indication, we must demonstrate with substantial
evidence gathered in preclinical studies and adequate and well-controlled clinical studies, and, with respect to approval in the United States, to the satisfaction of the FDA, that the product
candidate is safe and effective for use for that target indication. We cannot assure you that the FDA or non-U.S. regulatory authorities would consider our planned clinical trials to be sufficient to
serve as the basis for approval of gemcabene for any indication. The FDA and non-U.S. regulatory authorities retain broad discretion in evaluating the results of our clinical trials and in determining
whether the results demonstrate that gemcabene is safe and effective. If we are required to conduct clinical trials of gemcabene in addition to those we have planned prior to approval, such as a
cardiovascular outcomes trial, we will need substantial additional funds, and we cannot assure you that the results of any such outcomes trial or other clinical trials will be sufficient for approval. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=15,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=582337,FOLIO='13',FILE='DISK112:[15ZCH1.15ZCH40101]CK40101A.;27',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_ck40101_1_14"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If clinical trials of gemcabene or any future product candidate fail to demonstrate safety and
efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to
complete, the development and commercialization of such product candidate.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Before obtaining marketing approval from regulatory authorities for the sale of gemcabene, we must complete preclinical development (including, but
not limited to, two-year rat and mouse carcinogenicity studies), and supportive pharmacology studies and Phase&nbsp;2b and Phase&nbsp;3 clinical trials to demonstrate the safety and efficacy in
humans. Preclinical development and extensive clinical trials will also be required before obtaining marketing approval from regulatory authorities for any other product candidate we may pursue in the
future. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more clinical trials can occur at any
stage of development. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We,
or our future collaborators, may experience numerous unforeseen events during, or as a result of, clinical trials that could result in increased development costs, delay, limit or prevent our
ability to receive marketing approval or commercialize gemcabene or any other product candidate we may pursue in the future, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  regulators or institutional review boards (IRBs) may not authorize us or our
investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  government or regulatory delays and changes in regulatory requirements, policy
and guidelines may require us to perform additional clinical trials or use substantial additional resources to obtain regulatory approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we may have delays in reaching or fail to reach agreement on acceptable clinical
trial contracts or clinical trial protocols with prospective trial sites; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> clinical trials may produce negative or inconclusive results, and we may decide,
or regulators may require us, to conduct additional clinical trials or abandon product development programs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the number of patients required for clinical trials may be larger than we
anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our third-party contractors may fail to comply with regulatory requirements or
meet their contractual obligations to us in a timely manner, or at all; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our patients or medical investigators may be unwilling to follow our clinical
trial protocols; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we might have to suspend or terminate clinical trials for various reasons,
including a finding that the participants are being exposed to unacceptable health risks; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the cost of clinical trials may be greater than we anticipate; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the supply or quality of any product candidate or other materials necessary to
conduct clinical trials may be insufficient or inadequate; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the product candidate may have undesirable side effects or other unexpected
characteristics, causing us or our investigators, regulators or IRBs to suspend or terminate the trials. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we experience delays or difficulties in the enrollment of patients in clinical trials, our
receipt of necessary regulatory approvals could be delayed or prevented.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We or our future collaborators may not be able to initiate or continue clinical trials for gemcabene or any future product candidate if we are unable
to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or analogous regulatory authorities outside the United States. Orphan indications,
in particular, have small populations, and it may be difficult for us to locate and enroll sufficient patients in trials for orphan-designated indications. Patient enrollment can be affected by many
factors, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> severity of the disease under investigation; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=16,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=245906,FOLIO='14',FILE='DISK112:[15ZCH1.15ZCH40101]CK40101A.;27',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_ck40101_1_15"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  availability and efficacy of medications already approved for the disease under
investigation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  eligibility criteria for the trial in question; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  competition for eligible patients with other companies conducting clinical
trials for product candidates seeking to treat the same indication or patient population; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our payments for conducting clinical trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  perceived risks and benefits of the product candidate under study; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> efforts to facilitate timely enrollment in clinical trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> patient referral practices of physicians; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the ability to monitor patients adequately during and after treatment; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  proximity and availability of clinical trial sites for prospective patients. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>We
expect that our late stage clinical trials of gemcabene will commence by the end of 2016 and may take up to 12&nbsp;months to enroll; however, we cannot assure you that our timing and enrollment
assumptions are correct given the above factors. Our inability to enroll a sufficient number of patients for our clinical trials or retain sufficient enrollment through the completion of our trials
would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our
product candidates and cause our stock price to decline. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We or others could discover that gemcabene or any product candidate we may pursue in the future
lacks sufficient efficacy, or that it causes undesirable side effects that were not previously identified, which could delay or prevent regulatory approval or commercialization.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Because gemcabene has been tested in relatively small patient populations and for limited durations to date, it is possible that our clinical trials
have or will indicate an apparent positive effect of gemcabene that is greater than the actual positive effect, if any, or that additional and unforeseen side effects may be observed as its
development progresses. The discovery that gemcabene lacks sufficient efficacy, or that it causes undesirable side effects (including side effects not previously identified in our completed clinical
trials), could cause us or regulatory authorities to interrupt, delay or discontinue clinical trials and could result in the denial of regulatory approval by the FDA or other non-U.S. regulatory
authorities for any or all targeted indications. The most common events reported to date have been headache, weakness, nausea, dizziness, upset stomach, infection, abnormal bowel movements, myalgia
and abnormal kidney function tests. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
discovery that gemcabene or any future product candidate lacks sufficient efficacy or that it causes undesirable side effects that were not previously identified could prevent us from
commercializing such product candidate and generating revenues from its sale. In addition, if we receive marketing approval for gemcabene and we or others later discover that it is less effective, or
identify undesirable side effects caused by gemcabene:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  regulatory authorities may withdraw their approval of the product; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we may be required to recall the product, change the way this product is
administered, conduct additional clinical trials or change the labeling or distribution of the product (including REMS); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  additional restrictions may be imposed on the marketing of, or the
manufacturing processes for, the product; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we may be subject to fines, injunctions or the imposition of civil or criminal
penalties; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we could be sued and held liable for harm caused to patients; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the product may be rendered less competitive and sales may decrease; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our reputation may suffer generally both among clinicians and patients. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=17,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=443967,FOLIO='15',FILE='DISK112:[15ZCH1.15ZCH40101]CK40101A.;27',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_cm40101_1_16"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Any one or a combination of these events could prevent us from achieving or maintaining market acceptance of the affected product or could substantially increase the costs and
expenses of commercializing the product, which in turn could delay or prevent us from generating significant, or any, revenues from the sale of the product. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Changes in regulatory requirements or FDA guidance, or unanticipated events during our clinical
trials, may result in changes to clinical trial protocols or additional clinical trial requirements, such as the initiation or completion of a cardiovascular outcomes trial, which could result in
increased costs to us and could delay our development timeline.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Changes in regulatory requirements or FDA guidance, or unanticipated events during our clinical trials, may force us to amend clinical trial protocols
or the FDA may impose additional clinical trial requirements. Amendments to our clinical trial protocols would require resubmission to the FDA and IRBs for review and approval, and may adversely
impact the cost, timing or successful completion of a clinical trial. If we experience delays completing, or if we terminate, any of our Phase&nbsp;2b or Phase&nbsp;3 trials, or if we are required
to conduct additional clinical trials, such as a cardiovascular outcomes trial prior to approval, the commercial prospects for gemcabene may be harmed and our ability to generate product revenue will
be delayed. If the FDA requires us to conduct a cardiovascular outcomes trial sooner than planned, we may not be able to identify and enroll the requisite number of patients in that trial. Even if we
are successful in enrolling patients in a
cardiovascular outcomes trial, we may not ultimately be able to demonstrate that lowering LDL-C levels using gemcabene provides patients with an incremental lowering of cardiovascular disease risks,
and our failure to do so may delay or prejudice our ability to obtain FDA approval for gemcabene. Although the validity of lipid-lowering effects (including LDL-C reduction) as a surrogate endpoint
for cardiovascular benefit continues to be debated in the medical community, given historical precedent and recent FDA guidance, our current development timeline for gemcabene does not contemplate the
completion of a cardiovascular outcomes trial prior to approval. Such trial would be costly and time-consuming and, regardless of the outcome, would adversely affect our development timeline and
financial condition. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have not generated any revenue and may never be profitable.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our ability to become profitable depends upon our ability to generate revenue. To date, we have not generated any revenue from our development stage
product candidate, gemcabene, and we do not currently have any other products or product candidates. We do not know when, or if, we will generate any revenue. We do not expect to generate significant
revenue unless or until we obtain marketing approval of, and commercialize, gemcabene. Our ability to generate revenue depends on a number of factors, including our ability
to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  successfully complete preclinical carcinogenicity studies to remove the partial
clinical hold to allow us to complete longer term registration trials for marketing approval of gemcabene; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> obtain favorable results from and complete the clinical
development of gemcabene
for our planned indications, including successful completion of our Phase&nbsp;2b and Phase&nbsp;3 trials for these indications; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> submit an application to regulatory
authorities for gemcabene and receive
marketing approval in the United States and foreign countries; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> contract for the manufacture of commercial quantities of gemcabene, if approved,
at acceptable cost levels; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  establish sales and marketing capabilities to effectively market and sell
gemcabene, if approved, in the United States and the European Union, alone or with a pharmaceutical partner; and </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> achieve market acceptance of gemcabene in the medical
community and with
third-party payors. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Even
if gemcabene is approved for commercial sale in one or all of the initial indications that we are pursuing, it may not gain market acceptance or achieve commercial success. In addition, we
anticipate incurring significant costs associated with commercializing gemcabene. Moreover, some of the indications we are targeting are small enough to be eligible for orphan drug designation, and
our potential patient market is relatively smaller than other drugs, and therefore the price of gemcabene may need to be higher </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=18,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=922115,FOLIO='16',FILE='DISK112:[15ZCH1.15ZCH40101]CM40101A.;57',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_cm40101_1_17"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>than
other drugs. We may not achieve profitability soon after generating product revenue, if ever, and may be unable to continue operations without continued funding. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we fail to receive regulatory approval for any of our planned indications for gemcabene or fail
to develop additional product candidates, our commercial opportunity will be limited.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are initially focused on the development of gemcabene for our target indications. We are also exploring the utility of gemcabene for nonalcoholic
steatohepatitis (NASH) and/or nonalcoholic fatty liver disease (NAFLD). However, we cannot assure you that we will be able to obtain regulatory approval of gemcabene for any indication, or
successfully commercialize gemcabene, if approved. If we do not receive regulatory approval for, or successfully commercialize, gemcabene for one or more of our targeted or other indications, our
commercial opportunity will be limited. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
may pursue clinical development of additional product candidates, including product candidates that we acquire or in-license. Acquiring, in-licensing, developing, obtaining regulatory approval for
and commercializing additional product candidates will require substantial additional funding beyond the net proceeds of this offering
and are prone to the risks of failure inherent in drug product development. We cannot assure you that we will be able to successfully advance any additional product candidates through the development
process. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Even
if we obtain FDA approval to market additional product candidates, we cannot assure you that any such product candidates will be successfully commercialized, widely accepted in the marketplace or
more effective than other commercially available alternatives. If we are unable to successfully develop and commercialize additional product candidates, our commercial opportunity will be limited. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We depend on intellectual property licensed from Pfizer for gemcabene, and the termination of this
license would harm our business.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Pfizer has granted us a worldwide exclusive license to make, use, sell, offer for sale and import the clinical product candidate gemcabene, along with
certain intellectual property for the purposes of development and commercialization of gemcabene. We or Pfizer may terminate this license in the event of a material breach that remains uncured for
30&nbsp;days from the date that the breaching party is provided with notice of such breach, provided that if such breach is capable of being cured, the cure period may be extended up to an
additional 60&nbsp;days, or immediately upon certain insolvency events relating to the other party. Pfizer may immediately terminate this license in the event that we, or any of our affiliates,
consent, challenge, support or assist any third party to contest or challenge Pfizer's ownership of or rights in, or the validity, enforceability or scope of, any of the patents licensed under this
license. Additionally, Pfizer may revoke the license if we are unable to adequately commercialize gemcabene by April 2021. See "Business&nbsp;&#151; Pfizer Licensing Terms" for additional
information regarding our license agreement with Pfizer. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Disputes
may arise between us and Pfizer regarding intellectual property subject to this license agreement, including with respect to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the scope of rights granted under the license agreement and other
interpretation-related issues; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> whether and the extent to which our technology and processes infringe on
intellectual property of Pfizer that is not subject to the licensing agreement; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the amount and timing of milestone and royalty payments; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT
FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the rights of Pfizer under the license agreement; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our right to sublicense patent and other rights to third
parties under
collaborative development relationships; and </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the ownership of inventions and know-how resulting from the joint creation or
use of intellectual property by Pfizer and us and our partners. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Any
disputes with Pfizer may prevent or impair our ability to maintain our current licensing arrangement. We depend on the intellectual property licensed from Pfizer to develop and commercialize
gemcabene. Termination of our license agreement could result in the loss of significant rights and would harm our ability </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=19,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=372558,FOLIO='17',FILE='DISK112:[15ZCH1.15ZCH40101]CM40101A.;57',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_cm40101_1_18"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>to
further develop and commercialize gemcabene. In addition, Pfizer has a non-exclusive, sub licensable, royalty-free right and license for non-commercial research or development purposes to
intellectual property rights relating to gemcabene that are developed by us after the effective date of the license with Pfizer. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The development of gemcabene or pursuit of any future product candidate for broad patient
populations will be more costly and commercial pricing for any approved indication would likely be lower.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Although we are initially pursuing development of gemcabene for the treatment of patients with HoFH, we believe that gemcabene may be useful for the
treatment of elevated lipid and triglyceride levels in broader patient populations, including HeFH, ASCVD and SHTG. The Company is also exploring
indications in NASH and/or NAFLD. Expanding our development and commercialization of gemcabene or any future product candidate in these or other broader patient populations would be more costly and
take longer to complete and would be subject to development and commercialization risks that may not be applicable to HoFH orphan indication. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Specifically,
this may involve clinical trials with larger numbers of patients possibly taking the drug for longer periods of time. In addition, we believe that the FDA and, in some cases, the
European Medicines Agency (EMA) may require a clinical outcomes trial demonstrating a reduction in cardiovascular events either prior to or after the submission of an application for marketing
approval for the broader LDL-C indications. Clinical outcomes trials are particularly expensive and time consuming to conduct because of the larger number of patients required to establish that the
drug being tested has the desired effect. It may also be more difficult for us to demonstrate the desired outcomes in these trials than to achieve validated surrogate endpoints. In addition, in
considering approval of gemcabene for broader patient populations with less severely elevated lipid levels, the FDA and other regulatory authorities may place greater emphasis on the side effect and
risk profile of the drug in comparison to the drug's efficacy and potential clinical benefit than in smaller, more severely afflicted patient populations. These factors may make it more difficult for
us to achieve marketing approvals of gemcabene for these broader patient populations. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Moreover,
if we pursue and are able to successfully develop and obtain marketing approval of gemcabene and any future product candidate in broader patient populations, we likely will not be able to
obtain the same pricing level that we expect to obtain for orphan indications. The pricing of some drugs intended for orphan populations is often related to the size of the patient population, with
smaller patient populations often justifying higher prices. If the pricing is lower in broader patient populations, we may not be able to maintain higher pricing in the population of more severely
afflicted patients. This would lead to a decrease in revenue from sales to more severely afflicted patients and could make it more difficult for us to achieve or maintain profitability. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We do not have drug research or discovery capabilities and will need to acquire or license product
candidates from third parties to expand our product candidate pipeline.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We currently have no drug research or discovery capabilities. Accordingly, if we are to expand our product candidate pipeline beyond gemcabene, we
will need to acquire or license product candidates from third parties. We will face significant competition in seeking to acquire or license promising product candidates. Many of our competitors for
such promising product candidates may have significantly greater financial resources and more extensive experience in preclinical testing and clinical trials, obtaining regulatory approvals and
manufacturing and marketing pharmaceutical products, and thus, may be a more attractive option to a potential licensor than us. If we are unable to acquire or license additional promising product
candidates, we will not be able to expand our product candidate pipeline. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
we are able to acquire or license other product candidates, such license agreements will likely impose various obligations upon us, and our licensors may have the right to terminate the license
thereunder in the event of a material breach or, in some cases, at will. A termination of future licenses could result in our loss of the right to use the licensed intellectual property, which could
adversely affect our ability to develop and commercialize a
future product candidate, if approved, as well as harm our competitive business position and our business prospects. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=20,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=912949,FOLIO='18',FILE='DISK112:[15ZCH1.15ZCH40101]CM40101A.;57',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_cm40101_1_19"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may expend our limited resources to pursue a particular indication and fail to capitalize on
indications that may be more profitable or for which there is a greater likelihood of success.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Because we have limited financial and managerial resources, we are currently focusing only on development programs that we identify for specific
indications for gemcabene. As a result, we may forego or delay pursuit of opportunities for other indications, or with other potential product candidates that later prove to have greater commercial
potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and
development programs for specific indications or future product candidates may not yield any commercially viable product. If we do not accurately evaluate the commercial potential or target market for
gemcabene, we may not gain approval or achieve market acceptance of that candidate, and our business and financial results will be harmed. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks Related to our Financial Position and Need for Additional Capital  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have incurred only losses since inception. We expect to incur losses for the foreseeable future
and may never achieve or maintain profitability.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Since inception, we have incurred only operating losses. Our net losses were $0.3&nbsp;million, $9.0&nbsp;million and $2.1&nbsp;million for the
years ended December&nbsp;31, 2014 and 2015 and the three months ended March&nbsp;31, 2016, respectively. As of March&nbsp;31, 2016, we had an accumulated deficit of $14.5&nbsp;million. We
have financed our operations primarily through a private placement of our preferred stock and the issuance of convertible debt securities. We have devoted substantially all of our financial resources
and efforts on research and development, including clinical development of gemcabene. We expect that it will be a number
of years, if ever, before we have a product candidate ready for commercialization. We expect to continue to incur significant expenses and increased operating losses for the foreseeable future. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To
become and remain profitable, we must develop and eventually commercialize a product with market potential. This will require us to be successful in a range of challenging activities, including
completing preclinical testing and clinical trials, obtaining regulatory approval for a product candidate, manufacturing, marketing and selling any drug for which we may obtain regulatory approval and
satisfying any post-marketing requirements. We are in the early stages of most of these activities. We may never succeed in these activities and, even if we do, we may never generate revenues that are
significant or large enough to achieve profitability. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of the
company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company could also
cause you to lose all or part of your investment. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our recurring operating losses have raised substantial doubt regarding our ability to continue as a
going concern.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our recurring operating losses raise substantial doubt about our ability to continue as a going concern. As a result, for the fiscal year ended
December&nbsp;31, 2015, our independent registered public accounting firm has issued its report on our financial statements and has expressed substantial doubt about our ability to continue as a
going concern. We have no current source of revenue to sustain our present activities, and we do not expect to generate revenue until and unless the FDA or other applicable regulatory authorities
approve gemcabene and we successfully commercialize gemcabene. Accordingly, our ability to continue as a going concern will require us to obtain additional financing to fund our operations.
Uncertainty surrounding our ability to continue as a going concern may make it more difficult for us to obtain financing for the continuation of our operations and could result in the loss of
confidence by investors, suppliers, contractors and employees. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=21,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=536963,FOLIO='19',FILE='DISK112:[15ZCH1.15ZCH40101]CM40101A.;57',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_cm40101_1_20"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We will need substantial additional capital in the future. If additional capital is not available,
we will have to delay, reduce or cease operations.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Although we believe that the net proceeds from this offering, together with cash on hand, will be sufficient to fund our operations for at least the
next 24&nbsp;months, we will need to raise additional capital to continue to fund the further development of gemcabene and our operations. Our future capital requirements may be substantial and will
depend on many factors including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the scope, size, rate of progress, results and costs of researching and
developing gemcabene and initiating and completing our preclinical studies and clinical trials; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the cost, timing and outcome of our efforts to obtain marketing approval
for
gemcabene in the United States and other countries, including to fund the preparation and filing of an NDA with the FDA for gemcabene and to satisfy related FDA requirements and regulatory
requirements in other countries; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the number and characteristics of any additional product candidates we develop
or acquire, if any; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to establish and maintain collaborations on favorable terms, if at
all; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the timing and amount of milestone and royalty payments; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the amount of revenue,
if any, from commercial sales, should any product
candidate receive marketing approval; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the costs associated with commercializing gemcabene or any future product
candidates, if we receive marketing approval, including the cost and timing of developing sales and marketing capabilities or entering into strategic collaborations to market and sell gemcabene or any
future product candidates; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the cost of manufacturing gemcabene or any future product candidates and any
product we successfully commercialize; and </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the costs associated with general corporate activities, such as the cost of
filing, prosecuting and enforcing patent claims and making regulatory filings. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Changing
circumstances may cause us to consume capital significantly faster than we currently anticipate. Because the outcome of any clinical trial is highly uncertain, we cannot reasonably estimate
the actual amounts necessary to successfully complete the development, regulatory approval and commercialization of gemcabene and any future product candidates. Additional financing may not be
available when we need it or may not be available on terms that are favorable to us. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if
we believe we have sufficient funds for our current or future operating plans. If adequate funds are unavailable to us on a timely basis, or at all, we may not be able to continue the development of
gemcabene or any future product candidate, or commercialize gemcabene or any future product candidate, if approved, unless we find a strategic partner. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Raising additional capital may cause dilution to our stockholders, including purchasers of common
stock in this offering, restrict our operations or require us to relinquish rights to our technologies or product candidates.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity and
debt financings as well as potential strategic collaborations and licensing arrangements. We do not have any committed external source of funds. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To
the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include
liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing or preferred equity financing, if available, may involve agreements that include covenants
limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
we raise funds through strategic collaborations or marketing, distribution, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future
revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to
delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=22,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=385085,FOLIO='20',FILE='DISK112:[15ZCH1.15ZCH40101]CM40101A.;57',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_cm40101_1_21"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>candidates
that we would otherwise prefer to develop and market ourselves. This may reduce the value of our common stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
the past, we issued options to acquire common stock at prices significantly below the initial public offering price. Pursuant to our 2015 Plan, our management is authorized to grant stock options
to our employees, directors and consultants. The aggregate number of shares of our common stock that may initially be reserved under the amended and restated 2015 Plan is 2,400,000&nbsp;shares, with
269,522 shares remaining available for issuance following the grant of options to purchase an aggregate of 1,825,200 shares of common stock to certain officers, directors, employees and consultants in
connection with this offering. The number of shares of our common stock reserved for issuance under the amended and restated 2015 Plan will automatically increase on January&nbsp;1 of each year,
beginning on January&nbsp;1, 2017 and continuing through and including January&nbsp;1, 2026, to an amount equal to 20% of the fully-diluted shares as of December&nbsp;31 of the preceding
calendar year, or a lesser number of shares determined by our board of directors. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To
the extent these outstanding options are ultimately exercised or the number of shares available for future grant each year are increased, investors purchasing common stock in this offering will
sustain further dilution. See "Dilution" for a more detailed description of the dilution to new investors in the offering. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks Related to Government Regulation  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Gemcabene is subject to a partial clinical hold with respect to clinical trials of longer than six
months in duration until ongoing preclinical toxicology studies are complete, which may lead to a significant delay in the commencement of long term clinical trials by us or the failure of gemcabene
to obtain marketing approval.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In 2004, the FDA determined that gemcabene was a potential peroxisome proliferator-activated receptor (PPAR) agonist. As a result, the FDA imposed a
partial clinical hold, which restricts us from conducting clinical trials for gemcabene beyond six months in duration, and requires us to conduct two-year rat and mouse carcinogenicity studies before
conducting trials of longer than six months. The FDA has issued these notices to all sponsors of product candidates with PPAR properties based on preclinical studies. We plan to complete our two-year
rat and mouse carcinogenicity studies by the end of 2017, with draft reports issued soon after. Clinical trials may be delayed due to these clinical restrictions and additional oversight by the FDA.
For example, if the results of the two-year rat and mouse carcinogenicity studies do not address FDA concerns related to the partial clinical hold, our Phase&nbsp;3 long term safety exposure
registration trials of longer than six&nbsp;months could be delayed. Also, the findings in the carcinogenicity studies could impact the NDA review, and, if approved, labeling and use of gemcabene. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if we receive marketing approval for gemcabene or any product candidate we may pursue in the
future in the United States, we may never receive regulatory approval to market such product candidate outside of the United States.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In addition to the United States, we intend to seek regulatory approval to market gemcabene in Canada and Europe and potentially other markets. If we
pursue additional product candidates in the future, we may seek regulatory approval of such product candidates outside the United States. In order to market any product outside of the United States,
however, we must establish and comply with the numerous and varying safety, efficacy and other regulatory requirements of these other countries. Approval procedures vary among countries and can
involve additional product candidate testing and additional administrative review periods. The time required to obtain approvals in other countries might differ from that required to obtain FDA
approval. The marketing approval processes in other countries may include all of the risks detailed above regarding FDA approval in the United States as well as other risks. In particular, in many
countries outside of the United States, products must receive pricing and reimbursement approval before the product can be commercialized. Obtaining this approval can result in substantial delays in
bringing products to market in such countries. Marketing approval in one country does not ensure marketing approval in another, but a failure or delay in obtaining marketing approval in one country
may have a negative effect on the regulatory process in others. Failure to obtain marketing approval in other countries or any delay or other setback in obtaining such approval would impair our
ability to market gemcabene or any future product candidate in such foreign markets. Any such impairment would reduce the size of our potential market, which could have an adverse impact on our
business, results of operations and prospects. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=23,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=941543,FOLIO='21',FILE='DISK112:[15ZCH1.15ZCH40101]CM40101A.;57',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_co40101_1_22"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if we obtain marketing approval for gemcabene or any product candidate we may pursue in the
future, such product candidate could be subject to post-marketing restrictions or withdrawal from the market, and we may be subject to substantial penalties if we fail to comply with regulatory
requirements or experience unanticipated problems with a product candidate following approval.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Any product candidate for which we, or our future collaborators, obtain marketing approval in the future, as well as the manufacturing processes,
post-approval studies and measures, labeling, advertising and promotional activities for such drug, among other things, will be subject to continual requirements of and review by the FDA and other
regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements relating to
manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if
marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the drug may be marketed or to the conditions of approval, including
the requirement to implement a REMS, which could include requirements for a restricted distribution system. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product candidate. The FDA and other agencies,
including the Department of
Justice, closely regulate and monitor the post-approval marketing and promotion of drugs to ensure that they are manufactured, marketed and distributed only for the approved indications and in
accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers' communications regarding off-label use and if we, or our future collaborators, do not
market a product candidate for which we, or they, receive marketing approval for only their approved indications, we, or they, may be subject to warnings or enforcement action for off-label promotion.
Violation of the Federal Food, Drug, and Cosmetic Act (FDC Act) and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription drugs may lead to
investigations or allegations of violations of federal and state health care fraud and abuse laws and state consumer protection laws. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, later discovery of previously unknown AEs or other problems with our product candidate or its manufacturers or manufacturing processes, or failure to comply with regulatory requirements,
may yield various results, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  litigation involving patients taking our drug; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  restrictions on such drugs, manufacturers or manufacturing processes; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  restrictions on the labeling or marketing of a drug; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  restrictions on drug distribution or use; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  requirements to conduct post-marketing studies or clinical trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> warning letters or untitled letters; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  withdrawal of the drugs from the market; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> refusal to approve pending applications or supplements to approved applications
that we submit; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> product recall or public notification or medical product safety alerts to
healthcare professionals; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> fines, restitution or disgorgement of profits or revenues; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  suspension or withdrawal of marketing approvals; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> damage to relationships with any potential collaborators; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  unfavorable press coverage and damage to our reputation; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> refusal to permit the import or export of drugs; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> product seizure; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  injunctions or the imposition of civil or criminal penalties. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=24,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=348757,FOLIO='22',FILE='DISK112:[15ZCH1.15ZCH40101]CO40101A.;28',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_co40101_1_23"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may seek to avail ourselves of mechanisms to expedite the development or approval of gemcabene or
any other product candidate we may pursue in the future, such as fast track designation, but such mechanisms may not actually lead to a faster development or regulatory review or approval process.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We may seek fast track designation, priority review, or accelerated approval for gemcabene or any other product candidate we may pursue in the future.
For example, if a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical needs for this condition, the drug
sponsor may apply for FDA fast track designation. However, the FDA has broad discretion with regard to these mechanisms, and even if we believe a particular product candidate is eligible for any such
mechanism, we cannot assure you that the FDA would decide to grant it. Even if we do obtain fast track or priority review designation or pursue an accelerated approval pathway, we may not experience a
faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw a particular designation if it believes that the designation is no longer supported by data
from our clinical development program. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


A breakthrough therapy designation by the FDA for a product candidate may not lead to a faster
development or regulatory review or approval process, and it may not increase the likelihood that a product candidate will receive marketing approval.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Depending on the results of our late stage clinical trials, we may seek a breakthrough therapy designation for gemcabene or any other product
candidate we may pursue in the future. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening
disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. For
drugs that are designated as breakthrough therapies, interaction and communication between the FDA and the sponsor can help to identify the most efficient path for clinical development while
minimizing the number of patients placed in ineffective control regimens. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Designation
as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe a product candidate meets the criteria for designation as a breakthrough therapy, the FDA may
disagree and instead determine not to make such designation. We cannot be sure that our evaluation of a product candidate as qualifying for breakthrough therapy designation will meet the FDA's
requirements. In any event, the receipt of a breakthrough therapy designation for a product candidate may not result in a faster development process, review or approval compared to conventional FDA
procedures and does not assure ultimate approval by the FDA. In addition, even if one or more product candidate qualifies as a breakthrough therapy, the FDA may later decide that the product no longer
meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Recently-enacted and future legislation may increase the difficulty and cost for us and our future
collaborators to obtain marketing approval of our product candidate and affect its pricing.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the
healthcare system that could prevent or delay marketing approval of a product candidate, restrict or regulate post-approval activities and affect our ability, or the ability of our future
collaborators, to profitably sell any drug for which we, or they, obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future,
may result in more rigorous coverage criteria and cause downward pressure on the price that we, or our future collaborators, may receive for any approved drug. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For
example, in March 2010, President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the PPACA).
This is a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, improve healthcare quality, enhance remedies against fraud and abuse, add
new transparency </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=25,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=882190,FOLIO='23',FILE='DISK112:[15ZCH1.15ZCH40101]CO40101A.;28',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_co40101_1_24"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>requirements
for certain components of the health care and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. Among the
provisions of the PPACA of importance to gemcabene and any future product candidates are:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an annual, nondeductible fee on any entity that manufactures or imports
specified branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an increase in the statutory minimum rebates a manufacturer must pay under the
Medicaid Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a new methodology by which rebates owed by manufacturers under the Medicaid Drug
Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  extension of a manufacturer's Medicaid rebate liability to covered drugs
dispensed to individuals who are enrolled in Medicaid managed care organizations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  expansion of eligibility criteria for Medicaid programs by, among other things,
allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer's Medicaid rebate liability; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a Medicare Part&nbsp;D coverage gap discount program, in which manufacturers
must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for a manufacturer's
outpatient drugs to be covered under Medicare Part&nbsp;D; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  expansion of the entities eligible for discounts under the Public Health
Service pharmaceutical pricing program; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a new Patient-Centered Outcomes Research Institute to oversee, identify
priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>There
have been judicial and Congressional challenges and amendments to certain aspects of the PPACA, and we expect there will be additional challenges and amendments to the PPACA in the future. In
addition, other legislative changes have been proposed and adopted since the PPACA was enacted. These new laws have resulted in additional reductions in Medicare and other healthcare funding and
otherwise may affect the prices we may obtain for any product candidate for which marketing approval is obtained. Any reduction in reimbursement from Medicare or other government-funded programs may
result in a similar reduction in payments from private payors. Moreover, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed
products. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our drugs. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Legislative
and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional
legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of a product candidate,
if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA's approval process may significantly delay or prevent marketing approval, as well as subject us and our future
collaborators to more stringent drug labeling and post-marketing testing and other requirements. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Governments outside of the United States tend to impose strict price controls, which may adversely
affect our revenues from the sales of a drug, if any.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In some countries, particularly the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control.
In these countries, pricing negotiations with </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=26,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=1008418,FOLIO='24',FILE='DISK112:[15ZCH1.15ZCH40101]CO40101A.;28',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_co40101_1_25"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>governmental
authorities can take considerable time after the receipt of marketing approval for a drug. To obtain reimbursement or pricing approval in some countries, we, or our future collaborators,
may be required to conduct a clinical trial that compares the cost-effectiveness of our drug to other available therapies. If reimbursement of our drug is unavailable or limited in scope or amount, or
if pricing is set at unsatisfactory levels, our business could be harmed. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our relationships with healthcare providers and third-party payors will be subject to applicable
fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future
earnings, among other penalties and consequences.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Healthcare providers and third-party payors will play a primary role in the recommendation and prescription of any product candidate for which we
obtain marketing approval. Our current and future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that
may constrain the business or financial arrangements and relationships through which we market, sell and distribute any product candidate for which we obtain marketing approval. Restrictions and
obligations under applicable federal and state healthcare laws and regulations include the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the federal Anti-Kickback Statute prohibits, among other things, persons and
entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral
of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the federal false claims and civil monetary penalties laws, including the civil
False Claims Act imposes criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the
federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA)
imposes criminal and civil liability for, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> HIPAA, as amended by the Health Information Technology for Economic and Clinical
Health Act, and its implementing regulations, also imposes obligations, including mandatory contractual terms, on certain people and entities with respect to safeguarding the privacy, security and
transmission of individually identifiable health information; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the federal Physician Payments Sunshine Act under the PPACA requires certain
manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid, or the Children's Health Insurance Program, with specific exceptions, to report
annually to the Centers for Medicare&nbsp;&amp; Medicaid Services within the U.S. Department of Health and Human Services information related to physician payments and other transfers of value and
physician ownership and investment interests; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  analogous state and foreign laws and regulations, such as state anti-kickback
and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, and
some state laws require pharmaceutical companies to comply with the pharmaceutical industry's voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government
in addition to requiring drug manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures. Certain state and foreign laws also
govern the privacy and security of health information in ways that differ from each other and often are not preempted by HIPAA, thus complicating compliance efforts. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=27,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=468667,FOLIO='25',FILE='DISK112:[15ZCH1.15ZCH40101]CO40101A.;28',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_cq40101_1_26"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial
costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and
abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to
significant civil, criminal and administrative penalties, damages, fines, exclusion from government funded healthcare programs, such as Medicare and Medicaid, disgorgement, individual imprisonment,
contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with
whom we expect to do business is found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded
healthcare programs. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending
against any such actions that may be brought against us, our business may be impaired. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes,
anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face
criminal liability and other serious consequences for violations which can harm our business.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations,
various economic and trade sanctions regulations administered by the U.S. Treasury Department's Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S.
domestic bribery statute contained in 18 U.S.C. &sect;&nbsp;201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the
countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other partners from authorizing, promising,
offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties for clinical trials outside of
the United States, to sell our products abroad once we enter a commercialization phase, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We have
direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We can be held liable for the corrupt or
other illegal activities of our employees, agents, contractors, and other partners, even if we do not explicitly authorize or have actual knowledge of such activities. Our violations of the laws and
regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract
and fraud litigation, reputational harm, and other consequences. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our employees may engage in misconduct or other improper activities, including violating applicable
regulatory standards and requirements or engaging in insider trading, which could significantly harm our business.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with the
regulations of the FDA and applicable non-U.S. regulators, provide accurate information to the FDA and applicable non-U.S. regulators, comply with healthcare fraud and abuse laws and regulations in
the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare
industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a
wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of,
including trading on, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and
deter employee misconduct, </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=28,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=502413,FOLIO='26',FILE='DISK112:[15ZCH1.15ZCH40101]CQ40101A.;38',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_cq40101_1_27"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>and
the precautions we take to detect and prevent this activity may be ineffective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other
actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our
rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, fines, exclusion from government
funded healthcare programs such as Medicare and Medicaid, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or
restructuring of our operations. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the
promotion of off-label uses. If we are found to have improperly promoted off-label uses, we may become subject to significant liability.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, such as gemcabene, if
approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product's approved labeling. If we receive
marketing approval for gemcabene or any future product candidate for a certain indication, physicians may nevertheless prescribe gemcabene or such future product candidate to their patients in a
manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The federal government has levied large civil
and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into
consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of gemcabene or any future product candidate,
if approved, we could become subject to significant liability, which would adversely affect our business and financial condition. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks Related to the Commercialization of Gemcabene or Any Future Product Candidate  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We face substantial competition, which may result in others discovering, developing or
commercializing products before or more successfully than we do.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The development and commercialization of new drug products is highly competitive. We expect to face competition with respect to gemcabene, if
approved, and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical
companies, biotechnology companies, universities and other research institutions and government agencies worldwide. The lipid-lowering therapies market is highly competitive and dynamic and dominated
by the sale of statin treatments including the cheaper generic versions of statins. Our success will depend, in part, on our ability to obtain a share of the market for our planned indications. Other
pharmaceutical companies may develop lipid-lowering therapies for the same indications that compete with gemcabene, if approved, that do not infringe the claims of our patents, pending patent
applications or other proprietary rights which could adversely affect our business and results of operations. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Lipid-lowering
therapies currently on the market that would compete with gemcabene, if approved, include the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> statins, such as Crestor marketed by AstraZeneca, Livalo marketed by Kowa
Pharmaceuticals America,&nbsp;Inc. (Kowa), Zocor marketed by Merck&nbsp;&amp;&nbsp;Co.,&nbsp;Inc. (Merck), Lipitor marketed by Pfizer, and their generic versions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  cholesterol absorption inhibitors, such as Zetia, marketed by Merck; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> apoB antisense Kynamro marketed by Genzyme Corporation, a Sanofi company, and
MTTP inhibitor Juxtapid marketed by Aegerion Pharmaceuticals,&nbsp;Inc.; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  combination therapies, such as Vytorin and Liptruzet, both marketed by Merck; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=29,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=877845,FOLIO='27',FILE='DISK112:[15ZCH1.15ZCH40101]CQ40101A.;38',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_cq40101_1_28"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> other lipid-lowering monotherapies, including: fibrates, such as TriCor and
Trilipix, both marketed by AbbVie Inc. (AbbVie), and Lipofen marketed by Kowa; niacin, such as Niaspan marketed by AbbVie; bile acid sequestrants, such as Welchol, marketed by Daiichi
Sankyo&nbsp;Inc.; combination therapies, such as Advicor and Simcor, both of which are marketed by AbbVie; and their generic version of these drugs; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  prescription fish oils, such as Lovaza marketed by GlaxoSmithKline, Epanova
marketed by AstraZeneca and Vascepa marketed by Amarin Corporation&nbsp;plc; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> PCSK9 inhibitors, such as Praluent, developed by Sanofi-Aventis U.S. LLC, and
Regeneron Pharmaceuticals, Inc. and Repatha marketed by Amgen&nbsp;Inc. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Several
other pharmaceutical companies have other lipid-lowering therapies in development that may be approved for marketing in the United States or outside of the United States. Based on publicly
available information, we believe the current therapies in development that would compete with gemcabene include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> for HoFH, MBX-8025 developed by CymaBay Therapeutics,&nbsp;Inc. and RGEN-1500
being developed by Regeneron Pharmaceuticals,&nbsp;Inc.; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> for HeFH and ASCVD, drugs include: oral cholesteryl ester transfer protein
inhibitors, such as anacetrapib being developed by Merck and TA-8995 being developed by Amgen/Dezima; ATP citrate lyase inhibitor, ETC-1002 developed by current Esperion; and PCSK9&nbsp;inhibitors,
such as ALN-PCSsc being developed by The Medicines Company and Alnylam Pharmaceuticals,&nbsp;Inc. and bococizumab being developed by Pfizer; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> for SHTG, ISIS-APOCIII antisense being developed by Ionis Pharmaceuticals, Inc.
(formerly Isis Pharmaceuticals, Inc.). </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Our
competitors may develop products that are more effective, safer, more convenient or less costly than any that we are developing or that would render our product candidates obsolete or
non-competitive. Our competitors may also render our technologies obsolete by advances in existing technological approaches or the development of new or different approaches, potentially eliminating
the advantages in our drug discovery process. Our competitors may also obtain marketing approval from the FDA or other regulatory authorities for their products more rapidly than we may obtain
approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Many
of our competitors have significantly greater name recognition, financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials,
obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being
concentrated among a smaller number of our competitors. Smaller and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large
and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for
clinical trials and entering into strategic transactions, as well as in acquiring technologies complementary to, or necessary for, our programs. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We lack experience commercializing products, which may have an adverse effect on our business.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If gemcabene or any product candidate we may pursue in the future receives marketing approval, we will need to transition from a company with a
development focus to a company capable of supporting commercial activities, and we may not be successful in making that transition. We have never filed an NDA, and have not yet demonstrated an ability
to obtain marketing approval for, or to commercialize, any product candidate. As a result, our clinical development and regulatory approval process, and our ability to successfully commercialize any
approved products, may involve more inherent risk, take longer, and cost more than it would if we were a company with experience obtaining marketing approval for and commercializing a product
candidate. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=30,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=427776,FOLIO='28',FILE='DISK112:[15ZCH1.15ZCH40101]CQ40101A.;38',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_cq40101_1_29"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we are unable to establish sales and marketing capabilities or enter into agreements with third
parties to sell and market gemcabene, if approved, or any other product candidate we may pursue, we may not be successful in commercializing such product candidate if and when approved.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We do not have a global sales or marketing infrastructure and have no capabilities in place at the present time for the sale, marketing or
distribution of pharmaceutical products. To achieve commercial success for any approved product for which we retain sales and marketing responsibilities, we must either develop a sales and marketing
organization or outsource part or all of these functions to other third parties. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>There
are risks involved with both establishing our own sales and marketing capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and
training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing
capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if
we cannot retain or reposition our sales and marketing personnel. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Factors
that may inhibit our efforts to commercialize gemcabene or any future product candidate on our own include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our inability to recruit and retain adequate numbers of effective sales and
marketing personnel; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the inability of sales personnel to obtain access to physicians or persuade
adequate numbers of physicians to prescribe our product candidate; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the lack of complementary products to be offered by sales personnel, which may
put us at a competitive disadvantage relative to companies with more extensive product lines; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  unforeseen costs and expenses associated with creating an independent sales and
marketing organization; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> inability to obtain sufficient coverage and reimbursement from third-party
payors and governmental agencies. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>If
we enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenues or the profitability of these product revenues to us are likely to be lower
than if we were to market and sell a product that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market any product candidate
or may be unable to do so on terms that are favorable to us. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to
sell and market a drug effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in
commercializing gemcabene or any future product candidate. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if gemcabene or any future product candidate receives marketing approval, it may fail to
achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Even if gemcabene or any future product candidate receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by
physicians, patients, healthcare payors and others in the medical community. If such product candidate does not achieve an adequate level of acceptance, we may not generate significant product
revenues and we may not become profitable. The degree of market acceptance of a product candidate, if approved for commercial sale, will depend on a number of factors,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> efficacy and potential advantages compared to alternative treatments; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the ability to offer our product for sale at competitive prices; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the willingness of the target patient population to try new therapies and of
physicians to prescribe these therapies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> any restrictions on the use of our product together with other medications; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  interactions of our product with other medicines patients are taking; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=31,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=542553,FOLIO='29',FILE='DISK112:[15ZCH1.15ZCH40101]CQ40101A.;38',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_cq40101_1_30"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> inability of certain types of patients to take our product; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  demonstrated ability to treat patients and, if required by any applicable
regulatory authority in connection with the approval for target indications, to provide patients with incremental cardiovascular disease benefits, as compared with other available therapies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the relative convenience and ease of administration of gemcabene, including as
compared with other treatments available for approved indications; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the prevalence and severity of any adverse side effects; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  limitations or warnings contained in the labeling approved by the FDA; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  availability of alternative treatments already approved or expected to be
commercially launched in the near future; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the effectiveness of our sales and marketing strategies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to increase awareness through marketing efforts; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  guidelines and recommendations of organizations involved in research, treatment
and prevention of various diseases that may advocate for alternative therapies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to obtain sufficient third-party coverage and adequate
reimbursement; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the willingness of patients to pay out-of-pocket in the absence of third-party
coverage; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  physicians or patients may be reluctant to switch from existing therapies even
if potentially more effective, safe or convenient. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If the FDA or a comparable foreign regulatory authority approves generic versions of gemcabene or
any future product candidates that receive marketing approval, or such authorities do not grant our product candidates appropriate periods of data exclusivity before approving generic versions of our
products, the sales of our products could be adversely affected.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Once an NDA is approved, the product covered thereby becomes a "reference listed drug" in the FDA's publication, "Approved Drug Products with
Therapeutic Equivalence Evaluations." Manufacturers may seek approval of generic versions of reference listed drugs through submission of abbreviated new drug applications (ANDAs) in the United
States. In support of an ANDA, a generic manufacturer need not conduct clinical studies. Rather, the applicant generally must show that its product has the same active ingredient(s), dosage form,
strength, route of administration and conditions of use or labeling as the reference listed drug and that the generic version is bioequivalent to the reference listed drug, meaning it is absorbed in
the body at the same rate and to the same extent. Generic products may be significantly less costly to bring to market than the reference listed drug and companies that produce generic products are
generally able to offer them at lower prices. Thus, following the introduction of a generic drug, a significant percentage of the sales of any branded product or reference listed drug may be typically
lost to the generic product. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
FDA may not approve an ANDA for a generic product until any applicable period of non-patent exclusivity for the reference listed drug has expired. The FDC Act provides a period of five years of
non-patent exclusivity for a new drug containing a new chemical entity (NCE). Specifically, in cases where such exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration
of five years unless the submission is accompanied by a Paragraph&nbsp;IV certification that a patent covering the reference listed drug is either invalid or will not be infringed by the generic
product, in which case the applicant may submit its application four years following approval of the reference listed drug. It is unclear whether the FDA will treat the active ingredients in our
product
candidates as NCEs and, therefore, afford them five years of NCE data exclusivity if they are approved. If any product we develop does not receive five years of NCE exclusivity, it may nonetheless be
eligible for three years of exclusivity, which means that the FDA may approve generic versions of such product three years after its date of approval. Manufacturers may seek to launch these generic
products following the expiration of the applicable marketing exclusivity period, even if we still have patent protection for our product. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=32,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=168256,FOLIO='30',FILE='DISK112:[15ZCH1.15ZCH40101]CQ40101A.;38',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_cq40101_1_31"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Competition
that gemcabene or any future product candidates may face from generic versions of our products could materially and adversely impact our future revenue, profitability and cash flows and
substantially limit our ability to obtain a return on the investments we have made in any such product candidate. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if we are able to commercialize gemcabene or any future product candidate, the profitability of
such product candidate will likely depend in significant part on third-party reimbursement practices, which, if unfavorable, would harm our business.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our ability to commercialize a drug successfully will depend in part on the extent to which coverage and adequate reimbursement will be available from
government health administration authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance
organizations, decide which medications they will pay for and establish reimbursement levels. Government authorities and third-party payors have attempted to control costs by limiting coverage and the
amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging
the prices charged for medical products. We cannot be sure that coverage will be available for any product candidate that we commercialize and, if coverage is available, whether the level of
reimbursement will be adequate. Assuming we obtain coverage for gemcabene, if approved, by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments
that patients find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse
all or part of the costs associated with their prescription drugs. Patients are unlikely to use a product candidate, if approved, unless coverage is provided and reimbursement is adequate to cover all
or a significant portion of the cost of our products. Therefore, coverage and adequate reimbursement is critical to new product acceptance. If reimbursement is not available or is available only to
limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>There
may be significant delays in obtaining reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which a product candidate is approved by the FDA or similar
regulatory authorities outside the United States. Moreover, eligibility for reimbursement does not imply that any product will be paid for in all cases or at a rate that covers our costs, including
research, development, manufacture, sale and distribution. Interim reimbursement levels for a new product, if applicable, may also not be sufficient to cover our
costs and may not be made permanent. Reimbursement rates may vary according to the use of the product and the clinical setting in which it is used, may be based on reimbursement levels already set for
lower cost medicines and may be incorporated into existing payments for other services. Net prices for products may be reduced by mandatory discounts or rebates required by government healthcare
programs or private payors and by any future relaxation of laws that presently restrict imports of medicines from countries where they may be sold at lower prices than in the United States.
Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. However, no uniform policy requirement for coverage and reimbursement
for drug products exists among third-party payors in the United States. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage
determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no
assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved products that we develop could have an adverse effect on our
operating results, our ability to raise capital needed to commercialize products and our overall financial condition. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=33,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=973138,FOLIO='31',FILE='DISK112:[15ZCH1.15ZCH40101]CQ40101A.;38',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_cq40101_1_32"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Product liability lawsuits against us could cause us to incur substantial liabilities and could
limit commercialization of any product candidate that we may develop.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We face an inherent risk of product liability exposure related to the testing of our product candidate in human clinical trials and will face an even
greater risk if we commercially sell any products that we may develop. Product liability claims might be brought against us by patients, healthcare providers or others selling or otherwise coming into
contact with gemcabene or any future product candidate during product testing, manufacturing, marketing or sale. For example, we may be sued on allegations that a product candidate caused injury or
that the product is otherwise unsuitable. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the
product, including as a result of interactions with alcohol or other drugs, negligence, strict liability, and a breach of warranties. Claims could also be asserted under state consumer protection
acts. If we cannot successfully defend ourselves against claims that our product candidate caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability
claims may result in:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  decreased demand for any product candidate that we are developing; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> injury to our reputation and significant negative media attention; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  withdrawal of clinical trial participants; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  increased FDA warnings on product labels; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  significant costs to defend the related litigation; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  substantial monetary awards to trial participants or patients; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  distraction of management's attention from our primary business; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> loss of revenue; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the inability to commercialize any product candidate that we may develop. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>We
do not yet have product liability or clinical trial insurance coverage, and any coverage that we do obtain may not be adequate to cover all liabilities that we may incur. We may need to increase
our insurance coverage as we expand clinical trials and if we successfully commercialize gemcabene or any other product candidate we may pursue in the future. Insurance coverage is increasingly
expensive, and we may not be able to obtain product liability insurance on commercially reasonable terms or in an amount adequate to satisfy any liability that may arise. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we or our third-party manufacturers fail to comply with environmental, health and safety laws and
regulations, we could become subject to fines or penalties or incur costs that could have an adverse effect on the success of our business.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our research and development activities involve the controlled use of potentially hazardous substances, including chemical and biological materials,
by ourselves and our third-party manufacturers. Our manufacturers are subject to federal, state and local laws and regulations in the United States and abroad governing laboratory procedures and the
use, manufacture, storage, handling and disposal of medical and hazardous materials. Although we believe that our manufacturers' procedures for using, handling, storing and disposing of these
materials comply with legally prescribed standards, we cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such
contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident,
we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from medical or hazardous materials.
Although we maintain workers' compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may
not provide adequate coverage against potential liabilities. Compliance with applicable environmental, health and safety laws and regulations is expensive, and current or future environmental
regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=34,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=52306,FOLIO='32',FILE='DISK112:[15ZCH1.15ZCH40101]CQ40101A.;38',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_cs40101_1_33"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Federal legislation and actions by state and local governments may permit reimportation of drugs
from foreign countries into the United States, including foreign countries where the drugs are sold at lower prices than in the United States, which could adversely affect our operating results.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We may face competition for gemcabene, if approved, from cheaper lipid-lowering therapies sourced from foreign countries that have placed price
controls on pharmaceutical products. The Medicare Modernization Act contains provisions that may change U.S. importation laws and expand pharmacists' and wholesalers' ability to import cheaper
versions of an approved drug and competing products from Canada, where there are government price controls. These changes to U.S. importation laws will not take effect unless and until the Secretary
of Health and Human Services certifies that the changes will pose no additional risk to the public's health and safety and will result in a significant reduction in the cost of products to consumers.
The Secretary of Health and Human Services has so far declined to approve a reimportation plan. Proponents of drug reimportation may attempt to pass legislation that would directly allow reimportation
under certain circumstances. Legislation or regulations allowing the reimportation of drugs, if enacted, could decrease the price we receive for any product we may develop and adversely affect our
future revenues and prospects for profitability. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks Related to our Dependence on Third Parties  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We will be unable to directly control all aspects of our clinical trials due to our reliance on
clinical research organizations (CROs) and other third parties that assist us in conducting clinical trials.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We will rely on CROs to conduct our preclinical studies and clinical trials for any product candidate, including our Phase&nbsp;2b and
Phase&nbsp;3 trials for gemcabene. As a result, we will have limited control over the conduct, timing and completion of these clinical trials and the management of data developed through the
clinical trials. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties
may:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> have staffing difficulties; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> fail to comply with contractual obligations; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  experience regulatory compliance issues; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> undergo changes in priorities or become financially distressed; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> form relationships with other entities, some of which may be our competitors. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>These
factors may adversely affect the willingness or ability of third parties to conduct our clinical trials and may subject us to unexpected cost increases that are beyond our control. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Moreover,
the FDA requires us to comply with standards, commonly referred to as good clinical practices, for conducting, recording, and reporting the results of clinical trials to assure that data and
reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. Our reliance on third parties that we do not control does
not relieve us of these responsibilities and requirements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Problems
with the timeliness or quality of the work of any CRO may lead us to seek to terminate our relationship with any such CRO and use an alternative service provider. Making this change may be
costly and may delay our clinical trials, and contractual restrictions may make such a change difficult or impossible to effect. If we must replace any CRO that is conducting our clinical trials, our
clinical trials may have to be suspended until we find another CRO that offers comparable services. The time that it takes us to find alternative organizations may cause a delay in the
commercialization of gemcabene or may cause us to incur significant expenses to replicate data that may be lost. Although we do not believe that any CRO on which we may rely will offer services that
are not available elsewhere, it may be difficult to find a replacement organization that can conduct our clinical trials in an acceptable manner and at an acceptable cost. Any delay in or inability to
complete our clinical trials could significantly compromise our ability to </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=35,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=663543,FOLIO='33',FILE='DISK112:[15ZCH1.15ZCH40101]CS40101A.;54',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_cs40101_1_34"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>secure
regulatory approval of gemcabene and preclude our ability to commercialize gemcabene, thereby limiting or preventing our ability to generate revenue from its sales. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We rely completely on third parties to supply and manufacture our preclinical and clinical drug
supplies for gemcabene, and we intend to rely on third parties to produce commercial supplies of gemcabene and preclinical, clinical and commercial supplies of any future product candidate.  </I></B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We do not currently have, nor do we plan to acquire, the infrastructure or capability to internally manufacture our clinical drug supply of gemcabene,
or any future product candidates, for use in the conduct of our preclinical studies and clinical trials, and we lack the internal resources and the capability to manufacture any product candidates on
a clinical or commercial scale. The process of manufacturing drug
products is complex, highly regulated and subject to several risks. For example, the facilities used by our contract manufacturers to manufacture the active pharmaceutical ingredient (or drug
substance) and final drug product for gemcabene, or any future product candidates, must be inspected by the FDA and other comparable foreign regulatory agencies in connection with our submission of an
NDA or relevant foreign regulatory submission to the applicable regulatory agency. In addition, the manufacturing of drug substance or product is susceptible to product loss due to contamination,
equipment failure, improper installation or operation of equipment, or vendor or operator error. Moreover, the manufacturing facilities in which gemcabene or any future product candidates are made
could be adversely affected by equipment failures, labor shortages, natural disasters, power failures or other factors. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
do not control the manufacturing process of, and are completely dependent on, our contract manufacturers to comply with current good manufacturing practices (cGMP) for manufacture of both active
drug substances and finished drug products. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA
or applicable foreign regulatory agencies, we will not be able to secure and/or maintain regulatory approval for our products. In addition, we have no direct control over our contract manufacturers'
ability to maintain adequate quality control, quality assurance and qualified personnel. Failure to satisfy the regulatory requirements for the production of those materials and products may affect
the regulatory clearance of our contract manufacturers' facilities generally. If the FDA or a comparable foreign regulatory agency does not approve these facilities for the manufacture of gemcabene or
any future product candidates, or if it withdraws its approval in the future, we may need to find alternative manufacturing facilities, which would adversely impact our ability to develop, obtain
regulatory approval for or market gemcabene or such future product candidates. Furthermore, all of our contract manufacturers are engaged with other companies to supply and/or manufacture materials or
products for such companies, which exposes our manufacturers to regulatory and sourcing risks for the production of such materials and products. To the extent practicable, we attempt to identify more
than one supplier, but some raw materials are available only from a single source or only one supplier has been identified, even in instances where multiple sources exist. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have relied upon third-party manufacturers for the manufacture of our product candidate for preclinical and clinical testing purposes and intend to continue to do so in the future, including for
commercial purposes. If our third party manufacturers are unable to supply drug substance and/or drug product on a commercial basis, we may not be able to successfully produce and market gemcabene, if
approved, or could be delayed in doing so. For instance, we rely on one supplier for the drug substance for gemcabene. The manufacturer of the drug substance for gemcabene is in the process of
manufacturing batches of the drug substance that will serve as the validation batches that will be reviewed by the FDA in connection with its review of the NDA for gemcabene and as the supply of
gemcabene, if approved and successfully launched commercially. If there is any delay or problem with the manufacture of these batches of drug substance or if there is a delay in producing finished
product from these batches, the approval of gemcabene may be delayed or any potential launch of gemcabene may be adversely affected. We will rely on comparison of product specifications (identity,
strength, quality, potency) to demonstrate equivalence of the current drug substance and/or drug product to the drug substance and/or drug product used in previously completed </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>34</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=36,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=798920,FOLIO='34',FILE='DISK112:[15ZCH1.15ZCH40101]CS40101A.;54',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_cs40101_1_35"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>preclinical
and clinical testing. If we are unable to demonstrate such equivalence, we may be required to conduct additional preclinical and/or clinical testing of our product candidate. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>These
and other problems with any manufacturer may lead us to seek to terminate our relationship with any such manufacturer and use an alternative manufacturer. Making this change may be costly, time
consuming and difficult to effectuate, and may delay our research and development activities. If we must replace any manufacturer, our research and development activities may have to be suspended
until we find another manufacturer that offers comparable services. The time that it takes us to find alternative organizations may cause a delay in the development and commercialization of gemcabene
or any future product candidate. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may form or seek strategic alliances or enter into additional licensing arrangements in the
future, and we may not realize the benefits of such alliances or licensing arrangements.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We may form or seek strategic alliances, create joint ventures or collaborations or enter into additional licensing arrangements with third parties
that we believe will complement or augment our development and commercialization efforts with respect to gemcabene and any future product candidates that we may develop. Any of these relationships may
require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. Our
likely collaborators include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. If we enter into any such arrangements with any
third parties, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of gemcabene or any future product
candidate. Our ability to generate revenues from these arrangements will depend on our collaborators' abilities to successfully perform the functions assigned to them in these arrangements. We cannot
be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Collaborations
involving gemcabene or any future product candidate pose the following risks to us:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  collaborators have significant discretion in determining the efforts and
resources that they will apply to these collaborations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  collaborators may not perform their obligations as expected; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  collaborators may not pursue development and commercialization or may elect not
to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator's strategic focus or available funding or external factors such as an
acquisition that diverts resources or creates competing priorities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  collaborators may delay clinical trials, provide insufficient funding for a
clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  collaborators could independently develop, or develop with third parties,
products that compete directly or indirectly with our product candidate if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized
under terms that are more economically attractive than ours; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a collaborator with marketing and distribution rights to one or more product
candidates may not commit sufficient resources to the marketing and distribution of any such product candidate; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  collaborators may not properly maintain or defend our intellectual property
rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  collaborators may infringe the intellectual property rights of third parties,
which may expose us to litigation and potential liability; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>35</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=37,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=817707,FOLIO='35',FILE='DISK112:[15ZCH1.15ZCH40101]CS40101A.;54',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_cs40101_1_36"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> disputes may arise between the collaborators and us that result in the delay or
termination of the research, development or commercialization of our product candidate or that result in costly litigation or arbitration that diverts management attention and resources; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we may lose certain valuable rights under circumstances identified in our
collaborations, including if we undergo a change of control; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  collaborations may be terminated and, if terminated, may result in a need for
additional capital to pursue further development or commercialization of the applicable product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  collaborators may learn about our discoveries and use this knowledge to compete
with us in the future; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the results of collaborators' preclinical or clinical studies could harm or
impair other development programs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> there may be conflicts between different collaborators that could negatively
affect those collaborations and potentially others; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the number and type of our collaborations could adversely affect our
attractiveness to future collaborators or acquirers; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  collaboration agreements may not lead to development or commercialization of
our product candidate in the most efficient manner or at all. If a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our
product development or commercialization program under such collaboration could be delayed, diminished or terminated; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  collaborators may be unable to obtain the necessary marketing approvals. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>If
future collaboration partners fail to develop or effectively commercialize gemcabene or any future product candidate for any of these reasons, such product candidate may not be approved for sale
and our sales of such product candidate, if approved, may be limited, which would have an adverse effect on our operating results and financial condition. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we are not able to establish new collaborations on commercially reasonable terms, we may have to
alter our development and commercialization plans.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We face significant competition in attracting collaborators. Whether we reach a definitive agreement for collaboration will depend, among other
things, upon our assessment of the collaborator's resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator's evaluation of a number of factors
related to the associated product candidate. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the
United States, the potential market for the product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the
existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market
conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration
could be more attractive than the one with us. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Much
of the potential revenue from future collaborations may consist of contingent payments, such as payments for achieving regulatory milestones or royalties payable on sales of our product
candidate, if approved. The milestone and royalty revenue that we may receive under these collaborations will depend upon our collaborators' ability to successfully develop, introduce, market and sell
new our product candidate, if approved. In addition, collaborators may decide to enter into arrangements with third parties to commercialize products developed under collaborations related to our
product candidate, which could reduce the milestone and royalty revenue received, if any. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>36</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=38,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=1012494,FOLIO='36',FILE='DISK112:[15ZCH1.15ZCH40101]CS40101A.;54',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_cs40101_1_37"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
may also be restricted under existing collaboration agreements from entering into future agreements on certain terms with potential collaborators. Collaborations are complex and time-consuming to
negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential
future collaborators. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which
we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or
marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or
commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be
able to further develop our product candidate or bring it to market and generate product revenue. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks Related to our Intellectual Property  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we are unable to adequately protect our proprietary technology or maintain issued patents
sufficient to protect gemcabene or any future product candidate, others could compete against us more directly, which would have an adverse impact on our business, results of operations, financial
condition and prospects.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our commercial success will depend in part on our success obtaining and maintaining issued patents and other intellectual property rights in the
United States and elsewhere and protecting our proprietary technology. If we do not adequately protect our intellectual property and proprietary technology, competitors may be able to use our
technologies and erode or negate any competitive advantage we may have, which could harm our business and ability to achieve profitability. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
licensed patents relating to our current product candidate, gemcabene, from Pfizer. Pursuant to the license agreement, we are responsible for filing, prosecuting and maintaining the patent rights
in Pfizer's name at our own cost and expense. In connection with this obligation, we are granted the first right to control the enforcement of the license patents against any third-party infringement
actions. Risks related to our Pfizer license are discussed elsewhere in this "Risk Factors" section under "</FONT><FONT SIZE=2><I>We depend on intellectual property licensed from Pfizer for gemcabene,
and the termination of this license would harm our business.</I></FONT><FONT SIZE=2>" The termination of this license could result in the loss of significant rights, which would harm our business. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
of May&nbsp;2, 2016, our patent estate, including patents we own or license from third parties, on a worldwide basis, included four issued U.S. patents and eight pending U.S. patent applications
and 23 issued patents in foreign jurisdictions including Canada, France, Germany, Great Britain, Ireland, Italy, Mexico and Spain and 15 pending patent applications in foreign jurisdictions including
Australia, Canada, China, Europe, Hong Kong, Japan and Mexico. Our worldwide patents and pending applications all relate to our product candidate, gemcabene. Our patents claiming the gemcabene
composition of matter generically, which were in-licensed from Pfizer, have all expired; however, our clinical formulation comprises a specific calcium salt crystal form of gemcabene, which form is
claimed in U.S. Patent Number&nbsp;6,861,555. This patent, which was in-licensed from Pfizer, is expected to expire in 2021, and may be eligible for a patent term extension period of up to five
years. Our current patent estate includes four patent families that have claims directed to methods of treatment using gemcabene. These patent families include, for example, U.S. Patent Number
8,557,835, licensed from Pfizer that has claims directed to using a statin-gemcabene combination for treating hyperlipidemia, angina pectoris and atherosclerosis. U.S. Patent Number 8,557,835 is
expected to expire in 2021, absent any patent term extension, and corresponding foreign patents are expected to expire in 2018, absent any adjustment or extension. Additionally, U.S. Patent
Number&nbsp;8,846,761 and U.S. Patent Application Number&nbsp;14/370,722, are owned by us. U.S. patent number&nbsp;8,846,761 is directed to methods of decreasing a subject's risk for developing
pancreatitis by
administering gemcabene and is expected to expire in 2032, absent any patent term extension. Any foreign patent in this family that may issue is expected to expire in 2031, absent any patent term
extension. U.S. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>37</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=39,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=945234,FOLIO='37',FILE='DISK112:[15ZCH1.15ZCH40101]CS40101A.;54',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_cs40101_1_38"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Patent
Application Number&nbsp;14/370,722, is directed to methods of decreasing a patient's risk for developing coronary heart disease or preventing, delaying or reducing the severity of a secondary
cardiovascular event by administering gemcabene with a statin. Related patent applications are pending in foreign jurisdictions including Australia, Canada, China, Europe, Japan and Mexico. Any patent
that may issue in this family, absent any patent term adjustment or extension, is expected to expire in 2033. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
2015, we filed two new provisional patent applications, one for methods of treatment of mixed dyslipidemia using gemcabene in combination with statins and treatment of NASH using gemcabene as
monotherapy (U.S. Provisional Patent Application&nbsp;Number&nbsp;62/252,195), and the other relating to fixed dose combinations and modified release formulations of gemcabene and statins (U.S.
Provisional Patent Application&nbsp;Number&nbsp;62/252,147), as well as two non-provisional patent applications on methods of large scale manufacturing for making dicarboxyalkyl ethers (US
Application&nbsp;Number&nbsp;14/942,765 and corresponding PCT application Number&nbsp;PCT/US2015/060917). The two provisional applications, if issued, are expected to expire in 2036. The two
non-provisional applications, if issued, are expected to expire in 2035. As of May&nbsp;2, 2016, we filed four new provisional patent applications: U.S. Provisional Patent Application
Numbers&nbsp;62/295,292, 62/300,393, 63/30,0415 and 62/314,597. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
patent prosecution process is expensive and time-consuming, and we and our current or future licensors, licensees or collaboration partners may not be able to prepare, file and prosecute all
necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we or our licensors will fail to identify patentable aspects of inventions made in the
course of development and commercialization activities before it is too late to obtain patent protection on them. Our and our licensors' patent applications cannot be enforced against third parties
practicing the technology claimed in such applications unless and until a patent issues from such applications, and then only to the extent the issued claims cover the technology. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
cannot assure you that any of our patents have, or that any of our pending patent applications will mature into issued patents that will include, claims with a scope sufficient to protect gemcabene
or any future product candidate. Others have developed technologies that may be related or competitive to our approach, and may have filed or may file patent applications and may have received or may
receive patents that overlap or conflict with our patent applications, either by claiming the same methods or formulations or by claiming subject matter that could dominate our patent position. The
patent positions of biotechnology and pharmaceutical companies, including our patent position, involve complex legal and factual questions, and, therefore, the issuance, scope, validity and
enforceability of any patent claims that we may obtain cannot be predicted with certainty. Patents, if issued, may be challenged, deemed unenforceable, invalidated, or circumvented. U.S. patents and
patent applications may also be subject to interference proceedings, </FONT><FONT SIZE=2><I>ex parte</I></FONT><FONT SIZE=2> reexamination, or </FONT><FONT SIZE=2><I>inter partes</I></FONT><FONT SIZE=2>
review proceedings, supplemental examination and challenges in district court. Patents may be subjected to opposition, post-grant review, or comparable proceedings lodged in various national and
regional patent offices. These
proceedings could result in either loss of the patent or denial of the patent application or loss or reduction in the scope of one or more of the claims of the patent or patent application. In
addition, such interference, re-examination, opposition, post-grant review, </FONT><FONT SIZE=2><I>inter partes</I></FONT><FONT SIZE=2> review, supplemental examination or revocation proceedings may be
costly. Thus, any patents that we may own or exclusively license may not provide any protection against competitors. Furthermore, an adverse decision in an interference proceeding can result in a
third-party receiving the patent right sought by us, which in turn could affect our ability to develop, market or otherwise commercialize gemcabene. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Furthermore,
the issuance of a patent, while presumed valid, is not conclusive as to its validity or its enforceability and it may not provide us with adequate proprietary protection or competitive
advantages against competitors with similar products. Competitors may also be able to design around our patents. Other parties may develop and obtain patent protection for more effective technologies,
designs or methods. We may not be able to prevent the unauthorized disclosure or use of any technical knowledge or trade secrets by consultants, vendors, former employees and current employees. The
laws of some foreign countries do </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>38</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=40,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=680803,FOLIO='38',FILE='DISK112:[15ZCH1.15ZCH40101]CS40101A.;54',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_cs40101_1_39"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>not
protect our proprietary rights to the same extent as the laws of the United States, and we may encounter significant problems in protecting our proprietary rights in these countries. If these
developments were to occur, they could have a material adverse effect on our sales. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
ability to enforce our patent rights depends on our ability to detect infringement. It is difficult to detect infringers who do not advertise the components that are used in their products.
Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor's or potential competitor's product. Any litigation to enforce or defend our patent rights, if any, even
if we were to prevail, could be costly and time-consuming and would divert the attention of our management and key personnel from our business operations. We may not prevail in any lawsuits that we
initiate and the damages or other remedies awarded if we were to prevail may not be commercially meaningful. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
addition, proceedings to enforce or defend our patents could put our patents at risk of being invalidated, held unenforceable, or interpreted narrowly. Such proceedings could also provoke third
parties to assert claims against us, including that some or all of the claims in one or more of our patents are invalid or otherwise unenforceable. If, in any proceeding, a court invalidated or found
unenforceable our patents covering gemcabene or any future product candidate, our financial position and results of operations would be adversely impacted. In addition, if a court found that valid,
enforceable patents held by third parties covered gemcabene or any future product candidate, our financial position and results of operations would also be adversely impacted. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> any of our patents, or any of our pending patent applications, if issued, will
include claims having a scope sufficient to protect gemcabene; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> any of our pending patent applications will result in issued patents; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we will be able to successfully commercialize gemcabene or any future product
candidate, if approved, before our relevant patents expire; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we were the first to make the inventions covered by each of our patents and
pending patent applications; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we were the first to file patent applications for these inventions; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> others will not develop similar or alternative technologies that do not infringe
our patents; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> any of our patents will be valid and enforceable; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> any patents issued to us will provide a basis for an exclusive market for our
commercially viable products, will provide us with any competitive advantages or will not be challenged by third parties; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we will develop additional proprietary technologies or product candidates that
are separately patentable; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> that our commercial activities or products will not infringe upon the patents of
others. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Patents
have a limited lifespan. The natural expiration of a patent is generally 20&nbsp;years after its effective filing date. Various extensions may be available; however, the life of a patent,
and the protection it affords, is limited. Given the extensive period of time between patent filing and regulatory approval for a product candidate, the time during which we can market a product
candidate under patent protection is limited, and our patent may expire before we obtain such approval. Without patent protection for gemcabene or any future product candidates, we may be open to
competition from generic versions of our product candidates, which may affect the profitability of our product candidates. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>39</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=41,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=388511,FOLIO='39',FILE='DISK112:[15ZCH1.15ZCH40101]CS40101A.;54',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_cs40101_1_40"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we do not obtain protection under the Hatch-Waxman Act and similar foreign legislation by
extending the patent terms and obtaining data exclusivity for our product candidate, our business may be materially harmed.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Depending upon the timing, duration of regulatory review, and date of FDA marketing approval of gemcabene or any future product candidate, if any, one
of our U.S. patents may be eligible for patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Act. The Hatch-Waxman Act
provides for a patent restoration term of up to five years as compensation for the time the product is under FDA regulatory review (patent term extension). The duration of patent term extension is
calculated based on the time spent in the regulatory review process. Our basic U.S. composition of matter patent for gemcabene has expired. We plan to seek patent term extension for one of our patents
related to gemcabene. However, we may not be granted an extension because of, for example, failing to
apply within the applicable deadline, expiration of relevant patents prior to obtaining approval, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the
scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, our revenue could be
reduced, possibly materially. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, we believe that gemcabene is a NCE in the United States and may be eligible for data exclusivity under the Hatch-Waxman Act. A single-ingredient drug can be classified as a NCE if the FDA
has not previously approved any other new drug containing the same active ingredient. Under sections&nbsp;505(c)(3)(E)(ii) and 505(j)(5)(F)(ii) of the FDC Act, as amended, a NCE that is granted
marketing approval may, even in the absence of patent protections, be eligible for five years of data exclusivity in the United States following marketing approval. During the data exclusivity period,
if granted, the FDA is precluded from approving 505(b)(2) applications or abbreviated new drug applications submitted by another company that references the FDA's findings of safety and efficacy for
the approved NDA. In the European Union, NCEs qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity. This data exclusivity, if
granted, prevents regulatory authorities in the European Union from reviewing a generic application for eight years, after which generic marketing authorization can be approved but the generic drug
may not be marketed during the two-year marketing exclusivity period. However, gemcabene may not be considered to be a NCE for these purposes or be entitled to the period of data exclusivity. If we
are not able to gain or exploit the period of data exclusivity, we may face significant competitive threats to our commercialization of gemcabene from other manufacturers, including the manufacturers
of generic alternatives. Further, even if our compound is considered to be a NCE and we are able to gain the prescribed period of data exclusivity, another company nevertheless could gain marketing
approval for the same compound if they independently generate preclinical and clinical data and get market approval through the NDA process without benefit of our data. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we fail to maintain orphan drug exclusivity for gemcabene for HoFH, we will have to rely on data
and marketing exclusivity for HoFH that is not based on an orphan drug designation, if any, and on our intellectual property rights.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As part of our business strategy, in the United States we have obtained orphan drug designation for gemcabene for the treatment of HoFH. We intend to
submit an application to the FDA for orphan drug designation for gemcabene for the treatment of severe hypertriglyceridemia above 750 mg/dL. Under the Orphan Drug Act, the FDA may designate a product
as an orphan drug if it is a drug intended to treat a rare disease or condition, defined, in part, as a patient population of fewer than 200,000 in the United States. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
the United States, the company that first obtains FDA approval for a designated orphan drug for the specified rare disease or condition receives orphan drug marketing exclusivity for that drug for
a period of seven years. This orphan drug exclusivity prevents the FDA from approving another application, including a full NDA, to market the same drug for the same orphan indication, except in very
limited circumstances. For purposes of small molecule drugs, the FDA defines "same drug" as a drug that contains the same active pharmaceutical ingredient (API) and is intended for the same use as the
drug in question. A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In
addition, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines
that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>40</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=42,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=468103,FOLIO='40',FILE='DISK112:[15ZCH1.15ZCH40101]CS40101A.;54',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_cu40101_1_41"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The EMA grants orphan drug designation to promote the development of products that may offer therapeutic benefits for life-threatening or chronically debilitating conditions
affecting not more than five in 10,000 people in the European Union. Orphan drug designation from the EMA provides ten years of marketing exclusivity following drug approval, subject to reduction to
six years if the designation criteria are no longer met. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Even
if we are able to obtain and maintain orphan drug exclusivity for gemcabene for HoFH, the designation may not effectively protect it from competition for HoFH because different drugs can be
approved for the same condition. Moreover, even with an orphan drug designation, the FDA can subsequently approve a different formulation of the same API for the same condition if the FDA concludes
that the later formulation of the API is safer, more effective or makes a major contribution to patient care. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our
ability to protect gemcabene and any product candidate we may pursue in the future.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In 2011, the United States enacted wide-ranging patent reform legislation with the America Invents Act (AIA). </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>An
important change introduced by the AIA is that, as of March&nbsp;16, 2013, the United States transitioned to a "first-to-file" system for deciding which party should be granted a patent when two
or more patent applications are filed by different parties claiming the same invention. A third party that files&nbsp;a patent application in the U.S. Patent and Trademark Office (USPTO) after that
date but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by the third party. This will require us to be cognizant going
forward of the time from invention to filing of a patent application, but circumstances could prevent us from promptly filing patent applications on our inventions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Among
some of the other changes introduced by the AIA are changes that limit where a patentee may file&nbsp;a patent infringement suit and providing opportunities for third parties to challenge any
issued patent in the USPTO. This applies to all of our U.S. patents, even those issued before March&nbsp;16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the
evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim
invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to
invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. The AIA and its implementation could increase the
uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Additionally,
the U.S. Supreme Court has ruled on several patent cases in recent years, such as </FONT><FONT SIZE=2><I>Association for Molecular Pathology v. Myriad Genetics,&nbsp;Inc.
(Myriad&nbsp;I)</I></FONT><FONT SIZE=2>, </FONT><FONT SIZE=2><I>Mayo Collaborative Services v. Prometheus Laboratories,&nbsp;Inc.</I></FONT><FONT SIZE=2> and </FONT><FONT SIZE=2><I>Alice Coropration
Pty.&nbsp;Ltd. v. CLS Bank International</I></FONT><FONT SIZE=2>, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in
certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of
patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken
our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may not be able to protect or practice our intellectual property rights throughout the world.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In jurisdictions where we have not obtained patent protection, competitors may use our intellectual property to develop their own products and
further, may export otherwise infringing products to territories where we </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>41</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=43,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=539114,FOLIO='41',FILE='DISK112:[15ZCH1.15ZCH40101]CU40101A.;26',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_cu40101_1_42"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>have
patent protection, but where it is more difficult to enforce a patent as compared to the U.S. Competitor products may compete with gemcabene, if approved, or any future product candidate in
jurisdictions where we do not have issued or granted patents or where our issued or granted patent claims or other intellectual property rights are not sufficient to prevent competitor activities in
these jurisdictions. The legal systems of certain countries, particularly certain developing countries, make it difficult to enforce patents and such countries may not recognize other types of
intellectual property protection, particularly that relating to pharmaceuticals. This could make it difficult for us to prevent the infringement of our patents or marketing of competing products in
violation of our proprietary rights generally in certain jurisdictions. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and
attention from other aspects of our business. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws in the United States, and many companies have encountered significant difficulties in
protecting and defending such rights in such jurisdictions. If we, or our licensors, encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual
property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition from others in those jurisdictions. Many countries
have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government
agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we, or any of our licensors, are forced
to grant a license to third parties with respect to any patents relevant to our business, our competitive position in the relevant jurisdiction may be impaired and our business and results of
operations may be adversely affected. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may become involved in lawsuits to protect or enforce our patents and other intellectual property
rights, which could be expensive, time consuming and unsuccessful.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Competitors may infringe our patents and other intellectual property rights. To counter infringement or unauthorized use, we may be required to file
infringement claims, which can be expensive and time consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, or may refuse to stop
the other party from using the technology on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents
at risk of being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that
some of our confidential information could be compromised by disclosure during this type of litigation. Moreover, there can be no assurance that we will have sufficient financial or other resources to
file and pursue such infringement claims, which typically last for years before they are concluded. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Litigation
proceedings may fail and, even if successful, may result in substantial costs and distraction of our management and other employees. We may not be able to prevent, alone or with our
collaborators,
misappropriation of our proprietary rights, particularly in countries where the laws may not protect those rights as fully as in the United States. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be
negative, it could have a substantial adverse effect on the price of our common stock. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Third parties may initiate legal proceedings alleging that we are infringing their intellectual
property rights, the outcome of which would be uncertain and could have an adverse effect on the success of our business.  </I></B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell gemcabene and any other
product candidate we may pursue in the future and use our proprietary technologies without infringing the proprietary rights and intellectual property of third </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>42</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=44,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=504579,FOLIO='42',FILE='DISK112:[15ZCH1.15ZCH40101]CU40101A.;26',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_cu40101_1_43"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>parties.
The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual property rights. We may in the future become party to, or
threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our medicines and technology, including interference or derivation proceedings, post-grant
reviews, inter partes reviews, or other procedures before the USPTO or other similar procedures in foreign jurisdictions. Third parties may assert infringement claims against us based on existing
patents or patents that may be granted in the future. If we are found to infringe a third party's intellectual property rights, we could be required to obtain a license from such third party to
continue developing and marketing our medicines and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a
license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us. We could be forced, including by court order, to cease
developing and commercializing the infringing technology or medicine. In addition, we could be found liable for substantial monetary damages, potentially including treble damages and attorneys' fees,
if we are found to have willfully infringed. A finding of infringement could prevent us from commercializing a product candidate or force us to cease some of our business operations, which could harm
our business. Alternatively, we may need to redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. Claims that we have misappropriated the
confidential information or trade secrets of third parties could have a similar negative impact on our business. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
cost to us of any litigation or other proceeding relating to patent or other proprietary rights, even if resolved in our favor, could be substantial and may result in substantial costs and
distraction of our management and other
employees. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Uncertainties resulting
from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts and limit our ability to continue our operations. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be subject to damages resulting from claims that our employees or we have wrongfully used or
disclosed alleged trade secrets of their former employers.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our employees and consultants have been previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential
competitors. Although we are not aware of any claims currently pending against us, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade
secrets or other proprietary information or intellectual property of the former employers of our employees. Litigation may be necessary to defend against these claims. Even if we are successful in
defending against these claims, litigation could result in substantial costs and be a distraction to management. If we fail in defending such claims, in addition to paying money claims, we may lose
valuable intellectual property rights or personnel. A loss of key personnel or their work product could hamper or prevent our ability to commercialize gemcabene, which would adversely affect our
commercial development efforts. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we are not able to adequately prevent disclosure of trade secrets and other proprietary
information, the value of any product we may pursue could be significantly diminished.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We may rely upon trade secrets, know-how and continuing technological innovation to develop and maintain our competitive position. However, trade
secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers, contract manufacturers,
vendors and other advisors to protect our trade secrets and other proprietary information. These agreements may not effectively prevent disclosure of confidential information and may not provide an
adequate remedy in the event of unauthorized disclosure of confidential information. In addition, we cannot guarantee that we have executed these agreements with each party that may have or have had
access to trade secrets. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>43</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=45,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=23146,FOLIO='43',FILE='DISK112:[15ZCH1.15ZCH40101]CU40101A.;26',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_cu40101_1_44"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Moreover,
because we acquired certain rights to gemcabene from Pfizer, we must rely on Pfizer's practices, and those of its predecessors, with regard to parties that may have had access to trade
secrets related thereto. Any
party with whom they or we have executed such an agreement may breach that agreement and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate
remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In
addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed
by a competitor, we would have no right to prevent them, or those to whom they disclose such trade secrets, from using that technology or information to compete with us. If any of our trade secrets
were to be disclosed to or independently developed by a competitor or other third-party, our competitive position would be harmed. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have filed U.S. applications for certain of our trademarks, but we have not yet obtained
registration of any of our trademarks.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have filed U.S. applications for three trademarks, "Gemphire", the Gemphire logo and "Advancing a class on top of statins", but we have not yet
obtained registration of any of our trademarks in the United States or other countries. If we do not secure and maintain registrations for our trademarks, we may encounter more difficulty in enforcing
them against third parties than we otherwise would, which could affect our business. We have also not yet registered trademarks for any product candidate in any jurisdiction. When we file trademark
applications for a product candidate, those applications may not be allowed for registration, and registered trademarks may not be obtained, maintained or enforced. During trademark registration
proceedings in the United States and foreign jurisdictions, we may receive rejections. We are given an opportunity to respond to those rejections, but we may not be able to overcome such rejections.
In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered
trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, any proprietary name we propose to use with gemcabene or any future product candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or
applied to register it, as a trademark. The FDA typically conducts a review of proposed drug names, including an evaluation of potential for confusion with other drug names. If the FDA objects to any
proposed proprietary drug name for any product candidate, we may be required to expend significant additional resources in an effort to identify a suitable substitute proprietary drug name that would
qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
we register any of our trademarks, our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to infringe on other marks. We may not be able to
protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. If
we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Obtaining and maintaining our patent protection depends on compliance with various procedural,
document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment or other
provisions during the patent application process. In addition, periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages
over the lifetime of the patent. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>44</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=46,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=752447,FOLIO='44',FILE='DISK112:[15ZCH1.15ZCH40101]CU40101A.;26',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_cu40101_1_45"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>are
situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In
such an event, our competitors might be able to enter the market, which would have an adverse effect on our business. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks Related to Employee Matters and Managing Growth  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We are dependent on our key personnel, and if we are not successful in attracting and retaining
highly qualified personnel, we may not be able to successfully implement our business strategy.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are highly dependent on our management, scientific and medical personnel, including Dr.&nbsp;Charles L. Bisgaier, our co-founder, Chairman of our
board of directors and Chief Scientific Officer, and Mina Sooch, our President, Chief Executive Officer, Treasurer and director. We have entered into employment agreements with our executive officers,
but any employee may terminate his or her employment with us. The loss of the services of either Dr.&nbsp;Bisgaier or Ms.&nbsp;Sooch, any of our executive officers, other key employees or
consultants and other scientific and medical advisors in the foreseeable future, might impede the achievement of our research, development and commercialization objectives. We rely on consultants and
advisors, including scientific and clinical advisors, to assist us in formulating our development and commercialization strategy. Our consultants and advisors may be employed by employers other than
us and may have commitments under consulting or
advisory contracts with other entities that may limit their availability to us. Recruiting and retaining qualified scientific personnel and business and commercial personnel will also be critical to
our success. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also
experience competition for the hiring of scientific personnel from universities and research institutions. Failure to succeed in clinical trials may also make it more challenging to recruit and retain
qualified scientific personnel. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We will need to develop and expand our company, and we may encounter difficulties in managing this
development and expansion, which could disrupt our operations.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As of May&nbsp;2, 2016, we had eight full-time employees, and we expect to increase our number of employees and the scope of our operations as we
further the clinical development of gemcabene and become a public company. To manage our anticipated development and expansion, we must continue to implement and improve our managerial, operational
and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Also, our management may need to divert a disproportionate amount of its attention away
from its day-to-day activities and devote a substantial amount of time to managing these development activities. Due to our limited resources, we may not be able to effectively manage the expansion of
our operations or recruit and train additional qualified personnel. This may result in weaknesses in our infrastructure, and give rise to operational mistakes, loss of business opportunities, loss of
employees and reduced productivity among remaining employees. The physical expansion of our operations may lead to significant costs and may divert financial resources from other projects, such as the
development of gemcabene. If our management is unable to effectively manage our expected development and expansion, our expenses may increase more than expected, our ability to generate or increase
our revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize gemcabene or any future product candidate, if
approved, and compete effectively will depend, in part, on our ability to effectively manage the future development and expansion of our company. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>45</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=47,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=184775,FOLIO='45',FILE='DISK112:[15ZCH1.15ZCH40101]CU40101A.;26',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_cw40101_1_46"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


A variety of risks associated with operating internationally for us and our collaborators could
adversely affect our business.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In addition to our U.S. operations, we may pursue international operations in the future and would face risks associated with such global operations,
including possible unfavorable regulatory, pricing and reimbursement, legal, political, tax and labor conditions, which could harm our business. We plan to conduct clinical trials outside of the
United States. We are subject to numerous risks associated with international business activities, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  compliance with differing or unexpected regulatory requirements for gemcabene
or any other product candidate; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> different medical practices and customs affecting acceptance of gemcabene, if
approved, or any other approved product in the marketplace; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  language barriers; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the interpretation of contractual provisions governed by foreign law in the
event of a contract dispute; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  difficulties in staffing and managing foreign operations, and an inability to
control commercial or other activities where we are relying on third parties; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  workforce uncertainty in countries where labor unrest is more common than in
the United States; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  potential liability under the Foreign Corrupt Practice Act of 1977 or
comparable foreign regulations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  production shortages resulting from any events affecting raw material supply or
manufacturing capability abroad; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> foreign government taxes, regulations and permit requirements; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> U.S. and foreign government tariffs, trade restrictions, price and exchange
controls and other regulatory requirements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  economic weakness, including inflation, natural disasters, war, events of
terrorism or political instability in particular foreign countries; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  fluctuations in currency exchange rates, which could result in increased
operating expenses and reduced revenues; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  compliance with tax, employment, immigration and labor laws, regulations and
restrictions for employees living or traveling abroad; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> changes in diplomatic and trade relationships; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  challenges in enforcing our contractual and intellectual property rights,
especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our business and operations would suffer in the event of system failures or unplanned events.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Despite the implementation of security measures, our internal computer systems and those of our current and future contractors and consultants are
vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we are not aware of any such material system
failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our
business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our
costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of
confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidates could be delayed. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Furthermore,
any unplanned event, such as flood, fire, explosion, tornadoes, earthquake, extreme weather condition, medical epidemics, power shortage, telecommunication failure or other natural or
manmade </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>46</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=48,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=260884,FOLIO='46',FILE='DISK112:[15ZCH1.15ZCH40101]CW40101A.;47',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_cw40101_1_47"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>accidents
or incidents that result in us being unable to fully utilize the facilities, may have an adverse effect on our ability to operate our business, particularly on a daily basis, and have
significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our product candidates or
interruption of our business operations. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks Related to our Common Stock and this Offering  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The price of our common stock may be volatile and fluctuate substantially, which could result in
substantial losses for purchasers of our common stock in this offering.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The trading price of our common stock following this offering is likely to be highly volatile and could be subject to wide fluctuations in response to
various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this "Risk Factors" section and elsewhere in this prospectus, these
factors include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> adverse results or delays in preclinical studies, clinical trials, regulatory
decisions or the development status of gemcabene or any product candidates we may pursue in the future; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  decisions to initiate a clinical trial, not initiate a clinical trial, or
terminate an existing clinical trial; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> adverse regulatory decisions, including failure to receive regulatory approval
for gemcabene; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> changes in applicable laws, rules or regulations; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> disputes with Pfizer regarding our licensed rights to gemcabene; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> adverse developments concerning our manufacturers, suppliers, collaborators and
other third parties; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our failure to commercialize gemcabene or any product candidates we may pursue
in the future; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the success of competitive drugs; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  additions or departures of key scientific or management personnel; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  unanticipated safety concerns related to the use of gemcabene or any product
candidates we may pursue in the future; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our announcements or our competitor's announcements regarding new products,
enhancements, significant contracts, acquisitions or strategic partnerships and investments; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> changes in the structure of healthcare payment systems; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the size and growth of our target markets; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our failure, or companies perceived to be similar to us, to meet external
expectations or management guidance; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  fluctuations in our quarterly financial results or the quarterly financial
results of companies perceived to be similar to us; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  publication of research reports about us or our industry, recommendations,
earning results or estimates or withdrawal of research coverage by securities analysts; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> changes in the market valuations of similar companies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> changes in general economic, political and market conditions in any of the
regions in which we conduct our business; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> changes in our capital structure or dividend policy, future issuances of
securities, sales of large blocks of common stock by our stockholders or our incurrence of additional debt; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> trading volume of our common stock; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> changes in accounting practices and ineffectiveness of our internal controls; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  disputes, litigation or developments relating to proprietary rights; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> timing of milestones and royalty payments; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> other events or factors, many of which are beyond our control. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>47</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=49,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=20314,FOLIO='47',FILE='DISK112:[15ZCH1.15ZCH40101]CW40101A.;47',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_cw40101_1_48"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, the stock market in general, NASDAQ, and the stock of biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or
disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating
performance. In addition, the initial public offering price for our common stock was determined through our negotiations with the underwriters, and may not bear any relationship to the market price at
which our common stock will trade after this offering or to any other established criteria of the value of our business. If the market price of our common stock after this offering does not exceed the
initial public offering price or declines, you may not realize any return on your investment in us and may lose some or all of your investment. In the past, securities class action litigation has
often been instituted against companies following periods of volatility in the market price of a company's securities. This type of litigation, if instituted, could result in substantial costs and a
diversion of management's attention and resources, which would harm our business, operating results or financial condition. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Provisions in our corporate charter documents and under Delaware law could make an acquisition of
us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Provisions in our corporate charter and our bylaws that will become effective upon the closing of this offering may discourage, delay or prevent a
merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions
could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board
of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by
making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  establish a classified board of directors such that not all members of the
board are elected at one time; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> allow the authorized number of our directors to be changed only by resolution of
our board of directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> limit the manner in which stockholders can remove directors from the board; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  establish advance notice requirements for stockholder proposals that can be
acted on at stockholder meetings and nominations to our board of directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> require that stockholder actions must be effected at a duly called stockholder
meeting and prohibit actions by our stockholders by written consent; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> prohibit stockholders from calling special meetings; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  authorize our board of directors to issue preferred stock without stockholder
approval, which preferred stock may include rights superior to the rights of the holders of common stock, and which could be used to institute a shareholder rights plan, or so-called "poison pill,"
that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> require the approval of the holders of at least two-thirds of the votes that all
our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Moreover,
because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15%
of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting
stock, unless the merger or combination is approved in a prescribed manner. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>48</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=50,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=417412,FOLIO='48',FILE='DISK112:[15ZCH1.15ZCH40101]CW40101A.;47',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_cw40101_1_49"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If you purchase our common stock in this offering, you will incur immediate and substantial dilution
in the book value of your shares.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The initial public offering price is substantially higher than the net tangible book value per share of our common stock. As a result, investors
purchasing common stock in this offering will suffer immediate and substantial dilution in the net tangible book value of the common stock purchased. Based on the initial public offering price of
$10.00 per share, purchasers of common stock in this offering will experience immediate dilution of approximately $7.03 per share. In addition, investors purchasing common stock in this offering will
contribute approximately 75.3% of the total amount invested by stockholders since inception but will only own approximately 35.6% of the shares of common stock outstanding. For a further description
of the dilution that you will experience immediately after this offering, see "Dilution." </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We do not know whether an active, liquid and orderly trading market will develop for our common
stock or what the market price of our common stock will be and as a result it may be difficult for you to sell your shares of our common stock.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Prior to this offering there has been no public market for shares of our common stock. Although our common stock has been approved for listing on
NASDAQ, an active trading market for our shares may never develop or be sustained following this offering. You may not be able to sell your shares quickly or at the market price if trading in shares
of our common stock is not active. The initial public offering price for our common stock was determined through negotiations with the underwriters, and the negotiated price may not be indicative of
the market price of the common stock after the offering. Furthermore, the purchase of shares of our common stock in this offering by our affiliates through the directed share program or otherwise,
would reduce the available public float for our common stock. As a result, any purchase of shares of our common stock by affiliates may reduce the liquidity of our common stock relative to what it
would have been if such shares were purchased by non-affiliates. As a result of these and other factors, you may be unable to resell your shares of our common stock at or above the initial public
offering price. Further, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic partnerships or
acquire companies or products by using our shares of common stock as consideration. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If securities analysts do not publish research or reports about our business or if they publish
negative evaluations of our stock, the price of our stock could decline.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The trading market for our common stock will rely in part on the research and reports that industry or financial analysts publish about us or our
business. We may never obtain research coverage by industry or financial analysts. If no or few analysts commence coverage of us, the trading price of our stock would likely decrease. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Even
if we do obtain analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock or publish inaccurate or unfavorable research about our business,
the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price and
trading volume to decline. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our executive officers, directors, principal stockholders and their affiliates will continue to
exercise significant control over our company after this offering, which will limit your ability to influence corporate matters and could delay or prevent a change in corporate control.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As of May&nbsp;2, 2016, our officers, directors, five percent or greater stockholders and their respective affiliates directly or indirectly held in
the aggregate approximately 83.0% of our outstanding voting stock. Immediately following the closing of this offering, disregarding any shares of common stock that they purchase in this offering or
receive in connection with equity awards granted in connection with this offering, our officers, directors, five percent or greater stockholders and their respective affiliates will have beneficial
ownership, in the aggregate, of approximately 48.0% of our outstanding common stock, assuming </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>49</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=51,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=1018109,FOLIO='49',FILE='DISK112:[15ZCH1.15ZCH40101]CW40101A.;47',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_cw40101_1_50"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>no
exercise of the underwriters' option to acquire additional common stock in this offering. If certain of our existing stockholders and their affiliated entities purchase all of the shares they have
indicated an interest in purchasing in this offering, then our officers, directors, five percent or greater stockholders and their respective affiliates will beneficially own, in the aggregate,
approximately 55.0% of our outstanding common stock immediately following the closing of this offering. In addition, on April&nbsp;25 and 27, and June&nbsp;9, 2016, our Compensation Committee
approved the award of options to purchase an aggregate of 1,825,200 shares of common stock with a per share exercise price equal to the initial public offering price, in each case pursuant to the 2015
Plan, to be granted to certain officers, directors, employees and consultants in connection with this offering. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>At
our request, the underwriters have reserved up to 10% of the shares of our common stock offered by this prospectus for sale, at the initial public offering price, to our directors, officers,
employees and other individuals associated with us and members of their respective families. To the extent shares of common stock are purchased by our officers, directors, five percent or greater
stockholders and their respective affiliates pursuant to the directed share program or otherwise in this offering, the percentage of our outstanding voting stock held by such persons immediately
following the closing of this offering will increase. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>These
stockholders, if they act together, will be able to influence our management and affairs and control the outcome of matters submitted to our stockholders for approval, including the election of
directors, amendments of
our organizational documents, and any merger, consolidation, sale of all or substantially all of our assets or other major corporate transaction. These stockholders acquired their shares of common
stock for substantially less than the price of the shares of common stock being acquired in this offering, and these stockholders may have interests, with respect to their common stock, that are
different from those of investors in this offering. In addition, this concentration of ownership might adversely affect the market price of our common stock, have the effect of delaying, deferring or
preventing a change of control of our company, or discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control of us. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For
more information regarding the ownership of our outstanding common stock by our executive officers, directors, principal stockholders and their affiliates see "Principal Stockholders." </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We are an "emerging growth company," and we cannot be certain if the reduced reporting requirements
applicable to emerging growth companies will make our common stock less attractive to investors.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are an "emerging growth company," as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of
exemptions from various reporting requirements that are applicable to other public companies that are not "emerging growth companies," including exemption from compliance with the auditor attestation
requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002 (Sarbanes-Oxley Act), reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports
and proxy statements, and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously
approved. Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably
elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that
are not emerging growth companies. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
will remain an emerging growth company until the earlier of (1)&nbsp;the last day of the fiscal year (a)&nbsp;following the fifth anniversary of the closing of this offering, (b)&nbsp;in
which we have total annual gross revenue of at least $1&nbsp;billion, or (c)&nbsp;in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is
held by non-affiliates exceeds $700&nbsp;million as of the prior June&nbsp;30th, and (2)&nbsp;the date on which we have issued more than $1&nbsp;billion in non-convertible debt during the
prior three-year period. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>50</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=52,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=444845,FOLIO='50',FILE='DISK112:[15ZCH1.15ZCH40101]CW40101A.;47',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_cy40101_1_51"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Even after we no longer qualify as an emerging growth company, we may still qualify as a "smaller reporting company," which would allow us to take advantage of many of the same
exemptions from disclosure requirements including exemption from compliance with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act and reduced disclosure obligations
regarding executive compensation in our periodic reports and proxy statements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a
less active trading market for our common stock and our stock price may be more volatile. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We will incur increased costs as a result of operating as a public company, and our management will
be required to devote substantial time to new compliance initiatives.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As a public company, and particularly after we are no longer an "emerging growth company," we will incur significant legal, accounting and other
expenses that we did not incur as a private company. For example, we will be subject to the reporting requirements of the Exchange Act, which will require,
among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act and rules subsequently
implemented by the SEC and NASDAQ have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance
practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and
financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to
obtain director and officer liability insurance. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Further,
there are significant corporate governance and executive compensation related provisions in the Dodd-Frank Wall Street Reform and Consumer Protection Act that require the SEC to adopt
additional rules and regulations in these areas such as "say on pay" and proxy access. Recent legislation permits emerging growth companies to implement many of these requirements over a longer period
and up to five years from the pricing of this offering. We intend to take advantage of this new legislation but cannot guarantee that we will not be required to implement these requirements sooner
than budgeted or planned and thereby incur unexpected expenses. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may
lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently
anticipate. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>After
this offering, we will be subject to Section&nbsp;404 of the Sarbanes-Oxley Act and the related rules of the SEC that generally require our management and independent registered public
accounting firm to report on the effectiveness of our internal control over financial reporting. Beginning with the second annual report that we will be required to file with the SEC,
Section&nbsp;404 of the Sarbanes-Oxley Act requires an annual management assessment of the effectiveness of our internal control over financial reporting. However, for so long as we remain an
"emerging growth company" as defined in the JOBS Act, we intend to take advantage of certain exemptions from various reporting requirements that are applicable to public companies that are not
emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act. Once we are no longer
an "emerging growth company" or, if before such date, we opt to no longer take advantage of the applicable exemption, we will be required to include an opinion from our independent registered public
accounting firm on the effectiveness of our internal control over financial reporting. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To
date, we have never conducted a review of our internal control for the purpose of providing the reports required by these rules. To achieve compliance with Section&nbsp;404 within the prescribed
period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>51</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=53,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=382261,FOLIO='51',FILE='DISK112:[15ZCH1.15ZCH40101]CY40101A.;50',USER='CHE105948',CD=';5-AUG-2016;22:03' -->
<A NAME="page_cy40101_1_52"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>costly
and challenging. In this regard, we will need to continue to dedicate internal resources, hire additional finance and accounting personnel, potentially engage outside consultants and adopt a
detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control
processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial
reporting. During the course of our review and testing, we may identify deficiencies and be unable to remediate them before we must provide the required reports. We or our independent registered
public accounting firm may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could harm our operating results, cause investors to lose
confidence in our reported financial information and cause the trading price of our stock to fall. Furthermore, if we have a material weakness in our internal control over financial reporting, we may
not detect errors on a timely basis and our financial statements may be materially misstated. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, as a public company we will be required to timely file accurate quarterly and annual reports with the SEC under the Exchange Act. In order to report our results of operations and
financial statements on an accurate and timely basis, we will depend on CROs to provide timely and accurate notice of their costs to us. Any failure to report our financial results on an accurate and
timely basis could result in sanctions, lawsuits, delisting of our shares from NASDAQ or other adverse consequences that would materially harm our business. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Other than the dividends on our Series&nbsp;A convertible preferred stock, which will be paid in
stock in connection with this offering, we do not anticipate declaring or paying, in the foreseeable future, any cash dividends on our capital stock and, consequently, your ability to achieve a return
on your investment will depend on appreciation in the price of our common stock.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have never declared or paid any cash dividend on our capital stock and do not currently intend to do so in the foreseeable future. We currently
anticipate that we will retain future earnings for the development, operation and expansion of our business. Therefore, the success of an investment in shares of our common stock will depend upon any
future appreciation in their value. There is no guarantee that shares of our common stock will appreciate in value or even maintain the price at which you purchased them. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


A significant portion of our total outstanding shares are restricted from immediate resale but may
be sold into the market in the near future, which could cause the market price of our common stock to drop significantly, even if our business is doing well.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market
that holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Upon the closing of this offering, we will have 8,431,615&nbsp;shares of common
stock outstanding (or 8,881,615&nbsp;shares, if the underwriters exercise their option in full). This includes 3,000,000&nbsp;shares that we are selling in this offering (or 3,450,000 shares, if
the underwriters exercise their option in full), which, unless purchased by our affiliates, including our directors, officers, employees and other individuals associated with us and members of their
respective families pursuant to the directed share program or otherwise, may be resold in the public market immediately without restriction. The remaining 5,431,615 shares, as well as any shares
purchased by our affiliates through the directed share program
or otherwise in this offering, are currently or will be restricted as a result of securities laws or lock-up agreements and will be able to be sold as described in the "Shares Eligible for Future
Sale" section of this prospectus. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, certain of our existing security holders and their affiliated entities, and other entities and individuals associated with us and them have indicated an interest in purchasing
approximately $10&nbsp;million of shares (or 1,000,000 shares) in the aggregate of our common stock in this offering at the initial public offering price. Any shares purchased by these parties will
be restricted as a result of securities laws and </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>52</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=54,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=441216,FOLIO='52',FILE='DISK112:[15ZCH1.15ZCH40101]CY40101A.;50',USER='CHE105948',CD=';5-AUG-2016;22:03' -->
<A NAME="page_cy40101_1_53"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>lock-up
agreements and will be able to be sold as described in the "Shares Eligible for Future Sale" section of this prospectus. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Moreover,
after this offering, holders of an aggregate of approximately 2,124,880&nbsp;shares of our common stock will have rights, subject to some conditions, to require us to file registration
statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. See "Description of Capital Stock&nbsp;&#151;
Registration Rights." </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
also intend to register all the shares of common stock that we may issue under our equity incentive plans and employee stock purchase plan. Effective upon the effectiveness of the registration
statement of which this prospectus is a part, an aggregate of 2,550,000&nbsp;shares of our common stock will initially be reserved for future issuance under these plans, 269,522 shares will remain
available for issuance following the grant of options to purchase an aggregate of 1,825,200&nbsp;shares of common stock to our officers, directors, employees and consultants in connection with this
offering, and all 150,000&nbsp;shares reserved under our employee stock purchase plan will remain available for issuance. Once we register these shares, and the 302,842 shares issuable upon the
exercise of stock options outstanding under the 2015 Plan as of May&nbsp;2, 2016, which we plan to do shortly after the closing of this offering, they can be freely sold in the public market upon
issuance, subject to the lock-up agreements referred to above. If a large number of these shares are sold in the public market, the sales could reduce the trading price of our common stock. For a more
detailed description of sales that may occur in the future, see "Shares Eligible for Future Sale". </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our issuance of the common stock pursuant to this offering might result in an "ownership change" at
the time of issuance, which will increase the risk that we could experience an ownership change in the future. Any ownership change would significantly limit our ability to utilize our net operating
loss carryforwards and certain other tax attributes.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As of March&nbsp;31, 2016, we had approximately $9.3&nbsp;million in U.S. federal and state net operating loss carryforwards, which will begin to
expire in 2034 for federal and 2024 for state, that we can use in certain circumstances to offset any future taxable income and thus reduce any federal income tax liability. We also had net tax credit
carryforwards of $125,000 available to reduce future tax liabilities, if any, for U.S. federal purposes. Our ability to utilize these net operating losses and tax credit carryforwards to offset future
taxable income may be significantly limited if we experience an "ownership change," as defined in Section&nbsp;382 of the Internal Revenue Code of 1986, as amended, or the Code. In general, an
ownership change will occur if there is a cumulative change in our ownership by "5-percent shareholders" (as defined in the Code) that exceeds 50 percentage points over a rolling three-year period. A
corporation that experiences an ownership change will generally be subject to an annual limitation on the corporation's subsequent use of net operating loss carryovers that arose from pre-ownership
change periods and use of losses that are subsequently recognized with respect to assets that had a built-in-loss on the date of the ownership change. The amount of the annual limitation generally
equals the value of the corporation immediately before the ownership change multiplied by the long-term tax-exempt interest rate (subject to certain adjustments). To the extent that the limitation in
a post-ownership-change year is not fully utilized, the amount of the limitation for the succeeding year will be increased. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
do not expect to experience an ownership change as a result of our issuance of common stock in this offering. Nevertheless, the rules regarding the determination of whether an ownership change
exists are complicated and are subject to differing interpretations, and it is possible that such issuances might be treated as resulting in an ownership change. We have not completed a study to
assess whether an ownership change for purposes of Section&nbsp;382 has occurred, or whether there have been multiple ownership changes since our inception, due to the significant costs and
complexities associated with such study. Even if there will be no immediate ownership change as a result of such issuance, the issuance of stock pursuant to this offering will be taken into account in
determining the cumulative change in our ownership for Section&nbsp;382 purposes. As a result, this offering materially increases the risk that we could experience an ownership </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>53</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=55,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=57441,FOLIO='53',FILE='DISK112:[15ZCH1.15ZCH40101]CY40101A.;50',USER='CHE105948',CD=';5-AUG-2016;22:03' -->
<A NAME="page_cy40101_1_54"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>change
in the future. If we experience an ownership change, we may not be able to fully utilize our net operating losses, resulting in additional income taxes and a reduction in our stockholders'
equity. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our amended and restated bylaws will designate the Court of Chancery of the State of Delaware as the
sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders' ability to obtain a favorable judicial forum for
disputes with us or our directors, officers or employees.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our amended and restated bylaws will provide that, subject to limited exceptions, the Court of Chancery of the State of Delaware will be the sole and
exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to
us or our stockholders, any action asserting a claim against us arising pursuant to any provision of the Delaware General Corporation Law, as amended, our amended and restated certificate of
incorporation or our amended and restated bylaws, any action to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our amended and restated
bylaws or any other action asserting a claim against us that is governed by the internal affairs doctrine. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital
stock shall be deemed to have notice of and to have consented to the provisions of our amended and restated certificate of incorporation described above. This choice of forum provision may limit a
stockholder's ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and
our directors, officers and employees. Alternatively, if a court were to find these provisions of our amended and restated certificate of incorporation inapplicable to, or unenforceable in respect of,
one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business and
financial condition. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Unstable market and economic conditions may have serious adverse consequences on our business,
financial condition and stock price.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The global credit and financial markets have experienced extreme volatility and disruptions in the past several years, including severely diminished
liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. We cannot assure you that
further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn,
volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, or do not improve, it may make any necessary debt or
equity financing more difficult, more costly, and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth
strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers,
manufacturers and other partners may not survive these difficult economic times, which could directly affect our ability to attain our operating goals on schedule and on budget. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>54</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=56,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=834974,FOLIO='54',FILE='DISK112:[15ZCH1.15ZCH40101]CY40101A.;50',USER='CHE105948',CD=';5-AUG-2016;22:03' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_da40101_1_55"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="da40101_special_note_regarding_forward-looking_statements"> </A>
<A NAME="toc_da40101_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This prospectus, including the sections entitled "Prospectus Summary," "Risk Factors," "Management's Discussion and Analysis of Financial Condition
and Results of Operations" and "Business," contains forward-looking statements. We may, in some cases, use words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may,"
"plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes to identify these
forward-looking statements. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. Forward-looking statements in this prospectus
include, but are not limited to, statements about:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our anticipated timing of regulatory submissions; commencement and completion of
preclinical studies and clinical trials, meetings with the FDA and other regulatory authorities; and product approvals for gemcabene or any other product candidates we may pursue in the future; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the outcome of our ongoing preclinical toxicology studies related to our partial
clinical hold with respect to clinical trials of longer than six months in duration; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the outcome of our Phase&nbsp;2b and Phase&nbsp;3 clinical trials of
gemcabene and our ability to replicate positive results from a completed clinical trial in a future clinical trial; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our expected clinical trial designs and regulatory pathways; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our expectation that the FDA will not require us to complete a cardiovascular
outcomes trial prior to approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our expectations for the attributes of gemcabene or any other product candidate
we may pursue in the future, including pharmaceutical properties, efficacy, safety, dosing regimens and cost, as compared to other lipid-lowering therapies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to design an efficient development plan; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our expectation that our existing capital resources and the net proceeds from
this offering will be sufficient to enable us to complete our planned three late stage clinical trials, commence our Phase&nbsp;3 registration trials and complete certain preclinical studies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our plans to advance the late-stage clinical development of gemcabene across
multiple target indications, pursue oral combination opportunities for gemcabene, maximize the global commercial value of gemcabene and leverage the expertise and experience of our management team to
evaluate future in-license acquisition opportunities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our estimates regarding industry trends and market potential for gemcabene; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> if approved, our ability to maintain regulatory approval of gemcabene and
respond and adhere to regulatory requirements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to identify, in-license or acquire, develop and, if approved,
successfully commercialize best-in-class products, including gemcabene or any other product candidates we may pursue in the future; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to enhance brand awareness among key thought leaders and physicians; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> if approved, the rate and degree of market acceptance of gemcabene or any other
product candidates we may pursue in the future; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> if approved, our ability to compete with other companies that are, or may be,
developing or selling products that may compete with gemcabene; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  reimbursement policies, including any future changes to such policies or
related government legislation and our ability to sell gemcabene, if approved; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  regulatory and legal developments in the United States and in foreign
countries; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to obtain and maintain intellectual property protection for
gemcabene or any other product candidates we may pursue in the future and not infringe upon the intellectual property of others; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>55</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=57,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=214852,FOLIO='55',FILE='DISK112:[15ZCH1.15ZCH40101]DA40101A.;23',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_da40101_1_56"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to fund our working capital requirements; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our estimates of our expenses, ongoing losses, future revenue, capital
requirements and our needs for, or ability to, obtain additional financing; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the ability of any third parties with whom we collaborate for the development
and commercialization of gemcabene to successfully perform their assigned functions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to retain and recruit key scientific and management personnel; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our financial performance; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our expectations regarding the period during which we qualify as an emerging
growth company under the JOBS Act; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our expected use of the proceeds from this offering. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>These
forward-looking statements reflect our management's beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this prospectus and are subject
to risks and uncertainties. We discuss many of these risks in greater detail under "Risk Factors." Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from
time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may
cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking
statements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>You
should read this prospectus and the documents that we reference in this prospectus and have filed as exhibits to the registration statement, of which this prospectus is a part, completely and with
the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in this prospectus by these cautionary statements.
Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of
this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate
that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly
rely upon these statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>56</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=58,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=386343,FOLIO='56',FILE='DISK112:[15ZCH1.15ZCH40101]DA40101A.;23',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_da40101_1_57"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="da40101_statistical_data_and_market_information"> </A>
<A NAME="toc_da40101_2"> </A>
<BR></FONT><FONT SIZE=2><B>  STATISTICAL DATA AND MARKET INFORMATION    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This prospectus contains estimates and other statistical data made by independent parties and by us relating to market size, the incidence of certain
medical conditions and other industry data. These data, to the extent they contain estimates or projections, involve a number of assumptions and limitations, and you are cautioned not to give undue
weight to such estimates or projections. Industry publications and other reports we have obtained from independent parties generally state that the data contained in these publications or other
reports have been obtained in good faith or from sources considered to be reliable, but they do not guarantee the accuracy or completeness of such data. The industry in which we operate is subject to
risks and uncertainties due to a variety of factors, including those described in "Risk Factors." These and other factors could cause results to differ materially from those expressed in these
publications and reports. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>57</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=59,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=808481,FOLIO='57',FILE='DISK112:[15ZCH1.15ZCH40101]DA40101A.;23',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dc40101_1_58"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dc40101_use_of_proceeds"> </A>
<A NAME="toc_dc40101_1"> </A>
<BR></FONT><FONT SIZE=2><B>  USE OF PROCEEDS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We estimate that we will receive net proceeds of approximately $25.6&nbsp;million (or approximately $29.8&nbsp;million if the underwriters
exercise their option to purchase additional shares in full) from the sale of the shares of common stock offered by us in this offering, after deducting the underwriting discounts and commissions and
estimated offering expenses payable by us. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
principal purposes of this offering are to make significant investments in research and development and clinical activities related to gemcabene and for working capital and other general corporate
purposes as well as to establish a public market for our common stock and to facilitate our future access to the public equity markets. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
anticipate that we will use the net proceeds of this offering, together with our cash and cash equivalents, for the following purposes:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  approximately $20.0&nbsp;million to fund development costs associated with
our three late stage clinical trials of gemcabene for our target indications and for costs associated with our planned End of Phase 2 (EOP2) meetings with the FDA; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  approximately $4.0&nbsp;million to fund manufacturing-related activities for
gemcabene; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  approximately $3.5&nbsp;million to fund development costs associated with
preclinical studies and related activities for gemcabene; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the balance for general corporate purposes, including working capital, general
administrative costs, potential acquisition or in-licensing costs and the prosecution and maintenance of our intellectual property. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>We
may also use a portion of the remaining net proceeds to advance the development of any acquired or in-licensed product candidate. However, we have no current commitments or obligations to acquire
or in-license any product candidate. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
expect to have our EOP2 meetings with the FDA in the first half of 2018. Based upon our currently anticipated clinical trials, we will need to raise additional capital to continue to fund the
further development of gemcabene and our other operations. The amount and timing of our actual expenditures will depend upon numerous factors, including our ability to gain access to additional
financing and the relative success and cost of our research, preclinical and clinical development programs. We have based this estimate on assumptions that may prove to be wrong, however, and we could
use our cash resources sooner than we expect. Additionally, the process of advancing early-stage product candidates and testing product candidates in clinical trials is costly and the timing of
progress in these clinical trials is uncertain. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
expected use of the net proceeds from this offering represents our current intentions based upon our present plans and business condition, which could change in the future as our plans and
business conditions evolve. The amounts and timing of our actual use of the net proceeds will vary depending on numerous factors, including our
ability to access additional financing, the relative success and cost of our research, preclinical and clinical development programs, whether we are able to enter into future licensing arrangements
and the other factors described under "Risk Factors" in this prospectus. In addition, we might decide to postpone or not pursue clinical trials or preclinical activities if the net proceeds from this
offering and any other sources of cash are less than expected. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Pending
their use, we plan to invest the net proceeds from this offering in short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct
or guaranteed obligations of the U.S. government, or hold them as cash. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>58</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=60,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=946426,FOLIO='58',FILE='DISK112:[15ZCH1.15ZCH40101]DC40101A.;40',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<A NAME="page_dc40101_1_59"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dc40101_dividend_policy"> </A>
<A NAME="toc_dc40101_2"> </A>
<BR></FONT><FONT SIZE=2><B>  DIVIDEND POLICY    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Immediately prior to the closing of this offering, we intend to issue shares of common stock to our existing holders of Series&nbsp;A convertible
preferred stock representing accrued dividends (Accrued Dividends) due upon the conversion of their Series&nbsp;A convertible preferred stock into common stock in connection with this offering. We
expect to issue 81,568 shares of common stock with respect to such Accrued Dividends, based on an expected closing date of August&nbsp;10, 2016. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Other
than the Accrued Dividends, we do not anticipate declaring or paying, in the foreseeable future, any cash dividends on our capital stock. We currently intend to retain all available funds and
any future earnings to support our operations and finance the growth and development of our business. Any future determination related to our dividend policy will be made at the discretion of our
board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our
board of directors may deem relevant. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>59</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=61,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=830127,FOLIO='59',FILE='DISK112:[15ZCH1.15ZCH40101]DC40101A.;40',USER='CHE108053',CD=';5-AUG-2016;01:27' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_de40101_1_60"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="de40101_capitalization"> </A>
<A NAME="toc_de40101_1"> </A>
<BR></FONT><FONT SIZE=2><B>  CAPITALIZATION    <BR>    </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The following table sets forth our cash and cash equivalents and our capitalization as of March&nbsp;31,
2016:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> on an actual basis; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> on a pro forma basis to reflect (1)&nbsp;the conversion of all our outstanding
shares of our convertible preferred stock into 745,637&nbsp;shares of common stock immediately prior to the closing of this offering, (2)&nbsp;the issuance of 59,992 shares of common stock
immediately prior to the closing of the offering pursuant to the Accrued Dividends described elsewhere in this prospectus in the section titled "Dividend Policy" (assuming the closing of the offering
occurred on March&nbsp;31, 2016), (3)&nbsp;the issuance of 867,498&nbsp;shares of common stock pursuant to the automatic conversion of the principal and accrued and unpaid interest outstanding
on March&nbsp;31, 2016 on our convertible notes issued prior to March&nbsp;31, 2016, immediately prior to the closing of this offering, (4)&nbsp;the accelerated vesting of 162,945 shares of
restricted stock unvested as of March&nbsp;31, 2016 valued at approximately $14,000 held by certain employees upon the closing of this offering and (5)&nbsp;the filing of our amended and restated
certificate of incorporation immediately prior to the closing of this offering; and</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> on a pro forma as adjusted basis to reflect (1)&nbsp;the pro forma adjustments
set forth above and (2)&nbsp;our sale in this offering of 3,000,000 shares of common stock at the initial public offering price of $10.00 per share, after deducting the underwriting discounts and
commissions and estimated offering expenses payable by us. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>The
following table does not take into account: (i)&nbsp;our convertible notes that were issued after March&nbsp;31, 2016, which notes and accrued and unpaid interest thereon will automatically
convert immediately prior to the closing of this offering into 765,052 shares of common stock, based on an expected closing date of August&nbsp;10, 2016; (ii)&nbsp;24,257 shares of common stock
issuable upon the automatic conversion of the accrued and unpaid interest that accrued after March&nbsp;31, 2016 and through the expected closing date of August&nbsp;10, 2016 on our convertible
notes issued prior to March&nbsp;31, 2016; or (iii)&nbsp;21,576 shares of common stock issued immediately prior to the closing of the offering pursuant to the Accrued Dividends described elsewhere
in this prospectus in the section titled "Dividend Policy" that accrued after March 31, 2016 and through the expected closing date of August&nbsp;10, 2016. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>You
should read the following table together with "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Description of Capital Stock" and the financial statements
and related notes appearing elsewhere in this prospectus. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>60</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=62,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=896135,FOLIO='60',FILE='DISK112:[15ZCH1.15ZCH40101]DE40101A.;66',USER='CHE107256',CD=';5-AUG-2016;17:41' -->
<A NAME="page_de40101_1_61"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="55pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="56pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of March&nbsp;31, 2016 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Actual </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Pro Forma<BR>
(unaudited) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Pro Forma<BR>
As Adjusted<BR>
(unaudited)<BR> </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands, except share and per share amounts)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,629</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,629</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>27,229 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Convertible notes to related parties</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,866</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Convertible notes</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,595</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Premium conversion derivative</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>331</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;A convertible preferred stock, $0.001 par value per share; 2,325,581 shares authorized, 745,637 shares issued and outstanding, actual; 0 shares
authorized, 0 shares issued and outstanding, pro forma; 0 shares authorized, 0 shares issued and outstanding, pro forma as adjusted</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>8,102</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stockholders' (deficit) equity:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Preferred stock, $0.001 par value per share; 0 shares authorized, issued and outstanding, actual; 10,000,000&nbsp;shares authorized, 0&nbsp;shares issued
and outstanding, pro forma and pro forma as adjusted</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common stock, $0.001 par value per share; 17,674,419 shares authorized, 3,758,488 shares issued and outstanding, actual; 100,000,000 shares authorized,
5,431,615&nbsp;shares issued and outstanding, pro forma; and 100,000,000&nbsp;shares authorized, 8,431,615&nbsp;shares issued and outstanding, pro forma as adjusted</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>12</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>12</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>15</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Additional paid in capital</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>13,929</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>39,526</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated deficit</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(14,521</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(14,535</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(14,535</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stockholders' (deficit) equity</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(14,509</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(594</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>25,006 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total capitalization</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>385</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,035</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>52,235 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<P style="font-family:arial;"><FONT SIZE=2>The
table and calculations above exclude:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  302,842 shares of common stock issuable upon the exercise of stock options
outstanding as of March&nbsp;31, 2016 at a weighted-average exercise price of $2.428 per share; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  1,825,200 shares of common stock issuable upon the exercise of stock options
with a per share exercise price equal to the initial public offering price to be granted to certain officers, directors, employees and consultants in connection with this offering; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  269,522&nbsp;shares of common stock reserved for future issuance under our
2015 Equity Incentive Plan, which was amended and restated in connection with this offering, and 150,000&nbsp;shares of common stock reserved for future issuance under our 2016 Employee Stock
Purchase Plan, which became effective in connection with this offering, as well as any automatic increases in the number of shares of common stock reserved for future issuance under these plans; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> shares of common stock issuable upon conversion of our convertible notes issued
after March&nbsp;31, 2016, which notes and accrued and unpaid interest thereon will convert automatically immediately prior to the closing of this offering into 765,052 shares, based on an expected
closing date of August&nbsp;10, 2016; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>61</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=63,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=389304,FOLIO='61',FILE='DISK112:[15ZCH1.15ZCH40101]DE40101A.;66',USER='CHE107256',CD=';5-AUG-2016;17:41' -->
<A NAME="page_de40101_1_62"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 24,257 shares of common stock issuable upon the automatic conversion of the
accrued and unpaid interest that accrued after March&nbsp;31, 2016 and through the expected closing date of August&nbsp;10, 2016 on our convertible notes issued prior to March&nbsp;31, 2016; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 21,576 shares of common stock issued immediately prior to the closing of the
offering pursuant to the Accrued Dividends described elsewhere in this prospectus in the section titled "Dividend Policy" that accrued after March&nbsp;31, 2016 and through the expected closing date
of August&nbsp;10, 2016. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>62</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=64,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=301757,FOLIO='62',FILE='DISK112:[15ZCH1.15ZCH40101]DE40101A.;66',USER='CHE107256',CD=';5-AUG-2016;17:41' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dg40101_1_63"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dg40101_dilution"> </A>
<A NAME="toc_dg40101_1"> </A>
<BR></FONT><FONT SIZE=2><B>  DILUTION    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference between the
initial public offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock after this offering. Net tangible book value dilution
per share to new investors represents the difference between the amount per share paid by purchasers of shares of common stock in this offering and the pro forma as adjusted net tangible book value
per share of common stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Net
tangible book value per share is determined by dividing our total tangible assets less our total liabilities by the number of shares of common stock outstanding. Our pro forma net tangible book
deficit as of March&nbsp;31, 2016 was $0.6&nbsp;million, or $0.11 per share of common stock. Pro forma net tangible book value gives effect to: (1)&nbsp;the conversion of all our outstanding
shares of our convertible preferred stock into 745,637&nbsp;shares of common stock immediately prior to the closing of this offering, (2)&nbsp;the issuance of 59,992&nbsp;shares of common stock
immediately prior to the closing of the offering pursuant to the Accrued Dividends described elsewhere in this prospectus in the section titled "Dividend Policy" (assuming the closing of the offering
occurred on March&nbsp;31, 2016), (3)&nbsp;the issuance of 867,498&nbsp;shares of common stock pursuant to the automatic conversion of the principal and accrued and unpaid interest outstanding
on March&nbsp;31, 2016 on our convertible notes issued prior to March&nbsp;31, 2016,
immediately prior to the closing of this offering, (4)&nbsp;the accelerated vesting of 162,945&nbsp;shares of restricted stock unvested as of March&nbsp;31, 2016 valued at approximately $14,000
held by certain employees upon the closing of this offering and (5)&nbsp;the filing of our amended and restated certificate of incorporation immediately prior to the closing of this offering. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>After
giving effect to: (1)&nbsp;the pro forma adjustments set forth above and (2)&nbsp;the issuance and sale of 3,000,000&nbsp;shares of common stock in this offering at the initial public
offering price of $10.00 per share, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of
March&nbsp;31, 2016 would have been approximately $25.0&nbsp;million, or $2.97 per share of our common stock. This represents an immediate increase in pro forma net tangible book value of $3.08
per share to our existing stockholders and an immediate dilution of $7.03 per share to investors purchasing shares in this offering. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
following table illustrates this dilution on a per share basis: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="41pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="44pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Initial public offering price per share</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.00</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma net tangible book value (deficit) per share as of March&nbsp;31, 2016</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(0.11</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Increase in pro forma net tangible book value per share attributable to investors participating in this offering</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3.08</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma as adjusted net tangible book value per share after this offering</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2.97 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dilution in pro forma as adjusted net tangible book value per share to new investors in this offering</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7.03 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>If
the underwriters exercise in full their option to purchase 450,000 additional shares of our common stock in this offering, the pro forma as adjusted net tangible book value per share after this
offering will increase to $3.29
per share, representing an immediate increase in pro forma as adjusted net tangible book value to existing stockholders of $3.40 per share and an immediate decrease of dilution of $6.71 per share to
new investors participating in this offering. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
following table summarizes, on a pro forma as adjusted basis as of March&nbsp;31, 2016, the number of shares purchased or to be purchased from us, the total consideration paid or to be paid to
us, and the average price per share paid or to be paid to us by existing stockholders and investors participating in this </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>63</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=65,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=931265,FOLIO='63',FILE='DISK112:[15ZCH1.15ZCH40101]DG40101A.;81',USER='CHE105948',CD=';5-AUG-2016;21:57' -->
<A NAME="page_dg40101_1_64"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>offering
at the initial public offering price of $10.00 per share, before deducting the underwriting discounts and commissions and estimated offering expenses payable by us. As the table below shows,
investors participating in this offering will pay an average price per share substantially higher than our existing stockholders paid before this offering. </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:67%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"120%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="120%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="63pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="49pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="78pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="49pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="59pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>SHARES PURCHASED </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>TOTAL CONSIDERATION </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>AVERAGE<BR>
PRICE<BR>
PER SHARE </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>NUMBER </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>PERCENT </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>AMOUNT </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>PERCENT </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Existing stockholders before this offering</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5,431,615</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>64.4</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>9,839,951</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>24.7</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1.81</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Investors participating in this offering</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3,000,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>35.6</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>30,000,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>75.3</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.00 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>8,431,615</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>100.0</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>39,839,951</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>100.0</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>Except
as otherwise indicated, the tables and calculations above assume no exercise of the underwriters' option to purchase additional shares. If the underwriters exercise their option to purchase
additional shares in full, our existing stockholders before this offering would own 55.7% and our investors in this offering would own 44.3% of the total number of shares of our common stock
outstanding after the closing of this offering. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Certain
of our existing security holders and their affiliated entities, and other entities and individuals associated with us and them have indicated an interest in purchasing approximately
$10&nbsp;million of shares (or
1,000,000&nbsp;shares) in the aggregate of our common stock in this offering at the initial public offering price. As these indications of interest are non-binding, the foregoing discussion and
table do not reflect the potential purchase of any shares in this offering by our existing stockholders. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
tables and calculations above are based on 5,431,615&nbsp;shares of our common stock outstanding as of March&nbsp;31, 2016, which excludes:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  302,842&nbsp;shares of common stock issuable upon the exercise of stock
options outstanding as of March&nbsp;31, 2016 at a weighted-average exercise price of $2.428 per share; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  1,825,200&nbsp;shares of common stock issuable upon the exercise of options
with a per share exercise price equal to the initial public offering price to be granted to certain officers, directors, employees and consultants in connection with this offering; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  269,522&nbsp;shares of common stock reserved for future issuance under our
2015 Equity Incentive Plan, which was amended and restated in connection with this offering, and 150,000&nbsp;shares of common stock reserved for future issuance under our 2016 Employee Stock
Purchase Plan, which became effective in connection with this offering, as well as any automatic increases in the number of shares of common stock reserved for future issuance under these
plans;</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> shares of common stock issuable upon conversion of our convertible notes issued
after March&nbsp;31, 2016, which notes and accrued and unpaid interest thereon will convert automatically immediately prior to the closing of this offering into 765,052&nbsp;shares, based on an
expected closing date of August&nbsp;10, 2016; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 24,257 shares of common stock issuable upon the automatic conversion of the
accrued and unpaid interest that accrued after March&nbsp;31, 2016 and through the expected closing date of August&nbsp;10, 2016 on our convertible notes issued prior to March&nbsp;31, 2016; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 21,576 shares of common stock issued immediately prior to the closing of the
offering pursuant to the Accrued Dividends described elsewhere in this prospectus in the section titled "Dividend Policy" that accrued after March&nbsp;31, 2016 and through the expected closing date
of August&nbsp;10, 2016. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>To
the extent that outstanding options are exercised, you will experience further dilution. In addition, we may choose to raise additional capital through the sale of equity or convertible debt
securities due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent we issue additional shares of
common stock or other equity or convertible debt securities in the future, there will be further dilution to investors participating in this offering. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>64</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=66,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=667978,FOLIO='64',FILE='DISK112:[15ZCH1.15ZCH40101]DG40101A.;81',USER='CHE105948',CD=';5-AUG-2016;21:57' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_di40101_1_65"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="di40101_selected_financial_data"> </A>
<A NAME="toc_di40101_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SELECTED FINANCIAL DATA    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following selected financial data should be read together with "Capitalization," "Management's Discussion and Analysis of Financial Condition and
Results of Operations" and the financial statements, related notes and other financial information included elsewhere in this prospectus. The selected financial data in this section are not intended
to replace the financial statements and are qualified in their entirety by the financial statements and related notes included elsewhere in this prospectus. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
derived the statements of operations data for the years ended December&nbsp;31, 2014 and 2015 and the balance sheet data as of December&nbsp;31, 2014 and 2015 from our audited financial
statements included elsewhere in this prospectus. We derived the statements of operations data for the three months ended March&nbsp;31, 2015 and 2016 and the balance sheet data as of
March&nbsp;31, 2016 from our unaudited interim financial statements appearing elsewhere in this prospectus. The unaudited interim financial statements have been prepared on the same basis as our
audited financial statements and include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the financial information set forth in those statements.
Our historical results are not necessarily indicative of results to be expected in any future period, and results from any interim period may not necessarily be indicative of the results of a full
year or any other period. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>65</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=67,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=681003,FOLIO='65',FILE='DISK112:[15ZCH1.15ZCH40101]DI40101A.;95',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_di40101_1_66"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="70pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="70pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="70pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="70pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Three Months Ended<BR>
March&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2015 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2015 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2016 </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(unaudited)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands, except share and per share amounts)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Statements of Operations Data:</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating expenses:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>214</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3,177</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>475</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,050</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 52</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 3,991</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 206</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 1,176</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Acquired in-process research and development</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> &#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 908</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 908</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> &#151; </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 266</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 8,076</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 1,589</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 2,226 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss from operations</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (266</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (8,076</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (1,589</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (2,226</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest (expense) income</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (55</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (762</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (690</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 127</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss on convertible note extinguishment</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> &#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (198</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> &#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> &#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income (expense)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 7</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> &#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (4</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (320</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (9,029</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (2,279</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (2,103</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adjustment to redemption value on Series&nbsp;A convertible preferred stock</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> &#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (2,968</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (2,517</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (149</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Premium upon substantial modification of convertible notes with certain shareholders</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> &#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (1,047</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> &#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> &#151; </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss attributable to common stockholders</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(320</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(13,044</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,796</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2,252</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss per share attributable to common stockholders, basic and diluted<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(0.21</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4.54</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2.27</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(0.65</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 1,521,703</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 2,875,053</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 2,110,097</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 3,468,764 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma net loss per share attributable to common stockholders, basic and diluted (unaudited)<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2.95</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(0.42</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted-average shares used in computing pro forma net loss per share attributable to common stockholders, basic and diluted (unaudited)<SUP>(1)
</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 4,305,100</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 5,301,705 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2> </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">See
notes&nbsp;2 and 10 to our financial statements appearing elsewhere in this prospectus for further details on the calculation of net
loss per share attributable to common stockholders, basic and diluted, and pro forma net loss per share attributable to common stockholders, basic and diluted, and the weighted-average number of
shares used in computation of the per share amounts. On April&nbsp;22, 2016, our board of directors approved a 1-for-3.119 reverse stock split of our common stock and preferred stock, which became
effective on April&nbsp;27, 2016. All share and per share data in this table have been adjusted to reflect the reverse stock split. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>66</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=68,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=178797,FOLIO='66',FILE='DISK112:[15ZCH1.15ZCH40101]DI40101A.;95',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_di40101_1_67"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="49pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="55pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="55pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>March&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2015 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2016 </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(unaudited)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Balance Sheet Information:</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>317</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3,620</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,629</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Working capital</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 13</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 23</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (599</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total assets</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 348</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 4,500</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 2,637</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Convertible notes (including premium conversion derivative)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 810</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 6,769</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 6,792</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total liabilities</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 879</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 8,927</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 9,044</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;A convertible preferred stock</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> &#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 7,953</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 8,102</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated deficit/members' deficit</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (584</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (12,392</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (14,521</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stockholders' deficit</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (531</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (12,380</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (14,509</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>67</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=69,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=677567,FOLIO='67',FILE='DISK112:[15ZCH1.15ZCH40101]DI40101A.;95',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dk40101_1_68"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dk40101_management_s_discussion_and_an__man03466"> </A>
<A NAME="toc_dk40101_1"> </A>
<BR></FONT><FONT SIZE=2><B>  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS&nbsp;OF&nbsp;OPERATIONS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>The following discussion and analysis should be read in conjunction with "Selected Financial Data" and our financial statements
and related notes included elsewhere in this prospectus. This discussion and analysis and other parts of this prospectus contain forward-looking statements based upon current beliefs, plans and
expectations that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives, expectations, intentions and projections. Our actual results and the timing of
selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under "Risk Factors" and elsewhere in this
prospectus. You should carefully read the "Risk Factors" section of this prospectus to gain an understanding of the important factors that could cause actual results to differ materially from our
forward-looking statements. Please also see the section entitled "Special Note Regarding Forward-Looking Statements."  </I></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Overview  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious
medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of LDL-C, or bad cholesterol, triglycerides, or fat in the
blood, or both. We are developing our product candidate gemcabene, a novel, once-daily, oral therapy, for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently
approved therapies, primarily statin therapy. Gemcabene's mechanism of action is designed to enhance the clearance of VLDLs in the plasma and inhibit the production of fatty acids and cholesterol in
the liver. Gemcabene has been tested as monotherapy and in combination with statins and other drugs in 895 subjects, which we define as healthy volunteers and patients, across 18 Phase&nbsp;1 and
Phase&nbsp;2 clinical trials and has demonstrated promising evidence of efficacy, safety and tolerability. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
are initially pursuing gemcabene in the following four indications as a treatment in addition to maximally tolerated statin therapy for patients who are unable to reach their lipid-lowering goals:
HoFH, HeFH, ASCVD and SHTG. We believe we can design an efficient development plan to provide a new treatment alternative for HoFH patients. Furthermore, we believe that gemcabene's potential ability
to treat patients in the most severe segment of the dyslipidemia market will enhance brand awareness among key thought leaders and physicians. We are developing gemcabene for HeFH, ASCVD and SHTG
given gemcabene's: (1)&nbsp;promising clinical data in these indications; (2)&nbsp;cost-effective manufacturing process; (3)&nbsp;convenient oral dosing; (4)&nbsp;viability as adjunct
combination therapy; and (5)&nbsp;large commercial potential. By the end of 2016, we expect to initiate three late stage clinical trials for gemcabene in HoFH, hypercholesterolemia, including HeFH
and ASCVD patients on maximally tolerated statins, and SHTG. Upon completion of one or more of these clinical trials, we intend to request one or more End of Phase&nbsp;2 (EOP2) meetings with the
FDA to reach an agreement on the design of Phase&nbsp;3 registration trials and long term safety exposure for our target indications. We intend to pursue similar discussions with Canadian and
European health authorities. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
Company was co-founded in November 2008 as a limited liability company under the name Michigan Life Therapeutics,&nbsp;LLC (MLT) by former Pfizer employees, Dr.&nbsp;Charles Bisgaier and
Mr.&nbsp;David Lowenschuss, who were responsible for licensing exclusive worldwide rights to gemcabene from Pfizer in April 2011. In October 2014, we incorporated a new entity under the name
Gemphire Therapeutics&nbsp;Inc. in Delaware. In November 2014, we entered into a merger agreement with Gemphire whereby MLT was merged with and into Gemphire, with Gemphire as the surviving entity
and all outstanding units of membership interest in MLT were exchanged for shares of common stock of Gemphire. The purpose of the merger was to change the jurisdiction of our incorporation from
Michigan to Delaware and to convert from a limited liability company to a corporation. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>68</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=70,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=705908,FOLIO='68',FILE='DISK112:[15ZCH1.15ZCH40101]DK40101A.;64',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_dk40101_1_69"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To
date, our primary activities have been conducting research and development activities, planning clinical trials, performing business and financial planning, recruiting personnel and raising
capital. We do not have any products approved for sale and have not generated any revenue. We do not expect to generate revenue until, and unless, the FDA or other regulatory authorities approve
gemcabene and we successfully commercialize gemcabene. Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity and
debt financings as well as collaborations, strategic alliances and licensing arrangements. Through March&nbsp;31, 2016, we have funded our operations primarily through the issuance of preferred
stock and convertible notes, totaling $9.8&nbsp;million in gross proceeds. Our net losses were $0.3&nbsp;million, $9.0&nbsp;million and $2.1&nbsp;million for the years ended
December&nbsp;31, 2014 and 2015 and for the three months ended March&nbsp;31, 2016, respectively. As of March&nbsp;31, 2016, we had an accumulated deficit of $14.5&nbsp;million. We anticipate
that our expenses will increase substantially as we:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> continue clinical trials for gemcabene and for any other product candidate in
our future pipeline; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> develop additional product candidates that we identify, in-license or acquire; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> seek regulatory approvals for any product candidates that successfully complete
clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> contract to manufacture our product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  establish on our own or with partners, a sales, marketing and distribution
infrastructure to commercialize any products for which we may obtain regulatory approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  maintain, expand and protect our intellectual property portfolio; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> hire additional staff, including clinical, scientific, operational and financial
personnel, to execute our business plan; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> add operational, financial and management information systems and personnel,
including personnel to support our product development and potential future commercialization efforts; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> to enable us to operate as a public company. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Our
net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our preclinical studies, clinical trials and our expenditures on other research and
development activities. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Financial Operations Overview  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Revenue  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To date, we have not generated any revenue. We do not expect to generate revenue unless or until we obtain regulatory approval of and commercialize
gemcabene. If we fail to complete the
development of gemcabene, or any other product candidate we may pursue in the future, in a timely manner, or fail to obtain regulatory approval, our ability to generate future revenue would be
compromised. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Operating Expenses  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our operating expenses are classified into three categories: general and administrative, research and development and acquired in-process research and
development. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


General and Administrative  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>General and administrative expenses consist primarily of personnel-related costs, including salaries and share-based compensation costs, for personnel
in functions not directly associated with research and administrative activities. Other significant costs include legal fees relating to intellectual property and corporate matters and professional
fees for accounting and other services. We anticipate that our general and administrative expenses will significantly increase in the future to support our continued research and development
activities, potential commercialization of gemcabene, if approved, and any future product candidates we may develop and the increased costs of operating as a public company. These increases will
include increased costs related to the hiring of additional personnel and fees for legal and professional services, as well as other public-company related costs. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>69</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=71,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=944933,FOLIO='69',FILE='DISK112:[15ZCH1.15ZCH40101]DK40101A.;64',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_dk40101_1_70"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Research and Development  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To date, our research and development expenses have related primarily to the clinical stage development of gemcabene. Research and development
expenses consist of costs incurred in performing research and development activities, including compensation for research and development employees, costs associated with preclinical studies and
trials, regulatory activities, manufacturing activities to support
clinical activities, license fees, nonlegal patent costs, fees paid to external service providers that conduct certain research and development, clinical costs and an allocation of overhead expenses.
Research and development costs are expensed as incurred and costs incurred by third parties are expensed as the contracted work is performed. We accrue for costs incurred as the services are being
provided by monitoring the status of the study or project, and the invoices received from our external service providers. We adjust our accrual as actual costs become known. Research and development
activities are central to our business model. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
expect that gemcabene will have higher development costs during its later stages of clinical development, as compared to costs incurred during its earlier stages of development, primarily due to
the increased size and duration of the later-stage clinical trials, so we expect our research and development expenses to significantly increase over the next several years as we continue to conduct
preclinical studies and clinical trials for gemcabene and potentially develop other product candidates. However, it is difficult to determine with certainty the duration, costs and timing to complete
our current or future preclinical programs and clinical trials of gemcabene. The duration, costs and timing of clinical trials and development of gemcabene will depend on a variety of factors that
include, but are not limited to, the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> per patient trial costs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the number of patients that participate in the trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the number of sites included in the trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the countries in which the trials are conducted; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the length of time required to enroll eligible patients; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the number of doses that patients receive; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the drop-out or discontinuation rates of patients; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  potential additional safety monitoring or other studies requested by regulatory
agencies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the duration of patient follow-up; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the phase of development of the product candidate; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  arrangements with contract research organizations and other service providers;
and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the efficacy and safety profile of the product candidates. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Acquired In-Process Research and Development  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We include costs to acquire or in-license product candidates in acquired in-process research and development expenses. When we acquire the right to
develop and commercialize a new product candidate, any up-front payments, or any future milestone payments that relate to the acquisition or licensing of such a right are immediately expensed as
acquired in-process research and development in the period in which they are incurred. These costs are immediately expensed provided that the payments do not also represent processes or activities
that would constitute a "business" as defined under generally accepted accounting principles in the United States (GAAP), or provided that the product candidate has not achieved regulatory approval
for marketing and, and absent obtaining such approval, has no alternative future use. Royalties owed on future sales of any licensed product will be expensed in the period the related revenues are
recognized. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Interest (Expense) Income  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Interest expense consists of interest costs related to promissory notes outstanding as well as interest cost and the underlying premium conversion
derivative related to the convertible notes issued by us. The promissory and convertible notes we have issued have an annual interest rate of 8%. The interest on the promissory and convertible notes
issued subsequent to February 2015 compound on an annual basis while </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>70</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=72,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=151696,FOLIO='70',FILE='DISK112:[15ZCH1.15ZCH40101]DK40101A.;64',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_dk40101_1_71"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>the
interest on the convertible notes issued in or prior to February 2015 compounded daily. All of the convertible notes issued in or prior to February 2015 were converted to Series&nbsp;A preferred
shares in March 2015. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
expect to earn interest income in future periods from the investment of net proceeds from this offering in interest bearing instruments. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Other Income (Expense)  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Other income (expense) relates to foreign currency exchange gains and losses. Foreign currency exchange gains and losses relate to transactions and
monetary asset and liability balances denominated in currencies other than the U.S. dollar. Foreign currency gains and losses may continue to fluctuate in the future due to changes in foreign currency
exchange rates. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Provision for Income Taxes  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Provision for income taxes consists of federal and state income taxes in the United States, as well as deferred income taxes and changes in related
valuation allowance reflecting the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax
purposes. Currently, there is no provision for income taxes, as we have incurred operating losses to date, and a full valuation allowance has been provided on the net deferred tax assets as of
December&nbsp;31, 2014 and 2015 and March&nbsp;31, 2016. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Results of Operations  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following table summarizes our operating results for the periods indicated: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="35pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="36pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Three Months Ended March&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2015 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Change </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2015 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2016 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Change </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(unaudited)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=17 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating expenses:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>214</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3,177</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,963</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>475</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,050</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>575</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>52</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3,991</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3,939</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>206</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,176</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>970</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Acquired in-process research and development</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>908</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>908</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>908</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(908</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>266</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>8,076</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7,810</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,589</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,226</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>637 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss from operations</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(266</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(8,076</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(7,810</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(1,589</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2,226</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>637</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest (expense) income</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(55</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(762</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(707</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(690</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>127</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(817</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss on convertible note extinguishment</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(198</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(198</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income (expense)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>6</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(320</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(9,029</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(8,709</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2,279</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2,103</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(176</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>71</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=73,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=796031,FOLIO='71',FILE='DISK112:[15ZCH1.15ZCH40101]DK40101A.;64',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dm40101_1_72"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Comparison of Years Ended December&nbsp;31, 2014 and 2015  </I></B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


General and Administrative  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>General and administrative expenses for the year ended December&nbsp;31, 2014 were $0.2&nbsp;million compared to $3.2&nbsp;million for the year
ended December&nbsp;31, 2015. The $3.0&nbsp;million increase was primarily attributable to an increase in staffing and professional services. General and administrative expenses included $53,000
and $0.3 million in share-based compensation expense in the years ended December&nbsp;31, 2014 and 2015, respectively. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Research and Development  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Research and development expenses for the year ended December&nbsp;31, 2014 were $52,000 compared to $4.0&nbsp;million for the year ended
December&nbsp;31, 2015. The $3.9&nbsp;million increase was primarily attributable to preclinical studies and manufacturing activities to support clinical advancement of gemcabene and fees paid to
external service providers for clinical trial development and regulatory consulting. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Acquired In-process Research and Development  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Acquired in-process research and development expenses for the year ended December&nbsp;31, 2015 were $0.9&nbsp;million. There were no acquired
in-process research and development expenses during the prior year. The increase was attributable to an equity milestone payment under our license agreement with Pfizer. We issued 675,250 shares of
common stock to Pfizer and immediately expensed the equity milestone payment in the first quarter of 2015 as acquired in-process research and development expenses at the fair value equivalent of the
shares issued in the amount of $0.9&nbsp;million. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Interest (Expense) Income  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Non-cash interest expense for the year ended December&nbsp;31, 2014 was $55,000 compared to $0.8&nbsp;million for the year ended
December&nbsp;31, 2015. The $0.7&nbsp;million increase in interest expense was primarily due to the issuance of convertible notes in the first, third and fourth quarters of 2015. Cash interest
paid during the years ended December&nbsp;31, 2014 and 2015 was zero and $2,000, respectively. The convertible notes issued through the first quarter of 2015 were converted to Series&nbsp;A
preferred shares on March&nbsp;31, 2015. The convertible notes issued in July and December 2015 were outstanding at December&nbsp;31, 2015. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Loss on convertible note extinguishment  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Non-cash loss on convertible note extinguishment for the years ended December&nbsp;31, 2014 and 2015 was zero and $0.2&nbsp;million, respectively.
The convertible notes issued in July 2015 were amended in December 2015. The amendment added a new contingent conversion feature, served to extend the maturity date by five months and revised certain
conversion premiums. As a result of the modifications made to such convertible notes, we accounted for the amendment as a note extinguishment which gave rise to the $0.2&nbsp;million non-cash loss
in 2015. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Comparison of the Three Months Ended March&nbsp;31, 2015 and 2016  </I></B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


General and Administrative  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>General and administrative expenses for the three months ended March&nbsp;31, 2015 were $0.5&nbsp;million compared to $1.1&nbsp;million for the
three months ended March&nbsp;31, 2016. The $0.6&nbsp;million increase was primarily attributable to an increase in staffing and professional services. General and administrative expenses included
$23,000 and $123,000 in share-based compensation expense during the three months ended March&nbsp;31, 2015 and 2016, respectively. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Research and Development  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Research and development expenses for the three months ended March&nbsp;31, 2015 were $0.2&nbsp;million compared to $1.2&nbsp;million for the
three months ended March&nbsp;31, 2016. The $1.0&nbsp;million increase was primarily attributable to preclinical studies and manufacturing activities to support clinical advancement of gemcabene
and fees paid to external service providers for clinical trial development and regulatory consulting. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>72</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=74,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=267711,FOLIO='72',FILE='DISK112:[15ZCH1.15ZCH40101]DM40101A.;80',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_dm40101_1_73"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Acquired In-process Research and Development  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Acquired in-process research and development expenses during the three months ended March&nbsp;31, 2015 were $0.9&nbsp;million which was the
result of an equity milestone payment under our license agreement with Pfizer. We issued 675,250 shares of common stock to Pfizer and immediately expensed the equity milestone payment in the first
quarter of 2015 as acquired in-process research and development expenses at the fair value equivalent of the shares issued in the amount of $0.9&nbsp;million. No acquired in-process research and
development expenses were incurred during the three months ended March&nbsp;31, 2016. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Interest Income (Expense)  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Non-cash interest expense for the three months ended March&nbsp;31, 2015 was $0.7 million compared to non-cash interest income of $127,000 for the
three months ended March&nbsp;31, 2016. The change was primarily due to the amortization of the note premium associated with the July 2015 Interim Notes coupled with the bifurcation of the
conversion premium liability and subsequent fair value adjustments associated with the Convertible and Interim Notes. The Convertible Notes issued through the first quarter of 2015 were converted to
Series&nbsp;A preferred stock on March&nbsp;31, 2015. The Interim Notes issued in July 2015, December 2015 and in February 2016 were outstanding as of March&nbsp;31, 2016. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Liquidity and Capital Resources  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Capital Resources  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As of December&nbsp;31, 2015 and March&nbsp;31, 2016, our principal sources of liquidity consisted of cash and cash equivalents of approximately
$3.6&nbsp;million and $1.6&nbsp;million, respectively. Our cash and cash equivalents are invested primarily in cash deposits. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have not generated any revenue, and we anticipate that we will continue to incur losses for the foreseeable future. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
anticipate that our expenses will increase substantially as we:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> continue clinical trials for gemcabene and for any other product candidate in
our future pipeline; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> develop additional product candidates that we identify, in-license or acquire; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> seek regulatory approvals for any product candidates that successfully complete
clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> contract to manufacture our product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  establish on our own or with partners, a sales, marketing and distribution
infrastructure to commercialize any products for which we may obtain regulatory approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  maintain, expand and protect our intellectual property portfolio; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> hire additional staff, including clinical, scientific, operational and financial
personnel, to execute our business plan; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> add operational, financial and management information systems and personnel,
including personnel to support our product development and potential future commercialization efforts; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> to enable us to operate as a public company. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Historical Capital Resources  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our primary source of cash has been proceeds from the issuance of preferred stock and from the issuance of convertible notes and promissory notes.
From March 2009 through October 2014, we issued promissory notes for aggregate net proceeds of $0.3&nbsp;million. The promissory notes compounded at an 8% rate per annum basis and were exchanged for
convertible notes on November&nbsp;1, 2014. From November 2014 through February 2015, we issued convertible notes for aggregate net proceeds of $2.4&nbsp;million. The convertible notes compounded
on a daily basis at an 8% rate per annum and $0.7&nbsp;million was outstanding as of December&nbsp;31, 2014. The convertible notes were converted into shares of our Series&nbsp;A preferred stock
upon close of
the preferred stock financing in March 2015. The conversion equaled 125% of the unpaid principal plus unpaid accrued interest on the convertible notes. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>73</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=75,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=117984,FOLIO='73',FILE='DISK112:[15ZCH1.15ZCH40101]DM40101A.;80',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_dm40101_1_74"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
March 2015, we issued preferred stock for aggregate net proceeds of approximately $1.5&nbsp;million. In July and December 2015 we entered into convertible note financings in which we issued 8%
convertible notes in an aggregate principal amount of $5.5&nbsp;million to various investors. In February 2016, we issued additional 8% convertible notes in an aggregate principal amount of $0.2
million to various investors. In addition to our historical sources of cash through March&nbsp;31, 2016, on April 14, 2016, we amended the outstanding convertible notes and issued additional 8%
convertible notes in aggregate principal amount of $5.0&nbsp;million to various investors. The proceeds from the issuances of preferred stock and from the issuances of the convertible and promissory
notes have been used to fund our operations. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under
the amended terms of our outstanding convertible notes, upon the closing of a convertible preferred stock financing of at least $5&nbsp;million, 125% of the outstanding principal and accrued
interest under such notes shall convert into shares of the same series of stock issued in such financing at a conversion price equal to the per share price of the stock issued in such financing. In
the event that we approve a change of control transaction or firmly underwritten public offering of our common stock prior to the consummation of such a stock financing, the outstanding principal,
plus accrued interest, under such notes shall automatically convert into shares of our common stock at a conversion price of $6.70585 per share (which was adjusted from $2.15 in connection with the
1-for-3.119 reverse split of our stock, which became effective on April&nbsp;27, 2016). In the event that a stock financing, change of control or initial public offering has not occurred, the
convertible notes will become payable on demand any time after December&nbsp;31, 2016. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
following table summarizes our cash flows for the periods indicated: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="35pt" style="font-family:arial;"></TD>
<TD WIDTH="16pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Year Ended<BR>
December&nbsp;31, </FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Three Months<BR>
Ended<BR>
March&nbsp;31, </FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>2014 </FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>2015 </FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>2015 </FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>2016 </FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>(unaudited)</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>(in thousands)</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash used in operating activities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(195</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(5,433</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(620</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(2,056</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash used in investing activities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash provided by financing activities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>509</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>8,736</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2,307</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>65 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net increase (decrease) in cash</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>314</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3,303</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,687</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(1,991</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Cash Flow from Operating Activities  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For the year ended December 31, 2014, cash used in operating activities of $0.2&nbsp;million was attributable to a net loss of $0.3&nbsp;million,
partially offset by $108,000 in non-cash expenses and a net change of $17,000 in our net operating assets and liabilities. The non-cash expenses consisted of $53,000 of share-based compensation and
non-cash interest of $55,000 related to both the convertible notes and to the premium conversion derivative. The change in operating assets and liabilities was primarily attributable to increases in
accrued liabilities associated with our increased operating expenses. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For
the year ended December&nbsp;31, 2015, cash used in operating activities of $5.4&nbsp;million was attributable to a net loss of $9.0&nbsp;million, partially offset by $2.2&nbsp;million in
non-cash expenses and a net change of $1.4&nbsp;million in our net operating assets and liabilities. The non-cash expenses consist of $0.3&nbsp;million of share-based compensation, non-cash
interest of $0.8&nbsp;million related to both the convertible notes and to the premium conversion derivative, $0.9&nbsp;million related to a non-cash purchase of acquired in-process research and
development pursuant to the issuance of common stock and $0.2&nbsp;million related to a non-cash loss on extinguishment of convertible notes. The change in operating assets and liabilities was </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>74</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=76,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=131888,FOLIO='74',FILE='DISK112:[15ZCH1.15ZCH40101]DM40101A.;80',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_dm40101_1_75"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>attributable
to increases in accounts payable and accrued liabilities associated with our increased operating expenses. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For
the three months ended March&nbsp;31, 2015, cash used in operating activities of $0.6&nbsp;million was attributable to a net loss of $2.3&nbsp;million, partially offset by
$1.6&nbsp;million in non-cash expenses and a net change of $39,000 in our net operating assets and liabilities. The non-cash expenses consisted of $23,000 of share-based compensation, non-cash
interest expense of $0.7&nbsp;million related to both the convertible notes and to the premium conversion derivative, and $0.9&nbsp;million related to a non-cash purchase of acquired in-process
research and development pursuant to the issuance of common stock. The change in operating assets and liabilities was attributable to increases in accounts payable and accrued liabilities associated
with our increased operating expenses. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For
the three months ended March&nbsp;31, 2016, cash used in operating activities of $2.1&nbsp;million was attributable to a net loss of $2.1&nbsp;million coupled primarily with $(4,000) in
non-cash income adjustments and a net increase of $52,000 in our net operating liabilities. The non-cash (income) expenses consisted of $123,000 of share-based compensation offset by non-cash interest
income of $127,000 related to both the convertible notes and to the premium conversion derivative. The change in operating assets and liabilities was primarily attributable to a net increase in
accrued liabilities associated with fluctuations in our operating expense payments. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Cash Flow from Investing Activities  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>There were no sources or uses of funds from investing activities for all periods presented. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Cash Flow from Financing Activities  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Net cash provided by financing activities during the year ended December&nbsp;31, 2014 was $0.5&nbsp;million, consisting of $0.4&nbsp;million in
proceeds from the issuance of convertible notes and $0.1&nbsp;million in proceeds received from the issuance of promissory notes. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Net
cash provided by financing activities was $8.7&nbsp;million during the year ended December&nbsp;31, 2015. Net cash provided by financing activities during the year ended December&nbsp;31,
2015 consisted of $1.5&nbsp;million in proceeds from the issuance of Series&nbsp;A preferred stock and $7.4&nbsp;million in proceeds from the issuance of convertible notes, offset by financing
costs of $0.2&nbsp;million associated with the proposed initial public offering. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Net
cash provided by financing activities was $2.3&nbsp;million during the three months ended March&nbsp;31, 2015 and consisted of $0.3&nbsp;million in proceeds from the issuance of
Series&nbsp;A preferred stock and $2.0&nbsp;million in proceeds from the issuance of convertible notes. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Net
cash provided by financing activities during the three months ended March&nbsp;31, 2016 was $65,000 consisting of $0.2&nbsp;million in proceeds from the issuance of convertible notes in
February 2016 offset in part by financing costs of $86,000 associated with the proposed initial public offering. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Liquidity and Capital Resource Requirements  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have no current source of revenue to sustain our present activities, and we do not expect to generate revenue until, and unless, the FDA or other
regulatory authorities approve gemcabene and we successfully commercialize gemcabene. Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs
through a combination of equity and debt financings as well as collaborations, strategic alliances and licensing arrangements. We do not have any committed external source of funds. To the extent that
we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include
liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our
ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or
licensing arrangements with </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>75</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=77,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=604876,FOLIO='75',FILE='DISK112:[15ZCH1.15ZCH40101]DM40101A.;80',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_dm40101_1_76"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>pharmaceutical
partners, we may have to relinquish valuable rights to our technologies, future revenue streams or grant licenses on terms that may not be favorable to us. If we are unable to raise
additional funds through equity or debt financings or through collaborations, strategic alliances or licensing arrangements when needed, we may be required to delay, limit, reduce or terminate our
product development, future commercialization efforts, or grant rights to develop and market gemcabene that we would otherwise prefer to develop and market ourselves. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Future Capital Requirements  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our independent registered public accounting firm included an explanatory paragraph in its report on our financial statements as of and for the years
ended December&nbsp;31, 2014 and 2015, noting the existence of substantial doubt about our ability to continue as a going concern. This uncertainty arose from management's review of our results of
operations and financial condition and its conclusion that, based on our operating plans, we did not have sufficient existing working capital to sustain operations through December&nbsp;31, 2016. To
continue to fund operations, we will need to raise capital in addition to the net proceeds of this offering. We may obtain additional financing in the future through the issuance of our common stock,
through other equity or debt financings or through collaborations or partnerships with other companies. We may not be able to raise additional capital on terms acceptable to us, or at all, and any
failure to raise capital as and when needed could compromise our ability to execute on our business plan. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
believe that the net proceeds from this offering, together with cash on hand of $1.6&nbsp;million at March&nbsp;31, 2016, will be sufficient to fund our operations for at least the next 24
months, including our planned EOP2 meetings with the FDA. We expect that we will need at least an additional $100&nbsp;million to fund our operations and the development of gemcabene through such
time as we receive approval of an NDA for gemcabene for one or more of the targeted indications, if such approval is ever received and exclusive of any outcomes trials. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
development of gemcabene is subject to numerous uncertainties, and we have based these estimates on assumptions that may prove to be substantially different than we currently anticipate and could
use our cash resources sooner than we expect. Additionally, the process of advancing early-stage product candidates and testing product candidates in clinical trials is costly, and the timing of
progress in these clinical trials is uncertain. Our ability to successfully transition to profitability will be dependent upon achieving a level of product sales adequate to support our cost
structure. We cannot assure you that we will ever be profitable or generate positive cash flow from operating activities. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Furthermore,
we will need to raise additional capital to continue to fund the further development of gemcabene and other potential product candidates, our operations, and commercialization of
gemcabene and other potential product candidates, if approved. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Contractual Obligations and Commitments  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following table summarizes our contractual obligations as of December&nbsp;31, 2015, which represent material expected or contractually
committed future obligations. </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="84pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="84pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="84pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="84pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="84pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Payments Due by Period </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Less than 1&nbsp;year </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>1-3 Years </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>3-5 Years </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>More than 5&nbsp;years </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Total </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands)</B></FONT><BR></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Convertible notes</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,424</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,424 </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,424</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,424 </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>76</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=78,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=924638,FOLIO='76',FILE='DISK112:[15ZCH1.15ZCH40101]DM40101A.;80',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_do40101_1_77"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We lease a facility under a fixed cancellable operating lease effective on January&nbsp;1, 2015 that, as amended, expires on December&nbsp;31, 2016. We plan to terminate
this lease in August 2016. In May 2016, we entered into a 3 year non-cancellable facility lease commencing August&nbsp;1, 2016 and made an initial payment of approximately $91,000, $75,000 of which
will be treated as prepaid rent following this offering. The initial term of the agreement is three years with an initial monthly base rent of approximately $8,400. Additionally, in the course of our
normal operations, we have entered into cancellable purchase commitments with our suppliers for various key research and clinical services and raw materials. The purchase commitments covered by these
arrangements are subject to change based on our research and development efforts. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
April 2011, we entered into a license agreement with Pfizer (the Pfizer Agreement) for a worldwide exclusive license to certain patent rights to make, use, sell, offer for sale and import the
clinical product candidate gemcabene. In exchange for this license, we agreed to issue shares of our common stock to Pfizer representing 15% of our fully diluted capital at the close of our first
arms-length Series&nbsp;A financing, which occurred in March 2015. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
agreed to make milestone payments totaling up to $37&nbsp;million upon the achievement of certain milestones, including the first regulatory submission in any country, regulatory approval in each
of the United States, Europe and Japan, the first anniversary of the first regulatory approval in any country, and upon achieving certain aggregate sales levels of gemcabene or any product containing
gemcabene. Future milestone payments under the
Pfizer Agreement, if any, are not expected to begin for at least several years and extend over a number of subsequent years. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have also agreed to pay Pfizer tiered royalties on a country-by-country basis based upon the annual amount of net sales as specified in the Pfizer Agreement until expiration of the last valid claim
of the licensed patent rights, including any patent term extensions or supplemental protection certificates. The royalty rates range from the high single digits to the low teens depending on the level
of net sales. Under the Pfizer Agreement we are obligated to use commercially reasonable efforts to develop and commercialize gemcabene. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
Pfizer Agreement will expire upon expiration of the last royalty term. Either party may terminate the Pfizer Agreement for the other party's uncured material breach and specified bankruptcy
events. Pfizer may terminate the Pfizer Agreement if we or any of our sublicensees challenge the validity, enforceability or ownership of the licensed patents. Additionally, Pfizer may revoke the
license if we are unable to adequately commercialize gemcabene by April 2021. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
of March&nbsp;31, 2016, no obligations were recorded related to the Pfizer Agreement due to the inability to reasonably estimate the timing and outcomes of the gemcabene trials as well as the
timing and amounts of future sales of gemcabene, if any. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Upon
the issuance of our Series&nbsp;A preferred stock in March 2015, the Series&nbsp;A preferred stockholders effectively receive cumulative accruing dividends at a simple rate of 8% per year on
the original issue price of the preferred stock. The dividends are payable upon the earliest to occur of (1)&nbsp;the date determined by our board of directors, (2)&nbsp;our liquidation (including
a deemed liquidation event) or (3)&nbsp;the conversion or redemption of at least a majority of the outstanding shares of Series&nbsp;A preferred stock. If our board reasonably believes that we are
not legally able to pay the dividends in cash at the payment date, or if the dividends are paid upon the conversion of the Series&nbsp;A preferred in connection with our first firm commitment
underwritten public offering of its common stock, the dividends shall be paid in shares of common stock at the conversion price for the Series&nbsp;A preferred stock in effect at that time, which is
the original issue price of the Series&nbsp;A preferred stock as adjusted from time to time for any stock dividends, combinations, splits or recapitalizations. Since the dividends are payable upon a
contingent event, we have not recorded them our financial statements. At March&nbsp;31, 2016, cumulative unpaid dividends for the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>77</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=79,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=143950,FOLIO='77',FILE='DISK112:[15ZCH1.15ZCH40101]DO40101A.;78',USER='CHE106816',CD=';5-AUG-2016;17:45' -->
<A NAME="page_do40101_1_78"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Series&nbsp;A
preferred stock totaled $0.4&nbsp;million, which shall become payable in shares of common stock immediately prior to the closing of this offering. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>On
July&nbsp;31, 2015, December&nbsp;11, 2015, February&nbsp;25, 2016 and April&nbsp;14, 2016 we issued convertible notes as discussed above under "&#151;&nbsp;Liquidity and Capital
Resources&nbsp;&#151;&nbsp;Historical Capital Resources" pursuant to which certain investors agreed to loan us approximately $2.8&nbsp;million, $2.7&nbsp;million, $0.2&nbsp;million
and $5.0&nbsp;million, respectively. The convertible notes accrue interest at a rate of 8% per annum, compounded annually, and automatically convert into equity upon the occurrence of certain
events, including the consummation of this offering. The outstanding principal and accrued interest on the convertible notes as of May&nbsp;2, 2016 was $10.9&nbsp;million. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Critical Accounting Policies and Estimates  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our financial statements are prepared in accordance with GAAP. These accounting principles require us to make estimates and judgments that can affect
the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenue and expense during the periods presented. We believe that the
estimates and judgments upon which we rely are reasonably based upon information available to us at the time that we make these estimates and judgments. To the extent that there are material
differences between these estimates and actual results, our financial results will be affected. The accounting policies that reflect our more significant estimates and judgments and which we believe
are the most critical to aid in fully understanding and evaluating our reported financial results are described below. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
following is not intended to be a comprehensive list of all of our accounting policies or estimates. Our accounting policies are more fully described in Note&nbsp;2&nbsp;&#151; </FONT> <FONT SIZE=2><I>Summary of Significant Accounting
Policies</I></FONT><FONT SIZE=2>, in our audited financial statements included elsewhere in this prospectus. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Income Taxes  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We utilize the liability method of accounting for income taxes as required by Accounting Standards Codification (ASC) 740, </FONT> <FONT SIZE=2><I>Income Taxes</I></FONT><FONT SIZE=2>. Under this method, deferred tax assets and
liabilities are determined based on differences between financial reporting and the tax basis of
assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. Currently, there is no provision for income taxes, as we
have incurred operating losses to date, and a full valuation allowance has been provided on the net deferred tax assets. MLT was treated as a partnership for federal and state income tax purposes.
Accordingly, no provision was made for income taxes for periods prior to October&nbsp;30, 2014, since the net losses incurred up to that time (subject to certain limitations) was passed through to
the income tax returns of its members. Upon incorporation on October&nbsp;30, 2014 we became taxable as a corporation. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Since
incorporation, we have filed U.S. federal and Michigan state income tax returns. Our deferred tax assets were primarily comprised of federal and state tax net operating loss carryforwards,
acquired intangibles and tax credit carryforwards and were recorded using enacted tax rates expected to be in effect in the years in which these temporary differences are expected to be utilized. As
of December&nbsp;31, 2014, the tax effect of our federal and state net operating loss carryforwards was approximately $83,000 and $10,000, respectively, and our federal research and development
credit carryforward was $114. As of December&nbsp;31, 2015, the tax effect of our federal and state net operating loss carryforwards was approximately $2.4&nbsp;million and $0.3&nbsp;million,
respectively, and our federal research and development credit carryforward was $95,000. As of March&nbsp;31, 2016, the tax effect of our federal and state net operating loss carryforwards was
approximately $3.1&nbsp;million and $0.4&nbsp;million, respectively, and our federal research and development credit carryforward was $125,000. We did not have any state research and development
credit carryforwards. The federal net operating loss and tax credit carryforwards will begin to expire in 2034 if not utilized. The state net operating loss carryforwards will begin to expire in 2024
if not utilized. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>78</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=80,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=492977,FOLIO='78',FILE='DISK112:[15ZCH1.15ZCH40101]DO40101A.;78',USER='CHE106816',CD=';5-AUG-2016;17:45' -->
<A NAME="page_do40101_1_79"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Utilization
of the net operating loss and tax credit carryforwards may be subject to an annual limitation due to historical or future ownership percentage change rules provided by the Internal Revenue
Code of 1986, as amended, and similar state provisions. The annual limitation may result in the expiration of certain net operating loss and tax credit carryforwards before their utilization. However,
due to uncertainties surrounding our ability to generate future taxable income to realize these tax assets, a full valuation allowance has been established to offset our deferred tax assets. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Convertible Preferred Stock  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We initially record preferred stock that may be redeemed at the option of the holder, or based on the occurrence of events outside our control, in
mezzanine equity at the value of the proceeds received. Subsequently, if it is probable that the preferred stock will become redeemable, we recognize changes in the redemption value immediately as
they occur and adjust the carrying amount of the instrument to equal the redemption value at the end of each reporting period. If it is not probable that the preferred stock will become redeemable, we
do not adjust the carrying value. In the absence of retained earnings these charges are recorded against additional paid-in-capital, if any, and then to accumulated deficit. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Share-Based Compensation  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our share-based compensation for share-based awards is accounted for in accordance with authoritative guidance and is estimated at the grant date
based on the fair value of the award and recognized as expense ratably over the requisite vesting period of the award, net of estimated forfeitures. Determining the appropriate fair value of
share-based awards requires judgment. We calculate the fair value of each award to employees on the date of grant based on the fair value of our common stock. See "&#151;&nbsp;Common Stock
Valuation" below. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
calculate the fair value of each stock option award to employees on the date of grant under the Black-Scholes option-pricing model using certain assumptions related to the fair value of our common
stock, the option's expected term, our expected stock price volatility, risk free interest rates and our expected dividend rate. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For
options to purchase common stock issued to non-employees, including consultants, we record share-based compensation based on the fair value of the options. We calculate the fair value of each
share-based award to non-employees on each measurement date based on the fair value of our common stock. The fair value of options granted to non-employees is remeasured as the options vest and is
recognized in the statements of operations during the period the related services are rendered. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
fair value of each stock option grant was determined using the methods and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment and
estimation by management.  </FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I> Fair Value of Common
Stock.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;As discussed below in "&#151;&nbsp;Common Stock Valuation," because there is no public market for our common stock as we
are a private company, our board of directors has determined the fair value of the common stock by considering a number of objective and subjective factors, including based on contemporaneous
valuations of our common stock performed by an unrelated valuation specialist. The fair value of our common stock will be determined by our board of directors until such time as our common stock is
listed on an established stock exchange.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I> Expected
Term.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;The expected term represents the period that share-based awards are expected to be outstanding. The expected term for option grants
is determined using the simplified method. The simplified method deems the term to be the average of the time-to-vesting and the contractual life of the share-based awards. The expected term for
options issued to nonemployees is the contractual term.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I> Expected
Volatility.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Since we do not have a trading history of our common stock, the expected volatility was derived from the historical stock
volatilities of comparable peer public companies within our industry that we consider to be comparable to our business over a period equivalent to the expected term of the share-based awards. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>79</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=81,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=905147,FOLIO='79',FILE='DISK112:[15ZCH1.15ZCH40101]DO40101A.;78',USER='CHE106816',CD=';5-AUG-2016;17:45' -->
<A NAME="page_do40101_1_80"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I> Risk-Free Interest
Rate.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant for zero-coupon U.S. Treasury
notes with maturities approximately equal to the share-based awards' expected term.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I> Expected Dividend
Rate.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;The expected dividend is zero as we have not paid and do not anticipate paying any dividends on our common stock for the
foreseeable future.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>  Forfeiture
Rate.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;The forfeiture rate is estimated based on an analysis of actual forfeitures. Management will continue to evaluate the adequacy of
the forfeiture rate based on actual forfeiture experience, analysis of employee turnover behavior and other factors. The impact from any forfeiture rate adjustment would be recognized in full in the
period of adjustment and if the actual number of future forfeitures differs from management's estimates, we might be required to record adjustments to share-based compensation in future periods. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>The
estimated grant-date fair value of our share-based awards was calculated using Black-Scholes option-pricing model, based on the following assumptions for the following periods presented: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="39pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="39pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="74pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Three Months<BR>
Ended<BR>
March&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2015 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2016 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected volatility</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>71.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected term (in years)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>5.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected dividend rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk-free interest rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<P style="font-family:arial;"><FONT SIZE=2>If
any of the assumptions used in the Black-Scholes option-pricing model change significantly, share-based compensation for future awards may differ materially compared with the awards granted
previously. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For
2014 and 2015, share-based compensation was $53,000 and $0.3&nbsp;million, respectively. For the three months ended March&nbsp;31, 2015 and 2016, share-based compensation expense was $23,000
and $123,000, respectively. As of March&nbsp;31, 2016, we had unrecognized share-based compensation expense totaling $0.4&nbsp;million, $14,000 of which we will recognize upon the vesting of
certain awards that are expected to vest upon the closing of this offering. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Based
upon the initial public offering price of $10.00 per share, the aggregate intrinsic value of options outstanding as of March&nbsp;31, 2016 was approximately $2.3&nbsp;million, of which
approximately $1.1&nbsp;million related to vested options and approximately $1.2&nbsp;million related to unvested options. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Common Stock Valuation  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In the absence of a public trading market for our common stock, on each grant date, we develop an estimate of the fair value of our common stock in
order to determine an exercise price for each share-based award. We have determined the fair value of our common stock using methodologies, approaches and assumptions consistent with the </FONT> <FONT SIZE=2><I>American Institute of Certified Public
Accountants Practice Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation</I></FONT><FONT SIZE=2>. Our board
of directors exercised reasonable judgment and considered a number of objective and subjective factors to determine the best estimate of the fair value of our common stock, including having
contemporaneous and retrospective valuations of our common stock performed by an unrelated valuation specialist, valuations of comparable securities transactions, sales of our convertible preferred
stock to unrelated third parties, the rights, preferences and privileges of our common stock versus our preferred stock, our operating and financial performance, our stage of development, current
business conditions, our projections, business developments, the lack of liquidity of our capital stock and general and industry specific economic outlook. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>80</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=82,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=841691,FOLIO='80',FILE='DISK112:[15ZCH1.15ZCH40101]DO40101A.;78',USER='CHE106816',CD=';5-AUG-2016;17:45' -->
<A NAME="page_do40101_1_81"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For
our common stock valuations performed from November&nbsp;1, 2014 up until the issuance of our Series&nbsp;A convertible preferred stock (the Series&nbsp;A preferred stock) in March 2015, the
fair value of our common stock was estimated entirely using a hybrid of two market approaches, specifically a proposed Series&nbsp;A preferred stock </FONT><FONT SIZE=2><I>Securities
Transaction&nbsp;&#151; Backsolve</I></FONT><FONT SIZE=2> method and the Series&nbsp;A preferred stock post-money value. This later approach considers the implied equity value based on a
common equivalent capitalization table associated with an IPO exit. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Once
the Series&nbsp;A preferred stock round was consummated in March 2015, common stock valuations began to rely on the indications of value realized in the transaction through June&nbsp;30,
2015. The fair value of our common stock
was estimated using a hybrid of two market approaches, specifically the realized Series&nbsp;A preferred stock </FONT><FONT SIZE=2><I>Recent Securities Transaction&nbsp;&#151;
Backsolve</I></FONT><FONT SIZE=2> method and the Series&nbsp;A preferred stock post-money value. This later approach considers our implied equity value based on a common equivalent capitalization
table associated with an IPO exit. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Beginning
in the third quarter of 2015, the fair value of our common stock was estimated using a hybrid of two market approaches, specifically the value of a potential Series&nbsp;B convertible
preferred stock financing utilizing a </FONT><FONT SIZE=2><I>Proposed Securities Transaction&nbsp;&#151; Backsolve</I></FONT><FONT SIZE=2> method and the value of a potential Series&nbsp;B
financing post-money as a common stock equivalent for an IPO exit. Lastly, the completed Series&nbsp;A preferred stock </FONT><FONT SIZE=2><I>Recent Securities Transaction&nbsp;&#151;
Backsolve</I></FONT><FONT SIZE=2> method was considered in the event that a Series&nbsp;B convertible preferred stock financing or an IPO could not be achieved. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Beginning
in the fourth quarter of 2015 and through the first quarter of 2016, the fair value of our common stock was estimated using a hybrid of two market approaches, specifically the value of a
potential Series&nbsp;B convertible preferred stock financing utilizing a </FONT><FONT SIZE=2><I>Proposed Securities Transaction&nbsp;&#151; Backsolve</I></FONT><FONT SIZE=2> method and a
pre-money IPO value for an IPO exit. Lastly, the completed Series&nbsp;A preferred stock </FONT><FONT SIZE=2><I>Recent Securities Transaction&nbsp;&#151; Backsolve</I></FONT><FONT SIZE=2>
method was considered in the event that a Series&nbsp;B convertible preferred stock financing or an IPO could not be achieved. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
considered the various methods for allocating the enterprise value across our classes and series of capital stock to determine the fair value of our common stock at each valuation date. The methods
we used consisted of the following: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I> Option pricing method
(OPM).</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Under the option pricing method, shares are valued by creating a series of call options with exercise prices based on the
liquidation preferences and conversion terms of each equity class. The values of the preferred and common stock are inferred by analyzing these options.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>  Probability-weighted expected return method
(PWERM).</I></FONT><FONT SIZE=2>&nbsp;&nbsp;The PWERM is a scenario-based analysis that estimates the value per share based on the probability-weighted present value of
expected future investment returns, considering each of the possible outcomes available to us, as well as the economic and control rights of each share class. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Our
per share common stock value was estimated by allocating the equity value using a hybrid combination of OPM and PWERM. We used either PWERM or a combination of the OPM and the PWERM as described
above to allocate the equity value to each element of our capital structure, including our common stock. For both approaches, we applied a discount to the valuations due to the lack of marketability
of the ordinary shares. We
calculated the discount for lack of marketability using a Finnerty model and applied it as appropriate to each allocation. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
dates of our valuations did not always coincide with the dates of our option grants. In such instances, management's estimates were based on the most recent valuation of shares of our common
stock. For grants occurring between valuation dates, for financial reporting purposes, we considered the preceding valuations and our assessment of additional objective and subjective factors we
believed were relevant as of the grant date to determine the fair value of our common stock. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>81</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=83,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=307985,FOLIO='81',FILE='DISK112:[15ZCH1.15ZCH40101]DO40101A.;78',USER='CHE106816',CD=';5-AUG-2016;17:45' -->
<A NAME="page_do40101_1_82"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Off-Balance Sheet Arrangements  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We did not have during the periods presented, and we do not currently have any off-balance sheet financing arrangements. In addition, we did not have
during the periods presented, and we do not currently have any interest in entities referred to as variable interest entities, which includes special purpose entities and other structured finance
entities. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Recent Accounting Pronouncements  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In July 2013, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2013-11, </FONT><FONT SIZE=2><I>Income
Taxes&nbsp;&#151; Topic&nbsp;740</I></FONT><FONT SIZE=2>, which is an amendment to the accounting guidance on income taxes. This guidance provides clarification on the financial statement
presentation of an unrecognized benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The amendment was effective for us for interim and annual
periods beginning after December&nbsp;15, 2013, with early adoption permitted. The adoption of this standard did not have a material impact on our financial statements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
May 2014, the FASB issued ASU&nbsp;2014-09, </FONT><FONT SIZE=2><I>Revenue from Contracts with Customers&nbsp;&#151; Topic&nbsp;606</I></FONT><FONT SIZE=2>, which supersedes the revenue
recognition requirements in FASB ASC&nbsp;605. The new guidance primarily states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an
amount
that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. In 2015 the FASB agreed to allow companies to delay the implementation of this
standard for one year effective for annual reporting periods beginning after December&nbsp;15, 2017, including interim periods within that reporting period. Early application is permitted only for
periods beginning after December&nbsp;15, 2016. We are evaluating its implementation method and the impact of adopting this prospective guidance on our financial statements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
June 2014, the FASB issued ASU&nbsp;2014-10, </FONT><FONT SIZE=2><I>Elimination of Certain Financial Reporting Requirements, including an Amendment to Variable Interest Entities Guidance in
Topic&nbsp;810, Consolidation</I></FONT><FONT SIZE=2>. This guidance removed all incremental financial reporting requirements from GAAP for development stage entities, thereby improving financial
reporting by eliminating the cost and complexity associated with providing that information. The effective date of the amendment is staggered for public and nonpublic entities with the first date
being for annual periods beginning after December&nbsp;15, 2014, with early adoption permitted for financial statements that have not yet been issued or available to be issued. We elected to adopt
this standard early to take effect in the financial statements and related notes appearing elsewhere in this prospectus. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
June 2014, the FASB issued ASU&nbsp;2014-12, </FONT><FONT SIZE=2><I>Compensation&nbsp;&#151; Stock Compensation (Topic&nbsp;718): Accounting for Share-Based Payments When the Terms of
an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period</I></FONT><FONT SIZE=2> (ASU&nbsp;2014-12). The amendments in ASU&nbsp;2014-12 require that a
performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in
ASC&nbsp;718, as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in ASU&nbsp;2014-12 are effective for annual periods and interim
periods within those annual periods beginning after December&nbsp;15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU&nbsp;2014-12 either: (1)&nbsp;prospectively to
all awards granted or modified after the effective date; or (2)&nbsp;retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period
presented in the financial statements and to all new or modified awards thereafter. The adoption of this standard did not have a material impact on our financial statements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
August 2014, the FASB issued Accounting Standards Update No.&nbsp;2014-15, </FONT><FONT SIZE=2><I>Presentation of Financial Statements&nbsp;&#151; Going Concern (Subtopic&nbsp;205-40):
Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern</I></FONT><FONT SIZE=2> (ASU&nbsp;2014-15), which requires management to evaluate, in connection with preparing
financial statements for each annual and interim reporting period, whether there are conditions or </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>82</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=84,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=425085,FOLIO='82',FILE='DISK112:[15ZCH1.15ZCH40101]DO40101A.;78',USER='CHE106816',CD=';5-AUG-2016;17:45' -->
<A NAME="page_do40101_1_83"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>events,
considered in the aggregate, that raise substantial doubt about an entity's ability to continue as a going concern within one year after the date that the financial statements are issued (or
within one year after the date that the financial statements are available to be issued when applicable) and provide related disclosures. ASU&nbsp;2014-15 is effective for the annual period ending
after December&nbsp;15, 2016, and for annual and interim periods thereafter. Early adoption is permitted. We elected to adopt this standard early to take effect in the financial statements and
related notes appearing elsewhere in this prospectus. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
January 2015, the FASB issued ASU&nbsp;2015-01, </FONT><FONT SIZE=2><I>Income Statement&nbsp;&#151; Extraordinary and Unusual Items</I></FONT><FONT SIZE=2> (ASU&nbsp;2015-01).
ASU&nbsp;2015-01 eliminates from GAAP the concept of extraordinary items. As a result, an entity will no longer be required to separately present an extraordinary item on its statement of
comprehensive loss, net of tax, after income from continuing operations, or disclose income taxes and net income per share data applicable to an extraordinary item. However, ASU&nbsp;2015-01 will
still retain the presentation and disclosure guidance for items that are unusual in nature and occur infrequently. ASU&nbsp;2015-01 is effective for fiscal years, and interim periods within those
fiscal years, beginning after December&nbsp;15, 2015. Early adoption is permitted provided the guidance is applied from the beginning of the fiscal year of adoption. The adoption of this standard
did not have a material impact on our financial statements, absent any material transactions in future periods that would qualify for extraordinary item presentation under the prior guidance. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
April 2015, the FASB issued ASU&nbsp;2015-03, </FONT><FONT SIZE=2><I>Interest&nbsp;&#151; Imputation of Interest</I></FONT><FONT SIZE=2> (ASU&nbsp;2015-03). ASU&nbsp;2015-03 requires
that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts.
The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this update. For public entities, ASU&nbsp;2015-03 is effective for fiscal years, and interim
periods within those fiscal years, beginning after December&nbsp;15, 2015. The adoption of this standard did not have a material impact on our financial statements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
November 2015, the FASB issued ASU&nbsp;2015-17, </FONT><FONT SIZE=2><I>Income Taxes (Topic&nbsp;740): Balance Sheet Classification of Deferred Taxes</I></FONT><FONT SIZE=2>
(ASU&nbsp;2015-17). The new guidance simplifies the presentation of deferred income taxes by requiring that deferred tax liabilities and assets be classified as noncurrent in a classified statement
of financial position. ASU&nbsp;2015-17 applies to all entities that present a classified statement of financial position. The current requirement that deferred tax liabilities and assets of a
tax-paying component of an entity be offset and presented as a single amount is not affected by this ASU. For public entities, ASU&nbsp;2015-17 is effective for financial statements issued for
annual periods beginning after December&nbsp;15, 2016 with earlier application permitted. The new guidance may be applied either prospectively or retrospectively to all periods presented. We are
evaluating our implementation method and the impact of adopting this prospective guidance on our financial statements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
January 2016, the FASB issued ASU No.&nbsp;2016-01, </FONT><FONT SIZE=2><I>Financial Instruments&nbsp;&#151; Overall: Recognition and Measurement of Financial Assets and Financial
Liabilities.</I></FONT><FONT SIZE=2> The guidance affects the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements of
financial instruments. The guidance is effective in the first quarter of fiscal 2019. Early adoption is permitted for the accounting guidance on financial liabilities under the fair value option. We
are currently evaluating the impact of the new guidance on our financial statements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
February 2016, the FASB issued ASU&nbsp;2016-02, </FONT><FONT SIZE=2><I>Leases (Topic&nbsp;842)</I></FONT><FONT SIZE=2>. The objective of this update is to increase transparency and
comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This ASU is effective for fiscal
years beginning after December&nbsp;15, 2018, including interim periods within those annual periods and is to be applied utilizing a modified retrospective approach. We are currently evaluating the
new guidance to determine the impact it may have on our financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>83</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=85,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=320094,FOLIO='83',FILE='DISK112:[15ZCH1.15ZCH40101]DO40101A.;78',USER='CHE106816',CD=';5-AUG-2016;17:45' -->
<A NAME="page_do40101_1_84"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
March 2016, the FASB issued ASU&nbsp;2016-09, </FONT><FONT SIZE=2><I>Compensation&nbsp;&#151; Stock Compensation (Topic&nbsp;718): Improvements to Employee Share-Based Payment
Accounting</I></FONT><FONT SIZE=2>. This ASU simplifies the accounting for share-based payment award transactions including: income tax consequences, classification of awards as either equity or
liabilities and classification on the statement of cash flows. This ASU is effective for fiscal years beginning after December&nbsp;15, 2016, including interim periods within those fiscal years.
Early adoption is permitted. We are currently evaluating the requirements of the new guidance and have not yet determined its impact on our financial statements. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Quantitative and Qualitative Disclosures about Market Risk  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The market risk inherent in our financial instruments and in our financial position is the potential loss arising from adverse changes in interest
rates. As of December&nbsp;31, 2015, we had cash and cash equivalents of $3.6&nbsp;million. We generally hold our excess cash in interest-bearing money market accounts. Our primary exposure to
market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short-term maturities of our cash equivalents and the low risk profile of
our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


JOBS Act Accounting Election  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Jumpstart Our Business Startups Act of 2012 permits emerging growth companies such as us to delay adopting new or revised accounting standards
until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this and, therefore, we will be subject to the same new or revised accounting
standards as other public companies that are not emerging growth companies. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>84</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=86,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=808920,FOLIO='84',FILE='DISK112:[15ZCH1.15ZCH40101]DO40101A.;78',USER='CHE106816',CD=';5-AUG-2016;17:45' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dq40101_1_85"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dq40101_business"> </A>
<A NAME="toc_dq40101_1"> </A>
<BR></FONT><FONT SIZE=2><B>  BUSINESS    <BR>    </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Overview  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious
medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad
cholesterol, triglycerides, or fat in the blood, or both. We are developing our product candidate gemcabene (CI-1027), a novel, once-daily, oral therapy, for patients who are unable to achieve normal
levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy. Gemcabene's dual mechanism of action is designed to enhance the clearance of very low-density lipoproteins
(VLDLs) in the plasma and inhibit the production of fatty acids and cholesterol in the liver. Gemcabene is liver-directed and inhibits apolipoprotein C-III (apoC-III) protein in the liver and may
inhibit acetyl-CoA
carboxylase (ACC) in the liver. Gemcabene has been tested as monotherapy and in combination with statins and other drugs in 895&nbsp;subjects, which we define as healthy volunteers and patients,
across 18 Phase&nbsp;1 and Phase&nbsp;2 clinical trials and has demonstrated promising evidence of efficacy, safety and tolerability. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Cardiovascular
disease is a major health concern, causing more deaths globally than any other disease. Dyslipidemia is generally viewed as an important predictor of cardiovascular events including
heart attack and stroke, and a cause of cardiovascular disease. It comprises one of the largest therapeutic areas with annual worldwide drug sales of approximately $22&nbsp;billion in 2013. We
estimate more than 40% of Americans have LDL-C or triglycerides, or both, above a normal range. Statins, such as Lipitor, marketed by Pfizer&nbsp;Inc. (Pfizer), and Crestor, marketed by AstraZeneca
Pharmaceuticals LP (AstraZeneca), among others, are standard of care for LDL-C lowering, while fibrates, prescription fish oils and niacin are standard of care for triglyceride lowering. Although
these drugs are highly prescribed and capable of reducing LDL-C and triglyceride levels, many patients are unable to effectively manage their dyslipidemia with currently approved therapies and are in
need of better treatment alternatives. For example, approximately 40% of patients on statins are unable to meet their LDL-C lowering goal, and doubling a statin dose has shown to incrementally lower
LDL-C levels by a nominal percentage (approximately 6% based on historical evidence), while increasing safety and tolerability concerns. An even higher percentage of patients with severe
hypertriglyceridemia do not achieve triglyceride levels low enough to reduce the risk of developing co-morbidities such as pancreatitis. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
believe gemcabene possesses a differentiated product profile compared to other therapies in the market and in clinical development. Key attributes of our product candidate include the
following: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B> Cost-effective,
once-daily, oral therapy.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Gemcabene is a small molecule formulated as a tablet and is cost effective to manufacture. As a once-daily,
oral therapy, gemcabene, if approved, would be more convenient than other non-statin therapies, many of which require frequent injections or multiple daily doses. We expect to take a value-based
approach to pricing across the target indications.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B> Promising safety
and tolerability.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Gemcabene was observed to be well tolerated in 895&nbsp;subjects across 18 Phase&nbsp;1 and Phase&nbsp;2 trials
both as monotherapy and in combination with statins. No subjects died and no subjects experienced a serious adverse event (SAE) that was considered to be related to gemcabene. Adverse events (AEs)
reported were generally mild to moderate in intensity. Gemcabene did not appear to increase the reporting of myalgia (muscle pain) when added to statin therapy and no treatment related events of
myalgia were reported in any gemcabene monotherapy arm in the dyslipidemia trials.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B> Significant
lipid-lowering of LDL-C, high-sensitivity C-reactive protein (hsCRP) and triglycerides.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;In Phase&nbsp;2 trials, patients with
hypercholesterolemia treated with gemcabene as monotherapy were observed to have significantly lowered LDL-C by approximately 30% from baseline and significantly lowered hsCRP by approximately 40%
from baseline. In addition, patients with hypertriglyceridemia (<FONT FACE="SYMBOL">&#179;</FONT>200&nbsp;mg/dL) were observed to have significantly lowered triglycerides by approximately
40%, and </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>85</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=87,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=610837,FOLIO='85',FILE='DISK112:[15ZCH1.15ZCH40101]DQ40101A.;235',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_dq40101_1_86"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:arial;"><FONT SIZE=2>based
on post-hoc analysis, gemcabene was observed to lower triglycerides by up to 60% in patients with severe triglyceride levels (<FONT FACE="SYMBOL">&#179;</FONT>500&nbsp;mg/dL). Our
product candidate's ability to meaningfully lower levels of multiple key lipids attributable to cardiovascular disease may expand its use across multiple indications within the dyslipidemia market. </FONT></P>

</UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B> Additive effect
in combination with statins.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;In a Phase&nbsp;2 trial in patients with uncontrolled hypercholesterolemia while on stable statin therapy,
gemcabene was observed to significantly lower LDL-C by an additional 25% to 31% from baseline. This data indicates that gemcabene may better treat a large population of patients who are unable to
reach their lipid goal with statins and other currently prescribed therapies.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B> No drug-drug
interactions when combined with high-intensity statin doses.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;In two Phase&nbsp;1 trials, gemcabene was tested in combination with
high-intensity statin doses, 80&nbsp;mg simvastatin and 80&nbsp;mg atorvastatin. No clinically relevant drug-drug interactions were observed. In addition, gemcabene has been formulated as a
fixed-dose combination tablet with various atorvastatin doses, which may offer additional convenience and compliance to patients. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>We
are initially pursuing gemcabene in the following four indications (representing approximately 14&nbsp;million addressable patients in the United States) as a treatment in addition to maximally
tolerated statin therapy for patients who are unable to reach their lipid-lowering goals:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  homozygous familial hypercholesterolemia (HoFH), a rare genetic lipid disorder
which results in elevated LDL-C usually due to mutations in both alleles, a pair of genes on a chromosome responsible for a specific trait, of the LDL-receptor gene; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  heterozygous familial hypercholesterolemia (HeFH), a more prevalent genetic
lipid condition which results in elevated LDL-C usually due to a mutation in one allele of the LDL-receptor gene; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  atherosclerotic cardiovascular disease (ASCVD), patients with
hypercholesterolemia, or patients with elevated LDL-C who have had or are at risk for a cardiovascular event, such as heart attack or stroke; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> severe hypertriglyceridemia (SHTG), in which patients with elevated
triglycerides are at an increased risk of developing co-morbidities such as pancreatitis. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>We
are pursuing HoFH given that gemcabene has recently received orphan drug designation for this indication. We believe we can design an efficient development plan to provide a new treatment
alternative for those patients. Furthermore, we believe that gemcabene's potential ability to treat patients in the most severe segment of the dyslipidemia market, HoFH, will enhance brand awareness
among key thought leaders and physicians. We are developing gemcabene for HeFH, ASCVD and SHTG given gemcabene's: (1)&nbsp;promising clinical data in these indications; (2)&nbsp;cost-effective
manufacturing process; (3)&nbsp;convenient oral dosing; (4)&nbsp;viability as adjunct combination therapy; and (5)&nbsp;large commercial potential. By the end of 2016, we expect to initiate
three late stage clinical trials for gemcabene in HoFH, hypercholesterolemia, including HeFH and ASCVD patients on maximally tolerated statins, and SHTG. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>86</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=88,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=546606,FOLIO='86',FILE='DISK112:[15ZCH1.15ZCH40101]DQ40101A.;235',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_dq40101_1_87"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dq40101_gemcabene_pipeline_indications"> </A>
<A NAME="toc_dq40101_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Gemcabene Pipeline Indications    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g433713.jpg" ALT="GRAPHIC" WIDTH="679" HEIGHT="297">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Upon
completion of one or more of our trials, we intend to request one or more End of Phase&nbsp;2 (EOP2) meetings with the U.S. Food and Drug Administration (FDA) to reach an agreement on the
design of Phase&nbsp;3 registration trials and long-term safety exposure for our target indications. We intend to pursue similar discussions with Canadian and European health authorities. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
believe it is unlikely the FDA will require us to initiate a cardiovascular outcomes trial for our target indications. The FDA has not required the initiation or completion of cardiovascular
outcomes trials for recent approvals of certain dyslipidemia therapies, including non-statin therapies targeting LDL-C for the treatment of HoFH, HeFH and ASCVD and triglyceride lowering for treatment
of SHTG. Cardiovascular outcomes trials require evaluation of cardiovascular clinical conditions in large patient populations over a long period of time and are both costly and time-consuming.
However, for commercial and competitive reasons, such as the potential to broaden the label claims, we intend to review with the FDA a design for a cardiovascular outcomes trial which we may initiate
before an NDA submission and complete post-approval. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
company was co-founded by former Pfizer employees, Dr.&nbsp;Charles Bisgaier and David Lowenschuss, who were responsible for licensing exclusive worldwide rights to gemcabene from Pfizer in
April 2011. Prior to co-founding the original Esperion Therapeutics, Inc. (Esperion) in 1998, which was acquired by Pfizer in 2004, Dr.&nbsp;Bisgaier worked at Parke-Davis, a division of
Warner-Lambert Company from 1990 to 1998, and was instrumental in the discovery and development of gemcabene, as well as the development of Lipitor and Lopid. Many of our employees and
consultants have been involved in the historical development of gemcabene and other innovative dyslipidemia product candidates in development, including ETC-216, a synthetic high-density lipoprotein
mimetic based on ApoAI-Milano (developed by the original Esperion, Pfizer and currently The Medicines Company), ACP-501 (developed by AlphaCore Pharma, later acquired by AstraZeneca) and ETC-1002
(developed by the original Esperion, Pfizer and the current Esperion). We have organized a medical advisory board including Drs.&nbsp;John Kastelein, Evan Stein, Robert Hegele and Dirk Blom who
combined have been involved in numerous dyslipidemia and cardiovascular disease clinical trials (e.g., statins from their earliest trials, fibrates, ezetimibe, cholesteryl ester transfer protein
(CETP) inhibitors, extended release niacin, antisense oligonucleotides (mipomersen) and monoclonal antibodies including PCSK9 inhibitors and published numerous research papers. The management team,
led by our CEO Mina Sooch, collectively has significant experience in operating and
financing biopharmaceutical companies and discovering, developing and commercializing treatments in the cardiovascular and orphan markets. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>87</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=89,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=506166,FOLIO='87',FILE='DISK112:[15ZCH1.15ZCH40101]DQ40101A.;235',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_dq40101_1_88"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our Strategy  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our goal is to become a leading cardio-metabolic biopharmaceutical company that develops and commercializes best-in-class therapies for patients and
provides attractive solutions for physicians and payors. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
core elements of our strategy to achieve our goal are the following: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I> Advance the
late-stage clinical development of gemcabene across multiple target indications.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;We are focused on a broad spectrum of indications for
dyslipidemia patients ranging from the orphan indication HoFH to more prevalent conditions, such as HeFH, ASCVD and SHTG. The data from our 18 Phase&nbsp;1 and Phase&nbsp;2 trials and multiple
preclinical studies have provided us with a comprehensive set of information and key insights into gemcabene's mechanism of action, lipid-lowering effects and safety profile. Furthermore, recent
approvals of cardiovascular therapies in gemcabene's target indications, such as biologic PCSK9 inhibitors for HoFH, HeFH and ASCVD and prescription fish oils for SHTG have provided us with a better
understanding of current FDA views on approval of new dyslipidemia drugs. As a result, we believe that we have identified indications for gemcabene with favorable regulatory pathways and the highest
likelihood of commercial success compared to other potential indications for gemcabene. By the end of 2016, we plan to initiate three late stage clinical trials for gemcabene: an 8&nbsp;patient
trial for HoFH, a 212&nbsp;patient trial for hypercholesterolemia on high-intensity statin therapy including HeFH and ASCVD patients, and a 80 to 120&nbsp;patient trial for SHTG. We expect early
results from these trials starting by the end of 2016 continuing through the second half of 2017.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I> Expand the
breadth of indications beyond dyslipidemia for gemcabene.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;We are also exploring the utility of gemcabene in Nonalcoholic Steatohepatitis
(NASH) and/or Nonalcoholic Fatty Liver Disease (NAFLD) given its mechanism of action that decreases the production of the apoC-III protein and may inhibit ACC, which has been observed to result in the
lowering of triglycerides in the plasma and may reduce liver fat. We plan to test gemcabene in an established NASH preclinical model for further proof of concept. We will organize the appropriate
mid-stage clinical studies.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I> Pursue oral
combination opportunities for gemcabene.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;Oral combination therapy is the current paradigm for the treatment of dyslipidemia, as patients
typically require multiple drugs to address their dyslipidemia as well as other co-morbidities. Based on existing data demonstrating additive effects on LDL-C and triglyceride lowering as well as no
drug-drug interactions with statins, we believe that gemcabene has the potential to be developed as a fixed-dose combination with low to high dose statins, which, if approved, may enhance adoption in
the market and patient compliance. As part of our development strategy, we plan to formulate and manufacture gemcabene in fixed-dose combination with statins and other lipid-lowering agents. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I> Continue to
build out our patent portfolio for gemcabene.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;We believe our patents and patent applications provide us with a significant competitive
advantage. As of May&nbsp;2, 2016, we had 27 issued patents and 23 pending patent applications for gemcabene in the United States and internationally directed to formulations, compositions, methods
of use and methods of manufacturing. We intend to aggressively prosecute and defend our patent portfolio and pursue new patents in order to ensure the long term commercial success of gemcabene. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I> Maximize the
global commercial value of gemcabene.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;We have retained all commercial and manufacturing rights to gemcabene. We intend to evaluate our
strategic alternatives to collaborate with global biopharmaceutical companies for the development and commercialization of gemcabene. We believe we could independently commercialize gemcabene for the
treatment of patients with HoFH in the United States with a targeted sales force and would seek commercial partners outside of the United States. For larger indications, such as HeFH, ASCVD and SHTG,
we would assess partnership opportunities for Phase&nbsp;3 development and the worldwide commercialization of gemcabene. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>88</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=90,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=709429,FOLIO='88',FILE='DISK112:[15ZCH1.15ZCH40101]DQ40101A.;235',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_dq40101_1_89"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I> Leverage the
expertise and experience of our management team to evaluate future in-licensing and acquisition opportunities.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;Across our leadership
team, we have discovered and/or developed Lipitor, Lopid, ETC-1002, ETC-216, ACP-501, CER-209, CER-001 and PNT-2258, and commercialized many lipid regulating and orphan drugs including Crestor,
Myalept and Lynparza. Our team is well-qualified to identify and in-license or acquire clinical-stage cardio-metabolic assets, and we intend to evaluate these opportunities to diversify our pipeline
and generate long-term growth. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Overview of Dyslipidemia Market  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>According to the World Health Organization, cardiovascular disease is the number one cause of death in the world, responsible for 17.5&nbsp;million,
or approximately one in three, deaths in 2012. Cardiovascular disease is influenced by both environment and genetics. Environmental factors include diet, smoking, excess weight and sedentary
lifestyle. Genetic defects can cause certain types of cardiovascular disease, such as familial hypercholesterolemia, a condition in which mutations on a gene are responsible for the elevated LDL-C
levels in patients. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Dyslipidemia
is characterized by an elevation of LDL-C, triglycerides or both. Dyslipidemia is viewed as an important predictor of cardiovascular events, including heart attack and stroke, and a cause
of cardiovascular disease. It is estimated that 71&nbsp;million American adults, or approximately 33%, have high LDL-C levels, which is a major risk factor for cardiovascular disease. We estimate
from 2013 data that over 33&nbsp;million patients are prescribed statins, of which a little more than half, or 19&nbsp;million, are secondary prevention patients.<SUP>1</SUP> Of these
19&nbsp;million secondary prevention patients, approximately 10&nbsp;million are ASCVD&nbsp;patients who are not at goal. Furthermore, it is estimated that over 30% of American adults have
elevated triglycerides above 150&nbsp;mg/dL, and high levels of triglycerides are even evident in patients with normal cholesterol levels. If untreated, elevated triglycerides levels may lead to
more serious illnesses, such as atherosclerosis (plaque build-up in the arteries) and severely elevated triglyceride levels may lead to pancreatitis (inflammation of the pancreas). The dyslipidemia
market has achieved approximately $22&nbsp;billion in worldwide drug sales in 2013 and remains one of the largest therapeutic markets. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>89</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=91,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=257431,FOLIO='89',FILE='DISK112:[15ZCH1.15ZCH40101]DQ40101A.;235',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_dq40101_1_90"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dq40101_global_dyslipidemia_market_201__glo02270"> </A>
<A NAME="toc_dq40101_3"> </A>
<BR></FONT><FONT SIZE=2><B>  Global Dyslipidemia Market<BR>  2013 Worldwide Drug Sales of $22&nbsp;Billion<SUP>1</SUP>    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g244864.jpg" ALT="GRAPHIC" WIDTH="618" HEIGHT="426">
  </B></FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">1</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&copy;&nbsp;2015
DR/Decision Resources, LLC. All rights reserved. Reproduction, distribution, transmission or publication is
prohibited. Reprinted with permission. DR/Decision Resources, LLC ("DR") makes no representation or warranty as to the accuracy or completeness of the data ("DR Material") set forth herein and shall
have, and accept, no liability of any kind, whether in contract, tort (including negligence) or otherwise, to any third party arising from or related to use of the DR Material by Gemphire Therapeutics
Inc. Any use which Gemphire Therapeutics&nbsp;Inc. or a third party makes of the DR Material, or any reliance on it, or decisions to be made based on it, are the sole responsibilities of Gemphire
Therapeutics Inc. and such third party. In no way shall any data appearing in the DR Material amount to any form of prediction of future events or circumstances and no such reliance may be inferred or
implied. </FONT></DD></DL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Recent Developments in the Dyslipidemia Market  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In 2015 there have been key advisory panel meetings and regulatory approvals for non-statin LDL-C lowering drugs. Specifically, Biologics License
Applications (BLAs) for two PCSK9 inhibitors have been considered by the FDA and have subsequently been approved in the United States and Europe. We believe these approvals signal the FDA's continued
view that LDL-C lowering is an acceptable surrogate endpoint for traditional drug approval in certain lipid indications and that cardiovascular outcomes trials would not be required for such
approvals. The FDA however noted that one should accept very little risk from a novel
LDL-C-lowering drug when approving for a broad population only based on its effects on LDL-C. The approved PCSK9 products are described below. Their FDA-approved labels indicate that their effects on
cardiovascular morbidity and mortality have not yet been determined. </FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> On August&nbsp;27, 2015, Repatha, developed by Amgen&nbsp;Inc. (Amgen), was
approved in the United States for use along with diet and maximally tolerated statin therapy in adults with HoFH, HeFH and ASCVD, who need additional lowering of LDL-C. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>90</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=92,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=238891,FOLIO='90',FILE='DISK112:[15ZCH1.15ZCH40101]DQ40101A.;235',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_dq40101_1_91"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> On July&nbsp;24, 2015, Praluent, developed by Regeneron Pharmaceuticals, Inc.
(Regeneron) and Sanofi-Aventis U.S., LLC (Sanofi), was approved in the United States for use as adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH and ASCVD,
who require additional lowering of LDL-C. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> On July&nbsp;21, 2015 and September&nbsp;28, 2015, the European Commission
approved Repatha and Praluent respectively, each with a broader label compared to that in the United States. The approved indications in Europe included the treatment of adults with primary
hypercholesterolemia or mixed dyslipidemia as: (1)&nbsp;combination therapy with maximally tolerated dose of statin or statin and other lipid-lowering drugs; or (2)&nbsp;monotherapy or combination
therapy with other lipid-lowering drugs in patients who are statin-intolerant, or for whom statin is contraindicated. Repatha is also approved for the treatment of HoFH in adults and adolescents aged
12&nbsp;years and over in combination with other lipid-lowering drugs. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>In
November 2014, at the American Heart Association meeting, Merck&nbsp;&amp; Co., Inc. (Merck) announced data for ezetimibe from its IMPROVE-IT cardiovascular outcomes trial which was conducted over
seven years. The data showed that the addition of ezetimibe to 40&nbsp;mg simvastatin achieved the trial's primary endpoint, reduction in composite outcome events, comprised of cardiovascular death,
myocardial infarction (MI), unstable angina requiring hospitalization, coronary revascularization and stroke, by 6.4% more than patients who received simvastatin alone (p=0.016). Overall,
there was a significant 10% reduction in the risk of cardiovascular death, nonfatal MI, or nonfatal stroke. Based on data from the IMPROVE-IT trial, ezetimibe is the
first nonstatin cholesterol-lowering agent to demonstrate an incremental clinical benefit on top of a statin. According to the Expert Consensus Decision Pathways, which were issued in April 2016 to
complement existing American College of Cardiology guidelines, ezetimibe generally is recommended as the initial add-on agent to statin therapy, based upon its demonstrated efficacy in ASCVD risk
reduction, tolerability, safety and single tablet daily dose. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
August 2015, current Esperion announced guidance from its EOP2 meeting with the FDA for its LDL-C lowering product candidate, ETC-1002. The press release indicated the FDA's confirmation to
Esperion "that LDL-C remains an acceptable clinical surrogate endpoint for the approval of an LDL-C lowering therapy, such as ETC-1002 in patient populations who have a high unmet medical need,
including patients with HeFH and ASCVD, who are already taking maximally tolerated statins yet require additional LDL-C reduction and where there is a positive benefit/risk ratio." In September 2015,
Esperion announced final minutes from its EOP2 meeting and added "Any concern regarding the benefit/risk assessment of ETC-1002 could necessitate a completed cardiovascular outcomes trial before
approval." We believe this report of the EOP2 meeting minutes was consistent with recent PCSK9 drug guidance. A new Phase&nbsp;2 study of ETC-1002 in combination with high-intensity statins was also
added to ETC-1002's development program creating delays in ETC-1002 Phase&nbsp;3 program. ETC-1002 maintains a dual market strategy: (1)&nbsp;monotherapy for primary patients with statin
intolerance, and (2) high risk ASCVD and HeFH patients on maximally tolerated statins. In January 2016, Esperion focused its strategy on the statin intolerant indication and announced it will consider
the add-on statin market for ASCVD and HeFH with partners. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
April 2016 at the American College of Cardiology meeting, the GAUSS-3 study was presented, showing strong evidence that muscle-related statin intolerance is a real and reproducible condition. It is
estimated that 5&nbsp;-&nbsp;20% of patients with high cardiovascular risk refuse to take statins after reporting muscle pain or weakness following statin use. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>At
the same meeting in April 2016, researchers announced the clinical trial results from ACCELERATE for evacetrapib, the third failure in a class of drugs known as cholesteryl ester transfer protein
(CETP) inhibitors, explaining that the clinical trial was discontinued after preliminary analysis showed it did not reduce rates of major adverse cardiovascular events and also showed increased
hypertension. The first such drug, torcetrapib, was abandoned in 2006 after a Phase&nbsp;3 clinical trial revealed it increased the risk of cardiovascular events and death. Development of a second
CETP inhibitor, dalcetrapib, was stopped in 2012 when a large Phase&nbsp;3 clinical trial found the drug to be ineffective. In October 2015, Amgen </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>91</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=93,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=618756,FOLIO='91',FILE='DISK112:[15ZCH1.15ZCH40101]DQ40101A.;235',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_dq40101_1_92"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>acquired
Dezima Pharma B.V., a Netherlands-based company with an oral CETP inhibitor in Phase&nbsp;2 development. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
2012, Amarin's drug Vascepa (icosapent ethyl) was approved with a triglyceride endpoint as an adjunct to diet to reduce triglyceride levels in adults with SHTG, one of the target indications we are
pursuing. In a different
patient population in April 2015, the FDA concluded that, for regulatory approval purposes, there are insufficient data at this time from randomized controlled outcomes trials to support a reduction
in serum triglycerides as the single surrogate for reducing cardiovascular risk in adult patients on statin therapy with mixed dyslipidemia and high triglycerides (200-499&nbsp;mg/dL). As a
consequence, the FDA did not approve the supplemental NDA (sNDA) for Vascepa. However, in August of 2015, Amarin was granted a favorable ruling and was able to disseminate a summary of the ANCHOR
study results as well as the reprints regarding the potential cardioprotective effect of EPA in patients with high triglycerides. In March 2016, the FDA and Amarin proposed a settlement allowing
Amarin to engage in truthful and non-misleading speech promoting the off-label use of Vascepa to treat patients with persistently high triglycerides. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
of first quarter 2016, the sales of PCSK9 drugs have been limited post-launch as a result of the high price of the drug and difficulties with reimbursement. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


hsCRP Biomarker of Interest  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Inflammation plays a significant role in the propagation of atherosclerosis and susceptibility to cardiovascular events. Of the wide array of
inflammatory biomarkers that have been studied, hsCRP (or CRP) has received the most attention for its use in risk reclassification of cardiovascular disease. Recently, at the 2015 European Society
for Cardiology meeting, Merck presented a post-hoc analysis of the IMPROVE-IT trial which confirmed the importance of lowering both LDL-C and hsCRP levels to below 70&nbsp;mg/dL and 2&nbsp;mg/L,
respectively, with a 27% relative risk reduction in cardiovascular events occurring in patients that were able to attain target levels compared to those patients who achieved neither of the target
levels. These findings support the potential for novel non-statin therapies that can demonstrate clinical efficacy in both LDL-C and hsCRP reduction. Gemcabene's ability to substantially lower hsCRP
in conjunction with LDL-C may offer further benefit to the cardiovascular health of patients. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Regulatory Precedents for Approval in Dyslipidemia Indications  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Historical data confirm a linear relationship between LDL-C and cardiovascular disease, showing that lower LDL-C levels reduces the risk of mortality
and other cardiovascular events (for example, every 39&nbsp;mg/dL LDL-C lowering results in 24% cardiovascular risk reduction). The chart below by Cholesterol Treatment Trialist's Collaboration
(CTT) provides the foundation for this 'LDL-C hypothesis'. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>92</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=94,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=310183,FOLIO='92',FILE='DISK112:[15ZCH1.15ZCH40101]DQ40101A.;235',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_dq40101_1_93"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dq40101_lowering_ldl-c_decreases_cardi__low03790"> </A>
<A NAME="toc_dq40101_4"> </A>
<BR></FONT><FONT SIZE=2><B>  Lowering LDL-C Decreases Cardiovascular Risk<BR>  Elevated LDL-C lowering is the #1 Modifiable Risk Factor    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g1031628.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="477">
  </B></FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Sources: CTT Cholesterol Treatment Trialist's Collaboration and Study Papers for each Trial </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">CV = Cardiovascular; MACE=Major Adverse Cardiovascular Events  </FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">*</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">A-Z
p=.14 and IDEAL p=.07 </FONT></DD></DL>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Key For LDL-C Lowering Drug with Successful Trial Results:&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>Gemfibrozil:  </B></FONT><FONT  style="font-size:8pt;line-height:9pt;">HHS; </FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>Atorvastatin: </B></FONT><FONT  style="font-size:8pt;line-height:9pt;">IDEAL, TNT, PROVE-IT,
ASCOT-LLA, SPARCL; </FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>Pravastatin: </B></FONT><FONT  style="font-size:8pt;line-height:9pt;">ALLHAT,
CARE, PROSPER, LIPID, WOSCOPS; </FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>Simvastatin: </B></FONT><FONT  style="font-size:8pt;line-height:9pt;">A-Z, HPS, 4S; </FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>Lovastatin: </B></FONT><FONT  style="font-size:8pt;line-height:9pt;">AFCAPS; </FONT> <FONT  style="font-size:8pt;line-height:9pt;"><B>Rosuvastatin: </B></FONT><FONT  style="font-size:8pt;line-height:9pt;">JUPITER;
</FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>Ezetimibe: </B></FONT><FONT  style="font-size:8pt;line-height:9pt;">IMPROVE-IT. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For nearly three decades (1987 to 2015), the FDA has accepted LDL-C lowering as a surrogate endpoint for reducing cardiovascular risk for </FONT> <FONT SIZE=2><I>traditional</I></FONT><FONT SIZE=2> approval on over 15 lipid-lowering
drugs without requirements to initiate or complete a cardiovascular outcomes trial. Traditional approval
may be based on surrogate endpoints such as LDL-C and blood pressure that are </FONT><FONT SIZE=2><I>known</I></FONT><FONT SIZE=2> to predict clinical benefit, by contrast to accelerated approval
based on surrogate endpoints that are only </FONT><FONT SIZE=2><I>reasonably likely</I></FONT><FONT SIZE=2> to predict clinical benefit and require confirmatory evidence of actual benefit after
approval. With traditional approval based on LDL-C reduction, the FDA does not have a regulatory mechanism to require any further efficacy trials and does not require sponsors to conduct a
post-approval cardiovascular outcomes trial. Sponsors who have chosen to conduct cardiovascular outcomes trials before or after traditional approval, which is encouraged by the FDA, have voluntarily
done so to seek additional claims. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
approving drugs, the FDA considers the magnitude of effect in relation to the safety profile. Not only has the use of LDL-C as surrogate marker to predict the risk of cardiovascular events been
accepted by the FDA but the importance of LDL-C lowering has also been recognized by clinical organizations such as American College of Cardiology, American Heart Association (AHA), National
Cholesterol Education Program Adult </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>93</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=95,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=443108,FOLIO='93',FILE='DISK112:[15ZCH1.15ZCH40101]DQ40101A.;235',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_dq40101_1_94"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Treatment
Panel&nbsp;III (NCEP ATP-III), American Association of Clinical Endocrinologists, and National Lipid Association. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>These
approvals have occurred over the last decade, as have studies showing that certain LDL-C lowering statin and non-statin drugs did not in fact provide cardiovascular benefits (e.g., Niacin in
AIM-HIGH trial) and/or show unexpected safety concerns (e.g., ezetimibe in ENHANCE with cancer). In addition, a class of drugs known as cholesteryl ester transfer protein inhibitors (CETPi) with a
different mechanism (which increases high-density lipoprotein cholesterol (HDL-C) while sometimes lowering LDL-C), has 3 drugs that failed Phase&nbsp;3 cardiovascular outcome trials. The first CETPi
drug, Pfizer's torcetrapib, lowered LDL-C but showed increased cardiovascular event rates in patients due to off-target effects in ILLUMINATE, which we believe established a higher FDA standard for
cardiovascular outcomes trials for the CETPi class. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
patient populations such as HoFH and SHTG, we believe the FDA recognizes that an outcomes trial would be difficult and as a result has established precedent drug approvals over time based on
surrogate endpoints (LDL-C for cardiovascular risk and triglycerides for pancreatitis risk, respectively). Recent examples include Juxtapid (2012) and Kynamro (2013) for HoFH and Vascepa (2012) for
SHTG. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
the broader populations HeFH and ASCVD, the FDA recently approved PCSK9 inhibitors based on LDL-C as the surrogate endpoint and did not require the completion of cardiovascular outcomes trial in
these high-risk dyslipidemia patients. The FDA approved Praluent and Repatha based on LDL-C reduction as an adjunct to maximally tolerated statin therapy (and diet), but did not approve these drugs
for monotherapy or primary patients, noting that such approval may be premature in the absence of cardiovascular outcomes data. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Collectively,
recent approvals of new cardiovascular drugs, results from clinical trials of non-statin product candidates, and our recent regulatory guidance that we received from the FDA regarding
our development plans have provided us with some assurance that LDL-C lowering product candidates in development, such as gemcabene, will not be required to conduct cardiovascular outcomes trials in
the United States and Europe prior to approval for our target indications planned in combination with statins assuming a favorable benefit/risk profile. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Our Target Indications  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are developing gemcabene as a treatment for dyslipidemia patients for whom existing treatments are insufficient. The ATP-III guidelines of the NCEP
recommends that individuals at high risk of coronary heart disease maintain LDL-C levels &lt;100&nbsp;mg/dL, and that individuals with very high risk maintain LDL-C
levels&nbsp;&lt;70&nbsp;mg/dL. In addition, the American College of Cardiology and AHA set treatment-targeted guidelines in 2013 which focus on intensive statin therapy. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Despite
approval of new drugs, including injectable PCSK9 inhibitors, we believe physicians, patients and payors continue to seek efficacious, cost-effective add-on therapies. We believe that oral,
once-daily gemcabene as an add-on to statin therapy is differentiated by the ability to lower multiple lipids (LDL-C, hsCRP and triglycerides) and, if approved, presents a significant opportunity
across multiple indications. These indications span from HoFH to more prevalent conditions, such as HeFH, ASCVD and SHTG, in which therapies are required to reduce elevated levels of LDL-C,
triglycerides or both. Our target indications are summarized in the diagram below with a total of approximately 14&nbsp;million addressable patients in the United States who could be treated with
gemcabene, with an even larger number in the rest of world. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>94</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=96,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=651625,FOLIO='94',FILE='DISK112:[15ZCH1.15ZCH40101]DQ40101A.;235',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_dq40101_1_95"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dq40101_dyslipidemia_market_and_total_addressable_patients"> </A>
<A NAME="toc_dq40101_5"> </A>
<BR></FONT><FONT SIZE=2><B>  Dyslipidemia Market and Total Addressable Patients    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g251333.jpg" ALT="GRAPHIC" WIDTH="616" HEIGHT="274">
  </B></FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Source: Company estimates.  </FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">(*)</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Addressable
market for rest of the world (RoW) is estimated by extrapolating from the U.S. addressable market. </FONT></DD></DL>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Definitions: M=millions, CV=cardiovascular, TG=triglycerides. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Homozygous Familial Hypercholesterolemia (HoFH)  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>HoFH is a rare genetic disease that is usually caused by a mutation in both alleles of the LDL receptor gene responsible for removing LDL from the
blood. As a result, HoFH patients exhibit severely high LDL-C levels, are at very high risk of experiencing premature cardiovascular events, such as a heart attack or stroke, and develop premature and
progressive atherosclerosis. LDL-C levels in HoFH patients are typically in the range of 500&nbsp;mg/dL to 1,000&nbsp;mg/dL, compared to a normal target range of 70&nbsp;mg/dL to
100&nbsp;mg/dL. Unless treated, most patients with HoFH do not survive adulthood beyond 30&nbsp;years of age. There are approximately 300 to 2,000 HoFH patients in the United States and 6,000 to
45,000&nbsp;patients in the rest of the world based on an estimated prevalence rate of one in 160,000 to one in one million. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Current
available treatments for HoFH generally include a combination of dietary intervention, statins, ezetimibe and other approved LDL-C lowering therapies, including lipoprotein apheresis. However,
even when combination therapies are utilized, many patients still have high LDL-C levels and are still at high risk of cardiovascular disease. The FDA has approved two non-statin therapies for HoFH,
Juxtapid, marketed by Aegerion Pharmaceuticals, Inc. (Aegerion), and Kynamro, marketed by Sanofi. Although these drugs have demonstrated efficacy, they have significant safety and tolerability issues,
including boxed warnings for liver toxicity on the product labels. Recently, the FDA has also approved Amgen's PCSK9 inhibitor, Repatha, for HoFH patients, but this therapy has limitations due to its
mechanism of action reliant on functional LDL-receptors. In clinical trials, Repatha has shown substantially less LDL-C lowering from baseline in patients with HoFH compared to LDL-C
lowering in patients with other hypercholesterolemia indications. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On
February&nbsp;6, 2014, gemcabene received orphan drug designation by the FDA for treatment of HoFH. We believe that pursuing the HoFH indication may enable gemcabene to reach the market sooner
than for other indications due to: (1)&nbsp;approval pathway based on a single, small Phase&nbsp;3 trial; (2)&nbsp;no requirement for cardiovascular outcomes trials; and (3)&nbsp;potential for
priority review by the FDA in light of the unmet medical need in this orphan population. Furthermore, we believe that gemcabene's potential to treat patients in the most severe segment of the
dyslipidemia market on top of statins and other lipid-lowering therapies (including ezetimibe and Repatha) will enhance brand awareness among key thought leaders and physicians. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>95</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=97,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=645095,FOLIO='95',FILE='DISK112:[15ZCH1.15ZCH40101]DQ40101A.;235',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_dq40101_1_96"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Heterozygous Familial Hypercholesterolemia (HeFH)  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The HeFH patient population is generally comprised of individuals who have one defective gene that leads to elevated LDL-C levels between
190&nbsp;mg/dL and 500&nbsp;mg/dL. These patients are prone to premature cardiovascular events. The incidence of patients with HeFH is estimated to be between one in 200 and one in 500, and
accordingly, we estimate there are approximately 0.5 to 1.5&nbsp;million patients with HeFH in the United States and 15 to 30&nbsp;million in the rest of the world. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Current
available treatments for HeFH include statins, ezetimibe, bile acid sequestrants and the recently approved injectable PCSK9 inhibitors. Despite the availability of various treatments, many
patients are still unable to achieve recommended LDL-C levels. In addition, patients, physicians and payors may prefer more convenient, cost-effective, oral drugs. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
believe obtaining approval for the HeFH indication will enable gemcabene to reach a large market of patients with the inability to attain their LDL-C goal using current therapies (including
high-intensity statins, ezetimibe and
Repatha). An approval in HeFH would allow gemcabene to be introduced into another indication for very high LDL-C levels and enable physicians globally to have another oral, once-daily, cost-effective,
well-tolerated with high intensity statins option in treating this complex patient population, while also lowering LDL-C, hsCRP, and triglycerides. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Atherosclerotic Cardiovascular Disease (ASCVD)  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>ASCVD represents patients who have experienced or are at risk of a cardiovascular event and are unable to meet their LDL-C lowering goal of less than
70&nbsp;mg/dL with maximally tolerated statin therapy. This population also includes many patients who, in addition to not being able to meet their LDL-C lowering goal, have elevated triglyceride
levels greater than 150&nbsp;mg/dL and less than 500&nbsp;mg/dL, categorized as mixed dyslipidemia. If both cholesterol and triglyceride levels are high, it is difficult for physicians to optimize
the right combination of current therapies to reach lipid level goals, as for many patients, lowering the level of one may increase the level of the other. We estimate that approximately
10&nbsp;million patients in the United States and 200&nbsp;million patients in the rest of the world have a need for additional therapies to effectively and safely bring them closer to their LDL-C
and triglyceride lowering goals. Of those patients, we estimate that there are more than 1.5&nbsp;million secondary prevention patients who cannot tolerate any statins at all. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Current
available treatments for both primary hypercholesterolemia and ASCVD include statins, ezetimibe, bile acid sequestrants, niacin, fibrates and recently approved PCSK9 inhibitors. While these
drugs have demonstrated efficacy in lipid-lowering in this population, some of these do not sufficiently address the patients with mixed dyslipidemia who need to lower both LDL-C and triglycerides. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
believe that there is a meaningful number of underserved ASCVD patients who are: (1)&nbsp;unable to reach LDL-C and triglyceride goals on maximally tolerated statin therapy; (2)&nbsp;require
LDL-C reduction beyond the 6% reduction observed when statin dose is doubled; or (3)&nbsp;unable to tolerate higher doses of statins. If gemcabene is approved for this indication, it may potentially
offer patients a preferred well-tolerated combination therapy with a statin and/or ezetimibe that is convenient, oral, once-daily, cost effective, and effective in achieving LDL-C, hsCRP and
triglyceride goals. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Severe Hypertriglyceridemia (SHTG)  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Elevated triglycerides are often caused by an inherited disorder or exacerbated by uncontrolled diabetes mellitus, obesity, hypothyroidism and
sedentary habits. A recent scientific statement on "Triglycerides and Cardiovascular Disease" issued by the American Heart Association based on a review of the pivotal role of triglycerides in lipid
metabolism, reaffirmed that triglycerides are not directly atherogenic, but represent an important biomarker of cardiovascular disease. Patients with severe triglycerides greater than
500&nbsp;mg/dL, or SHTG, have increased risk of developing pancreatitis, a painful and potentially life-threatening inflammation of the pancreas. Based on a 1.1% prevalence rate in the United
States, as published by the American Heart Association, we estimate there are approximately 3.5&nbsp;million patients with SHTG in the United States and 75&nbsp;million patients in the rest of the
world. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>96</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=98,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=578802,FOLIO='96',FILE='DISK112:[15ZCH1.15ZCH40101]DQ40101A.;235',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_dq40101_1_97"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Current
available treatments for SHTG consist of dietary modifications to lower the intake of fatty foods and the use of fibrates, prescription fish oils and niacin. These treatments are often
inadequate in lowering triglyceride levels below 500&nbsp;mg/dL, the level at which patients are at an increased risk for developing pancreatitis. Due to the severely elevated triglyceride levels in
this patient population, reducing triglyceride levels below 500&nbsp;mg/dL may require reductions in triglyceride levels of 40% or more. Current therapies, even in combination, are often
insufficient in achieving such a result. In addition, many of the existing treatments do not combine well with statins for treating SHTG. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
believe that pursuing SHTG may enable gemcabene to reach a large population of patients with triglyceride levels above 500&nbsp;mg/dL and offer a convenient, oral, once-daily dosing with no food
effects that may have the potential to result in better efficacy than standard of care, while being well-tolerated with statins. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our Product Candidate&nbsp;&#151; Gemcabene  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our product candidate, gemcabene, is a novel, once-daily, oral therapy designed to target known lipid metabolic pathways to lower levels of LDL-C,
hsCRP and triglycerides. Gemcabene shares many of the attributes of statin therapy, including broad therapeutic applications, convenient route of administration and cost-effective manufacturing
process, but does not appear to increase the reporting of myalgia when added to statin therapy. Gemcabene has also shown additive LDL-C lowering in combination with stable low,
moderate or high-intensity statin therapy. We also plan to develop a fixed-dose combination product of gemcabene with atorvastatin to enhance market adoption and maximize the likelihood of commercial
success. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
are developing multiple indications for gemcabene, ranging from HoFH, an orphan indication, to more prevalent conditions, such as HeFH, ASCVD and SHTG. By the end of 2016, we plan to initiate three
late stage clinical trials for gemcabene: an 8&nbsp;patient trial for HoFH, a 212&nbsp;patient trial for hypercholesterolemia on high-intensity statin therapy including HeFH and ASCVD patients,
and a 80 to 120&nbsp;patient trial for SHTG. We expect early results from the first of these trials to start reading out by the end of 2016 and continuing through the second half of 2017. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
licensed global rights to gemcabene from Pfizer in April 2011. We will continue to leverage the extensive preclinical, clinical, manufacturing and formulation work previously conducted to further
advance the development of gemcabene. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Mechanism of Action  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Gemcabene has a mechanism of action that involves: (1)&nbsp;enhancing the clearance of VLDL; and (2)&nbsp;blocking the overall production of
hepatic triglyceride and cholesterol synthesis. Based on prior clinical trials, the combined effect for these mechanisms has been observed to result in a reduction of plasma VLDL-C, LDL-C,
triglycerides and hsCRP, as well as elevation of HDL-C. Gemcabene-calcium rapidly converts to gemcabene free acid when added to media or administered to animals and humans. Gemcabene distributes to
the liver where it has its effect as the active molecule. </FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>Gemcabene
enhances the clearance of VLDL by decreasing the production of messenger RNA (mRNA) of the ApoC-III gene, thereby decreasing the production of the
apoC-III protein. ApoC-III protein is known to be causal in cardiovascular disease. ApoC-III is a small protein that inhibits hepatic uptake of triglyceride-rich particles such as VLDL. VLDL are
catabolized to VLDL remnants in plasma. The VLDL remnants are either cleared from the plasma via remnant receptors or mature to LDL. The reduction in apoC-III exposes Apolipoprotein E
(ApoE). ApoE is essential for the normal catabolism of triglyceride-rich particles. This favors the enhanced clearance of the VLDL remnants via ApoE remnant receptors and reduces the formation of LDL
particles, while also breaking down triglycerides by lipoprotein lipase to deliver more fatty acids to muscle and adipose tissue. We have observed in preclinical studies that gemcabene significantly
clears VLDL in the plasma with corresponding reductions in the liver apoC-III mRNA levels and apoC-III plasma protein levels in </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>97</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=99,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=536824,FOLIO='97',FILE='DISK112:[15ZCH1.15ZCH40101]DQ40101A.;235',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_dq40101_1_98"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:arial;"><FONT SIZE=2>rats.
In a hypertriglyceridemic human clinical trial, gemcabene was shown to significantly decrease both apoC-III and triglycerides. </FONT></P>

</UL>
</UL>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


  </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="50%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="50%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B>Reduction of Plasma ApoC-III and TG<BR>
in Rats</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><B> Reduction of Plasma ApoC-III and TG<BR>
in Humans</B></FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B><BR>
<BR>
 <IMG SRC="g146740.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="382">
<BR> </B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>Gemcabene
blocks the overall production of hepatic triglycerides and cholesterol. Given its structural similarities to long-chain fatty acid, gemcabene may
act as an inhibitor of ACC targeting the rate-limiting enzyme in fatty acid synthesis, subsequently leading to a decreased hepatic triglyceride production. Gemcabene may also inhibit one or more
enzymes in the cholesterol synthesis pathway leading to less cholesterol in the cell. This decrease in liver cholesterol activates processing of sterol regulatory element binding proteins (SREBPs),
thereby increasing the number of LDL receptors displayed on the liver cell. The newly produced LDL receptors remove LDL from the blood. In preclinical studies in primary rat hepatocyte and mice
models, gemcabene was observed to inhibit both triglyceride and cholesterol production. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>98</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=14,SEQ=100,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=379830,FOLIO='98',FILE='DISK112:[15ZCH1.15ZCH40101]DQ40101A.;235',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_du40101_1_99"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The diagram below depicts the novel mechanisms of gemcabene. We will continue to undertake preclinical studies to further clarify gemcabene's involvement in various metabolic
pathways. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="du40101_gemcabene_novel_mechanism_of_action"> </A>
<A NAME="toc_du40101_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Gemcabene Novel Mechanism of Action    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g805213.jpg" ALT="GRAPHIC" WIDTH="676" HEIGHT="460">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, we believe gemcabene may result in the reduction of inflammation, inflammatory markers and triglycerides (as a result of reduced apoC-III production) in the plasma of a patient in an
inflammatory state. C-reactive Protein (CRP) is an inflammatory marker protein. CRP levels increase in response to inflammatory states and are associated with medical conditions such as
atherosclerosis and other cardiovascular diseases, arthritis, hypertension, obesity, insulin resistance, and fatty liver disease. CRP expression is regulated by proteins in the nucleus of cells known
as nuclear hormone receptors (NHRs). In inflammatory states, cytokines, such as interleukin-6 (IL-6) and interleukin (IL1-<FONT FACE="SYMBOL">b</FONT>), activate NHRs, such as
C/EPB-<FONT FACE="SYMBOL">b</FONT>, C/EPB-<FONT FACE="SYMBOL">d</FONT> and nuclear factor kappa B (NF-<FONT FACE="SYMBOL">k</FONT>B), and lead them to bind to the CRP
promoter and increase CRP mRNA production. Based on preclinical studies, gemcabene may inhibit the interaction of these NHRs on the CRP promoter and therefore reduce CRP mRNA production. Gemcabene has
also been shown in preclinical studies to inhibit tissue necrosis factor-<FONT FACE="SYMBOL">a</FONT> (TNF-<FONT FACE="SYMBOL">a</FONT>) induced expression of the inflammatory
cytokine IL-6 in human coronary artery endothelial cells and in a human hepatoma cell line. Overall, gemcabene may not only decrease the expression of CRP, but may also decrease the expression of the
inflammatory cytokine IL-6 resulting in a reduction of inflammation. Gemcabene has been shown to reduce the level of CRP in human clinical trials, to decrease inflammation in a mouse model of
arthritis, and to decrease pain in a rat model of thermal hyperalgesia. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
apoC-III promoter also contains a NF-<FONT FACE="SYMBOL">k</FONT>B binding site, and as such, the apoC-III gene may be upregulated under a chronic inflammatory state. Gemcabene's
ability to reduce apoC-III&nbsp;mRNA levels may </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>99</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=101,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=695537,FOLIO='99',FILE='DISK112:[15ZCH1.15ZCH40101]DU40101A.;116',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_du40101_1_100"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>result
from gemcabene inhibiting NF-<FONT FACE="SYMBOL">k</FONT>B interaction with its binding site on the apoC-III promoter. We are further exploring this common transcription factor
NF-<FONT FACE="SYMBOL">k</FONT>B as a binding site for gemcabene to reduce hsCRP and apoC-III. In contrast, Gemcabene has not been shown to directly or strongly bind to PPARs. See
"Additional Studies and Trials." </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Clinical Experience  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Gemcabene has been assessed in 18 Phase&nbsp;1 and Phase&nbsp;2 clinical trials. One Phase&nbsp;1 trial was not completed when the program was
previously discontinued. Across all trials, 1,272 adult subjects, including healthy volunteers and patients with various underlying conditions, such as hypercholesterolemia, hypertriglyceridemia,
osteoarthritis and hypertension, participated. Of the subjects, 895 have been exposed to at least one dose of gemcabene. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
believe that gemcabene's efficacy in Phase&nbsp;1 and Phase&nbsp;2 trials support our development plan focused on HoFH, HeFH, ASCVD and SHTG patients. Specifically, patients treated with
gemcabene were observed to have significantly lowered LDL-C, hsCRP and triglycerides with results from the trials summarized below:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> In a four week, double-blind, multiple dose, Phase&nbsp;1 trial in 50 healthy
subjects (Trial 1027-003), gemcabene monotherapy doses (450&nbsp;mg, 600&nbsp;mg and 900&nbsp;mg) significantly lowered LDL-C from baseline by approximately 30%. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> In an eight week, double-blind, placebo-controlled, Phase&nbsp;2 trial in 66
patients with elevated LDL-C on background stable statin therapy (Trial 1027-018), both gemcabene doses (300&nbsp;mg and 900&nbsp;mg) in combination with statins significantly lowered LDL-C from
baseline by approximately 25% to 30%. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> In an eight week, double-blind, placebo-controlled, Phase&nbsp;2 trial in 277
patients with hypercholesterolemia (Trial A4141001), gemcabene monotherapy doses (300&nbsp;mg, 600&nbsp;mg and 900&nbsp;mg) significantly lowered LDL-C, with the 600&nbsp;mg and 900&nbsp;mg
doses lowering LDL-C by approximately 30%. Gemcabene monotherapy doses (600&nbsp;mg and 900&nbsp;mg) also significantly lowered hsCRP by approximately 40%. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> In a 12-week, double-blind, placebo-controlled, Phase&nbsp;2 trial (Trial
1027-004), 94 of the 161 patients had elevated triglycerides (<FONT FACE="SYMBOL">&#179;</FONT>200&nbsp;mg/dL). For those patients, gemcabene lowered triglycerides in all dose arms, with
the 300&nbsp;mg dose lowering triglycerides by 40%. A post-hoc analysis of nine patients with severe triglyceride levels (<FONT FACE="SYMBOL">&#179;</FONT>500&nbsp;mg/dL) treated with
150&nbsp;mg and 300&nbsp;mg suggest gemcabene has the potential to lower triglycerides by as much as 60%. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Gemcabene
was observed to be well tolerated at single doses up to 1,500&nbsp;mg and multiple doses up to 900&nbsp;mg/day. This includes 837&nbsp;subjects who received multiple doses of up to
900&nbsp;mg for up to 12&nbsp;weeks. Safety of the subjects in these trials was evaluated by AE monitoring, clinical laboratory assessments, electrocardiograms (ECGs), physical examinations, and
vital sign assessments. Across all trials (1,272 adult subjects), 10 healthy volunteers or patients reported a treatment-emergent SAE, none of which were considered by the clinician to be related to
gemcabene. No deaths occurred in any of the trials. AEs reported were generally mild to moderate in
intensity with the most common events being headache, weakness, nausea, dizziness, upset stomach, infection and abnormal bowel movements. Gemcabene did not appear to increase the reporting of myalgia
when added to statin therapy and no treatment related events of myalgia were reported in any gemcabene monotherapy arm in the dyslipidemia trials. Small mean increases in serum creatinine and blood
urea nitrogen (BUN) have been observed in some trials. The increase was reversible with all creatinine values returning to baseline within approximately two&nbsp;weeks of cessation of gemcabene.
Elevated levels of liver enzymes, specifically alanine transaminase (ALT) and/or aspartate aminotransferase (AST), were observed in a few patients (0.23% of gemcabene patients compared to 0.26% of
placebo patients had ALT or AST levels more than three times the upper limit of normal (ULN)) returning to baseline after cessation of treatment. No clinically meaningful changes were observed in
physical examinations or vital signs, including blood pressure. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>100</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=102,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=757143,FOLIO='100',FILE='DISK112:[15ZCH1.15ZCH40101]DU40101A.;116',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_du40101_1_101"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, gemcabene demonstrated promising clinical pharmacology attributes across 10 completed Phase&nbsp;1 trials in healthy subjects, such as once-daily dosing, no meaningful drug-drug
interactions with high-intensity statins and no observed food effect. Gemcabene was observed to: (1) be rapidly absorbed following oral administration with time of maximum concentration within two
hours and (2)&nbsp;reach maximum plasma concentration (Cmax) and area under the curve over 24&nbsp;hours (AUC 0-24) that were dose proportional following both single- and multiple-dose
administration. Steady state concentrations were achieved within six days of repeated dose administration. Average half-life ranged from 32 to 41&nbsp;hours. Gemcabene's primary route of elimination
was renal. In addition, no significant drug-drug interactions were observed with digoxin, a cardiovascular drug for the treatment of atrial fibrillation. There were no observed clinically relevant
effects on QTc, a measure of cardiac rhythm, and no observed clinically relevant effect on blood pressure. Renal clearance was slightly decreased and was associated with a slight increase in serum
creatinine. Treatment with gemcabene was associated with a mean increase in the percent change from baseline in the glucose disposal rate, but the comparison to placebo was not statistically
significant. Based on PK&nbsp;AUC(0- </FONT> <FONT SIZE=2><B>
<IMG SRC="g667216.jpg" ALT="LOGO" WIDTH="16" HEIGHT="7">
  </B></FONT><FONT SIZE=2>)&nbsp;data, the extent of absorption following administration of gemcabene with food was similar to that
observed in fasting subjects. Gemcabene can be taken with or without
food. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Based
on the results of these trials, we believe gemcabene has the potential to have a differentiated profile as an oral once-daily, well tolerated adjunct therapy with promising evidence of efficacy
in lowering of LDL-C, hsCRP and triglycerides in patients with dyslipidemia. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>101</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=103,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=5100,FOLIO='101',FILE='DISK112:[15ZCH1.15ZCH40101]DU40101A.;116',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_du40101_1_102"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Gemcabene Phase&nbsp;2 Clinical Trials  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Gemcabene has been evaluated in seven Phase&nbsp;2 trials across a diverse patient population. These trials explored safety, tolerability and
efficacy and multiple doses of gemcabene as monotherapy and in combination with low-, moderate- and high-intensity statins. The table below summarizes our completed Phase&nbsp;2 clinical trials. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="du40101_summary_of_phase_2_clinical_tr__sum02400"> </A>
<A NAME="toc_du40101_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Summary of Phase&nbsp;2 Clinical Trials with Gemcabene in Patients    <BR>    </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="50pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="102pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="21%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="78pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="75pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="44pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="10%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="CENTER" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:25pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Trial<BR>
Number

<!-- COMMAND=ADD_SCROPPEDRULE,25pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Patient / Indication </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Trial Objectives </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Doses </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B># Patients </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Duration </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Key Lipid and<BR>
Other Endpoints </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"><B><U>1027-004</U></B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Low HDL-C and normal or elevated TG (including SHTG)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Double-blind, placebo-controlled, randomized trial to determine the efficacy and safety of gemcabene in subjects with low HDL-C and either normal or elevated triglycerides</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">150, 300, 600, 900&nbsp;mg</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">GEM=129<BR>
placebo=32</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">12&nbsp;weeks</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">HDL-C, TG, LDL-C, hsCRP, apoB, Total cholesterol</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;background-color:#dcddde;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 1027-012</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 Hypertension</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT>
</TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 Double-blind, placebo-controlled, randomized trial to determine the effect of gemcabene compared to quinapril</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 900&nbsp;mg<BR>
(with quinapril 20&nbsp;mg)</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>&nbsp;


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 GEM=43<BR>
quinapril=18<BR>
placebo=41</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;"><BR><BR>&nbsp;


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT>
</TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 12&nbsp;weeks</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 Systolic&nbsp;BP, Diastolic&nbsp;BP</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">1027-014</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Healthy Obese Non-diabetic</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Double-blind, placebo-controlled, randomized trial to determine the effect of gemcabene on insulin sensitivity</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">900&nbsp;mg</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">GEM=26<BR>
placebo=27</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">4&nbsp;weeks</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Insulin sensitivity</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;background-color:#dcddde;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">



<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 1027-015</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT>
</TD>
<TD ALIGN="CENTER" style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 Hypertension</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 Double-blind, placebo-controlled, randomized trial to determine the effect of gemcabene on blood pressure</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 900&nbsp;mg</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT>
</TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 GEM=23</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 4&nbsp;weeks</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 Systolic&nbsp;BP, Diastolic&nbsp;BP</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"><B><U>1027-018</U></B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Hypercholesterolemia<BR>
(not at goal on stable statin)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Double-blind, placebo-controlled, randomized trial to determine the efficacy and safety of gemcabene on stable statin therapy</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">300, 900&nbsp;mg<BR>
(with various low, moderate and high intensity statins)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">GEM=42<BR>
placebo=24</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">8&nbsp;weeks</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">LDL-C, hsCRP, apoB, TG, HDL-C, VLDL, Total cholesterol</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;background-color:#dcddde;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT> <FONT  style="font-size:8pt;line-height:9pt;"><B><U>A4141001</U></B></FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 Hypercholesterolemia</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 Double-blind, placebo-controlled, randomized trial to determine the efficacy and safety of gemcabene as monotherapy or in combination with atorvastatin (after statin washout)</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 300, 600, 900&nbsp;mg<BR>
(with 10, 40, 80&nbsp;mg atorvastatin)</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>&nbsp;


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 GEM=208<BR>
atorvastatin=52<BR>
placebo=17</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;"><BR><BR>&nbsp;


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT>
</TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 8&nbsp;weeks</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 LDL-C, hsCRP, apoB, TG, HDL-C, Total cholesterol</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">A4141004</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Osteoarthritis</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Double blind, placebo controlled, randomized trial to determine the efficacy and safety of gemcabene in patients with osteoarthritis of the knee</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">150, 450, 900&nbsp;mg<BR>
(with rofecoxib 25&nbsp;mg)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">GEM=242<BR>
rofecoxib=79<BR>
placebo=83</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">4&nbsp;weeks</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Pain assessment, CGIC, PGIC, SODA</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">SODA=Sequential occupational dexterity assessment, PGIC=Patients global impression of change, CGIC=Clinical global impression of change, GEM=gemcabene;
TG=triglycerides. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>102</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=104,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=753812,FOLIO='102',FILE='DISK112:[15ZCH1.15ZCH40101]DU40101A.;116',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_du40101_1_103"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I>Gemcabene Phase&nbsp;2 Trial in Patients with Hypercholesterolemia on Stable Statin Therapy (Trial 1027-018)</I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This
Phase&nbsp;2 double-blind, placebo-controlled, randomized trial in patients with hypercholesterolemia was designed to assess the efficacy and safety of gemcabene when added to stable statin
therapy. Patients in this trial were on low- (20% of patients), moderate- (60% of patients) and high-intensity (20% of patients) statin therapy. Gemcabene was administered at 300&nbsp;mg and
900&nbsp;mg once-daily for eight weeks. A majority of the patients were on moderate- to high-intensity statin therapy for at least three months. The primary endpoint was median percent change from
baseline in LDL-C. Other endpoints included median perecent change from baseline in hsCRP, apoB, total cholesterol, VLDL-C and triglycerides at Week&nbsp;8. A total of 66&nbsp;patients were
randomized and 61 patients were evaluated for efficacy. Baseline LDL-C levels were similar across the treatment arms at approximately 150&nbsp;mg/dL. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Efficacy:</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;As presented in the figure below, patients treated with gemcabene were observed to have significantly lowered LDL-C from baseline at 300&nbsp;mg and
900&nbsp;mg by 25% (p=0.005) and 31% (p&lt;0.001), respectively. Of clinical interest, patients treated with gemcabene were observed to have significantly lowered hsCRP, apoB and total
cholesterol. At 900&nbsp;mg, patients treated with gemcabene were observed to have significantly lowered hsCRP by 54% (p&lt;0.001). At 300&nbsp;mg and 900&nbsp;mg, patients treated with
gemcabene were observed to have significantly lowered apoB by 20% (p=0.033) and 24% (p=0.003), respectively. At 300&nbsp;mg and 900&nbsp;mg, patients treated with gemcabene were observed to have
significantly lowered total cholesterol by 18% (p=0.008) and 22% (p&lt;0.001), respectively. It was further observed that all four (4) patients treated with 900&nbsp;mg gemcabene on
high-intensity statins have a mean LDL-C reduction of 24%. The pharmcodynamic response observed at 900&nbsp;mg is similar to 600&nbsp;mg of gemcabene. In addition, patients on moderate-intensity
(n=12) and low-intensity (n=5) statins were observed to have a mean LDL-C lowering of 24% and 41%, respectively. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
believe these results support the continued development of gemcabene for the treatment HoFH, HeFH and ASCVD indications on maximally tolerated statins. Classification of statin dose intensity is
defined in the 2013 ACC guidelines. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="du40101_median_percent_change_from_bas__med04761"> </A>
<A NAME="toc_du40101_3"> </A>
<BR></FONT><FONT SIZE=2><B>  Median Percent Change from Baseline at Week&nbsp;8 in Patients with Hypercholesterolemia<BR>  on Background Stable Statin Therapy    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g640635.jpg" ALT="GRAPHIC" WIDTH="618" HEIGHT="328">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>103</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=105,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=369889,FOLIO='103',FILE='DISK112:[15ZCH1.15ZCH40101]DU40101A.;116',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_du40101_1_104"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="du40101_ldl-c_median_percent_change_fr__ldl04926"> </A>
<A NAME="toc_du40101_4"> </A>
<BR></FONT><FONT SIZE=2><B>  LDL-C Median Percent Change from Baseline at Week&nbsp;8 in Patients with Hypercholesterolemia<BR>  on Background Stable Statin Therapy    <BR>    </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:67%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"120%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="120%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="78pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="121pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="121pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Placebo&nbsp;+&nbsp;Statin </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>GEM 300&nbsp;mg&nbsp;+&nbsp;Statin </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>GEM 900&nbsp;mg&nbsp;+&nbsp;Statin </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>n</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>22</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>21</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Median Baseline LDL-C</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>153.3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>143.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>142.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Median Week&nbsp;8 LDL-C</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>137</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>101.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>103</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Median % Change</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#150;7.9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#150;24.8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#150;31.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>p-Value vs. Placebo</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>N/A</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.005</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&lt;0.001</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">*N/A = not applicable </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Safety:</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Gemcabene was observed to be well tolerated. Patients taking either 300&nbsp;mg or 900&nbsp;mg of gemcabene were observed to have a safety profile
similar to that of placebo. Slightly more patients experienced an associated AE in the placebo treatment arm (29%) than those in the gemcabene treatment arms (300&nbsp;mg: 20%; 900&nbsp;mg: 23%).
One patient experienced an SAE in the gemcabene 900&nbsp;mg treatment arm, which was not considered related to treatment. Three patients (placebo: 2, gemcabene 300&nbsp;mg: 1)&nbsp;withdrew from
the trial due to an AE, all of which were considered possibly related to treatment. AEs reported were generally mild to moderate in intensity. The
most frequent AE in the placebo arm was infection (13%). The most frequent AEs in the gemcabene treatment arms were headache (10%) and infection (10%). There were no meaningful changes in liver
enzymes ALT and AST. One patient in the 300&nbsp;mg gemcabene treatment arm had an unverified rise in creatine kinase of 5 &times; upper limit of normal (ULN). No clinically meaningful changes
in physical examinations or vital signs from baseline to the end of the trial were observed for any patient. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Gemcabene Phase&nbsp;2 Trial in Patients with Hypercholestrolemia (Trial A4141001)  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This Phase&nbsp;2 double-blind, placebo-controlled, randomized trial was designed to assess the efficacy and safety of gemcabene administered as
monotherapy, atorvastatin monotherapy or gemcabene in combination with atorvastatin in the treatment of patients with hypercholesterolemia. When applicable, patients were washed out of statins and
other lipid-lowering therapies. Gemcabene was administered as monotherapy once-daily at 300&nbsp;mg, 600&nbsp;mg or 900&nbsp;mg or in combination with atorvastatin once-daily at 10&nbsp;mg,
40&nbsp;mg and 80&nbsp;mg. The primary endpoint was percent change in LDL-C from baseline at Week&nbsp;8. Secondary endpoints included percent change in hsCRP, apoB, HDL-C and triglycerides from
baseline at Week&nbsp;8. A total of 277&nbsp;patients were randomized and 255 patients with at least one post baseline assessment were included in the efficacy analysis. Baseline LDL-C levels for
the evaluable patients after washout were similar across treatment arms at approximately 175&nbsp;mg/dL. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I>Efficacy:</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;As presented in the figure below, patients treated with gemcabene were observed to have significantly lowered LDL-C by 17%
(p=0.0013), 26% (p=0.0001) and 29% (p=0.0001) as monotherapy at 300 mg, 600&nbsp;mg and 900&nbsp;mg, respectively. The LDL-C lowering effect was seen within two weeks and was stable for the
duration of the eight week trial. It is important to note that the patients included in this trial were statin responsive (able to reach goal near or below 100&nbsp;mg/dL) at 10&nbsp;mg,
40&nbsp;mg and 80&nbsp;mg atorvastatin monotherapy. While the trial demonstrated gemcabene provided additional dose dependent LDL-C lowering (statistically significant at 600&nbsp;mg and
900&nbsp;mg when compared to atorvastatin alone), the gemcabene treatment effect was less pronounced due to the patients already being at or below LDL-C goal of 100&nbsp;mg/dL on atorvastatin
monotherapy. Patients treated with gemcabene were observed to have lowered hsCRP by 26% (p=0.1612), 42% (p=0.0070) and 35% (p=0.0018) as monotherapy at 300&nbsp;mg, 600&nbsp;mg and 900&nbsp;mg,
respectively. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>104</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=106,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=617044,FOLIO='104',FILE='DISK112:[15ZCH1.15ZCH40101]DU40101A.;116',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dw40101_1_105"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Patients treated with gemcabene in combination with atorvastatin aggregated over the dose range were observed to have mean LDL-C lowering of 50% (p=0.0852), 52% (p=0.0045) and
54% (p=0.0006) at 300&nbsp;mg, 600&nbsp;mg and 900&nbsp;mg, respectively. Patients treated with gemcabene in combination with atorvastatin aggregated over the dose range were observed to have
median hsCRP lowering of 47% (p=0.0237), 54% (p=0.0017) and 60% (p=0.0001) at 300&nbsp;mg, 600&nbsp;mg and 900&nbsp;mg, respectively. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
a post-hoc analysis of patients with mixed dyslipidemia, we observed that gemacabene in combination with atorvastatin synergystically lowers triglyceride levels while further lowering LDL-C levels. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
believe these results support the continued development of gemcabene for the treatment HoFH, HeFH and ASCVD indications including mixed dyslipidemia. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dw40101_ldl-c_mean_percent_change_from__ldl04009"> </A>
<A NAME="toc_dw40101_1"> </A>
<BR></FONT><FONT SIZE=3><B>LDL-C Mean Percent Change from Baseline in Patients with Hypercholesterolemia<BR>  (with wash-out of statins)  <BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g864922.jpg" ALT="GRAPHIC" WIDTH="631" HEIGHT="402">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Safety:</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Gemcabene was observed to be well tolerated. Patients taking any dose of gemcabene (300 mg, 600 mg or 900 mg) were observed to have a safety profile similar
to that of atorvastatin monotherapy. A similar percentage of patients experienced an associated AE between placebo (18%), atorvastatin monotherapy arms (14%) compared to gemcabene monotherapy (18%)
and gemcabene plus atorvastatin treatment arms (17%). Three patients in the gemcabene plus atorvastatin arm experienced a SAE, none of which were considered related to treatment. 16 patients (placebo:
1, atorvastatin monotherapy: 2, gemcabene monotherapy: 6, gemcabene plus atorvastatin: 7)&nbsp;withdrew from the trial due to AEs, nine (atorvastatin monotherapy: 2, gemcabene monotherapy: 4,
gemcabene plus atorvastatin: 3)&nbsp;of which were considered possibly related to treatment. AEs reported were generally mild to moderate in intensity. 14&nbsp;patients (placebo: 1, atorvastatin
monotherapy: 2, gemcabene monotherapy: 1, gemcabene plus atorvastatin: 10)&nbsp;reported an AE considered severe in intensity, one (gemcabene plus atorvastatin: 1)&nbsp;of which was considered
possibly related to treatment. The most frequently occurring AEs across all treatment </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>105</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=107,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=19400,FOLIO='105',FILE='DISK112:[15ZCH1.15ZCH40101]DW40101A.;81',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_dw40101_1_106"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>arms
were infection (8%), pain (6%) and headache (6%). Small mean increases in serum creatinine and BUN were observed in the gemcabene monotherapy arms. One patient treated with 600 mg gemcabene plus
atorvastatin had a clinically significant ALT elevation (&gt;3 &times; ULN on two separate occasions) that returned to near normal levels while treatment continued. No other patient had a
pre-specified clinically significant lab abnormality in ALT, AST, creatinine kinase or serum creatinine. No clinically meaningful changes in physical examinations or vital signs from baseline to the
end of the trial were observed for any patient. The AEs experienced by more than 10% of patients in any treatment group are summarized below. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Adverse Events by Body System Occurring With <FONT FACE="SYMBOL">&#179;</FONT>10% of Patients in<BR>
Any Treatment Group for Study A4141001</B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="34pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Atorvastatin Mono </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=7 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Gemcabene 300 mg&nbsp;+<BR>
Atorvastatin </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=7 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Gemcabene 600 mg&nbsp;+<BR>
Atorvastatin </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=7 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Gemcabene 900 mg&nbsp;+<BR>
Atorvastatin </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:36pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>AE Category

<!-- COMMAND=ADD_SCROPPEDRULE,36pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Pbo<BR>
N=17 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>10 mg<BR>
N=17 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>40 mg<BR>
N=18 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>80 mg<BR>
N=17 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Mono<BR>
N=16 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>10 mg<BR>
N=17 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>40 mg<BR>
N=18 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>80 mg<BR>
N=18 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Mono<BR>
N=18 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>10 mg<BR>
N=18 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>40 mg<BR>
N=16 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>80 mg<BR>
N=18 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Mono<BR>
N=17 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>10 mg<BR>
N=18 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>40 mg<BR>
N=16 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>80 mg<BR>
N=18 </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=33 style="font-family:arial;"><p style="font-family:arial;margin-left:6pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"><B> All Adverse Events</B></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:6pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Body as a whole</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 5 (29)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 4 (24)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 5 (28)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 4 (24)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 5 (31)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 3 (18)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 5 (28)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 4 (22)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 7 (39)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 7 (39)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 4 (25)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 4 (22)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 4 (24)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 5 (28)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 8 (50)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 10 (56)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Asthenia</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 2 (11)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 0 (0)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 1 (6)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 2 (11)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 1 (6)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Back Pain</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 0 (0)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 1 (6)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 2 (11)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 2 (11)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 0 (0)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Headache</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 3 (17)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 1 (6)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 1 (6)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 2 (11)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 1 (6)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 2 (11)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Infection</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 3 (18)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 3 (19)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 3 (17)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 2 (11)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 0 (0)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 2 (11)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 3 (17)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Pain</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 2 (12)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 0 (0)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 3 (17)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 2 (11)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 0 (0)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 2 (11)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:6pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Digestion</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> 2 (12)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> 2 (12)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> 5 (28)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> 3 (18)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B> </B></FONT><FONT  style="font-size:8pt;line-height:9pt;"><B> 3 (31)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> 3 (18)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> 4 (22)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> 3 (17)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B> </B></FONT><FONT  style="font-size:8pt;line-height:9pt;"><B> 4 (22)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> 5 (28)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> 3 (19)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> 4 (22)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B> </B></FONT><FONT  style="font-size:8pt;line-height:9pt;"><B> 4 (24)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> 3 (17)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> 3 (17)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Constipation</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 3 (17)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 0 (0)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 2 (12)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 1 (6)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 1 (6)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Diarrhea</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 3 (18)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 2 (13)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 1 (6)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 0 (0)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Dyspepsia</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 1 (6)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 0 (0)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 2 (11)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 1 (6)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Flatulence</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 2 (13)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 1 (6)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 0 (0)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Nausea</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 2 (13)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 2 (11)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 2 (11)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 0 (0)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 3 (18)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 2 (11)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:6pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Musculoskeletal</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> 2 (12)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> 3 (17)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> 2 (12)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B> </B></FONT><FONT  style="font-size:8pt;line-height:9pt;"><B> 0 (0)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> 2 (11)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> 2 (11)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B> </B></FONT><FONT  style="font-size:8pt;line-height:9pt;"><B> 0 (0)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> 3 (17)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> 3 (19)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B> </B></FONT><FONT  style="font-size:8pt;line-height:9pt;"><B> 0 (0)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> 3 (17)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Arthralgia</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 2 (12)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 2 (11)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 0 (0)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 0 (0)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 2 (13)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 0 (0)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 2 (11)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Myalgia</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 0 (0)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 0 (0)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 2 (11)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 0 (0)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 1 (6)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"> 0 (0)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
AE&nbsp;= adverse event; Mono&nbsp;= monotherapy; Pbo&nbsp;= placebo.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Source:
Report A4141001, Table&nbsp;40 (Cowmeadow et al., 2003) </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Gemcabene Phase&nbsp;2 Trial in Patients with Elevated Triglycerides (Trial 1027-004)  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This Phase&nbsp;2 double-blind, placebo-controlled, randomized trial was designed to assess the efficacy and safety of gemcabene in patients with
low HDL-C and either normal or elevated triglycerides. Gemcabene was administered at 150, 300, 600 and 900 mg once-daily for 12&nbsp;weeks. The objectives of this trial were to evaluate percentage
change from baseline in HDL-C, LDL-C, triglycerides and other lipids and apolipoprotein variables at Week 12. A total of 161 patients were randomized. At baseline, 67 patients were
normotriglyceridemic (&lt;200 mg/dL) and 94 patients were hypertriglyceridemic (<FONT FACE="SYMBOL">&#179;</FONT>200 mg/dL). Baseline triglycerides were approximately 370 mg/dL
across the treatment arms with hypertriglyceridemia with the exception of the 600 mg treatment arm (580 mg/dL). A total of 155 patients (89 hypertriglyceridemic patients) had a post randomization
assessment to be evaluated for efficacy. Baseline LDL-C levels for the evaluable patients, regardless of the triglyceride stratum, were similar across the treatment arms at approximately 110 mg/dL. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Efficacy:</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;As presented in the figure below, patients with triglyceride levels greater than 200 mg/dL (hypertriglyceridemic patients), treated with gemcabene at 150
mg and 300 mg were observed to have lowered triglycerides by 27% (p=0.002) and 39% (p&lt;0.001), respectively compared to baseline. Although patients treated with gemcabene at 600 mg and 900
mg were observed to have lower triglycerides, the lowering effect was not significant when compared to placebo. Therefore, the anticipated dose for treatment of patients with elevated triglyceride
levels is 150 mg or 300 mg. Notably, patients treated with gemcabene were observed to have significantly lowered LDL-C by 19% (p&lt;0.001) and 20% (p&lt;0.001) at 600 mg and 900 mg,
respectively, compared to baseline. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>106</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=108,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=20769,FOLIO='106',FILE='DISK112:[15ZCH1.15ZCH40101]DW40101A.;81',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_dw40101_1_107"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A
post-hoc analysis of the nine patients with severe triglyceride levels (<FONT FACE="SYMBOL">&#179;</FONT>500 mg/dL; baseline means of two weeks prior and time zero was approximately 600
mg/dL) treated with 150 mg and 300 mg suggest gemcabene has the potential to lower triglycerides by as much as 60%. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
believe these results support the continued development of gemcabene for the treatment SHTG and ASCVD patients with mixed dyslipidemia. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dw40101_triglyceride_median_percent_ch__tri04422"> </A>
<A NAME="toc_dw40101_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Triglyceride Median Percent Change From Baseline at Week 12 in Patients with High to Severe Hypertryglyceridemia    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g612051.jpg" ALT="GRAPHIC" WIDTH="618" HEIGHT="315">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Safety:</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Gemcabene was observed to be well tolerated. Patients taking any dose of gemcabene (150 mg, 300 mg, 600 mg or 900 mg) were observed to have a safety profile
similar to that of placebo. Fewer patients experienced an associated AE in the placebo arm (9%) compared to gemcabene treatment arms (17%). Three patients (placebo: 1, gemcabene: 2)&nbsp;experienced
SAEs, none of which were considered related to treatment. Six patients (placebo: 2, gemcabene: 4)&nbsp;withdrew from the trial due to AEs, four (placebo: 1, gemcabene: 3)&nbsp;of which were
considered possibly related to treatment. AEs reported were generally mild to moderate in intensity. Two patients (placebo: 1, gemcabene: 1)&nbsp;reported an AE considered severe in intensity. The
most frequent AEs in the placebo arm were infection (16%), accidental injury (6%), back pain (6%), dyspepsia (6%), headache (6%) and sinusitis (6%). The most frequently observed AEs in the gemcabene
arms were infection (12%), headache (7%) and asthenia (5%). Two patients had ALT values that met the definition of a clinically important laboratory abnormality (placebo: 1, 600 mg gemcabene: 1). One
patient had elevated BUN values considered clinically significant (600
mg gemcabene: 1). All of these laboratory abnormalities were considered mild to moderate. No clinically meaningful changes in physical examinations or vital signs from baseline to the end of the trial
were observed for any patient. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Gemcabene Phase&nbsp;1 Clinical Trials  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Gemcabene has been evaluated in ten completed Phase&nbsp;1 trials in healthy volunteers. These trials explored safety, tolerability,
pharmacokinetics, pharmacodynamics and dose response as monotherapy and in combination with high-intensity statin doses and other drugs. The table below summarizes our completed Phase&nbsp;1 trials. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>107</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=109,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=147819,FOLIO='107',FILE='DISK112:[15ZCH1.15ZCH40101]DW40101A.;81',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_dw40101_1_108"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dw40101_summary_of_phase_1_clinical_tr__sum02733"> </A>
<A NAME="toc_dw40101_3"> </A>
<BR></FONT><FONT SIZE=2><B>  Summary of Phase&nbsp;1 Clinical Trials of Gemcabene in Healthy Volunteers    <BR>    </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:75%;margin-left:12%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="55pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="40%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="20%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="64pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="56pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:41pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Trial Number

<!-- COMMAND=ADD_SCROPPEDRULE,41pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Trial Objectives </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Doses </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B># Volunteers </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Duration </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">1027-001</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Single-dose trial to evaluate safety, tolerability and pharmacokinetics (PK) of gemcabene</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">25, 100, 300, 600, 1,050, 1,500&nbsp;mg</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">GEM&nbsp;= 12</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Single Dose</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;background-color:#dcddde;"><p style="font-family:arial;margin-top:10pt;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 1027-002</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><p style="font-family:arial;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 Single-dose trial to evaluate the effect of food on the PK of gemcabene</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT>
</TD>
<TD style="font-family:arial;background-color:#dcddde;"><p style="font-family:arial;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 450&nbsp;mg</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><p style="font-family:arial;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 GEM&nbsp;= 12</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><p style="font-family:arial;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">



<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 Single Dose</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:10pt;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"><B><U>1027-003</U></B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Double blind, placebo controlled, randomized trial to evaluate the PK and pharmacodynamics (PD) at multiple doses of gemcabene</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">50, 150, 450, 750/600, 900&nbsp;mg</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">GEM&nbsp;= 40<BR>
placebo&nbsp;= 10</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">4 Weeks</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;background-color:#dcddde;"><p style="font-family:arial;margin-top:10pt;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT> <FONT  style="font-size:8pt;line-height:9pt;"><B><U>1027-008</U></B></FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><p style="font-family:arial;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 Trial to determine the potential drug-drug interactions of simvastatin with gemcabene</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT>
</TD>
<TD style="font-family:arial;background-color:#dcddde;"><p style="font-family:arial;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 900&nbsp;mg<BR>
(with 80&nbsp;mg simvastatin)</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>&nbsp;


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><p style="font-family:arial;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 GEM&nbsp;= 20</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><p style="font-family:arial;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">



<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 15 Days</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:10pt;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">1027-009</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Trial to evaluate the bioequivalence between a capsule and tablet formulation of gemcabene</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">300&nbsp;mg</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">GEM&nbsp;= 16</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Single Dose</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;background-color:#dcddde;"><p style="font-family:arial;margin-top:10pt;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 1027-010</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><p style="font-family:arial;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 Trial to evaluate the mass balance and metabolism of gemcabene</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT>
</TD>
<TD style="font-family:arial;background-color:#dcddde;"><p style="font-family:arial;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 600&nbsp;mg</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><p style="font-family:arial;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 GEM&nbsp;= 6</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><p style="font-family:arial;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">



<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 Single Dose</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:10pt;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">1027-011</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Trial to determine the potential drug-drug interactions of digoxin with gemcabene</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">900&nbsp;mg<BR>
(with 0.25&nbsp;mg digoxin)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">GEM&nbsp;= 12</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">10 Days</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;background-color:#dcddde;"><p style="font-family:arial;margin-top:10pt;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT> <FONT  style="font-size:8pt;line-height:9pt;"><B><U>A4141002</U></B></FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><p style="font-family:arial;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">



<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 Trial to determine the potential drug-drug interactions of atorvastatin with gemcabene</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT>
</TD>
<TD style="font-family:arial;background-color:#dcddde;"><p style="font-family:arial;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 300, 900&nbsp;mg<BR>
(with 80&nbsp;mg atorvastatin)</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>&nbsp;


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><p style="font-family:arial;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 GEM&nbsp;= 20</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT>
</TD>
<TD style="font-family:arial;background-color:#dcddde;"><p style="font-family:arial;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 22 Days</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:10pt;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">A4141003</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Trial to evaluate the effect of gemcabene on QT interval</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">900&nbsp;mg</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">GEM&nbsp;= 20</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">8 Days</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;background-color:#dcddde;"><p style="font-family:arial;margin-top:10pt;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 A4141005</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;



<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT>
</TD>
<TD style="font-family:arial;background-color:#dcddde;"><p style="font-family:arial;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 Trial to evaluate the effect of gemcabene on the glomerular filtration rate</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><p style="font-family:arial;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 900&nbsp;mg<BR>
(with 3,235&nbsp;mg lohexol)</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>&nbsp;


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><p style="font-family:arial;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 GEM&nbsp;= 12</FONT></TD>
<TD style="font-family:arial;background-color:#dcddde;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


</FONT>
</TD>
<TD style="font-family:arial;background-color:#dcddde;"><p style="font-family:arial;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"background-color:#dcddde;" -->


 10 Days</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>Note:</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>One
trial (A4141006; 23&nbsp;volunteers) was stopped prior to completion as a result of discontinuation of the program. The trial was designed to
evaluate multiple fixed-dose combinations of gemcabene with atorvastatin. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>108</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=110,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=199280,FOLIO='108',FILE='DISK112:[15ZCH1.15ZCH40101]DW40101A.;81',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dy40101_1_109"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Gemcabene Phase&nbsp;1 Drug-Drug Interaction Trials to Assess PK on Statins (Trials 1027-008 and
A4141002)  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Two open-label, multiple-dose, Phase&nbsp;1 trials were conducted to assess PK of gemcabene in combination with high-intensity statins. In
Trial&nbsp;1027-008, 900&nbsp;mg of gemcabene was co-administered with 80&nbsp;mg simvastatin in 20 healthy volunteers. In Trial A4141002, 300&nbsp;mg and 900&nbsp;mg of gemcabene were
co-administered with 80&nbsp;mg atorvastatin in 20 healthy volunteers. In both trials, treatment with gemcabene in combination with statins was observed to be well tolerated by volunteers.
Furthermore, as presented in the figures below, the PK profiles with and without 900&nbsp;mg gemcabene were observed to be similar, suggesting no clinically relevant drug-drug interactions with
either 80&nbsp;mg simvastatin or 80&nbsp;mg&nbsp;atorvastatin. Trial 1027-008 also demonstrated LDL-C lowering of 18% at a very low baseline of 59&nbsp;mg/dL on highest dose of 80&nbsp;mg
simvastatin. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dy40101_pk_profiles_of_high-intensity___pk_02670"> </A>
<A NAME="toc_dy40101_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PK Profiles of High-Intensity Statins Co-administered with Gemcabene    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g419181.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="225">
  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Gemcabene Phase&nbsp;1 Dose Escalation Trial to Assess PK and PD (Trial&nbsp;1027-003)  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This Phase&nbsp;1 randomized, double-blind, rising, multiple-dose trial was designed to assess PK characteristics and PD effect of gemcabene.
Gemcabene was administered at doses ranging from 150&nbsp;mg to 900&nbsp;mg once-daily to 50 healthy volunteers over four weeks. Primary values measured were AUC(0-24) and Cmax. PD endpoints
measured were total cholesterol, LDL-C, HDL-C, triglyercides, apoB and apoA1. Baseline LDL-C levels for the evaluable patients were similar across the treatment arms at approximately 120&nbsp;mg/dL. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Efficacy:</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;As presented in the figure below, volunteers treated with gemcabene were observed to demonstrate a dose response and significantly
(p<FONT FACE="SYMBOL">&#163;</FONT>0.05) lowered LDL-C by approximately 30% at 450&nbsp;mg to 900&nbsp;mg. Treated volunteers were observed to significantly
(p<FONT FACE="SYMBOL">&#163;</FONT>0.05) lower total cholesterol by 18% to 20% and apoB by 8% to 21% at 450&nbsp;mg to 900&nbsp;mg doses of gemcabene. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>109</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=111,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=909592,FOLIO='109',FILE='DISK112:[15ZCH1.15ZCH40101]DY40101A.;119',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_dy40101_1_110"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dy40101_ldl-c_mean_percent_change_from__ldl02715"> </A>
<A NAME="toc_dy40101_2"> </A>
<BR></FONT><FONT SIZE=2><B>  LDL-C Mean Percent Change from Baseline at Week&nbsp;4 in Healthy Volunteers    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g197595.jpg" ALT="GRAPHIC" WIDTH="612" HEIGHT="354">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Safety:</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Gemcabene was observed to be well tolerated. In general, frequency of AEs did not increase with dose. Healthy volunteers taking any dose of gemcabene
(50&nbsp;mg, 150&nbsp;mg, 300&nbsp;mg, 600/750&nbsp;mg or 900&nbsp;mg) were observed to have a safety profile similar to that of placebo. Slightly more patients experienced an associated AE
in the placebo arm (60%) compared to those in the gemcabene treatment arms (40%). No patients experienced an SAE. One patient (placebo: 1)&nbsp;withdrew from the trial due to an AE. AEs reported
were generally mild to moderate in intensity. Two patients (placebo: 1, gemcabene: 1)&nbsp;reported an AE considered severe. The most frequent AEs in the placebo arm were headache (60%),
photosensitivity (20%), diarrhea (20%), skin and appendages (20%) and contact dermatitis (20%). The most frequent AEs in the gemcabene arms were headache (43%), infections (15%), asthenia (13%),
photosensitivity (13%), nausea (15%) and rhinitis (13%). Mild elevations in BUN were observed, but overall, laboratory abnormalities were sporadic, transient, and appeared unrelated to gemcabene
administration. No clinically meaningful changes in physical examinations or vital signs from baseline to the end of the trial were observed. No clinically significant ECG abnormalities were observed. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Gemcabene Preclinical Studies  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As part of a comprehensive nonclinical toxicology program, over 30 exploratory and definitive single and repeated-dose toxicity studies with gemcabene
were conducted in mice, rats, dogs and monkeys. There are very few outstanding nonclinical studies needed for registration such as two-year carcinogenicity studies in rodents and juvenile toxicology.
Gemcabene was well tolerated in these completed studies, including a 26-week repeat dose study in rats and monkeys and 52-week repeat dose study in monkeys. The completed studies support conducting
clinical trials up to six months. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
multiple preclinical efficacy studies, gemcabene was observed to have lowering effects on plasma LDL-C, triglycerides and anti-inflammatory markers in diet-induced and genetic preclinical models of
dyslipidemia. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


In Vivo Proof of Principle Study for HoFH  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In LDL-receptor deficient mice, gemcabene at 60&nbsp;mg/kg/day was observed to reduce LDL-C up to 55% as monotherapy and 72% in combination with
statins. This dose in mice is equivalent to approximately a </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>110</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=112,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=410156,FOLIO='110',FILE='DISK112:[15ZCH1.15ZCH40101]DY40101A.;119',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_dy40101_1_111"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>450&nbsp;mg
gemcabene tablet per day in humans. This LDL-receptor deficient animal model has been reported in literature to be fairly predictive of HoFH therapies in practice. For example, statin
lowering of approximately 20% in LDL-receptor deficient-mice model correlates well to the approximately 15% to 20% LDL-C lowering observed in HoFH patients, and Juxtapid lowering of approximately 50%
to 80% in LDL-receptor deficient-rabbits model correlates well to the approximately 40% to 50% in HoFH patients. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dy40101_gemcabene_preclinical_hofh_mice_model"> </A>
<A NAME="toc_dy40101_3"> </A>
<BR></FONT><FONT SIZE=2><B>  Gemcabene Preclinical HoFH Mice Model    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g363356.jpg" ALT="GRAPHIC" WIDTH="585" HEIGHT="406">
  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Gemcabene Clinical Development Plan  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In June and September 2015, Gemphire received FDA feedback from its Type&nbsp;C meetings related to the development of gemcabene for the treatment
of patients with HoFH. The FDA indicated that historically LDL-C has been accepted as a surrogate endpoint for cardiovascular risk reduction for lipid-altering drugs to support traditional approval,
including patients with HoFH. The FDA reiterated weighing the magnitude of LDL-C reduction in light of the drug's safety profile (e.g., benefit/risk) when using a surrogate endpoint such as LDL-C. Our
investigational new drug application (IND) was submitted to the FDA in December 2015 and is in effect. Canada and Denmark have also accepted our clinical trial application. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
plan to initiate three late stage clinical trials by the end of 2016. Upon completion of one or more of these clinical trials, we intend to request one or more EOP2 meetings with the FDA and other
foreign regulatory authorities to discuss the design and scope of the Phase&nbsp;3 registration trials and long-term safety exposure needed for registration. We would expect to launch multiple
Phase&nbsp;3 registration trials no later than 2018 for our targeted indications. The development programs for our targeted indications are described below. The in-vitro drug transport studies have
been completed in accordance with FDA guidelines, and we expect to conduct a few additional clinical pharmacology Phase&nbsp;1 trials to support registration. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>111</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=113,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=682472,FOLIO='111',FILE='DISK112:[15ZCH1.15ZCH40101]DY40101A.;119',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_dy40101_1_112"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


HoFH: COBALT-1 Trial (GEM-201)  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The clinical development program for patients 17 and older with HoFH with elevated LDL-C is expected to include one Phase&nbsp;2b dose finding trial
(GEM-201) followed by a Phase&nbsp;3 registration trial. The GEM-201 protocol has been reviewed by the FDA and may proceed. We expect to initiate the Phase&nbsp;2b open-label, dose-escalation,
dose-finding trial in patients with HoFH on stable statin therapy (including other approved lipid-lowering therapies such as Zetia and Repatha) in the first half of 2016 in the United States and
Canada. This trial is designed to evaluate the LDL-C lowering effect of gemcabene in a HoFH population at three doses. The trial is expected to enroll 8&nbsp;patients with a clinical diagnosis of
HoFH. Patients will be sequentially administered 300&nbsp;mg, 600&nbsp;mg and 900&nbsp;mg doses escalated every 4&nbsp;weeks for a total of 12&nbsp;weeks. The primary endpoint will be LDL-C
lowering from baseline at 4, 8, and 12&nbsp;weeks, the acceptable surrogate endpoint for approval. Other endpoints will include hsCRP, apoB, non HDL-C, triglycerides, VLDL and total cholesterol.
Safety of these patients will be assessed by AE monitoring, clinical laboratory assessments, ECGs, physical examinations and vital sign assessments. We expect to report data for this open-label
Phase&nbsp;2b trial beginning in the end of 2016 and through the first half of 2017. The Phase&nbsp;2b trial, along with dose response
data from other trials, is expected to provide the necessary data for us to determine the clinical dose for the Phase&nbsp;3 registration trial. The Phase&nbsp;3 registration trial (GEM-202,
COBALT-2) is estimated to enroll 30 to 60&nbsp;patients, and will be conducted globally with the potential for patients to continue in an open-label safety extension. It is anticipated that a single
Phase&nbsp;3 registration trial is expected to be sufficient to support registration. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Hypercholesterolemia: ROYAL-1 Trial (GEM-301)  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The clinical development program for adult patients with hypercholesterolemia (including but not limited to HeFH and ASCVD) with elevated LDL-C levels
while on maximally tolerated high-intensity statin therapy is expected to include one Phase&nbsp;2b dose finding trial (GEM-301) followed by Phase&nbsp;3 registration trials. The GEM-301 protocol
has been reviewed by the FDA and may proceed. We expect to initiate the Phase&nbsp;2b double-blind, randomized, parallel-group, placebo-controlled, dose finding trial in patients with
hypercholesterolemia on high-intensity therapy (with or without ezetimibe) in the second half of 2016 in the United States and several other countries. We may consider further amendments to this trial
design. This trial will be designed to evaluate the LDL-C lowering effect of gemcabene at three doses in combination with statins and/or ezetimibe with entry LDL-C&nbsp;&gt;100&nbsp;mg/dL. The
trial is expected to enroll 212&nbsp;patients with hypercholesterolemia on maximally tolerated high-intensity statins. Patients will be treated with 300&nbsp;mg, 600&nbsp;mg or 900&nbsp;mg
gemcabene once-daily for 12&nbsp;weeks. The primary endpoint will be LDL-C lowering from baseline at 12&nbsp;weeks. Other endpoints will include hsCRP, apoB, non HDL-C, triglycerides, VLDL and
total cholesterol. Safety of these patients will be assessed by AE monitoring, clinical laboratory assessments, ECGs, physical examinations and vital sign assessments. We expect to report data for
this Phase&nbsp;2b trial in the second half of 2017. Currently available data suggests 600&nbsp;mg gemcabene would be the dose selected for the Phase&nbsp;3 registration trial. After our
Phase&nbsp;2b trial and after discussions with the FDA in our EOP2 meeting and other regulatory agencies, we believe we will be able to better define the Phase&nbsp;3 registration trials and
long-term safety exposure needed for registration. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


SHTG: INDIGO-1 Trial (GEM-401)  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The clinical development program for adult patients with SHTG with elevated triglyceride levels is expected to include one Phase&nbsp;2b trial
(GEM-401) designed to meet anticipated registration standards, followed by a Phase&nbsp;3 registration trial. The Phase&nbsp;2b protocol is still being finalized and the draft design under
consideration is a double-blind, randomized, placebo-controlled trial in patients with SHTG to be initiated in the second half of 2016 in the United States and Canada. The trial will be designed to
evaluate the triglyceride lowering effect. The trial is expected to enroll 80 to 120&nbsp;patients (40 to 60&nbsp;patients per arm) with triglycerides
<FONT FACE="SYMBOL">&#179;</FONT>500&nbsp;mg/dL. Patients will be treated with 300&nbsp;mg of gemcabene or placebo with or without background statin therapy once-daily for
12&nbsp;weeks. The primary endpoint will be TG lowering from baseline after 12&nbsp;weeks with the potential for patients to continue in an open-label safety extension. Other endpoints will
include LDL-C, hsCRP, apoB, non HDL-C, VLDL and total cholesterol. A sub-analysis may be </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>112</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=114,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=911222,FOLIO='112',FILE='DISK112:[15ZCH1.15ZCH40101]DY40101A.;119',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_dy40101_1_113"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>conducted
to determine the number of patients at the end of the study achieving triglyceride levels below 500&nbsp;mg/dL. Safety of these patients will be assessed by AE monitoring, clinical
laboratory assessments, ECGs, physical examinations and vital sign assessments. We expect to report top-line data for this Phase&nbsp;2b trial in the second half of 2017. After our Phase&nbsp;2b
trial and after discussions with the FDA in our EOP2 meeting and other regulatory agencies, we believe we will be able to better define the Phase&nbsp;3 registration trials and long-term safety
exposure needed for registration. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Additional Studies and Trials  </I></B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Studies in Response to Partial Clinical Hold for Compounds in PPAR Class  </I></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Peroxisome proliferation-activated receptor (PPAR) agonists are drugs which bind and turn on the many PPARs in the nucleus. PPARs comprises three
subtypes, PPAR<FONT FACE="SYMBOL">a</FONT>, PPAR<FONT FACE="SYMBOL">g</FONT> and PPAR<FONT FACE="SYMBOL">b</FONT> (also referred to as
PPAR<FONT FACE="SYMBOL">d</FONT>). When the PPARs are activated by natural or pharmaceutical molecules those molecules can regulate (turn-off or turn-on) the transcription (making the
messenger RNA) of genes that regulate the storage and mobilization of lipids (fats), glucose metabolism, and inflammatory responses. PPAR-<FONT FACE="SYMBOL">a</FONT> and
PPAR<FONT FACE="SYMBOL">g</FONT> are the molecular targets of a number of marketed drugs to treat metabolic syndrome including lowering triglycerides and cholesterol such as fibrate drugs
and to treat diabetes mellitus and insulin resistance such as thiazolidinediones drugs. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Beginning
in 2004, the FDA began issuing partial clinical holds to all sponsors of PPARs or agents deemed to have PPAR-like properties from preclinical studies. The FDA takes the position that
preclinical data suggest PPAR agonists are carcinogenic in rodents. In 2004, the FDA determined that gemcabene was a PPAR agonist and issued a partial clinical hold. Our current IND is subject to the
same partial clinical hold. The partial clinical hold permits clinical trials of up to six months for gemcabene and also requires us to conduct two-year rat and mouse carcinogenicity studies before
conducting clinical trials of longer than six months. Our two-year rat and mouse
carcinogenicity studies are underway and scheduled for completion by the end of 2017 and draft reports will be issued shortly thereafter. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
believe the apparent weak PPAR<FONT FACE="SYMBOL">a</FONT> effects observed in rodents (for example, peroxisome proliferation and elevation of liver weight) are likely rodent-specific
phenomena, and, based on scientific publications reviewing nonclinical and clinical experience, share little apparent relevance for human risk assessment. In a recently completed PPAR agonist receptor
binding assays we observed essentially no gemcabene binding to the mouse, rat, or human PPAR<FONT FACE="SYMBOL">a</FONT>, PPAR<FONT FACE="SYMBOL">b</FONT>, or
PPAR<FONT FACE="SYMBOL">g</FONT> receptors, whereas reference agents for each of the receptors showed the expected binding, including the marketed
PPAR<FONT FACE="SYMBOL">a</FONT> agents, such as fibrates, including gemfibrozil. We believe the PPAR<FONT FACE="SYMBOL">a</FONT> responses in the rat are secondary and perhaps
related to the mobilization or formation of a naturally occurring molecule that binds to PPAR<FONT FACE="SYMBOL">a</FONT> in response to gemcabene administration. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Cardiovascular Outcomes Trials  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We believe it is well accepted that every 1.6&nbsp;mg/dL lowering of LDL-C through the cholesterol synthesis pathway results in a 1% lowering of
cardiovascular disease risk. The FDA has not required any approved therapy targeting LDL-C lowering, including non-statin therapies, to initiate or complete a cardiovascular outcomes trial in
connection with its approval of HoFH, HeFH and ASCVD therapies. Based on recent drug approvals, we believe it is unlikely that the FDA will require us to initiate or complete a cardiovascular outcomes
trial for any of the targeted indications, although we would plan to initiate a cardiovascular outcomes trial, for illustration in high-risk ASCVD patients with mixed dyslipidemia, prior to NDA filing
to pursue broader label indications related to cardiovascular disease risk reduction. Notwithstanding our current expectations, the FDA could require us to initiate or complete a cardiovascular
outcomes trial as a condition to filing or approving an NDA for gemcabene. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>113</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=115,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=831041,FOLIO='113',FILE='DISK112:[15ZCH1.15ZCH40101]DY40101A.;119',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_dy40101_1_114"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Additional Indications and Patient Populations</I></B></FONT><FONT SIZE=2>: </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Nonalcoholic
steatohepatitis (NASH) is a severe disease of the liver caused by inflammation and a buildup of fat in the organ. NASH is part of a group of conditions called
nonalcoholic fatty liver disease (NAFLD) that affects one out of four people in the United States. In the United States NASH affects up to approximately 2-5% of the population, or between six to
eight&nbsp;million people. The presentation of NASH resembles alcoholic liver disease but occurs in people who drink little or no alcohol. The major feature of NASH is excess fat content in the
liver, along with inflammation and liver damage. It can lead to liver cirrhosis, fibrosis, hepatocellular carcinoma, liver failure, liver-related death and liver transplantation. NASH can also lead to
an increased risk of cardiovascular disease. Prevalence has increased due to the growing number of obese and diabetic patients. It is more common in women than in men and currently there are no
specific therapies for treating NASH. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Gemcabene
may be effective in treating patients for NASH given its mechanism of action around inflammation and triglycerides. In the plasma, gemcabene significantly reduces both hsCRP
(&#150;36% to &#150;40%) in combination with a statin and triglycerides (&#150;39% to &#150;60%) as monotherapy. This suggests gemcabene may reduce the
inflammation state and amount of fat in the blood in patients that suffer from NASH. In the liver, gemcabene also affects both the triglycerides and cholesterol synthesis pathway; specifically in the
triglyceride pathway it inhibits the conversion of ACC into triglycerides (see figure below). We are exploring further proof of concept for NASH in both preclinical models and different patient
populations such as Familial Partial Lipodystrophy (FPL) patients. The FPL condition leads to loss of metabolic control resulting in an extreme metabolic like state, in which the FPL patient can
present with diabetes, cardiovascular disease, hypertriglyceridemia and NASH. In addition, we have filed new provisional applications for the treatment of NASH. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>Gemcabene
Inhibits </FONT><FONT SIZE=2><I>de novo</I></FONT><FONT SIZE=2> Synthesis of Both<BR>
Cholesterol and Triglycerides </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g395948.jpg" ALT="GRAPHIC" WIDTH="463" HEIGHT="324">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Source: Research Report 76100065 (2013) </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Future In-licensing and Acquisition Opportunities  </I></B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Our scientific team is well-qualified to identify, in-license or acquire, and develop additional product candidates to diversify our pipeline and
generate long-term growth. We continually evaluate and prioritize interesting product candidates based on scientific merit, regulatory pathways, and commercial </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>114</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=116,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=784510,FOLIO='114',FILE='DISK112:[15ZCH1.15ZCH40101]DY40101A.;119',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_dy40101_1_115"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>differentiation.
Our focus is on product candidates that allow us to manage across the continuum of care from acute to chronic dyslipidemia patients. We have a particular interest in acute therapies
in the cardio-metabolic space since we believe a next frontier will be to reverse the cholesterol-related effects of atherosclerosis, which leverages the team's expertise. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Sales and Marketing  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Given our current stage of development, we have not yet established a commercial organization or distribution capabilities, nor have we entered into
any partnership or co-promotion arrangements with an established pharmaceutical company. To develop the appropriate commercial infrastructure to launch gemcabene in the United States, if approved, for
the narrower indications of HoFH, we may build out a specialty sales force to reach a concentrated number of approximately 50 lipid centers and 500&nbsp;lipidologists across the country. This would
require additional financial and managerial resources. We may engage in partnering discussions with third parties from time to time. When we seek approval and launch commercial sales of gemcabene
outside of the United States or for broader patient populations in the United States, including patients with HeFH, ASCVD and SHTG, we may establish alliances with one or more pharmaceutical company
collaborators, depending on, among other things, the applicable indications, the related costs and our available resources. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Manufacturing  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We rely on contract manufacturers to produce both
the drug substance and drug product amounts required for our clinical trials and preclinical toxicology work. Drug supply in an amount anticipated to be sufficient for our planned late stage clinical
trials was manufactured in 2015. All lots of drug substance and drug product used in clinical trials are manufactured under current good manufacturing practices (cGMP), a quality system regulating
manufacturing. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Gemcabene
is a small molecule drug that can be synthesized as a crystalline monocalcium single polymorph with readily available raw materials and using conventional chemical processes. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Previous
development has demonstrated the drug substance manufacture can be scaled up to 200&nbsp;kg and drug product tablets can be manufactured at varying dosages. Previous stability data suggest
an anticipated expiry of at least 18&nbsp;months. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Gemcabene
drug substance analytical development and production has been completed and scaled-up to meet clinical&nbsp;II/III cGMP requirements with sufficient chemistry, manufacturing, and control
to support Phase&nbsp;2b and Phase&nbsp;3 trials. We have also selected a drug product manufacturer that has completed the analytical and process development to support the manufacture of tablets
of various strengths. We are also planning additional stability studies for both the drug substance and drug product lots manufactured in order to extend expiry and to support regulatory approval and
commercial stage. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
contract manufacturers are currently producing, and will produce in the future, our bulk drug substance and drug product for use in our preclinical studies and clinical trials utilizing reliable
and reproducible synthetic processes and common manufacturing techniques. We obtain such supplies from manufacturers on a purchase order basis, and do not have any long-term arrangements. We intend to
identify and qualify our current manufacturers as well as alternative manufacturers to provide bulk drug substance and drug product prior to the NDA submission to the FDA to ensure the regulatory
support necessary for multiple manufacturing sites in order to supply sufficient commercial quantities at the drug launch and forward. We plan to continue to rely upon contract manufacturers and,
potentially, collaboration partners to manufacture commercial quantities of our drug substances and drug product candidates, if approved for marketing by the applicable regulatory authorities. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>115</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=117,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=325607,FOLIO='115',FILE='DISK112:[15ZCH1.15ZCH40101]DY40101A.;119',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ea40101_1_116"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Pfizer License Agreement  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In April 2011, we entered into a license agreement with Pfizer (the Pfizer Agreement) for a worldwide exclusive license to certain patent rights to
make, use, sell, offer for sale and import the clinical product candidate gemcabene. In exchange for this license, we agreed to issue shares of our common stock to Pfizer representing 15% of our fully
diluted capital at the close of the first arms-length series&nbsp;A financing, which occurred on March&nbsp;31, 2015. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
agreed to make milestone payments totaling up to $37&nbsp;million upon the achievement of certain milestones, including the first regulatory submission in any country, regulatory approval in each
of the United States, Europe and Japan, the first anniversary of the first regulatory approval in any country, and upon achieving certain aggregate sales levels of gemcabene or any product containing
gemcabene. Future milestone payments under the Pfizer Agreement, if any, are not expected to begin for at least several years and extend over a number of subsequent years. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
have also agreed to pay Pfizer tiered royalties on a country-by-country basis based upon the annual amount of net sales as specified in the Pfizer Agreement until expiration of the last valid claim
of the licensed patent rights, including any patent term extensions or supplemental protection certificates. The royalty rates range from the high single digits to the low teens depending on the level
of net sales. Under the Pfizer Agreement we are obligated to use commercially reasonable efforts to develop and commercialize gemcabene. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Pfizer Agreement will expire upon expiration of the last royalty term. Either party may terminate the Pfizer Agreement for the other party's uncured material breach and specified bankruptcy
events. Pfizer may terminate the Pfizer Agreement if we or any of our sublicensees challenge the validity, enforceability or ownership of the licensed patents. Additionally, Pfizer may revoke the
license if we are unable to adequately commercialize gemcabene by April 2021. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Intellectual Property  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our patent estate includes patents and/or patent applications to forms of gemcabene, methods of using gemcabene, and methods of manufacturing
gemcabene. Charles Bisgaier, a co-founder of Gemphire, is an inventor on six of the eight patent families. The active pharmaceutical ingredient and clinical formulations of the drug are protected by
patents. Subsequent to obtaining the license from Pfizer, additional patents have been filed that are entirely owned by Gemphire. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>As
of May&nbsp;2, 2016, Gemphire's patent estate, including patents we own or license from third parties, on a worldwide basis, included four issued U.S. patents, eight pending U.S. patent
applications, 23 issued patents in foreign jurisdictions including Canada, France, Germany, Great Britain, Ireland, Italy, Mexico and Spain and 15 pending patent applications in foreign jurisdictions
including Australia, Canada, China, Europe, Hong Kong, Japan and Mexico. Of our worldwide patents and pending applications, all relate to our product candidate gemcabene. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>U.S.
Patent number&nbsp;6,861,555, which was in-licensed from Pfizer, includes claims directed to the calcium salt crystal form of gemcabene that is used in our clinical formulations and will
constitute the commercial product as well as other crystalline forms of gemcabene. This patent is expected to expire in 2021; however, we will likely select this patent for patent term extension from
the U.S. Patent and Trademark Office (USPTO) if such an extension is available. Given the expected length of the regulatory review, the expiry date of this patent may be extended to 2023, or possibly
2024. Assuming market approval of gemcabene in 2019, data exclusivity would provide exclusivity for gemcabene out to about 2024. Furthermore, and importantly in our case, the FDA orphan designation
for HoFH may provide us seven years of market exclusivity for gemcabene in the United States for HoFH. This market exclusivity would provide protection for gemcabene for treating HoFH out to about
2026. Related foreign patents, which have issued in jurisdictions including Canada, Denmark, Finland, France, Germany, Great Britain, Ireland, Italy, the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>116</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=118,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=2016,FOLIO='116',FILE='DISK112:[15ZCH1.15ZCH40101]EA40101A.;89',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_ea40101_1_117"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Netherlands,
Sweden, Spain, Japan, Mexico and New Zealand, are expected to expire in 2021, absent any adjustments or extensions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>U.S.
Patent Number&nbsp;8,557,835, which was also in-licensed from Pfizer, includes claims directed to pharmaceutical compositions comprised of combinations of gemcabene with statins and methods of
using a combination of gemcabene and a statin for treating several conditions including hyperlipidemia. This patent is expected to expire in 2020, absent any extensions. Related foreign patents, which
have issued in jurisdictions including France, Germany, Great Britain, Ireland, Italy, Spain, Mexico, and Singapore are expected to expire in 2018, absent any adjustments or extensions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>U.S.
Patent No.&nbsp;8,846,761, which is owned by Gemphire, includes claims directed to methods of reducing risk of pancreatitis for patients with
TG<FONT FACE="SYMBOL">&#179;</FONT>500&nbsp;mg/dL with gemcabene treatment. This patent is expected to expire in 2032, absent any adjustments or extensions. Foreign counterpart patent
applications are pending in Australia, Canada, China, Europe, Hong Kong, Mexico and Japan, and any patents issuing from such applications are expected to expire in 2031, absent any adjustments or
extensions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>U.S.
patent application number&nbsp;14/370,722, which we own, is directed to methods of decreasing a patient's risk for developing coronary heart disease or preventing, delaying or reducing the
severity of a secondary cardiovascular event by administering gemcabene with a statin. Related patent applications are pending in foreign jurisdictions including Australia, Canada, China, Europe,
Japan and Mexico. Any patent that may issue in this family, absent any patent term adjustment or extension, is expected to expire in 2033. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
2015, we filed two new provisional patent applications, one for methods of treatment of mixed dyslipidemia using gemcabene in combination with statins and treatment of NASH using gemcabene as
monotherapy (U.S. Provisional Patent Application&nbsp;Number&nbsp;62/252,195), and the other relating to fixed dose combinations and modified release formulations of gemcabene and statins (U.S.
Provisional Patent Application&nbsp;Number&nbsp;62/252,147), as well as two non-provisional patent applications on methods of large scale manufacturing for making dicarboxyalkyl ethers (US
Application&nbsp;Number&nbsp;14/942,765, and corresponding PCT application Number&nbsp;PCT/US2015/060917). The two provisional applications, if issued, are expected to expire in 2036. The two
non-provisional applications if issued, are expected to expire in 2035. As of May&nbsp;2, 2016, we filed four new provisional patent applications: U.S. Provisional Patent Application
Numbers&nbsp;62/295,292, 62/300,393, 63/30,0415 and 62/314,597. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
background, the patent term is typically 20&nbsp;years from the date of filing a non-provisional application. In the United States, a patent's term may be lengthened several ways. First, patent
term adjustment (PTA) compensates a patentee for administrative delays by the USPTO in granting a patent. Second, in certain instances, a patent
term extension (PTE) can be granted to recapture a portion of the term effectively lost as a result of the FDA regulatory review period, as provided under the Drug Price Competition and Patent Term
Restoration Act of 1984, referred to as the Hatch-Waxman Act. This restoration period cannot be longer than five years for approval of a drug compound, and the total patent term, including the
restoration period, must not exceed 14&nbsp;years following FDA approval. Only one patent applicable to an approved drug is eligible for the PTE and the application for the extension must be
submitted prior to the expiration of the patent and within 60&nbsp;days from market approval. Independent of patent protection, in the United States, the Hatch-Waxman Act provides a five-year period
of non-patent data exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity (NCE). Under this provision, gemcabene may be eligible for up to
five years of data and market exclusivity under the Hatch-Waxman Act, because it is considered a NCE because the FDA has not previously approved any other drug containing the active ingredient of
gemcabene. In Europe, under the Data Exclusivity Directive, pharmaceutical companies may receive up to 11&nbsp;years to market their product without risk of competition. In Japan, under the
Pharmaceuticals Act of Japan, the market authorization holder, based on the length of a required study period reexamination, may have up to 10&nbsp;years before a generic can enter the market. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>117</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=119,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=529040,FOLIO='117',FILE='DISK112:[15ZCH1.15ZCH40101]EA40101A.;89',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_ea40101_1_118"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Competition  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our industry is highly competitive and subject to rapid and significant innovation and change. The market for lipid regulating therapies is especially
large and competitive. Our potential competitors include large pharmaceutical and biopharmaceutical companies, specialty pharmaceutical and generic drug companies, academic institutions, government
agencies and research institutions. Gemcabene, if approved, will face intense competition. Key competitive factors affecting its commercial success will include efficacy, safety, tolerability,
reliability, convenience of dosing, price and reimbursement. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Statins
are the most commonly used therapy to lower LDL-C in the dyslipidemia market. They are used by patients with HoFH as well as HeFH and ASCVD. Branded statins include AstraZeneca's Crestor
(rosuvastatin), Merck's Zocor (simvastatin) and Pfizer's Lipitor (atorvastatin) among others. Generic statins are marketed by several companies including Apotex Inc., Mylan&nbsp;N.V. (Mylan),
Dr.&nbsp;Reddy's Laboratories Ltd. and Lupin Pharmaceuticals, Inc. (Lupin) among others. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Non-statin
based therapies are also used to lower LDL-C in dyslipidemia patients. Merck's Zetia (ezetimibe) is a common non-statin therapy that is often combined with statins for HoFH, HeFH and ASCVD
patients. Merck's Vytorin and Liptruzet are fixed-dose combination therapies that combine ezetimibe with statins. Non-statin therapies are combined with statins to improve LDL-C lowering or to offer
other efficacy benefits, including Daiichi Sankyo Inc.'s (Daiichi Sankyo) Welchol, a bile acid sequestrant and niacin. Non-statin therapies are also used to treat HoFH. These therapies include
Aegerion's Juxtapid, a once-daily oral microsomal triglyceride transfer protein (MTP) inhibitor and Ionis and Genzyme Corporation's, a Sanofi Company (Genzyme), Kynamro, a
once-weekly injectable apoB antisense therapy. These agents have boxed warnings associated with liver toxicity and significant tolerability issues on their labels. Amgen's Repatha, an injectable PCSK9
inhibitor, was recently approved for HoFH, HeFH and ASCVD, and Sanofi's and Regeneron's PCSK9 inhibitor, Praluent, was recently approved for HeFH and ASCVD. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>There
are multiple product candidates in late stage development for HoFH, HeFH and ASCVD. CymaBay Therapeutic's (CymaBay) MBX-8025 (Phase&nbsp;2) and Regeneron's RGEN-1500 (Phase&nbsp;2) are in
development for the treatment of HoFH. For hypercholesterolemia, including HeFH and ASCVD, drugs in development include oral CETPi, Merck's anacetrapib (Phase&nbsp;3), Eli Lilly and Company's
evacetrapib (recently discontinued Phase&nbsp;3), and Amgen/Dezima's TA-8995 (Phase&nbsp;2), current Esperion's oral product, ETC-1002 (completed Phase&nbsp;2), The Medicines Company/Alnylam
Pharmaceuticals, Inc.'s (Alnylam) injectable PCSK9 inhibitor, ALN-PCSsc (completed Phase&nbsp;1), and Pfizer's injectable PCSK9 inhibitor, bococizumab (Phase&nbsp;3). </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>118</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=120,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=525964,FOLIO='118',FILE='DISK112:[15ZCH1.15ZCH40101]EA40101A.;89',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_ea40101_1_119"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
market for LDL lowering therapy is both large and competitive, and the diagram below depicts the opportunity for gemcabene in 2<SUP>nd</SUP> line oral therapy, especially with discontinuation
of competing oral CETPi. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ea40101_competitive_ldl-c_lowering_landscape"> </A>
<A NAME="toc_ea40101_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Competitive LDL-C Lowering Landscape    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g95314.jpg" ALT="GRAPHIC" WIDTH="621" HEIGHT="412">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Fibrates,
niacin and prescription fish oil are common therapies used to lower triglycerides in patients with severe hypertriglyceridemia. Examples of branded fibrates include AbbVie&nbsp;Inc.'s
(AbbVie) Tricor and Trilipix, and an example of a branded niacin includes AbbVie's Niaspan, an extended-release niacin. In addition, AbbVie markets combination therapies, such as Advicor (niacin
extended release and lovastatin) and Simcor (niacin extended release and simvastatin). Prescribed generic versions of fibrates, such as gemfibrozil, are manufactured by many
companies including Impax Laboratories, Inc. (Impax), Teva Pharmaceutical Industries Ltd. (Teva), Mylan and Lupin among others. Generic versions of niacins are manufactured by many companies including
Teva, Lupin and Zydus Pharmaceuticals (USA), Inc., among others. Commonly used prescription fish oils include GlaxoSmithKline plc's (GlaxoSmithKline) Lovaza, AstraZeneca's Epanova and Amarin's
Vascepa. Drugs that are in late stage development for SHTG include Ionis' volanesorsen (Phase&nbsp;3). </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Government Regulation  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Government authorities at the federal, state and local level in the United States and in other countries extensively regulate, among other things, the
research, development, testing, manufacture (including any manufacturing changes), packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval
monitoring and reporting, import and export of pharmaceutical products, such as those we are developing. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>119</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=121,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=517602,FOLIO='119',FILE='DISK112:[15ZCH1.15ZCH40101]EA40101A.;89',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_ea40101_1_120"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


United States&nbsp;&#151; FDA Regulation  </I></B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


FDA Approval Process  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In the United States, pharmaceutical products are subject to extensive regulation by the FDA. The Federal Food, Drug and Cosmetic Act (FDC Act) and
other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing,
distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products. Failure to comply with applicable U.S. requirements may subject a company to a variety
of administrative or judicial sanctions by the FDA, including FDA refusal to approve pending
NDAs, partial or full clinical holds, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties and
criminal prosecution. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Pharmaceutical
product development for a new product or certain changes to an approved product in the United States typically involves preclinical laboratory and animal tests, the submission of an
investigational new drug application (IND) to the FDA, which must become effective before clinical trials may commence, and adequate and well-controlled clinical trials to establish the safety and
effectiveness of the drug for each indication for which FDA approval is sought. Satisfaction of the FDA's pre-market approval requirements typically takes many years and the actual time required may
vary substantially based upon the type, complexity and novelty of the product or disease. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Preclinical
studies include laboratory evaluation of product chemistry, formulation and toxicity, as well as animal trials to assess the characteristics and potential safety and efficacy of the
product. The conduct of the preclinical studies must comply with federal regulations and requirements, including good laboratory practices, or GLP. The results of preclinical studies are submitted to
the FDA as part of an IND along with other information, including information about product chemistry, manufacturing and controls, available clinical data, and a proposed clinical trial protocol. Long
term preclinical studies, such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>An
IND automatically becomes effective 30&nbsp;days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places
the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Clinical
trials involve the administration of the investigational new drug to healthy volunteers or patients under the supervision of a qualified investigator. Clinical trials must be conducted:
(1)&nbsp;in compliance with federal regulations; (2)&nbsp;in compliance with good clinical practice (GCP), an international standard meant to protect the rights and health of patients and to
define the roles of clinical trial sponsors, administrators and monitors; as well as (3)&nbsp;under protocols detailing the objectives of the trial, the parameters to be used in monitoring safety,
and the effectiveness criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
FDA may order the temporary or permanent discontinuation of a clinical trial at any time, or impose other sanctions if it believes that the clinical trial is either not being conducted in
accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. The clinical trial protocol and informed consent information for patients in clinical trials must also
be submitted to an IRB, for approval. An IRB must operate in compliance with FDA regulations. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently,
for failure to comply with the IRB's requirements or may impose other conditions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Clinical
trials to support NDAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap. </FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Phase&nbsp;1 trials: The drug is initially introduced into healthy volunteers
or patients, with the target disease or condition. The drug is tested to assess metabolism, pharmacokinetics, pharmacological </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>120</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=122,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=135912,FOLIO='120',FILE='DISK112:[15ZCH1.15ZCH40101]EA40101A.;89',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_ea40101_1_121"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:arial;"><FONT SIZE=2>actions,
side effects associated with increasing doses, and, if possible, early evidence of effectiveness. </FONT></P>

</UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Phase&nbsp;2 trials: The drug is administered to a limited patient population
to determine the effectiveness of the drug for a particular indication, dosage tolerance, optimum dosage and to identify common adverse effects and safety risks. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Phase&nbsp;3 trials: If the drug demonstrates evidence of effectiveness and an
acceptable safety profile in Phase&nbsp;2 trials, Phase&nbsp;3 trials, including registration trials, are undertaken to obtain additional information about clinical efficacy and safety in a larger
number of patients, typically at geographically dispersed clinical trial sites, to permit the FDA to evaluate the overall benefit-risk relationship of the drug and to provide adequate information for
the labeling of the drug. In most cases, the FDA requires two adequate and well-controlled Phase&nbsp;3 registration trials to demonstrate the efficacy of the drug. A single Phase&nbsp;3
registration trial with other confirmatory evidence may be sufficient in rare instances where the study is a large multicenter trial demonstrating internal consistency and a statistically very
persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with a potentially serious outcome and confirmation of the result in a second trial
would be practically or ethically impossible. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Progress
reports detailing the results of the clinical trials must be submitted at least annually to the FDA and, more frequently, if SAEs occur. Phase&nbsp;1, Phase&nbsp;2 and Phase&nbsp;3
trials may not be completed successfully within any specified period, or at all. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>After
completion of the required clinical trials, an NDA is prepared and submitted to the FDA. FDA approval of the NDA is required before marketing of the product may begin in the United States. The
NDA must include, among other things, the results of all preclinical studies, clinical trials and other testing, a compilation of data relating to the product's pharmacology, chemistry, manufacture
and controls, and the proposed product labeling. The cost of preparing and submitting an NDA is substantial. The submission of most NDAs is additionally subject to a substantial application user fee,
currently exceeding $2,374,000 for fiscal year 2016, and the manufacturer and/or applicant under an approved NDA are also subject to annual product and establishment user fees, currently exceeding
$114,000 per product and $585,000 per establishment. These fees are typically increased annually. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
FDA has 60&nbsp;days from its receipt of an NDA to determine whether the application will be accepted for filing based on the agency's threshold determination that it is sufficiently complete to
permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA has agreed to certain performance goals in the review of new drug applications. Most
such applications for standard review drug products are reviewed within ten to twelve months; most applications for priority review drugs are reviewed in six to eight months. Priority review can be
applied to drugs that the FDA determines offer major advances in treatment, diagnosis, or prevention of diseases or provide a treatment where no adequate therapy exists. For biologics, priority review
is further limited only for drugs intended to treat a serious or life-threatening disease relative to the currently approved products. The review process for both standard and priority review may be
extended by the FDA for three additional months to consider certain late-submitted information, or information intended to clarify information already provided in the submission. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
FDA may also refer applications for novel drug products, or drug products that present difficult questions of safety or efficacy, to an advisory committee&nbsp;&#151; typically a panel
that includes clinicians and other experts&nbsp;&#151; for review, evaluation and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation
of an advisory committee, but it generally follows such recommendations. Before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally,
the FDA will inspect the facility or the facilities at which the drug is manufactured. The FDA will not approve the product unless it is compliant with cGMP, is </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>121</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=123,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=482724,FOLIO='121',FILE='DISK112:[15ZCH1.15ZCH40101]EA40101A.;89',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_ea40101_1_122"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>satisfactory
and the NDA contains data that provide substantial evidence that the drug is safe and effective in the indication studied. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>After
the FDA evaluates the NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter. A complete response letter generally outlines the deficiencies in
the submission and may require substantial additional testing, or information, in order for the FDA to reconsider the application. If, or when, those deficiencies have been addressed to the FDA's
satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information
included. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>An
approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. Even if the FDA approves a product, it may limit the approved indications
for use for the product, require that contraindications, warnings or precautions be included in the product labeling, or require that post-approval studies, including Phase&nbsp;4 clinical trials,
be conducted to further assess a drug's safety after approval. As a condition of NDA approval, the FDA may also require a risk evaluation and mitigation strategy (REMS) to help ensure that the
benefits of the drug outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe use. Elements to assure safe use
can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient
registries. The requirement for a REMS can materially affect the potential market and profitability of the drug. Moreover, product approval may require substantial post-approval testing and
surveillance to monitor the drug's safety or efficacy. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following
initial marketing. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Changes
to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a
new NDA or NDA supplement before the change can be implemented. An NDA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses
the same procedures and actions in reviewing NDA supplements as it does in reviewing NDAs. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Fast Track Designation and Accelerated Approval  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The FDA is required to facilitate the development, and expedite the review, of drugs that are intended for the treatment of a serious or
life-threatening disease or condition for which there is no effective treatment and which demonstrate the potential to address unmet medical needs for the condition. Under the fast track program, the
sponsor of a new product candidate may request that the FDA designate the product candidate for a specific indication as a fast track drug concurrent with, or after, the filing of the IND for the
product candidate. The FDA must determine if the product candidate qualifies for fast track designation within 60&nbsp;days of receipt of the sponsor's request. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Under
the fast track program and the FDA's accelerated approval regulations, the FDA may approve a drug for a serious or life-threatening illness that provides meaningful therapeutic benefit to
patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible
morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the
condition and the availability or lack of alternative treatments. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
clinical trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how a patient feels, functions, or
survives. Surrogate endpoints can
often be measured more easily or more rapidly than clinical endpoints. A product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the
completion of Phase&nbsp;4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or confirm a clinical benefit during
post-marketing studies, will </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>122</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=124,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=529010,FOLIO='122',FILE='DISK112:[15ZCH1.15ZCH40101]EA40101A.;89',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_ea40101_1_123"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>allow
FDA to withdraw the drug from the market on an expedited basis. All promotional materials for product candidates approved under accelerated regulations are subject to prior review by FDA. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition to other benefits such as the ability to use surrogate endpoints and engage in more frequent interactions with the FDA, the FDA may initiate review of sections of a fast track drug's NDA
before the application is complete. This rolling review is available if the applicant provides, and the FDA approves, a schedule for the submission of the remaining information and the applicant pays
applicable user fees. However, the FDA's time period goal for reviewing an application does not begin until the last section of the NDA is submitted. Additionally, the fast track designation may be
withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Breakthrough Therapy Designation  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The FDA is also required to expedite the development and review of the application for approval of drugs that are intended to treat a serious or
life-threatening disease or condition where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant
endpoints. Under the breakthrough therapy program, the sponsor of a new product candidate may request that the FDA designate the product candidate for a specific indication as a breakthrough therapy
concurrent with, or after, the filing of the IND for the product candidate. The FDA must determine if the product candidate qualifies for breakthrough therapy designation within 60&nbsp;days of
receipt of the sponsor's request. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development and review of an application for
approval of a breakthrough therapy. Even if a product qualifies for this program, the FDA may later decide that the product no longer meets the conditions for qualification. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Orphan Drugs  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition&nbsp;&#151;
generally a disease or condition that affects fewer than 200,000&nbsp;individuals in the U.S. Orphan Drug Designation must be requested before submitting an NDA. After the FDA grants orphan drug
designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the
regulatory review and approval process. The first NDA applicant to receive FDA approval for a particular active ingredient to treat a particular disease with FDA orphan drug designation is entitled to
a seven-year exclusive marketing period in the United States for that product, for that indication. During the seven-year exclusivity period, the FDA may not approve any other applications to market
the same drug for the same disease, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent the
FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for
certain research and a waiver of the NDA application user fee. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Pediatric Information  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under the Pediatric Research Equity Act (PREA), NDAs or supplements to NDAs must contain data to assess the safety and effectiveness of the drug for
the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the drug is safe and effective. The FDA may grant
full or partial waivers for submission of data, as well as deferrals for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric studies are
complete or that additional safety or effectiveness data needs to be collected before the pediatric studies begin. Unless otherwise required by regulation, PREA does not apply to any drug for an
indication for which orphan designation has been granted. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Best Pharmaceuticals for Children Act (BPCA) provides NDA holders a six-month extension of any exclusivity&nbsp;&#151; patent or non-patent&nbsp;&#151; for a drug if certain
conditions are met. Conditions for exclusivity include the FDA's determination that information relating to the use of a new drug in the pediatric </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>123</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=125,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=299235,FOLIO='123',FILE='DISK112:[15ZCH1.15ZCH40101]EA40101A.;89',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_ea40101_1_124"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>population
may produce health benefits in that population, the FDA making a written request for pediatric studies, and the applicant agreeing to perform, and reporting on, the requested studies within
the statutory timeframe. Applications under the BPCA are treated as priority applications, with all of the benefits that designation confers. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Special Protocol Assessment  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A company may reach an agreement with the FDA under the Special Protocol Assessment (SPA) process as to the required design and size of clinical
trials intended to form the primary basis of an efficacy claim. Under the FDC Act and FDA guidance implementing the statutory requirement, an SPA is generally binding upon the FDA except in limited
circumstances, such as if the FDA identifies a substantial scientific issue essential to determining safety or efficacy after the clinical trial begins, public health concerns emerge that were
unrecognized at the time of the protocol assessment, the sponsor and FDA agree to the change in writing, or if the clinical trial sponsor fails to follow the protocol that was agreed upon with the
FDA. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Disclosure of Clinical Trial Information  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Sponsors of clinical trials of FDA-regulated products, including drugs, are required to register and disclose certain clinical trial information.
Information related to the product, patient population, phase of investigation, clinical trial sites and investigators, and other aspects of the clinical trial is then made public as part of the
registration. Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed until the new product or new
indication being studied has been approved. Competitors may use this publicly-available information to gain knowledge regarding the progress of development programs. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Post-Approval Requirements  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Once an NDA is approved, a product will be subject to certain post-approval requirements. For instance, the FDA closely regulates the post-approval
marketing and promotion of drugs, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional
activities involving the internet. Drugs may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>AE
reporting and submission of periodic reports is required following FDA approval of an NDA. The FDA also may require post-marketing testing, known as Phase&nbsp;4 testing, REMS and surveillance to
monitor the effects of an approved product, or the FDA may place conditions on an approval that could restrict the distribution or use of the product. In addition, quality-control, drug manufacture,
packaging and labeling procedures must continue to conform to cGMPs after approval. Drug manufacturers and certain of their subcontractors are required to register their establishments with the FDA
and certain state agencies. Registration with the FDA subjects entities to periodic unannounced inspections by the FDA, during which the agency inspects manufacturing facilities to assess compliance
with cGMPs. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality-control to maintain compliance with cGMPs. Regulatory authorities may
withdraw product approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized
problems are subsequently discovered. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


The Hatch-Waxman Amendments  </I></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Orange Book Listing  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>In seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent whose claims cover the applicant's product.
Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as
the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential generic competitors in support of approval of an abbreviated new drug application (ANDA). An ANDA provides for
marketing of a drug product that has the same active ingredient in the same strength, route of administration and dosage form as the listed drug and has been shown to be bioequivalent to the listed
drug.
Other than the requirement for bioequivalence testing, ANDA applicants are not required to conduct, or submit results of, preclinical studies or clinical trials to prove the safety or </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>124</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=126,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=855158,FOLIO='124',FILE='DISK112:[15ZCH1.15ZCH40101]EA40101A.;89',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_ea40101_1_125"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>effectiveness
of their drug product. Drugs approved in this way are commonly referred to as "generic equivalents" to the listed drug, and can often be substituted by pharmacists under prescriptions
written for the original listed drug. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
ANDA applicant is required to certify to the FDA concerning any patents listed for the approved product in the FDA's Orange Book. Specifically, the applicant must certify that: (1)&nbsp;the
required patent information has not been filed; (2)&nbsp;the listed patent has expired; (3)&nbsp;the listed patent has not expired, but will expire on a particular date and approval is sought
after patent expiration; or (4)&nbsp;the listed patent is invalid or will not be infringed by the new product. The ANDA applicant may also elect to submit a section&nbsp;viii statement certifying
that its proposed ANDA label does not contain (or carves out) any language regarding the patented method-of-use rather than certify to a listed method-of-use patent. If the applicant does not
challenge the listed patents, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A
certification that the new product will not infringe the already approved product's listed patents, or that such patents are invalid, is called a Paragraph&nbsp;IV certification. If the ANDA
applicant has provided a Paragraph&nbsp;IV certification to the FDA, the applicant must also send notice of the Paragraph&nbsp;IV certification to the NDA and patent holders once the ANDA has been
accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph&nbsp;IV certification. The filing of a patent
infringement lawsuit within 45&nbsp;days of the receipt of a Paragraph&nbsp;IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30&nbsp;months,
expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable to the ANDA applicant. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
ANDA application also will not be approved until any applicable non-patent exclusivity listed in the Orange Book for the referenced product has expired. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Exclusivity  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Upon NDA approval of a drug containing a NCE, which is a drug substance that contains an active moiety that has not been approved by the FDA in any
other NDA, that moiety will receive five years of marketing exclusivity during which the FDA cannot approve any ANDA seeking approval of a generic version of that moiety. Certain changes to a drug,
such as the addition of a new indication to the package insert,
may receive a three-year period of exclusivity during which the FDA cannot approve an ANDA for a generic drug that includes the change. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
no Paragraph&nbsp;IV certification is made, an ANDA may not be filed until expiry of the NCE exclusivity period, however, if a Paragraph&nbsp;IV certification is filed, the ANDA may be
submitted one year before the NCE exclusivity period expires. If there is no listed patent in the Orange Book, there may not be a Paragraph&nbsp;IV certification, and, thus, no ANDA may be filed
before the expiration of the exclusivity period. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Patent Term Extension  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>After NDA approval, owners of relevant drug patents may apply for up to a five year patent extension. The allowable patent term extension is
calculated as half of the drug's testing phase&nbsp;&#151; the time between IND application and NDA submission&nbsp;&#151; and all of the review phase&nbsp;&#151; the time
between NDA submission and approval up to a maximum of five years. The time can be shortened if the FDA determines that the applicant did not pursue approval with due diligence. The extension may not
extend the patent beyond 14&nbsp;years from market approval. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For
patents that might expire during the application phase, the patent owner may request an interim patent extension. An interim patent extension increases the patent term by one year and may be
renewed up to four times. For each interim patent extension granted, the post-approval patent extension is reduced by one year. The director of the USPTO must determine that approval of the drug
covered by the patent for which a patent extension is being sought is likely. Interim patent extensions are not available for a drug for which an NDA has not been submitted. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>125</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=127,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=409642,FOLIO='125',FILE='DISK112:[15ZCH1.15ZCH40101]EA40101A.;89',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ec40101_1_126"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Prescription Drug Marketing Act  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As part of the sales and marketing process, pharmaceutical companies frequently provide samples of approved drugs to physicians. The Prescription Drug
Marketing Act (PDMA) imposes requirements and limitations upon the provision of drug samples to physicians, as well as prohibits states from licensing distributors of prescription drugs unless the
state licensing program meets certain federal guidelines that include minimum standards for storage, handling and record keeping. In addition, the PDMA sets forth civil and criminal penalties for
violations. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


United States&nbsp;&#151; Anti-Kickback, False Claims Laws and Other Healthcare Laws  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal laws have been applied to restrict
certain general business and marketing practices in the pharmaceutical industry in recent years. These laws include anti-kickback statutes, false claims statutes and other statutes pertaining to
health care fraud and abuse. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce, or in return for, purchasing, leasing,
ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid, or other federally financed healthcare programs. The Patient Protection
and Affordable Care Act as amended by the Health Care and Education Reconciliation Act (PPACA) amended the intent element of the federal Anti-Kickback Statute so that a person or entity no longer
needs to have actual knowledge of the statute or specific intent to violate it in order to be in violation. This statute has been interpreted to apply to arrangements between pharmaceutical
manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common
activities from prosecution or other regulatory sanctions, the exemptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchases, or
recommendations may be subject to scrutiny if they do not qualify for an exemption or safe harbor. Violations of the Anti-Kickback Statute are punishable by penalties including imprisonment, criminal
fines, civil monetary penalties, damages, disgorgement and exclusion from participation in federal healthcare programs. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Federal
false claims laws, including the civil False Claims Act, prohibit any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal
government, or knowingly making, or causing to be made, a false statement to have a false claim paid. This includes claims made to programs where the federal government reimburses, such as Medicaid,
as well as programs where the federal government is a direct purchaser, such as when it purchases off the Federal Supply Schedule. Recently, several pharmaceutical and other healthcare companies have
been prosecuted under these laws for allegedly inflating drug prices they report to pricing services, which in turn were used by the government to set Medicare and Medicaid reimbursement rates, and
for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. In addition, certain marketing practices, including off-label
promotion, may also violate false claims laws. Additionally, PPACA amended the federal Anti-Kickback Statute such that a violation of that statute can serve as a basis for liability under the federal
civil False Claims Act. The majority of states also have statutes or regulations similar to the federal Anti-Kickback Statute and False Claims Act, which apply to items and services reimbursed under
Medicaid and other state programs, or, in several states, apply regardless of the payor. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Other
federal statutes pertaining to healthcare fraud and abuse include the Civil Monetary Penalties Statute, which prohibits the offer or payment of remuneration to a Medicaid or Medicare beneficiary
that the offerer/payor knows or should know is likely to influence the beneficiary to order a receive a reimbursable item or service from a particular supplier, and the healthcare fraud provisions of
the Health Insurance Portability and Accountability Act of 1996 (HIPAA), which prohibits knowingly and willfully executing or attempting to execute a scheme to
defraud any healthcare benefit program or obtain by means of false or fraudulent pretenses, representations, or promises any money or property owned by or under the control of any </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>126</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=128,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=814214,FOLIO='126',FILE='DISK112:[15ZCH1.15ZCH40101]EC40101A.;51',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_ec40101_1_127"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>healthcare
benefit program in connection with the delivery of or payment for healthcare benefits, items, or services. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For
example, several pharmaceutical and other healthcare companies have been prosecuted under these laws for, among other things, allegedly inflating drug prices they report to pricing services, which
in turn were used by the government to set Medicare and Medicaid reimbursement rates, and for allegedly providing free product to customers with the expectation that the customers would bill federal
programs for the product. In addition, certain marketing practices undertaken by pharmaceutical companies, including off-label promotion, may violate false claims laws. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Pursuant
to PPACA, the Centers for Medicare&nbsp;&amp; Medicaid Services (CMS) has issued a final rule that requires manufacturers of certain prescription drugs, devices, biologics, and medical supplies
for which payment is available under Medicare, Medicaid, or the Children's Health Insurance Program, with specific exceptions, to collect and report information on payments or transfers of value to
physicians and teaching hospitals, as well as investment interests held by physicians and their immediate family members. The first reports were due in 2014 and must be submitted on an annual basis.
The reported data were posted by CMS in searchable form on a public website on September&nbsp;30, 2014, and will be posted on an annual basis. Failure to submit required information may result in
civil monetary penalties. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, several states now require prescription drug companies to report expenses relating to the marketing and promotion of drug products and to report gifts and payments to individual
physicians in these states. Other states prohibit various other marketing-related activities. Still other states require the posting of information relating to clinical studies and their outcomes. In
addition, California, Connecticut, Nevada and Massachusetts require pharmaceutical companies to implement compliance programs and/or marketing codes. Several additional states are considering similar
proposals. Compliance with these laws is difficult and time consuming, and companies that do not comply with these state laws may face civil penalties. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Other
federal and state requirements include the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> HIPAA, as amended by the Health Information Technology for Economic and Clinical
Health Act (the HITECH Act) and its implementing regulations, which imposes obligations, including mandatory contractual terms, on certain people and entities with respect to safeguarding the privacy,
security and transmission of individually identifiable health information; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> State and foreign laws also govern the privacy and security of health
information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


United States Healthcare Reform  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Current and future legislative proposals to further reform healthcare or reduce healthcare costs may result in lower reimbursement for our products.
The cost containment measures that payors and providers are instituting and the effect of any healthcare reform initiative implemented in the future could significantly reduce our revenues from the
sale of our products. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For
example, in March 2010, PPACA was signed into law. PPACA has begun to, and will likely continue to, substantially change healthcare financing and delivery by both governmental and private
insurers, and significantly impact the pharmaceutical industry. The PPACA, among other things: established an annual, nondeductible fee on any entity that manufactures or imports certain specified
branded prescription drugs and biologic agents; revised the methodology by which rebates owed by manufacturers to the state and federal government for covered outpatient drugs under the Medicaid Drug
Rebate Program are calculated; increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; extended the Medicaid Drug Rebate program to utilization of
prescriptions of individuals enrolled in Medicaid managed care organizations; implemented a new Medicare Part&nbsp;D coverage gap discount program; expanded the entities eligible for discounts under
the Public Health Services pharmaceutical </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>127</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=129,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=553334,FOLIO='127',FILE='DISK112:[15ZCH1.15ZCH40101]EC40101A.;51',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_ec40101_1_128"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>pricing
program; created a new Patient Centered Outcomes Research Institute; and provided incentives to programs that increase the federal government's comparative effectiveness research. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, other legislative changes have been proposed and adopted since the PPACA was enacted. In August 2011, the President signed into law the Budget Control Act of 2011, which, among other
things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction of at
least $1.2&nbsp;trillion for the years 2012 through 2021, triggering the legislation's automatic reduction to several government programs. This includes reductions to Medicare payments to providers
of 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2025 unless additional Congressional action is taken. Additionally, in January 2013, President Obama
signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government
to recover overpayments to providers from three to five years. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare
products and services, which could result in reduced demand for our products or additional pricing pressure. We are unsure of the ways in which PPACA will continue to be challenged and amended in the
years to come. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Review and Approval of Drug Products in the European Union  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other
countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of drug products.
Whether or not it obtains FDA approval for a product, the company would need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can commence clinical trials
or marketing of the product in those countries or jurisdictions. The approval process ultimately varies between countries and jurisdictions and can involve additional product testing and additional
administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval
in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the
regulatory process in others. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Pursuant
to the European Clinical Trials Directive, a system for the approval of clinical trials in the European Union has been implemented through national legislation of the member states. Under
this system, an applicant must obtain approval from the competent national authority of a European Union member state in which the clinical trial is to be conducted. Furthermore, the applicant may
only start a clinical trial after a competent ethics committee has issued a favorable opinion. Clinical trial application must be accompanied by an investigational medicinal product dossier with
supporting information prescribed by the European Clinical Trials Directive and corresponding national laws of the member states and further detailed in applicable guidance documents. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To
obtain marketing approval of a drug under European Union regulatory systems, an applicant must submit a marketing authorization application (MAA) either under a centralized or decentralized
procedure. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid for all European Union member states. The centralized procedure is
compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy products and products with
a new active substance indicated for the treatment of certain diseases. For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative
or for which a centralized process is in the interest of patients, the centralized procedure may be optional. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>128</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=130,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=971963,FOLIO='128',FILE='DISK112:[15ZCH1.15ZCH40101]EC40101A.;51',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_ec40101_1_129"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under
the centralized procedure, the Committee for Medicinal Products for Human Use, or the CHMP, established at the European Medicines Agency (EMA) is responsible for conducting the initial
assessment of a drug. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing marketing
authorization. Under the centralized procedure in the European Union, the maximum timeframe for the evaluation of an MAA is 210&nbsp;days, excluding clock stops, when additional information or
written or oral explanation is to be provided by the applicant in response to questions of the CHMP. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product
is of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation. In this circumstance, the EMA ensures that the opinion of the CHMP is given
within 150&nbsp;days. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
decentralized procedure is available to applicants who wish to market a product in various European Union member states where such product has not received marketing approval in any European Union
member states before. The decentralized procedure provides for approval by one or more other, or concerned, member states of an assessment of an application performed by one member state designated by
the applicant, known as the reference member state. Under this procedure, an applicant submits an application based on identical dossiers and related materials, including a draft summary of product
characteristics, and draft labeling and package leaflet, to the reference member state and concerned member states. The reference member state prepares a draft assessment report and drafts of the
related materials within 210&nbsp;days after receipt of a valid application. Within 90&nbsp;days of receiving the reference member state's assessment report and related materials, each concerned
member state must decide whether to approve the assessment report and related materials. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
a member state cannot approve the assessment report and related materials on the grounds of potential serious risk to public health, the disputed points are subject to a dispute resolution
mechanism and may eventually be referred to the European Commission, whose decision is binding on all member states. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Data and Market Exclusivity in the European Union  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In the European Union, NCEs qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market
exclusivity. This data exclusivity, if granted, prevents regulatory authorities in the European Union from referencing the innovator's data to assess a generic (abbreviated) application for eight
years, after which generic marketing authorization can be submitted, and the innovator's data may be referenced, but not approved for two years. The overall ten-year period will be extended to a
maximum of eleven years if, during the first eight years of those ten years, the marketing authorization (MA) holder obtains an authorization for one or more new therapeutic indications which, during
the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be a NCE and the
sponsor is able to gain the prescribed period of data exclusivity, another company nevertheless could also market another version of the drug if such company can complete a full MAA with a complete
database of pharmaceutical test, preclinical studies and clinical trials and obtain marketing approval of its product. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Data and Market Exclusivity in Japan  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Japan has no established system for data exclusivity or marketing exclusivity. However, the Pharmaceuticals Act of Japan (PAA) provides for a
re-examination system after drug approval. This system imposes an obligation on the MA holder to continue to collect clinical data after market approval during a study period. The MA holder must apply
for reexamination to the Minster of Health Labor and Welfare within three months of the expiration of the study period. During the study and reexamination period no generic drug may be approved,
effectively providing a form of market exclusivity. The study period is determined by the drug category. The study period for an orphan drug is 10&nbsp;years from MA, the study period for an NCE is
eight&nbsp;years from MA, and for an improvement (new indication, formulation, etc.) the study period is four to six&nbsp;years from MA. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>129</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=131,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=86827,FOLIO='129',FILE='DISK112:[15ZCH1.15ZCH40101]EC40101A.;51',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_ec40101_1_130"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Patent Term Extension in Japan  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The term of a patent that covers the approved drug may be extended for the shorter of five years, or the period during which the patent could not be
worked (exploited) due to obtaining regulatory approval. This period is calculated from the later of the patent registration date (grant date) or the clinical trial start date to the regulatory
approval date. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Foreign Regulation  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In order to market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of other
countries regarding safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of our products. Whether or not we obtain FDA
approval for a product, we would need to obtain the necessary approvals by the comparable regulatory authorities of foreign countries before we can commence clinical trials or marketing of the product
in those countries. The approval process varies from country to country and can involve additional product testing and additional administrative review periods. The time required to obtain approval in
other countries might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in
obtaining regulatory approval in one country may negatively impact the regulatory process in others. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Pharmaceutical Coverage, Pricing and Reimbursement  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Significant uncertainty exists as to the coverage and reimbursement status of any drug products for which we obtain regulatory approval. Sales of any
of our product candidates, if approved, will depend, in part, on the extent to which the costs of the products will be covered by third-party payors, including government health programs such as
Medicare and Medicaid, commercial health insurers and managed care organizations. The process for determining whether a payor will provide coverage for a drug product may be separate from the process
for setting the price or reimbursement rate that the payor will pay for the drug product once coverage is approved. Third-party payors may limit coverage to specific drug products on an approved list,
or formulary, which might not include all of the approved drugs for a particular indication. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
order to secure coverage and adequate reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical
necessity and
cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. Our product candidates may not be considered medically necessary or
cost-effective. A payor's decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, one payor's determination to provide coverage
for a drug product does not assure that other payors will also provide coverage or adequate reimbursement for the drug product. Third-party reimbursement may not be sufficient to enable us to maintain
price levels high enough to realize an appropriate return on our investment in product development. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of drugs have been a focus in this effort. Third-party payors are increasingly
challenging the prices charged for medical products and services and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy.
If these third-party payors do not consider our products to be cost-effective compared to other available therapies, they may not cover our products after approval as a benefit under their plans or,
if they do, the level of payment may not be sufficient to allow us to sell our products at a profit. The U.S. government, state legislatures and foreign governments have shown significant interest in
implementing cost containment programs to limit the growth of government-paid health care costs, including price controls, restrictions on reimbursement and requirements for substitution of generic
products for branded prescription drugs. Adoption of such controls and measures, and tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for
pharmaceuticals such as the product candidates that we are developing and could adversely affect our net revenue and results. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>130</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=132,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=489323,FOLIO='130',FILE='DISK112:[15ZCH1.15ZCH40101]EC40101A.;51',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_ec40101_1_131"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Pricing
and reimbursement schemes vary widely from country to country. Some countries provide that drug products may be marketed only after a reimbursement price has been agreed. Some countries may
require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies. For example, the European Union provides options
for its member states to restrict the range of drug products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use.
European Union member states may approve a specific price for a drug product or may instead adopt a system of direct or indirect controls on the profitability of the company placing the drug product
on the market. Other member states allow companies to fix their own prices for drug products, but monitor and control company profits. The downward pressure on health care costs in general,
particularly prescription drugs, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports
from low-priced markets exert competitive pressure that may reduce pricing within a country. There can be no assurance that any country that has price controls or reimbursement limitations for drug
products will allow favorable reimbursement and pricing arrangements for any of our products. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide coverage and adequate reimbursement.
In addition, the emphasis on managed care in the United States has increased and we expect will continue to increase the pressure on drug pricing. Coverage policies, third-party reimbursement rates
and drug pricing regulation may change at any time. In particular, the PPACA contains provisions that may reduce the profitability of drug
products, including, for example, increased rebates for drugs sold to Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare
Part&nbsp;D beneficiaries and annual fees based on pharmaceutical companies' share of sales to federal health care programs. Even if favorable coverage status and adequate reimbursement level status
are obtained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Employees  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As of May&nbsp;2, 2016, we had eight employees, all of whom are full-time, two of whom hold Ph.D. or M.D. degrees, three of whom were engaged in
research and development activities and five of whom were engaged in business development, finance, information systems, facilities, human resources or administrative support. We have begun a search
for a Chief Medical Officer. None of our employees is represented by a labor union or subject to a collective bargaining agreement. We consider our relationship with our employees to be good. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Facilities  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We lease an approximately 1,450 square foot facility in Northville, Michigan that is primarily used for administrative and research and development
activities. The cancellable lease commenced on January&nbsp;1, 2015 and, as amended, expires on December&nbsp;31, 2016. We plan to terminate this lease in August 2016. In May 2016, we entered into
a 3 year non-cancellable facility lease in Livonia, Michigan, commencing August&nbsp;1, 2016 for approximately 5,300 square feet that will be used for the Company's headquarters. We believe that
these facilities are adequate to meet our current needs, and that suitable additional alternative spaces will be available in the future on commercially reasonable terms. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Legal Proceedings  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a
party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us
because of defense and settlement costs, diversion of management resources and other factors. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>131</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=133,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=304441,FOLIO='131',FILE='DISK112:[15ZCH1.15ZCH40101]EC40101A.;51',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ei40101_1_132"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ei40101_management"> </A>
<A NAME="toc_ei40101_1"> </A>
<BR></FONT><FONT SIZE=2><B>  MANAGEMENT    <BR>    </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Executive Officers and Directors  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The following table sets forth certain information regarding our current executive officers and directors as of May&nbsp;2, 2016: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="218pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="23pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:23pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>NAME

<!-- COMMAND=ADD_SCROPPEDRULE,23pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>AGE </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>POSITION(S) </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Executive Officers</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Mina Sooch</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>48</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>President, Chief Executive Officer, Treasurer and Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jeffrey S. Mathiesen</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>55</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Chief Financial Officer</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Charles L. Bisgaier</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>62</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Chief Scientific Officer and Chairman of the Board</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Seth Reno</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>50</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Chief Commercial Officer</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David Lowenschuss</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>47</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Chief Legal Officer and Secretary</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Carmen Daniela Oniciu</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>59</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Vice President of Preclinical Research and Development and Manufacturing</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Non-Employee Directors</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Steve Gullans</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>63</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>P. Kent Hawryluk<SUP>(1)</SUP><SUP>(2)</SUP><SUP>(3)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>47</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Kenneth Kousky<SUP>(2)</SUP><SUP>(3)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>61</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pedro Lichtinger<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>61</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Andrew Sassine<SUP>(1)</SUP><SUP>(2)</SUP><SUP>(3)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>51</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Director</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Member
of the compensation committee.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Member
of the audit committee.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Member
of the nominating and corporate governance committee. </FONT></DD></DL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Executive Officers  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>Mina Sooch</B></FONT><FONT SIZE=2> has served as our President and Chief Executive Officer and as a member of our board of
directors since November 2014. Prior to joining us, she served from July 2012 to May 2014 as the President and Chief Executive Officer of ProNAi Therapeutics,&nbsp;Inc., a public clinical-stage
oncology company that she co-founded and as a member of the board of directors from its founding in 2004 through May 2014 as well as a business development advisor from December 2010 to June 2012. In
addition, Ms.&nbsp;Sooch founded Apjohn Ventures Fund, a venture capital firm that invests primarily in early-stage life sciences
companies, and has served as its Managing Partner since its founding in 2003. She also serves as Manager of Tara Ventures I,&nbsp;LLC, an angel fund organized in 2002, for life sciences investments.
Ms.&nbsp;Sooch also served as an entrepreneur in residence at North Coast Technology Investors&nbsp;LP from 2001 to 2002. Ms.&nbsp;Sooch co-founded three life sciences start-ups: ProNAi
Therapeutics,&nbsp;Inc., Afmedica,&nbsp;Inc. and CytoPherx&nbsp;Inc. (formerly known as Nephrion&nbsp;Inc.). Ms.&nbsp;Sooch has served on over 10 private, public and non-profit venture
capital boards including ProNAi Therapeutics,&nbsp;Inc., ZyStor Therapeutics,&nbsp;Inc., Asterand&nbsp;Inc., CytoPherx&nbsp;Inc., Svelte Medical Systems,&nbsp;Inc., Wolverine Venture Fund
and Michigan Venture Capital Association. From 1993 to 2000, she last served as global account manager at Monitor Deloitte (formerly known as Monitor Company Group), a global strategy consulting firm
based in Boston. Ms.&nbsp;Sooch received an M.B.A. from Harvard Business School and a B.S. in chemical engineering from Wayne State University. Our board of directors believes Ms.&nbsp;Sooch
should serve as a director based on her extensive experience founding and developing biopharmaceutical companies and managing and negotiating venture capital investments and strategic transactions. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>132</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=134,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=262437,FOLIO='132',FILE='DISK112:[15ZCH1.15ZCH40101]EI40101A.;74',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_ei40101_1_133"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>Jeffrey S. Mathiesen</B></FONT><FONT SIZE=2> has served as our Chief Financial Officer since September 2015 and as a consultant to us from August 2015 until September 2015. Prior
to joining us, Mr.&nbsp;Mathiesen served as Chief Financial Officer of Sunshine Heart,&nbsp;Inc., a publicly traded medical device company, from March 2011 to January 2015. From December 2005 to
April 2010, Mr.&nbsp;Mathiesen served as Vice President and Chief Financial Officer of Zareba Systems,&nbsp;Inc., a manufacturer and marketer of medical products, perimeter fencing and security
systems, which was purchased by Woodstream Corporation in April 2010. Mr.&nbsp;Mathiesen has held executive positions with publicly traded companies dating back to 1993, including vice president and
chief financial officer positions. Mr.&nbsp;Mathiesen also serves as a director and audit committee chairman of Sun BioPharma,&nbsp;Inc., a publicly traded biopharmaceutical company that develops
therapies for pancreatic diseases. Mr.&nbsp;Mathiesen received a B.S. in Accounting from the University of South Dakota and is also a Certified Public Accountant. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>Dr.&nbsp;Charles Bisgaier</B></FONT><FONT SIZE=2>, one of our co-founders, has served as our Chief Scientific Officer and Chairman of our board of directors since November
2014. He also currently serves as an Adjunct Associate Professor of Pharmacology at the University of Michigan. Prior to our founding, he served from September 2008 to November 2014 as the Chief
Executive Manager for our predecessor, Michigan Life Therapeutics,&nbsp;LLC. In addition, he co-founded Michigan Life Ventures,&nbsp;LLC, a venture capital firm investing primarily in
Michigan-based life sciences companies, where since 2008 he has served as the Chief Executive Manager. He also served as the Interim President and Chief Executive Officer of ProNAi
Therapeutics,&nbsp;Inc., a clinical-stage oncology company, from September 2010 to April 2012, and as a member of its board of directors from 2009 to March 2014. In 1998, Dr.&nbsp;Bisgaier
co-founded the original Esperion, which was acquired by Pfizer in 2003. After the acquisition, he served as the Senior Director of Pharmacology for the Esperion Division of Pfizer Global Research and
Development from 2004 to 2006. From 2006 to 2008, Dr.&nbsp;Bisgaier also served as a director, board member and president of Pipex Pharmaceuticals,&nbsp;Inc., currently known as Synthetic
Biologics,&nbsp;Inc., a specialty pharmaceutical company. From 1990 to 1998, Dr.&nbsp;Bisgaier was an Associate Research Fellow in the Department of Cardiovascular Diseases in the Parke-Davis
division of Warner-Lambert&nbsp;Co. Currently he is a board member at Hygieia,&nbsp;Inc., a privately held health service company, and at BioSavita&nbsp;Inc., a privately held life sciences
company. He received a B.A. in biology from the State University of New York at Oneonta and an M.S. and Ph.D. in biochemistry from George Washington University. After receiving his Ph.D., he studied
lipoprotein metabolism within the Specialized Center of Research for atherosclerosis at Columbia University College of Physicians and Surgeons. Our board of directors believes
Dr.&nbsp;Bisgaier should serve as a director based on his depth of experience in founding and developing biopharmaceutical companies as well as his knowledge of our product candidate gemcabene. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B>Seth Reno</B></FONT><FONT SIZE=2> has served as our Chief Commercial Officer since August 2015. Prior to joining us, he served in several commercial roles including Head of
Commercial Operations for Medimmune,&nbsp;LLC, a biologics company, from June 2010 to April 2015. From April 2001 to June 2010, Mr.&nbsp;Reno worked at AstraZeneca, a public biopharmaceutical
company, in a number of roles, including in the sales, commercial operations, managed markets and brand team spaces. Prior to joining AstraZeneca in 2001, Mr.&nbsp;Reno spent 11&nbsp;years at
Wyeth Pharmaceuticals,&nbsp;Inc., a pharmaceutical company, in commercial operations and sales account management. Mr.&nbsp;Reno holds a B.S. in human resources from the University of Delaware and
an M.B.A. from Strayer University. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>David Lowenschuss</B></FONT><FONT SIZE=2>, one of our co-founders, has served as our Chief Legal Officer since November&nbsp;2014 and was a member of our board of directors
from November&nbsp;2014 to April&nbsp;2016. From 2008 to present, Mr.&nbsp;Lowenschuss has had a private legal practice (David H. Lowenschuss&nbsp;PLC) where he acts as counsel to a number of
life science companies. Mr.&nbsp;Lowenschuss also co-founded Michigan Life Ventures,&nbsp;LLC and currently serves as its Chief Legal Manager. In 2008, Mr.&nbsp;Lowenschuss co-founded Michigan
Life Therapeutics,&nbsp;LLC, where he served as Chief Legal Manager from 2008 to November 2014. Mr.&nbsp;Lowenschuss served as Corporate Counsel and later Michigan Legal Site Head at Pfizer, a
public biopharmaceutical company, from 2004 to 2008. Prior to joining Pfizer, from 2001 to 2004, Mr.&nbsp;Lowenschuss was in-house counsel at the original Esperion. Mr.&nbsp;Lowenschuss has
lectured at the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>133</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=135,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=910441,FOLIO='133',FILE='DISK112:[15ZCH1.15ZCH40101]EI40101A.;74',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_ei40101_1_134"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>University
of Michigan on various topics including historical perspectives on human subject research and also serves as a moot court judge at the University of Michigan Law School. He holds a J.D.
from George Washington University and an M.U.P. and a B.A. from the University of Michigan. He is admitted to practice law in Michigan. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B>Dr.&nbsp;Carmen Daniela Oniciu</B></FONT><FONT SIZE=2> has served as our Vice President of Preclinical Research and Development and Manufacturing since March 2015. Prior to
joining us, Dr.&nbsp;Oniciu worked as an independent consultant focused on preclinical research and development and regulatory affairs related to chemistry, manufacturing and controls for
pharmaceuticals and fine chemicals that span small molecules. Prior to that, from 2006 to February 2014, Dr.&nbsp;Oniciu served as Senior Director of Chemistry at Cerenis Therapeutics
Holding&nbsp;SA, a French biotechnology company. Prior to joining Cerenis, from 2001 to 2004, Dr.&nbsp;Oniciu was Senior Director of Chemical Research and Development at the original Esperion,
where she served as co-chair of the preclinical research team. Following Pfizer&nbsp;Inc.'s acquisition of the original Esperion, Dr.&nbsp;Oniciu served as Associate Director of Chemistry at
Pfizer from 2004 to 2005. Prior to joining the original Esperion in 2001, Dr.&nbsp;Oniciu co-founded Alchem Laboratories Corporation, a custom research organization that specialized in drug design
and process development support for the pharmaceutical industry. In addition, Dr.&nbsp;Oniciu has served as Courtesy Professor of Chemistry at the University of Florida at Gainesville since 2004.
Dr.&nbsp;Oniciu holds a Ph.D. and an M.S. in organic chemistry and chemical engineering, both from the Polytechnic University of Bucharest in Romania. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Non-Employee Directors  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>Dr.&nbsp;Steve Gullans</B></FONT><FONT SIZE=2> has served as a member of our board of directors since April 2016. He is
currently Managing Director at Excel Venture Management, LLC (Excel), a Boston-based venture capital firm which he co-founded and where he has been employed since February 2008. At Excel, he focuses
on investing in life science technology companies with a particular interest in disruptive platforms that can impact multiple industries. Prior to Excel, Dr.&nbsp;Gullans co-founded RxGen, Inc., a
pharmaceutical services company where he served as chief executive officer from January 2004&nbsp;to February 2008. Dr.&nbsp;Gullans is currently a director at Molecular Templates, Inc., a private
biotechnology company, Cleveland HeartLab, Inc., a private cardiovascular testing company, and N-of-One,&nbsp;Inc., an oncology diagnostics company. He was previously a board member of Activate
Networks, Inc. which was acquired by Decision Resource Group, BioTrove, Inc. which was acquired by Life Technologies Corporation, Biocius Life Sciences, Inc. which was acquired by Agilent Technologies
Inc., nanoMR&nbsp;Inc. which was acquired by DNA Electronics Ltd and Tetraphase Pharmaceuticals, Inc. which went public in 2013. Dr.&nbsp;Gullans was a faculty member at Harvard Medical School and
Brigham and Women's Hospital for almost 20&nbsp;years. Dr.&nbsp;Gullans holds a B.S. from Union College and a Ph.D. from Duke University. Our board of directors believes Dr.&nbsp;Gullans should
serve as a director based on his extensive experience in the life sciences industry and his board experience. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>P. Kent Hawryluk</B></FONT><FONT SIZE=2> has served as a member of our board of directors since February 2015. He is the Co-Founder and has served as the Chief Business Officer
of Avidity NanoMedicines&nbsp;LLC, a precision nanomedicines company, since January 2013. He was also Co-Founder and served as the Chief Executive Officer of MB2&nbsp;LLC, a clinical-stage company
focused on diabetes and obesity, from May 2014 to March 2016. MB2 was acquired by Novo Nordisk in October 2015. Previously, in January 2006, Mr.&nbsp;Hawryluk co-founded Marcadia
Biotech&nbsp;Inc., which was acquired by Roche Holding&nbsp;Ltd., where he served as Chief Business Officer and Vice President, Business Development from January 2006 to April 2011. He currently
serves as partner of Twilight Venture Partners,&nbsp;LLC, a private seed and early-stage life science venture capital fund. He was a founding partner of JEGI Capital,&nbsp;LLC, a venture capital
fund co-sponsored by GE Capital Corp. that launched in 2000. Mr.&nbsp;Hawryluk holds a B.A. from Princeton University, an M.B.A. from Kellogg School of Management at Northwestern University, and an
M.S. degree in biology from Indiana University-Purdue University Indianapolis. Our board of directors believes Mr.&nbsp;Hawryluk should serve as a director based on his experience founding and
developing biopharmaceutical companies and his knowledge of the biopharmaceutical industry. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>134</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=136,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=310557,FOLIO='134',FILE='DISK112:[15ZCH1.15ZCH40101]EI40101A.;74',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_ei40101_1_135"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>Kenneth Kousky</B></FONT><FONT SIZE=2> has served as a member of our board of directors since March 2015. Mr.&nbsp;Kousky has also served as the Chief Executive Officer of the
Mid-Michigan Innovation Center, a privately funded, non-profit business incubator, since 2010. He has also served as the President and Chief Executive Officer of IP3,&nbsp;Inc., an information
security consulting firm, since 2002. Also, Mr.&nbsp;Kousky is a founding member and has served as Executive Director of the Blue Water Angels Investment Network, a Michigan-based funding network
that assists in private equity investments in early-stage tech startups, since 2008. In 1988, Mr.&nbsp;Kousky founded an IT services
company, Wave Technologies International&nbsp;Inc., which he led through an initial public offering in 1994. In 1989, he established Washington University's graduate program in Telecommunication
Management, and he has lectured at Saginaw Valley State University, Washington University and at the Wharton School of Business at the University of Pennsylvania. Mr.&nbsp;Kousky is a member of
several corporate boards, including Michigan Sugar Corporation, RetroSense Therapeutics&nbsp;LLC and Foodjunky&nbsp;LLC. Mr.&nbsp;Kousky holds a B.A. in economics and urban studies from
Washington University, and an M.S. in economics from University of Pennsylvania. Our board of directors believes Mr.&nbsp;Kousky should serve as a director based on his extensive financial and
strategic business planning experience. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>Pedro Lichtinger</B></FONT><FONT SIZE=2> has served as a member of our board of directors since December 2015. He was the President and Chief Executive Officer of Asterias
Biotherapeutics,&nbsp;Inc., a publicly traded company with a focus on neurology and oncology from June 2014 to February 2016. Mr.&nbsp;Lichtinger served as President, Chief Executive Officer, and
a director of Optimer Pharmaceuticals,&nbsp;Inc., from May 2010 to February 2013. Mr.&nbsp;Lichtinger previously served as an executive of Pfizer,&nbsp;Inc. from 1995 to 2009, including as
President of Pfizer's Global Primary Care Unit from 2008 to 2009, Area President, Europe from 2006 to 2008, President, Global Animal Health from 1999 to 2006, and Regional President Europe Animal
Health from 1995 to 1999. Before joining Pfizer, Mr.&nbsp;Lichtinger was an executive of Smith Kline Beecham Plc, last serving as Senior Vice-President Europe Animal Health from 1987 to 1995.
Mr.&nbsp;Lichtinger serves as a director of Sanfer de Mexico, a leading Mexican pharmaceutical company. Mr.&nbsp;Lichtinger previously served as a director of BioTime,&nbsp;Inc. and Optimer
Pharmaceuticals,&nbsp;Inc. Mr.&nbsp;Lichtinger holds an MBA degree from the Wharton School of Business and an engineering degree from the National University of Mexico. Our board of directors
believes Mr.&nbsp;Lichtinger should serve as director based on his extensive pharmaceutical industry and public company leadership experience. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>Andrew Sassine</B></FONT><FONT SIZE=2> has served as a member of our board of directors since May 2015. Mr.&nbsp;Sassine served in various positions at Fidelity Investments
from 1999 to 2012, including as a Portfolio Manager for various funds from 2005 to December 2011. Mr.&nbsp;Sassine has also served on several boards of life science companies. Mr.&nbsp;Sassine
currently serves on the board of directors of iCAD,&nbsp;Inc., a public cancer detection and radiation therapy solutions company, and CNS Response,&nbsp;Inc., a public psychiatric clinical
decision support company and previously served on the board of directors of FluoroPharma Medical,&nbsp;Inc., a public biopharmaceutical company, and Acorn Energy,&nbsp;Inc., a public holding
company focused on technology solutions for energy infrastructure asset management. Mr.&nbsp;Sassine also serves on the board of directors of Freedom Meditech,&nbsp;Inc., a private medical device
company, and Comhear&nbsp;Inc., a private digital audio software and device company, where he is also the chairman of the board of directors. Mr.&nbsp;Sassine serves on the Strategic Advisory
Board of MD Revolution&nbsp;Inc., a private digital health service company. Mr.&nbsp;Sassine has been a member of the Henry B. Tippie College of Business, University of Iowa Board of Advisors
since 2009 and served on the board of trustees at the Clarke Schools for Hearing and Speech from 2009 through 2014. Mr.&nbsp;Sassine holds a B.A. from the University of Iowa and an M.B.A. from the
Wharton School at the University of Pennsylvania. Our board of directors believes Mr.&nbsp;Sassine should serve as a director based on his extensive experience in the public markets as well as his
financial expertise. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Board Composition  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The voting agreement entered into in connection with the closing of our Series&nbsp;A convertible preferred stock financing provides for two
directors to be elected by the holders of a majority of our common stock, voting as a single class; two directors to be elected by the holders of a majority of our common stock and Series&nbsp;A
convertible preferred stock, voting collectively as a single class; and one director to be elected by the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>135</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=137,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=318800,FOLIO='135',FILE='DISK112:[15ZCH1.15ZCH40101]EI40101A.;74',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_ei40101_1_136"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>holders
of our Series&nbsp;A convertible preferred stock, voting as a single class, who is designated as Mr.&nbsp;Kousky. Excel Venture Fund&nbsp;II, L.P. is entitled to designate one member of
the board, who is initially Dr.&nbsp;Gullans. Mr.&nbsp;Gullans was appointed by the board of directors to fill the vacancy created by Mr.&nbsp;Lowenschuss's resignation. The voting agreement by
which our directors were elected will terminate in connection with this offering and there will be no continuing contractual obligations regarding the election of our directors. Each of our current
directors will continue to serve until the election and qualification of his or her successor, or his or her earlier death, resignation or removal. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
business and affairs are organized under the direction of our board of directors. The board of directors currently consists of seven members. The primary responsibilities of our board of directors
are to provide oversight, strategic guidance, counseling and direction to our management. Our board of directors meets on a regular basis and additionally as required. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Our
board of directors has determined that all of our directors, except Ms.&nbsp;Sooch and Dr.&nbsp;Bisgaier, are independent directors, as defined by Rule&nbsp;5605(a)(2) of the NASDAQ Listing
Rules. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
accordance with the terms of our amended and restated certificate of incorporation and amended and restated bylaws, which will be effective immediately prior to the consummation of this offering,
our board of directors will be divided into three classes, Class&nbsp;I, Class&nbsp;II and Class&nbsp;III, with members of each class serving staggered three-year terms. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Effective
upon the closing of this offering, our board of directors will be comprised of the following classes:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Class&nbsp;I, which will consist of Mr.&nbsp;Kousky and Dr.&nbsp;Bisgaier,
whose terms will expire at our annual meeting of stockholders to be held in 2017; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Class&nbsp;II, which will consist of Dr.&nbsp;Gullans and
Mr.&nbsp;Hawryluk, whose terms will expire at our annual meeting of stockholders to be held in 2018; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Class&nbsp;III, which will consist of Mr.&nbsp;Lichtinger, Ms.&nbsp;Sooch
and Mr.&nbsp;Sassine, whose terms will expire at our annual meeting of stockholders to be held in 2019. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Each
director's term continues until the election and qualification of his successor, or his earlier death, resignation, or removal. Our amended and restated certificate of incorporation and amended
and restated bylaws, which will be in effect immediately prior to the consummation of this offering, will authorize only our board of directors to fill vacancies on our board of directors unless the
board determines that such vacancies shall be filled by stockholders. Any increase or decrease in the number of directors will be distributed among the three classes so that, as nearly as possible,
each class will consist of one-third of the directors. This classification of our board of directors may have the effect of delaying or preventing changes in control of our company. See "Description
of Capital Stock&nbsp;&#151; Anti-Takeover Provisions." </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Board Leadership Structure  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our board of directors is currently chaired by our Chief Scientific Officer, Dr.&nbsp;Bisgaier, who has authority, among other things, to call and
preside over meetings of our board of directors, to set meeting agendas and to determine materials to be distributed to the board of directors and, accordingly, has substantial ability to shape the
work of the board of directors. The positions of our chairman of the board and Chief Executive Officer are presently separated. Separating these positions allows our Chief Executive Officer,
Ms.&nbsp;Sooch, to focus on our day-to-day business, while allowing, Dr.&nbsp;Bisgaier, our co-founder who was also instrumental in the discovery and development of gemcabene, to lead the board of
directors. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Role of the Board in Risk Oversight  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>One of the key functions of our board of directors is informed oversight of our risk management process. Our board of directors does not have a
standing risk management committee, but rather administers this oversight function directly through the board of directors as a whole, as well as through various standing committees of our board of
directors that address risks inherent in their respective areas of oversight. In particular, our board of directors is responsible for monitoring and assessing strategic risk exposure and our </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>136</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=138,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=501788,FOLIO='136',FILE='DISK112:[15ZCH1.15ZCH40101]EI40101A.;74',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_ei40101_1_137"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>audit
committee has the responsibility to consider and discuss our major financial risk exposures and the steps our management has taken to monitor and control these exposures, including guidelines
and policies to govern the process by which risk assessment and management is undertaken. The audit committee also monitors compliance with legal and regulatory requirements. Our nominating and
corporate governance committee monitors the effectiveness of our corporate governance practices, including whether they are successful in preventing illegal or improper liability-creating conduct. Our
compensation committee assesses and monitors whether any of our compensation policies and programs has the potential to encourage excessive risk-taking. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Committees of the Board of Directors  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our board of directors has established an audit committee, a compensation committee and a nominating and corporate governance committee, each of which
has the composition and responsibilities described below. Members serve on these committees until their resignation or until otherwise determined by our board of directors. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Audit Committee  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our audit committee is comprised of Mr.&nbsp;Kousky, Mr.&nbsp;Hawryluk and Mr.&nbsp;Sassine and Mr.&nbsp;Kousky is currently the chairman.
Each member of our audit committee meets the requirements for
independence under the current NASDAQ and SEC rules and regulations and is financially literate. In addition, our board of directors has determined that Mr.&nbsp;Kousky is an "audit committee
financial expert" as defined in Item&nbsp;407(d)(5)(ii) of Regulation&nbsp;S-K promulgated under the Securities Act. This designation does not impose on him any duties, obligations or liabilities
that are greater than are generally imposed on members of our audit committee and our board of directors. Our audit committee is directly responsible for, among other things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our accounting and financial reporting processes, including our financial
statement audits and the integrity of our financial statements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our compliance with legal and regulatory requirements; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the qualifications, independence and performance of our independent auditors;
and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the preparation of the audit committee report to be included in our annual proxy
statement. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Compensation Committee  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our compensation committee is currently comprised of Mr.&nbsp;Hawryluk, Mr.&nbsp;Lichtinger and Mr.&nbsp;Sassine and Mr.&nbsp;Hawryluk is
currently the chairman. Each member of our compensation committee meets the requirements for independence under the current NASDAQ and SEC rules and regulations, is an outside director, as defined
pursuant to Section&nbsp;162(m) of the Internal Revenue Code of 1984, as amended, or the Code, and is a non-employee director as defined in Rule&nbsp;16b-3 promulgated under the Exchange Act. Our
compensation committee is responsible for, among other things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  evaluating, recommending, approving and reviewing executive officer and
director compensation arrangements, plans, policies and programs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  administering our cash-based and equity-based compensation plans; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> making recommendations to our board of directors regarding any other board of
director responsibilities relating to executive compensation. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Nominating and Corporate Governance Committee  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our nominating and corporate governance committee is comprised of Mr.&nbsp;Hawryluk, Mr.&nbsp;Kousky and Mr.&nbsp;Sassine and Mr.&nbsp;Sassine
is currently the chairman. Each member of our nominating and corporate governance committee meets the requirements for independence under the current NASDAQ and SEC rules and regulations. As of the
closing of this offering, we expect that the nominating and corporate governance committee will comply with the applicable rules and regulations of the NASDAQ and SEC. Our nominating and corporate
governance committee is responsible for, among other things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  identifying, considering and recommending candidates for membership on our
board of directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  overseeing the process of evaluating the performance of our board of directors;
and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> advising our board of directors on other corporate governance matters. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>137</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=139,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=170212,FOLIO='137',FILE='DISK112:[15ZCH1.15ZCH40101]EI40101A.;74',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_ei40101_1_138"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Compensation Committee Interlocks and Insider Participation  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have established a compensation committee, which has and will make decisions relating to compensation of our executive officers. None of the
directors serving on the compensation committee has ever been an executive officer or employee of ours. None of our executive officers currently serves, or has served during the last completed fiscal
year, on the compensation committee or board of directors of any other entity that has one or more executive officers serving as a member of our board of directors or compensation committee. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Limitation on Liability and Indemnification of Directors and Officers  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our amended and restated certificate of incorporation and amended and restated bylaws, which will become effective immediately prior to the closing of
this offering, limit our directors' liability to the fullest extent permitted under Delaware corporate law. Delaware corporate law provides that directors of a corporation will not be personally
liable for monetary damages for breach of their fiduciary duties as directors, except for liability:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> for any transaction from which the director derives an improper personal
benefit; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> for any act or omission not in good faith or that involves intentional
misconduct or a knowing violation of law; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> under Section&nbsp;174 of the Delaware General Corporation Law (unlawful
payment of dividends or redemption of shares); or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> for any breach of a director's duty of loyalty to the corporation or its
stockholders. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>If
the Delaware General Corporation Law is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of our directors shall be
eliminated or limited to the fullest extent permitted by the Delaware General Corporation Law, as so amended. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Delaware
law and our amended and restated certificate of incorporation and our amended and restated bylaws provide that we will, in certain situations, indemnify our directors and officers and may
indemnify other employees and other agents, to the fullest extent permitted by law. Any indemnified person is also entitled, subject to certain limitations, to payment or reimbursement of reasonable
expenses (including attorneys' fees and disbursements) in advance of the final disposition of the proceeding. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, we have entered, and intend to continue to enter, into separate indemnification agreements with our directors and officers. These agreements, among other things, require us to indemnify
our directors and officers for certain expenses, including attorneys' fees, judgments, fines and settlement amounts incurred by a director or officer in any action or proceeding arising out of their
services as one of our directors or officers or any other company or enterprise to which the person provides services at our request. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
maintain a directors' and officers' insurance policy pursuant to which our directors and officers are insured against certain liability for actions taken in their capacities as directors and
officers. We believe that these
provisions in our amended and restated certificate of incorporation and amended bylaws and these indemnification agreements are necessary to attract and retain qualified persons as directors and
officers. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or control persons, in the opinion of the SEC, such indemnification is against
public policy as expressed in the Securities Act and is therefore unenforceable. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>138</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=140,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=425969,FOLIO='138',FILE='DISK112:[15ZCH1.15ZCH40101]EI40101A.;74',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ek40101_1_139"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ek40101_executive_officer_and_director_compensation"> </A>
<A NAME="toc_ek40101_1"> </A>
<BR></FONT><FONT SIZE=2><B>  EXECUTIVE OFFICER AND DIRECTOR COMPENSATION    <BR>    </B></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Executive Officer Compensation  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following tables and accompanying narrative disclosure discuss the compensation awarded to, earned by, or paid
to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Mina Sooch, our President, Chief Executive Officer, Treasurer and Director; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  Charles&nbsp;L. Bisgaier, Ph.D., our Chief Scientific Officer and Chairman of
our Board of Directors; and</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Jeffrey&nbsp;S. Mathiesen, our Chief Financial Officer. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>We
refer to these three executive officers as the "named executive officers." </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Summary Compensation Table  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following table presents summary information regarding the total compensation for services rendered in all capacities that was earned by our named
executive officers during the fiscal years ended December&nbsp;31, 2015 and 2014. Our named executive officers in 2015 were Mina Sooch, Charles&nbsp;L. Bisgaier, Ph.D. and Jeffrey&nbsp;S.
Mathiesen. </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="31pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="49pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="56pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="49pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="49pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:84pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>NAME AND PRINCIPAL<BR>
POSITION

<!-- COMMAND=ADD_SCROPPEDRULE,84pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>YEAR </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>SALARY<BR>
($)<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font> </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>STOCK<BR>
AWARDS ($)<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font> </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>OPTION<BR>
AWARDS<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font><BR>
($) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>TOTAL<BR>
($) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Mina Sooch</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2015</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>315,000<SUP>(4)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,009</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>319,009</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>President, Chief Executive Officer and Treasurer</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2014</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>56,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>56,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Charles L. Bisgaier, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
2015</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
270,000<SUP>(5)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
3,436</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
273,436</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Chief Scientific Officer</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2014</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>20,832</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>20,832</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Jeffrey S. Mathiesen<SUP>(6)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
2015</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
104,833</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR><SUP>(7)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
115,965</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR><SUP>(8)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
220,798</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Chief Financial Officer</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">We
did not pay a salary, bonus, non-equity incentive plan compensation or any other cash compensation to any of our named executive officers
during the year ended December&nbsp;31, 2014. We did not pay any bonus or non-equity incentive plan compensation to any of our executive officers during the year ended December&nbsp;31, 2015. As
discussed further below, we entered into employee agreements with Ms.&nbsp;Sooch and Dr.&nbsp;Bisgaier in November 2014 that provided for grants of restricted stock during the fiscal year ended
December&nbsp;31, 2014 and salary payments commencing January&nbsp;1, 2015.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
amounts reported do not reflect the amounts actually received by our named executive officers. Instead, these amounts reflect the
aggregate grant date fair value of each equity award granted to our named executive officers during the fiscal year ended December&nbsp;31, 2014, as computed in accordance with FASB Accounting
Standards Codification Topic&nbsp;718 (ASC&nbsp;718). Assumptions used in the calculation of these amounts are included in Note&nbsp;9 to our financial statements included in this prospectus. As
required by SEC rules, the amounts shown exclude the impact of estimated forfeitures related to service-based vesting conditions.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
amounts reported in this column represent the aggregate grant date fair value of the stock options granted to our named executive officers
during the year ended December&nbsp;31, 2015 as computed in accordance with ASC&nbsp;718. The assumptions used in calculating the aggregate grant date fair value of the stock options reported in
this column are set forth in Note&nbsp;9 to our financial statements included in this prospectus. The amounts reported in this column reflect the accounting cost for these stock options, and do not
correspond to the actual economic value that may be received by our named executive officers from the stock options.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(4)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Amount
includes $35,000 in salary foregone by Ms.&nbsp;Sooch in exchange for a stock option award for 5,220&nbsp;shares granted on
June&nbsp;29, 2015 as described in the table below under "&#151;&nbsp;Outstanding Equity Awards at Fiscal Year-End."
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(5)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Amount
includes $30,000 in salary foregone by Dr.&nbsp;Bisgaier in exchange for a stock option award for 4,474&nbsp;shares granted on
June&nbsp;29, 2015 as described in the table below under "&#151;&nbsp;Outstanding Equity Awards at Fiscal Year-End." </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>139</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=141,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=663219,FOLIO='139',FILE='DISK112:[15ZCH1.15ZCH40101]EK40101A.;118',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_ek40101_1_140"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(6)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Mr.&nbsp;Mathiesen
provided consulting services to us during August and September 2015. He began serving as our Chief Financial Officer in
September 2015.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(7)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Amount
includes $34,000 paid to The Mathiesen Group,&nbsp;Inc. for consulting services provided by Mr.&nbsp;Mathiesen.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(8)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Amount
includes $6,867 of aggregate grant date fair value of stock options granted to Mr.&nbsp;Mathiesen in connection with the consulting
agreement, computed as described in note&nbsp;(3) above. </FONT></DD></DL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Agreements with Our Named Executive Officers  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have entered into written employment agreements with each of our named executive officers, as described below. For a discussion of the severance
pay and other benefits to be provided in
connection with a termination of employment and/or a change in control under the arrangements with our named executive officers, please see "&#151;&nbsp;Potential Payments Upon Termination or
Change in Control" below. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Each
of our named executive officers has also executed our standard form of confidential information and invention assignment agreement. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Employment Agreement with Mina Sooch  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We initially entered into an employment agreement with Ms.&nbsp;Sooch in November 2014 that, as amended, governs the terms of her employment with
us. Under the terms of this agreement, Ms.&nbsp;Sooch is entitled to an annual base salary of $350,000 beginning on January&nbsp;1, 2015. Ms.&nbsp;Sooch agreed to defer 20% of her salary until
June&nbsp;30, 2015, to be paid in cash or stock at Ms.&nbsp;Sooch's election. In June 2015, we granted her a fully-vested stock option exercisable for 5,220&nbsp;shares of our common stock, at
an exercise price equal to $1.34 per share, in satisfaction of our obligations under such deferral arrangement. Effective February&nbsp;29, 2016, Ms.&nbsp;Sooch agreed to defer 25% of her base
salary from March&nbsp;1, 2016 through the earlier of (i)&nbsp;the closing of an arms-length equity financing (including a public financing); (ii)&nbsp;a change of control of the Company; or
(iii)&nbsp;June&nbsp;30, 2016. Pursuant to the employee agreement, Ms.&nbsp;Sooch was granted 641,232&nbsp;shares of common stock, with 320,616&nbsp;shares vesting immediately and the other
320,616&nbsp;shares vesting in 24 equal monthly installments at the end of each month beginning in November 2014, subject to continued service. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Employment Agreement with Charles&nbsp;L. Bisgaier, Ph.D.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We initially entered into an employment agreement with Dr.&nbsp;Bisgaier in November 2014 that, as amended, governs the terms of his employment with
us. Under the terms of this agreement, Dr.&nbsp;Bisgaier is entitled to an annual base salary of $300,000 beginning on January&nbsp;1, 2015. Dr.&nbsp;Bisgaier agreed to defer 20% of his salary
from January&nbsp;1, 2015 until June&nbsp;30, 2015, to be paid in cash or stock at Dr.&nbsp;Bisgaier's election. In June 2015, we granted him a fully-vested stock option exercisable for 4,474
shares of our common stock, with an exercise price equal to $1.34 per share, in satisfaction of our obligations under such deferral arrangement. Effective February&nbsp;29, 2016, Dr.&nbsp;Bisgaier
agreed to defer 25% of his base salary from March&nbsp;1, 2016 through the earlier of (i)&nbsp;the closing of an arms-length equity financing (including a public financing); (ii)&nbsp;a change
of control of the Company; or (iii)&nbsp;June&nbsp;30, 2016. In connection with the merger with MLT, we agreed to issue to Dr.&nbsp;Bisgaier 1,192,690&nbsp;shares of our common stock, of which
238,538&nbsp;shares vest in 18 equal monthly installments at the end of each month beginning in November 2014, subject to continued service. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Employment Agreement with Jeffrey S. Mathiesen  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We initially entered into a letter agreement with Mr.&nbsp;Mathiesen in September 2015 that governs the terms of his employment with us. Under the
terms of this agreement, as amended, Mr.&nbsp;Mathiesen is entitled to an annual base salary of $250,000. Effective February&nbsp;29, 2016, Mr.&nbsp;Mathiesen agreed to defer 25% of his base
salary from March&nbsp;1, 2016 through the earlier of (i)&nbsp;the closing of an arms-length equity financing (including a public financing); (ii)&nbsp;a change of control of the Company; or
(iii)&nbsp;June&nbsp;30, 2016. Mr.&nbsp;Mathiesen is also entitled to a one-time relocation and housing/travel expense reimbursement of $50,000 beginning 30&nbsp;days following the close of
the Company's initial public offering. Pursuant to the agreement, Mr.&nbsp;Mathiesen was granted an option exercisable for 48,093&nbsp;shares of our common stock, </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>140</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=142,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=340278,FOLIO='140',FILE='DISK112:[15ZCH1.15ZCH40101]EK40101A.;118',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_ek40101_1_141"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>vesting
in 36 equal monthly installments at the end of each month, and Mr.&nbsp;Mathiesen has the right to receive, upon a financing and establishment of a larger option pool, additional equity
awards so that his holdings represent 1% of our total capitalization on a fully-diluted basis, which right will be satisfied by the grants of options upon the effectiveness of this registration
statement, as discussed further below. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Amended Employment Agreements with Named Executive Officers  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have entered into new employment agreements with Ms.&nbsp;Sooch, Dr.&nbsp;Bisgaier and Mr.&nbsp;Mathiesen to be effective on the closing of
the offering that will supersede the prior agreements and govern the terms of their employment with us (the Amended Employment Agreements). The initial term (the Initial Term) of each Amended
Employment Agreement is from the effective date through the third anniversary of the effective date and automatically renews for an additional one year period at the end of the Initial Term and each
anniversary thereafter, provided that at least 90&nbsp;days prior to the expiration of the Initial Term or any renewal term the board does not notify such officer of its intention not to renew the
employment period. Under the terms of the Amended Employment Agreement, Ms.&nbsp;Sooch, Dr.&nbsp;Bisgaier and Mr.&nbsp;Mathiesen are entitled to annual base salaries of $425,000, $300,000 and
$325,000, respectively, each reviewed at least annually. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Each
Amended Employment Agreement also entitles such officer to, among other benefits, the following compensation: (i)&nbsp;eligibility to receive an annual cash bonus of up to a percentage of such
officer's annual base salary as specified in his or her individual Amended Employment Agreement at the sole discretion of the board and as determined by the Compensation Committee commensurate with
the policies and practices applicable to
other senior executive officers of the Company; (ii)&nbsp;an opportunity to participate in any stock option, performance share, performance unit or other equity based long-term incentive
compensation plan commensurate with the terms and conditions applicable to other senior executive officers (the Plans); and (iii)&nbsp;participation in welfare benefit plans, practices, policies and
programs provided by the Company and its affiliated companies (including, without limitation, medical, prescription, dental, disability, employee life, group life, accidental death and travel accident
insurance plans and programs) to the extent available to our other senior executive officers. Each such officer is entitled to retain all shares of our common stock and stock options he or she held as
of the Effective Date (the Officer's Equity), and to the extent such officer remains employed as of the closing date of a change in control or, with respect to Ms.&nbsp;Sooch and
Dr.&nbsp;Bisgaier, an initial public offering, the Officer's Equity will fully vest, effective as of the closing date of the change in control or, with respect to Ms. Sooch and Dr. Bisgaier, the
initial public offering date. Ms.&nbsp;Sooch, Dr.&nbsp;Bisgaier and Mr.&nbsp;Mathiesen are additionally entitled to certain severance benefits pursuant to their employment agreements, the terms
of which are described below under "&#151;&nbsp;Potential Payments Upon Termination or Change in Control." </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On
April 25, 2016, our Compensation Committee approved the award of options to purchase 600,000, 150,000 and 210,000&nbsp;shares of our common stock to Ms.&nbsp;Sooch, Dr.&nbsp;Bisgaier and
Mr.&nbsp;Mathiesen, respectively, with a per share exercise price equal to the initial public offering price, in each case, to be granted in connection with this offering. For Ms.&nbsp;Sooch,
240,000&nbsp;shares underlying her award are subject to performance conditions, with 120,000&nbsp;shares to be earned upon the initiation of our first clinical trial and 120,000&nbsp;shares to
be earned upon the initiation of our second clinical trial. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Potential Payments Upon Termination or Change in Control  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Pursuant to the Amended Employment Agreements, regardless of the manner in which a named executive officer's service terminates, the named executive
officer is entitled to receive amounts earned during his or her term of service, including salary and other benefits. In addition, each of our named executive officers is eligible to receive certain
benefits pursuant to his or her agreement with us described above under "&#151;&nbsp;Agreements with our Named Executive Officers." </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>141</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=143,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=370525,FOLIO='141',FILE='DISK112:[15ZCH1.15ZCH40101]EK40101A.;118',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_ek40101_1_142"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company is permitted to terminate the employment of Ms.&nbsp;Sooch, Dr.&nbsp;Bisgaier and Mr.&nbsp;Mathiesen for the following reasons: (1)&nbsp;death or disability, (2)&nbsp;Termination
for Cause (as defined below) or (3)&nbsp;for any other reason or no reason. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Each
such officer is permitted Termination for Good Reason (as defined below) of such officer's employment. In addition, each such officer may terminate his or her employment upon written notice to
the Company 30&nbsp;days prior to the effective date of such termination. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
the event of such officer's death during the employment period or a termination due to such officer's disability, such officer or his or her beneficiaries or legal representatives shall be provided
the sum of (a)&nbsp;any annual base salary earned, but unpaid, for services rendered to the Company on or prior to the date on which the employment period ends and (b)&nbsp;the bonus that would
have been payable to such officer subject to any performance conditions and (c)&nbsp;certain other benefits provided for in the employment agreement (the Unconditional Entitlements). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
the event of such officer's Termination for Cause by the Company or the termination of such officer's employment as a result of such officer's resignation other than a Termination for Good Reason,
such officer shall be provided the Unconditional Entitlements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
the event of a Termination for Good Reason by such officer or the exercise by the Company of its termination rights to terminate such officer other than by Termination for Cause, death or
disability, such officer shall be provided the Unconditional Entitlements and, subject to such officer signing and delivering to the Company and not revoking a general release of claims in favor of
the Company and certain related parties, the Company shall provide such officer a severance amount equal to (i)&nbsp;0.5-1.0 (which ratio varies based on the negotiated terms in the agreement of
such officer) times such officer's annual base salary as of the termination date less the Non-Compete Amount (if applicable) (as defined in his or her employment agreement) and (ii)&nbsp;a prorated
cash bonus for the year as well as continued medical coverage for 12&nbsp;months following such termination, immediate vesting of all stock options, which become immediately exercisable in
accordance with the stock option award documents, subject to the same conditions that would be applicable to such officer if he or she remained employed through the end of the employment period and
continued vesting of equity awards in accordance with the terms of the award agreements (the Conditional Benefits). </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
the event of a change in control during the employment period or within two years after a change in control, if the Company terminates such officer other than due to such officer's death or
disability or a Termination for Cause, or such officer effects a Termination for Good Reason, the Company will pay to such officer, in a lump sum in cash within 30 days after the termination date, the
aggregate of: (i)&nbsp;the Unconditional Entitlements; and (ii)&nbsp;the amount equal to the product of 1.0-1.5 (which ratio varies based on the negotiated terms in the agreement of such officer)
times the sum of (y)&nbsp;such officer's annual base salary, and (z)&nbsp;the greater of the target bonus for the then current fiscal year under the Plans or any successor annual bonus plan and
the average annual bonus paid to or for the benefit of such officer for the prior three full years (or any shorter period during which such officer had been employed by the Company). In addition, the
Company shall provide such officer the Conditional Benefits minus such officer's severance amount. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under
the employment agreements, "Termination for Cause" means a termination of the officer's employment by the Company due to (A)&nbsp;an intentional act or acts of dishonesty undertaken by the
officer and intended to result in substantial gain or personal enrichment to the officer at the expense of the Company, (B)&nbsp;unlawful conduct or gross misconduct that is willful and deliberate
on the officer's part and that, in either event, is materially injurious to the Company, (C)&nbsp;the conviction of the officer of, or the officer's entry of a no contest or nolo contendre plea to,
a felony, (D)&nbsp;material breach by the officer of the officer's fiduciary obligations as an officer or director of the
Company, (E)&nbsp;a persistent failure by the officer to perform the duties and responsibilities of the officer's employment hereunder, which failure is willful and deliberate on the officer's part
and is not remedied by the officer within 30&nbsp;days after the officer's receipt </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>142</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=144,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=329474,FOLIO='142',FILE='DISK112:[15ZCH1.15ZCH40101]EK40101A.;118',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_ek40101_1_143"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>of
written notice from the Company of such failure; or (F)&nbsp;material breach of any terms and conditions of the respective employment agreement by the officer, which breach has not been cured by
the officer within ten days after written notice thereof to the officer from the Company. No act or failure to act on the officer's part shall be considered "dishonest," "willful" or "deliberate"
unless intentionally done or omitted to be done by the officer in bad faith and without reasonable belief that the officer's action or omission was in the best interests of the Company. Any act, or
failure to act, based upon authority given pursuant to a resolution duly adopted by the Board shall be conclusively presumed to be done, or omitted to be done, by the officer in good faith and in the
best interests of the Company. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under
the employment agreements, "Termination for Good Reason" means a termination of the officer's employment by such officer within 30&nbsp;days of the Company's failure to cure, in accordance
with the procedures set forth below, any of the following events: (A)&nbsp;a reduction in the officer's annual base salary as in effect immediately prior to such reduction by more than 10% without
the officer's written consent, unless such reduction is made pursuant to an across the board reduction applicable to all senior executives of the Company; (B)&nbsp;the removal of the officer by the
Company from the executive officer position held; (C)&nbsp;a material reduction in the officer's duties and responsibilities as in effect immediately prior to such reduction; or (D)&nbsp;a
material breach of any material provision of the employment agreement by the Company to which the officer shall have delivered a written notice to the board within 45&nbsp;days of the officer's
having actual knowledge of the occurrence of one of such events stating that the officer intends to terminate the officer's employment by Termination for Good Reason and specifying the factual basis
for such termination, and such event, if capable of being cured, shall not have been cured within 21&nbsp;days of the receipt of such notice. Notwithstanding the foregoing, a termination shall not
be treated as a Termination for Good Reason if the officer shall have consented in writing to the occurrence of the event giving rise to the claim of Termination for Good Reason. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Outstanding Equity Awards at Fiscal Year-End  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>No named executive officer was granted any stock options prior to January&nbsp;1, 2015. The following table sets forth information regarding
restricted stock awards and outstanding stock options held by our named executive officers as of December&nbsp;31, 2015: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="75pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="75pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="55pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="64pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="39pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="75pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="54pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="54pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=10 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>OPTION AWARDS<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font> </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>STOCK AWARDS<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font> </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:17pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>NAME

<!-- COMMAND=ADD_SCROPPEDRULE,17pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>GRANT DATE </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>VESTING<BR>
COMMENCEMENT<BR>
DATE </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>NUMBER OF<BR>
SECURITIES<BR>
UNDERLYING<BR>
UNEXERCISED<BR>
OPTIONS<BR>
EXERCISABLE<BR>
(#) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>NUMBER OF<BR>
SECURITIES<BR>
UNDERLYING<BR>
UNEXERCISED<BR>
OPTIONS<BR>
UNEXERCISABLE<BR>
(#) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>OPTION<BR>
EXERCISE<BR>
PRICE<BR>
($) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>OPTION<BR>
EXPIRATION<BR>
DATE </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>NUMBER OF<BR>
SHARES THAT<BR>
HAVE NOT<BR>
VESTED<BR>
(#) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>MARKET<BR>
VALUE OF<BR>
SHARES THAT<BR>
HAVE NOT<BR>
VESTED<BR>
($)<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font> </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:6pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Mina Sooch</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">November&nbsp;1, 2014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">November&nbsp;1, 2014<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(4)</font></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">133,590</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">778,830</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:6pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">June&nbsp;29, 2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">June&nbsp;29, 2015<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(5)</font></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">5,220</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1.34</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">June&nbsp;28, 2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:6pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Charles&nbsp;L. Bisgaaier,&nbsp;Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
November&nbsp;1, 2014</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
November&nbsp;1, 2014<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(6)</font></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
53,009</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
309,043</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:6pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">June&nbsp;29, 2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">June&nbsp;29, 2015<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(5)</font></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">4,474</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1.34</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">June&nbsp;28, 2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:6pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Jeffrey&nbsp;S. Mathiesen</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
September&nbsp;25, 2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
September&nbsp;25, 2015<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(5)</font></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
3,207</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
3.59</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
September&nbsp;24, 2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:6pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">September&nbsp;25, 2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">September&nbsp;25, 2015<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(7)</font></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">5,344</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">42,749</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">3.59</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">September&nbsp;24, 2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">All
of the outstanding stock option awards were granted under our 2015 Plan.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Unless
otherwise noted, all of the shares of restricted stock were granted prior to our adoption of the 2015 Plan and under an employee
agreement with each named executive officer, the terms of which employee agreements are described above under "&#151;&nbsp;Agreements with our Named Executive Officers."
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Market
value is calculated by multiplying the number of shares that were unvested as of December&nbsp;31, 2015 by $5.83, which was the fair
market value of one share of our common stock based upon the latest independent valuation as of December&nbsp;31, 2015.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(4)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">50%
of the shares vested on the Vesting Commencement Date with the remaining vesting monthly in equal increments over a 24-month period
beginning on November&nbsp;30, 2014. The awards are also eligible for accelerated vesting on the closing of this offering, a qualifying termination or change of control as described above under
"&#151;&nbsp;Potential Payments Upon Termination or Change of Control."
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(5)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Options
fully vested upon grant.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(6)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
shares vest monthly in equal increments over an 18-month period beginning on November&nbsp;30, 2014. The awards are also eligible for
accelerated vesting on the closing of this offering, a qualifying termination or change of control as described above under "&#151;&nbsp;Potential Payments Upon Termination or Change of
Control."
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(7)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
shares underlying the option vest monthly in equal increments over a 36 month period beginning on September&nbsp;30, 2015. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>143</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=145,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=573405,FOLIO='143',FILE='DISK112:[15ZCH1.15ZCH40101]EK40101A.;118',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_em40101_1_144"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Employee Benefit and Stock Plans  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Amended and Restated 2015 Equity Incentive Plan  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our board of directors initially adopted the 2015 Plan in April 2015, and our stockholders approved the 2015 Plan in April 2015. In April 2016, our
board of directors and stockholders approved the amendment and restatement of the 2015 Plan in order to increase the share reserve under the 2015 Plan, include an "evergreen" provision, allow limited
delegation of award authority to an executive officer and include certain annual limits on equity awards, which amendments became effective immediately upon the
execution and delivery of the underwriting agreement related to this offering. We refer to such amended and restated plan as the 2015 Plan. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Stock Awards.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The 2015 Plan provides for the grant of incentive stock options (ISOs), nonstatutory stock options (NSOs), stock appreciation rights, restricted stock
awards, restricted stock unit awards (RSUs), performance-based stock awards, and other forms of equity compensation, or collectively, stock awards, all of which may be granted to employees, including
officers, non-employee directors and consultants of us and our affiliates. Additionally, the 2015 Plan provides for the grant of performance cash awards. ISOs may be granted only to employees. All
other awards may be granted to employees, including officers, and to non-employee directors and consultants. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Share Reserve.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;When initially adopted, the aggregate number of shares of our common stock that may be issued pursuant to stock awards under the 2015 Plan was
1,000,000 shares. In addition, the maximum number of shares of our common stock that were issuable upon the exercise of ISOs under our 2015 Plan is 1,000,000 shares. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
aggregate number of shares of our common stock that may be issued pursuant to stock awards under the 2015 Plan is 2,400,000 shares plus the number of shares that are Returning Shares (as defined
in the 2015 Plan). The number of shares that will remain available for issuance under the 2015 Plan at the closing of this offering will be 269,522. Additionally, the number of shares of our common
stock reserved for issuance under our 2015 Plan will automatically increase on January&nbsp;1 of each year, beginning on January&nbsp;1, 2017 and continuing through and including January&nbsp;1,
2026, to an amount equal to 20% of the fully diluted shares as of December&nbsp;31 of the preceding calendar year, or a lesser number of shares determined by our board of directors. The maximum
number of shares of our common stock that may be issued upon the exercise of ISOs under our 2015 Plan is 4,800,000 shares. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>No
person may be granted stock awards covering more than 1,000,000 shares of our common stock under our 2015 Plan during any calendar year pursuant to stock options, stock appreciation rights and
other stock awards whose value is determined by reference to an increase over an exercise or strike price of at least 100% of the fair market value on the date the stock award is granted.
Additionally, no person may be granted in a calendar year a performance stock award covering more than 1,000,000 shares of our common stock or a performance cash award having a maximum value in excess
of $1,000,000. Such limitations are designed to help ensure that any deductions to which we would otherwise be entitled with respect to such awards will not be subject to the $1,000,000 limitation on
the income tax deductibility of compensation paid to any covered executive officer imposed by Section&nbsp;162(m) of the Code. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
a stock award granted under the 2015 Plan expires or otherwise terminates without being exercised in full, or is settled in cash, the shares of our common stock not acquired pursuant to the stock
award again will become available for subsequent issuance under the 2015 Plan. In addition, the following types of shares of our common stock under the 2015 Plan may become available for the grant of
new stock awards under the 2015 Plan: (1)&nbsp;shares that are forfeited to or repurchased by us prior to becoming fully vested; (2)&nbsp;shares withheld to satisfy
income or employment withholding taxes; or (3)&nbsp;shares used to pay the exercise or purchase price of a stock award. Shares issued under the 2015 Plan may be previously unissued shares or
reacquired shares bought by us on the open market. As of the date hereof, no awards have been granted and no shares of our common stock have been issued under the 2015 Plan. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>144</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=146,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=710535,FOLIO='144',FILE='DISK112:[15ZCH1.15ZCH40101]EM40101A.;51',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_em40101_1_145"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Administration.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors, or a duly authorized committee thereof, has the authority to administer the 2015 Plan. Our board of directors may also
delegate to one or more of our officers the authority to (1)&nbsp;designate employees (other than other officers) to be recipients of certain stock awards, and (2)&nbsp;determine the number of
shares of common stock to be subject to such stock awards. Subject to the terms of the 2015 Plan, our board of directors or the authorized committee, referred to herein as the plan administrator,
determines recipients, dates of grant, the numbers and types of stock awards to be granted and the terms and conditions of the stock awards, including the period of their exercisability and vesting
schedule applicable to a stock award. Subject to the limitations set forth below, the plan administrator will also determine the exercise price, strike price or purchase price of awards granted and
the types of consideration to be paid for the award. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
plan administrator has the authority to modify outstanding awards under our 2015 Plan. Subject to the terms of our 2015 Plan, the plan administrator has the authority to reduce the exercise,
purchase or strike price of any outstanding stock award, cancel any outstanding stock award in exchange for new stock awards, cash or other consideration, or take any other action that is treated as a
repricing under generally accepted accounting principles, with the consent of any adversely affected participant. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Stock Options.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;ISOs and NSOs are granted pursuant to stock option agreements adopted by the plan administrator. The plan administrator determines the exercise price
for a stock option, within the terms and conditions of the 2015 Plan, provided that the exercise price of a stock option generally cannot be less than 100% of the fair market value of our common stock
on the date of grant. Options granted under the 2015 Plan vest at the rate specified by the plan administrator. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
plan administrator determines the term of stock options granted under the 2015 Plan, up to a maximum of ten years. Unless the terms of an optionholder's stock option agreement provide otherwise,
if an optionholder's service relationship with us, or any of our affiliates, ceases for any reason other than disability, death or cause, the optionholder may generally exercise any vested options for
a period of three months following the cessation of service. The option term may be extended in the event that exercise of the option following such a termination of service is prohibited by
applicable securities laws or our insider trading policy. If an optionholder's service relationship with us or any of our affiliates ceases due to disability or death, or an optionholder dies within a
certain period following cessation of service, the optionholder or a beneficiary may generally exercise any vested
options for a period of 12&nbsp;months in the event of disability and 18&nbsp;months in the event of death. In the event of a termination for cause, options generally terminate immediately upon
the termination of the individual for cause. In no event may an option be exercised beyond the expiration of its term. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Acceptable
consideration for the purchase of common stock issued upon the exercise of a stock option will be determined by the plan administrator and may include (1)&nbsp;cash, check, bank draft or
money order, (2)&nbsp;a broker-assisted cashless exercise, (3)&nbsp;the tender of shares of our common stock previously owned by the optionholder, (4)&nbsp;a net exercise of the option if it is
an NSO, and (5)&nbsp;other legal consideration approved by the plan administrator. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Unless
the plan administrator provides otherwise, options generally are not transferable except by will, the laws of descent and distribution, or pursuant to a domestic relations order. An
optionholder may designate a beneficiary, however, who may exercise the option following the optionholder's death. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Tax Limitations On Incentive Stock Options.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The aggregate fair market value, determined at the time of grant, of our common stock with respect to ISOs that are
exercisable for the first time by an optionholder during any calendar year under all of our stock plans may not exceed $100,000. Options or portions thereof that exceed such limit will generally be
treated as NSOs. No ISO may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any of our
affiliates unless (1)&nbsp;the option exercise price is at least 110% of the fair market </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>145</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=147,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=538747,FOLIO='145',FILE='DISK112:[15ZCH1.15ZCH40101]EM40101A.;51',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_em40101_1_146"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>value
of the stock subject to the option on the date of grant, and (2)&nbsp;the term of the ISO does not exceed five years from the date of grant. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><I> Restricted Stock Awards.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Restricted stock awards are granted pursuant to restricted stock award agreements adopted by the plan administrator. Restricted stock
awards may be granted in consideration for (1)&nbsp;cash, check, bank draft or money order, (2)&nbsp;services rendered to us or our affiliates, or (3)&nbsp;any other form of legal consideration.
Common stock acquired under a restricted stock award may, but need not, be subject to a share repurchase option in our favor in accordance with a vesting schedule to be determined by the plan
administrator. A restricted stock award may be transferred only upon such terms and conditions as set by the plan administrator. Except as otherwise provided in the applicable award agreement,
restricted stock awards that have not vested may be forfeited or repurchased by us upon the participant's cessation of continuous service for any reason. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Restricted Stock Unit Awards.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Restricted stock unit awards are granted pursuant to restricted stock unit award agreements adopted by the plan administrator.
Restricted stock unit awards may be granted in consideration for any form of legal consideration. A restricted stock unit award may be settled by cash, delivery of stock, a combination of cash and
stock as deemed appropriate by the plan administrator, or in any other form of consideration set forth in the restricted stock unit award agreement. Additionally, dividend equivalents may be credited
in respect of shares covered by a restricted stock unit award. Except as otherwise provided in the applicable award agreement, restricted stock units that have not vested will be forfeited upon the
participant's cessation of continuous service for any reason. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Stock Appreciation Rights.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Stock appreciation rights are granted pursuant to stock appreciation grant agreements adopted by the plan administrator. The plan
administrator determines the strike price for a stock appreciation right, which generally cannot be less than 100% of the fair market value of our common stock on the date of grant. Upon the exercise
of a stock appreciation right, we will pay the participant an amount equal to the product of (1)&nbsp;the excess of the per share fair market value of our common stock on the date of exercise over
the strike price, multiplied by (2)&nbsp;the number of shares of common stock with respect to which the stock appreciation right is exercised. A stock appreciation right granted under the 2015 Plan
vests at the rate specified in the stock appreciation right agreement as determined by the plan administrator. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
plan administrator determines the term of stock appreciation rights granted under the 2015 Plan, up to a maximum of ten years. Unless the terms of a participant's stock appreciation right
agreement provides otherwise, if a participant's service relationship with us or any of our affiliates ceases for any reason other than cause, disability or death, the participant may generally
exercise any vested stock appreciation right for a period of three months following the cessation of service. The stock appreciation right term may be further extended in the event that exercise of
the stock appreciation right following such a termination of service is prohibited by applicable securities laws. If a participant's service relationship with us, or any of our affiliates, ceases due
to disability or death, or a participant dies within a certain period following cessation of service, the participant or a beneficiary may generally exercise any vested stock appreciation right for a
period of 12&nbsp;months in the event of disability and 18&nbsp;months in the event of death. In the event of a termination for cause, stock appreciation rights generally terminate immediately
upon the occurrence of the event giving rise to the termination of the individual for cause. In no event may a stock appreciation right be exercised beyond the expiration of its term. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><I> Performance Awards.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The 2015 Plan permits the grant of performance-based stock and cash awards that may qualify as performance-based compensation that is not
subject to the $1,000,000 limitation on the income tax deductibility of compensation paid to a covered executive officer imposed by Section&nbsp;162(m) of the Code. To help assure that the
compensation attributable to performance-based awards will so qualify, our compensation committee can structure such awards so that stock or cash will be issued or paid pursuant to such award only
after the achievement of certain pre-established performance goals during a designated performance period. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>146</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=148,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=145577,FOLIO='146',FILE='DISK112:[15ZCH1.15ZCH40101]EM40101A.;51',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_em40101_1_147"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
performance goals that may be selected include one or more of the following: (1)&nbsp;earnings (including earnings per share and net earnings); (2)&nbsp;earnings before interest, taxes and
depreciation; (3)&nbsp;earnings before interest, taxes, depreciation and amortization; (4)&nbsp;earnings before interest, taxes, depreciation, amortization and legal settlements;
(5)&nbsp;earnings before interest, taxes, depreciation, amortization, legal settlements and other income (expense); (6)&nbsp;earnings before interest, taxes, depreciation, amortization, legal
settlements, other income (expense) and stock-based compensation; (7)&nbsp;earnings before interest, taxes, depreciation, amortization, legal settlements, other income (expense), stock-based
compensation and changes in deferred revenue; (8)&nbsp;total stockholder return; (9)&nbsp;return on equity or average stockholder's equity; (10)&nbsp;return on assets, investment or capital
employed; (11)&nbsp;stock price; (12)&nbsp;margin (including gross margin); (13)&nbsp;income (before or after taxes); (14)&nbsp;operating income; (15)&nbsp;operating income after taxes;
(16)&nbsp;pre-tax profit; (17)&nbsp;operating cash flow; (18)&nbsp;sales or revenue targets; (19)&nbsp;increases in revenue or product revenue; (20)&nbsp;expenses and cost reduction goals;
(21)&nbsp;improvement in or attainment of working capital levels; (22)&nbsp;economic value added (or an equivalent metric); (23)&nbsp;market share; (24)&nbsp;cash flow; (25)&nbsp;cash flow
per share; (26)&nbsp;share price performance; (27)&nbsp;debt reduction; (28)&nbsp;implementation or completion of projects or processes (including, without limitation, clinical trial initiation,
clinical trial enrollment, clinical trial results, new and supplemental indications for existing products, regulatory filing submissions, regulatory filing acceptances, regulatory or advisory
committee interactions, regulatory approvals and product supply); (29)&nbsp;stockholders' equity; (30)&nbsp;capital expenditures; (31)&nbsp;debt levels; (32)&nbsp;operating profit or net
operating profit; (33)&nbsp;workforce diversity; (34)&nbsp;growth of net income or operating income; (35)&nbsp;billings; (36)&nbsp;bookings; (37)&nbsp;employee retention;
(38)&nbsp;initiation of phases of clinical trials and/or studies by specific dates; (39)&nbsp;patient enrollment rates; (40)&nbsp;budget management; (41)&nbsp;submission to, or approval by, a
regulatory body (including, but not limited to the U.S. Food and Drug Administration) of an applicable filing or a product candidate; (42)&nbsp;regulatory milestones; (43)&nbsp;progress of
internal research or clinical programs; (44)&nbsp;progress of partnered programs; (45)&nbsp;partner satisfaction; (46)&nbsp;timely completion of clinical trials; (47)&nbsp;submission of INDs
and new drug applications and other regulatory achievements; (48)&nbsp;research progress, including the development of programs; (49)&nbsp;strategic partnerships or transactions (including
in-licensing and out-licensing of intellectual property); and (50)&nbsp;to the extent that an award is not intended to comply with Section&nbsp;162(m) of the Code, other measures of performance
selected by our board of directors. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
performance goals may be based on a company-wide basis, with respect to one or more business units, divisions, affiliates, or business segments, and in either absolute terms or relative to the
performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise (i)&nbsp;in the award agreement at the time the award is granted or
(ii)&nbsp;in such other document setting forth the performance goals at the time the goals are established, we will appropriately make adjustments in the method of calculating the attainment of
performance goals as follows: (1)&nbsp;to exclude restructuring and/or other nonrecurring charges; (2)&nbsp;to exclude exchange rate effects; (3)&nbsp;to exclude the effects of changes to
generally accepted accounting principles; (4)&nbsp;to exclude the effects of any statutory adjustments to corporate tax rates; (5)&nbsp;to exclude the effects of any "extraordinary items" as
determined under generally accepted accounting principles; (6)&nbsp;to exclude the dilutive effects of acquisitions or joint ventures; (7)&nbsp;to assume that any business divested by us achieved
performance objectives at targeted levels during the balance of a performance period following such divestiture; (8)&nbsp;to exclude the effect of any change in the outstanding shares of our common
stock by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, spin-off, combination or exchange of shares or other similar corporate
change, or any distributions to common stockholders other than regular cash dividends; (9)&nbsp;to exclude the effects of stock-based compensation and the award of bonuses under our bonus plans;
(10)&nbsp;to exclude costs incurred in connection with potential acquisitions or divestitures that are
required to be expensed under generally accepted accounting principles; (11)&nbsp;to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally
accepted accounting principles; (12)&nbsp;to exclude the effect of any other unusual, non-recurring gain or loss or other extraordinary item; and (13)&nbsp;to exclude the effects of the timing of
acceptance for review and/or approval of submissions to the FDA </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>147</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=149,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=141426,FOLIO='147',FILE='DISK112:[15ZCH1.15ZCH40101]EM40101A.;51',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_em40101_1_148"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>or
any other regulatory body. In addition, we retain the discretion to reduce or eliminate the compensation or economic benefit due upon attainment of the performance goals and to define the manner of
calculating the performance criteria we select to use for such performance period. The performance goals may differ from participant to participant and from award to award. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><I> Other Stock Awards.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The plan administrator may grant other awards based in whole or in part by reference to our common stock. The plan administrator will set the
number of shares under the stock award and all other terms and conditions of such awards. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Changes to Capital Structure.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In the event that there is a specified type of change in our capital structure, such as a stock split or recapitalization, appropriate
adjustments will be made to (1)&nbsp;the class and maximum number of shares reserved for issuance under the 2015 Plan, (2)&nbsp;the class and maximum number of shares by which the share reserve
may increase automatically each year, (3)&nbsp;the class and maximum number of shares that may be issued upon the exercise of ISOs, (4)&nbsp;the class and maximum number of shares subject to stock
awards that can be granted in a calendar year (as established under the 2015 Plan pursuant to Section&nbsp;162(m) of the Code) and (5)&nbsp;the class and number of shares and exercise price,
strike price, or purchase price, if applicable, of all outstanding stock awards. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Corporate Transactions.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In the event of certain specified significant corporate transactions, the plan administrator has the discretion to take any of the following
actions with respect to stock awards:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> arrange for the assumption, continuation or substitution of a stock award by a
surviving or acquiring entity or parent company; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> arrange for the assignment of any reacquisition or repurchase rights held by us
to the surviving or acquiring entity or parent company; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  accelerate the vesting of the stock award and provide for its termination prior
to the effective time of the corporate transaction; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> arrange for the lapse of any reacquisition or repurchase right held by us; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> cancel or arrange for the cancellation of the stock award in exchange for such
cash consideration, if any, as our board of directors may deem appropriate; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> make a payment equal to the excess of (1)&nbsp;the value of the property the
participant would have received upon exercise of the stock award over (2)&nbsp;the exercise price otherwise payable in connection with the stock award. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Our
plan administrator is not obligated to treat all stock awards, even those that are of the same type, in the same manner. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Under
the 2015 Plan, a corporate transaction is generally the consummation of (1)&nbsp;a sale or other disposition of all or substantially all of our consolidated assets, (2)&nbsp;a sale or other
disposition of at least 90% of our outstanding securities, (3)&nbsp;a merger, consolidation or similar transaction following which we are not the surviving corporation, or (4)&nbsp;a merger,
consolidation or similar transaction following which we are the surviving corporation but the shares of our common stock outstanding immediately prior to such transaction are converted or exchanged
into other property by virtue of the transaction. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Change of Control.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The plan administrator may provide, in an individual award agreement or in any other written agreement between a participant and us that the
stock award will be subject to additional acceleration of vesting and exercisability in the event of a change of control. For example, certain of our employees may receive an award agreement that
provides for vesting acceleration upon the individual's termination without cause or resignation for good reason (including a material reduction in the individual's base salary, duties,
responsibilities or authority, or a material relocation of the individual's principal place of employment with us) in connection with a change of control. Under the 2015 Plan, a change of control is
generally (1)&nbsp;the acquisition by a person or entity of more than 50% of our combined voting power other than by merger, consolidation or similar transaction; (2)&nbsp;a consummated merger,
consolidation or similar transaction immediately after which our stockholders cease to own more than 50% of the combined voting </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>148</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=150,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=343313,FOLIO='148',FILE='DISK112:[15ZCH1.15ZCH40101]EM40101A.;51',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_em40101_1_149"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>power
of the surviving entity; (3)&nbsp;a consummated sale, lease or exclusive license or other disposition of all or substantially of our consolidated assets; or (4)&nbsp;the replacement of a
majority of the directors who were on the board of directors at the time the 2015 Plan became effective, or the Incumbent Board, by directors who were not elected to the board by a majority of the
directors who were sitting on the Incumbent Board. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Amendment and Termination.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors has the authority to amend, suspend, or terminate our 2015 Plan, provided that such action does not materially
impair the existing rights of any participant without such participant's written consent. No ISOs may be granted after the tenth anniversary of the date our board of directors adopted our 2015 Plan. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


2016 Employee Stock Purchase Plan  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In April 2016, our board of directors and stockholders approved the 2016 Employee Stock Purchase Plan (ESPP), in order to enable eligible employees to
purchase shares of our common stock at a discount following the date of this offering. The ESPP became effective immediately upon the execution and delivery of the underwriting agreement related to
this offering. The purpose of the ESPP is to retain the services of new employees and secure the services of new and existing employees while providing incentives for such individuals to exert maximum
efforts toward our success and that of our affiliates. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Share Reserve.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The ESPP authorizes the issuance of 150,000&nbsp;shares of our common stock pursuant to purchase rights granted to our employees or to employees of
any of our designated affiliates. The number of shares of our common stock reserved for issuance will automatically increase on January&nbsp;1 of each calendar year, from January&nbsp;1, 2017
(assuming the ESPP becomes effective before such date) through January&nbsp;1, 2026 by the least of (1)&nbsp;1.0% of the total number of shares of our common stock outstanding on
December&nbsp;31 of the preceding calendar year and (2)&nbsp;75,000&nbsp;shares. The ESPP is intended to qualify as an "employee stock purchase plan" within the meaning of Section&nbsp;423 of
the Code. As of the date hereof, no shares of our common stock have been purchased under the ESPP. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Administration.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors has delegated its authority to administer the ESPP to our compensation committee. The ESPP is implemented through a series of
offerings of purchase rights to eligible employees. Under the ESPP, we may specify offerings with durations of not more than 27&nbsp;months, and may specify shorter purchase periods within each
offering. Each offering will have one or more purchase dates on which shares of our common stock will be purchased for employees participating in the offering. An offering may be terminated under
certain circumstances. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Payroll Deductions.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Generally, all regular employees, including executive officers, employed by us or by any of our designated affiliates, may participate in the
ESPP and may contribute, normally through payroll deductions, up to an amount determined by the board of directors, but not exceeding 15% of their earnings for the purchase of our common stock under
the ESPP. Unless otherwise determined by our board of directors, common stock will be purchased for accounts of employees participating in the ESPP at a price per share equal to the lower of
(1)&nbsp;85% of the fair market value of a share of our common stock on the first date of an offering or (2)&nbsp;85% of the fair market value of a share of our common stock on the date of
purchase. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Limitations.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Employees may have to satisfy one or more of the following service requirements before participating in the ESPP, as determined by our board of
directors: (1)&nbsp;customarily employed for more than 20&nbsp;hours per week, (2)&nbsp;customarily employed for more than five months per calendar year or (3)&nbsp;continuous employment with
us or one of our affiliates for a period of time, not to exceed two years. No employee may purchase shares under the ESPP at a rate in excess of $25,000 worth of our common stock based on the fair
market value per share of our common stock at the beginning of an offering for each year such a purchase right is outstanding. Finally, no employee will be eligible for the grant of any purchase
rights under the ESPP if immediately after such rights are granted, such employee has voting power over 5% or more of our outstanding capital stock measured by vote or value pursuant to
Section&nbsp;424(d) of the Code. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>149</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=151,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=998641,FOLIO='149',FILE='DISK112:[15ZCH1.15ZCH40101]EM40101A.;51',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_em40101_1_150"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Changes to Capital Structure.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In the event that there occurs a change in our capital structure through such actions as a stock split, merger, consolidation,
reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, liquidating dividend, combination of shares, exchange of
shares, change in corporate structure or similar transaction, the board of directors will make appropriate adjustments to (1)&nbsp;the number of shares reserved under the ESPP, (2)&nbsp;the
maximum number of shares by which the share reserve may increase automatically each year and (3)&nbsp;the number of shares and purchase price of all outstanding purchase rights. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><I> Corporate Transactions.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In the event of certain significant corporate transactions, including the consummation of: (1)&nbsp;a sale of all our assets,
(2)&nbsp;the sale or disposition of 90% of our outstanding securities, (3)&nbsp;a merger or consolidation where we do not survive the transaction and (4)&nbsp;a merger or consolidation where we
do survive the transaction but the shares of our common stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction, any
then-outstanding rights to purchase our stock under the ESPP may be assumed, continued or substituted for by any surviving or acquiring entity (or its parent company). If the surviving or acquiring
entity (or its parent company) elects not to assume, continue or substitute for such purchase rights, then the participants' accumulated payroll contributions will be used to purchase shares of our
common stock within ten business days prior to such corporate transaction, and such purchase rights will terminate immediately. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Plan Amendments, Termination.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors has the authority to amend or terminate our ESPP, provided that except in certain circumstances any such
amendment or termination may not materially impair any outstanding purchase rights without the holder's consent. We will obtain stockholder approval of any amendment to our ESPP as required by
applicable law or listing requirements. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Non-Employee Director Compensation  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our non-employee directors currently receive share-based compensation which is intended to encourage non-employee directors to continue to serve on
our board of directors, further align the interests of the directors and stockholders, and attract new non-employee directors with outstanding
qualifications. Directors who are employees or officers of the Company do not receive any additional compensation for Board service. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
the year ended December&nbsp;31, 2014, we did not have any non-employee directors; therefore, we did not pay any fees to, make any equity awards or non-equity awards to, or pay any other
compensation to non-employee members of our board of directors and none of our non-employee directors held any outstanding equity awards as of December&nbsp;31, 2014. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
following table provides compensation information for the fiscal year ended December&nbsp;31, 2015 for each non-employee member of our Board. </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="44pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="44pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="44pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:21pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,21pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Stock<BR>
Awards<BR>
($)<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font> </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Option<BR>
Awards<BR>
($)<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font> </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Total ($) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>P. Kent Hawryluk<SUP>(3)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,700</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,700</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Kenneth Kousky<SUP>(4)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,271</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,271</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pedro Lichtinger<SUP>(5)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>71,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>71,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Andrew Sassine<SUP>(6)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>25,698</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>25,698</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
amounts reported do not reflect the amounts actually received by our non-employee directors. Instead, these amounts reflect the aggregate
grant date fair value of each equity award granted to our non-employee directors during the fiscal year ended December 31, 2015, as computed in accordance with ASC 718. Assumptions used in the
calculation of these </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>150</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=152,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=825935,FOLIO='150',FILE='DISK112:[15ZCH1.15ZCH40101]EM40101A.;51',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_em40101_1_151"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">amounts
are included in Note 9 to our financial statements included in this prospectus. As required by SEC rules, the amounts shown exclude the impact of estimated forfeitures related to service-based
vesting conditions.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Stock
option awards were granted under our 2015 Plan.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Reflects
32,062&nbsp;shares of restricted stock awarded upon Mr.&nbsp;Hawryluk's appointment as director. The shares vest quarterly over a
two-year period commencing in February 2015. The amounts reported represent the grant date fair value of the shares which is based on the share price of our common stock on the grant date of $0.209.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(4)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Reflects
stock options for 8,016&nbsp;shares of common stock upon Mr.&nbsp;Kousky's appointment as director. The options vest monthly over
a 12-month period commencing in June 2015. The amounts reported represent the grant date fair value of the stock options. Valuation assumptions used in determining the grant date fair value are
included in Note&nbsp;9 to our financial statements included in this prospectus. The grant date fair value of each stock option was $0.783.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(5)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Reflects
stock options for 32,062&nbsp;shares of common stock upon Mr.&nbsp;Lichtinger's appointment as director. The options vest monthly
over a two-year period commencing in December 2015. The amounts reported represent the grant date fair value of the stock options. Valuation assumptions used in Black-Scholes option-pricing model in
determining the grant date fair value are: expected stock price volatility, 72.0%; expected life of options, 5.5&nbsp;years; expected dividend yield, 0%; and, risk free interest rate, 1.8%. The
grant date fair value of each stock option was $2.214.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(6)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Reflects
stock options for 32,062&nbsp;shares of common stock upon Mr.&nbsp;Sassine's appointment as director. The options vest monthly
over a two-year period commencing in June 2015. The amounts reported represent the grant date fair value of the stock options. Valuation assumptions used in determining the grant date fair value are
included in Note&nbsp;9 to our financial statements included in this prospectus. The grant date fair value of each stock option was $0.802. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>As of December&nbsp;31, 2015, Mr.&nbsp;Hawryluk had 32,062&nbsp;shares of restricted stock outstanding and each of the following non-employee directors had
shares underlying outstanding stock options as follows: Mr.&nbsp;Kousky, 8,016; Mr.&nbsp;Lichtinger, 32,062; and Mr.&nbsp;Sassine, 32,062. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have adopted a policy for compensating our non-employee directors with a combination of cash and equity that will become effective following the closing of this offering. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>151</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=153,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=826762,FOLIO='151',FILE='DISK112:[15ZCH1.15ZCH40101]EM40101A.;51',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_eo40101_1_152"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="eo40101_certain_relationships_and_related_party_transactions"> </A>
<A NAME="toc_eo40101_1"> </A>
<BR></FONT><FONT SIZE=2><B>  CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following includes a summary of transactions since January&nbsp;1, 2012 to which we have been a party, in which the amount involved in the
transaction exceeded $120,000, and in which any of our directors, executive officers or, to our knowledge, beneficial owners of more than 5% of our capital stock or any member of the immediate family
of any of the foregoing persons had or will have a direct or indirect material interest, other than equity and other compensation, termination, change of control and other arrangements, which are
described under "Executive Officer and Director Compensation." </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Merger with Michigan Life Therapeutics,&nbsp;LLC  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In November 2014, pursuant to the Plan and Agreement of Merger with MLT, Dr.&nbsp;Bisgaier, our Chief Scientific Officer, chairman of our board of
directors and co-founder, and Mr.&nbsp;Lowenschuss,
our Chief Legal Officer, Secretary and co-founder, who were the only two members of MLT, received 1,192,690 and 795,127&nbsp;shares of our common stock, respectively, of which 238,538&nbsp;shares
and 318,051&nbsp;shares, respectively, are subject to vesting schedules pursuant to the employee agreements with such officers. Dr.&nbsp;Bisgaier and Mr.&nbsp;Lowenschuss are also both
beneficial owners of more than 5% of our capital stock. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Lease with Michigan Life Ventures,&nbsp;LLC  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On January&nbsp;1, 2015, we entered into an office space sublease agreement with MLV. Pursuant to the lease, as amended, we currently lease an
approximately 1,450 square foot facility in Northville, Michigan for a fixed rental fee of $2,500 per month, plus monthly cleaning fees. The current lease expires on December&nbsp;31, 2016.
Dr.&nbsp;Bisgaier, our Chief Scientific Officer, Chairman of our board of directors and co-founder, and Mr.&nbsp;Lowenschuss, our Chief Legal Officer, Secretary and co-founder, are members of MLV.
Dr.&nbsp;Bisgaier and Mr.&nbsp;Lowenschuss are also both beneficial owners of more than 5% of our capital stock. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Pfizer&nbsp;Inc. License Agreement  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In April 2011, we entered into the Pfizer Agreement for a worldwide exclusive license to certain patent rights to make, use, sell, offer for sale and
import the clinical product candidate gemcabene. In exchange for this license, we agreed to issue shares of our common stock to Pfizer representing 15% of our fully diluted capital at the close of our
first arms-length Series&nbsp;A financing. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
agreed to make milestone payments totaling up to $37&nbsp;million upon the achievement of certain milestones, including the first regulatory submission in any country, regulatory approval in each
of the United States, Europe and Japan, the first anniversary of the first regulatory approval in any country, and upon achieving certain aggregate sales levels of gemcabene or any product containing
gemcabene. Future milestone payments under the Pfizer Agreement, if any, are not expected to begin for at least several years and extend over a number of subsequent years. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
have also agreed to pay Pfizer tiered royalties on a country-by-country basis based upon the annual amount of net sales as specified in the Pfizer Agreement until expiration of the last valid claim
of the licensed patent rights, including any patent term extensions or supplemental protection certificates. The royalty rates range from the high single digits to the low teens depending on the level
of net sales. Under the Pfizer Agreement we are obligated to use commercially reasonable efforts to develop and commercialize gemcabene. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
March 2015, upon the closing of our Series&nbsp;A preferred stock financing, we issued 675,250&nbsp;shares of our common stock to Pfizer in connection with the first equity payment, pursuant to
which Pfizer became the owner of more than 5% of our capital stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Pfizer Agreement will expire upon expiration of the last royalty term. Either party may terminate the Pfizer Agreement for the other party's uncured material breach and specified bankruptcy
events. Pfizer may terminate the Pfizer Agreement if we or any of our sublicensees challenge the validity, enforceability or ownership of the licensed patents. Additionally, Pfizer may revoke the
license if we are unable to adequately commercialize gemcabene by April 2021. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>152</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=154,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=458834,FOLIO='152',FILE='DISK112:[15ZCH1.15ZCH40101]EO40101A.;79',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_eo40101_1_153"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Promissory Notes, Convertible Note Financings and Preferred Stock  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>From March 2009 to October 2014, we borrowed an aggregate of $318,200 from, and issued promissory notes to, Dr.&nbsp;Bisgaier and our former Chief
Operating Officer, Ms.&nbsp;McShane. These promissory notes were refinanced in connection with the convertible note financing discussed below. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>On
November&nbsp;1, 2014, we entered into a convertible note financing pursuant to which we issued 8% convertible notes in an aggregate principal amount of $2.7&nbsp;million to various investors
from November&nbsp;1, 2014 to February&nbsp;18, 2015. On March&nbsp;31, 2015, we also entered into a stock purchase agreement pursuant to which we agreed to issue and sell to various investors
shares of our Series&nbsp;A convertible preferred stock at a per share price of $6.70585 (which was adjusted from $2.15 in connection with the 1-for-3.119 reverse split of our stock, which became
effective April&nbsp;27, 2016). In connection with the stock purchase agreement, 125% of the unpaid principal plus any unpaid accrued interest on the notes was converted into shares of our
Series&nbsp;A convertible preferred stock. Each share of Series&nbsp;A convertible preferred stock will convert into one share of our common stock upon the closing of this offering. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
following table summarizes the principal amount of convertible notes and shares of Series&nbsp;A convertible preferred stock purchased or received upon conversion by members of our board of
directors, executive officers or related parties. </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="67pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="86pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="74pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="73pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="73pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:71pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Name of Noteholder

<!-- COMMAND=ADD_SCROPPEDRULE,71pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Principal<BR>
Amount of<BR>
Convertible<BR>
Note ($) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Shares of Series&nbsp;A<BR>
Convertible Preferred Stock<BR>
Received Upon<BR>
Conversion (#) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Value of Shares<BR>
of Series&nbsp;A<BR>
Convertible Preferred Stock<BR>
Received Upon<BR>
Conversion<BR>
of Principal<BR>
and Interest ($) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Additional<BR>
Series&nbsp;A<BR>
Convertible Preferred Stock<BR>
Investment (#) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Additional<BR>
Series&nbsp;A<BR>
Convertible Preferred Stock<BR>
Investment ($) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>The Charles L. Bisgaier Trust Dated November&nbsp;8, 2000<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>311,517</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>59,561</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>399,406</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>The Margaret M. McShane Revocable Trust<SUP>(2)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>47,532</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>9,088</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>60,942</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Arvinder S. Sooch Trust Dated September 2006<SUP>(3)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>40,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7,567</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>50,743</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3,511</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>23,544</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Edward Lowenschuss<SUP>(4)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>25,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,708</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>31,574</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>18,641</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>125,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michelle Johnson<SUP>(5)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>25,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,693</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>31,467</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>P. Kent Hawryluk Revocable Trust<SUP>(6)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7,457</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>50,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Andrew Sassine<SUP>(7)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>400,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>75,080</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>503,473</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>BWA Gemphire Investment Group,&nbsp;LLC<SUP>(8)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>95,439</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>640,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Western Michigan University Research Foundation acting on behalf of Biosciences Research and Commercialization Center<SUP>(9)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>250,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>46,997</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>315,150</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Dr.&nbsp;Bisgaier,
our Chief Scientific Officer and Chairman of our board of directors and a beneficial owner of more than 5% of our capital
stock, is the trustee of The Charles&nbsp;L. Bisgaier Trust Dated November&nbsp;8, 2000.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Ms.&nbsp;McShane,
our former Chief Operating Officer is the trustee of The Margaret&nbsp;M. McShane Revocable Trust.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
spouse of Ms.&nbsp;Sooch, our Chief Executive Officer and a member of our board of directors and a beneficial owner of more than 5% of
our capital stock, is the trustee of the Arvinder&nbsp;S.&nbsp;Sooch Trust Dated September 2006. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>153</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=155,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=1048247,FOLIO='153',FILE='DISK112:[15ZCH1.15ZCH40101]EO40101A.;79',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_eo40101_1_154"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(4)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Edward
Lowenschuss is the brother of Mr.&nbsp;Lowenschuss, our Chief Legal Officer and Secretary and a beneficial owner of more than 5% of
our capital stock.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(5)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Michelle
Johnson is the sister-in-law of Dr.&nbsp;Bisgaier, our Chief Scientific Officer and Chairman of our board of directors and a
beneficial owner of more than 5% of our capital stock.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(6)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Mr.&nbsp;Hawryluk
is a member of our board of directors.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(7)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Mr.&nbsp;Sassine
is a member of our board of directors.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(8)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Kenneth
Kousky, a member of our board of directors, is the manager of BWA Gemphire Investment Group,&nbsp;LLC.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(9)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Stephen
Haakenson, a former member of our board of directors, is an Executive Director of Biosciences Research&nbsp;&amp; Commercialization
Center. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>On July&nbsp;31, 2015, December&nbsp;11, 2015, February&nbsp;25,&nbsp;2016 and April&nbsp;14, 2016, we entered into convertible note financings in
which we issued 8% convertible notes in an aggregate principal amount of $10.6&nbsp;million to various investors. Under the terms of the convertible notes, upon the closing of a convertible
preferred stock financing of at least $5&nbsp;million, 125% of the outstanding principal and accrued interest under such notes shall convert into shares of the same series of stock issued in such
financing at a conversion price equal to the per share price of the stock issued in such financing. In the event that we approve a change of control transaction or firmly underwritten public offering
of our common stock prior to the consummation of such a stock financing, the outstanding principal, plus accrued interest, under such notes shall automatically convert into shares of our common stock
at a conversion price of $6.70585 per share (which was adjusted from $2.15 in connection with the 1-for-3.119 reverse split of our stock, which became effective on April&nbsp;27, 2016) immediately
prior to the closing of such transaction. In the event that a stock financing, change of control or initial public offering has not occurred, the convertible notes will become payable on demand
anytime after December&nbsp;31, 2016. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
following table summarizes the principal amount of convertible notes purchased by members of our board of directors, executive officers or related parties. </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="63pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:71pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Name of Noteholder

<!-- COMMAND=ADD_SCROPPEDRULE,71pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Principal<BR>
Amount of<BR>
Convertible<BR>
Note($) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>The Charles L. Bisgaier Trust Dated November&nbsp;8, 2000<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>100,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>The Margaret M. McShane Revocable Trust<SUP>(2)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>20,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Arvinder S. Sooch Trust Dated September 2006<SUP>(3)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>175,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Edward Lowenschuss<SUP>(4)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>150,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michelle Johnson<SUP>(5)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>50,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>P. Kent Hawryluk Revocable Trust<SUP>(6)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>150,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Andrew Sassine<SUP>(7)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>200,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Western Michigan University Research Foundation acting on behalf of Biosciences Research and Commercialization Center<SUP>(8)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>100,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>The Beverly Selnick Revocable Living Trust<SUP>(9)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>75,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bisgaier Family,&nbsp;LLC<SUP>(10)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>125,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jeffrey S.&nbsp;Mathiesen<SUP>(11)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>25,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>BWA Gemphire Investment Group II,&nbsp;LLC<SUP>(12)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>746,500</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pedro Lichtinger<SUP>(13)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>250,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dena Marie Bisgaier<SUP>(14)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>25,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stanley Bisgaier<SUP>(15)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>25,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Excel Venture Fund&nbsp;II, L.P.<SUP>(16)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,000,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Dr.&nbsp;Bisgaier,
our Chief Scientific Officer, Chairman of our board of directors and a beneficial owner of more than 5% of our capital
stock, is the trustee of The Charles&nbsp;L. Bisgaier Trust Dated November&nbsp;8, 2000. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>154</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=156,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=569233,FOLIO='154',FILE='DISK112:[15ZCH1.15ZCH40101]EO40101A.;79',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_eo40101_1_155"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Ms.&nbsp;McShane,
our former Chief Operating Officer is the trustee of The Margaret&nbsp;M. McShane Revocable Trust.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
spouse of Ms.&nbsp;Sooch, our Chief Executive Officer, a member of our board of directors and a beneficial owner of more than 5% of our
capital stock, is the trustee of the Arvinder&nbsp;S.&nbsp;Sooch Trust Dated September 2006.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(4)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Edward
Lowenschuss is the brother of Mr.&nbsp;Lowenschuss, our Chief Legal Officer and Secretary and a beneficial owner of more than 5% of
our capital stock.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(5)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Michelle
Johnson is the sister-in-law of Dr.&nbsp;Bisgaier, our Chief Scientific Officer, Chairman of our board of directors and a
beneficial owner of more than 5% of our capital stock.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(6)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Mr.&nbsp;Hawryluk
is a member of our board of directors.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(7)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Mr.&nbsp;Sassine
is a member of our board of directors.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(8)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Stephen
Haakenson, a former member of our board of directors, is an Executive Director of Biosciences Research&nbsp;&amp; Commercialization
Center.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(9)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Ms.&nbsp;Selnick,
the mother of Mr.&nbsp;Lowenschuss, our Chief Legal Officer and Secretary and a beneficial owner of more than 5% of our
capital stock, is the trustee of The Beverly Selnick Revocable Living Trust.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(10)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Dr.&nbsp;Bisgaier,
our Chief Scientific Officer, Chairman of our board of directors and a beneficial owner of more than 5% of our capital
stock, is the manager of the Bisgaier Family,&nbsp;LLC.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(11)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Mr.&nbsp;Mathiesen,
our Chief Financial Officer, holds these notes jointly with his spouse.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(12)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Kenneth
Kousky, a member of our board of directors, is the manager of BWA Gemphire Investment Group II,&nbsp;LLC.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(13)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Mr.&nbsp;Lichtinger
is a member of our board of directors.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(14)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Ms.&nbsp;Bisgaier
is the daughter of Dr.&nbsp;Bisgaier, our Chief Scientific Officer, Chairman of our board of directors and a beneficial
owner of more than 5% of our capital stock.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(15)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Mr.&nbsp;Bisgaier
is the son of Dr.&nbsp;Bisgaier, our Chief Scientific Officer, Chairman of our board of directors and a beneficial
owner of more than 5% of our capital stock.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(16)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Dr.
Gullans, a member of our board of directors, is the Manager of Excel Venture Fund&nbsp;II, L.P. </FONT></DD></DL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Investor Agreements  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On November&nbsp;1, 2014, we entered into a shareholders agreement with the Charles&nbsp;L. Bisgaier Trust dated November&nbsp;8, 2000, as
amended, of which Dr.&nbsp;Bisgaier is the Trustee, Mr.&nbsp;Lowenschuss, Ms.&nbsp;McShane, Dr.&nbsp;Oniciu and Ms.&nbsp;Sooch. The agreement contains rights of first offer, drag-along
rights and tag-along rights. These rights will terminate upon the closing of this offering. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On
November&nbsp;1, 2014, we entered into a voting agreement with the Charles L. Bisgaier Trust dated November&nbsp;8, 2000, as amended, of which Dr.&nbsp;Bisgaier is the Trustee,
Mr.&nbsp;Lowenschuss, Ms.&nbsp;McShane, Dr.&nbsp;Oniciu and Ms.&nbsp;Sooch (collectively, the "Voting Agreement Shareholders"). The agreement obligates the Voting Agreement Shareholders to
vote all of their shares of capital stock so as to elect three members of the Board as designated by the Voting Agreement Shareholders. These rights will terminate upon the closing of this offering. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
connection with our Series&nbsp;A convertible preferred stock financing, we entered into an investor rights agreement and right of first refusal and co-sale agreement containing voting rights,
information rights, rights of first refusal and co-sale and registration rights, among other things, with each of the holders of our Series&nbsp;A convertible preferred stock. On April&nbsp;14,
2016, we amended the investor rights agreement to provide registration rights to certain holders of our convertible notes. As detailed above, certain members of our board of directors, executive
officers and related parties are holders of our Series&nbsp;A convertible preferred stock. These rights will terminate upon the closing of this offering, except for the registration rights as more
fully described below in "Description of Capital Stock&nbsp;&#151; Registration Rights." </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>155</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=157,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=290671,FOLIO='155',FILE='DISK112:[15ZCH1.15ZCH40101]EO40101A.;79',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_eo40101_1_156"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Indemnification Agreements  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have entered, and intend to continue to enter, into separate indemnification agreements with our directors and executive officers, in addition to
the indemnification provided for in our amended and restated certificate of incorporation and amended and restated bylaws, which will become effective immediately prior to the closing of this
offering. For more information regarding these indemnification arrangements, see "Management&nbsp;&#151; Limitation on Liability and Indemnification of Directors and Officers." We believe
that these provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Potential Insider Participation in this Offering  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Certain of our existing security holders, their affiliated entities, other entities and individuals associated with us and them have indicated an
interest in purchasing approximately $10&nbsp;million of shares (or 1,000,000 shares) in the aggregate of our common stock in this offering at the initial public offering price. The underwriters
will receive the same underwriting discount on any shares purchased by these entities as they will on any other shares sold to the public in this offering. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Directed Share Program  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>At our request, the underwriters have reserved up to 10% of the shares of our common stock offered by this prospectus for sale, at the initial public
offering price, to our directors, officers, employees and other individuals associated with us and members of their respective families. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
directed share program will not limit the ability of such persons to purchase more than $120,000 in value of our common stock. We do not currently know the extent to which these related persons
will participate in the directed share program, if at all. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Policies and Procedures for Transactions with Related Parties  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The charter of our audit committee provides that it is the responsibility of our audit committee to review, approve and oversee any transaction
between us and any related person and any other potential conflict of interest situations on an ongoing basis, in accordance with our policies and procedures, and to develop policies and procedures
for the approval of related party transactions. Related party transactions also may be reviewed and approved at the full board level. Prior to consideration of a transaction with a related person, the
material facts as to the related person's relationship or interest in the transaction are disclosed to our audit committee or the disinterested directors. The transaction is not approved unless a
majority of the members of the committee or the full board who are not interested in the transaction approve the transaction. The audit committee takes into account, among other factors that it deems
appropriate, whether the related person transaction is on terms no less favorable to us than terms generally available in a transaction with an unrelated third-party under the same or similar
circumstances and the extent of the related person's interest in the related
person transaction. Our current policy with respect to approval of related person transactions is not set forth in writing. We expect to adopt a written related person transaction policy to be
effective upon the closing of this offering. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>156</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=158,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=852639,FOLIO='156',FILE='DISK112:[15ZCH1.15ZCH40101]EO40101A.;79',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_eq40101_1_157"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="eq40101_principal_stockholders"> </A>
<A NAME="toc_eq40101_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PRINCIPAL STOCKHOLDERS    <BR>    </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The following table sets forth information regarding beneficial ownership of our capital stock by:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> each person, or group of affiliated persons, known by us to beneficially own
more than 5% of our common stock; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> each of our named executive officers; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> each of our directors; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> all of our current executive officers and directors as a group. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Beneficial
ownership prior to this offering is based on 6,242,500&nbsp;shares of common stock outstanding as of May&nbsp;2, 2016, and assumes (i)&nbsp;the automatic conversion of all outstanding
shares of our preferred stock into 745,637&nbsp;shares of common stock, (ii)&nbsp;the automatic conversion of the principal and accrued and unpaid interest outstanding as of the expected closing
date of August&nbsp;10, 2016 on our convertible notes into 1,656,807&nbsp;shares of common stock and (iii)&nbsp;the issuance of 81,568&nbsp;shares of common stock pursuant to the Accrued
Dividends described elsewhere in this prospectus in the section titled "Dividend Policy" immediately prior to the closing of the offering, based on the expected closing date of August&nbsp;10, 2016. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
percentage of shares beneficially owned after this offering is based on 9,242,500&nbsp;shares of common stock, after taking into account the assumptions described above and the issuance of
3,000,000&nbsp;shares of common stock in this offering assuming no exercise of the underwriters' option to purchase additional shares. We have assumed that no shares of our common stock are
purchased by our directors or executive officers or by the beneficial owners of more than 5% of our capital stock pursuant to the directed share program or otherwise in the offering. The table below
excludes the 1,825,200&nbsp;shares issuable upon exercise of options to be granted to certain officers, directors, employees and consultants in connection with this offering. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Certain
of our existing security holders, their affiliated entities, other entities and individuals associated with us and them have indicated an interest in purchasing approximately
$10&nbsp;million of shares (or 1,000,000 shares) in the aggregate of our common stock in this offering at the initial public offering price. The following table does not reflect any potential
purchases by these parties. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Information
with respect to beneficial ownership has been furnished by each director, officer or beneficial owner of more than 5% of our common stock. We have determined beneficial ownership in
accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those
securities. In addition, the rules include shares of our common stock issuable pursuant to the exercise of stock options that are either immediately exercisable or exercisable within 60&nbsp;days of
May&nbsp;2, 2016. These shares are deemed to be outstanding and beneficially owned by the person holding those options for the purpose of computing the percentage ownership of that person, but they
are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Unless otherwise indicated, the persons or entities identified in this table have sole voting
and investment power with respect to all shares shown as beneficially owned by them, subject to applicable community property laws. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>157</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=159,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=389587,FOLIO='157',FILE='DISK112:[15ZCH1.15ZCH40101]EQ40101A.;81',USER='CHE107256',CD=';5-AUG-2016;17:45' -->
<A NAME="page_eq40101_1_158"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Except
as otherwise noted below, the address for each person or entity listed in the table is c/o Gemphire Therapeutics&nbsp;Inc., 43334 Seven Mile Road, Suite&nbsp;1000, Northville, Michigan
48167. </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="72pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>PERCENTAGE OF<BR>
SHARES BENEFICIALLY<BR>
OWNED </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>NUMBER OF<BR>
SHARES<BR>
BENEFICIALLY<BR>
OWNED </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:171pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>NAME AND ADDRESS OF BENEFICIAL OWNER

<!-- COMMAND=ADD_SCROPPEDRULE,171pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>BEFORE<BR>
OFFERING </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>AFTER<BR>
OFFERING </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Greater than 5% stockholders</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pfizer&nbsp;Inc.<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>675,250</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.8</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7.3</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David Lowenschuss<SUP>(2)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>797,454</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>12.8</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>8.6</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Directors and Named Executive Officers</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Mina Sooch<SUP>(3)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>685,883</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>11.0</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7.4</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Charles L. Bisgaier, Ph.D.<SUP>(4)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,298,612</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>20.8</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>14.0</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jeffrey S. Mathiesen<SUP>(5)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>20,493</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Steve Gullans, Ph.D.<SUP>(6)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>306,025</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4.9</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3.3</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>P. Kent Hawryluk<SUP>(7)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>63,951</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1.0</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Kenneth Kousky<SUP>(8)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>230,785</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3.7</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2.5</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pedro Lichtinger<SUP>(9)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>48,626</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Andy Sassine<SUP>(10)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>132,512</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2.1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1.4</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All current executive officers and directors as a group (11&nbsp;persons)<SUP>(11)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3,754,644</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>59.4</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>40.3</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">*</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Represents
beneficial ownership of less than one percent.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Represents
675,250&nbsp;shares of common stock beneficially owned by Pfizer&nbsp;Inc. The address for Pfizer&nbsp;Inc. is
235&nbsp;East&nbsp;42nd&nbsp;St., New&nbsp;York, New&nbsp;York 10017.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Represents
(a)&nbsp;795,127&nbsp;shares of common stock held by Mr.&nbsp;Lowenschuss, which become fully vested upon the closing of this
offering, and (b)&nbsp;2,327&nbsp;shares underlying options to purchase common stock that are exercisable within 60&nbsp;days of May&nbsp;2, 2016.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Represents
(a)&nbsp;641,232&nbsp;shares of common stock held by Ms.&nbsp;Sooch, which become fully vested upon the closing of this
offering, (b)&nbsp;5,220&nbsp;shares underlying options to purchase common stock that are exercisable within 60&nbsp;days of May&nbsp;2, 2016, (c)&nbsp;38,219&nbsp;shares of common stock
issuable upon conversion of Series&nbsp;A convertible preferred stock and convertible notes held by Arvinder&nbsp;S. Sooch Trust dated September&nbsp;20, 2006, of which Ms.&nbsp;Sooch's spouse
is the trustee and (d)&nbsp;1,212&nbsp;shares of common stock issuable to the Arvinder&nbsp;S. Sooch Trust dated September&nbsp;20, 2006 pursuant to Accrued Dividends.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(4)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Represents
(a)&nbsp;1,192,690&nbsp;shares of common stock held by Dr.&nbsp;Bisgaier, which become fully vested upon the closing of this
offering, (b)&nbsp;4,474&nbsp;shares underlying options to purchase common stock that are exercisable within 60&nbsp;days of May&nbsp;2, 2016, (c)&nbsp;94,933&nbsp;shares of common stock
issuable upon conversion of Series&nbsp;A convertible preferred stock and convertible notes held by The Charles L. Bisgaier Trust dated November&nbsp;8, 2000, of which Dr.&nbsp;Bisgaier is the
trustee, and Bisgaier Family,&nbsp;LLC and (d)&nbsp;6,515&nbsp;shares of common stock issuable to The Charles&nbsp;L. Bisgaier Trust dated November&nbsp;8, 2000 and Bisgaier Family, LLC
pursuant to Accrued Dividends.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(5)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Represents
(a)&nbsp;16,566&nbsp;shares underlying options to purchase common stock that are exercisable within 60&nbsp;days of
May&nbsp;2, 2016 and (b)&nbsp;3,927 shares of common stock issuable upon conversion of convertible notes.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(6)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Represents
306,025&nbsp;shares of common stock issuable upon conversion of convertible notes held by Excel Venture
Fund&nbsp;II,&nbsp;L.P., of which Dr.&nbsp;Gullans is the Manager. Dr.&nbsp;Gullans may be deemed to have voting and investment power over the shares owned by Excel Venture
Fund&nbsp;II,&nbsp;L.P.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(7)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Represents
(a)&nbsp;32,062&nbsp;shares of common stock held by P.&nbsp;Kent Hawryluk, subject to vesting as described under "Executive
Officer and Director Compensation&#151;Non-Employee Director Compensation," (b)&nbsp;31,073&nbsp;shares of common stock issuable upon conversion of Series&nbsp;A convertible preferred
stock and convertible notes held by the P.&nbsp;Kent Hawryluk Revocable Trust, </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>158</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=160,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=166403,FOLIO='158',FILE='DISK112:[15ZCH1.15ZCH40101]EQ40101A.;81',USER='CHE107256',CD=';5-AUG-2016;17:45' -->
<A NAME="page_eq40101_1_159"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">of
which Mr.&nbsp;Hawryluk is the trustee and (c)&nbsp;816&nbsp;shares of common stock issuable to the P.&nbsp;Kent Hawryluk Revocable Trust pursuant to Accrued Dividends. </FONT></P>

</UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(8)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Represents
(a)&nbsp;8,016&nbsp;shares underlying options to purchase common stock exercisable within 60&nbsp;days of May&nbsp;2, 2016,
(b)&nbsp;212,330&nbsp;shares of common stock issuable upon conversion of Series&nbsp;A convertible preferred stock and convertible notes held by BWA Gemphire Investment Group, LLC or BWA
Gemphire Investment Group&nbsp;II, LLC, of which Mr.&nbsp;Kousky is a Manager and (c)&nbsp;10,439&nbsp;shares of common stock issuable to BWA Gemphire Investment Group, LLC pursuant to Accrued
Dividends. Mr.&nbsp;Kousky may be deemed to have voting and investment power over the shares owned by BWA Gemphire Investment Group,&nbsp;LLC.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(9)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Represents
(a)&nbsp;9,352&nbsp;shares underlying options to purchase common stock that are exercisable within 60&nbsp;days of
May&nbsp;2, 2016 and (b)&nbsp;39,274&nbsp;shares of common stock issuable upon conversion of convertible notes.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(10)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Represents
(a)&nbsp;17,367&nbsp;shares underlying options to purchase common stock that are exercisable within 60&nbsp;days of
May&nbsp;2, 2016, (b)&nbsp;106,933&nbsp;shares of common stock issuable upon conversion of Series&nbsp;A convertible preferred stock and convertible notes held by Mr.&nbsp;Sassine and
(c)&nbsp;8,212&nbsp;shares of common stock issuable pursuant to Accrued Dividends.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(11)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Includes
(a)&nbsp;the shares referenced in footnotes&nbsp;(2)&nbsp;-&nbsp;(10) above as well as (b)&nbsp;an additional
149,919&nbsp;shares of common stock, which will be fully vested upon the closing of this offering, 17,902&nbsp;shares underlying options to purchase common stock that are exercisable within
60&nbsp;days of May&nbsp;2, 2016, 2,237&nbsp;shares of common stock issuable upon conversion of Series&nbsp;A convertible preferred stock and 245&nbsp;shares of common stock issued pursuant
to Accrued Dividends. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>159</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=161,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=189245,FOLIO='159',FILE='DISK112:[15ZCH1.15ZCH40101]EQ40101A.;81',USER='CHE107256',CD=';5-AUG-2016;17:45' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_es40101_1_160"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="es40101_description_of_capital_stock"> </A>
<A NAME="toc_es40101_1"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF CAPITAL STOCK    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following is a summary of the rights of our common and preferred stock and some of the provisions of our amended and restated certificate of
incorporation and amended and restated bylaws that will become effective upon the closing of this offering, and of the Delaware General Corporation Law. This summary is not complete. For more detailed
information, please see our amended and restated certificate of incorporation and amended and restated bylaws, which are filed as exhibits to the registration statement of which this prospectus is a
part, as well as the relevant provisions of the Delaware General Corporation Law. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


General  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Upon the closing of this offering and the filing of our amended and restated certificate of incorporation, our authorized capital stock will consist
of 100,000,000 shares of common stock, par
value $0.001 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share. All of our authorized preferred stock upon the closing of this offering will be undesignated. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Common Stock  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Outstanding Shares  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As of May&nbsp;2, 2016, there were 3,758,488 shares of common stock outstanding, held of record by 15&nbsp;stockholders. Based on such number of
shares of common stock outstanding as of May&nbsp;2, 2016, and assuming (1)&nbsp;the conversion of all of our convertible preferred stock outstanding as of May&nbsp;2, 2016 into 745,637 shares
of common stock immediately prior to the closing of this offering, (2) the conversion of the principal and accrued and unpaid interest outstanding as of the expected closing date of August&nbsp;10,
2016 on our convertible notes into 1,656,807 shares of common stock immediately prior to the closing of this offering, (3)&nbsp;the issuance of 81,568 shares of common stock pursuant to the Accrued
Dividends described elsewhere in this prospectus in the section titled "Dividend Policy" immediately prior to the closing of the offering, based on the expected closing date of August&nbsp;10, 2016
and (4)&nbsp;the issuance by us of 3,000,000 shares of common stock in this offering, there will be 9,242,500 shares of common stock outstanding upon closing of this offering. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
of May&nbsp;2, 2016, 302,842 shares of common stock were issuable upon the exercise of stock options outstanding as of May&nbsp;2, 2016 at a weighted-average exercise price of $2.428 per share
that were issued under our 2015 Plan. Our Compensation Committee has approved the award of stock options to purchase an aggregate of 1,825,200 shares of common stock with a per share exercise price
equal to the initial public offering price, in each case pursuant to the 2015 Plan, to be granted to certain officers, directors, employees and consultants in connection with this offering. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Voting  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our common stock is entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders, including the election
of directors, and does not have cumulative voting rights. Accordingly, the holders of a plurality of the shares of our common stock present at the meeting and entitled to vote in any election of
directors can elect all of the directors standing for election. For most other
matters, the approval of a majority of the shares voting at an annual or special meeting of stockholders will be required. Exceptions to this include removing directors for cause and amending certain
sections of our amended and restated certificate of incorporation and amended and restated bylaws, which will be effective upon the closing of this offering, each of which will require the approval of
the holders of at least 66<SUP>2</SUP>/<SMALL>3</SMALL>% of the voting power of all of our then outstanding capital stock. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Dividends  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Subject to preferences that may be applicable to any then outstanding preferred stock, the holders of common stock are entitled to receive dividends,
if any, as may be declared from time to time by our board of directors out of legally available funds. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>160</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=162,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=838392,FOLIO='160',FILE='DISK112:[15ZCH1.15ZCH40101]ES40101A.;61',USER='CHE105063',CD=';5-AUG-2016;17:51' -->
<A NAME="page_es40101_1_161"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Liquidation  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in the net assets legally
available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the satisfaction of any liquidation preference granted to the holders of any
outstanding shares of preferred stock. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Rights and Preferences  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Holders of our common stock have no preemptive, conversion or subscription rights, and there are no redemption or sinking fund provisions applicable
to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of
our preferred stock that we may designate and issue in the future. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Fully Paid and Nonassessable  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>All of our outstanding shares of common stock are, and the shares of common stock to be issued in this offering will be, fully paid and nonassessable. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Convertible Preferred Stock  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As of May&nbsp;2, 2016, we had outstanding an aggregate of 745,637 shares of Series&nbsp;A convertible preferred stock held of record by 40
stockholders. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Immediately
prior to the closing of this offering, all outstanding shares of preferred stock at May&nbsp;2, 2016 will convert into 745,637 shares of our common stock and we expect to issue 81,568
shares of common stock pursuant to the Accrued Dividends described elsewhere in this prospectus in the section titled "Dividend Policy", based on an expected closing date of August&nbsp;10, 2016. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under
the amended and restated certificate of incorporation, our board of directors will have the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred
stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued
series and any qualifications, limitations or restrictions thereon and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then
outstanding. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of the common stock.
The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or
preventing a change in our control that may otherwise benefit holders of our common stock and may adversely affect the market price of the common stock and the voting and other rights of the holders
of common stock. We have no current plans to issue any shares of preferred stock. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Stock Options  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As of May&nbsp;2, 2016, 302,842 shares of common stock were issuable upon the exercise of outstanding stock options, at a weighted-average exercise
price of $2.428 per share. On April&nbsp;25 and 27, 2016, our Compensation Committee approved the award of stock options to purchase an aggregate of 1,825,200 shares of common stock with a per share
exercise price equal to the initial public offering price, in each case pursuant to the 2015 Plan, to be granted to certain officers, directors, employees and consultants in connection with this
offering. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Convertible Notes  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under the terms of our outstanding convertible notes, upon the closing of a convertible preferred stock financing of at least $5 million, 125% of the
outstanding principal, plus accrued interest, under such notes shall convert into shares of the same series of stock issued in such financing at a conversion price equal to </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>161</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=163,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=917386,FOLIO='161',FILE='DISK112:[15ZCH1.15ZCH40101]ES40101A.;61',USER='CHE105063',CD=';5-AUG-2016;17:51' -->
<A NAME="page_es40101_1_162"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>the
per share price of the stock issued in such financing. In the event that we approve a change of control transaction or firmly underwritten public offering of our common stock prior to the
consummation of such a stock financing, the outstanding principal, plus accrued interest, under such notes shall automatically convert into shares of our common stock at a conversion price of $6.70585
per share (which was adjusted from $2.15 in connection with the 1-for-3.119 reverse split of our stock, which became effective on April&nbsp;27, 2016). Convertible notes with a principal balance,
plus accrued interest, totaling $10.9&nbsp;million were outstanding as of May&nbsp;2, 2016. As of May&nbsp;2, 2016, 1,622,043 shares of common stock would have been issuable upon the conversion
of the outstanding convertible notes, if such notes had converted on such date. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Registration Rights  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Following the closing of this offering, certain holders of our common stock, or their transferees, will be entitled to the registration rights set
forth below with respect to registration of the resale of such shares under the Securities Act pursuant to the investors' rights agreement by and among us and certain of our stockholders and
convertible noteholders. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Demand Registration Rights  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>At any time beginning six months after the public offering date set forth on the cover page of this prospectus, upon the written request of certain of
the holders of the registrable securities then outstanding that we file&nbsp;a registration statement under the Securities Act covering the registration of the registrable securities having an
aggregate offering price to the public of not less than $5&nbsp;million, we will be obligated to notify all holders of registrable securities of such request and to use our reasonable best efforts
to register the sale of all registrable securities that holders may request to be registered. We are not required to effect more than two registration statements which are declared or ordered
effective. We may postpone the filing or effectiveness of a registration statement for up to 90&nbsp;days once in any twelve month period if our board of directors determines in its good faith
judgment that such registration and offering would materially and adversely affect us. With certain exceptions, we are not required to effect the filing of a registration statement during the period
starting with the date of the filing of, and ending on a date 180&nbsp;days following the effective date of the registration statement for this offering. Upon the closing of this offering, the
holders of 2,124,880 shares will be entitled to these demand registration rights. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


"Piggyback" Registration Rights  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If we register any securities for public sale, holders of registration rights will have the right to include their shares in the registration
statement. These piggyback registration rights are subject to specified conditions and limitations, including the right of the underwriters of any underwritten offering to limit the number of shares
having registration rights to be included in the registration statement, but not below 30% of the total number of shares included in the registration statement, except this offering, in which the
holders may be entirely excluded. Upon the closing of this offering, the holders of 2,124,880 shares will be entitled to these piggyback registration rights. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Form&nbsp;S-3 Registration Rights  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If we are eligible to file&nbsp;a registration statement on Form&nbsp;S-3, holders of at least 20% of the outstanding registrable securities will
have the right to demand that we file&nbsp;a registration statement on Form&nbsp;S-3 so long as the aggregate price to the public of the securities to be sold under the registration statement on
Form&nbsp;S-3 is at least $5&nbsp;million. We are not required to effect more than two registrations on Form&nbsp;S-3 in any 12-month period. The right to have such shares registered on
Form&nbsp;S-3 is further subject to other specified conditions and limitations. Upon such a request, we will be required to use our reasonable best efforts to file the registration as soon as
practicable. Upon the closing of this offering, the holders of 2,124,880 shares will be entitled to these Form&nbsp;S-3 registration rights. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>162</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=164,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=382042,FOLIO='162',FILE='DISK112:[15ZCH1.15ZCH40101]ES40101A.;61',USER='CHE105063',CD=';5-AUG-2016;17:51' -->
<A NAME="page_es40101_1_163"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Expenses of Registration  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Generally, we are required to bear all registration and selling expenses incurred in connection with the demand, piggyback and Form&nbsp;S-3
registrations described above. All selling expenses incurred in connection with such registrations shall be borne by the holders of the securities so registered. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Expiration of Registration Rights  </I></B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The demand, piggyback and Form&nbsp;S-3 registration rights discussed above will terminate as to a given holder of registrable securities upon the
earlier of (i)&nbsp;five years following the closing of this offering or (ii)&nbsp;after the consummation of a liquidation event. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Anti-Takeover Provisions  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Delaware Anti-Takeover Law  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are subject to Section&nbsp;203 of the Delaware General Corporation Law, or Section&nbsp;203. Section&nbsp;203 generally prohibits a public
Delaware corporation from engaging in a "business combination" with an "interested stockholder" for a period of three years after the date of the transaction in which the person became an interested
stockholder, unless:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> prior to the date of the transaction, the board of directors of the corporation
approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the interested stockholder owned at least 85% of the voting stock of the
corporation outstanding upon consummation of the transaction, excluding for purposes of determining the number of shares outstanding (a)&nbsp;shares owned by persons who are directors and also
officers and (b)&nbsp;shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered
in a tender or exchange offer; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> on or subsequent to the consummation of the transaction, the business
combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66<SUP>2</SUP>/<SMALL>3</SMALL>%
of the outstanding voting stock which is not owned by the interested stockholder. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Section&nbsp;203
defines a business combination to include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> any merger or consolidation involving the corporation and the interested
stockholder; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> any sale, transfer, pledge or other disposition involving the interested
stockholder of 10% or more of the assets of the corporation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> subject to exceptions, any transaction involving the corporation that has the
effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> subject to exceptions, any transaction that results in the issuance or transfer
by the corporation of any stock of the corporation to the interested stockholder; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the receipt by the interested stockholder of the benefit of any loans, advances,
guarantees, pledges or other financial benefits provided by or through the corporation. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>In
general, Section&nbsp;203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person
affiliated with or controlling or controlled by the entity or person. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>163</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=165,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=858030,FOLIO='163',FILE='DISK112:[15ZCH1.15ZCH40101]ES40101A.;61',USER='CHE105063',CD=';5-AUG-2016;17:51' -->
<A NAME="page_es40101_1_164"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Provisions of our amended and restated certificate of incorporation and amended and restated bylaws, which will become effective upon the closing of
this offering, may delay or discourage transactions involving an actual or potential change in our control or change in our management, including transactions in which stockholders might otherwise
receive a premium for their shares or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our common
stock. Among other things, our amended and restated certificate of incorporation and amended and restated bylaws:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> permit our board of directors to issue up to 10,000,000 shares of preferred
stock, with any rights, preferences and privileges as they may designate; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> provide that the authorized number of directors may be changed only by
resolution adopted by a majority of the board of directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> provide that the board of directors or any individual director may only be
removed with cause and the affirmative vote of the holders of at least 66<SUP>2</SUP>/<SMALL>3</SMALL>% of the voting power of all of our then outstanding capital stock; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> provide that all vacancies, including newly created directorships, may, except
as otherwise required by law or subject to the rights of holders of preferred stock as designated from time to time, be filled by the affirmative vote of a majority of directors then in office, even
if less than a quorum; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> divide our board of directors into three classes; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> require that any action to be taken by our stockholders must be effected at a
duly called annual or special meeting of stockholders and not be taken by written consent or electronic transmission; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> provide that stockholders seeking to present proposals before a meeting of
stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner and also specify requirements as to the form and content
of a stockholder's notice; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> do not provide for cumulative voting rights, which means that holders of a
majority of the shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> provide that special meetings of our stockholders may only be called by the
chairman of the board of directors, our Chief Executive Officer or by the board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors (whether or not
any vacancies exist); and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> provide that the Court of Chancery of the State of Delaware will be the sole and
exclusive forum for (i)&nbsp;any derivative action or proceeding brought on our behalf, (ii)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any of our directors or
officers to us or our stockholders, (iii)&nbsp;any action asserting a claim against us arising pursuant to any provision of the DGCL, or (iv)&nbsp;any action asserting a claim against us governed
by the internal affairs doctrine. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>The
amendment of any of these provisions, with the exception of the ability of our board of directors to issue shares of preferred stock and designate any rights, preferences and privileges thereto,
would require the affirmative vote of the holders of at least 66<SUP>2</SUP>/<SMALL>3</SMALL>% of the voting power of all of our then outstanding capital stock. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


NASDAQ Global Market Listing  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our common stock has been approved for listing on the NASDAQ Global Market under the symbol "GEMP." </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Transfer Agent and Registrar  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The transfer agent and registrar for our common stock is Computershare, Inc. The transfer agent and registrar's address is 250&nbsp;Royal Street,
Canton, Massachussets&nbsp;02021 and the telephone number is 781-575-2000. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>164</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=166,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=713329,FOLIO='164',FILE='DISK112:[15ZCH1.15ZCH40101]ES40101A.;61',USER='CHE105063',CD=';5-AUG-2016;17:51' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_eu40101_1_165"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="eu40101_shares_eligible_for_future_sale"> </A>
<A NAME="toc_eu40101_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SHARES ELIGIBLE FOR FUTURE SALE    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Prior to this offering, there has been no public market for our common stock. Future sales of substantial amounts of common stock in the public
market, or the possibility of these sales occurring, could adversely affect prevailing market prices. Furthermore, since only a limited number of shares will be available for sale shortly after this
offering because of contractual and legal restrictions on resale described below, sales of substantial amounts of common stock in the public market after the restrictions lapse could adversely affect
the prevailing market price for our common stock as well as our ability to raise equity capital in the future. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Upon
the closing of this offering, 9,242,500&nbsp;shares of common stock will be outstanding, or 9,692,500&nbsp;shares if the underwriters exercise the option to purchase additional shares in
full. All of the shares sold in this offering will be freely tradable unless purchased by our "affiliates" as that term is defined in Rule&nbsp;144 under the Securities Act or purchased by existing
stockholders and their affiliated entities or pursuant to the directed share program and therefore are subject to lock-up agreements described below and under "Underwriting" included elsewhere in this
prospectus. The remaining 6,242,500&nbsp;shares of common stock outstanding after this offering will
be restricted as a result of securities laws or lock-up agreements. These remaining shares will generally become available for sale in the public market as
follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> No restricted shares will be eligible for immediate sale upon the closing of
this offering; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Up to 6,242,500 restricted shares will be eligible for sale under
Rule&nbsp;144 or Rule&nbsp;701, subject to the volume limitations and manner of sale and notice provisions described below under "Rule&nbsp;144," upon expiration of lock-up agreements at least
180&nbsp;days after the date of this offering. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Certain
of our existing security holders and their affiliated entities, and other entities and individuals associated with us and them have indicated an interest in purchasing approximately
$10&nbsp;million of shares (or 1,000,000&nbsp;shares) in the aggregate of our common stock in this offering at the initial public offering price. Any such shares purchased by these stockholders
who are considered to be our affiliates could not be resold in the public market immediately following this offering as a result of restrictions under securities laws, but would be able to be sold
following the expiration of these restrictions, as described below. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters may determine to
sell more, fewer or no shares in this offering to any of these parties, or any of these parties may determine to purchase more, fewer or no shares in this offering. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Rule&nbsp;144  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In general, under Rule&nbsp;144 as currently in effect, beginning 90&nbsp;days after the effective date of the registration statement of which
this prospectus is a part, any person who is not an affiliate of ours and has held their shares for at least six months, including any period of consecutive ownership of preceding non-affiliated
holders, may sell shares without restriction, provided current public information about us is available. In addition, under Rule&nbsp;144, any person who is not an affiliate of ours and has held
their shares for at least one year, including any period of consecutive ownership of preceding non-affiliated holders, would be entitled to sell an unlimited number of shares immediately upon the
closing of this offering without regard to whether current public information about us is available. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Beginning
90&nbsp;days after the effective date of the registration statement of which this prospectus is a part, a person who is an affiliate of ours and who has beneficially owned restricted
securities for at least six months, including
any period of consecutive ownership of preceding non-affiliated holders, is entitled to sell a number of restricted shares within any three-month period that does not exceed the greater
of:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 1% of the number of shares of our common stock then outstanding, which will
equal approximately 92,425&nbsp;shares immediately after this offering assuming no exercise of the underwriters' option to purchase additional shares; or </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>165</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=167,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=611976,FOLIO='165',FILE='DISK112:[15ZCH1.15ZCH40101]EU40101A.;48',USER='CHE105948',CD=';5-AUG-2016;22:01' -->
<A NAME="page_eu40101_1_166"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the average weekly trading volume of our common stock on the NASDAQ Global
Market during the four calendar weeks preceding the filing of a notice on Form&nbsp;144 with respect to the sale. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Sales
of restricted shares under Rule&nbsp;144 by our affiliates are also subject to requirements regarding the manner of sale, notice and the availability of current public information about us.
Rule&nbsp;144 also provides that affiliates relying on Rule&nbsp;144 to sell unrestricted shares of our common stock must nonetheless comply with the same restrictions applicable to restricted
shares, other than the holding period requirement. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Notwithstanding
the availability of Rule&nbsp;144, the holders of substantially all of our restricted shares have entered into lock-up agreements as described below and their restricted shares will
become eligible for sale at the expiration of the restrictions set forth in those agreements. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Rule&nbsp;701  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Rule&nbsp;701 under the Securities Act, as in effect on the effective date of the registration statement of which this prospectus is a part, permits
resales of shares in reliance upon Rule&nbsp;144 but without compliance with certain restrictions of Rule&nbsp;144, including the holding period requirement. Most of our employees, consultants or
advisors who purchased shares from us in connection with a qualified compensatory stock plan or other written agreements are entitled to rely on the resale provisions of Rule&nbsp;701, but all
holders of
Rule&nbsp;701 shares are required to wait until 90&nbsp;days after the effective date of the registration statement of which this prospectus is a part before selling their shares. However,
substantially all Rule&nbsp;701 shares are subject to lock-up agreements as described below and under "Underwriting" included elsewhere in this prospectus and will become eligible for sale upon the
expiration of the restrictions set forth in those agreements. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Lock-Up Agreements  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>All of our directors and executive officers and the holders of all or substantially all our outstanding capital stock and other securities have signed
a lock-up agreement in favor of the underwriters which prevents them from selling our common stock or any securities convertible into or exercisable or exchangeable for common stock for a period of
180&nbsp;days from the date of the registration statement of which this prospectus is a part without the prior written consent of the representatives subject to certain exceptions set forth in
"Underwriting". Jefferies&nbsp;LLC may, with the agreement of RBC Capital Markets, LLC, at any time or from time to time release some or all of the shares subject to lock-up agreements prior to the
expiration of the 180-day period. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Registration Rights  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Upon closing of this offering, the holders of 2,124,880&nbsp;shares of our common stock will be entitled to rights with respect to the registration
of their shares under the Securities Act, subject to the lock-up agreements described under "&#151;&nbsp;Lock-Up Agreements" above. Registration of these shares under the Securities Act would
result in the shares becoming freely tradable without restriction under the Securities Act, except for shares purchased by affiliates, immediately upon the effectiveness of the registration statement
of which this prospectus is a part. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock. See "Description of Capital
Stock&nbsp;&#151; Registration Rights." </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Equity Incentive Plans  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We intend to file with the SEC a registration statement on Form&nbsp;S-8 under the Securities Act covering the shares of common stock reserved for
issuance under the 2015 Plan. The registration statement is expected to be filed and become effective as soon as practicable after the closing of this offering. Accordingly, shares registered under
the registration statement will be available for sale in the open market
following its effective date, subject to Rule&nbsp;144 volume limitations and the lock-up agreements described above, if applicable. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>166</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=168,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=501394,FOLIO='166',FILE='DISK112:[15ZCH1.15ZCH40101]EU40101A.;48',USER='CHE105948',CD=';5-AUG-2016;22:01' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ew40101_1_167"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ew40101_material_u.s._federal_income_t__mat03201"> </A>
<A NAME="toc_ew40101_1"> </A>
<BR></FONT><FONT SIZE=2><B>  MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES<BR>  TO NON-U.S. HOLDERS OF OUR COMMON STOCK    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This section discusses the material U.S. federal income tax consequences of the acquisition, ownership and disposition of our common stock by a
"Non-U.S. Holder". For purposes of this discussion, a "Non-U.S. Holder" is any beneficial owner of common stock that, for U.S. federal income tax purposes, is neither a U.S. person nor an entity
treated as a partnership. The term "U.S. person" means:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an individual who is a citizen or resident of the United States; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a corporation or other entity treated as a corporation created or organized in
or under the laws of the United States, any state thereof or the District of Columbia; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an estate the income of which is subject to U.S. federal income taxation
regardless of its source; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a trust (i)&nbsp;whose administration is subject to the primary supervision of
a court within the United States and which has one or more U.S. persons who have authority to control all substantive decisions of the trust, or (ii)&nbsp;which has a valid election in effect under
applicable U.S. Treasury regulations to be treated as a U.S. person. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>This
discussion does not address entities that are, or are treated as, partnerships for U.S. federal income tax purposes (regardless of their place of organization or formation) and their equity
holders, or entities that are disregarded for U.S. federal income tax purposes (regardless of their place of organization or formation). Therefore, these entities and persons are not considered
"Non-U.S. Holders" for the purposes of this discussion. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>This
discussion generally does not address U.S. federal income tax considerations that may be relevant to particular investors because of their specific circumstances, or because they are subject to
special rules. Investors subject to special rules not covered in this discussion include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> financial institutions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  insurance companies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  tax-exempt organizations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  tax-qualified retirement plans; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  broker-dealers and traders in securities, commodities or currencies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> U.S. expatriates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  "controlled foreign corporations;" </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> "passive foreign investment companies;" </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  corporations that accumulate earnings to avoid U.S. federal income tax; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> persons that hold our common stock as part of a "straddle," "conversion
transaction," or other risk reduction strategy, holders deemed to sell our common stock under the constructive sale provisions of the Code; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> holders who hold or receive our common stock pursuant to the exercise of
employee stock options or otherwise as compensation; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> holders who are subject to the alternative minimum tax or the Medicare
contribution tax. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Such
Non-U.S. Holders are urged to consult their own tax advisors to determine the U.S. federal, state, local and other tax consequences that may be relevant to them. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
following discussion describes the material U.S. federal income tax consequences of the acquisition, ownership and disposition of our common stock acquired in this offering by Non-U.S. Holders.
This discussion does not provide a complete analysis of all potential tax considerations and does not address any federal gift or estate tax consequences (except to the limited extent set forth
below), or state or local or non-U.S. tax consequences. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>167</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=169,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=647048,FOLIO='167',FILE='DISK112:[15ZCH1.15ZCH40101]EW40101A.;30',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_ew40101_1_168"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
discussion below is based upon the provisions of the Code and U.S. Treasury regulations, published administrative pronouncements, rulings and judicial decisions thereunder as of the date hereof.
Such authorities may be repealed, revoked or modified, perhaps retroactively, so as to result in U.S. federal income tax consequences different from those discussed below. We have not requested a
ruling from the U.S. Internal Revenue Service, or the IRS, with respect to the statements made and the conclusions reached in the following discussion. This discussion assumes that the Non-U.S. Holder
holds our common stock as a "capital asset" within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
following discussion is for general information only and is not tax advice for any Non-U.S. Holders under their particular circumstances. Persons considering the purchase of our common stock
pursuant to this offering should consult their own tax advisors concerning the U.S. federal income tax consequences of acquiring, owning and disposing of our common stock in light of their particular
situations as well as any consequences arising under the laws of any other taxing jurisdiction, including any state, local and non-U.S. tax consequences and any U.S. federal tax consequences other
than income or estate tax consequences. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Distributions on Our Common Stock  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As described above in the "Dividend Policy" section of this prospectus, we do not anticipate paying any cash dividends in the foreseeable future.
However, if we do make distributions of cash or property on our common stock, such distributions made to a Non-U.S. Holder generally will constitute dividends for U.S. tax purposes to the extent made
out of our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. To the extent those dividends exceed our current and accumulated earnings and profits,
the dividends will constitute a return of capital and will first reduce a holder's basis, but not below zero, and then will be treated as gain from the sale of stock (described below). </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
gross amount of any dividend (out of earnings and profits) paid to a Non-U.S. Holder generally will be subject to withholding tax at a 30% rate, unless the holder is entitled to an exemption from
or reduced rate of withholding under an applicable income tax treaty. In order to receive an exemption or a reduced treaty rate, prior to the payment of a dividend, a Non-U.S. Holder must provide us
with an IRS Form&nbsp;W-8BEN, Form&nbsp;W-8BEN-E, or other appropriate form, certifying the Non-U.S. Holder's qualification for the exemption or reduced rate. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
generally are not required to withhold tax on dividends paid to a Non-U.S. Holder that are effectively connected with the Non-U.S. Holder's conduct of a trade or business within the United States
(and, if required by an applicable income tax treaty, are attributable to a permanent establishment that such holder maintains in the United States) if a properly executed IRS Form&nbsp;W-8ECI,
stating that the dividends are so connected, is furnished to us (or, if stock is held through a financial institution or other agent, to such agent). In general, such effectively connected dividends
will be subject to U.S. federal income tax, on a net income basis at the regular graduated rates, unless a specific treaty exemption applies. A corporate Non-U.S. Holder receiving effectively
connected dividends may also be subject to an additional "branch profits tax," which is imposed, under certain circumstances, at a rate of 30% (or such lower rate as may be specified by an applicable
treaty) on the corporate Non-U.S. Holder's effectively connected earnings and profits, subject to certain adjustments. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>A
Non-U.S. Holder of common stock that is eligible for a reduced rate of withholding tax pursuant to an income tax treaty may obtain a refund of any excess amounts currently withheld, if an
appropriate claim for refund is timely filed with the IRS. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Distributions
on our common stock will also be subject to the discussion below regarding back-up withholding and foreign accounts. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>168</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=170,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=914363,FOLIO='168',FILE='DISK112:[15ZCH1.15ZCH40101]EW40101A.;30',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_ew40101_1_169"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Gain on Disposition of Our Common Stock  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Subject to the discussion below regarding backup withholding and foreign accounts, a Non-U.S. Holder generally will not be subject to U.S. federal
income tax with respect to gain realized on a sale or other disposition of our common stock, unless:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the gain is effectively connected with a trade or business of such holder in the
United States (and, if required by an applicable income tax treaty, is attributable to a permanent establishment that such holder maintains in the United States), in which case, the Non-U.S. Holder
generally will be required to pay tax on the net gain derived from the sale at regular graduated U.S. federal income tax rates, unless a specific treaty exemption applies, and if the Non-U.S. Holder
is a corporation, an additional branch profits tax may apply, at a 30% rate or such lower rate as may be specified by an applicable income tax treaty; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the Non-U.S. Holder is a nonresident alien individual and is present in the
United States for 183 or more days in the taxable year of the disposition and certain other conditions are met, in which case the Non-U.S. Holder will be required to pay a flat 30% tax (or such lower
rate as may be specified by an applicable income tax treaty between the United States and such Non-U.S. Holder's country of residence) on the net gain derived from the disposition, which tax may be
offset by U.S. source capital losses (even though such Non-U.S. Holder is not considered a resident of the United States); or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we are or have been a "U.S. real property holding corporation," or a USRPHC,
within the meaning of Section&nbsp;897(c)(2) of the Code at any time within the shorter of the five-year period preceding such disposition or such holder's holding period. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>We
believe that we are not, and do not anticipate becoming, a USRPHC. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Information Reporting Requirements and Backup Withholding  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Generally, we must report annually to the IRS the amount of dividends paid, the name and address of the recipient, and the amount, if any, of tax
withheld. A similar report is sent to the holder. Pursuant to tax treaties or other agreements, the IRS may make its report available to tax authorities in the Non-U.S. Holder's country of residence. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>A
Non-U.S. Holder will be subject to backup withholding for dividends paid to such holder unless such holder certifies under penalty of perjury that it is a Non-U.S. Holder (and the payor does not
have actual knowledge or reason to know that such holder is a U.S. person as defined under the Code), or such holder otherwise establishes an exemption. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Information
reporting and, depending on the circumstances, backup withholding will apply to the proceeds of a sale of our common stock within the United States or conducted through certain
U.S.-related financial intermediaries, unless the beneficial owner certifies under penalty of perjury that it is a Non-U.S. Holder (and the payor does not have actual knowledge or reason to know that
the beneficial owner is a U.S. person as defined under the Code), or such owner otherwise establishes an exemption. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Backup
withholding is not an additional tax. Rather, the U.S. federal income tax liability of persons subject to backup withholding will be reduced by the amount of tax withheld. If withholding
results in an overpayment of taxes, a credit or refund may be obtained from the IRS, so long as the required information is furnished to the IRS in a timely manner. If backup withholding is applied to
you, you should consult with your own tax advisor to determine if you are able to obtain a tax refund or credit with respect to the amount withheld. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Foreign Accounts  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Sections&nbsp;1471 through 1474 of the Code (such Sections commonly referred to as FATCA), generally may impose a U.S. federal withholding tax of
30% on dividends paid on our common stock and the gross </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>169</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=171,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=949929,FOLIO='169',FILE='DISK112:[15ZCH1.15ZCH40101]EW40101A.;30',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<A NAME="page_ew40101_1_170"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>proceeds
of a disposition of our common stock paid to non-U.S. financial institutions and certain non-U.S. non-financial entities (including, in some instances, where such an institution or entity is
acting as an intermediary) unless they satisfy certain reporting requirements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
withholding provisions described above generally apply to payments of dividends on our common stock and will apply to payments of gross proceeds from a sale or other disposition of our common
stock on or after January&nbsp;1, 2019. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under
certain circumstances, a Non-U.S. Holder might be eligible for refunds or credits of such taxes. Prospective investors are encouraged to consult with their own tax advisors regarding possible
implications of FATCA on their investment in our common stock. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


U.S. Federal Estate Tax  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The estates of nonresident alien individuals are generally subject to U.S. federal estate tax on property with a U.S. situs. Because we are a U.S.
corporation, our common stock will be U.S. situs property and therefore will be included in the taxable estate of a nonresident alien decedent. The U.S. federal estate tax liability of the estate of a
nonresident alien may be affected by a tax treaty between the United States and the decedent's country of residence. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>THE
PRECEDING DISCUSSION OF MATERIAL U.S. FEDERAL TAX CONSEQUENCES IS FOR GENERAL INFORMATION ONLY. IT IS NOT TAX ADVICE FOR ANY NON-U.S. HOLDERS UNDER THEIR PARTICULAR
CIRCUMSTANCES. EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS OWN TAX ADVISOR REGARDING THE TAX CONSEQUENCES OF ACQUIRING, HOLDING AND DISPOSING OF OUR COMMON STOCK, INCLUDING THE CONSEQUENCES OF ANY
PROPOSED CHANGE IN APPLICABLE LAW, AS WELL AS TAX CONSEQUENCES ARISING UNDER ANY STATE, LOCAL, NON-U.S. OR U.S. FEDERAL TAX LAWS OTHER THAN INCOME TAXES. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>170</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=172,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=898333,FOLIO='170',FILE='DISK112:[15ZCH1.15ZCH40101]EW40101A.;30',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ey40101_1_171"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ey40101_underwriting"> </A>
<A NAME="toc_ey40101_1"> </A>
<BR></FONT><FONT SIZE=2><B>  UNDERWRITING    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Subject to the terms and conditions set forth in the underwriting agreement, dated August&nbsp;4, 2016, among us and Jefferies&nbsp;LLC and RBC
Capital Markets, LLC, as the representatives of the underwriters named below and the joint book-running managers of this offering, we have agreed to sell to the underwriters, and each of the
underwriters has agreed, severally and not jointly, to purchase from us, the respective number of shares of common stock shown opposite its name below: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="63pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:57pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>UNDERWRITER

<!-- COMMAND=ADD_SCROPPEDRULE,57pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>NUMBER OF<BR>
SHARES </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jefferies&nbsp;LLC</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,395,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RBC Capital Markets, LLC</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>945,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Canaccord Genuity Inc.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>405,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Laidlaw &amp; Company (UK) Ltd.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>150,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>LifeSci Capital LLC</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>105,000 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3,000,000 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>The
underwriting agreement provides that the obligations of the several underwriters are subject to certain conditions precedent such as the receipt by the underwriters of officers' certificates and
legal opinions and approval of certain legal matters by their counsel. The underwriting agreement provides that the underwriters will purchase all of the shares of common stock if any of them are
purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the nondefaulting underwriters may be increased or the underwriting agreement may be
terminated. We have agreed to indemnify the underwriters and
certain of their controlling persons against certain liabilities, including liabilities under the Securities Act, and to contribute to payments that the underwriters may be required to make in respect
of those liabilities. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>At
our request, the underwriters have reserved up to 10% of the shares of our common stock offered by this prospectus for sale, at the initial public offering price, to our directors, officers,
employees and other individuals associated with us and members of their respective families. We do not know if these persons will choose to purchase all or any portion of these reserved shares, but
any purchases they do make will reduce the number of shares available to the general public. The underwriters will receive the same underwriting discount on any shares purchased by these investors as
they will on any other shares sold to the public in this offering. Any shares purchased by such investors will be subject to the lock-up restrictions described herein. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
underwriters have advised us that, following the closing of this offering, they currently intend to make a market in the common stock as permitted by applicable laws and regulations. However, the
underwriters are not obligated to do so, and the underwriters may discontinue any market-making activities at any time without notice in their sole discretion. Accordingly, no assurance can be given
as to the liquidity of the trading market for the common stock, that you will be able to sell any of the common stock held by you at a particular time or that the prices that you receive when you sell
will be favorable. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
underwriters are offering the shares of common stock subject to their acceptance of the shares of common stock from us and subject to prior sale. The underwriters reserve the right to withdraw,
cancel or modify offers to the public and to reject orders in whole or in part. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>171</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=173,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=711989,FOLIO='171',FILE='DISK112:[15ZCH1.15ZCH40101]EY40101A.;57',USER='CHE105889',CD=';5-AUG-2016;17:59' -->
<A NAME="page_ey40101_1_172"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Commission and Expenses  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The underwriters have advised us that they propose to offer the shares of common stock to the public at the initial public offering price set forth on
the cover page of this prospectus and to certain dealers, which may include the underwriters, at that price less a concession not in excess of $0.42 per share of common stock. The underwriters may
allow, and certain dealers may reallow, a discount from the concession not in excess of $0.14 per share of common stock to certain brokers and dealers. After the offering, the initial public offering
price, concession and reallowance to dealers may be reduced by the representatives. No such reduction will change the amount of proceeds to be received by us as set forth on the cover page of this
prospectus. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
following table shows the public offering price, the underwriting discounts and commissions that we are to pay the underwriters and the proceeds, before expenses, to us in connection with this
offering. Such amounts are shown assuming both no exercise and full exercise of the underwriters' option to purchase additional shares. </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="61pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="61pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="78pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="78pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>PER SHARE </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>TOTAL </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>WITHOUT<BR>
OPTION TO<BR>
PURCHASE<BR>
ADDITIONAL<BR>
SHARES </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>WITH<BR>
OPTION TO<BR>
PURCHASE<BR>
ADDITIONAL<BR>
SHARES </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>WITHOUT<BR>
OPTION TO<BR>
PURCHASE<BR>
ADDITIONAL<BR>
SHARES </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>WITH<BR>
OPTION TO<BR>
PURCHASE<BR>
ADDITIONAL<BR>
SHARES </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Public offering price</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.00</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.00</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>30,000,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>34,500,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Underwriting discounts and commissions paid by us</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>0.70</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>0.70</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,100,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,415,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds to us, before expenses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>9.30</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>9.30</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>27,900,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>32,085,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>We
estimate expenses payable by us in connection with this offering, other than the underwriting discounts and commissions referred to above, will be approximately $2.3&nbsp;million. We have also
agreed to reimburse the underwriters for up to $52,500 for certain FINRA-related expenses. In accordance with FINRA 5110, this
reimbursed fee is deemed underwriting compensation for this offering. In addition, subject to FINRA Rule&nbsp;5110(f)(2)(E), we have granted a right of first refusal to Jefferies&nbsp;LLC with
respect to certain transactions during the three-year period beginning on the date of commencement of sales in this offering. FINRA deems this right of first refusal to be an additional item of
compensation received by the underwriters. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Determination of Offering Price  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Prior to this offering, there has not been a public market for our common stock. Consequently, the initial public offering price for our common stock
was determined by negotiations between us and the representatives. Among the factors considered in these negotiations were prevailing market conditions, our financial information, market valuations of
other companies that we and the underwriters believe to be comparable to us, estimates of our business potential, the present state of our development and other factors deemed relevant. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
offer no assurances that the initial public offering price will correspond to the price at which the common stock will trade in the public market subsequent to the offering or that an active
trading market for the common stock will develop and continue after the offering. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Listing  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our common stock has been approved for listing on the NASDAQ Global Market under the symbol "GEMP." </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>172</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=174,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=456467,FOLIO='172',FILE='DISK112:[15ZCH1.15ZCH40101]EY40101A.;57',USER='CHE105889',CD=';5-AUG-2016;17:59' -->
<A NAME="page_ey40101_1_173"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Stamp Taxes  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>If you purchase shares of common stock offered in this prospectus, you may be required to pay stamp taxes and other charges under the laws and
practices of the country of purchase, in addition to the offering price listed on the cover page of this prospectus. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Option to Purchase Additional Shares  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have granted to the underwriters an option, exercisable for 30&nbsp;days from the date of this prospectus, to purchase, from time to time, in
whole or in part, up to an aggregate of 450,000&nbsp;shares from us at the public offering price set forth on the cover page of this prospectus, less underwriting discounts and commissions. If the
underwriters exercise this option, each underwriter will be obligated, subject to specified conditions, to purchase a number of additional shares proportionate to that underwriter's initial purchase
commitment as indicated in the table above. This option may be exercised only if the underwriters sell more shares than the total number set forth on the cover page of this prospectus. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


No Sales of Similar Securities  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We, our officers, directors and holders of all or substantially all our outstanding capital stock and other securities have agreed, subject to
specified exceptions, not to directly or indirectly:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> sell, offer, contract or grant any option to sell (including any short sale),
pledge, transfer, establish an open "put equivalent position" within the meaning of Rule&nbsp;16a-l(h) under the Securities Exchange Act of 1934, as amended, </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  otherwise dispose of any shares of common stock, options or warrants to acquire
shares of common stock, or securities exchangeable or exercisable for or convertible into shares of common stock currently or hereafter owned either of record or beneficially, </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> enter into any swap, hedge or similar arrangement or agreement that transfers,
in whole or in part, the economic risk of ownership of shares of our common stock, or of options or warrants to shares of our common stock, or securities or rights exchangeable or exercisable for or
convertible into shares of our common stock, </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> make any demand for, or exercise any right with respect to, the registration
under the Securities Act of the offer and sale of any shares of our common stock, or of options or warrants to shares of our common stock, or securities or rights exchangeable or exercisable for or
convertible into shares of our common stock, or cause to be filed a registration statement, prospectus or prospectus supplement (or an amendment or supplement thereto) with respect to any such
registration, or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> publicly announce an intention to do any of the foregoing for a period of
180&nbsp;days after the date of this prospectus without the prior written consent of Jefferies&nbsp;LLC, with the agreement of RBC Capital Markets, LLC. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>This
restriction terminates after the close of trading of the common stock on and including the 180<SUP>th</SUP> day after the date of this prospectus. In addition, the foregoing shall not apply to
issuances of common stock or grants of stock options, restricted stock or other incentive compensation pursuant to the terms of certain stock plans or arrangements described herein. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Jefferies&nbsp;LLC
may, with the agreement of RBC Capital Markets, LLC, at any time or from time to time before the termination of the 180-day period, release all or any portion of the securities
subject to lock-up agreements. There are no existing agreements between the underwriters and any of our stockholders who will execute a lock-up agreement, providing consent to the sale of shares prior
to the expiration of the lock-up period. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Stabilization  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The underwriters have advised us that they, pursuant to Regulation&nbsp;M under the Securities Exchange Act of 1934, as amended, certain persons
participating in the offering may engage in short sale transactions, </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>173</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=175,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=856236,FOLIO='173',FILE='DISK112:[15ZCH1.15ZCH40101]EY40101A.;57',USER='CHE105889',CD=';5-AUG-2016;17:59' -->
<A NAME="page_ey40101_1_174"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>stabilizing
transactions, syndicate covering transactions or the imposition of penalty bids in connection with this offering. These activities may have the effect of stabilizing or maintaining the
market price of the common stock at a level above that which might otherwise prevail in the open market. Establishing short sales positions may involve either "covered" short sales or "naked" short
sales. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>"Covered"
short sales are sales made in an amount not greater than the underwriters' option to purchase additional shares of our common stock in this offering. The underwriters may close out any
covered short position by either exercising their option to purchase additional shares of our common stock or purchasing shares of our common stock in the open market. In determining the source of
shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they
may purchase shares through the option to purchase additional shares. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>"Naked"
short sales are sales in excess of the option to purchase additional shares of our common stock. The underwriters must close out any naked short position by purchasing shares in the open
market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the shares of our common stock in the open market
after pricing that could adversely affect investors who purchase in this offering. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A
stabilizing bid is a bid for the purchase of shares of common stock on behalf of the underwriters for the purpose of fixing or maintaining the price of the common stock. A syndicate covering
transaction is the bid for or the purchase of shares of common stock on behalf of the underwriters to reduce a short position incurred by the underwriters in connection with the offering. Similar to
other purchase transactions, the underwriter's purchases to cover the syndicate short sales may have the effect of raising or maintaining the market price of our common stock or preventing or
retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. A penalty bid is an
arrangement permitting the underwriters to reclaim the selling concession otherwise accruing to a syndicate member in connection with the offering if the common stock originally sold by such syndicate
member are purchased in a syndicate covering transaction and therefore have not been effectively placed by such syndicate member. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Neither
we nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our common
stock. The underwriters are not obligated to engage in these activities and, if commenced, any of the activities may be discontinued at any time. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
underwriters may also engage in passive market making transactions in our common stock on the NASDAQ Global Market in accordance with Rule&nbsp;103 of Regulation&nbsp;M during a period before
the commencement of offers or sales of shares of our common stock in this offering and extending through the completion of distribution. A passive market maker must display its bid at a price not in
excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker's bid that bid must then be lowered when specified purchase limits
are exceeded. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Electronic Distribution  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A prospectus in electronic format may be made available by e-mail or on the web sites or through online services maintained by one or more of the
underwriters or their affiliates. In those cases, prospective investors may view offering terms online and may be allowed to place orders online. The underwriters may agree with us to allocate a
specific number of shares of common stock for sale to online brokerage account holders. Any such allocation for online distributions will be made by the underwriters on the same basis as other
allocations. Other than the prospectus in electronic format, the information on the underwriters' web sites and any information contained in any other web site maintained by any of the underwriters is
not part </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>174</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=176,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=202484,FOLIO='174',FILE='DISK112:[15ZCH1.15ZCH40101]EY40101A.;57',USER='CHE105889',CD=';5-AUG-2016;17:59' -->
<A NAME="page_ey40101_1_175"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>of
this prospectus, has not been approved and/or endorsed by us or the underwriters and should not be relied upon by investors. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Other Activities and Relationships  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The underwriters and certain of their affiliates are full service financial institutions engaged in various activities, which may include securities
trading, commercial and investment banking, financial
advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. The underwriters and certain of their affiliates have, from time to time,
performed, and may in the future perform, various commercial and investment banking and financial advisory services for us and our affiliates, for which they received or will receive customary fees
and expenses. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
the ordinary course of their various business activities, the underwriters and certain of their affiliates may make or hold a broad array of investments and actively trade debt and equity
securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers, and such investment and securities
activities may involve securities and/or instruments issued by us and our affiliates. If the underwriters or their respective affiliates have a lending relationship with us, they routinely hedge their
credit exposure to us consistent with their customary risk management policies. The underwriters and their respective affiliates may hedge such exposure by entering into transactions which consist of
either the purchase of credit default swaps or the creation of short positions in our securities or the securities of our affiliates, including potentially the common stock offered hereby. Any such
short positions could adversely affect future trading prices of the common stock offered hereby. The underwriters and certain of their respective affiliates may also communicate independent investment
recommendations, market color or trading ideas and/or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that
they acquire, long and/or short positions in such securities and instruments. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Disclaimers About Non-U.S. Jurisdictions  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Australia  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This prospectus is not a disclosure document for the purposes of Australia's Corporations Act 2001 (Cth) of Australia, or Corporations Act, has not
been lodged with the Australian Securities&nbsp;&amp; Investments Commission and is only directed to the categories of exempt persons set out below. Accordingly, if you receive this prospectus in
Australia: </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>You
confirm and warrant that you are either:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a "sophisticated investor" under section&nbsp;708(8)(a) or (b) of the
Corporations Act; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a "sophisticated investor" under section&nbsp;708(8)(c) or (d) of the
Corporations Act and that you have provided an accountant's certificate to the company which complies with the requirements of section&nbsp;708(8)(c)(i) or (ii) of the Corporations Act and related
regulations before the offer has been made; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a person associated with the company under Section&nbsp;708(12) of the
Corporations Act; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a "professional investor" within the meaning of section&nbsp;708(11)(a) or (b)
of the Corporations Act. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>To
the extent that you are unable to confirm or warrant that you are an exempt sophisticated investor, associated person or professional investor under the Corporations Act any offer made to you under
this prospectus is void and incapable of acceptance. </FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>You
warrant and agree that you will not offer any of the shares issued to you pursuant to this prospectus for resale in Australia within 12&nbsp;months of those shares being issued unless any such
resale offer is exempt from the requirement to issue a disclosure document under section&nbsp;708 of the Corporations Act. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>175</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=177,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=653897,FOLIO='175',FILE='DISK112:[15ZCH1.15ZCH40101]EY40101A.;57',USER='CHE105889',CD=';5-AUG-2016;17:59' -->
<A NAME="page_ey40101_1_176"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Canada  </I></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


</I></FONT><FONT SIZE=2>(A)&nbsp;&nbsp;Resale Restrictions </FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The
distribution of common stock in Canada is being made only in the provinces of Ontario, Quebec, Alberta and British Columbia on a private placement basis exempt from the
requirement that we prepare and file a prospectus with the securities regulatory authorities in each province where trades of these securities are made. Any resale of the common stock in Canada must
be made under applicable securities laws which may vary depending on the relevant jurisdiction, and which may require resales to be made under available statutory exemptions or under a discretionary
exemption granted by the applicable Canadian securities regulatory authority. Purchasers are advised to seek legal advice prior to any resale of the securities. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


</I></FONT><FONT SIZE=2>(B)&nbsp;&nbsp;Representations of Canadian Purchasers </FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>By
purchasing common stock in Canada and accepting delivery of a purchase confirmation, a purchaser is representing to us and the dealer from whom the purchase confirmation
is received that:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the purchaser is entitled under applicable provincial securities laws to
purchase the common stock without the benefit of a prospectus qualified under those securities laws as it is an "accredited investor" as defined under National
Instrument&nbsp;45-106&nbsp;&#151; </FONT><FONT SIZE=2><I>Prospectus Exemptions</I></FONT><FONT SIZE=2>, </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the purchaser is a "permitted client" as defined in National
Instrument&nbsp;31-103&nbsp;&#151; </FONT><FONT SIZE=2><I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I></FONT><FONT SIZE=2>, </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> where required by law, the purchaser is purchasing as principal and not as
agent, and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the purchaser has reviewed the text above under Resale Restrictions. </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


</I></FONT><FONT SIZE=2>(C)&nbsp;&nbsp;Conflicts of Interest </FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Canadian
purchasers are hereby notified that the underwriters are relying on the exemption set out in section&nbsp;3A.3 or 3A.4, if applicable, of National
Instrument&nbsp;33-105&nbsp;&#151; </FONT><FONT SIZE=2><I>Underwriting Conflicts</I></FONT><FONT SIZE=2> from having to provide certain conflict of interest disclosure in this document. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


 </I></FONT><FONT SIZE=2>(D)&nbsp;&nbsp;Statutory Rights of Action </FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Securities
legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if the offering memorandum (including
any amendment thereto) such as this document contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the
securities legislation of the purchaser's province or territory. The purchaser of these securities in Canada should refer to any applicable provisions of the securities legislation of the purchaser's
province or territory for particulars of these rights or consult with a legal advisor. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


 </I></FONT><FONT SIZE=2>(E)&nbsp;&nbsp;Enforcement of Legal Rights </FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>All
of our directors and officers as well as the experts named herein may be located outside of Canada and, as a result, it may not be possible for Canadian purchasers to
effect service of process within Canada upon us or those persons. All or a substantial portion of our assets and the assets of those persons may be located outside of Canada and, as a result, it may
not be possible to satisfy a judgment against us or those persons in Canada or to enforce a judgment obtained in Canadian courts against us or those persons outside of Canada. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


 </I></FONT><FONT SIZE=2>(F)&nbsp;&nbsp;Taxation and Eligibility for Investment </FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Canadian
purchasers of common stock should consult their own legal and tax advisors with respect to the tax consequences of an investment in the common stock in their
particular circumstances and about the eligibility of the common stock for investment by the purchaser under relevant Canadian legislation. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


European Economic Area  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In relation to each member state of the European Economic Area which has implemented the Prospectus Directive, each referred to herein as a Relevant
Member State, an offer to the public of any common shares which are the subject of the offering contemplated by this prospectus may not be made in that Relevant Member State except that an offer to
the public in that Relevant Member State of any common shares may </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>176</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=178,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=656595,FOLIO='176',FILE='DISK112:[15ZCH1.15ZCH40101]EY40101A.;57',USER='CHE105889',CD=';5-AUG-2016;17:59' -->
<A NAME="page_ey40101_1_177"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>be
made at any time under the following exemptions under the Prospectus Directive, if they have been implemented in that Relevant Member State: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>to
any legal entity which is a "qualified investor" as defined in the Prospectus Directive;
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>to
fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010 PD Amending Directive, 150, natural or legal persons
(other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the underwriters or the underwriters
nominated by us for any such offer; or
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(c)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>in
any other circumstances falling within Article&nbsp;3(2) of the Prospectus Directive, </FONT></DD></DL>
</UL>
<UL>
<UL>

<P style="font-family:arial;"><FONT SIZE=2>provided
that no such offer of securities shall require us or any of the underwriters to publish a prospectus pursuant to Article&nbsp;3 of the Prospectus Directive or supplement a prospectus
pursuant to Article&nbsp;16 of the Prospectus Directive. </FONT></P>

</UL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>For
the purposes of this provision, the expression an "offer of securities to the public" in relation to any securities in any Relevant Member State means the communication in any form and by any
means of sufficient information on the terms of the offer and the securities to be offered so as to enable an investor to decide to purchase or subscribe the securities, as the same may be varied in
that Relevant Member State by any measure implementing the Prospectus Directive in that Relevant Member State and the expression "Prospectus Directive" means Directive&nbsp;2003/71/EC (and
amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member State), and includes any relevant implementing measure in the Relevant Member State and
the expression "2010 PD Amending Directive" means Directive&nbsp;2010/73/EU. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Notice to Prospective Investors in France  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Neither this prospectus nor any other offering material relating to the shares described in this prospectus has been submitted to the clearance
procedures of the </FONT><FONT SIZE=2><I>Autorit&eacute; des March&eacute;s Financiers</I></FONT><FONT SIZE=2> or of the competent authority of another member state of the European
Economic Area and notified to the </FONT><FONT SIZE=2><I>Autorit&eacute; des March&eacute;s Financiers.</I></FONT><FONT SIZE=2> The shares have not been offered or sold and will not be
offered or sold, directly or indirectly, to the public in France. Neither this prospectus nor any other offering material relating to the shares has been or will
be:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  released, issued, distributed or caused to be released, issued or distributed
to the public in France; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> used in connection with any offer for subscription or sale of the shares to the
public in France. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Such offers, sales and distributions will be made in France
only:</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> to qualified investors (</FONT><FONT SIZE=2><I>investisseurs
qualifi&eacute;s</I></FONT><FONT SIZE=2>) and/or to a restricted circle of investors (</FONT><FONT SIZE=2><I>cercle restreint&nbsp;d'investisseurs</I></FONT><FONT SIZE=2>), in each case
investing for their own account, all as defined in, and in accordance with, articles&nbsp;L. 411-2, D. 411-1, D. 744-1, D. 754-1 and D. 764-1 of the French </FONT><FONT SIZE=2><I>Code
mon&eacute;taire et financier</I></FONT><FONT SIZE=2> and applicable regulations thereunder; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> to investment services providers authorized to engage in portfolio management on
behalf of third parties </FONT><FONT SIZE=2><I>(personnes fournissant le service d'investissement de gestion de portefeuille pour compte de tiers)</I></FONT><FONT SIZE=2> as defined in
Article&nbsp;L.411-2-II of the French </FONT><FONT SIZE=2><I>Code mon&eacute;taire et financier</I></FONT><FONT SIZE=2>; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> in a transaction that, in accordance with article&nbsp;L. 411-2 of the French </FONT> <FONT SIZE=2><I>Code mon&eacute;taire et financier</I></FONT><FONT SIZE=2>
and article&nbsp;211-2 of the General Regulations (</FONT><FONT SIZE=2><I>R&egrave;glement
G&eacute;n&eacute;ral</I></FONT><FONT SIZE=2>) of the </FONT><FONT SIZE=2><I>Autorit&eacute; des March&eacute;s Financiers</I></FONT><FONT SIZE=2>, does not constitute a
public offer (</FONT><FONT SIZE=2><I>appel public &agrave; l'&eacute;pargne</I></FONT><FONT SIZE=2>). </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>The
shares may be resold directly or indirectly, only in compliance with articles&nbsp;L. 411-1, L. 411-2, L.&nbsp;412-1 and L. 621-8 through L. 621-8-3 of the French </FONT><FONT SIZE=2><I>Code
mon&eacute;taire et financier</I></FONT><FONT SIZE=2> and applicable regulations thereunder. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>177</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=179,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=683929,FOLIO='177',FILE='DISK112:[15ZCH1.15ZCH40101]EY40101A.;57',USER='CHE105889',CD=';5-AUG-2016;17:59' -->
<A NAME="page_ey40101_1_178"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Hong Kong  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>No securities have been offered or sold, and no securities may be offered or sold, in Hong Kong, by means of any document, other than to persons whose
ordinary business is to buy or sell shares or debentures, whether as principal or agent; or to "professional investors" as defined in the Securities and Futures Ordinance (Cap.&nbsp;571) of Hong
Kong, or SFO, and any rules made under that Ordinance; or in other circumstances which do not result in the document being a "prospectus" as defined in the Companies Ordinance (Cap.&nbsp;32) of Hong
Kong, or CO, or which do not constitute an offer or invitation to the public for the purpose of the CO or the SFO. No document, invitation or advertisement relating to the securities has been issued
or may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be
accessed or read by, the public of Hong Kong (except if permitted under the securities laws of Hong Kong) other than with respect to securities which are or are intended to be disposed of only to
persons outside Hong Kong or only to "professional investors" as defined in the SFO and any rules made under that Ordinance. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>This
prospectus has not been registered with the Registrar of Companies in Hong Kong. Accordingly, this prospectus may not be issued, circulated or distributed in Hong Kong, and the securities may not
be offered for subscription to members of the public in Hong Kong. Each person acquiring the securities will be required, and is deemed by the acquisition of the securities, to confirm that he is
aware of the restriction on offers of the securities described in this prospectus and the relevant offering documents and that he is not acquiring, and has not been offered any securities in
circumstances that contravene any such restrictions. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Japan  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The offering has not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948 of Japan, as
amended), or FIEL, and the underwriters will not offer or sell any securities, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means any
person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for re-offering or resale, directly or indirectly, in Japan or to, or for the
benefit of, any resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the FIEL and any other applicable laws, regulations and
ministerial guidelines of Japan. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Singapore  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This prospectus has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this
prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the securities may not be circulated or distributed, nor may the
securities be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional
investor under Section&nbsp;274 of the Securities and Futures Act, Chapter&nbsp;289 of Singapore, or the SFA, (ii)&nbsp;to a relevant person pursuant to Section&nbsp;275(1), or any person
pursuant to Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275, of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of,
any other applicable provision of the SFA. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Where
the securities are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>a
corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the
entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>a
trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who
is an accredited investor, </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>178</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=180,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=964488,FOLIO='178',FILE='DISK112:[15ZCH1.15ZCH40101]EY40101A.;57',USER='CHE105889',CD=';5-AUG-2016;17:59' -->
<A NAME="page_ey40101_1_179"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:arial;"><FONT SIZE=2>securities
(as defined in Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries' rights and interest (howsoever described) in that trust shall not be transferred within six months
after that corporation or that trust has acquired the shares of common stock pursuant to an offer made under Section&nbsp;275 of the SFA except: </FONT></P>

</UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(i)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>to
an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising from an offer referred to in
Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA;
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(ii)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>where
no consideration is or will be given for the transfer;
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(iii)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>where
the transfer is by operation of law;
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(iv)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>as
specified in Section&nbsp;276(7) of the SFA; or
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(v)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>as
specified in Regulation&nbsp;32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations&nbsp;2005 of Singapore. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Switzerland  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock exchange or
regulated trading facility in Switzerland. This prospectus has been prepared without regard to the disclosure standards for issuance prospectuses under art.&nbsp;652a or art.&nbsp;1156 of the
Swiss Code of Obligations or the disclosure standards for listing prospectuses under art.&nbsp;27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading
facility in Switzerland. Neither this prospectus nor any other offering or marketing material relating to the securities or the offering may be publicly distributed or otherwise made publicly
available in Switzerland. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Neither
this prospectus nor any other offering or marketing material relating to the offering, the company or the securities have been or will be filed with or approved by any Swiss regulatory
authority. In particular, this prospectus will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, and the offer of
securities has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor protection afforded to acquirers of interests in collective
investment schemes under the CISA does not extend to acquirers of securities. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


United Kingdom  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This prospectus is only being distributed to, and is only directed at, persons in the United Kingdom that are qualified investors within the meaning
of Article&nbsp;2(1)(e) of the Prospectus Directive that are also (i)&nbsp;investment professionals falling within Article&nbsp;19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005, as amended, or the Order, and/or (ii)&nbsp;high net worth entities falling within Article&nbsp;49(2)(a) to (d)&nbsp;of the Order and other persons to whom it may lawfully
be communicated, each such person being referred to as a relevant person. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This
prospectus and its contents are confidential and should not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other persons in the United Kingdom.
Any person in the United Kingdom that is not a relevant person should not act or rely on this document or any of its contents. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>179</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=181,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=264078,FOLIO='179',FILE='DISK112:[15ZCH1.15ZCH40101]EY40101A.;57',USER='CHE105889',CD=';5-AUG-2016;17:59' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ez40101_1_180"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ez40101_legal_matters"> </A>
<A NAME="toc_ez40101_1"> </A>
<BR></FONT><FONT SIZE=2><B>  LEGAL MATTERS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The validity of the shares of common stock offered hereby and certain legal matters in connection with this offering will be passed upon for us by
Honigman Miller Schwartz and Cohn&nbsp;LLP, Kalamazoo, Michigan. Cooley&nbsp;LLP, New York, New York, is counsel for the underwriters in connection with this offering. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ez40101_experts"> </A>
<A NAME="toc_ez40101_2"> </A>
<BR></FONT><FONT SIZE=2><B>  EXPERTS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Ernst&nbsp;&amp; Young&nbsp;LLP, independent registered public accounting firm, has audited our financial statements at December&nbsp;31, 2014 and
2015 and for the years then ended, as set forth in their report (which contains an explanatory paragraph describing conditions that raise substantial doubt about our ability to continue as a going
concern as described in Note&nbsp;1 to the financial statements). We have included our financial
statements in the prospectus and elsewhere in the registration statement in reliance on Ernst&nbsp;&amp; Young&nbsp;LLP's report, given on their authority as experts in accounting and auditing. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ez40101_where_you_can_find_additional_information"> </A>
<A NAME="toc_ez40101_3"> </A>
<BR></FONT><FONT SIZE=2><B>  WHERE YOU CAN FIND ADDITIONAL INFORMATION    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have filed with the SEC a registration statement on Form&nbsp;S-1, including exhibits and schedules, under the Securities Act, with respect to
the shares of common stock being offered by this prospectus. This prospectus, which constitutes part of the registration statement, does not contain all of the information in the registration
statement and its exhibits. For further information with respect to us and the common stock offered by this prospectus, we refer you to the registration statement and its exhibits. Statements
contained in this prospectus as to the contents of any contract or any other document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract or other
document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by this reference. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>You
can read our SEC filings, including the registration statement, over the Internet at the SEC's website at www.sec.gov. You may also read and copy any document we file with the SEC at its public
reference facilities at 100&nbsp;F Street, NE, Washington, D.C. 20549. You may also obtain copies of these documents at prescribed rates by writing to the Public Reference Section of the SEC at
100&nbsp;F Street, NE, Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the operation of the public reference facilities. You may also request a copy of these
filings, at no cost, by writing us at 43334 Seven Mile Road, Suite&nbsp;1000, Northville, Michigan 48167, or telephoning us at (248)&nbsp;681-9815. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Upon
the closing of this offering, we will be subject to the information reporting requirements of the Securities Exchange Act of 1934 and we will file reports, proxy statements and other information
with the SEC. These reports, proxy statements and other information will be available for inspection and copying at the public reference room and web site of the SEC referred to above. We also
maintain a website at www.gemphire.com, at which, following the closing of this offering, you may access these materials free of charge as soon as reasonably practicable after they are electronically
filed with, or furnished to, the SEC. Information contained on or accessible through our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is an
inactive textual reference only. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>180</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=182,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=873499,FOLIO='180',FILE='DISK112:[15ZCH1.15ZCH40101]EZ40101A.;34',USER='CHE108053',CD=';5-AUG-2016;02:01' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fc40101_1_1"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="fc40101_index_to_the_financial_statements"> </A>
<BR></FONT><FONT SIZE=2><B>  Index to The Financial Statements    <BR>    </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="fc40101_gemphire_therapeutics_inc._(fo__gem04960"> </A>
<BR></FONT><FONT SIZE=2><B>  Gemphire Therapeutics&nbsp;Inc.<BR>  (Formerly Known as Michigan Life Therapeutics,&nbsp;LLC)<BR>  Financial Statements<BR>  For the years ended December&nbsp;31, 2014 and 2015    <BR>    </B></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Contents  </B></FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<A NAME="FC40101_TOC"></A> </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="22pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#aa2"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Report of Independent Registered Public Accounting Firm</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#aa2"><FONT SIZE=2> F-2</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Financial Statements</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#fe40101_gemphire_therapeutics_inc._(fo__gem05398"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance Sheets</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#fe40101_gemphire_therapeutics_inc._(fo__gem05398"><FONT SIZE=2><BR>
F-3</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#fg40101_gemphire_therapeutics_inc._(fo__gem06208"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Statements of Comprehensive Loss</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#fg40101_gemphire_therapeutics_inc._(fo__gem06208"><FONT SIZE=2> F-4</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#fi40101_gemphire_therapeutics_inc._(fo__gem07956"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Statements of Changes in Convertible Preferred Stock and Stockholders' and Members'
Deficit</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#fi40101_gemphire_therapeutics_inc._(fo__gem07956"><FONT SIZE=2> F-5</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#fk40101_gemphire_therapeutics_inc._(fo__gem04455"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Statements of Cash Flows</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#fk40101_gemphire_therapeutics_inc._(fo__gem04455"><FONT SIZE=2> F-6</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#aa1"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Notes to Financial Statements</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#aa1"><FONT SIZE=2> F-7</FONT></A></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-1</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=183,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=254959,FOLIO='F-1',FILE='DISK112:[15ZCH1.15ZCH40101]FC40101A.;7',USER='CHE108053',CD=';5-AUG-2016;01:29' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fd40101_1_2"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


<A NAME="aa2"></A>Report of Independent Registered Public Accounting Firm  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Board of Directors and Shareholders<BR>
Gemphire Therapeutics&nbsp;Inc. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have audited the accompanying balance sheets of Gemphire Therapeutics&nbsp;Inc. (formerly known as Michigan Life Therapeutics,&nbsp;LLC) (the Company) as of December&nbsp;31, 2014 and 2015,
and the related statements of comprehensive loss, changes in convertible preferred stock and stockholders' and members' deficit and cash flows for each of the two years in the period ended
December&nbsp;31, 2015. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Company's internal control over financial reporting. Our
audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an
opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement
presentation. We believe that our audits provide a reasonable basis for our opinion. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Gemphire Therapeutics&nbsp;Inc. (formerly known as Michigan Life
Therapeutics,&nbsp;LLC) at December&nbsp;31, 2014 and 2015, and the results of its operations and its cash flows for each of the two years in the period ended December&nbsp;31, 2015, in
conformity with U.S. generally accepted accounting principles. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note&nbsp;1 of the financial statements, the Company has
recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also
described in Note&nbsp;1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>/s/
Ernst&nbsp;&amp; Young&nbsp;LLP<BR>
Detroit, Michigan<BR>
March&nbsp;18, 2016, except for the effects of the reverse stock split described in Note&nbsp;14, as to which the date is May&nbsp;6, 2016. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-2</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=184,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=68377,FOLIO='F-2',FILE='DISK112:[15ZCH1.15ZCH40101]FD40101A.;9',USER='CHE108053',CD=';5-AUG-2016;01:29' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fe40101_1_3"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="fe40101_gemphire_therapeutics_inc._(fo__gem05398"> </A>
<A NAME="toc_fe40101_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Gemphire Therapeutics&nbsp;Inc.<BR>  (Formerly Known as Michigan Life Therapeutics,&nbsp;LLC)<BR>  Balance Sheets<BR>  (in thousands, except share amounts and par value)    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="35pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>March&nbsp;31,<BR>
2016 </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Pro forma<BR>
March&nbsp;31,<BR>
2016 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2015 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(unaudited)</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Assets</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Current assets:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>317</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3,620</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,629</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,629</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepaid expenses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>13</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>23</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>24</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>24 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total current assets</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>330</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3,643</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,653</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,653</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred offering costs</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>847</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>979</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred tax assets</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>18</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total assets</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>348</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,500</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,637</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,658 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Liabilities, convertible preferred stock and stockholders' deficit</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Current liabilities:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts payable</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>21</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>531</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>224</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>224</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued liabilities</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>30</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,617</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,023</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,023</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred tax liabilities</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>18</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Convertible notes to related parties</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>377</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,795</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,866</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Convertible notes</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>360</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,629</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,595</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Premium conversion derivative</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>73</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>345</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>331</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total current liabilities</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>879</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>8,927</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>9,044</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,252 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total liabilities</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>879</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>8,927</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>9,044</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,252</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Commitments and contingencies (Note&nbsp;5)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;A convertible preferred stock, $0.001 par value; no shares authorized as of December&nbsp;31, 2014 and 2,325,581&nbsp;shares authorized as of
December&nbsp;31, 2015 and March&nbsp;31, 2016 (unaudited), no shares issued as of December&nbsp;31, 2014 and 745,637&nbsp;shares issued as of December&nbsp;31, 2015 and March&nbsp;31, 2016 (unaudited), no aggregate liquidation preference as of
December&nbsp;31, 2014 and aggregate liquidation preference of $7,953 and $8,102 as of December&nbsp;31, 2015 and March&nbsp;31, 2016 (unaudited), respectively, actual; no shares authorized, issued and outstanding as of March&nbsp;31, 2016, pro forma
(unaudited)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7,953</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>8,102</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stockholders' deficit:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common stock, $0.001 par value; 20,000,000&nbsp;shares authorized as of December&nbsp;31, 2014 and 17,674,419&nbsp;shares authorized as of
December&nbsp;31, 2015, and March&nbsp;31, 2016 (unaudited) respectively, 3,036,236, 3,758,488 and 3,758,488&nbsp;shares issued and outstanding at December&nbsp;31, 2014 and 2015 and March&nbsp;31, 2016 (unaudited), respectively, actual;
100,000,000&nbsp;shares authorized, 5,431,615&nbsp;shares issued and outstanding as of March&nbsp;31, 2016, pro forma (unaudited)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>9</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>12</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>12</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>12</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Additional paid-in capital</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>44</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>13,929</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated deficit</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(584</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(12,392</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(14,521</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(14,535</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stockholders' deficit</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(531</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(12,380</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(14,509</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(594</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total liabilities, convertible preferred stock and stockholders' deficit</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>348</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,500</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,637</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,658 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>See
accompanying notes. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-3</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=185,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=475006,FOLIO='F-3',FILE='DISK112:[15ZCH1.15ZCH40101]FE40101A.;24',USER='CHE108053',CD=';5-AUG-2016;01:29' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fg40101_1_4"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="fg40101_gemphire_therapeutics_inc._(fo__gem06208"> </A>
<A NAME="toc_fg40101_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Gemphire Therapeutics&nbsp;Inc.<BR>  (Formerly Known as Michigan Life Therapeutics,&nbsp;LLC)<BR>  Statements of Comprehensive Loss<BR>  (in thousands, except share and per share amounts)    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="70pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="70pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="70pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="70pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Three Months Ended<BR>
March&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2015 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2015 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2016 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(unaudited)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating expenses:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>214</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3,177</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>475</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,050</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>52</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3,991</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>206</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,176</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Acquired in-process research and development</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>908</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>908</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>266</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>8,076</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,589</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,226 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss from operations</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(266</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(8,076</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(1,589</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2,226</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest (expense) income</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(55</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(762</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(690</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>127</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss on convertible note extinguishment</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(198</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income (expense)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(320</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(9,029</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2,279</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2,103</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other comprehensive loss, net of tax</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Comprehensive loss</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(320</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(9,029</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2,279</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2,103</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(320</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(9,029</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2,279</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2,103</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adjustment to redemption value on Series&nbsp;A convertible preferred stock</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2,968</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2,517</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(149</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Premium upon substantial modification of convertible notes with certain stockholders</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(1,047</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss attributable to common stockholders</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(320</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(13,044</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,796</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2,252</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss per share:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Basic and diluted (Note&nbsp;10)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(0.21</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4.54</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2.27</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(0.65</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Number of shares used in per share calculations:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Basic and diluted</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,521,703</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,875,053</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,110,097</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3,468,764 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma net loss per share attributable to common stockholders, basic and diluted (unaudited) (Note&nbsp;2)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2.95</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(0.42</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted-average shares used in computing pro forma net loss attributable to common stockholders, basic and diluted (unaudited) (Note&nbsp;2)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,305,100</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5,301,705 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>

<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:arial;"> <FONT SIZE=2>
See accompanying notes. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-4</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=186,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=704937,FOLIO='F-4',FILE='DISK112:[15ZCH1.15ZCH40101]FG40101A.;13',USER='CHE108053',CD=';5-AUG-2016;01:29' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fi40101_1_5"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="fi40101_gemphire_therapeutics_inc._(fo__gem07956"> </A>
<A NAME="toc_fi40101_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Gemphire Therapeutics&nbsp;Inc.<BR>  (Formerly Known as Michigan Life Therapeutics,&nbsp;LLC)<BR>  Statements of Changes in Convertible Preferred Stock and Stockholders' and Members' Deficit<BR>  (in thousands, except
share amounts)    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="50pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="36pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="41pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="56pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="34pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="44pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="55pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="45pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH ROWSPAN=3 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=3 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Series&nbsp;A Convertible<BR>
Preferred Stock </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Common Stock </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</B></FONT><BR></TH>
<TH ROWSPAN=3 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=3 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Members'<BR>
Deficit </B></FONT></TH>
<TH ROWSPAN=3 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=3 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Additional<BR>
Paid-In<BR>
Capital </B></FONT></TH>
<TH ROWSPAN=3 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=3 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Accumulated<BR>
Deficit </B></FONT></TH>
<TH ROWSPAN=3 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=3 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Total<BR>
Deficit </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Shares </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Amount </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</B></FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Shares </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Amount </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR style="font-size:1.5pt;" VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;">&nbsp;<BR></TH>
<TH style="font-family:arial;">&nbsp;</TH>
<TH ALIGN="CENTER" style="font-family:arial;border-right:solid #000000 1.0pt;"><B>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</B><BR></TH>
<TH style="font-family:arial;">&nbsp;</TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Balance at January&nbsp;1, 2014</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(264</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(264</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Net loss prior to merger</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(124</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(124</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Effect of merger</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">388</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,987,817</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">6</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(6</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(388</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Restriction of initial common stock issuances</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(556,589</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(2</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">2</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Issuance of restricted stock awards</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,605,008</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">5</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(5</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Share-based compensation&nbsp;&#151; employee</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">53</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">53</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Net loss post-merger</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(196</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(196</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;">


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Balance at December&nbsp;31, 2014</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">3,036,236</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">9</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">44</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(584</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(531</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:9pt;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Issuance of convertible Series&nbsp;A preferred stock, net of issuance costs</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
745,637</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
4,985</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Redemption value adjustment&nbsp;&#151; Series&nbsp;A preferred stock</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">2,968</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1,130</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1,838</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(2,968</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Issuance of common stock</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">677,685</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">3</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">908</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">911</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Convertible note extinguishment loss</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(106</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(941</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1,047</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Issuance of restricted stock awards</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">44,567</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Share-based compensation&nbsp;&#151; employee</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">131</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">131</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Share-based compensation&nbsp;&#151; non-employee</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">153</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">153</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(9,029</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(9,029</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="BOTTOM">
<TD style="font-family:arial;">&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Balance at December&nbsp;31, 2015</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">745,637</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">7,953</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">3,758,488</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">12</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(12,392</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(12,380</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:9pt;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Redemption value adjustment&nbsp;&#151; Series&nbsp;A preferred stock</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
149</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
(123</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
(26</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
(149</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>)</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Share-based compensation&nbsp;&#151; employee</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">46</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">46</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Share-based compensation&nbsp;&#151; non-employee</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">77</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">77</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(2,103</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(2,103</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;">


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Balance at March&nbsp;31, 2016</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">745,637</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">8,102</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">3,758,488</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">12</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(14,521</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(14,509</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="BOTTOM">
<TD style="font-family:arial;">&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;">


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD style="font-family:arial;">&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>

<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:arial;"> <FONT SIZE=2>
See accompanying notes. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-5</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=187,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=827409,FOLIO='F-5',FILE='DISK112:[15ZCH1.15ZCH40101]FI40101A.;11',USER='CHE108053',CD=';5-AUG-2016;01:29' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fk40101_1_6"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="fk40101_gemphire_therapeutics_inc._(fo__gem04455"> </A>
<A NAME="toc_fk40101_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Gemphire Therapeutics&nbsp;Inc.<BR>  (Formerly Known as Michigan Life Therapeutics,&nbsp;LLC)<BR>  Statements of Cash Flows<BR>  (in thousands)    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="32pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="41pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="41pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="41pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Three Month Ended<BR>
March&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2015 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2015 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2016 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(unaudited)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>Operating activities</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(320</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(9,029</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(2,279</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(2,103</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Adjustments to reconcile net loss to net cash used in operating activities:</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:16pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Share-based compensation</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">53</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">284</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">23</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">123</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:16pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Non-cash interest on promissory notes to related parties</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">19</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:16pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Non-cash interest on convertible notes to related parties</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">5</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">40</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">11</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">31</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:16pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Non-cash interest on convertible notes</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">100</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">22</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">78</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:16pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Non-cash discount amortization on convertible notes to related parties</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">7</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">62</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">49</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(55</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:16pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Non-cash discount amortization on convertible notes</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">5</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">261</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">227</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(159</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:16pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Revaluation of premium conversion derivative</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">18</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">297</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">380</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(22</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:16pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Non-cash loss on extinguishment of convertible notes</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">198</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:16pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Non-cash acquisition of in-process research and development</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">908</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">908</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:16pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Change in assets and liabilities:</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:24pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Prepaid expenses</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">2</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(10</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(226</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:24pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Accounts payable</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(6</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">444</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">104</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(242</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:24pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Accrued liabilities</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">21</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,012</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">161</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">294 </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Net cash used in operating activities</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(195</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(5,433</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(620</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(2,056</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>Investing activities</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Net cash provided by (used in) investing activities</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>Financing activities</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Proceeds from issuance of convertible notes</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">390</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">5,560</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,650</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">101</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Proceeds from issuance of convertible notes to related parties</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">25</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,856</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">315</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">50</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Proceeds from issuance of promissory notes to related parties</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">94</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Proceeds from issuance of Series&nbsp;A convertible preferred stock</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,522</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">342</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Proceeds from issuance of common stock</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">3</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Deferred offering costs</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(205</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(86</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Net cash provided by financing activities</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">509</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">8,736</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">2,307</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">65 </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Net increase in cash and cash equivalents</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">314</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">3,303</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,687</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1,991</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Cash and cash equivalents at beginning of period</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">3</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">317</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">317</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">3,620 </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Cash and cash equivalents at end of period</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">317</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">3,620</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">2,004</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,629 </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"><I>Supplemental disclosure of cash flow information:</I></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Cash paid for income taxes</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Cash paid for interest</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">2</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"><I>Supplemental non-cash financing transactions:</I></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Conversion of convertible notes to Series&nbsp;A preferred stock</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">2,778</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">2,778</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Exercise of premium conversion derivative</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">685</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">685</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Redemption value change of Series&nbsp;A preferred stock</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">2,968</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">2,517</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">149 </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Series&nbsp;A preferred stock issue proceeds receivable from investors</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,180</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Issuance of common stock for acquisition of in-process research and development</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">908</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">908</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Bifurcation of premium conversion derivative related to convertible notes</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">55</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">842</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">232</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">9 </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Convertible note extinguishment</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,426</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Premium conversion derivative reduction upon convertible note extinguishment</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">182</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Conversion of related party promissory notes to convertible notes</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">359</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Deferred offering costs in accounts payable and accrued liabilities</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">642</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">46 </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>See
accompanying notes. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-6</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=188,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=911522,FOLIO='F-6',FILE='DISK112:[15ZCH1.15ZCH40101]FK40101A.;24',USER='CHE108053',CD=';5-AUG-2016;01:29' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fm40101_1_7"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="aa1"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B><BR>
Gemphire Therapeutics&nbsp;Inc.<BR>
(Formerly Known as Michigan Life Therapeutics,&nbsp;LLC)<BR>
Notes to Financial Statements  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


1. The Company and Basis of Presentation  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On November&nbsp;10, 2008, Michigan Life Therapeutics,&nbsp;LLC (MLT) was organized as a limited liability company (LLC) in Michigan. On
October&nbsp;30, 2014, Gemphire Therapeutics&nbsp;Inc. (Gemphire) was incorporated as a C corporation in the state of Delaware. On November&nbsp;1, 2014, MLT entered into a merger agreement with
Gemphire whereby MLT was merged with and into Gemphire with Gemphire as the surviving entity; all outstanding membership interests of MLT were exchanged for shares of Gemphire's common stock. The
purpose of the merger was to change the jurisdiction of MLT from Michigan to Delaware and to convert from an&nbsp;LLC to a corporation. All financial results presented prior to November&nbsp;1,
2014 are from the operations of MLT. MLT and Gemphire are collectively referred to as the "Company" in the accompanying notes to the financial statements. The Company's headquarters are located in
Northville, Michigan. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
are a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life
threatening cardiovascular disease. The Company's primary activities have been conducting research and development activities, planning clinical trials, performing business and financial planning,
recruiting personnel and raising capital. The Company is subject to certain risks, which include the need to research, develop, and clinically test potentially therapeutic products, initially one
product candidate gemcabene (also known as CI-1027); obtain regulatory approval for its products and commercialize them around the world; expand its management scientific staff; finance its
operations; and, find collaboration partners to further advance development and commercial efforts. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company has sustained operating losses since inception and expects such losses to continue over the next several years. Management plans to continue financing the operations with equity issuances.
If adequate funds are not available, the Company may be required to delay, reduce the scope of, or eliminate part or all of its research and development programs. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Going Concern  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company's ability to continue operating as a going concern is contingent upon, among other things, its ability to secure additional financing and
to achieve and maintain profitable operations. The Company plans to issue additional convertible debt and equity instruments to finance operating and working capital requirements. While the Company
expects to obtain the additional financing that is needed, there is no assurance that the Company will be successful in obtaining the necessary funding for future operations. These factors raise
substantial doubt as to the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of these uncertainties. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Unaudited Interim Financial Statements  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The accompanying financial statements and the financial data disclosed in the notes to the financial statements for the three months ended
March&nbsp;31, 2015 and 2016 have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). The unaudited interim financial
statements have been prepared on the same basis as the annual financial statements, and in the opinion of management, all adjustments, consisting of only normal recurring adjustments that are
necessary to present fairly the financial position, results of operations, and cash flows for the interim periods, have been made. The results of operations for the interim periods are not necessarily
indicative of the operating results for the full fiscal year or any future periods. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-7</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=189,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=891852,FOLIO='F-7',FILE='DISK112:[15ZCH1.15ZCH40101]FM40101A.;30',USER='CHE108053',CD=';5-AUG-2016;01:29' -->
<A NAME="page_fm40101_1_8"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B><BR>
Gemphire Therapeutics&nbsp;Inc.<BR>
(Formerly Known as Michigan Life Therapeutics,&nbsp;LLC)<BR>
Notes to Financial Statements &#151; (Continued) </B></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Use of Estimates  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates
and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Cash and Cash Equivalents  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company considers all highly liquid investments with an original maturity of 90&nbsp;days or less at the time of deposit to be cash equivalents. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Fair Value of Financial Instruments  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company's financial instruments include principally cash and cash equivalents, other current assets, accounts payable, accrued liabilities and
debt. The carrying amounts for these financial instruments reported in the balance sheets approximate their fair values. See Note&nbsp;11&nbsp;&#151; Fair Value Measurements, for further
discussion of fair value. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


General and Administrative Expenses  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>General and administrative expenses consist primarily of personnel-related costs, including salaries and share-based compensation costs, for personnel
in functions not directly associated with research and development activities. Other significant costs include legal fees related to intellectual property and corporate matters and professional fees
for accounting and other services. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Research and Development Expenses  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Research and development expenses consist of costs incurred in performing research and development activities, including compensation for research and
development employees, costs associated with preclinical studies and trials, regulatory activities, manufacturing activities to support clinical activities, license fees, non-legal patent costs, fees
paid to external service providers that conduct certain research and development, clinical costs and an allocation of overhead expenses. Research and development costs are expensed as incurred. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Acquired In-Process Research and Development Expenses  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company includes costs to acquire or in-license product candidates in acquired in-process research and development expenses. The Company has
acquired the right to develop and commercialize its product candidate gemcabene. These costs are immediately expensed provided that the payments do not also represent processes or activities that
would constitute a "business" as defined under GAAP or provided that the product candidate has not achieved regulatory approval for marketing and, and absent obtaining such approval, has no
alternative future use. Royalties owed on future sales of any licensed product will be expensed in the period the related revenues are recognized. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Income Taxes  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company utilizes the liability method of accounting for income taxes as required by Accounting Standards Codification (ASC) 740, </FONT> <FONT SIZE=2><I>Income Taxes</I></FONT><FONT SIZE=2>. Under this method, deferred tax assets
and liabilities are determined based on differences between financial reporting and the tax basis of
assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-8</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=190,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=36363,FOLIO='F-8',FILE='DISK112:[15ZCH1.15ZCH40101]FM40101A.;30',USER='CHE108053',CD=';5-AUG-2016;01:29' -->
<A NAME="page_fm40101_1_9"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B><BR>
Gemphire Therapeutics&nbsp;Inc.<BR>
(Formerly Known as Michigan Life Therapeutics,&nbsp;LLC)<BR>
Notes to Financial Statements &#151; (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>reverse.
Currently, there is no provision for income taxes, as the Company has incurred operating losses to date, and a full valuation allowance has been provided on the net deferred tax assets. MLT
was treated as a partnership for federal and state income tax purposes. Accordingly, no provision was made for income taxes for periods prior to November&nbsp;1, 2014, since the Company's net loss
(subject to certain limitations) was passed through to the income tax returns of its members. Upon incorporation on October&nbsp;30, 2014, the Company became taxed as a corporation. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Share-Based Compensation  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The Company accounts for share-based compensation in accordance with the provisions of ASC 718, </FONT> <FONT SIZE=2><I>Compensation&nbsp;&#151; Stock Compensation</I></FONT><FONT SIZE=2> (ASC 718). Accordingly, compensation costs
related to equity instruments granted are recognized at
the grant-date fair value. Additionally, under the provisions of ASC&nbsp;718, the Company is required to include an estimate of the number of awards that will be forfeited in calculating
compensation costs, which are recognized over the requisite service period of the awards (typically the vesting period of the awards). Share-based compensation arrangements to non-employees are
accounted for in accordance with the applicable provisions of ASC 718 and ASC 505, </FONT><FONT SIZE=2><I>Equity</I></FONT><FONT SIZE=2>, using a fair value approach. The compensation costs of these
arrangements are subject to re-measurement as the equity instruments vest and are recognized as expense over the related service period (typically the vesting period of the awards). </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Common Stock Valuation  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Due to the absence of an active market for the Company's common stock, the Company utilized methodologies in accordance with the framework of the
American Institute of Certified Public Accountants' Technical Practice Aid, </FONT><FONT SIZE=2><I>Valuation of Privately-Held Company Equity Securities Issued as Compensation</I></FONT><FONT SIZE=2>,
to estimate the fair value of its common stock. The valuation methodology includes estimates and assumptions that require the Company's judgment. These estimates and assumptions include a number of
objective and subjective factors, including external market conditions affecting the biopharmaceutical industry sector, and the likelihood of achieving a liquidity event, such as an initial public
offering (IPO) or sale. Significant changes to the key assumptions used in the valuations could result in different fair values of common stock at each valuation date. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Convertible Preferred Stock  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On March&nbsp;31, 2015, the Company issued 745,637 shares of Series&nbsp;A convertible preferred stock (the Series&nbsp;A preferred stock). The
Series&nbsp;A preferred stock is classified outside of permanent equity, in mezzanine equity, on the Company's December&nbsp;31, 2015 balance sheet. The Company initially records preferred stock
that may be redeemed at the option of the holder, or based on the occurrence of events outside of the Company's control, at the value of the proceeds received. Subsequently, if it is probable that the
preferred stock will become redeemable, the Company recognizes changes in the redemption value immediately as they occur and adjusts the carrying amount of the instrument to equal the redemption value
at the end of each reporting period. If it is not probable that the preferred stock will become redeemable, the Company does not adjust the carrying value. In the absence of retained earnings, these
charges are recorded against additional paid-in-capital, if any, and then to accumulated deficit. See Note&nbsp;7&nbsp;&#151; </FONT><FONT SIZE=2><I>Convertible Series&nbsp;A Preferred
Stock</I></FONT><FONT SIZE=2> for further discussion. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Segment Information  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the Company's
chief operating decision maker in deciding how to allocate </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-9</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=191,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=7424,FOLIO='F-9',FILE='DISK112:[15ZCH1.15ZCH40101]FM40101A.;30',USER='CHE108053',CD=';5-AUG-2016;01:29' -->
<A NAME="page_fm40101_1_10"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B><BR>
Gemphire Therapeutics&nbsp;Inc.<BR>
(Formerly Known as Michigan Life Therapeutics,&nbsp;LLC)<BR>
Notes to Financial Statements &#151; (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>resources
and assessing performance. The Company's chief operating decision maker is its Chief Executive Officer. The Company's Chief Executive Officer views the Company's operations and manages its
business in one operating segment, which is the business of development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. Accordingly, the Company has a single
reporting segment. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Jumpstart Our Business Startups Act Accounting Election  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As an emerging growth company under the Jumpstart Our Business Startups Act (JOBS Act), the Company is eligible to take advantage of certain
exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. The Company has irrevocably elected not to avail itself of this
exemption and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Unaudited Pro Forma Balance Sheet and Net Loss Per Common Share  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The unaudited pro forma balance sheet as of March&nbsp;31, 2016 reflects: (1)&nbsp;the automatic conversion of all outstanding shares of the
Company's Series&nbsp;A preferred stock into an aggregate of 745,637 shares of common stock immediately prior to the completion of an IPO; (2)&nbsp;the issuance of 59,992 shares of common stock in
accrued dividends to the Company's existing holders of the Series&nbsp;A preferred stock upon the conversion of their Series&nbsp;A preferred stock into common stock in connection with an IPO, as
described in Note&nbsp;5 below, immediately prior to the closing of an IPO; (3)&nbsp;the conversion of the convertible notes into 867,498 shares of common stock and the extinguishment of the
premium conversion derivative related to the convertible notes immediately prior to the closing of an IPO, and (4)&nbsp;the accelerated vesting of 162,945 shares of restricted stock unvested as of
March&nbsp;31, 2016, valued at approximately $14,000, held by certain employees upon the closing of an IPO. The pro forma basic and diluted net loss per share attributable to common stockholders
does not include shares expected to be sold and related proceeds to be received from an IPO. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Recent Accounting Pronouncements  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In July 2013, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2013-11, </FONT><FONT SIZE=2><I>Income
Taxes&nbsp;&#151; Topic 740</I></FONT><FONT SIZE=2>, which is an amendment to the accounting guidance on income taxes. This guidance provides clarification on the financial statement
presentation of an unrecognized benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The amendment was effective for the Company for interim and
annual periods beginning after December&nbsp;15, 2013, with early adoption permitted. The adoption of this standard did not have a material impact on the Company's financial statements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
May 2014, the FASB issued ASU 2014-09, </FONT><FONT SIZE=2><I>Revenue from Contracts with Customers&nbsp;&#151; Topic 606</I></FONT><FONT SIZE=2>, which supersedes the revenue recognition
requirements in FASB ASC 605. The new guidance primarily states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the
consideration to which the entity expects to be entitled in exchange for those goods and services. In 2015, the FASB agreed to allow companies to delay the implementation of this standard for one year
effective for annual reporting periods beginning after December&nbsp;15, 2017, including interim periods within that reporting period. Early application is permitted only for periods beginning after
December&nbsp;15, 2016. The Company is evaluating its implementation method and the impact of adopting this prospective guidance on its financial statements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
June 2014, the FASB issued ASU 2014-10, </FONT><FONT SIZE=2><I>Elimination of Certain Financial Reporting Requirements, including an Amendment to Variable Interest Entities Guidance in Topic 810,
Consolidation</I></FONT><FONT SIZE=2>. This guidance </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-10</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=192,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=27278,FOLIO='F-10',FILE='DISK112:[15ZCH1.15ZCH40101]FM40101A.;30',USER='CHE108053',CD=';5-AUG-2016;01:29' -->
<A NAME="page_fm40101_1_11"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B><BR>
Gemphire Therapeutics&nbsp;Inc.<BR>
(Formerly Known as Michigan Life Therapeutics,&nbsp;LLC)<BR>
Notes to Financial Statements &#151; (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>removed
all incremental financial reporting requirements from GAAP for development stage entities, thereby improving financial reporting by eliminating the cost and complexity associated with
providing that information. The effective date of the amendment is staggered for public and nonpublic entities with the first date being for annual periods beginning after December&nbsp;15, 2014,
with early adoption permitted for financial statements that have not yet been issued or available to be issued. The Company elected to adopt this standard early to take effect in the accompanying
financial statements and related footnotes. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
June 2014, the FASB issued ASU 2014-12, </FONT><FONT SIZE=2><I>Compensation&nbsp;&#151; Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award
Provide That a Performance Target Could Be Achieved after the Requisite Service Period</I></FONT><FONT SIZE=2> (ASU 2014-12). The amendments in ASU 2014-12 require that a performance target that
affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in ASC 718, as it relates to
awards
with performance conditions that affect vesting to account for such awards. The amendments in ASU 2014-12 are effective for annual periods and interim periods within those annual periods beginning
after December&nbsp;15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU 2014-12 either: (1)&nbsp;prospectively to all awards granted or modified after the effective
date; or (2)&nbsp;retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new
or modified awards thereafter. The adoption of this standard did not have a material impact on the Company's financial statements. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
August 2014, the FASB issued Accounting Standards Update No.&nbsp;2014-15, </FONT><FONT SIZE=2><I>Presentation of Financial Statements&nbsp;&#151; Going Concern (Subtopic 205-40):
Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern</I></FONT><FONT SIZE=2> (ASU 2014-15), which requires management to evaluate, in connection with preparing financial
statements for each annual and interim reporting period, whether there are conditions or events that, considered in the aggregate, raise substantial doubt about an entity's ability to continue as a
going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued, when applicable) and
provide related disclosures. ASU 2014-15 is effective for the annual period ending after December&nbsp;15, 2016, and for annual and interim periods thereafter. Early adoption is permitted. The
Company elected to adopt this standard early to take effect in the accompanying financial statements and related footnotes. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
January 2015, the FASB issued ASU 2015-01, </FONT><FONT SIZE=2><I>Income Statement&nbsp;&#151; Extraordinary and Unusual Items</I></FONT><FONT SIZE=2> (ASU 2015-01). ASU 2015-01 eliminates
from GAAP the concept of extraordinary items. As a result, an entity will no longer be required to separately present an extraordinary item on its statement of comprehensive loss, net of tax, after
income from continuing operations, or disclose income taxes and net income per share data applicable to an extraordinary item. However, ASU 2015-01 will still retain the presentation and disclosure
guidance for items that are unusual in nature and occur infrequently. ASU&nbsp;2015-01 is effective for fiscal years, and interim periods within those fiscal years, beginning after
December&nbsp;15, 2015. Early adoption is permitted provided the guidance is applied from the beginning of the fiscal year of adoption. The adoption of this standard did not have a material impact
on the Company's financial statements, absent any material transactions in future periods that would qualify for extraordinary item presentation under the prior guidance. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
April 2015, the FASB issued ASU 2015-03, </FONT><FONT SIZE=2><I>Interest&nbsp;&#151; Imputation of Interest</I></FONT><FONT SIZE=2> (ASU 2015-03). ASU&nbsp;2015-03 requires that debt
issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The
recognition and measurement guidance for debt issuance costs are not affected by the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-11</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=193,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=1010993,FOLIO='F-11',FILE='DISK112:[15ZCH1.15ZCH40101]FM40101A.;30',USER='CHE108053',CD=';5-AUG-2016;01:29' -->
<A NAME="page_fm40101_1_12"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B><BR>
Gemphire Therapeutics&nbsp;Inc.<BR>
(Formerly Known as Michigan Life Therapeutics,&nbsp;LLC)<BR>
Notes to Financial Statements &#151; (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>amendments
in this update. For public entities, ASU 2015-03 is effective for fiscal years, and interim periods within those fiscal years, beginning after December&nbsp;15, 2015. The adoption of this
standard did not have a material impact on the Company's financial statements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
November 2015, the FASB issued ASU 2015-17, </FONT><FONT SIZE=2><I>Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes</I></FONT><FONT SIZE=2> (ASU 2015-17). The new guidance
simplifies the presentation of deferred income taxes by requiring that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. ASU 2015-17
applies to all entities that present a classified statement of financial position. The current requirement that deferred tax liabilities and assets of a tax-paying component of an entity be offset and
presented as a single amount is not affected by this ASU. For public entities, ASU 2015-17 is effective for financial statements issued for annual periods beginning after December&nbsp;15, 2016 with
earlier application permitted. The new guidance may be applied either prospectively or retrospectively to all periods presented. The Company is evaluating its implementation method and the impact of
adopting this prospective guidance on its financial statements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
January 2016, the FASB issued ASU No.&nbsp;2016-01, </FONT><FONT SIZE=2><I>Financial Instruments&nbsp;&#151; Overall: Recognition and Measurement of Financial Assets and Financial
Liabilities.</I></FONT><FONT SIZE=2> The guidance affects the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements of
financial instruments. The guidance is effective in the first quarter of fiscal 2019. Early adoption is permitted for the accounting guidance on financial liabilities under the fair value option. The
Company is currently evaluating the impact of the new guidance on its financial statements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
February 2016, the FASB issued ASU 2016-02, </FONT><FONT SIZE=2><I>Leases (Topic</I></FONT><FONT SIZE=2> 842). The objective of this update is to increase transparency and comparability among
organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This ASU is effective for fiscal years beginning after
December&nbsp;15, 2018, including interim periods within those annual periods and is to be applied utilizing a modified retrospective approach. The Company is currently evaluating the new guidance
to determine the impact it may have on its financial statements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
March 2016, the FASB issued ASU 2016-09, </FONT><FONT SIZE=2><I>Compensation&nbsp;&#151; Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment
Accounting</I></FONT><FONT SIZE=2>. This ASU simplifies the accounting for share-based payment award transactions including: income tax consequences, classification of awards as either equity or
liabilities and classification on the statement of cash flows. This ASU is effective for fiscal years beginning after December&nbsp;15, 2016, including interim periods within those fiscal years.
Early adoption is permitted. The Company is currently evaluating the requirements of the new guidance and has not yet determined its impact on the Company's financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-12</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=194,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=526385,FOLIO='F-12',FILE='DISK112:[15ZCH1.15ZCH40101]FM40101A.;30',USER='CHE108053',CD=';5-AUG-2016;01:29' -->
<A NAME="page_fm40101_1_13"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B><BR>
Gemphire Therapeutics&nbsp;Inc.<BR>
(Formerly Known as Michigan Life Therapeutics,&nbsp;LLC)<BR>
Notes to Financial Statements &#151; (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


3. Accrued Liabilities  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Accrued liabilities consist of the following (in thousands): </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="44pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="44pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="55pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>March&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2015 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2016 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(unaudited)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued offering costs</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>575</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>687</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal costs</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>234</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>281</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Payroll</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>34</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other research and development expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>759</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>859</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other general and administrative expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>47</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>162 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>30</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,617</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2,023 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


4. Debt  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Promissory Notes to Related Parties  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The Company issued promissory notes to related parties (the Promissory Notes) at a compound interest rate of 8% per annum for an aggregate principal
amount of $0.3&nbsp;million on various dates from March 2009 through October 2014 with maturity dates through October&nbsp;31, 2014. The Promissory Notes along
with accrued interest were exchanged for convertible notes (the Convertible Notes) on November&nbsp;1, 2014, in the amount of $0.4&nbsp;million inclusive of accrued interest. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Convertible Notes  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company issued a series of Convertible Notes with certain investors beginning with the Promissory Note conversion on November1, 2014 and ending on
February&nbsp;18, 2015, whereby a total of $2.7&nbsp;million was loaned to the Company, of which $2.0&nbsp;million was loaned in 2015. Interest for the Convertible Notes compounded on a daily
basis at a rate of 8&nbsp;percent per annum. The Convertible Notes were converted into shares of the Company's Series&nbsp;A preferred stock upon close of the preferred stock financing (the
Preferred Financing) on March&nbsp;31, 2015. The conversion equaled 125% of the unpaid principal plus unpaid accrued interest on the Convertible Notes. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>At
the time of their issuance, the Convertible Notes contained a conversion premium with regard to the conversion into the Series&nbsp;A preferred stock. The Company determined that the redemption
feature under the Convertible Notes qualified as an embedded derivative and was separated from its debt host. The bifurcation of the embedded derivative from its debt host resulted in a discount to
the Convertible Notes. The discount was amortized to interest expense over the term of the Convertible Notes using the straight-line method. The embedded derivative was accounted for separately on a
fair market value basis. The embedded derivative was included as a premium conversion derivative on the accompanying balance sheets as of December&nbsp;31, 2014 and amounted to $73,000. The Company
recorded the fair value changes of the premium conversion derivative to interest expense that amounted to $18,000 and $0.4&nbsp;million for the years ended December&nbsp;31, 2014 and 2015,
respectively, and $18,000 and zero for the three months ended March&nbsp;31, 2015 and 2016, respectively. The Convertible Notes were converted into Series&nbsp;A preferred stock on
March&nbsp;31, 2015. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-13</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=195,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=126879,FOLIO='F-13',FILE='DISK112:[15ZCH1.15ZCH40101]FM40101A.;30',USER='CHE108053',CD=';5-AUG-2016;01:29' -->
<A NAME="page_fm40101_1_14"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B><BR>
Gemphire Therapeutics&nbsp;Inc.<BR>
(Formerly Known as Michigan Life Therapeutics,&nbsp;LLC)<BR>
Notes to Financial Statements &#151; (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Interim Notes  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On July&nbsp;31, 2015, the Company entered into a convertible interim note financing (the Interim Notes), pursuant to which certain investors agreed
to loan the Company approximately $2.8&nbsp;million. The Interim Notes accrue interest at a rate of 8% per annum, compounded annually, and automatically convert into shares issued to investors in
the Company's next equity financing round that results in gross proceeds of at
least $5.0&nbsp;million (a Qualified Financing). The conversion would be equal to unpaid principal at 115% plus any unpaid accrued interest. The investors would be paid out principal at 200% if a
change of control occurred before the next financing round. In the event that a Qualified Financing, change of control, or an IPO does not occur before July&nbsp;31, 2016, the parties would then
negotiate a price for conversion into a new round of stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
December 2015, the Company amended the Interim Notes and certain investors agreed to loan the Company an additional $2.7&nbsp;million for a revised financing total of $5.5&nbsp;million. The
Interim Notes continue to accrue interest at an 8% rate per annum compounded annually, but have been amended to automatically convert into shares of the same class of the Company's next convertible
preferred stock financing round (the Preferred Stock Financing). The conversion into shares issued in the Preferred Stock Financing would be equal to unpaid principal at 115% plus unpaid accrued
interest. In the event that either a change of control occurs or the Company completes a public transaction which results in the Company's stockholders holding securities listed on a national
securities exchange, including an IPO, before the Preferred Stock Financing, the Interim Notes, as amended, would automatically convert into shares of the Company's common stock at a conversion price
of $6.70585 per share (which was adjusted from $2.15 in connection with the 1-for-3.119 reverse split of our stock, which became effective on April&nbsp;27, 2016) based on 100% of outstanding
principal and unpaid accrued interest. Lastly, if a Preferred Stock Financing, change of control, or public transaction does not occur before December&nbsp;31, 2016, the parties have agreed to then
negotiate a conversion price into a new round of stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
December 2015 amendment resulted in a substantial modification to the original July 2015 Interim Notes whereby a contingent conversion feature was added to the Interim Notes. The Company recorded
the Interim Note amendment under the provisions of extinguishment accounting. The fair value of the amended Interim Notes was $1.2&nbsp;million higher than the carrying value of the Interim Notes
and the underlying premium conversion derivative on the date of the modification. The portion of the fair value increase over carrying value attributed to Interim Note holders who were also equity
investors in the Company was recorded as an adjustment to equity in the amount of $1.0&nbsp;million. The remaining $0.2&nbsp;million of the increase in fair value over carrying value was recorded
as a loss on convertible note extinguishment on the accompanying statements of comprehensive loss for the year ended December&nbsp;31, 2015. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
February 2016, certain investors agreed to loan the Company an additional $0.2&nbsp;million for a revised financing total of $5.6&nbsp;million. The Interim Notes accrue interest at an 8% rate
per annum compounded annually and automatically convert into shares of the same class of the Company's next Preferred Stock Financing. The conversion into shares issued in the Preferred Stock
Financing would be equal to unpaid principal at 115% plus unpaid accrued interest. In the event that either a change of control occurs or the Company completes a public transaction which results in
the Company's stockholders holding securities listed on a national securities exchange, including an IPO, before the Preferred Stock Financing, the Interim Notes would automatically convert into
shares of the Company's common stock at a conversion price of $6.70585 per share (which represents the original issue price of the Series&nbsp;A preferred stock) based on 100% of outstanding
principal and unpaid accrued interest. Lastly, if a Preferred Stock Financing, change of control, or public transaction does not occur before December&nbsp;31, 2016, the parties have agreed to then
negotiate a conversion price into a new round of stock. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-14</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=196,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=309413,FOLIO='F-14',FILE='DISK112:[15ZCH1.15ZCH40101]FM40101A.;30',USER='CHE108053',CD=';5-AUG-2016;01:29' -->
<A NAME="page_fm40101_1_15"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B><BR>
Gemphire Therapeutics&nbsp;Inc.<BR>
(Formerly Known as Michigan Life Therapeutics,&nbsp;LLC)<BR>
Notes to Financial Statements &#151; (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>At
the time of their issuance, the Interim Notes contained a conversion premium with regard to the conversion into shares at the time of the next Qualified Financing. The Company determined that the
redemption feature under the Interim Notes qualified as embedded derivative and was separated from its debt host. The bifurcation of the embedded derivative from its debt host resulted in a discount
to the Interim Notes. The discount was amortized to interest expense over the term of the Interim Notes using the straight-line method. The embedded derivative was accounted for separately on a fair
market value basis. The fair value of the derivative associated with the Interim Notes was $0.3&nbsp;million at December&nbsp;31, 2015 and March&nbsp;31, 2016 and was included as premium
conversion derivative on the accompanying balance sheets. The Company recorded the fair value changes of the premium conversion derivative to interest (income) expense that amounted to
$(0.1)&nbsp;million for the year ended December&nbsp;31, 2015 and $(22,000) for the quarter ended March&nbsp;31, 2016. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


5. Commitments and Contingencies  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Pfizer License Agreement  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In April 2011, the Company and Pfizer&nbsp;Inc. (Pfizer) entered into an exclusive license agreement (the Pfizer Agreement) for the clinical product
candidate gemcabene. In exchange for this worldwide exclusive right and license to certain patent rights to make, use, sell, offer for sale and import the clinical product gemcabene, the Company
agreed to certain milestone and royalty payments on future sales (See Note&nbsp;6&nbsp;&#151; </FONT><FONT SIZE=2><I>License Agreement)</I></FONT><FONT SIZE=2>. As of December&nbsp;31,
2015, there was sufficient uncertainty with regard to both the outcome of the clinical trials and the ability to obtain sufficient funding to support any of the cash milestone payments under the
license agreement, and as such, no liabilities were recorded related to the license agreement. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Series&nbsp;A Preferred Stock Dividends  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Holders of the Series&nbsp;A preferred stock are entitled to cumulative accruing dividends at a simple rate of 8% per year on the original issue
price of the preferred stock of $6.70585 per share (which was adjusted from $2.15 in connection with the 1-for-3.119 reverse split of our stock, which became effective on April&nbsp;27, 2016). The
dividends effectively accrue daily on each share of preferred stock. The dividends are payable upon the earliest to occur of (1)&nbsp;the date determined by the Board, (2)&nbsp;the liquidation of
the Company
(including a deemed liquidation event) or (3)&nbsp;the conversion or redemption of at least a majority of the outstanding shares of Series&nbsp;A preferred stock. If the board reasonably believes
that the Company is not legally able to pay the dividends in cash at the payment date, or if elected by the majority of the Series&nbsp;A preferred stockholders or if issued in connection with an
IPO, the dividends shall be paid in shares of common stock at the conversion price for the Series&nbsp;A preferred stock in effect at that time, which is the original issue price of the
Series&nbsp;A preferred stock as adjusted from time to time for any stock dividends, combinations, splits or recapitalizations. Since the dividends are payable upon a contingent event, the Company
has not recorded them in the accompanying financial statements. Cumulative unpaid dividends for the Series&nbsp;A preferred stock totaled zero as of December&nbsp;31, 2014, and $0.3&nbsp;million
and $0.4&nbsp;million as of December&nbsp;31, 2015 and March&nbsp;31, 2016, respectively. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Other Agreements  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A cancellable facility agreement was in place that provided for fixed monthly rent for the years ended December&nbsp;31, 2014 and 2015 and three
months ended March&nbsp;31, 2106. The total rent expense for the years ended December&nbsp;31, 2014 and 2015 was $6,000 and $23,000, respectively. The rent expense for the three months ended
March&nbsp;31, 2015 and 2016 was $5,000 and $8,000, respectively. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-15</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=197,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=1000652,FOLIO='F-15',FILE='DISK112:[15ZCH1.15ZCH40101]FM40101A.;30',USER='CHE108053',CD=';5-AUG-2016;01:29' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fo40101_1_16"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B><BR>
Gemphire Therapeutics&nbsp;Inc.<BR>
(Formerly Known as Michigan Life Therapeutics,&nbsp;LLC)<BR>
Notes to Financial Statements &#151; (Continued)  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


6. License Agreement  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In April 2011, the Company entered into the Pfizer Agreement for a worldwide exclusive license to certain patent rights to make, use, sell, offer for
sale and import the clinical product candidate gemcabene. In exchange for this license, the Company agreed to issue shares of its common stock to Pfizer representing 15% of the Company's fully diluted
capital at the close of its first arms-length Series&nbsp;A financing, which occurred on March&nbsp;31, 2015. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company agreed to make milestone payments totaling up to $37&nbsp;million upon the achievement of certain milestones, including the first regulatory submission in any country, regulatory
approval in each of the United States, Europe and Japan, the first anniversary of the first regulatory approval in any country, and upon achieving certain aggregate sales levels of gemcabene or any
product containing gemcabene. Future milestone payments under the Pfizer Agreement, if any, are not expected to begin for at least several years and extend over a number of subsequent years. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
Company also agreed to pay Pfizer tiered royalties on a country-by-country basis based upon the annual amount of net sales, as specified in the Pfizer Agreement until expiration of the last valid
claim of the licensed patent rights including any patent term extensions or supplemental protection certificates. Under the Pfizer Agreement, the Company is obligated to use commercially reasonable
efforts to develop and commercialize gemcabene. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On
March&nbsp;31, 2015, upon the closing of the Series&nbsp;A preferred stock financing, the Company issued 675,250 shares of its common stock, at a fair market value of $0.9&nbsp;million, to
Pfizer in connection with the first equity payment, pursuant to which Pfizer became the owner of more than 5% of the Company's capital stock. The transaction was recorded as acquired in-process
research and development expenses based on the fair market value of the common shares issued since no processes or activities that would constitute a "business" were acquired and none of the rights
and underlying assets acquired had alternative future uses or reached a stage of technological feasibility. None of the other milestone or royalty payments were triggered as of March&nbsp;31, 2016. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Pfizer Agreement will expire upon expiration of the last royalty term. Either party may terminate the Pfizer Agreement for the other party's uncured material breach or upon specified bankruptcy
events. Pfizer may terminate the Pfizer Agreement if the Company or any of its sublicenses challenge the validity, enforceability or ownership of the licensed patents. Additionally, Pfizer may revoke
the license if the Company is unable to adequately commercialize gemcabene by April 2021. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


7. Convertible Series&nbsp;A Preferred Stock  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On March&nbsp;31, 2015, the Company issued 745,637 shares of Series&nbsp;A preferred stock at a per share price of $6.70585, or
$5.0&nbsp;million in the aggregate, consisting of $1.5&nbsp;million in cash and $3.5&nbsp;million representing 125% of the principal and accrued and unpaid interest on the Convertible Notes, all
of which converted into shares of Series&nbsp;A preferred stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Series&nbsp;A preferred stock has the following rights and preferences: </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Dividend Rights  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Dividends effectively accrue on a daily basis at a simple rate of 8% per annum on the sum of the original per share issue price. Dividends are
effectively deemed declared daily and are payable upon the occurrence of certain events. In addition, the holders of the Series&nbsp;A preferred stock have rights to participate in common stock
dividends, entitling holders of Series&nbsp;A preferred stock to a dividend payable at the same </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-16</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=198,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=197418,FOLIO='F-16',FILE='DISK112:[15ZCH1.15ZCH40101]FO40101A.;40',USER='CHE108053',CD=';5-AUG-2016;01:29' -->
<A NAME="page_fo40101_1_17"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B><BR>
Gemphire Therapeutics&nbsp;Inc.<BR>
(Formerly Known as Michigan Life Therapeutics,&nbsp;LLC)<BR>
Notes to Financial Statements &#151; (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>time
as the dividend paid on common stock based on the number of shares of common stock each share of Series&nbsp;A preferred stock would convert into if such shares had converted on the record
date. There were no dividends deemed payable and accrued, but unpaid dividends were $0.3&nbsp;million and $0.4&nbsp;million as of December&nbsp;31, 2015 and March&nbsp;31, 2016, respectively
(See Note&nbsp;5&nbsp;&#151; </FONT><FONT SIZE=2><I>Commitments and Contingencies</I></FONT><FONT SIZE=2>). </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Voting Rights  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Each share of Series&nbsp;A preferred stock shall be entitled to vote together with the common stock on all actions to be taken by the stockholders
of the Company, based on the number of shares of common stock into which each share of Series&nbsp;A preferred stock could be converted. A separate vote of a majority of the outstanding shares of
Series&nbsp;A preferred stock is required to (1)&nbsp;issue or authorize any class or series of equity securities or equivalents, (2)&nbsp;effect any transaction that results in a change in
control, (3)&nbsp;change the principal business of the Company, enter new lines of business, or exit the current line of business, (4)&nbsp;issue of convertible debt above a certain threshold, or
(5)&nbsp;materially sell, transfer, license, pledge or encumber technology or intellectual property. A management stock option plan approved by the board of directors, however, is not subject to a
separate vote of the Series&nbsp;A preferred stockholders, but any subsequent increases to the authorized option pool are subject to approval by the Series&nbsp;A preferred stock holders via a
separate vote. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Liquidation Rights  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In the event of any liquidation, dissolution, or winding-up of the Company, whether voluntary or involuntary, merger, consolidation or transaction in
which over 50% of the Company's voting power is transferred, or a sale, lease, transfer, exclusive license or disposition of all or substantially all of the assets of the Company, the Series&nbsp;A
preferred stock holders shall be entitled to the assets of the Company legally available for distribution before any distribution or payment is made to the holders of common stock. The distribution
amount shall equal the original issue price of the Series&nbsp;A preferred stock (as adjusted for any stock dividends, combinations, splits or other recapitalizations since issuance), plus any
accrued or declared but unpaid dividends thereon. After payment of the full liquidation preference to the Series&nbsp;A preferred stock holders, the remaining assets legally available for
distribution shall be distributed to the holders of common stock and holders of the Series&nbsp;A preferred stock pro rata based on the number of shares of common stock each share of Series&nbsp;A
preferred stock would convert into if such shares had converted immediately prior to such liquidation, dissolution, or winding-up. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Conversion Rights  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Shares of Series&nbsp;A preferred stock, at the option of the holder, may be converted at any time into shares of common stock. The conversion rate
shall be obtained by dividing the Series&nbsp;A preferred stock original issue price of $6.70585 per share (which was adjusted from $2.15 in connection with the 1-for-3.119 reverse split of our
stock, which became effective on April&nbsp;27, 2016) by the conversion price per share in effect at the time of conversion. The Series&nbsp;A conversion price is initially equal to the original
issue price, but shall be adjusted on a broad-based weighted average basis in connection with certain dilutive events. The conversion price for the Series&nbsp;A preferred stock was $6.70585 per
share at December&nbsp;31, 2015 and March&nbsp;31, 2016. The Series&nbsp;A holder would also be entitled to receive additional shares of common stock for any unpaid Series&nbsp;A dividends
(whether or not declared). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Shares
of Series&nbsp;A preferred stock shall automatically be converted into common stock based upon the then-effective Series&nbsp;A conversion price upon the affirmative vote or consent of the
holders of at least a majority of the outstanding shares of the Series&nbsp;A preferred stock, or at the closing of a firmly underwritten public offering whereby the common stock of the Company is
listed on a U.S. national securities exchange and with a public offering price of at least 1.5 times the Series&nbsp;A original issue price of $6.70585 and net cash proceeds before underwriting
discounts of at least $50&nbsp;million. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-17</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=199,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=390051,FOLIO='F-17',FILE='DISK112:[15ZCH1.15ZCH40101]FO40101A.;40',USER='CHE108053',CD=';5-AUG-2016;01:29' -->
<A NAME="page_fo40101_1_18"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B><BR>
Gemphire Therapeutics&nbsp;Inc.<BR>
(Formerly Known as Michigan Life Therapeutics,&nbsp;LLC)<BR>
Notes to Financial Statements &#151; (Continued) </B></FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Redemption Rights  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The holders of at least 80% of the outstanding shares of Series&nbsp;A preferred stock may require the Company to redeem all outstanding shares of
Series&nbsp;A preferred stock at any time on or after December&nbsp;31, 2020 at a redemption price equal to the greater of 150% of the liquidation preference of the Series&nbsp;A preferred stock
or the fair market value per share plus any unpaid declared dividends. The liquidation preference of the Series&nbsp;A preferred stock is defined as an amount per share equal to $6.70585, as
adjusted from time to time for any stock dividends, combinations, splits or recapitalizations, plus any accrued or declared but unpaid dividends thereon. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
redemption value for redeemable preferred stock may at times be based on fair market value. The assumptions used in calculating the estimated fair market value at each reporting period represent
the Company's best estimate, however, inherent uncertainties are involved. As a result, if factors or assumptions change, the estimated fair value could be materially different. As of
December&nbsp;31, 2015 and March&nbsp;31, 2016, the estimated fair value of the Series&nbsp;A preferred stock was $7.2&nbsp;million and $7.6&nbsp;million, respectively. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company recognizes changes in the redemption value immediately as they occur and adjusts the carrying amount of the instrument to equal the redemption value at the end of each reporting period
since it is probable that the instruments will become redeemable. In the absence of retained earnings, these charges are recorded against additional paid-in-capital, if any, and then to accumulated
deficit. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company evaluated the Series&nbsp;A preferred stock and determined that it is considered an equity host under ASC 815</FONT><FONT SIZE=2><B>, </B></FONT><FONT SIZE=2><I>Derivatives and
Hedging.</I></FONT><FONT SIZE=2> In making this determination, the Company's analysis followed the whole instrument approach that compared an individual feature against the entire Series&nbsp;A
preferred stock instrument that included that feature. The Company's analysis was based on a consideration of the economic characteristics and risks of the Series&nbsp;A preferred stock. More
specifically, the Company evaluated all of the stated and implied substantive terms and features of the Series&nbsp;A preferred stock, including: (1)&nbsp;redemption features and their underlying
exercisability, (2)&nbsp;existence of any protective covenants, (3)&nbsp;nature of dividends rights, (4)&nbsp;nature of voting rights, and (5)&nbsp;the existence and nature of any conversion
rights. As a result of the above, the Company concluded that the Series&nbsp;A preferred stock represented an equity host, and as such, the redemption and/or conversion features of the
Series&nbsp;A preferred stock were considered to be clearly and closely related to the associated Series&nbsp;A preferred stock host instrument. Accordingly, the redemption and/or conversion
features of the Series&nbsp;A preferred stock were not considered an embedded derivative that required bifurcation. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


8. Stockholders' and Members' Deficit  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The membership interests of MLT were converted to 1,431,228 shares of the Company's common stock on November&nbsp;1, 2014. The MLT members' deficit
was transferred to stockholders' deficit on the accompanying balance sheets upon conversion to a C Corporation at that time. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Common Stock  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company had 3,758,488 shares of its common stock issued and outstanding as of December&nbsp;31, 2015 and March&nbsp;31, 2016. Voting, dividend
and liquidation rights of the holders of the common stock are subject to the Company's articles of incorporation, corporate bylaws and underlying shareholder agreements. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Dividend Rights  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Common stock holders are entitled to receive dividends at the sole discretion of the board of directors of the Company. There have been no dividends
declared on common stock as of March&nbsp;31, 2016. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-18</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=200,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=889502,FOLIO='F-18',FILE='DISK112:[15ZCH1.15ZCH40101]FO40101A.;40',USER='CHE108053',CD=';5-AUG-2016;01:29' -->
<A NAME="page_fo40101_1_19"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B><BR>
Gemphire Therapeutics&nbsp;Inc.<BR>
(Formerly Known as Michigan Life Therapeutics,&nbsp;LLC)<BR>
Notes to Financial Statements &#151; (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Voting Rights  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The holders of common stock are entitled to one vote for each share of common stock along with all other classes and series of stock of the Company on
all actions to be taken by the stockholders of the Company, including actions that would amend the certificate of incorporation of the Company to increase the number of authorized shares of the common
stock. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Liquidation Rights  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In the event of any liquidation, dissolution, or winding-up of the Company, the holders of common stock shall be entitled to share in the remaining
assets of the Company available for distribution post preferential distributions made to the Series&nbsp;A preferred stockholders. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Deferred Offering Costs  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Deferred offering costs, primarily consisting of legal, accounting and other direct fees and costs relating to the IPO, are capitalized. The deferred
offering costs will be offset against the Company's planned IPO proceeds upon the closing of the offering. In the event the offering is terminated, all of the deferred offering costs will be expensed
within income from operations. There was $0.8&nbsp;million and $1.0&nbsp;million in deferred offering costs capitalized as of December&nbsp;31, 2015 and March&nbsp;31, 2016, respectively.
There were no deferred offering costs capitalized as of December&nbsp;31, 2014. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


9. Share-Based Compensation  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company recognized $53,000 and $0.3&nbsp;million of share-based compensation related to employees and non-employees for the years ended
December&nbsp;31, 2014 and 2015, respectively, and $23,000 and $123,000 for the three months ended March&nbsp;31, 2015 and 2016, respectively. Share-based compensation was included in general and
administrative expense in the accompanying statements of comprehensive loss for all periods presented. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Restricted Stock Awards  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>During the years ended December&nbsp;31, 2014 and 2015, and the three month periods ended March&nbsp;31, 2015 and 2016 the Company granted an
aggregate of 1,605,008, 44,567, 44,567 and zero restricted stock awards (RSAs), respectively, to certain of its employees, members of its board of directors and consultants subject to a 2014
Shareholders Agreement (the Agreement). The RSAs are subject to various vesting schedules and generally vest ratably over a six to 24&nbsp;month period coinciding with their respective service
periods. During the years ended December&nbsp;31, 2014 and 2015, and the three month periods ended March&nbsp;31, 2015 and 2016, 610,395, 691,087, 174,241 and 165,505 RSAs vested, respectively,
and no RSAs were forfeited during these periods. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
grant-date fair value of the RSAs issued during the years ended December&nbsp;31, 2014 and 2015 and the three months ended March&nbsp;31, 2015 and 2016 was $140,000, $9,000, $9,000 and zero,
respectively. Grant date fair market value was based on traditional valuation techniques and methods in determining the fair value of the Company's equity as a private company including market,
income, and cost valuation approaches. A number of objective and subjective factors were considered including contemporaneous and retrospective valuations of its
common stock performed by an unrelated valuation specialist, sales of the Company's convertible preferred stock to unrelated third parties, valuations of comparable peer public companies, the lack of
liquidity of the Company's capital stock and general and industry-specific economic outlook. The fair value of the Company's common stock will be determined by the Company's board of directors until
such time as the Company's common stock is listed on an established stock exchange. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-19</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=201,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=755773,FOLIO='F-19',FILE='DISK112:[15ZCH1.15ZCH40101]FO40101A.;40',USER='CHE108053',CD=';5-AUG-2016;01:29' -->
<A NAME="page_fo40101_1_20"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B><BR>
Gemphire Therapeutics&nbsp;Inc.<BR>
(Formerly Known as Michigan Life Therapeutics,&nbsp;LLC)<BR>
Notes to Financial Statements &#151; (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A
summary of RSA grant activity is as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="63pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Number of<BR>
Shares </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Non-vested at January&nbsp;1, 2014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Granted</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,605,008</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vested</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(610,395</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Non-vested at December&nbsp;31, 2014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>994,613</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Granted</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>44,567</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vested</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(691,087</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Non-vested at December&nbsp;31, 2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>348,093</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Granted</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vested</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(165,505</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Non-vested at March&nbsp;31, 2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>182,588 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Stock Options  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In April 2015, the Company adopted a 2015 Equity Incentive Plan (the 2015 Plan) under which 320,615 shares of the Company's common stock were reserved
for issuance to employees, directors and consultants. The 2015 Plan permits the grant of incentive and non-statutory stock options, appreciation rights, restricted stock, restricted stock units,
performance stock and cash awards, and other stock-based awards. Under this plan, 305,278 stock options were granted beginning on May&nbsp;1, 2015 through December&nbsp;31, 2015 and no options
were granted in the first quarter ended March&nbsp;31, 2016. Options granted under the 2015 Plan either generally vested immediately, or ratably over a two to 36&nbsp;month period coinciding with
their respective service periods. As of December&nbsp;31, 2015 and March&nbsp;31, 2016, 15,337 shares were available for future issuance under the 2015 Plan. During the year ended
December&nbsp;31, 2015 and the three months ended March&nbsp;31, 2016, 104,907 and 35,385 stock options vested, respectively, and no stock options were forfeited. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company measures the fair value of stock options with service-based and performance-based vesting criteria to employees, consultants and directors on the date of grant using the Black-Scholes
option pricing model. The fair value of equity instruments issued to non-employees is re-measured as the award vests. The Company does not have history to support a calculation of volatility and
expected term. As such, the Company has used a weighted-average volatility considering the volatilities of several guideline companies. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For
purposes of identifying similar entities, the Company considered characteristics such as industry, length of trading history, and stage of life cycle. The assumed dividend yield was based on the
Company's expectation of not paying dividends in the foreseeable future. The average expected life of the options was determined based on the mid-point between the vesting date and the end of the
contractual term according to the "simplified method" as described in Staff Accounting Bulletin 110. The risk-free interest rate is determined by reference to implied yields available from U.S.
Treasury securities with a remaining term equal to the expected life assumed at the date of grant. Forfeitures are estimated based on the Company's historical analysis of both options and awards that
forfeited prior to vesting. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-20</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=202,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=114627,FOLIO='F-20',FILE='DISK112:[15ZCH1.15ZCH40101]FO40101A.;40',USER='CHE108053',CD=';5-AUG-2016;01:29' -->
<A NAME="page_fo40101_1_21"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B><BR>
Gemphire Therapeutics&nbsp;Inc.<BR>
(Formerly Known as Michigan Life Therapeutics,&nbsp;LLC)<BR>
Notes to Financial Statements &#151; (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
weighted-average assumptions used in the Black-Scholes option-pricing model are as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="39pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="39pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="74pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Three Months<BR>
Ended<BR>
March&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2015 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2016 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected stock price volatility</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>71.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected life of options (years)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>5.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected dividend yield</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk free interest rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>The
following table summarizes the Company's stock option plan activity for the year ended December&nbsp;31, 2015 and the three months ended March&nbsp;31, 2016 as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="59pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="59pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="59pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="70pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Number of<BR>
Options </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Weighted<BR>
Average<BR>
Exercise<BR>
Price </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Weighted-<BR>
Average<BR>
Remaining<BR>
Contractual<BR>
Term (years) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Aggregate<BR>
Intrinsic<BR>
Value<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font> </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding at December&nbsp;31, 2014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Granted</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>305,278</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2.42</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,042,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercised</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(2,436</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.34</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(11,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Forfeited/Cancelled</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding at December&nbsp;31, 2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>302,842</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2.43</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>9.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,031,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Granted</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercised</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Forfeited/Cancelled</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding at March&nbsp;31, 2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>302,842</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2.43</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>9.3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,461,000 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vested and exercisable at March&nbsp;31, 2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>140,292</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2.05</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>9.3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>724,000 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vested and expected to vest at March&nbsp;31, 2016<SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>302,842</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2.43</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>9.3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,461,000 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Options
that are expected to vest are net of estimated future option forfeitures in accordance with the provisions of ASC&nbsp;718, </FONT> <FONT  style="font-size:8pt;line-height:9pt;"><I>Compensation&nbsp;&#151; Stock Compensation</I></FONT><FONT  style="font-size:8pt;line-height:9pt;">
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of our
common stock as of December&nbsp;31, 2015 and March&nbsp;31, 2016 of $5.83 and $7.20 per share, respectively. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>The weighted average fair value per share of options granted during the year ended December&nbsp;31, 2015 was $1.50. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Unrecognized
share-based compensation cost for the RSAs and stock options issued under the Agreement and the 2015 Plan was $0.4&nbsp;million (net of estimated forfeitures) as of March&nbsp;31,
2016. Approximately $40,000 of the unrecognized compensation cost was related to the RSAs as of March&nbsp;31, 2016, and $0.3&nbsp;million was related to the stock options. The non-employee
portion of the unrecognized compensation cost was estimated utilizing the Company's fair market value for its common stock as of March&nbsp;31, 2016. The unrecognized share-based expense is expected
to be recognized over a weighted average period of 0.5&nbsp;years for the RSAs and 1.4&nbsp;years for the stock options at March&nbsp;31, 2016. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-21</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=203,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=264196,FOLIO='F-21',FILE='DISK112:[15ZCH1.15ZCH40101]FO40101A.;40',USER='CHE108053',CD=';5-AUG-2016;01:29' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fq40101_1_22"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B><BR>
Gemphire Therapeutics&nbsp;Inc.<BR>
(Formerly Known as Michigan Life Therapeutics,&nbsp;LLC)<BR>
Notes to Financial Statements &#151; (Continued)  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


10. Net Loss Per Common Share  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Basic earnings or loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding
during the period. The holders of the Series&nbsp;A preferred stock have rights to participation in common stock dividends, entitling the holders of Series&nbsp;A preferred stock to a dividend
payable at the same time and rate per share as the dividend paid on common stock based the number of shares of common stock each share of Series&nbsp;A preferred stock would convert into if such
shares had converted on the record date. The Series&nbsp;A preferred stock, however, does not have a contractual obligation to share in the losses of the Company, and as such, no losses were
allocated to the Series&nbsp;A preferred stock for the purposes of the basic loss per share calculation. Prior to the Company's incorporation, no common shares were outstanding when the Company
operated as MLT. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Diluted
earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares
from the assumed exercise of any common stock equivalents, if dilutive. The Company's RSAs, stock options, shares of Series&nbsp;A preferred stock and convertible notes are considered common stock
equivalents for this purpose. Diluted earnings is computed utilizing the treasury method for the RSAs and stock options, and in the case of the Series&nbsp;A preferred stock, either the two-class
method or the if-converted method, whichever is more dilutive. Diluted earnings with respect to the convertible notes utilizing the if-converted method was not applicable during the years ended
December&nbsp;31, 2014 and 2015 and three months ended March&nbsp;31, 2015 and 2016, as no conditions required for conversion have occurred during these periods. No incremental common stock
equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss
reported for the years ended December&nbsp;31, 2014 and 2015 and three months ended March&nbsp;31, 2015 and 2016. The following table sets forth the computation of basic and diluted loss per share
(in thousands, except share and per share amounts): </FONT></P>
 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="70pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="70pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="70pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="70pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Three Months Ended<BR>
March&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2015 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2015 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2016 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(unaudited)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Numerator:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(320</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(9,029</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2,279</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2,103</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adjustment for Series&nbsp;A preferred stock redemption value accretion</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2,968</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2,517</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(149</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Premium upon substantial modification of convertible notes with certain stockholders</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(1,047</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss attributed to common stock holders</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(320</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(13,044</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,796</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2,252</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Denominator:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Basic and diluted weighted average common shares outstanding</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,521,703</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,875,053</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,110,097</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3,468,764 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Basic and diluted net loss per share</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(0.21</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4.54</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2.27</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(0.65</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-22</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=204,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=197942,FOLIO='F-22',FILE='DISK112:[15ZCH1.15ZCH40101]FQ40101A.;58',USER='CHE108053',CD=';5-AUG-2016;01:29' -->
<A NAME="page_fq40101_1_23"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B><BR>
Gemphire Therapeutics&nbsp;Inc.<BR>
(Formerly Known as Michigan Life Therapeutics,&nbsp;LLC)<BR>
Notes to Financial Statements &#151; (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
following potential common shares were not considered in the computation of diluted net loss per share as their effect would have been anti-dilutive: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="51pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="51pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="51pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="51pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Three Months Ended<BR>
March&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2015 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2015 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2016 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(unaudited)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Restricted stock awards</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>994,613</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>348,093</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>864,932</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>182,588</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stock options</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>302,842</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>302,842</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;A</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>745,637</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>745,637</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>745,637</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Convertible notes</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>828,751</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>867,498</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


11. Fair Value Measurements  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company follows accounting guidance that emphasizes that fair value is a market-based measurement, not an entity specific measurement. Fair value
is defined as "the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date." Fair value measurements
are defined on a three level hierarchy: </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>Level&nbsp;1 inputs:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Unadjusted quoted prices for identical assets or liabilities in active markets; </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>Level&nbsp;2 inputs:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or
inputs which are observable, weather directly or indirectly, for substantially the full term of the asset or liability; </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>Level&nbsp;3 inputs:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Unobservable inputs that reflect the Company's own assumptions about the assumptions market participants would use in
pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>As
of December&nbsp;31, 2014 and 2015 and March&nbsp;31, 2016, the fair values of cash and cash equivalents, other assets, accounts payable and accrued liabilities approximated their carrying
values because of the short-term nature of these assets or liabilities. The estimated fair value of the Company's Convertible Notes and Interim Notes was based on amortized cost which was deemed to
approximate fair value. The derivative liability associated with the conversion premium on the Convertible Notes and Interim Notes was based on cash flow models discounted at current implied market
rates evidenced in recent arms-length transactions representing expected returns by market participants for similar instruments which were based on Level&nbsp;3 inputs. There were no transfers
between fair value hierarchy levels for the years ended December&nbsp;31, 2014 and 2015 and for the three months ended March&nbsp;31, 2015 and 2016. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-23</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=205,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=845508,FOLIO='F-23',FILE='DISK112:[15ZCH1.15ZCH40101]FQ40101A.;58',USER='CHE108053',CD=';5-AUG-2016;01:29' -->
<A NAME="page_fq40101_1_24"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B><BR>
Gemphire Therapeutics&nbsp;Inc.<BR>
(Formerly Known as Michigan Life Therapeutics,&nbsp;LLC)<BR>
Notes to Financial Statements &#151; (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
fair value of financial instruments measured on a recurring basis is as follows (in thousands): </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="36pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="36pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="36pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="36pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=13 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>December&nbsp;31, 2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:40pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Description

<!-- COMMAND=ADD_SCROPPEDRULE,40pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Total </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Level&nbsp;1 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Level&nbsp;2 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Level&nbsp;3 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Liabilities:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Premium conversion derivative</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>73</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>73 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total liabilities at Fair Value</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>73</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>73 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="36pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="36pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="36pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="36pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=13 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>December&nbsp;31, 2015 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:40pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Description

<!-- COMMAND=ADD_SCROPPEDRULE,40pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Total </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Level&nbsp;1 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Level&nbsp;2 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Level&nbsp;3 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Liabilities:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Premium conversion derivative</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>345</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>345 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total liabilities at Fair Value</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>345</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>345 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="36pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="36pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="36pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="36pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=13 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>March&nbsp;31, 2016 (unaudited) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:40pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Description

<!-- COMMAND=ADD_SCROPPEDRULE,40pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Total </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Level&nbsp;1 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Level&nbsp;2 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Level&nbsp;3 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Liabilities:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Premium conversion derivative</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>331</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>331 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total liabilities at Fair Value</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>331</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>331 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>The
following table provides a roll-forward of the Company's premium conversion derivative liabilities measured at fair value on a recurring basis using unobservable level&nbsp;3 inputs (in
thousands): </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="37pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="37pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="37pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="37pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Three Months Ended<BR>
March&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2015 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2015 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2016 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(unaudited)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance as of beginning of period</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>73</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>73</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>345</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Issuance of underlying convertible notes</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>55</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>842</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>842</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>8</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value of premium conversion derivative</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>18</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>297</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>297</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(22</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Reversal of premium conversion derivative associated with note extinguishment</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(182</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(182</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Redemption of underlying convertible notes</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(685</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(685</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance as of end of period</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>73</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>345</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>345</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>331 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>There
were no financial instruments measured on a non-recurring basis for any of the periods presented. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


12. Income Taxes  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The effective tax rate for the years ended December&nbsp;31, 2014 and 2015 and three months ended March&nbsp;31, 2015 and 2016 was zero percent.
MLT was treated as a partnership for federal and state income tax purposes. Accordingly, no provision was made for income taxes for periods prior to the merger, since the Company's net loss (subject
to certain limitations) was passed through to the income tax returns of its members. Upon the incorporation of Gemphire on October&nbsp;30, 2014, the Company became taxed as a corporation. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-24</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=206,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=526878,FOLIO='F-24',FILE='DISK112:[15ZCH1.15ZCH40101]FQ40101A.;58',USER='CHE108053',CD=';5-AUG-2016;01:29' -->
<A NAME="page_fq40101_1_25"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B><BR>
Gemphire Therapeutics&nbsp;Inc.<BR>
(Formerly Known as Michigan Life Therapeutics,&nbsp;LLC)<BR>
Notes to Financial Statements &#151; (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A
reconciliation of income tax computed at the statutory federal income tax rate to the provision (benefit) for income taxes included in the accompanying statements of comprehensive loss is as
follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="34pt" style="font-family:arial;"></TD>
<TD WIDTH="18pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="34pt" style="font-family:arial;"></TD>
<TD WIDTH="18pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="34pt" style="font-family:arial;"></TD>
<TD WIDTH="18pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="34pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Three Months Ended<BR>
March&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2015 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2015 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2016 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(unaudited)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Income tax (benefit) provision at federal statutory rate</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (34.0</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (34.0</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (34.0</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> (34.0</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Non-benefited losses from valuation allowance</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>36.8</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>38.2</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>37.6</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>37.0</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>State income tax, net of federal benefit</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4.0</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4.0</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4.0</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4.0</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Convertible notes</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1.2</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>0.6</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2.0</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(0.8</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>0.4</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(1.0</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Effective tax rate</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

<P style="font-family:arial;"><FONT SIZE=2>Significant
components of the Company's deferred tax assets and liabilities are summarized in the tables below as of (in thousands): </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="49pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="49pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="55pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of<BR>
March&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2015 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2016 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(unaudited)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred tax assets:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Federal and state operating loss carryforwards</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>93</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,723</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3,525</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Acquired intangibles</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>345</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>345</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Convertible notes</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>11</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>460</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>369</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Charitable contributions</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accruals and reserves</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>41</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>73</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development credit carryforwards</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>95</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>125 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>104</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3,668</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,441</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Valuation allowance</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(72</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(3,657</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,436</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total deferred tax assets, net of valuation allowance</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>32</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>11</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred tax liabilities:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Restricted stock awards</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(32</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(11</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(5</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total deferred tax liabilities</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(32</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(11</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(5</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net deferred tax assets</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="30pt" style="font-family:arial;"></TD>
<TD WIDTH="18pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="30pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="55pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of<BR>
March&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2015 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2016 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(unaudited)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>As reported on the balance sheets:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Non-current deferred tax assets, net</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Current deferred tax liabilities, net</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:28pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net deferred tax assets or liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-25</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=207,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=419094,FOLIO='F-25',FILE='DISK112:[15ZCH1.15ZCH40101]FQ40101A.;58',USER='CHE108053',CD=';5-AUG-2016;01:29' -->
<A NAME="page_fq40101_1_26"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B><BR>
Gemphire Therapeutics&nbsp;Inc.<BR>
(Formerly Known as Michigan Life Therapeutics,&nbsp;LLC)<BR>
Notes to Financial Statements &#151; (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
of December&nbsp;31, 2014 and 2015 and March&nbsp;31, 2016, the Company had gross deferred tax assets of approximately $0.1&nbsp;million, $3.7&nbsp;million and $4.4&nbsp;million,
respectively. Realization of the deferred assets is primarily dependent upon future taxable income, if any, the amount and timing of which are uncertain. The Company has had significant pre-tax losses
since its inception. The Company has not yet generated revenues and faces significant challenges to becoming profitable. Accordingly, the net deferred tax assets have been fully offset by a valuation
allowance of $72,000, $3.7&nbsp;million and $4.4&nbsp;million as of December&nbsp;31, 2014 and 2015 and March&nbsp;31, 2016, respectively. U.S. net deferred tax assets will continue to require
a valuation allowance until the Company can demonstrate their realizability through sustained profitability or another source of income. Except for the Convertible Notes and a portion of the RSAs, the
deferred tax assets and liabilities are non-current as of the dates reported. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
of December&nbsp;31, 2014 and 2015 and March&nbsp;31, 2016, the tax effect of the Company's federal net operating loss carryforwards was approximately $83,000, $2.4&nbsp;million and
$3.1&nbsp;million, respectively. The Company had federal research credit carryforwards as of December&nbsp;31, 2014 and 2015 and March&nbsp;31, 2016 of approximately $114, $95,000 and $125,000,
respectively. The federal net operating loss and tax credit carryforwards will begin to expire in 2034 if not utilized. As of December&nbsp;31, 2014 and 2015 and March&nbsp;31, 2016, the Company
had state net operating loss carryforwards with a tax effect of approximately $10,000, $0.3&nbsp;million and $0.4&nbsp;million, respectively. The Company did not have state research credit
carryforwards as of December&nbsp;31, 2014 and 2015 and March&nbsp;31, 2016. The state net operating loss carryforwards will begin to expire in 2024 if not utilized. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Utilization
of the net operating loss carryforwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by Section&nbsp;382 of the Internal
Revenue Code of 1986, as amended, and similar state provisions. Generally, in addition to certain entity reorganizations, the limitation applies when one or more "5-percent shareholders" increase
their ownership, in the aggregate, by more than 50&nbsp;percentage points over a 36-month time period testing period, or beginning the day after the most recent ownership change, if shorter. The
annual limitation may result in the expiration of net operating losses and credits before utilization. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company recognizes interest and/or penalties related to uncertain tax positions in income tax expense. There were no uncertain tax positions as of December&nbsp;31, 2014 and 2015 and
March&nbsp;31, 2016, and as such, no interest or penalties were recorded to income tax expense. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company's corporate returns are subject to examination for the 2014 tax year in the federal and Michigan jurisdictions. Prior to this period, the Company filed partnership returns, resulting in
its income being passed through to its members. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


13. Related Party Transactions  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company rented an office in Northville, Michigan from an&nbsp;LLC owned by two officers under a short-term agreement during the years ended
December&nbsp;31, 2014 and 2015 and three months ended March&nbsp;31, 2016. Rent expense under the related party agreement was $6,000, $23,000, $5,000 and $8,000 during the years ended
December&nbsp;31, 2014 and 2015 and three months ended March&nbsp;31, 2015 and 2016, respectively. A prepaid rent balance related to the short-term agreement amounted to $3,000 as of both
December&nbsp;31, 2014 and 2015 and March&nbsp;31, 2016. As of December&nbsp;31, 2014, amounts owed to an officer and a member of management of the Company under the Convertible Notes, inclusive
of interest, were $0.3&nbsp;million and $48,000, respectively. In addition, amounts owed to an investor related to one of the Company's officers, inclusive of interest, as of December&nbsp;31,
2014 under the Convertible Note were $25,000. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-26</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=208,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=725548,FOLIO='F-26',FILE='DISK112:[15ZCH1.15ZCH40101]FQ40101A.;58',USER='CHE108053',CD=';5-AUG-2016;01:29' -->
<A NAME="page_fq40101_1_27"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B><BR>
Gemphire Therapeutics&nbsp;Inc.<BR>
(Formerly Known as Michigan Life Therapeutics,&nbsp;LLC)<BR>
Notes to Financial Statements &#151; (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>During
the first quarter of 2015, the Company issued $2.0&nbsp;million of additional Convertible Notes (the 2015 Notes) as part of the Convertible Notes described in
Note&nbsp;4&nbsp;&#151; </FONT><FONT SIZE=2><I>Debt</I></FONT><FONT SIZE=2>. The 2015 Notes included four notes in the aggregate of $0.3&nbsp;million issued to investors who were related
to one board member and three officers of the Company. On March&nbsp;31, 2015, all of the Convertible Notes (including the 2015 Notes) were converted into 516,421&nbsp;shares of Series&nbsp;A
preferred stock. The conversion included a total of 68,649&nbsp;shares of Series&nbsp;A preferred
stock issued to two officers of the Company, and 63,967&nbsp;shares of Series&nbsp;A preferred stock issued to investors related to one board member and three officers of the Company. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>During
the third quarter of 2015, the Company issued $2.8&nbsp;million of Interim Notes as described in Note&nbsp;4&nbsp;&#151; </FONT><FONT SIZE=2><I>Debt</I></FONT><FONT SIZE=2>. The
Interim Notes included five notes issued to two officers and three board members (or entities they control) in the amount of $0.5&nbsp;million. In addition, the Interim Notes included four notes to
investors who were related to three of the Company's officers and to one of the Company's key employees in the amount of $0.3&nbsp;million. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
December 2015, the Company issued an additional $2.7&nbsp;million of Interim Notes, as described in Note&nbsp;4&nbsp;&#151; </FONT><FONT SIZE=2><I>Debt,</I></FONT><FONT SIZE=2> which
included six notes issued to two officers and four board members in the amount of $0.6&nbsp;million. The December 2015 Interim Note issuances also included five notes to investors who were related
to three of the Company's officers in the amount of $0.2&nbsp;million. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
February 2016, the Company issued an additional $151,000 of Interim Notes, as described in Note&nbsp;4&nbsp;&#151; </FONT><FONT SIZE=2><I>Debt</I></FONT><FONT SIZE=2>, which included two
notes issued to two board members (or entities they control) in the amount of $81,000. The February 2016 Interim Note issuances also included a $20,000 note to an investor who is related to an officer
of the Company. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


14. Subsequent Events  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company has evaluated subsequent events that may require adjustment to or disclosure in the financial statements through March&nbsp;18, 2016,
the date the financial statements were originally issued, through May&nbsp;6, 2016, the date on which the retrospectively revised financial statements were issued to reflect the Reverse Stock Split
and interim financial statements for the three months ended March&nbsp;31, 2016 were issued, and through June&nbsp;13, 2016 for inclusion in the registration statement on Form&nbsp;S-1. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Reverse Stock Split  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In April 2016, the Board of Directors and shareholders approved a 1-for-3.119 reverse stock split (the Reverse Stock Split) for all common and
Series&nbsp;A preferred stock, which became effective on April&nbsp;27, 2016 upon the filing of an amendment to the Company's certificate of incorporation. The authorized shares and par value of
the common stock and Series&nbsp;A preferred stock were not adjusted as a result of the Reverse Stock Split. All issued and outstanding common and Series&nbsp;A preferred stock, options for common
stock
and per share amounts contained in the financial statements have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Interim Notes  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In April 2016, the Company amended the Interim Notes and certain investors agreed to loan the Company an additional $5.0&nbsp;million for a revised
financing total, including Interim Notes previously issued, of $10.6&nbsp;million. The Interim Notes continue to accrue interest at an 8% rate per annum compounded annually, but have been amended so
that 125% of the unpaid principal and accrued interest, automatically converts into shares of the same class of the Company's next convertible preferred stock financing round of at least
$5.0&nbsp;million (the Qualified Financing). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
April 2016 Interim Note issuances included two notes to investors who were related to two of the Company's officers in the aggregate amount of $0.2&nbsp;million. The April 2016 Interim Note
issuances also </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-27</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=209,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=975608,FOLIO='F-27',FILE='DISK112:[15ZCH1.15ZCH40101]FQ40101A.;58',USER='CHE108053',CD=';5-AUG-2016;01:29' -->
<A NAME="page_fq40101_1_28"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B><BR>
Gemphire Therapeutics&nbsp;Inc.<BR>
(Formerly Known as Michigan Life Therapeutics,&nbsp;LLC)<BR>
Notes to Financial Statements &#151; (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>included
three notes to investors who were related to three of the Company's directors in the aggregate amount of $2.3&nbsp;million. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
the event that either a change of control occurs or the Company completes a public transaction which results in the Company's stockholders holding securities listed on a national securities
exchange, including an IPO, before the Qualified Financing, 100% of outstanding principal and unpaid accrued interest on the Interim Notes, as amended, would automatically convert into shares of the
Company's common stock at a conversion price of $6.70585 per share, as adjusted for the Reverse Stock Split. Lastly, if a Qualified Financing, change of control, or public transaction does not occur,
the Interim Notes will become payable on demand anytime after December&nbsp;31, 2016. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Amendment and Restatement of 2015 Equity Incentive Plan  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In April 2016 the Company's board of directors approved the Company's amended and restated 2015 Plan (the A&amp;R 2015 Plan). The Company's stockholders
also approved the A&amp;R 2015 Plan in April, which will become effective immediately upon the execution and delivery of the underwriting agreement related to this offering. The A&amp;R 2015 Plan provides for
the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance-based stock awards and other forms of equity awards, as well as performance
cash awards. The Company initially reserved 2,400,000&nbsp;shares of common stock for issuance under the A&amp;R 2015 Plan. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Adoption of 2016 Employee Stock Purchase Plan  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In April 2016 the Company's board of directors approved the 2016 Employee Stock Purchase Plan (the ESPP) in order to enable eligible employees to
purchase shares of the Company's common stock at a discount following the date of this offering. The Company's stockholders also approved the ESPP in April, which will become effective immediately
upon the execution and delivery of the underwriting agreement related to this offering. The Company initially reserved 150,000&nbsp;shares of common stock for issuance under the ESPP. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Stock-Based Compensation  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In April and June 2016, the compensation committee of the board of directors of the Company approved the award of options to purchase an aggregate of
1,825,200&nbsp;shares of common stock to the Company's officers, directors and employees, with an exercise price equal to the per share price of this offering, to be granted in connection with this
offering. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Lease Agreement  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In May 2016, the Company entered into a new lease agreement, commencing August&nbsp;1, 2016, for approximately 5,300 square feet of office space to
be used for the Company's headquarters. The initial term of the agreement is 3&nbsp;years with an initial monthly base rent of approximately $8,400. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-28</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=210,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=1009903,FOLIO='F-28',FILE='DISK112:[15ZCH1.15ZCH40101]FQ40101A.;58',USER='CHE108053',CD=';5-AUG-2016;01:29' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg40101a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><div
style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g684562.jpg" ALT="LOGO" WIDTH="684" HEIGHT="244">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>3,000,000 Shares  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>Common Stock  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="28%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="28%" ALIGN="CENTER" >


  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B>PROSPECTUS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B>


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="28%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="28%" ALIGN="CENTER" >


 </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><I>Joint Book-Running Managers  </I></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>Jefferies<BR>
RBC Capital Markets  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><I>Co-Lead Manager  </I></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>Canaccord Genuity  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><I>Co-Managers  </I></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>Laidlaw &amp; Company (UK) Ltd.<BR>
LifeSci Capital  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>August&nbsp;4, 2016 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><div
style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=211,EFW="2229387",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=658079,FOLIO='blank',FILE='DISK112:[15ZCH1.15ZCH40101]HO40101A.;49',USER='CHE105889',CD=';5-AUG-2016;18:05' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g342833.jpg
<DESCRIPTION>G342833.JPG
<TEXT>
begin 644 g342833.jpg
M_]C_X  02D9)1@ ! 0$ @0"!  #__@ N35),3%]'4D%02$E#4SI;4%)/2D5#
M5%]=1T5-4$A)4D5?-$-?3$]'3RY%4%/_VP!#  $! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !G +0# 2(  A$! Q$!
M_\0 '  !  ,!  ,!              @)"@<!!08"_\0 -!   00#  (!! $#
M P(& P  !0,$!@<! @@ "1$2$Q0A%18Q00I1D6&!%Q@B(V)QL='A_\0 &P$!
M  ,! 0$!              0%!@,' @'_Q  L$0 " P " P " @$#! ,    "
M P$$!0 1!A(3%"$B,0<C05,5%B0R,U)A_]H # ,!  (1 Q$ /P#?QX\>/'''
MCQX\<<>/'CQQQX\>/'''CQX\<<>/'CQQQX\>/'''CQX\<<?V_OY5GV?W1:<6
MF3_DW@JIVO2?:[P,P*'6!1TH+HSF6,GFZRXB>=)3[51N.!/"K5++Z$5.U(HS
MN<MOH)MVC,'LV=DNZ=(W//R4V!\F\W$6@WH&PHPXE<ILAZ-:'@'+]-JNW816
MZ)$#>Z[CY',SYMH]BE$5T2QJTG$U9&) ;34KZNIUOKV?GWGBLN:*^;U[60IV
MBV<%"$HE\KD#]603^SK .[:+2JSK1F3W7^7G-BRYXGAW()074W<+?0W',$AP
M,>+%,=!0"EE"G2U*@:#F1#L['>3 K.&"F!NZI)-;YI28D**26I?>D2:Q]>H*
M_P ZN>;K9'6JME"PF0M7 ZE@%,1,HJ>T$'W]9[8\Q($=B(@QTE\,V-F_Z?CM
M#N-FUE/L.]I$NFTRU5<E15>UK50Y>H:\,O$=4MDXH,*G8B)59-D<[,]EAT&C
M3]XEC.RK[;=555;G7.G*7L ]%W47,,18WUMTWZZNC[UB5 3$#@$0 J55/K@?
M9#0^7JP=V\E6T)>.YB\;:I2:&R9['I8FF_C\R#B2Y&+/?-@GGH9%%H[+6K!C
M)0HXXT%GH]*![<DV3=),I%$S+*0QHRVU4QG[1$(<',2@YSI\*-GC5%;3/SK^
M]BO_ "SY*^F[#V%Y.CXO92])^/+PL6A2J?53%*M9<TJ"&T+M(CA]6PMGM#A@
MG?7V+VI2\0RUV T*7Y-;740&.D5RV][O4@(UVX:\A>ET#Z,7(Q'I,B'K'ZY[
MW'SG&/GX^?\ /Q_;YQ_?X^?W\?/]O//C^WCSR[FKX\>/'CCCQX\@#W_[*>8/
M7#6S6=7]*':A^1Y=MJZJJ(-VYFR['),]=/R4(X#5=-&[44PW50U,RD\\%QL1
MLNW;+D%2CM@,>3LW-T-B]6S<NG8OW[;(56J55&Y[CF)GH0")GH1B3,YZ!8"3
M#(0$BCA9M5Z2&6;;EUZZ1]F-:4  1WU'<S_O,S B,=D13 C$E,1,_<YQKCYV
MSC&/GX^<YQC'SG^V/W_G/GCZL9SG'QM^O_AOC'_;.=?C/_;.?*4*!!^R;O<:
MSM_I2;F?7USS*$TRT"Y<H;9NWZ<D<5>)8=AB%\]!R44[-5N]>([H.MH94<9A
M,L0;+ZMS9Z/O45F*TYV?K^Y&U5R\D=."K,+[M-FBTBND_,[ND[C55-)-=9>1
MVS)9B6RY<81TV6<).45-MOG.N=,9SCRQO9%+*<52_K*==7V+TXZ@U$56C/15
MW7BM4ZCFA/<$><V_5_4>MHB]A&*BY8MA#:U,A041*V76E4-H3'<,6@4V'"$Q
M_46!KLG_ (X'HIF/A37/Q\?5G&?\XTWSC]9^,X^K&N<8SC/ZSC.?UG&?G^V?
M/UC.,X^<9QG&?[9QGYQ_SCRB_K_TAU%.X,=D?#4XL?A7HX8W6*PN4TA:UHPB
MM)&>:-L8'@["KT%*?X% 2453U;N95$18F4C'*^I9UM(VK=P#(>J_T_=^]K7E
MR_<@WM<P0E<SHWI";4* E\G18XG9+-=B032; Y84%HMF4K<0^:N2()I+E$5"
M9?";I$H^(KL-'JMF[QC/=XS;\ER/($VQS;=.GIY%^D69K(F_+!JV:JUVM"I>
MJF:6B1JM@]4!).KA$CW&#4LAIIS+N<:"LI<ZM<KO_+IG\/66+89)K.2V!,)B
M#3Z%,S &41[3?-X\>/,;RZX\>/'CCCQX\>../'CQXXX\COTW?X_GBN49$B >
M3FPIG) ]9TM5XITDR,VI<$NPY2A\)8O5M5$A(]3\1_(9E*'"*S"#U^ EDW*)
M[#8\YUWD \=M6#5R^?.6[-FS06=.W;I9-NU:MFZ>RJ[ERX5VU20;H):;JKKJ
M[:IHI:;J*;:Z:[9Q6IRFM_YQ[;(=[G6ZRM3 VTJJ_A4,^;Y3;.:R</=1=C]2
MX9.MLN$3W0Y03J&KMZNU:.AG/\< O1WV-;7E2+FUS:BC%^A<"2SZ'SEH1)!-
MNT[Z?AYX&,Q(E9)36.(2$U4J]MZY)JEK.)::<2NL@HBS8]O0NHGXJ#UAUF8F
M)B85!B*XF)$WL4!= 1$,AN8*D$TXQE@^5S(-8/2EB$&%I=$SI+&K8M*Y2=;;
MB FPL2X76(@*HAH@/K7E/Q[.V[$%$8RBT7<OY0XDQ,C)G8R-T,) -G6N"ZPU
M<NDSSHI]>XYL[;,5W.-_H^U]*;IVV2VUSO\ <^5==L:_1\[8C]T?0Q6W0PB1
M5Q/2%/7Q7JKTK4UL"Q_\VW#D':&$R$5GT2W<LV5CU),-$F[*=U\3=-</4T&$
MCBQ6+V!'(G+0E1T>]ED9A_=0Z#=>Q)[SYT/&>8RE<YIQEI(IOO<UHR6[A+F)
MXY>*-PK'2Y(G:@.-(%( NS;#I$)?N",+L9E&)''"B:=G4QK_ )+^7>IF=ZTA
M#K%ZDE43;K@D8A+$55]0>9Z0M '6&%Y\@-5ZJZBI,M0VWDY<IKO&$)-JU5[!
MG,J;[S,LAC2[D;43[,.&S,V8F7+-AP\$Z!O'G/JS?6$6C"1FS XB+R$R[=$4
M8>)=ZE=X>&7SI_$QTZ?;NG(V02IFVU^Y)B0'Z(VD77<BX\N7$C6TA,]!\S)C
M(&03(E(E(S(%!A,Q/4^IC,B8]_T0S(E'[&9&8F;42]Q$NB&"B)B"B1*(G^O8
M9_8SU_8E$%']%$3$Q#QX\>?//KCQX\>..03]C7=];>NSEN;]$3]),V48_9C5
M95^F_P #B=F6::3<8C4/'N_LN=F3;?#9X:DA?5LY_@HL(,EL-W*[9NT<YS_2
M;Q':OL!O*0^XWV'_ %6(7.G,[<O1&2L<;1G12/DG*+:PPL7=?<8B*_KERBM&
MZ3!?;5;JG$9!8KU)V:1"GW\6?;U(9E[7O==27K9A1@@QK&E3K&OY&_$KJ/&[
M R6CS&S.B+$PS^ZDTU)PZ!,FD'$?D8U5;& ;Q#"^-2RB&VY"NX!$*J@<-K2O
MP+&+P> Q@'#XA'!B.$& .-QP:W$AA;5+7Y^E)FP:H(_.<[;J;Z[JJ;;*;[[9
M]OO^G^-? ,NG4B%^:?Y%S8T].]'ZLX_ASSZH9M0XGV2>W($ZZ82)DD&57#T"
M3'"HB?)O(;3G?SQ/'+'XU6O/_P 5S9"()]IP_N&#2[@4"78P9"V/[*.?8XQC
M7&,8Q\8Q_P!_[_O.<YS^\YSGYSG.<YSG.<YSG.<^>?'G$+H:]%NFH;7GT]2P
M![C\_)]U<<4GTM:9U^MAD=_$L(+,X4KCX2U)Z/<OR.V,;J,5F^/I0<HN/%4K
MAS07+5)@IF):Z2%0=1,]G( 9=3UU'J!3,S$=<V[#E8$< ;)CK^"XB3+N8C^,
M$0Q^N^Y[*/U$\[?G'S_SC/\ QGY\^%KNM855,=4BL#!-@ 9Q(9;+'J"*B[A<
MC)YW*"TSF$@)OG:J[TB8D4G.%3)4@\76<NGCQ3???Z<)Z:90NB?9G[9T_95#
M?67SS9O&TZLT[B+)3*<0[G>>L8Y5CL@Q*3&6(R=&7W;8:KU* URD.D\J6:;-
ME]U7K*.LV3$\LIIOI6LBZHIQQST-F_0UF2">OXXQCT54/H1$1FQ[LL\ZKH,C
MT2KVKZ_%#6YVP[$D*N@F&U]$!.RRJZR*&ZN6K(D:TUNUX;L82,(&VJ=MGE->
MOHYF9GMN.N6*C9-=&ZZJRHB%C8(W+IPR?NR/J2U_*9.:>CM4KYWC%+T#EL;6
MM6;0)6I3@@#>@&BYGM(1 $WT[6,B,&4'ZC,H?'F?>Q>[O:<1NZJ*ZI*B.1G$
MKG<W!JS+E@O+YY9EYT+1JWY2INV.I+C@1X+25%/MV[1!J"A \=8A$X?*Y"0D
MC8CJ/&-=KN+HN& \_P!36'=EIG$(W7M7Q(Y-9:87V2QEJ%!,U7B^C5)55'#L
MF]SHDP$CM-\+DBKMF/;Z[+N4]<U>CXYH9LYBV%3LOUHF:M7/MIO6/:&B@ -=
M>3B?NTO6JU1-KVY$YK.; %U*JZ=:W%HP%RETRZ:VRHD+Z]/H1#+.ICYA^VBR
M 8KN(8 S,<ZAX\H6CGO?H:N.$*E[)['"JTY);[=V#(JAYW@B^)_;<KJX9/),
M%@4J0!NW89-FS*Q42.(G99('D;A295WA(:0^@@*9+2![ ]QW+O'O/\'NN5B;
M*F$CL>M8/:L;I&)QG12T $.L)F.6CY^VDG3K^G*<C_\ (E&L=7-SDRR0)2;5
MS'HBA*2[9=HG.+P7RZ+B* X-]MBUJ7<:I*50U%O1SG"B\FK9 IKV JN* =94
MTJP3W[.CHNN,;V1\6/*^@ 355<=[EZFFN\/HDFA,>X$P/Y LH^A#U,!,3$S;
M1YXSG&,?.?\ ]_\ &,?O.<_XQC]YS^L><4YNNEET=0-,WX,BLDA(RY*TAMEC
M8G+T6R$E CYF$:'&0XQHS46:;.T6KQ+.RS53=NX3V371S]M37&(#>VGMN0<P
M5%#*<H[<R7Z_ZZE:=,<]1R&Q_:9S4!L2PDE.[C'0_1\*T,(U7'72A,8B1+!P
MCB8O(VD>,"(VC(#(NJS\/0TME6$E4#>.TRLV&3_IU?QY.;C[# ]X"M24IUBT
MZ/85H2QG[$>2[%^M6I%?8?=>%"T)&)DFPR!^(+"8@B8XC %!U!$9B/7<\]#$
MO9U,>@O89+N+.2Z*96?6?/CM%IUGU-*9H1C=?UR:T<:HD(! 10B+',SR>I.D
MW0)F.?&@"#L\.D2GTHQV*DCSFX/S'MP-/.SN$/9SS7ZMQ]/TY >>YQ5,GNBP
M8]&3C"U+AE")>(S%Z_Z#Z&O+=@(4=W:O.X>S#2"/QH0TK5F))"X?"EI&+0 2
MI?4!U=TU6G'?/-I=(V\1R/A%6Q=T??MT-]-21XGONFQCT1!)J?&KB0RV0.QT
M<!M\YUUW($4=U=DT$UE--;YMXTK.V<#+P:5=U?6Q\Q^0=*Z6G>VYN6+%,+MX
M0<ZO6T+]Q#97G4)FI5KE60#+#8=8;48>F5FEH6KSFBRI<LKN0]$5D4_BM;22
MCL1-B$*,8)[O]5C(81"N/58P']A-C%.B[@J[U2U/("0P_P!!1Y_9'84OC+I=
M$I4O$D=?:L)D'T?M,?6'E_21O9O2T57SLHN.CIB8'_Q],HC%][9XW' 40CP*
M)Q<0.C\:C(<9'H\!$-46(D(""L4!@@.+9-]$T&8X8.:MF+%J@FFD@V0223TU
MUUQCS%35GL9L_D;C?ICV<)UY%KFZJ[!LN+R.TK2GAQ^)HVH6Q)1X!H'D*K7;
M!'>27E-JG@3<C+;$AL$?A8E7*&I459%A")S'M8F^U+>O SU-+>2*FL'LHL$=
MWW9P?:R)-'(Y$F$,"UV(F6VI>(UTV$-%W;O9Y&(PL,3/NC9 D8WDCLPV7>[M
MVC1-*3YEXM>P<:B/TJ+RL[2L9$]V1*YK^21619WKZ:H"3!H48FGG5G/E ,I*
MH7$JD])Q%RQ=:MHW7R,.9:L5EV^X7_X]7.EAKI(ETS DYTPU[ 5].G$Y1E_X
M\0':+NI?6YQH@*O)7$88-'"RI!X-%-B)S?3?">$/X9P6=K@!3E'/W]MGI",2
M%;YW3_%PR^VK^31G*/33#;#Z^G5@*W%<L'O.*4%$#_/UU1^T)7(3M"35M9MC
MBHR7&!CSY!E+6IX /<XLJ./$A$-()'3P:"!(,HNW.^3L]IWL:6X0KVM8O5D,
M%V]UKTO/AE2<TTZ_).&3,U*S3QB*5F$IP/QDG_146(F K8@@Q59.C9<N*!MR
M8E-T],#+)(:,.-0$>=S;,=?6)_2D=%S0[&QBPP44-CV6%"^0[=ZN\)-(]D^[
M,/ HUZ^>*L6KWZ5%UE]UUU:3.O>3>+9=;7J/.A4W T*5 Q)(NMIJNK1?,DR)
M&_.-I?AMBP,U;AC:I^K@5<5$NU4RM:XRLY</?0*NZQW[^BB:!_ 8."B L0$?
M8/G_ #5$K;,B9*+D7.0)?9>1!:J[^=RAE?, 9L4I8'-.!IR&2@9E5=FSM.D)
MRA'09J75C+5T=EOXF9.2=C5H7W_HV?:MW>@<M))H^4H=X^U03S-W!R!R%!&%
M?G)+/#"T\Z6DTJP0(N:BY\_%>((M8DQCKO)@A;EBDQ^$H1$6@\Z:DBK$#'@\
M3.&)Q'-FWP/6/4_NT-E8JOQ#P37,7K"13"/1U&9]%34$?M7448?LFND[EM*Q
M>?QO2KH*CATJ[)MW\EF=AC S1=Q((K$BOU"V_7_M#7TGYUQ@8^#6WZC-.DS5
MUJ652_'%[ZQ&J;K5M]7/K-.K6 ;%@JY*;_J*8M[/P=>G478K 5S0;GL&NT:M
M9MM_<@LX@_C!!$@#!AK#E0>XG B,C(#?;X\AMTWUV(YM80.%-HN0N?I:VT23
M&GZ&@:[8,6GQ..LV2TOE1<^<5=!*KIN#Z/42]@6G-7G\)$@Z[5BVTDDN(@XT
M9KXYGZT]D-Q]GQ>O\I\86YS$)!R%UTG8E A[6>0FC)4@V([1.HH+T')YDH"Z
M!N%1\J)WGPR.5N $0@,CNI)&<6*E![-2HI>-:-VA9T_:I4IUZMBV#+UD:TVE
M5OI!_BB421_5RSJU6-A2+=X9H5FMNB2(F/U*R+*:DPYKVL6KT2OW^1,]9CZ%
MW$=@!0UHA)L4CI[ %4B<WH>/&/GXQ\_'S\?OX_M\_P"?C_IX\S_++F&3_3$P
MH[._8-WO==\-WBW0L,B2 DZD?TQDL-EMKV<>7M!\LFX<N7"11)[!!X95;19S
MA%H_=M?RMDW.OWMS?E)]H^MFX:6[BE7L4]?,OKD)8]NA< >G>:[I4D0>G[X9
MZY9N%)2"GD/&GSU665JX$L'S8GF(R>.O)!L[,$&C9,Q)6AR:Z=Z]>)#5</N(
M'&Y]+7?7\<+TO4#Z,KKX^C[>6IXNRCQW+';ZMOJ<.X8S>:83VS@:IG;3&WJ7
M^1]5'G&^CR7+LYZZUW(QJI93;M7/9AV:&?7J6LT4WG5_>H-E;K%2Q6EU9E=X
M>[%V!>E63\;JG@9Y9=M=DVHM6V1;76?9&\ISS:NR1UEM@72LA!JV^C(,)F((
M9$IFQG.,8SG.<8QC]YSG/QC&/]\YS_;RJOV'^PESSQ!K=@/.@X)8_3,(J63V
M9)]RKU-O57,4'&1]Z82MWI"3ZZKMXVR4:M57%;58BFZL>Z3B+<3%@'].:'Y0
M&ZW((-W1?&/X:56%77'];D&C74TVH4@0N3H4BDKHNF2'![?L&'0^M:PROIOI
MIL6!5#8,C:I_4J D@$EJW*-Z6/<_&PL"IKGOTY<,QAB$N/O^VFI2=ZZO21V2
M/:XCQ9N:GELW'-#:Q693$O*Y,)8OI?/)@=,2(]%H+-&SE^XT:H-M:WPO SK_
M )'DTK[ZMV668?<K@9'FYV;2 KNIH:]T)!3:]*@E]B:M!K L>D@Z]5]?C8D[
M.C:3G6WUU.KB*Y6EIC VK5ETPFK7I5Y]F QSS );86!+B>UUV]R:H[?Z63G2
M:3Z0]4^RBYU",EFEIR(E5T,F,DU17-R,P2-)SZ^9ANIOG'T+%Y0O$HWL\:HI
M-TW(:0B6F^C1NHWUD^"&Q_W*>WB_!%A%I*_X[]6B#2 0B#Q>7R*&M; Z7F)
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MU#ZK+QZHDG62LSZ8C P-TGQ-37+6#8:M"#.5CG]8'[*G)L>Z9(29(&/J.Q;
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8CCCQX\>../'CQXXX\>/'CCCQX\>..?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g433713.jpg
<DESCRIPTION>G433713.JPG
<TEXT>
begin 644 g433713.jpg
M_]C_X  02D9)1@ ! 0$!LP&S  #__@ ^1$E32S$Q,CI;,35:0T@Q+C$U6D-(
M-# Q,#$N3U544%5473$X.# Q7S%?4$E014Q)3D5?2U]40DPN15!3_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_\  "P@!* *G 0$1 /_$ !X  0 !!0$! 0$
M           ' 04&" D$ P(*_\0 ;!    8" 0$"!@D,# @)" H# @,$!08'
M 0@ $0D2$Q05&"$Q%A<X45=XD=36(D%66&%QDI67L;?5-SE)=X&)DY:VN,C1
M&2,D)5-VH=(R-39'5%64M? G*"DT0D92X3-G:7)S>8*'P<9E:'7_V@ ( 0$
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MZ>O 1 'UR 8!XQTQGN""+IG..N,9[N<].N/3CKZ\>KGZXXXXXYF%>?L@0/\
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M(Y5A8S.>V)G6#2AO/>EX&MI+5M)Y67%R-"(1:!(+TEF+# @&(M/D83# @&(
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MK4JD:5Q&4,*%2K0ED'+4Q"K.,$FGHRE*8U44 8AD%J"!FA"$T&1>4&<&"+"
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M")0:C6(5I8DJQ*K)%W#DJA,=@!Q*@D?U)I(P!,+%]2(.,^CGE[X.]W.^#O\
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ML".65$5 E3*ZKH\8G2JG4TMH96X\UQ=ABG8'%*2J;%L9P$2P<?",A),&N7)
M)VD0&_R86(/@,XA?LL@\E"TE151&%^4KR^FHU$?1K$AR&+*BTX6EE<2S8K%T
MB<"<8.^F:09?%+8(*D)CL:4JQ@>$3F8%R: U0A5/BAYD$>3SE(\X6GJE2Q"E
M5OZ$R/IS5"G&<"(\EIL!1%$FF 3)R@D]TKH$'*-"DA'!X0L4F8)3)+J5*U)H
ML"R$I.E8(2>>:+ <"%D)9)8QBP$(A9P'. ASGIC,LFW)&!6J06V-K8Q0L^["
M)V_2D+K('4Q]+;ESB6A>/%''(BF5(8G7'+CD+8C!D8S2B\A 61@O-W8[(@R\
MIHD;V]19%-D;#.&\PS,>;VDHT)LZ1G1U.8K1PR0I6XXB*A5"0&I&%4X+D@SV
MT2Q&I4&'BN7LSI[)EF)@.\41LKW(I8XH!-[0?AR5H7&+IR6HCR.LB;@@D"+R
MQX0;>B3ND85QUR$H5&9%D7A\X/;,RKAY@;:U1/V.?XHR)F,;:D1K$\BC@4;-
MX"2$+\8BS:E3A6+<F87942>2&/*K)3DG"FR4+N_-K?8PBKQ$4HLAE<W]]CS-
M%Y0A>A/RI1%H(B?4CAB'Q*.)&,+0YN."P&*7!R=G8&,Y\.WMX,>&$L%E,VE,
M'DLJJ N,N; YN+5;99)IS2062H]C"E[C@H_@T1,3B:<*7 R5&2FQ.0O+9S!Y
M29<5IN33Q8 R3^,1:$N:%P9D<FD*2[ULI;692\OS)E"0C:#"$[YE0RY*RK)"
MXD81#0*#_!F=\0Q%=,8'S+6"W&->R,*&5N3",,B=KW>)\@5LB=4 E3*$'C\3
M 0>>WJU+<2M?\@$F"UJ0#P:F3"7C[I !8R F:U.1%HDUF/,,<1L+C6#@B*=6
M%0,)>$",\N8 <VELAZ$]'U6F@"O )[E:QP& 3VH (@'B1WM*GM2$R9>Y%/4>
M$_J80VHT+\Y)\*FAM=D\I5*G!$*3D5R88O7K8\:G(+=5,)./*1I\,8EH1F9.
M+A-D7PUUM&;F'RU/ 8 _E/Y*OR.%Q;$S\T*CTIN(NWC$T+5[,W/*TO"D9QK8
M YO;R3 DI F8)38FIFLZ/&+'\+Q/:Z;L*+!@3D:6%F?92PN-?,$4RRN+ V&/
MD</<CW;*# &H]T7IV]4M4C5 )6)RE0>:YOAS:H@#RH9B!I6<^ZG,]I2F![HT
MS6=$U!C<G&#J+N"(1"(*$#O"[F0=SO9[O7F6Q2S(]#H#!\89&^2RZ.6%*9*@
M3K'A_:L, C43#Y*=#D[2,A.\)U:E(8 2%8?DH04@@#  )P\YR8%F1MUA*&,/
MSHRG$'T],PN!)S$G/6I[)6316[,A:=?A!EP(4E)5:A:@3)5Q3:#*@WPH\'F8
M&&1W2?5$)5&!)WN"K\QZ5N.6X]4U*DY)4:50A0W(A?YK@* ,=, ^!*.2%80R
MT,><@IUR]0L$/_)?*USZGV^0R98E=HP8XK0P0T]W?VO.6UP0H6U43+&0AP;Z
M_<!O)QZS"4QR5%QN/*)5@>087)QI<'<U^@;BQ!D4G-%*VF),ICJA=4$=D">3
M^P^4(V^0G+D+2]*H^/+TBPQDC(<V8HT@X*M60!,LR7@)N#/$^/#7(+N4OK*I
M5K&EXL]N<D"M<7@E4I(5R5 ;@XPKP962@"'D?BQ8RBS0),)PG "=@S',)EO_
M "MEG^M4F_[]<.6$&>@P9]708!9S[V,#QG.?X,8YNA,K8K^3&7 H-=R!/!F&
MY@ACH4G4A(E4/,E$;D)20WJFP8!7%U;>\83#4A($:UN $^/">)%XQ:GEXKHU
M_MDU79C*Z,EOR5E2DH6DF0FEL+-B5)7QTD3_ )<&A&D3+&YK2'(FTINRO//6
M+NX$820C&78[IL*!65&\J6=S=BGN,S%8%D;GU @2"/AKTD(2^3V 36:I"%I8
MU+2@5IR'(296$"U3T*[PA!QJ]R089_R<M;_41!^D&$<C[CCCCCCC.>F,YZ=>
MF,YZ8]>>GIZ8^[GU8^MUSZ>G-N036K<5G[4F9*Y>#/KA2<:Z8;TF8B"R%"P,
MM*5C49%A]$YIW(HJ,EJ"T&4840LEY.R# A8]9=K0PL9 ,.+"0EC>=?7.,&)(
MZC+<$SHUJ4)5GG 7$M(5RQ42V84I5_CIYH3"0!+;L",Q@6?KB=U\>\+E#G)H
MRK>CIC=#I'Y,J93W9H9E<A:V(->OSHCRSA$H1( $*T(,&-JWQ%R*RJ.3']SQ
MHWW0A^B+],8ZS&N<3DK\OMR$+52EBB9K VOJ)OKN0H7QQ);U9.0'D#>#4Q:Y
M7X!K*>%N,.!#(C+%CGG1S>O$[@V+U\MASC,FJ$/")7(VV+A8&%T6*Y<0>SMA
M)QT'=LM[JQ18LY,<>GB652PDSR,0N*,R-3B\J;+J\QY;R3'^.J(<UVC.7E(Q
MY:#<HB4C]%T@XD_ 0!CQY8VIIDXW(YQ)& Q2B4'A.-;%Y28HLFQCGT!-=I H
M;)# H[*CT$"+-F"J-+I(PO2-I6N8Y<W$>'AJ#&7MS1F-(%#BDB;8G=L) D$F
M$'EC4E8@R63'V*^;-L!*[D9;5B.Q54:7X+4>#<G!<G)-8DY / X- )Q4$X)+
MR>62 .19R<,L.>]R43[,J-.HAK"@?V\^+Q>P7=W!E4@5")$W2&"R]<N6F$"1
M"P,HB620EC"'(1FY/1%GA!@C&#L6.'V-6J1$QX6.<<+D#?6-3L07%_2*AH$X
M6$U]%+XWE0&)RL92LWQE )40G;"\/*7JB(=TP@9,!X 3RL28(X$H'&.LJY(H
M=G*/MK0T*C7 +MF;EN[/XXRO<54#\;2-H.XDE::4E>*LX"FTUHP: 285_/L2
MOE<ND3H9-89XLNL@]ZDRITB*A\'-ZN4-20MMB3(>;&SSDCDV9+6HES>,AM-&
MM4D+\.RO!(AFX"1/X'F'DQ4P3(%C'4TR"8V',J0;N";XF:E=$4 WO+>-R"Z)
MF$80HS"W'"$H1IAAQWA1!&&0GJQJC/D,9/;C8")K;W=Q5,?AVIX(,CS(=%E"
M AI<?$8*G)CZD+F-,<@..!-A-STFP\#'D@P82];+B<8P[30:Z*KRG-$:R,05
MRLA,224-Z)1>"<\85D-+$!Y,",)6%#YEG;AN1_A!C(SDOPID6<<<<<<<F&@O
MV78;_P#BOW]$Y!S\W_\ LU65_K*+_NQMY$'''''''7/O\KUS[^>.N??SQUS[
M^>.N??S\O*=<^_\ =_A]_CKGW_N_P^_QQQQQQS,*\_9 @?\ KM$?Z1-G+ \?
M\<.__P#UW;_O%5RW<KUS[^?E][U?)RG7/O\ W?X??XXY(*C]BAG_ 'S9)_0R
M*<C[E>N??SQUS[^?3Z_N\IRO7/JZYZ>]UYF%>YS[8$#].?\ EM$?Z1-G,?>/
M^-W?'UO*[M_WBJY;^N??SZ/5]SCKGW\_+[WJ^3CKGKUZYZ^_]?E.N<>K/3E>
MN??SZ?7Z?7S/_P#FF_\ W4__ *+R/^.N??\ N?P>]QUS[_\ XQZODXZY]_U^
MOCF01+_E;$_]:HS_ -^M_$M_Y6RS_6J3?]^N',?XZY]_E>N??S\O*<<D&&?\
MG+6_U$0?I!A'(^XXXXXXXXXZY]__ ,8]7*]<^_GGU(4*$QI:A,>>F/*%WRCT
MQYJ<\H?3..^4<2,LTL?3.<=X PBZ9SCKTSG&?EUSGUYS\O'7/OY]_P!?U_?Y
M3KGW_7Z^.N??]?KY7KGW\_+QUS[^?5T_@][[W*<KUS[^>4ZY]_[G\'O<=<^_
MZO5QQQQQQQQR8:"_9=AO_P"*_?T3D'-L[)U&E$WGLKER.8L"%+('7+@0C4MC
MF<H3%Y2)4^"SC23PE&#P).(7> ' >@L8Z=<9YA/F.S'[.XS^)W?YQQYCLQ^S
MN,_B=W^<<>8[,?L[C/XG=_G''F.S'[.XS^)W?YQQYCLQ^SN,_B=W^<<>8[,?
ML[C/XG=_G''F.S'[.XS^)W?YQQYCLQ^SN,_B=W^<<>8[,?L[C/XG=_G''F.S
M'[.XS^)W?YQQYCLQ^SN,_B=W^<<>8[,?L[C/XG=_G''F.S'[.XS^)W?YQQYC
MLQ^SN,_B=W^<<>8[,?L[C/XG=_G''F.S'[.XS^)W?YQQYCLQ^SN,_B=W^<<>
M8[,?L[C/XG=_G''F.S'[.XS^)W?YQS&YCKX;KW$I/?D\G;3F#T?'WBX)GAIC
MKPN=<Q2L6]1.)'AL185 RL<<L[$MPA2X$'*A5DHGKCO\NC3J&_S-M0S!GG<?
M\DRM(GDS9XRQO!*CR=(2@/*'!Y65.<E'X2+B<'%YSG(#,"#USTY</,=F/V=Q
MG\3N_P XX\QV8_9W&?Q.[_../,=F/V=QG\3N_P XX\QV8_9W&?Q.[_../,=F
M/V=QG\3N_P XYA951(W"?N&JA$Z;_;.B,59]AW7(XR\A8LP.Q75\JY@"G<O&
M^Z:[XD=7R02Q#@&,D(?$5'>SA1TQFGF.S'[.XS^)W?YQQYCLQ^SN,_B=W^<<
M>8[,?L[C/XG=_G''F.S'[.XS^)W?YQQYCLQ^SN,_B=W^<<QN8Z^&Z]Q*3WY/
M)VTY@]'Q]XN"9X:8Z\+G7,4K%O43B1X;$6%0,K''+.Q+<(4N!!RH59*)ZX[_
M "Z-.H;_ #-M0S!GG<?\DRM(GDS9XRQO!*CR=(2@/*'!Y65.<E'X2+B<'%YS
MG(#,"#USTY</,=F/V=QG\3N_SCCS'9C]G<9_$[O\XX\QV8_9W&?Q.[_../,=
MF/V=QG\3N_SCCS'9C]G<9_$[O\XY@WM3M_MA^:=[.T/MH^Q;SC>OL8>?(/L
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MTY<,E(@F*3WU(UT%8"T]GD)N.H@NJ!O2GGI7H[_%NB4@1"\8'0!9[EVLH_\
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M=*V>U9$],[3,6FQH7L1!<U>F01YN>7&7$O<5F[7 "FPU]Y^H?VSVNEB6[6L
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M /0'_P B;_N<> /_ - ?_(F_[G/SX(WO9!X(WOX#@>0>#'W\ %G(<#R#IW\
MR((@X'D. Y$$0<9SD(L8_7@#_P#0'_R)O^YQX __ $!_\B;_ +G'@#_] ?\
MR)O^YR]QN*227OK7&8TRN#P^O2LM$VMR1./)J@\SKG.1#'@!*=.26$9ZI6H,
M*2I$Q9JA0:626,6.\^KVK[#0C!Y0<?%'NR7M( $@D  9&0WD#[AN8_'LFAP8
M0U$&!#E4JR$M4]*BPJE02R"T2))9>T9_:^=ZOB<;/_H/G7)YH_\ 89J;][.
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M2L&>TIS@'(U@2B#@ *&;E=JVX[5FJ9$S;3%PVH%X(7G'*JO9HJZIF42(U*4
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M29:UL.=:JV$ENI6W[5\ID.)PEE8LD4=B&+*0Q*3@AW,D<NC1R<YQ"I$:BPC
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MH*\.A5IBV_O%1_[#-3?O9P#^B#-R4N....<T?W7S^+A_M5<Z7<<<<<UHW/\
M<@[3_%PO7]%4MXTP]R#JQ\7"BOT51+FR_''''.>VYGNB>RV^._.?Z@6ZW.A
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MH<9/QY*LO^$V^Y.S7%V>S&U2S(DR]69.:GL2O49I*M4-(4! OF<=94CDI":
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MI'MD2F0!5P%M8E4O0'$#/!ET*6M"<;0# A..$W3&,](:[O&'V<PR611YIL1
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MR^ZXC'WR4-5I-M!VG3MW+X)/\(66Z'A),)(L=4ZJ#&.K3-&J<V2[16O1NO\
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MYSC&,^JP=L]<JJE"^%V';D1B<H;$R)8O9792L+6I4SDD"N0G&A)1'%X I2#
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M3I3%+(F4+B#=81+')IQ'1JH4V>SMA?U3@A-5.#XTJ4R.#MDLDSNP1]WP$WM
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M: )A9A8X,^A&686/ @&%C#G(1EC"( PYR$0<ASG&?YPRW=W+++++=W@
M  .SD    #@    !4$    $(   $(  #@(<8#C&,?ORR]?\ 73U^.73YWQY9
M>O\ KIZ_'+I\[X\LO7_73U^.73YWQY9>O^NGK\<NGSOCRR]?]=/7XY=/G?/A
MAP<,*1K<.#CA:8G+2&+<."W"TQ(4:8H*2&+,'X5#2%*#CE!209HDQ2@XX\LH
M)QQHQ_?RR]?]=/7XY=/G?'EEZ_ZZ>OQRZ?.^/++U_P!=/7XY=/G?+Q'YQ,8L
M]-DB8)0_-KRSJRES<M+=5QV2%!6<].^0I/-3*2# 9&2I2J2C4RI.8:G/+&48
M(.>[NKVT+!?;!Y.<?%&2R61( <ACP!Y 0X$ R$K,ACV#1",/:CS!!PJ2Y$8J
M951@4JH1A!B):KLO:,_M?.]7Q.-G_P!!\ZY/-'_L,U-^]G /Z(,W)2XXXXYS
M1_=?/XN'^U5SI=QQQQS6C<_W(.T_Q<+U_15+>-,/<@ZL?%PHK]%42YLOQQQQ
MSGMN9[HGLMOCOSG^H%NMS:VYJ$I/8R)(8)?545[<4,;I(PS)!%[*B3+,F)%*
MXR>-2PR%*V/J18E(=VLPY0%(N++"> A4L2"$-(L5$'2YC'3D%[/4DEV5UQOG
M7E;(5$21WE3]C5(JE"1M*>%4=3V%$W6+'/:=I/6-Y+D<UEN@EA2 U<C+5C)P
M0-40$>3 Z [*=DI7^R%5;(P-SM%]B$PO'9-RV,B=IL,5;3)+5"F35555+SVO
M$J4]X*)F$&L>N:[=XM.&MR5M2=Y;)AX3"5,\12/.Y-Y=>S;E4D5VY 9-L$VK
M=8KPVT6;6V14C73>6FQ)(K.DT)G954++G.M1T0I:Z53:OXZLD)K)53/,'J.8
M<8LGDK04XG.8;AGLZY)"90EM6E;L9F"VTML;CRI<9953AL&K)K4.Z]KMMP67
M2,[@K1/82_N*5@E\9AKK"IPS3ME<&YP8G##E'W1CE3VQ#P"I.RUE=!*&RS:C
MV#CS+L*UW/=EJA?#:%8V*AE\6V+A5*Q:UJ0/HJ 3>(*FRMPN=#5W+:]<&.QT
M<WBC]&651(Y#/LF2T<OV6I30^"PU]D5MW8X-MZ[(3J["M@I;:YT:-A#.U3YI
M@\5J^&-5:0A'(7T<1@D KB$1J,1AC?Y/-W<\XEXD4@D3L^2%Q4<G:GZ)25)8
M&S4\32-0]&[(W2RW&N;3FPE 5%%3/15-TAAB2JBEBD;N0H35"GD0W \E :6I
M?3V["492 I8JUMOC0!HO%=MTL56:YQW.V$#U=@[@6GBR-RQ"R=9IM-)FA<$8
MC7M'E\,EQDQ-;U:90%M SEH0*"#G 2@114'[)=EN]7?+;&D+'?Q;$PVW>TQN
M&?5G,*_D$MKAY(E^KU':T($[E'(O;E;ERN4UN13!T^K=SG)LC@J!^G#ZD?JW
M>S$#.])9@TRT5F.G\>*:FF\6V6KWO.MS=82LZJO)2.11?7;5:%ZR)&AA2#L%
MT41=REH*[B<Z7/BA9( M*TMYCZ1H5(W),XMGLL[L_6BRMCU.PZBSG)I6J;.T
MULH47)BJ-6E"?J".]!MS3AU&]D'9)G.;N5>.J\H<#8/8\G\6(=/*)OB< 23L
MG%0G1NEL(OTIGFD<LWVT8T?*JLS)8P4\9[3&0]HSEO?69IL2*NSHV>.25?4?
M^;Y"RK,HRDDTPI I"=&C(>N#L5)+8,;10M@V@0)XH@999ED:["J.4SA' IV]
M[?VAMTFL.O(XS7Q"(0V2A[<I^QU98;[)(K*I,ZP* LID#?J[=7!Q%R[6'V-;
MY/7V4R!?=-1O*^2/FX#*DS.M:G&9HXK4NWVQ#WM$]HV)I47FWLRZW:^L^;V$
M@CTRE3=(:PD\$=XW'9O2SLKC;@[R?HG;>E-77 _ZFG29!'G""ZIR*3O;-6D@
M@L9DT4EJ5[HN84>T-:YL7DDLK.7&$,J+?VTU$Q*B0JVDAO2HF],:$Y-&%^]G
M9"[H57(%CEY=7,5JZ'3_ $6;XQ%H.SA9(-')Q(G1_!,V1 C<V5$,QCRY91(X
MF2D;6XTH@(\.:;OY+#K#,.R6G\LV5>[_ #=GV8Q0=.=@Y#&%<JH\RR[!CD,V
M"HF:TF;5P7>Q[8DU4FP.HD\I2.]71!%2K9!W).V#:K4B4^4KE;P?AC?V,#HC
MCT24#MNHE,HKBT'6=5O6JJD;27:BPIGE-0JZIF[+%J/<=H5L]A2Z5*#T<\SF
M W=%H,P2%C:D3+7A213)5D@W$GN@#J\:<4?I[6]Q-E=Q2LET #8@A5.G##KU
MB,32.RV45M,:_JF>4IF-P"S)FN12&:QV%2QG2.[*A5P1TPZQB12%.X0+9O9?
MW9-,OA,1V>IZJ6BS-/!Z*6[%*_TZ0L<-Q0V; L.3)55(1LN]SD]0S]GA]D/\
M"95#D?85>)P*3)*JKU4N3,K>T[$[;]GG&=I$%=M)=B.E=M5<4W95--*1''B)
M.(]GL&6:Z28EP.4KWMM.\882=>F]K+)'D[+D&2*UAZE.8VE$KIA:M9GZ(I]V
M'"O[:<8A.=MYNX6+'IH5$VYU/I67CUPJJ@6%V:6A:ZA13,<=4U6VSU.0ZF-"
M98X+ALBDG")+XXJU#K_LNAQ^!5I6TSL:IW^-UOL'2>QJI=$M=W:-S*W)]59+
M^3)I!?DUGM\W _6[-+.RZ-JU\G<B4>7&UP:S!$A7MJAN:F3:ZO\ 4M/43_M[
M**HFB2"/6S[M&)(P":8$PA:*BD\1H*(4FS/#<PEK"&N7>#6PY#.%*)P(9R%:
MPXQD49,2ARN,TZA?9>S:'U&SP0-W5.JG<(L^E]A(C<3;KC*&RPIUL93SUAR/
ML_9^3O\ LE.9-L#FS6M0\1N=(U#[#'MN:7U23 )-#TC5&VYFFU@[/\E/3D2@
M<GM$;O/@;K1/>RT;":X;Y*;YY:[+>K?=CLPLD06RMZ,AD,/+:6FO(PE')9*Z
M1R),S6<O721X L5+,7C/9S*8SL,T6 DM&/AI*-;=VQO2PUNGJPI%:0MA+EK6
M65[+B'Z[$\S"G=:Q*/GTPDS='2:Y02P\2J/P]YFSE"XPG:5W4+&,8QC&/5C&
M,8^]CT<KRF<9SCT9Z9]'K]6<8SC.<9^_CKCKZ>G7KC'HYP#/[,;8.1; *)NN
M3:X4Z]N,YM]QM'=*@9//8!=VS586'$;$C;3 ;KU6BU>0NC'66A)EL.)E5FR2
MSYZX#7UDCG$+;8U+I B'$,<K3LI-CF*FY*A42FM(;L!5M):BU]JM-W6X[MV
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M#9VLH_\ 89J;'_U9P#^B#-R4N....<T?W7S^+A_M5<Z7<<<<<UHW/]R#M/\
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MC^#;'\ZIE](.7V,ZB:\1%^:Y,QUTC)>&54!<V*%KQ(G8A*M*QGP"K"!U=UJ
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M-C7L=0SBXK]>+O2(4"&XZW6K5BM15TL*3I4B1+)CE"E0H-& HD@DH9AI@P@
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@I4>(HDU08$E.1)S#C1%IR3CQX+ +("2C31= %C%C_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g244864.jpg
<DESCRIPTION>G244864.JPG
<TEXT>
begin 644 g244864.jpg
M_]C_X  02D9)1@ ! 0$!A0&%  #__@!"1$E32S$Q,CI;,35:0T@Q+C$U6D-(
M-# Q,#$N3U544%5473$X.# Q7S%?1%E33$E0241%34E!7TM?4$E%+D504__;
M $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_   L( :D":@$!$0#_Q  >  $  00#
M 0$             " 4&!PD! @0#"O_$ &@0   '  (! 0,$"0T*# ("$P$"
M P0%!@< "!$2"1,A%!4Q0187(C4V476TU1@C5E=A<71VD926M=,R-%-4@9.A
MI;'4&21"57>5E[;1TM;P)C-2<D/!X6)ELPHE.#E$1G.$DK*WPO'_V@ ( 0$
M #\ _?QQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQRG2_GYK
MDO F+_Q![\2F$I@_XJK\2F#P)1#Z0$/B @ A\0YJ3D9F;;/WK=&=FRI(.5D4
MBC+/C""::AB$ 3&7$QA H!Y,(^1'XC\>>'[()[SX^?YGR/T!\ZO/(_N^/?\
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MX"8K"H'K4H257S9O!O;D^=79S5PL3.HQ;5K\QM)M>33B2R,O,/CK).62$?\
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M<<<<<<<<<<<<<<<<<<<<<<<<<<<<<ITO]ZY+^ /?S5;FH.9*(RLF E$0%ZZ
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M=VJSBO6F10:5BYLY"MOVCU=]3I>>9Q2ZH1<NNPEB*,BY)^T+D   _82P^/U
MXF1-_E($AZ@^KXB'UA^,.=_M!9"/_P"Y,=_.I?\ 2/'V@LA_83'?SJ7_ $CQ
M]H+(?V$QW\ZE_P!(\?:"R']A,=_.I?\ 2/'V@LA_83'?SJ7_ $CQ]H+(?V$Q
MW\ZE_P!(\?:"R']A,=_.I?\ 2/'V@LA_83'?SJ7_ $CQ]H+(?V$QW\ZE_P!(
M\?:"R']A,=_.I?\ 2/'V@LA_83'?SJ7_ $CQ]H+(?V$QW\ZE_P!(\?:"R']A
M,=_.I?\ 2/'V@LA_83'?SJ7_ $CQ]H+(?V$QW\ZE_P!(\?:"R']A,=_.I?\
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M6T9:B4FP050L-M@0T"2JT))MIL^ +_[7"P,M'ZVP-%ZR[]*3ESW7M+ULV+K
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MVN34W"S%CK[O'9Q>SUME8XI2.IMXC6,!;2OM)^]E<Q%KJ4^7([U1>SG:[/\
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M!Y\E7;9!5L@LX116>JG09I*JII*NEDD%72B39,YBG<*$;(+N#D1*<Q4$553
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M 3"5,0\>D3>"^/ > \"/T> \ 'CZ \!^+G/ZW]T;[CZ?NA^Y^D0 /NA_&("
M?'Z0$ YS]SY](^GR)1  ^'D2_#R'C_Z/T>?J^C@@$ /N *!?/_(\>//U_1\/
M/.0\"(B'@1^@1#QY^'GX#^]Y'X?5Y'\?.# 0W@# 4PA\0 P /CZO( /\GGG
ME3$?N@()O@'Q HCY\>0#X_'Z $0#\0<Y]) -ZO!?6/P ? >H0 /B'GZ1\!_H
MX])?C]R7X^?/P#X^KQZO/P^/J\!Y\_3X#SSGP ^?( /D/ _#Z0#SX ?Q@'D?
MY1YP)"&#P)2B'GSX$H"'D?I'XA]/P#^3G4_N@ /7[L"E$ #U^GP ^/@ >?@
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MF^H]'[,FS.Q.[?HF0Z[B5ED;7C&ZXY+P<'IV;R,_'%A+A&1I[56[E2[+3K[
M$)!WJA7RG6JFV9FWCG3V&+-0D#*QD;W/LJL1D\YO$%/ZCV"GMST#9Z5V*F^Y
M#F\5J.[.M-KS*,/7,QN->G(*C168U^'SNEKR% K&7Q^6DR0M'F[- 2]'ED[9
M9G$MYGWLIL>O$%LR>\;)V%[$Z-N<=C-8M>TZ;8LVC= @L[P358S:<ZR_/XS,
M\KH&:4BC-M'CW-FL+:(H'SY;9&8D'%AGGRS:"/"YLVSH3BFXZ'?=0E9;3Z'<
M=3P.5Z[Z7*Y-?7N?N+Q3RV%O;<\L4T[BV:DBCI&(68)66QR_1#Z,G*JG9[1
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M/Q\K%Z7:]"Z*S; NG#9*="P9:4P0UB+B&EHK\Q!6-,D#:I*2A'E8+#-64P?
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M]%\?J@MA_9A_J*N_HOC]4%L/[,/]15W]%\?J@MA_9A_J*N_HOC]4%L/[,/\
M45=_1?'ZH+8?V8?ZBKOZ+YT4W[75DU$E+=ZDU2'34+\Q5X/410AB'#R$6 @(
ME,( 8! Q1'R40$ $)5T PA0Z2 #X *C6P /@/@ AF0!\?'Q^')*<<P?V-T(V
M8XW=K0V6*E+?-@PT"(G$A_GR>4+%1ZJ7@Q1,=D=R>1$I1\^[9G-X$"^!_/<
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M02-(0YU#A'L%I-X(D2D5#I@BQ05<>5 ("A2>A+WBIR)FQP!R&+ZP,42^ 'U
M8!* " #Y$?/@/@(>?/CQY^/CG/J+X ?47P/T#ZB^!_'X'SX'Q]?@?AX'S] \
M>HOD ]9/(@ @'J+Y$!^(" >?(@(?$! ! 0^/'J+_ /2+Y\"/CU%$?!0\F\!Y
M\CX\#Y\!\/ A]/*E*Q3^$61;RJ!6BSABQDD2&<-5@.RDD <LEO6W663)[]$0
M/[HYRKI^?2LDF?R7E-$Q2^/4<A0'P "8Y2@/GXAX$1 !\A\0\>>54L)+GBU)
MLD:]-$I+D;*2 -E1;%5.18X?K@%\"D -UB*."^6R2Q ;JJD<'32-2^......
M;"Z!^ E*_BE7/ZG9<DKQS6)[16ZF*AGN=MU1 %UI&YRR("/W1&I30D'Y^'CT
MF5<S2H!Y'[MN00\>/(ZNN...............2AZN_P!_[+_T*3W_ 'KIW,@&
M^D?WQ_V\X^(^  !$1$  "@)C&$?@!2E#XF,(_ I0^)A$  !$0YL+S>GA1*7'
MQ"Z?NYN6]U.V01 />)O7*)0919A])3 2*9^A(Y!,8!='65#P)N7KQQQSZHHJ
MN#B1%,RA@#U&\> *0H?$3J'$0(F0 ^(G4,4H!](\P)HW8N@4+Y1'1"B=\M"7
MJ3%C%.O17(U?T_ LK.IE.1T=,PA[QE$E=* 8ID7"C8?NP@=H6M7G37(*6B7,
M>.14%1C78\HL:]'>#&,G\GC$SF(NLF!A*#U^=X]$/H<%+X*&-N....<E 3*%
M2* F5.( 1(H"94XC\  B90$YQ$?H A3"(_  YGS*<NV EJJ]O@J5,M6\'-QD
MO\YS9$JY'&:M729GA?E$VHR,LDX9"X;F^3HK@H"HD\#Y'QN1*(&*!BB!BF#U
M%,40$HE'XE$!#X" @(>!#X"'Q#G;@0 0$!^@0\#^\/-4O:7V0'5CLO<76DBT
MNN?Z';>PN';QJ]CK&O=@(IEH[C'I*HMUXUU5*KLM2JD!8YRATZ+HT+H$)#M[
M%1FZ#29@!"19)&&1/8SJ6[[&2E(A9?29^F9A0*%J*->BJ?[Q*[LMKN=%>9=0
M-@;6^55D10DL3IUEO4Y0&GR51XEJ,W7[^XDBR5)A@/ACV;?0*8Z,Q&J(3-GR
M-PIH9LMBF5(Z\X\[P?%X.-R&DJT=C>0SY]=] <N=FU)LLG*[#=?G\C:PGA:?
M%MX__P"&5)>8V<<<<<ITO]ZY+^ /?S5;FH";^^<M_"GH?Y1.IX#_ "\F&PM-
M?0U#*&2L'672X4BL%-:UWSXLC&'" E %J7W3\D204A**7I<MC*A\K.!A]8HB
M2AU%!)1A3C132F.:,J>>^VXYF4J^=XD[&5D!7&1</S!,-R)L!;GKPQA@(<_H
M,/D@@(VE9Y^GL*!E[1Q4XJVE",MA&"K^:EV#R(:C85/DA54(MPD!U7*!D%S@
M^)Z_6AX*'I.KRJLK)!QM<Z_M'D!7)YSZG!#OI-Y()NZ^;[+F@>^2(P?-T$SB
M!@=@$@DH3U-B#Z?<^]*:QY>&96S=IF+6=MDHJ1O<BJ]?'<($:EB6RQGC]8'!
MU"H"51HW523-Z_!E%2 'D1\<RG;Y>JZ-$N7D5/FFWU9T6&FFK*1B30PLZK//
MH^#<PD>BY<KEEF3/Y$V=JK(I(@)0$3M"%5+Y]]OCQ0-=VMCBJ:TKZ5VK;?-2
M1;6OH2"DB>SM4I=JD6+\O54S,#. L"$P4HIJ@HD1,J!2%+Z[ P3;2%K;VJ,I
M+*LH7^K(YT$>UKR#LST;4T)-M_3&^72B'S:+H;&C-E*5(Y54P(1L4I2VJC)!
M+6?56]9CZ@6W0+GYKS5D6+KJ#,8=&S/#SSB+2DB_-,A/*MA2<%<.C&4,@JL5
MN!6X>[#TN8VI6&P25$?_ &*Q<W.5.G3,[)L/D"$9$WF$D"+6EE'NVOAJV-(5
M]4WR]NU6!J+]NI]R*IE##6Z?*UJ=3M4U7(".=R2]]40<131"DL3(T%FR0:Q!
M7*-J;F:H5YXFW45FEX<$Y07RRJHJB8H>GM3BLDG%1=41A46]?1T.R*7\[Y>O
M/746FE,^:T5M*R!DWGR!M'^@M?<PIOUYP"0 !DE%A4B+."12P3!@$BA#3\J<
MI@])B&*:6<F*<HAY*)1*(&*8!$!*(" B @/)/R$E')]DK#)D6C5V?V,R?I55
M5058.#%S] @-U%"J@DJ154@H'2!4!.(F2 0-Y\?:FO:U9&N>3]D;5Y:VNJ[H
MS-@FV8UN)*YFHM[&$J[91@N@G!)/4&2CXD$,HU!L=<"F4]X)?5SI+/(B+E+9
M*.*]!-[)&Y8F\7:3GV)2QUY]*P-/F]])1=>(G!-9T&WW;EFR*4'*";<RJ7N3
MF*IZJTDP?9^0TBVA7:%AI=YE'J[>/J+%@>U'5DG35J[7>*N+*[M+<Y??-&T,
M2*BHUF1, 1,"3?GVD(_Y/'G"3BJ:VS<^0QCN9<E:P"$U]E:U;(I%KE53],^6
M=6>BV^;@(0&JZ!U%">\=B81YK[:M$?RXQ,>P<VT*!F*D.TBB5$K\Q5F"HV=>
M*2LZ*M>/)BI[@9@[E,7PM! $S H<1-Z:^2#4G[JG#5V.9&<V>$*^&N.Z38',
M00L2W^<VTG&3::,6:DN7ZJZ\FK7GR;EK(B\:@*!&I!&.ECM<Q&I6B@1TM'.Z
M@-EE'"9(MJ"4>Z.633<).8XWRARHW8@+8B;9HDY6:$;F5)Y<>\(XYCCCCCCC
MCFPN@?@)2OXI5S^IV7)*\"/@!'\0>>:'^X]I&T=@KJ5-456E:)$5-H'GR5,8
MF/37D"%^H!"7D) I_'T&*)1\B'GD7^...............2AZN_W_ ++_ -"D
M]_WKIW,@&^D?WQ_V\SE@U+)8[6,_(H"I!T_W$FN4Y0%%[,BH PL</J*)#@"Y
M!?N"" ^$6R93>"KAYF@HH=50ZJAO4HH<RAS#]9C"(B/[WD? !]0> #X!SIQS
ML0AU#E33(90YQ\%(0HF.8?Q%*4!$?\@<QGH>OT',"JMY^2&5L1">I*H0"B+F
M5*<0\IA+NO4+.#1-Y*(_+% ='3$3MFZQBB7D#-+[!7S1BKQ@N25BJJ"8"UF
M5611<)"(^GYYDA$CZ94,02@JFL9"/,8OJ+'E, &Y@P         \  !X  #Z
M   ^  'U 'P#CCG B!0]1A I?/CU&$"E\C] >1$ \C^_R^*QFN@7,2_8O3K#
M,I&,4GRMO&KI1Q!-] J2;P&L<0OTCY,Z / "/T (\S?"]4[:H)#W"T52H)>H
M05:).5;3,D  \F_XE#^AD0WG[D/7*> 'Z?(<RW"=?<@A/=J21;5>71 'UA(O
MTJU#G-Y^Y$K&& TB9,?K(O(F\AY*/T^>9;AB0]73!*H5BL5,H$]'OH:&:%D3
MAX\>5I5V1S(+'\"(>\,N!_B(^0$1Y]7;QX_,)WSMR\,/UN5U5_'_ -4%#& H
M?N%  #Z@#DBZB]^7UR*6$?)R-@;*?'R(':&,V'R/XS D!_W0, _7R,%K[S8)
M1^Z.==#K7*S<)N6L8W+[3GYWL6W3I5EAX6P34$YJ+&P_.0N/M@KH5FS6./KB
ML01*0K=<FGS235=,5& ]LO[G479+@O5,^S_6IIK#]ANPG6FXV\T!6F=3HM]Z
MXM'*MJD+*Y<7 LO]BUJDFX0-#DH6&F)"6EE4PEX>OQX+/TI%U/2L\OGV0#1[
MU3;C]BDLY@;1]BEH@K']CDXS]?RN&GOF60??,\LU]VI\HC9+Y*]1]!_>(%]!
MO%D%WFGRTCER5!;O=9K>F72T4E70<OE*9;*'G[VJ4VU6Q_)7Z=;VM$S*,6>U
M<:4W3KS2RS"-RFH9E)1,?%&DYB,O>O:3GEMG9VKU:]4ZQV6KH1CFRUZ!M$#,
MSE>;S;4CV&7G8B-D'4A$(RS,Y'48K(MFR<@V,5=H99(Q3C>W'''*=+_>N2_@
M#W\U6YJLD*)>7CYX[9TJV.VKERLNV=-J_*+-W""JACI+H+)MC)JI*D,4Z:A#
M"4Y# 8HB @//%]KG0/ A]@%P\#\1#[&)7P(C](B'R3P(C]8B CS@<YOXB C0
M;@(AX\"-9E1$/'Q#P(M/(>!^(?B'XAX'G(9UH("(A0KB C](A698!']\0:>1
M\?5Y\^/JX^UUH'Q_^ ;A]U_=?_#,K]U]7W7_ !3[KX?#X^?A\/HX^UUH'CT_
M8#<!*'T%&LRHE#Q]'@OR3Q\/J^'P^KGV;T+1FKEL[1H=P*X:.$';<YJO*']V
MNV5(LB< ,S$!]*B91$!^!@#TCY 1#E1?U?4Y*?=69W1[:>9>2GSRX<DJ4BD0
M\@#@CH%?<$9^[*3WR9#>Z !3$"^D0$OPY\9BGZ;.RTE-R=%MJTC+O%W[]9.I
MR2!5G+DWK6,"2;,"$*8?'ZV7[D    / <IPYUH AZ1H-P$OP\%&LRHE#Q]'@
M/DG@/'U> ^'U>./M=:!X OV W#TA]!?L8E?2'CXAX+\D](>!^/T?3\?IX'.=
M -_=4&X&\?1ZJS*F_P!K0?I^L/K^OG YS?Q_NJ!<#> \?=5B5'X?B^+0?A^Y
M]'.WVN]!_8%<@_>K4L ?R?)/ASC[7-_\>G[ ;AZ0^@OV,2H%#X^?(%^2> 'S
M\?(!]/Q^G@<ZT ?/F@W ?5X]7FLROW7CZ/5_Q3X^/J\^?'U>./M<W\   H-P
M  'R !6)4/ _C#PT^!A^L0^(_6/.#9Q?S>?50+>/J#P(C6)41$/WQ9B/XO _
M2'@/'T!XK,W6-3L3ML^EJ1;5W3.,C8=!1.I2*'H81*'R9BD()LP]1TDO)3*B
M(G4$1,<?(\HWVN;^(>!H%P\>?/C[&)7QY_'X^2?2/UC](_'R/Q'@<YOX@ #0
M+>(!] #6)40 /Q 'R3P #\/(!\!\!\/@'.WVN]"_8'<OZ-2WP_$ ?\4^ !]0
M<?:[T+]@=R_HU+_[KQ]KO0OV!W+^C4O_ +KQ]KO0OV!W+^C4O_NO'VN]"_8'
M<OZ-2_\ NO'VN]"_8'<OZ-2_^Z\?:[T+]@=R_HU+_P"Z\X-GN@$*8QZ+<2$*
M4QSF-6Y8I2D(43',81:^ *4H"8QA^ % 1'X!R;M  1HE*$ $0&I5OP( /@0^
M9V7@0_<'DE.=3F*0ICF,!2E#U&,(^  I?NC"(_B H"(_N //S37.;4LUPMEC
M5/[Q2>L]@F#'\B/D)*7>.T_B(B/@$E4RAY$?N0 /JY;7''''''''''''''')
M0]7?[_V7_H4GO^]=.YD1-)5=8B""2BZZZI$4$$BB=5994X)I(I$ !$RBJABI
MIE !$QS% /IYL8I=32HE3BJP7TB_(7YSL*Q! 0<3SY),SA,#%$0.C') FP;C
M_@T1$?NA$>7'Q_[_ '_Q 'XQ'Z@Y;-SN]0SI@60NLVC$^^3,HRB$2_++%* 7
MX>(^(3,"XD$?!3.G/N&B(B K*D+\>0:T;M-;[,5S$TE$]$KZH"DHX;. 7M<D
ME\0$7DRGX)&IJAX,+2(*11+U&(,DL41#D6S&,<QCF,8QSF,<YS&$QSG,/DYU
M#F$3'4./Q.<XF.8?B8PC\><?4(_4'Q$?J /QC^+E:@ZY8;.Y!G6X*8GW(_\
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MW?YBKWA_)SCFU:!48.O4NI4JPRSQ%U,3\RXKT#!K/W-GYI[3K%+!=NN^'[)
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M0\U2M?D&('^1BW'F'\8PL^1RULE#6H]A^RCY)X0-%#' Q^2O9%Y\#C)/_?\
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M>ZO2UW[^+0MV:W2M7NL+2<2L#>4CT9^K2<K$J/HUP8J#]H1V+AFL8$G":1Q
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M3M$?-H+(-Y>&8F9D:M8A@HFJ<[\BP+F6,0I43$%,3*%,38)QQ_[_ /?\H\X
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M............/WP ?W!^(#^X/[G-SG5VYFNV&5-1=4RTG3%7="E#'.!E!2B
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M8:PR!MF>A::NI3W5_FY7*7@?/M+CHB\0%>5L#6%E;5$61:M5T(R2Z\1$.?G
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MRZ3T^DUQY'!6YRPNDIRMV26W%<<<<<<<<<<<<<<<\,G][GW\#=_FZO(^YY^
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MYQ]G%+_9=6/Z01'^^<\<C=J:=@]*6V5DQC-'0%*6?B3"(BW5    >"(B(^
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MR@/DARF(8 ,4P!U:0,H_<KLF,%(O7C7U?*6;.'=NG;8"^0-\I;(-5%F_I$!
M??D3\" A](" 4XR!2',0Z!"'(8Q#D.@4BA#E$0,0Y#D*<ARB @8AR@8I@$#
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M0AE5/2F4YR%$P&.4!Z^[2_P27^:3_P#+Q[M+_!)?YI/_ ,O'NTO\$E_FD_\
MR\>[2_P27^:3_P#+Q[M+_!)?YI/_ ,O'NTO\$E_FD_\ R\>[2_P27^;)_P"7
MFPZ@_@)2OXI5S^IV7-,?>'HIV8[*6_=ZK/\ 2?J7L.A7.>GPZD>TE9ZK'X#O
M/56JV5@0E&5MQ*7F)=LF;;UIL)WLM4@SW0)2'UR'95R-LB]2?/;*X+>6U]/.
M^<?+=J@RMRE<$]"V+HYKB.CQ&CYSF^P:W5\EZ]5G"]QK-+L%RH%]B^OFT_9+
M0(31Z_HJ,8LU?5^>E*Q5+E0K,J%CB[3ZS]+.Z^7VC/YZZY)$*IU+VJ(=MUQD
M^VTQN=J=X=M/2RV=9K4M.Z?I==B[?;],QB<F8R;L\-*M$8FUQI7L)E\VO#Q4
M,1;)_7SV;V[9EF=BK%H6S5Q8I#V1U5Z.1[Z/GW[Q-+6(RY=B;!+G,]7KC9RA
M1';;2J8<99,AG;ITQ>@M"!\VM57&%H+H/W;SOL+E<AD=1C,S:(7+IS8]3U^N
M=G']AZ]:95L?R#$<^V!3;^DNBU"SQE@[#$BLNGZ'EFOX>[RB0>QY,=O-@N$!
M-TR>C7OZ1 #X>!_=_P @>?@'T_2 >/CY^D//-87<7JNHJ>3U[-8PZJIS*/KS
M5XY HF.!2&.YM4.U1(!SK^2^]L#!$IU' ">8;D%8C\B^KT! 0 0$! 0 0$!
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M(Q#@("("!@$!'Z>>?CCCCCE4B&3QX[3%H(I"B8ISN? ^E'Q__><P>0*EY^[
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M2K-EED3%.-(XXXXXXXXXXXXYP( 8!*;^Y, E, ?2)3 (" ?O@(\WCX;<AO\
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MOL % IO/A$"NW;LI4B^0](% #AZ0 5!#R T W0+"S&,8'-^(!C&$"%M" E(
MB(@0HGACG$I0^Y*)SG.( 'J,8WD1]R'0S D@2!1G;W0IB43F7MS\HK^DWD05
M*U1;$ #A]R;W)$?N?[GTF^ZY=\?TUZYQXI&^UXD_.D)A]4K/V:1(IY,)@]\@
MXF!;*^GX%*!T1#T@!1 WD1'*L#C635@4SP&;TB+61 2IN6M9B =E 1*(_P#'
M%&JCH1$2E,)C+"(F#U"/D1$<D$3(0I2$*4I"@!2D* %(4H?0!2  %* >/@
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+...........?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g1031628.jpg
<DESCRIPTION>G1031628.JPG
<TEXT>
begin 644 g1031628.jpg
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MOZ63_CVWKVTXBQG2MV;?QMG^7D\_;-5.(L7LX4NO+^E<]W?7U!L6+'TTNO\
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M7//\.ZQH%BQ8992EUZO^;)_Q^@V+%CZ:77_6R?\ 'OKKYQIQ&C.E;K_K9/\
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M]85M#!_^36T_8*_R@\YZV52E*H.P1'8&L=6>S7L#6.SDKQ$?R4AAW8>*^$.
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MW]W?!M';5-\GO6T1[\??NZJ[Y/>MHG;Z]>[/!WP[!]RJ;Y/:_(T3[\??N[X
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MS=<H.!%%0"K8O:S;V;.'EFW;;-VM&ITDG3JV9V+G6[91=(%T"+K1;ITFD=9
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MW'@F)\7IP3.?C0X\$Q/B_P!>>HMI%S0RDP4+E<%,7@[=&X+BQW6;8^7W(MQ
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MP.QI)5LKD4<ELG$>P<2&3J2L&\;:O%@R61;NW=MS#&71;*N&Y';8JYV:RN]
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M@8P%$2E$VY Q@#,I1, &W(".0".Y-D&O(=@^<A<.<1;NQGN#$I7!&^X.TG^
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MRN*RS&=M-WA^QN.+7ED"NHAWBI*+PN'C=Z0(D034NV5;+L8<"F,"[A(Y3BD
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ME$I@[.::RB @(9\'9ZP$0$=O77-E]:'&&=^SJ,_-*2;IVBMOY#.E&#DR:NZ
M^^(&5C#"@?=@ [M(2F 0W6>=;TMG#AA:<6A$0\U<3=HB4  G9[4<Q ,MUKCM
MO)SY;<QK(>+RWXPW%S>?FO[N^';0+>6#_:&XO=?-1_\ ;OKWZ<7EOQAN+W\T
M_=U.+ZWXPW%[]:?NZHBX8)5. G%!GI\X)P\F<4U'C4R2@%9+B)5"@P*)B&RW
M)P Q1W(CN1 ==2:-OK"BD/&&X0S23U ]:  9D+J#ROSR#8&8B.777TXOK:OO
MAN+5_P <UU]WROIQ?6S]$-Q>_FG[8ZG%Y;++C#<7OYIGW^#LZ<7UOQAN+WZT
M_=U.+ZWXPW%MS\^M.]VNV4XOK?C#<7+^'->4?:_DV!S!3B^M^,-Q>_6GP^5U
M.+ZWXPW%[]:?NZG%Y;\8;BVY^?FO>[799=58K+M&<-+)R,O=LG&1C"VYM\^E
MI*6CF31@U;/H4RRKI\Z:)-6K0A#"JNJX,4A02*8RA"$-GP;<VFN[Q#GGU@:%
M%HWII,7>R%5I,WNG,(6M@A9#S?.QP//WO)134LZLV.&_FBK=,=1VWR.T?*Y[
MD;NV= 2?Q3?L;TTY,7)C2#N-HY+(0N&\:*MLX*68X-N3'28VNV!(+H<%%- A
MI&;03(L"&9V2F[,8WH%%62Q@HUC#PC^3B(B,;(LHZ+C#1K".8,VY 30:LV36
M+2;MD$B% I$T4R%VB("81$;_ (O+?C#<7OYI^[J<7UOQAN+N]G-/W=3B^M^,
M-Q;,O/S3J_)VW5R]=.+RVO[X;B]_->;+H_ZB&=4"WE@_VAN/W7S7]WU7B^M^
M,-Q>_6G[NJH6^MGZ(;BVA^&M.3+\GAMRUAGEK&OG9Y!3M]DF)U%!34D""HJ(
M&54$DH^*)U# 4H&.?+=&$"E 1$1 I0U!D]<T8RCE<[#;VA:\@CZ82G,%;-P>
M_DUM/V"OMSS[8/-N>OYJV52K20,N1@],U<M&;DK1R9L[?I&78M5RHG%%R\0(
MY9'6:H* 55PD1XT,HB0Y"N4!$%2>2<_I28[XL7+AO9^$L_8<1>*,DK#76A!X
MB1%NX?W6N\=M'$3?EE7C>^$E^*8@PS:'82;F8P(9I8?8II(2!7[.Y).&9!.U
MZ[%SW(;H0$V6L0#<@(\X%$1$H#M !$1 -0B(AF-<@UZ@U[>ONTR -@959R/:
M]][#=?$'I'=KV/L-K\02KRE*4I2E*AW.7#47M\Z2W-EGG&^[L^&IBN--.2P[
MQQ'PIL:W+(1NP)@ND5HXS+F5LEI'O+BMB#@L7[7E9Z[&9):,FHE).VXMLYE7
M3F4B)./;-VZBSMDX1*8@\B7OH\8Q)8A:4#!"X,;[S1O*Z_L?SBV,5).*L,]S
M%:V5B=,O[U=VNK 8?PEF+DP]CSI2\FI(6?*%8E>'7EBR""B:*6<WSH^+<9])
M%GBS<FDYB#9TU Z+$[:>*5K04/)XI6W>V'5[X@7##RV'K3"?#B')(N</K@&
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M2G%&V^B6W?5^DH%I6X YA$MM0@.U7:&S_6?X=\:^=GID2M]FDD4")I*2"29
MV%(G*/B$*&>O(I0  SS'(-8B.NLGKF?&;T4,-6?E U_T<_3&4Y<PK9V#_P#)
MK:FSSBXV;.V#SO=SDV5LJE8]=W8HVK<H/HI.<9&@)H'D*JGOR4NU&,==D1:J
M0E/OB<@CNVAT]P?=E6$FY-GD/YCH?$O #%/$BVU<6;1P#2?3T!85Q2N,$?\
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M   ?V_&:5V&PX<1MP2D#;4/B98-Y1F)-B3EPS+R'A6R"%K@$%C)&)OIV3%!
MI</)]G'MB)'DYE,ZY1'O$-=*59R/:]][#=?$'I'=KV/L-K\02KRE*4I2E*AW
M(>747[$E?TQH5,4I2E*4I2HR(\ZJ^V<WL]N7_P!1ZZDZ4I2E*4K66*^)%@X6
MVMQMQ&N^W[+MN/D8Y=U+W%)MHUJ!$':*JA4-_4*H\< 0!,5HS3<.E!R*FB81
MRK@LVE3I':43E6#T,L,%+,L4%Q2<Z3&.\&^C+5<M@  %7#RPC@C,W4N<#%5:
M/W@ECMQD9RW3 Q14VG@_H$8:V7=S?%[%R=N#2+QX,1-9SB3BBJ22:13TIA,
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M)%\S4U+.[=C'EDGQ-O1[/8G2=S.'#-I;1&CAP@9Y?4<V*]C4#)*(H^I91$0
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MH3=*Q];T51W]'YKY1@/K_E604I2E*4I2L;M//@-MGZXD_E9_625S/C,7.Z&
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M\>,<[OPZ1QIE\'6MI,[MQ0L*3P\8K2%M-Q7?GPWP^N>.M%C;13MT&CM65='
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MP:R^@JO $'GGP/%9YY]KF7T&=1]H$*G -$R$*F1-61(0A2@4I"%E7Q2$*4H
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MP$XF1PN)U(>4(0!CI0H"8S)<"YF.Q*0H9B'W1C 4 UB(  U)HW7"%21*+EP
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MD2$<N!KC[HPCO+]'Z:<9$NA[C\"._P"[3C(ET/<?@1W^TM.,B70UQ^!'??\
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M[5GQ8Y,^W75GT30,;LQ .+&TN?;KX.U- QNS !XL;1$.W7-G^2>JOY#'#/\
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M-G^2>JJ_;N_Y8Y##VZ_W1RZ)Y:H.-^0Y<6.4 [=<_P"::K]N[;][&PV7;KK
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C#!9;U&I--Z[-!QNM[=O5=\W8LT,L]_W.XW Y;G/=#NL@_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g251333.jpg
<DESCRIPTION>G251333.JPG
<TEXT>
begin 644 g251333.jpg
M_]C_X  02D9)1@ ! 0$!A0&%  #__@! 1$E32S$Q,CI;,35:0T@Q+C$U6D-(
M-# Q,#$N3U544%5473$X.# Q7S%?3$%.1%-#05!%7TM?1DQ/5RY%4%/_VP!#
M  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  +" $2 F@! 1$ _\0 '@ !  $#!0$
M              <%!@@! P0)"@+_Q !E$  !! ("  $%!0T3"@0$ PD% @,$
M!@$'  @1"1(3%"$5%A<QU!@9(C=15%56E)6SMM4C-#8X05-A<7)U=G>1DY:7
MTM/6)#(S5W-T@;2UMR4F6-$U4K'P0F*ALD-$9H6DIL'A_]H " $!   _ .Y3
MX=-U_P"MO8G]+"_RGCX=-U_ZV]B?TL+_ "GCX=-U_P"MO8G]+"_RGCX=-U_Z
MV]B?TL+_ "GCX=-U_P"MO8G]+"_RGCX=-U_ZV]B?TL+_ "GCX=-U_P"MO8G]
M+"_RGCX=-U_ZV]B?TL+_ "GCX=-U_P"MO8G]+"_RGCX=-U_ZV]B?TL+_ "GC
MX=-U_P"MO8G]+"_RGG.&=A-Y"2,$G%VQ>ER1\IB8PB<?FDH3CC#F'$MS!\UQ
MZ)-BN>'HY$62TME]I2VU8QXX4GNUZS]F*YOZN9;<Q&";!"1FLVBKX=SE"DYR
MEK!T#EU679@&6[G"<^.5R1$E>($_.<YBRIF4/'(PV%/G0GQ6(<R3%PXS+RYA
MAU3>%Y0N/YN583G'CE.%*QC.?B\<_5Y'7NX:^RQ#[J=_]^/=PU]EB'W4[_[\
M>[AK[+$/NIW_ -^/=PU]EB'W4[_[\>[AK[+$/NIW_P!^/=PU]EB'W4[_ ._'
MNX:^RQ#[J=_]^/=PU]EB'W4[_P"_'NX:^RQ#[J=_]^/=PU]EB'W4[_[\>[AK
M[+$/NIW_ -^7C5;F]$=Q",ON/Q'E_F<QY65NQ7%9^)U>?:J,K.?'*L^*F,Y\
M?:UG.$3$E25)PI.<*2K&%)4G.,I4G./'&<9Q[,XSCVXSCV9Q[<<UY$V^R) 1
MHW<Q85-E#2@S5&Q2 TC!>7&FP)\*G&9,.;$D-Y2XQ*BR6FWX[S:L+:>;0XC.
M%)QGGB?8[;=ILL1\Y[&[KSG,=A6<YV)8<YRI3*,YSG/K?QYSG.<_LYYN_-:]
MI?\ U&;J_K$L/ROCYK7M+_ZC-U?UB6'Y7Q\UKVE_]1FZOZQ+#\KX^:U[2_\
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M;RIZL+735F\]EYW22MKVNXKUTV\5K&M:U J$R0%DTJ9?;W:5"LF+9Y#S8%A
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M(1Z5M;?G(5DM5M(:[SN#M%4;<1NTVF==ZQNZS1O>J1K(RVV1O5NP15,%PY!
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M:E(&$U^&<^Z#;3:LQ9JO9.:;RW)4F8A+DO+_ #\6?VL__3F%]^_1E8_WS<_
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MYOF>'NG8_#S/C\SP]ZOAYGC[?,_S?V./G;F[,Y5G-EUCG*L>:K.2ECSE2?\
MY59S5?%2?_RY\<?L<?.W-V>.<^^76/G*QYJE>ZEC\Y2?#P\U6?>KXYQC'LQC
M.<XQCV8]G&/)N;LQYOA9=88PCVHQ@G8\81GXO%.,57&$YSC.<9RGP\?'/U<\
M8\FYNQ.,839=8)PG.<IPDG8\83E7^=E.,57'FY5_^+P\/']7QX^=N;L^B_\
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MZ]DPYULU]:ZN1JB!M>!70+NLOL,O;0==*4U4?K@%JNH)NR TVIE2QN75Y6M
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MOT?-B/JW6T=M#6:%3YJ6;P>V9%48K08ZX/V%9YZR9VZ"73<(@X&LI":OTBS
MA4&:RA#+,=YEEI",5;WDTK,ZS$\TNFY)W6&@==">:C6\DKH/;C*AMC[D0R+S
M,MH]N&M41$&QODXB8JE1DLX8SEO-4#!0M<%0 5=#!ZZ"%1TQ!8.O"1P((+B(
M4I:8@P.(BPA@Z*E:UK3&A16&<+6M>&_.6K.:EQQSL\Z\?2>J?[DW^,!7D-7[
M]&5C_?-S\!'Y9_ACQSGPQXY\/'/A[<^'Q>.?U?#]3G&G08)2%,&%(,$H,(Q)
M$ B,)PHI(:2@2VE,2X!$=.9D0B$"6PM;$N%,COQ93"ULOLN-K4G-E/:GU1(J
M$;7LC56KI&OH4M)"%0']:T5ZAPR"'7Y")\.DNU]=5BST/R9+Z9T<0U+2])D/
M8>PX^\I=[Q(D0?$BP!\2) @08T>%!@0(L># @PHC26(L*#!B-LQ(4**PA#$6
M)%99C1F4(98:;;0E&. ?KU>M88A7+77P%JKA9E,8M7;0#$V2OE8Z'FI"(Y0$
M<AD!)%A$AEF0AF;#?;1(99?0E+S3:T\V' @CX4,8.@P1PT=%C0!PT?"BP!HZ
M##91&AP1X^&TQ"@08<9MN-#A0V&8L6.VVQ':;9;0A/!/5VNVH*0K=IKU?M-<
M+,ICEJ[9P8FR5XK'2\W(1'* CD.>((L(D,LR$,S8;[:)#++Z$X>:;6FB$M<:
MY,BY8(SKK7A@&0#@Z[/!EZ%4"H2?7JN\_)K%>FAR 62,F *Q)DR9%:!R8KHF
MNR),E\)#@/27UN5=58K*W8CZZU6UO#Y8&? >57PRGH$ZJ1WXE5FP'<P<N09E
M6B2I,2KRXBF9-;B29$4&Z/8D/-N5*#!@C(<<>,@PAH^(WZ*(/&PXP^!$:\];
MGHHD*&TQ%C-9<<<<RVPRVCTBUK\WSEJSGE<<<<Z4H$&84G0A@Z.[,($ID0?
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M Z%6BS1>P@#Q^NJ&3E9/]3^V?S4EL[8C(%*36:GU[[!R]+4:T8+N$E[:KPH
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M$KR&-/K/&LL^NV,TRF-+.$'7I,SQ3EMIJNWK2VOKYI^PZ*DA8]6UM8J\U5W
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M%->[>Q]\3#]\QLV'NBYMWNM0;3OFM[?D4AZ^TS9SL"@1@356(,:YIXL1&UT
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M6FUX52#NL*'>P,*&0V3 /W7#,9-$'=0]LTNX]=]12BK'AMF<*IO8R-5\6XL
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M'&+F5RF\B5#I=QF^OE;"1#,UZPV4@BHA[#//C0@Y$LQ8E@@H,DIVI.3@D 5
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M\;N[;7>D]>[($ZSKRI[!L6UHVEA84V2.6FC'K.YNXCJ*,:JX[5YNX'R\JSP
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M$1@O"E0XC5BL](M3[*!PNK5R([&BSZ3&C(0^ER60B3GUEITV<WF4_P Q[?\
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MVQ"NM]STG9%[M:AEK:.ORG-G M.RS8+S9VAIHRQ66+.NW7WD]C.IQ^E"VO\
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M*_N[TI_6WK75Z5LJQ&K9MNE7W<>(-NA[!"0J.R?V!=2FP[&4M#FEKI$LHBR
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MR@E]1W2<JM :79AA0F5!:^/R+-Z]82X8Q&M>G)>T)35-I86A/; /37F(^'Q
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MTZW>I,ZO6NO0@&2%H'5.N6QH;;XM=.>D%-3G[]L7E"]+UN3O5@E7+>.7HZ]
MM;$<&S6J@2CEQLNQ7=8@Q4Z,3V$T;U8.FGVL&H5HW2"U_7S6O/#8==DEQ"FX
MBZ-'\I)H^2[I13=7N^8.[;4 H@\G[K:DPT"M]@W#)T8D4R,>V8S9MFC!%ZCL
MR3UOT^ O-0&4@K7KJHR]!-Q8:.+CRE>D5THM<4U:UC_5=L#]/! UIM>E*@\5
MMDT)<[(^S9C)39[H;3<T$%U_9)-DJ>YGZ3>Q$K  ;BKRY5D'X1FKJC9-5W-K
M2C[8I69ZZIL2M#[0$28'9%&&8<_#B5PRXU3C_J10?,8E0)[")$J/B5%=<ARY
MD)R-+?D'&,8QX8QC&,?%C&,8QCV^/Q?%\?M_;]O'FI\?'S<>./BSX8\?;X^/
M\OCG^7/U>/#'U,>W'AGV8]N,?%C]K]CCS4^.<^;CQSCPSGPQXYQ]3.?C\/V.
M,XQG'AG&,XS\>,X\<9_X9X\,>&,>&/#'AX8\,>&/#XO#'ZGA^I]3FO'.SSKQ
M])ZI_N3?XP%>0U?OT96/]\W/P$?D.A]C:]L-RN.N0-\IAO8.NXU=F[ H@BT!
M"5RHT.WQ'I]4EW"LPYKQFMQK-"CORP+QB'$;*QFEO0U.MXPK-+VMLB%JBH-6
M^>)G&V'[MJJCM#ATB/&E+G[7VK2M4"I2792'&<L#"EVA%)C/FX=DPH4B-'6W
M(>:<1"47O?T](";L<%]@*67&Z^>!QK(H4/NQ @J5:+8<H59@U8%&J3A_8I&P
MWFLV*EAAVM!=RG3K8",5YICW4&S(S-2A]UNJ12-+D@MY4^S^IUG7EO7$J,.V
MW K*";;FMC-6I$A:O62Y<[8-B%%NBZ=20<(C>CA* 9A1:UE^O6% JH1^X76"
M6;U]78N[J5(+[3:J[M%CLXL+L8LY=S!ZNTR 1,( J!4TU:['5K/6Z[7;Z4JM
MA+V.N'J_#%.F Y"%'X47NAU<(525=@^Y 5@KT6QP:FAZM5[8%D,$S92MSKH,
M16ZB#IL^YV\01I HO>!]KJ-=.TZ=2 QBWP[ _7!4\E'HA?O%UNC[,U5J"K[,
MJNP=@;8OFOZ8("4\NX29'P]CZ]-;3 65ZP,#9%3(MN4(8/M^*L/L"K>]4K$'
MMGN4S7WDSG;AMW;?1E0N1.DS=@4_).D6EFM[F=(V5BN1=+MS=0V_= PC;Y1J
M R-GOD:=4EE6JZ%*/'&*^0Q;I+#8(?)6]2A?=#09NT@ @JYPI0"QU268&V]]
M@Z*0[<6-OUK3$?4ZJ2:KXW8#6Q9]FL\*5' R*]'(H%-N$7AR1&<EV]O9/<C4
M&I=ZKT??B::PZ,TLC=5GNIA1=D"''&=B1M8T2HAH(ZM%Y=YNEYLZI[ L%6);
MI=&8T" .$V R9;&P+]HW9SK[LVP5&J:\VY3[G9+Y09VTZD%KSQ6?.+Z\%V$Q
M4"EL6G I#08<+M]?.5$E'L;H8M M@F?698UD[&6/Q.O''.DZ+*E094:="D/P
MYL*2Q,ARXSJV),67%>1(C28[S>4N-/QWVVWF74*2MMQ"5ISA2<9Y59-B,$;'
M[ZC4^6<..F(IN>0*27),PG.C2V)67)LI?G.N+>S'0TM?QH;\$H3A*$)Q)PW=
MQX39(]IAA!/K\>,S&91(<F/1LML[0G;/<2YE'H7U-OSB+X5Q#;[*DPLIG-.(
MG8QC%-A;/C@7@7O/I@JN0*Y:ZC<($%TT;/J?)U)5C4U[HSIRV'7DD/?(^PZJ
M"R-Q#C0HB([3DMR7-D7U"[&38)F$8;I\>0L0V*]PE$+86FE!4@<>FV"1Z(TZ
M-](R.+R94>.3'AX(.2^P*'K454^HBY/XD3?[HY(%4"E0</@YSDAAXA8B)-<6
M'*C6> 3'U^4Z.9+5UHQ#LS^9R6RI 4S/ALS10,:AUR(G=;[#2U$J^1(4Z,7]
MYA\?9*8@C:S;LD01BUQ5<F8(SL1?_&8A%&(Y-4-F(%C0"#"D06VX,N7$=BJL
M7B75XH&+&'Q9:0%ME6Z.J0XXG+\N56$5=41Y*$92EA$5'K&'4^+BG%+94GT.
M<^,GJ[#G8"8DBK!&*Z;B!5A&K$\8D'S#4%U=26X*;F$!S,V57,)JN8S88]-/
M2<03$Z"HRJ(A#+L?@-B.52RF[%6ZZ(&()D0Y >%6[,F"P20MQ"7**/B9<4W+
MDCL2@C0Q#3K[,A@8]YC<G,B,T\KD&MC1IM<DU %4A]8K3L5+4<>T9*FY$:4[
M;H]QGS53R:4+D9E38<*#'B^@89@08C;GG3"#DB8_MAM@PAXD!!+TH'9Y]0?*
M/5,F5F$&XL)HK,<*+'6  QA0VW"H1MZ08@02*HF$ORI4&<Z0%/>HHX[FQB[F
MMD:U5%A9@(L2S63./2)++'K<60Q6%X1A,;W#;L;KMG;;2A*TE7,X2E+"$)Q'
MO+EI?Z-*9_#&I_C$,YZ-]D_Z<1_LR'X:/R,^/''U?C^+]GCCCCC_ .__ +_E
MQQQ__KX^/''Q>/MQ\>/J>/Q<<T\Y/M^BQ[,XQGVX]F<Y\,8S]3.<^S&/U<\U
M\<?%X^W'QX^IX_%QS<V-^EBW]_%?M7_M\1YX9F/SO&_W:/\ @&^7?2[K8]?V
M!FS5:8Q#)M0# EY$T</,BR0:PBI8,\#-!BT:8+,!30B=+@$AA"*_&DL/>U"7
M6V76Y+7V.VI(D2')\ZI%H,H0" /5\OKFB$*KD/5ZJS3*U!:K3P' J(V K\:)
M%$NPV(\F-(AQR"GW9N'G7]PAV8W,57,DD;,)F%I9B>;;LC]%H3EM$R2=F'W&
M?"K=J76E'*T#DV87"+* !)L(4T\AYF/&9B3B$:74\]JMP+EQYCSVNY"H4Z66
M@1GM-ZK]1'&YMD&6]\_!ALU-EID]FS"8YI)9?I9?KCY%+JWHA!^+RR;+NO8U
MPKKM9LI4.6BR,Q$3"[]-IK=RGPX!PE9!XDA>HX%FW2P8\X7GD((=TQF#'4ZU
M%PTJ!#A0XT4\<<<<<<<S"\GY^G8ZS?QH0O\ H1[GI:[1?3,C_P $PO\ S17F
M.><8SC.,_%G'AG]K/,5+#TJZYVJRGK2=IY^;*L9W9UIGA$[(V+#I$>U[HI&-
M=[9M8:A0K/'J(.S;#JOI(EG-#!,>7,(2)IYA44X0($)>U,Z3=?"1<X?)!M@D
M39:3(EBBTW=6W7"6N79&SX&Y_#3Q%NY,S]3(C;/&0+9 ]Y4H8N _%:#Q7&ZT
MA(/'%E]&.MTZ2(FR*[L!4P5$J4:1,1O7>*)EI>H>P3&U::6V#+^$+,K8IZM;
M!L)RSB2UT>-/QYA21'RE8]J!#A;<+HQUY@85(8@;3]\#,FIO!;VYO[=N=E5"
M)1(5X%4\'2-BM7IFW5.M@@FR+N 9!"BC<$B"L,P:=06;1&6QD[4JJ"HU6KE+
MK$1Z!7*F$&UX%"D$BIF3%%"8R(D)J28.SB9LM*PTWA4HF8)$"D^0IV7/FR93
MSKR[AXXXXXXXYV>=>/I/5/\ <F_Q@*\AJ_?HRL?[YN?@(_(. :EU;5=@W_;%
M9UU2J_L_:L6KP=F["#UT:/N6P(=*A.#:A%M]@CLH('6*T/=7##MS77,1(_F(
MQYWHF<M_.T==P-HU:)5B1.6)C0[YJ6^IEP6&)+ZYNI-LTC;0P>IN2MMM,4P3
MH\,//?PK+\6!/DRHJ')+++:L/)G0(1%1HTM2]S6VFW[KD&H<?4]R]YE6L\*!
M8*)L/;EW:.V.F%)\0;8X)\5NFY4TS7VBH5QF%[EV(188!R"WSYN'0$/>J!8:
MS;=RV:UW _L?KSMV?L.UZ^H4]LG?>OE0FTZ)*LFOZYFFU@K6KN.+F_=NMA9=
M1?!HF0\ #[<X7[JSXK8\EF%@3].R!?82UP!FG3.K;H#!8U-KY02'L76^T[)M
MDC<*97XI<=2]>YV-8;405=XT:GV:QS'8HR3B\/QU'19^B1/)/#&ZB'K\WL!.
ME3JM<!ENIH]O2-99U#7)K6L+KJNT2XFCE[$?KXP]?1EQ9L]AF:_L6N*8/M]6
MKS];UP* X*@B<L:T\G0&U'8-:L4[<UE@ZEU=O^A=GX>HUZTH$./+W%3NN;G6
MPC/5; :PGO7IUJ )CV]ZD@JA%B5VVMR(( FS49"*[#E#;'30)M +L<8UL,Q6
MIFP=UV3>>9RJ52[H-$V2Q=6W^K>0LNI7)@E5[;6FJV]BP$!]E&R6C;N7ZW+9
M9&/-SH\#U_R7]3%3:A;R&Z;A*VMJAVP$]!WX56&X47KL</WO7US>:U#6K;=]
MA3H%&?@4<E0[!KRT7*R"K11MC;! N$ PLQ%&0<F]X]8&MM7P+M8+M*R:MO\
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MYQG'AG/LQ[<_JXQG]3'/KPQ[/9CV8SC'[&,_'C'U,9_5QCCCCCCCCCERTO\
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HCCG9YUX^D]4_W)O\8"O(:OWZ,K'^^;GX"/RT..............?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g146740.jpg
<DESCRIPTION>G146740.JPG
<TEXT>
begin 644 g146740.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@ ^1$E32S$Q,CI;,35:0T@Q+C$U6D-(
M-# Q,#$N3U544%5473$X.# Q7S%?4D%44U](54U?2U]"05(N15!3_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_\  "P@!?@*L 0$1 /_$ !\  0 " 00# 0
M           ("0<! @8* P4+!/_$ &H0  $#!0   @$($0X)"04&!P8$!0<
M 0(#" D1,1(3%!4A-W&Q"A87&#(S.$%1<W9W>+.UMK<B-#E68761DI:7M-'2
MUADV4E-8<H&RUQHC)"5"5]/5\"94DYBA)S5#14=BU"E&58;!X?_:  @! 0
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M@$I9-$G=G>&[;%[FMU,:4C] :>-R%"(I&^A=$HJ-36^"TY%LH1-+O4T'0FU
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M3K-9BISA:V&)NHA(3*$6Z."&8<'/"Z.0,;IDX6L$-*HRT5NS?XT1Z[1!U2P
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MDJ,HHVM[^D9^8RAXQR@87G9C%W'\K3!S9#&OGEDG:=4<A1F(*X\D7IH9B@X
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MSBD!M70K1-TJ"Z]<^/R\I2,4MO73&T8:MCQDZ[,M!IT-<=>BKVQ=="%&&8$
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MRO2_V:?X:#PM?]-R"/Y7I?[-/\-!X6O^FY!'\KTO]FN= GBG\!RDL<6^,>E
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M[&/\3#^S3U5_L8_Q,/[-/57^QC_$P_LUV]_D5C/*UNXO*]\?/#G?S]3^I_\
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MTI7:C^19_?QZT^\D#_I.25W1:4I5Q?*WO$ _P$'YT/52%I2JO/&O_8DO$8_
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ME*4I2E*C;TE^LH8_".A7\YME21Q]%O@M\5;-OT-OMFG\;A7PCNL_JI.D/O\
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M+'5KQQPQQM7&_P#DH7@H_P"CI('_ ,QLX_WRI_R4+P4?]'20/_F-G'^^5/\
MDH7@H_Z.D@?_ #&SC_?*I!<S?(\?A=<A2BEF.!(=. ^0$;"_C2=Y539*)-JP
M9R9)@A>4UVLE(71LRR4IL,=>._)+??HO^KT;->?ZJK%/G.(7_P#<R;^5"_\
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MF*[#7.FE*5'OK7ZEKI'[P<S?HT**^$?M^BM]KT_BL*\=*5VH_D6?W\>M/O)
M_P"DY)7=%I2M<?3;X;?'5R_,GO%1W^]*S\MNM9XI2J?/'Y_8<O$&_!\?/S@&
MZ^,=N^F[?MF?^]>O'2E=V#Y%N^IUZM^_9'/Z/7NNT12E;-GTK;]JV_B\JOAC
MKWOP?[CQC\AH*YE2J-?&?)X:2L@")R2[3.$.[A!W7Q;N/X0E&-(_-G"(AL,
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MRM6]N$_F07P;-[SE9C_Z5_UO?%H3*76_M=[)_P"K4^]?^M-.S=C"[N;&V(N
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MV(8PWQNY*\- _9E%V9WMJ3:O^@:?;EW>,K([6]7EDJOFJSF92E*4J"?='^+
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MLZ@ZAB?\<7=1LQ<+;TJ#8FI[;A&?9;[YY",$O+<^P8]\T2/.+1-VLE*6YWX
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M:+^'Y,<'<9AT*#OB.Q6-=!N7*,.Z8#YNZC7R-PK/<W<V1!-L4*S$V3W*!:7
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MM<?3;X;?'5W$%^\[&?W%#_\ 0-=97I2E5=>+@I#=O+XV+2("0"2@LAS_  J
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MX8Z][\'^X\8_(:"N94JA[Q/H\,F6:8ADZ2YPZ91<B.EI V2"GC/BOESLYOA
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M$CUDS/C0/)V+9M0Z<4JI%%1P\-N9B(P7=,DO4 ?CW"DF.*96#)/%N?-[' #
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M^3A*%L\IC4=&;9&*#T\+R31U!(T)23)*#:\OF>"!"E<.<6]HA(>#-;8C1[1
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M=*4I2E*4I2E*4I2E*KV[N],8?"7_ !#E5\4I6N/IM\-OCJ[B"_>=C/[BA_\
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MH<=65"CQ%><1+HO3S>Y[I)WO>J0 :&R*4&N*S1T@,)G.4&EK?(U@XTF9&W;
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MR@B9!EL=!<\0,;@+K\5;TX)$N%W/ D9$VG7[(RO=P<4B'&^:E1IU[.:D4C
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M3T0D(TJVR+'DF/#4X#(V4L3NV/(ZW#FW3D1[<M;RO5I]>ELKFF'BN1(()S$
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%E*5__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g805213.jpg
<DESCRIPTION>G805213.JPG
<TEXT>
begin 644 g805213.jpg
M_]C_X  02D9)1@ ! 0$!KP&O  #__@ _1$E32S$Q,CI;,35:0T@Q+C$U6D-(
M-# Q,#$N3U544%5473$X.# Q7S%?345#2$%.25--7TM?3U)'+D504__; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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M56F4E>8*N)4I[08?Q1==E9EVJH[>D"]:NY!H=OFKI6ZI<ZK9;#CB<:5G($'
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M1I5PD4/*2]J6 I3)N9NXGZ?2:GVA8J(B(BHVBM,]+AV&*[N58NB$+,-"!R'
MJ-^4U.W;Q>$3&+]0_@B(#SP.MT0.4:;.$3!"51;JJ&X*DZ,5(W?T$3]DQ_\
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M5ZD\679-ZLHSI3;FL=;=.F'!LXK;%N$OVP>T[A9F[X"R]/VAA@/*ILVR5O\
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M5 353,0,T>.D13 I#EY >.QR\\=P'N _R#].P:#CY%XD4P&.8.3"/;C@>?D
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M#@93IT[QT(IV,%U+INVR %X:-\Q;.L)2U:]I$.4T7J^-INASS9N;CGEF\4=
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M1EW>1< 3FX+#[.2A*PT+?L80*ES-)S3@WVF=.*U"UME27-KN4=/(M9"&J\C
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M% !$.1#CT ?CZ>OIV[CV^NL&B1,0PAR #R ?=].!Y^?R_#\-9XQ3'@IP*/H
M@(\\]A'Y_I[=^?AZZ#G&J8%6$P& /$(@( ''(!WX^H<=N._8..>^LQ:+BCX>
M.!#@.WRXY[\<_P GZ!#OK#TC<*%'CTY'X<^GQ_2/'K^G7T*2*@CP!@(  ';C
MO^//R] X]/AH,_"6(4!'DO/;@ 'CN'RYX[\_J^8<ZUE8\7X6N4U,V2WXGQC9
M[+9*L:DV&P6*CUF9G)NG&$!&K2LK(1CAZ^@.Q0"+<+J-BD J8$!, ('I5E1*
M<2 <>1'N(B''<?@'T[]P$-?,:2 3G$YC"' @3@W A\N?IZ#\?PT'J6PSM]6K
MTE45L,8F6JLRZC7LO6E:)6%8*4>PZTRYB'DA%'CA9/'<4YL=A<1SE9(Z[%U.
M2[EJ=)>0=**_<OB+ [Z2)*OL+XE=2P5:+I1)1QCVI*/R4N%!J6(JA'0Q7G%K
M<8FR:(LH4#A'-VK5!F1N#-,&^N-)(>(X!R/Q[^+MZ? ._P#@U^C2B@G,8#&_
M>B\ '8.0 1 0#L(#W[ASZZ#ZF6"<+(6AS:S4J(=G5Q]*XKCZR[:,%J)6Z%9;
M2%XNL%6*81DE"Q".0;@DSL=^6\ITM9I..8"X,@V04;+ZQLR.SJ$R$:@V/;]C
M1_,VJ:+-V)P.&X![[9:7KM[*P,BL@$ J>Q/;!*VVS.?>K94Z2#N6L2LF)PF9
M %MPQDD[=&*FU1<+K^'[J:"2BQ^!'CGP)%-P _,Q0^/)@'MKCY#&/O6^5G(D
MA!2/OJK,7[-L(-"F(O[27ABY=$ ?-%>&\Y\=BH4@F(9X/(@#=(NA4:5CDWQ'
MXOQ$=+(S9ICJDQ)LO1,K!90>0E<AX23O$?-Q+R$D$K#)1K1N[DU58Y^[1!9R
MHJ=)57VLHBX#S=9+"X?Q)7H&"AF./ZF[3K\K"6=E)RM?A96?<7*OU%K0X^^2
MDTK'E=R-Z&HLT(!W:E^)-U&"HQ44!HH9OK7L;-JI'(G]\ABFX,4X&(J0?7@Z
M9^!+\^#% 0]?CVVA'S0*(@4YQ,J/;@..!#@.#?\ 0 \!\/G;GG*5'*/9&Z:V
MQ;;F]2>8W;;?L)-\?.Y]&U.:2WQ;2$*HXLK<AD6M@7@D84L<,TS0.=JSDQ0%
MVS9G48M54F:BC<V28WQK5*5,6"1KT.FS?V^:C9*9<^4@!C(0,(SK=7@(\C=N
MV1C*G3Z^Q1AJC7&22<= L5'96I!6?/5E]E3*A5E#G#U, @/<1[^+X\!\OEZ\
MZ]=?.4[M(O?DG)Q'T#@>P<CW].X<?0.!^.HNBK#J]+ K:NF&WY#[O4JP<///
M/A*$-8R\<\=@]1 .>W/< U)R\/!">(B4?$)%3!R/(B >(P!^@.>WI\.> XU$
M_JX.4U+ETR" (B8>I3A$>X?_ ,IL7/?\ _5W]-21N"XC:7@"(_O:OA#X^@B/
M/'P[#WXY#GU^.M3_ !X?]OE(UXN_VAORD' 6Q#&. "(E'M_8EY-Z^H^G/I\-
M?-N!I5WR7@O(U#Q?<5Z'D"S1D1'URW,K!*5=] +)6NO2,L\8V&$0=R\.^5KK
M&98LGK%LLJ5T[12.4&ZBQR0IW"R&X51/"L!M\4OB<E9;+E-C<5J-8*=33MF+
M+!]RDZ*ZL%WO=*O5;J\,VR4A6W8BZB6SBPKH!6F+T5Y(K5QP<_C3J3HQ<@]C
MLTN+!8)6;R>U;1U6M^)<?5NMKJ5/'C'"MS:$M&*+2[D,9L;>AE"<R3BUP\<W
M66:2E491C_V.--'A(VFX[3T\Y]LJX64V8;RHZ]9%EX7=+9)['#[*,)/5:BV#
M,V5X92XXKC,@$GHK&=@M\1#R%SQ1+U2C)LZTXN=$L$S*9#7CEOM,G['.2#A'
M4]1V4;Z:-C""Q)7L^U6M1E;H<HSB9FM7_**CMO.RF&,>4)>DL8P*XU3B*:TM
M%(M%FB;S%N@M$'(90F;E%UUI:H9925SI[B'J0,<O%RLC:6D]+0A1JDX"F5L>
M156R-CA;-&1+6G7L>U8U#(OBN"84Z<QT]=,+LZG+2^FJ7,,VMC\4F0LIBT]A
M/J'7O#EIHV3<@R<U<G%2P4[CYR#S+0JS5)>R4N7V\V&[1;>*@L:QUNA;C(3]
M-S6_E;VO<V%+L;>TUR,;0"K("-X'5S6O#F(Q[<HVOK6:S&)OOY7XTQ><3J\H
M;,M[4E:9Z0C-SL]CV!EZ!:8BO5&$SQENV%QPXEX:U,XVC,[9=J?*62Z,TYB9
MA; 3+<NFTN4 >+]T0[!:*CXDAYQXBQQD[&^"Z?3<QVIE=,@PYK":7GV$Q9;"
MB=F_L<G(P,:,];G"\[,.82$<L(IW(. :LUW#508N/CHTK5HE%>C8CZAU>A_<
M-:N,##BRQ[DDE=!E;,;MJ3%3LK4,U+5R#?U$M$4FW^1'67;!BVWQ&4&-B;4"
MMU.+E8*?K3]Z623F=HS&/-\L5A*Y0MEOSVVWIMFS&LQ7)5G<\;PF0)[!!<>8
MV5R]3H>]*T12E5&WO,H_E)2ILO8:JX".J2;!L1ZB1W%O&V=MNU9]Z^9-]/7S
MS'9M)5,4G(@4#^ 3\ ;@WA4$O'B*!AY*80Y ! !$2\@ \<AK.8LIQ3*(C]T2
M&$.P@ !X/3GTY].1_$?CJ#.V;#.::/<,CY S]8HZVY O=$V\5Y_.1$NB[B%I
M.A4N=:7A",AF[*/;0C7[52J:YU6;)@PL,DI*3T?'LFCM%JWGM%@7RCD .W@,
M( (=P#CT$>>?B "'RYY-J*K9Z?13AU">KEP \%S7M^ 0[\=\:V8 ] ]1^7'/
MPX^7>+PZT-'XRH[(Y3$,C68H3%, A]]9$RYNP^@_O@"(?A\]=)7IP,/>'48Z
ML[$I!,=YGK;PU3\("(B8^-K&''(#QP'B#@0Y'D>_'(:[S\*P&-BHQB4 *5DP
M9- #XE*W:)(\=PYY\2??\1'0<QIIIH&FFF@::::!IIIH&FFH2=0[*=ZP_M(S
M1=,:S[JJ7>-J _9VSL4(YT^@)!].P<2$FQ;R[&3BU'K9O(N#M?>$<^:$7\"J
MS58" 01.(F>2;7(?,/UAIR'S#]8:K>';)N15.L=#=]N4!#SW!40-8\/"8$B+
M*$3 QAP6 F$"E* FX^\/)N.X:\_FP[E?XW^Y/^V/#WS_ -PL?A^H?GSV"R#D
M/F'ZPTY#YA^L-5O?FP[EOXW^Y+]%CP]_D+#3\V'<M_&_W)?VQX>_R%Z"R'D/
MF'ZPTY#YA^L-5O?FP[EOXW^Y+^V/#W^0O^?RT_-AW+?QO]R7]L>'O\A??]F@
MLAY#YA^L-.0^8?K#5;_YL&Y7^-_N3X_VQ8=_R&!I^;#N5Y_JO]R?'^V/#PC_
M ,18<_LT%D'(?,/UAIR'S#]8:K?_ #8-RW\;_<G_ &Q8>_R%]_V:\?FP[EOX
MW^Y/^V/#WZQ_ZQ?[/VZ"R'D/F'ZPTY#YA^L-5O\ YL.Y7^-_N3^O_5'A[Z_'
M\A?X?#YZ\?FP[E^W_9?;D_[8\.]O_K%_X.?T:"R'D/F'ZPTY#YA^L-5O?FP[
MEOXW^Y/^V/#W^0O]G[1T_-AW+?QO]R7]L>'O\A>@LAY#YA^L-.0^8?K#5;P[
M8=RWPW?[DA__  CP]_D+_ET_-AW+?QO]R?H'_P!T>'>P_'_N&#SQ^C060\A\
MP_6&G(?,/UAJM[\V'<M_&^W)C_\ A'AW^7!?\^/CSV?FP[EOXW^Y+^V/#WZ?
M^X7_ #^N@LAY#YA^L-.0^8?K#5;_ .;#N5^.[[<F/X6/#OIQ\AP7\_K_ ,NO
M'YL.Y;^-_N2_MCP]_D+T%D/(?,/UAIR'S#]8:K>_-AW+?QOMR8_0+'AW_"."
M]/S8-RW\;_<G^'VCP]_A_(7_ #]./CH+(>0^8?K#3D/F'ZPU6]^;#N6Y_JO]
MR7'^V/#W/']PO3\V#<M_&_W)?VQX>_R%_P#3]-!9#R'S#]8:<A\P_6&JWOS8
M=R_\;_<E_;'A[_(7I^;#N6_C?[DO[8\/?Y"_Y_X LAY#YA^L-.0^8?K#5;WY
ML&Y;^-_N2_MBP]_D+T_-AW+?QO\ <E_;'A[_ "%_/X?MT%D/(?,/UAIR'S#]
M8:K>_-AW+=_^R_W)_3_JCP]_D+_F.OF>;;=R,>V5>+[OMRADFY?,4 MCP\(F
M*4>3 '_6+[?=Y[]^/7C065Z:A)L(R->\A[<X^8R):)6\6>(R;G*E*VF?)#(S
MDM%43,MXJ5>4EOL]#0,.L_;P,1',W#MG#L"O#MQ<JH>>JJ<S0N.?GDQ[IMZ:
M:CONZL=@J&U?<?:*HW<NK-7\&95EJ^BS472=#,,J3-+1ZC=1JNV<D51<E(N4
MS9PBY**?B;JIK 0P!5_N<ZQN.Z7DN0PWAF9JKB6BC3I)K(5H256JY6]<4"/L
M4I773J0@:HM$04ZX809[!-V,&DQ+*N6$%$R8().G%8;/KZC;ZWFFLYF"4@<:
MIQ"=+>6Q]20K3V5?SAIF%G6F/[137=BA$9%,J /X5W),I]@FP*J+Y4%2IN'%
M+MECBY)S%,X6QUGMCN/MF3FYJQ6:?D6DI3>/<?-& 'DI6O6MVP=1,G6W$,]0
M8,8&:A%&L-'D!TNF\!^T40')*SM[L\PG;8MC*NL/XXVZ-GF,5&EFN-;R-1\D
MY<F4DXQE+,,2MTFS:+BTG\O(R,I+Q2SH&!56*1"2,FV?OD0[.V)W5Z?[7H_>
M7M(WF6^P8C]P.K,\IF4V2YY:)68>0BO49:+?/[/"#8VYG3=NFV-'Q;&5(ZC9
M&*>*1DFP?*7)[:LBV7+.!<89%MS9BRLEJKC>2EDXM%1NQ45*^=M2O&S=55<[
M9.2;-4GXMP54(W,Z,BD84B$UU3-ITOD#'FVC>WA2Q93@,L3D6;:K+W.P4U)"
M/HL=)VNRY!8,J_56!0;*B9.ITRJ,I$ZC!HH8T(1LW0"+9,N.U+M_L5!6P70H
MJAV6MR[:K8QJC=RV@Y>.E%HQ5"MM@.G*-&;M59DY%XDY!PW=@@I[01=(P$.0
MP%"!^X"U,E[U+,A?(GEERNY%-D503._=K=VFS]M%(G)DT"KJ)($6/X2G5$2I
MB84U/#7?*P5*P_+7'+*2,ZBC(M6Z+^#B"\QHNWKLIE7)&) 11(9V^.FIYSM5
M-C&*J.5$O 9V<HX/E*EYH<Y?N 2LL\GK)(&=29K(S?'AFDQ!D>@FW!DF#A$C
M)JQ$Z"!H(AQ+&&* E!5/PNU=FXPJ%B85F?B[ZU4=!*/1 &DF\][$<Q2T>F@L
MD?S%E@306/XP\H1#Q<^:0.1 ^@R]A9(VQQ49/1#@'49*-2N6BH=N2F ?$FH3
MD11<(*%.BY1/P=%9,Z9PY+WX!XX\1SF#P@)O3CG^7]O/80[^FM45*EV3&%BM
M$>B];*XN724F(U>0?@5U%/#F'QMTRF'@@H)$.G)NE11:N6Q63L#B\\\FLF>R
M(@<ZA#@8@@ IF*8#%.0P <I@'N!@$H@)1*/ ]C!R ]P\2;LPCP8_/AY 2EXX
MY >W/';Y_3G6(*+&%43"8.QA$O<?7XB// =NW_RAZ?A\_.8X?>$?$/''H  /
MS$>PCQW^'/IR&N+7<B(>$O #P' E'TXXY^8]^WRX#]H<\FYX$0[B<>P@';D?
M@(#R/P^7ZO0-:)W%95FL38Z&7IT*XL^3+9.-J1BZN-(IU/.']ND&KB1<298)
MHBX6F$:M#-',Q[L%$[=^_-%M793LU'29]LH/?"<I>/$(  <=A'L'?Z\CP(C\
M?CQVU7%U#;.[@'&"WACSR<(_C<V04H>M32M;G4O?C6D1KY6&FP:O4HZ6)$K)
M@@LNS>-EVIW3!\V68/%TQ"IJZ23FX!8(_)T.:U6=Q:WUA=6"UN[ G:XBTKBB
MSL"CPJ<@T;R)WY6#9![&6&.>HQZ[)$\>DR%(41RR$KE,AK7C>,M-FK5GD[6U
M4EW&+H&QNH*Q()*Q*\K5H&PVE]'H0%<6M@D9(.5F4DZ<UYJ_:E?+,7SYNHVP
M.OT*?7@[1-5V'ML]6:F;WK9K%(>?,FA&DDX%%DO8YHB*30KAP"0 4B2:7F>4
MX5;-$VB)Q3R:XG8Q"N.8FQ6;'=JFT81J]6JT"DR6NU;@%#)23:L72=2@V#AV
MHO$+J>PL1GIPE=1>*12J[!9(&B(;0V][A['A;(LF]D*TXJF/IZPC'Y!Q82Q&
MLC=C$(JD;GE&,BHY>E);ZD8[IU$2JCAW("BW6@)9V_9/G937HF3%HN9!-P@]
M3 4E&[]N(BW?-%TTW+.0;"/_ .RR#)9N\;\AXO(<)\AXN0UU^[6ZA[1:\AWW
M(66(P]$@J]&C *T?#1H55HF\<E852G?9!JK76[4D40RD=-3ZKM=BU1;(H1SF
MPNGL>56[7#<B[DL.X4=O?:O;G>&\:+NQ>D62=BH:M,TT1=)."D<$7%B1F(@N
M4JO@$@F*7GC0;^BE/$(>("@'Q$.0XYY !X'Y_7MZ\>O?/H]0!*(_(/B( /H'
MTX_GZ?$=>1(#PF @(&   0Y ?01$!$ ]>0X]0#CD/IK+$E3)< 0#<CP(]_3Z
M>@<?4/CH,I64 B8F Q0$?3D?A\P[_C^K6..GY04*'/)1#L(B/WNX\<CQW'CO
MQV#G7J5<^(/"<PAWY'GCP_P1[ 'X>O/P^? CK&WRIC& 2=DQ'CU'GL'<..P\
M#Z\^@<]Q'X!R9WB B(E-XC_>,)>X_> >0#G@/PUQYG_F>(I2\ 3DPC]X/0.P
M<_$!$?7CY?(=<>/FI "A>![\FY'D1 0[]OQ$!$.. $ [:>>'@4,8I2^(WH4.
M_)A_;P'KZ:#EDEB^(B@B(#V-\Q].0]>0X].0Y'MZ=]<Y",%Y^438HJ@DD('7
M=.3$\96;%N &<N3$Y+XS% P$22\117<*(HE$HJ<AB*:H 0I1'[PA\_0..W?T
M#T].WPUE,2\GH>KSDU6X-6ROD[%6F4C$MI$L2^>5XA9"1DV[&0'Q>RN'"Z#!
M,RQ0\0( MP=$0\](,)SQ4\]2$>[AL#NJK"EE'%)086*95<$GJG[JF1>3TT55
M-9)K*&=D*FN^8."^3(LR%AFY2MR>5J0\M982&,5)Y)QI7QW<>P(V.]8,51=2
M;Q!BT.X*X7*2-9J.G"1EG3D2M6"2A15.803*KK3;],Y5G<<I2N8Z_P#9BVKV
MFX@QAG"Q7$BWIB4\X+3C3:Q#"FK+J1/!7*I>!<-TV;A4I5UE>=3WG!DU/Y$@
M;E8L@KV6A8O;Y/M3?%J;9K[=)REKBGQFS9\Z1(9<[%!TL*J:;Y)R8SEA&D1\
MP#&31"1V.,K4[++&=<P,JE)$J5KFJ)/+)J)/'-?LT%[.9\R!Z@<Z<G'"B\:O
M&RJ:AVSUDX*NT\A<IB%V,V<.&SI1!0?WQ XI' H^(OB  $#$,' &3.40.0X?
MPB&*//?C4*-O5]QC%6W)6'\:49[5:A2X:&R$\GSP$I#(2=FMC9Y)72/=M'GM
M#MR]A$(]*0"03,= M?3;IG!,$F@N98KSS%ZUK\U%/&DE&S4&U>,Y%@NFY:OV
M95G"3)ZV<I&.DN@LS(AY:R9A*<I>>>0'@,T,Y!8Y2\]Q$>>/GR =^0'Z>@_A
MQKF(LAD5Q5 HCX2CXN?X( 'Q#CYC\.?3D>^L#9.Q55()!$0$P"/ \CW'O^(\
M]^1#OQ]>=;'9* DCXA#NH7@>P\\<!V^'Z1^OU =!4!U9E"*7WIC\& 0+U(<'
M*&'@1 ##%V41 ?\ 8^$ Y >.>_A$?74G[&8KBUR!AX$"NS%'@1X#D>>_(<\\
M"(_(..!XXXU$/JJ+F/?.FV<1'A/J1X. H<\@'$39#<?#ZC^.I8/!57L4B;CG
MS'J@^OP\?81[<CV[]O3CO\>=3_'A_P!OE(W[_:$3I97? WW1W^!QY)V1C@FS
MP]"=0DQ+8^A;=3J['P."\IRMTC*C*)S<))P-WM^7(JC5([UZNX%FM9&4\C'O
M@CV)0TC*[D]]<M<XC;"P0EHZ[_D%JDQ)P=0@64GE"+?U[&>V2QOK9,Y)"X2,
M_$72PY!M68:U:*E/0T>@,17(T8V?L"M@?G4MM?J3L=2[7(5E)DI9X^G69_6P
M?M7#YDI86-?D74&D[9LCI/7K9241:IK,VJB;AR0XMTSE.H ZI\QKU#-W4/4K
M;9KMAF"RV,K"2CZFNZ]5KA0%X&9I6!MK-[L$?8(\:Z4'..T[+E[(+P[U634M
M+&6J-IA&*J$3$-RL9':)[S$9V[QSC3F>?'FGK&\CZQN&WO7]VWE(:*CY&BQ&
M=;]A.;M% P[7;^:QN\+R)*Q+7ME#KY!I#6O8FS/;G4RB:WLYR0#%S"C':1Y#
M.)E9<>"J^0>IK:_>41<*G4Z&:0R7,1J\G'8J>NSU*D-<?YIF5F$,]?V*.CK;
M%R5AKN):U5LGL'[EXRG;HNX=!*E%&+B>5S=OTRAB;#VU^]IX7JSN\YZB\H/'
MV.UI^VR122N.Z&XN\16L>NZA 2[Z3E\HF;)1=+&=BV\=&.;##+6=\U09R;I;
M6URWVYZ>9N6QE5L;0=2JL3E)&O3-QFJMD";DP@ 9Y/K#VMR[5S$LHJ/MCFY0
M%/D(6RQ GK2K>9BV!#3-?E2V*5GI_P 5Q7V]ZKK%3&SBI8ZM"DQ4:RVBI.#>
M48)JI.H.7PEAAD^R':+:M<I"9RSF&)O,EEQZCB25JXIP%KJ[(S>1G59 S6Q3
M<Q+?-^\YFS'-<SUCR-;8BEL2HRESLM=QB:IQ$)>$(MXX*:;E[)/+3;2<F)%.
M/:JU&';JI0BKAVQ?U1BR3)9D(HTO?YNFH]&QV_O>VZ(NLJK#X^^VD[4D,@E<
MG1D]O&)]QUIGU8)O56J+&68T&3S'%O8:.9IPPY8J=8I,*0J,PX:%W7)=1#++
M.3N;:Q;?V,=$T+;W6L^7%V#?)3%Y#0J)L,VG), B>9@&L9+2T'BG*D[.UT(1
MU(MU[1B^U0SUR_\ &\85RQ<Q$5'*\1,YCZ\O5//CS32=8:&H%BW[1.4J9$6>
MEOG&*29*KT/;#6&H%D9M>H7O)>Z0+5;"WEU85):-:8TJE9P(^CF'LCUF,;=V
M+$Y$F"B#-K:A&H 8!/R( 9,W(?#^"/?TY'[W(=_EVUK_ !W.6F\8TH=ZNE<8
MU&RW&NL[4]K,>N]=I0;.>47DZ\Q76D4T7@RA*RZAE9PBJ296TZXDVC<OLJ"(
MCL^)3$W!0 1^Z81$.>P#S]WCTY_GQVU%0UZ0M>"<ZJO5&9F 3)EW&;=U%@'N
M4$F^+[$Y.)N0[ !2#R(\!QP&N[#ZZZB70QKH275/ZQDBHEXT8#+>!G(B8O($
M6<XIL3=(?AP81,8 X[_,/GV[?35G7TCX@>!$"@(CZ  B/X!W'6E\79[Q_E^W
M9SI5-7F%IS;SE!KB'(Q)*&<QC5O<7= I62D485VN84YN-&L7ZOJ&DVH%0*^4
M>,!#SF:HCN<X>(IBA_7%$/U@(:IPJ%3W7;6=ZF7ED76S=;"&^W>)7+Q6%+WF
M3*E9SXX3A]O6/JW=:E1L>Q>()FG6BX1=2PM:[M&,7-YC8U>-;*#+2D>0@>"#
M8N*>KWM4RO-42+;0FX&C1N6VN2U<,7;)V!+S2L=YC?XEAK-8KI7L<7MX@YK4
M[9VL#3;/+Q=?7?QTC/,H5\>'2>*(&2"=FW_.%$W+81Q3N Q@O*NL>9DH59R/
M2G$Y$N(*87K-LC$9:(5DH=T8[F,>G9N$S.&2QC*-U!%,QA$.=4<X>Z:V^4<=
M[/L 9BF=K=<PQLOM>9<I5N<QU<LH7+(V7\B6NH9LJF,F$XTL6+Z9 XVJ$$?,
MSV;N*L9)W25EU85G%1[=%HZ<."3?Z8.%M[NV'!F'-L.Y&N;80QM@3 =)Q=4;
MUAC*&4;==K98J4WBH-N[L56NF)J+!04.^A4'SU9:-L$N\0DR-&B;0[195RW"
MT?3330---- U7%U5_P"HGS;_ +6&/[+C5!U8[JN/JK_U$^;?]J['_AC5/\'K
MHG%I/:?A8HV'A'GY*+C_ /[U-0AH_4*V_P"0-].7^GI!$R$3/V$\<P63K>K(
M4:0:4!>O3S6KO4$H>W@NJ1P_;MKA!'-[?'1L=(*+/6T%(RSF)DTFTWFG](#_
M .F+?^_4^7;7'H5Z";33^R-X6)0L,HR91TE.(QK)&8D(^-.NI'L7THF@5^\9
ML5'3D[-JY<*H-3N%S-TTS+*"8KF-5!=8_=YE+9[B+;19,9YAH& 6V6-X>,\)
MY)S)DK'*64JQCK&5KI>2IJPVQQ459^L^VJ0SRLQ3L13F&:AVZ;AL"J17!E26
M^ZBUN:VIU#=!);:Y*V62SUU7;+N<Q[NBJJ=:]S^78;9CJ&MD-&5VQ^]XV1-]
MFGR%N>+/_=)H^7\]JT%K(H$\XJH4,89ZJN[&V*XM@V^2</YUQV^ZK6VK:%";
MM<?X3L6/*)N2POE;$%OOV2VM4IEFL4PE W;&EJC(NH2MKJLU,PBCA4C=HV4=
M&547FDEUV]LL-(Y8:Y.Q)N*Q.VQM@K)NXV++;:Q0G]JN>,<266%J-L57QI5,
MBS^1L36Q:8L$0O!4W.=:QO-2<$[-8%$V48S?*M[#=S>TJE[H'&W5>U62U5@-
MN&XJD;CZPG4E(II[\LU&AK1",8&:7>Q[MPT@GC>U/%W+B!5BYQN[;M'$?)M5
M"'$U;&+^A!A3%9(%O ;D=RB*%3P)F[;C4GL2;"U,LM?H6:I2IS,C-'M='Q-7
MIRW9'BI"HL1=7W(CBYRUWCUW,)>RSL*JHP4#9B'6(Q^KB['&10VT[B)%[E+<
MK1=L=*J51=X+R -RMV2,;VW)=4G:!D:CY@G<-WJN#'U1:OV48;(9)>DVAU[O
MML=$-F;M\7W;=.L=B?<!E7%V)G&WC<YB>4RI.Y\QM#3^0ZI15Z\SSUMAC)F>
MS=@UQ]B;_:YU];*? P;QZA88B#?46ROP^S]9L<K-H/&C;B<3]%?!6+)ZKW-#
M*>2YF[06['#.[.4EF=6PAC>N6"U8+QK?\84RKGQCA_%^/\90$,^B,BSLM<+%
M7:I'WZVSY63J8M"S-HW8I;&J?2>PW5+?CRW-\E98<N,=[BM\.XQ@T![6(P']
MBWV5*XT_(D M(Q, SE8^&IL?=)!U07L0[93[.0:,'$S)ROE*%4#[-J'54Q+N
MKSS*[=66*,SXAR&?%4SFZGL,K-,<I/;)C2"M4739%_8*W2<A7&WX?MZ$Q-1B
M_P"33,\!1KV:'=DDAA2D3722C#CWJSVZE;BMU6,L]8CRI:<547J,5C:+2LZ8
MYHM/:XOQ%%91I^'([%<!E"0?WME=+3-S.3;R]0F)VI4V;:U>&FZ^YLJL<@LT
M*YWKLTZ1.*]E^5,993I^9<KWA[B?;W<=L]4@;=7L*0<,7'%HMU2MZ#R94QEB
M^B2MFOC-_46A9;(%JD)ZUW(SMPYM,F_7;L!:[&F.F7BR9C<[QJV0<C))Y[WT
MXDWY6!1(*D8\)D+#\SAJ:A*9"%5KYTS4:47PO!HRY9,KVPF0EYD&<PV.+$[4
M- 9$ZPU%:9*RQMVAL3YAQSE-*C;M_P B-RR3#8\2KUUO6U?'MKMEK<OL;M<A
MN\P4^GN?L\>4H=IR30*G6<J1+=1:I2+M!PBJ;4FPOJ#;P-T&[7 &([K6(*$Q
M6ETN]M&[#*=EC*[3A=9)RAN)J;%^UM<<L6_FEJ!0&MAC[%!5RGQ=6F; M)QT
MLXM(Q%=-6Y-_LV%Z'N%(')+;(;3.>:7!8JW;P+3!5]Y!X0 K/\]2HWRK95:3
MUTC<61F2\ANHH+XZ=T6<R3<K9*UEO$1D(W5-$*23=_++;!T\<;;6LF5S*%2O
M-^L<M6]D^VS8\UCK-]F/=KBA;9QG!JUP<>YX..=_;2P^_7'VC\IPG7_WA#W3
M#L/WSQA V^=1#.]5W99EQ(YL4:VI]0ZIFRG:918F"QA79Z:F<?YRVIDRY;*?
M-3$[=ZLA&/[#<P7"/R*F+][56QFD>2N2#)5T^::4VZ]<.W5S"S')N[_'TJ]R
M-N#SWN>8;>L.8_5P)CF/KV%]LUL^PE\6E\EY/SW!4R4?52PMC0#ES:K)7;5?
M;ZL\A\9U6R5DD9/KV56_I>8GN.;[1G-[D7);6?M.]O;COD=P[3[(^Y&U^VV8
M<##-7IS7SZ\K(_8J?@P"6L7G/%+![X_TJF&##_.NM.R_19PJOC3"M0K&9LP4
MN\8$N6Z&R4/+3*!P;<+#[BW<9)F,FY7HT]3LHXHOF+YJ!+.R+!2IR2]-):*P
MXK\5)QTX5^K*J2 28ENI3MN:;*<;[[(%6\W7$^94,:M<25BJU11YD_(-SR[:
M&='H6-X2J.GS1JC=):Y/2UURWDYEE#1+ML_=R$RC&,U'@UN;PNKSFUOB2.I.
MV[ &1L-;NUMW&WC:[D[&V?:WB^;M&'4MPC"6L>/+=#1L;E]#&&24LHQ4!*P^
M/IICD0U-83,;/I7=_7SQ*0K6?Y(V!XBR=M&I^T.<L^36=?QV&-IF@Y5B;'&L
MLQ53)&)+%'7*BY9CK 6"^SI[Q&7"-1L#H'-65K,BLN]CW-?]TN19$CBPZ1&-
M7(1]ER'N W Y>S.ZW8;=]V-\SED!YC@]VO\ .[7V<S&XDQH_AZM0JS1*UBZO
MQT_,HI0M/J\-*>U2TK)C+&D)!=80S;J1;EMTVUO$47E7#[7;W5\>TVJ6RVYW
MS-N+:7ZSP51<1;*%C\>T*LXLP_,QUSL=CRG=I?W&K8FDLM T=DU.[78SJKYJ
MFG [-?5(WV4; ."]X$3A_:G2,)WO#VTZU,L77^_V"[YQW19KW &C7%XP/M;4
MQM:!9QL_CYG)M&4*^M51N#BTRJR[P\6QK\/*2"-KVZ_9ZYW+26.K75MQVX3;
M3?\ &J%XB8NV8-LE93:3]8R-#H0MJKMUH>0ZM>,=6Q+R6K5_6IF5JZMAILPC
M[RK<HP4<.R+P"-T/J=5\B88OV%=X>YS"X[>,%TO;[A6$AX7;MD1GCJF5A %)
M^7JSK,6&;ZZ@+WDR;5?3^1+O >Z+#-KO"PZ#YG68Z+A682HWQ;Q\P;9LS[ <
M<XTP\WR3";K-RCW#60I!S(P3*1K4(VQK:[H1&JC)W6M()VSP0#VS*OI-M*UL
M*I4+3$%'[63-2:O<)PCU;<-YOR5B:MQN&]PM.P_N-N=RQUMDW07FH5:(PGGN
M[45C:9*5A:K[+=)'(E9+.Q]+LSZ@2&0:/5V5[;0[LT$H=4J:2DG]T&T6$W,S
M&VJU.LD7W&URVN9WA<]4&QTE"GO3R4ZQJ-HH<S7K+%W"MV**>UVS5*XS\5(@
MS:L95F9V1Y%2#-T@D<L5L'](O$F#\GXFLK#.6XF[89VXW:]9'VQ[6;U9*3*8
M1P-=+\TLT<[EJN=E18[)%D3JD9<K3'8[8WR]V9M2FLVZ]V@=<J2Q ^#J']0?
M)NVN\XBQQM]I--O,N;*NVY'<C9+J$RZKV+L3;ALX0."Z-$Q2$#)Q*KC+F1K%
M+S,S3F+]Z>/AZ?0;;99B,?H+0S9YLJL;N-PK_J82&SR[8;HU#PPIMKR-FJ@W
MQ"[JW.^Y)7IV5J#0D9ES&,&D/$8Z@2M[2\2/5Y%*SSTB\*WD??<4W:J1SOT;
MQ>DSLVWJ33JYY-QVA%9+E;3B&=L>2JPHLTM5GA<0V"-E(RF38N7"\2YK\W",
M7%-E%R1J4XTKDH_+"2D9)>S/V\F%-KU/-NIIFZU"<L+6T4?;M;-M\344?=0U
M(]1M=\I]]6EEQ48'G??L<]ID?&L13E"1PQSAT+IFN[%%PF%=^[WJ,Y=VL=02
M-PY&X@R'GK#9-@UTW&S>.\,5&FOLD,K/3\R%@)R[/K=>+O2H.-IM?H#20%2O
MF>+RU@GE8]C76,K+.DV09/D#K-8)K$8:WT3"6YS.&,JCM]Q%NBSODK%N/ZVY
M@-OF%\YTM;(6.YN_1MINU:LT_8GM*;KVR9I6-(:Z6.OUQ%24DFI">!(\KLE[
M(J'D[<G/;F96WW*.M-@V?7O9NYKT;[@^SB%)OMQ-<I"UH>UQ+B6^US)\<6C'
MS7ZD%['_ -LQ2R_[[J%]FZ*6)I>I1% JNYC=1BJC3^V7!VT[<75<;6C'D3%[
MH,68!I7Y/*6ID=29QW/252MKJD*O*C8+-B1_1'TI6W9XLWEE207(&T[1U9<&
MU^G;E+XPIF0;36-MVX#;%@*2E( ]15;WY]NJC<'S% NU)4=V!L4]091F=ZR\
MF#SGNJ8%&.EAC8UX;V$'6I[YUN,)8_3S&[FL#[A6\'B?<[-;.6=[EV&,Z?BJ
M_;AHS*-HQRG2J]E.\9#K=(@F"4?5U[[8;E>Y:KT^IUJ1BXR9F2W!9Q76WU98
MZ*>&<C7C(\U7,_;B\1XQRG>]MN4K=MZQY*8U3P^_R'M<;XTAL:SOL]AQY-7=
M)@A5,4U2 ?UAO<D*XX49H3AHXTLPC5F>[K9TRJ#8\,Y)P_'9DR]56^1=W&5]
MX+R<C$<:SS?[99;O<W?)[']FQ[?*';L5Y*Q*@^G7#1&HY%I=B.JFUC9)60+.
M,$)$ EOMISW&[EL05S+L71,A8W;3[B:9'J63(B,C+&P=0,N[A73A!W7YFQU2
MRUZ169F?UFWU"QSU7L\(X9RT/)KH+B5/?6HA;(MF6-=B6#TL'8OE[1/PR]VN
M^1IJ9M1H!JYD+=D*;4GK$M%5JFP=7HE'KJ;HY&\'3*)6*]5H1DB4C.-]J7>N
MW4O= UP=E_T@E?\ S-7^37.:X.R_Z02O_F:G\F@@9TWN/S:WGK_J^[H_3Q<?
MU1.2OEVY^>FG3? P;;'@ '_=]W1\]^._YQ.2^?00_G\=-&*O-7=9N8_QSB8Z
M[;0L/UQ,_!15H@IFM3K)*1A+#$R,',1Z_B\A_%2S->/D62W@$IO*=,W"R"GA
M$!\*@B @/ ZY;31MTT-T'3;OFSC)^1\H0^-[MFFCRM+>QE*E**?W6JXEDGRR
M];>W1C6FC>8E;O!QIBQ#M_+O7BDHFB%FA5@F2+&;Q!IVW')UMF,082Q_MPMK
MB9:*3F4\@7@65@NCZ7R4[#WK 1#A=G-1D9$@WLQ8V,EV4W,-XF+C(EZ^7?E(
MFX6D._8(!\?7U["(#P'X=Q#OW#T^>J\=Y-=OC6QTVW5[=Y'[:JZI'JUEK!RX
MR#&%L%C!R^F'4BX70D4(Y5S[N%!$I'D>84D6IS%<CYXIE"I-/9!.;1-M.+,7
MWB4KL_N'W8[DXF]YDD:U&L8J&;K144M7*=0H-&,3;LUX.@MK9[.>30;H!+6*
M8G9),19.(\C:[>N[8<(;;XW)-TQ?6'=>EK'6BPKU1:?F91NE'IN@7(U9)2CQ
MUY!578D<+',==<3)$(FJFD!DS1'QAMKNV8,GXOR-DC>/2,ZQ6++$WLL)$5,8
M^3>&=,GC&3%F*C=^FE'H/7D9''DU5&3IV9NU(BB9(P@J6?NY"9")QG(%,?RS
M/GB#,..WB+P=8X]Q]>$P[?B//H.@ZRO4OR@XH&*(&VL,S1& I,F?\)1$9E:V
MQBLOCNMR4C:'B#4V58QI:Z=(O<7K*@0]L)'R;L2^RQJ\G"RU?1F$2>-A]'@Z
M;C._?8W=:&[3'DW?HUY4;J?*#C+[RO/(W'-)AL@1DK='$W/D),6[(32P9)>U
M.+=H5^EH6MA"0#%LQ)P?Y]_I,AJ8OJ1*0URL]K,AF.NM\P)8 J='O6X53%R-
M;M[V2-A2H9 CIB)F[*A9D:PXLP0\3)VV)QX6US-?9J+,US%^?8<]R$TV^2A,
MAQ%QB2_E;RD3'9LHT''N,,SR>)&TJP:T.4S92\8Q\368C**R*,FTFO.C(ZQ.
MHIE!N[(Q:RJRJ1;M?6OCI]^VYYYYR2*R/!L+/!24 _%0&KY$R?C2$0405 X*
M-W!0 0 YD52D5\I3E)8"F35 2&'47:9-2\*[>8\LH**O89(R\-(^%51)W%A_
M2B&5$#>%$B1@,S45. $(!V!Q%9 @#*.9?%.!A$WWN_W>P]N.>>?IQ_RZT=<5
M'ZC"1&(<(-Y4[<4VRRZ1#AP4XJ EXC" AXA$X)"?QI)+'!4Z1N#<P?.Y>^8H
M(&  XX #!P/TYX 1_P"3GM\!YXM=\("8P"4/N]AYX,/'8>/D'Q^?'SUKNOV,
MTPW%%X H2\>'D/T1*"9CB4? #DJ?;P^,P"1<@!PDMSQ^]G3YY0ZPAXC&,/83
M#XA$0XYY[\?X0^GTT&5)OC%(<_/<1[FY]>.W8?B/P[<_']&A=RN)E,^8I>4Z
M+,T3N<'*)6V@+O5BMF[F=;M%F$E6%GJAB(LD[?$K!'M7;HQ636;9PRKLR;<5
M5T=G L<Q>0./A'OZ]O7Y:UQ9<WXEJL2[G[1DFF0,"R>WB(?2LK,(-(UO(XT4
M10R''K.3D\L'=+5<H)V9O]X\8=9,JX")]!0Q/-O!6Y_&=QC+?%2$79S2:3)K
M.R%75AK&W:DAY>-MU=49J^]4C,D$TB(&/&24>X3.5)ZM&OW;97EKNO#H4_%S
MU>!N4K<)=NZ8&MS2CUV.I#.LQCY:&85Z4NC&+1GK/:X5)J15PK-RZYHR,<,H
MAM'&233D#VZ9=LFS[(+2<FLP63&4HO3'%:JDU<4K@:N6ZN/[7")6&FUY[881
M874J^EJXHC,5J(FH^SG"#$SEDT18)J>7KI]A39=1J;'Y!LUFG%<8/%8N6B7]
MNS>4,;RJ]B233A'C'[-04&K-N)QN9(D<:'D0D91N!025603.4H0@VT8HN.5;
M][! R<O6:FP;&)DJW1ZKIJWCJ@\%,)&OF70413D)JUHD"+A*Z*HK/7*I9)5)
M..BW;UM>&HX;'745:MDV"'A1091Z @+>/8-$4V<;&MOC[/',$&S%$1X,9)N4
MP_>$=:[IDE2EZ=64L9C54L=N6"<M4$**=D>I/6+\"",['.V"SDDTL^*H0KJP
M/7DC(N3"5%[(&, )A[:5=JAD*!;6RA6B"N=:>.Y-@TGZU(H2\0X>PLDYB)=L
MB^;&.BJO&2K)U'O$P$?)=H*)CSP4Q@W;%+&(4#B;@1* @/Q#]GI_A#MR'.N>
M.]$@!R E$?7@.PAZ<C]X>_?G@ ]/AP/.L&CEQ\)2"/(B/<.>.>0X_'Y" <!\
M?0.>,C!QX4>#C]X $ $?4"_7Y\\?I'XAH/K67.*@<F$?$/)0#D.W <\_4._\
MFOB=J@8O'H!#"/B#UY$.!   0X[#QQ\>>VO0FH*H"83^(0Y\(#QR!0^/X>H#
M\OF&O0"AE .!P-R!@#TY$?CSP'' ]O4/U\\Z#W )C% 3#V$1 ._'W1[AR/H
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MXG Q1_JCK8<W)#&,F(&&=Y$R9S&.00'E,YC&+X3&$1MT4;>6R%-,G(E+P4O
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M (F)T1 P"00#)R% !\!>Q3%,/TY,;@._KR #P/IZ?3M6CE;ISUC(:5Z43O\
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M-N^;;;1=[U/+&I/WK;+%]V]72E&I&5<'S#HTG&RK.4B7RD+1:RQGG4V,?%L
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M%@^?-7P*MT]I&ZA&T,F=_P W$^5Q3RB;)1<+@4]!R83'Y\S'K86\F'BYF-3
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MZ#^'//'R'X_X1^N@XT" 4  3!W'Y>HB \< (CWY$!YY'T#Z:]:R";M!9LX2
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MN^7&L:8+?8*M!$9)1T2[>'6.@DD",7$MWCAFV;/)1M#PS:5<O4(B-3:E2!U
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MG\.0[<=^X]OGK)EDRI 4I" <#FY$..X>$. X$.>!'O\ ,.WISWT'$> 5P$0
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M2F3(85.0,4 [\@ "(!V'T]#"'Q#GM^.LZ;.C* F4G'F'/R'?GP_^4'8./@/
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M* &,';@?"'?YCQW_ !XYY#TT'JL]19W.GVJHO73EDQMU4L]2>O&7EB]9L[/
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M,X( @(<B';@.W?X /^'MZ:#355_?DT^2CV\(=_X//QY_5^L YUN>$B#'<)J
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M!VX_9K.614P$"^+N/ ?>Y#D?3X<<<>@_ /V:QF) "\ )0\2@"!1#T^8B/H/
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M"\!X@#UX#CGGY!Z:DA]EP%,"@CXB^   P%'UXX]>!#CZ!V[Z#431L5$"#X!
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M';6NTX>LD:@ID&DDE"^UMS0BM>C8BUUJ;9,E$%6RM+<3J]>,J9DO! 9FNJ7
M*=:*1GC/ZN8\BJ%5VU[;G!8^EPKP2D2R)>S.4ET)5PV<?YT3C74BDTL4\Z>\
M(-H%A4(14CAP_<M%?QN,Z\E,QKFNN8AJI4+:2VNU8F#EL<-0F&SEZN1TU0=M
M)VQLP2G&K*<2,P>A$PK0%TFCL473)=U%@O!-7IS8&QW*4>^Y'J3_ #'&8MR2
MV<5!'"F3UA/'5"?@Y45K%-0$JT7;,+4",D"<=!VT:Y#3+%9C*-'YG$D1V"4:
M]U/2FR%DK)C=ZSS;.57"C_)$%D^4CJ5CIK.2+"R5Z*9MF!AK$*YC!;K.Y*,9
MOI6<C4W"#CQNWRC)"0!ND>#-#_=(05RK9%M64J18(QM4KRQKM4B9BLQT4K<$
M7$6ZD;"@Z*U"-<Q$Q#N$D5E'(&79.32Q6@ING;%V[7[/F&,ZPN7:I0;(:(DJ
MLKD>BUK(=1:RZ2J:$_6[1 Q]A9KQ+M=!J=1^S82*'OB$>-V<S%J@<RS-1IY;
MM0.NH.PG=,GD>8R8VW&[=T7-6Q>3&-&A'S*9C74Z55\Y</)>=BWL4V4BG; !
M S(SENM)+.G[P4R-C(NC/Y![;.D5B.,H>$@R3#67,V8J,PL;^T6=26GZ7@-2
MPVYS-F.LWAW<9$3EP8U6.ETHN(:,6:*4TK'I.9AVFQ41;H]AW@.P\ (AZ"/<
M0_2/?3C^?Z>?4>1^&@Z[U;OF0L07.T;+>F%BJMQS2B3\W,9)R ,7"OGMGN9G
MB;6US+AQ9WB=7@(*.EQ+6V)Y%64?/UXX6T.FBBB!G<.^JJAU)\7[1K]N7W$&
M@;O6L/*ULS6FQUBKC6.BGUSL+*E,[K+5^EP3>+D6, _GF02:SI\K(^PNS-60
MH-57ZQ+2,+8;S]M8W^79I6Z ]O&#MQ,C/33VWMU 1CJG%A*2%L(\F)04CIQ\
M]4Y27D85*$?"B%NCI5NYB%57R1R,[,=R6#JIN8P!F/;_ 'ALDXJV8\;V['<O
MYJ8JBS2M$*ZC&\H@!1 2/85\LUEV*Y!\QN\8H+IB!TRB ?R0MLNY9ECW>EM[
MW0;CF5LSS"XIS#2<@VZ(FK'(2]BE8BKS))5!K#/9Y>4,1*MR";&PPE334;0K
M]2"9UPH1[)YY[?\ KW8NR71<RXZI&5\966,N./LBU>%N5.M$0L"\=.5VPL49
M*,D6Y@X,3SVRY/.;JE3<-'!5FCE))R@JF3^1MG/IR[NMMF%#Y\S#BFTU''C+
M<%?-M3Z5GJ_/UZ11O=#1;G0L*T7-1;!0*'?U"RJ- MK55S%3\A!2C%NOYHQQ
MGW<F_<FV\M]DW;9ES9M<)D[V=VV6)A<L9)/'*BCD,/91=2"KN#8HF$WACJ9D
M1A-F3[E(V:7.+8H$!)L %#MOZ:::!IIIH&FFF@::::!IIIH&FFF@::::!III
MH&FFF@::::!IIIH&FFF@::::!IIIH&FFF@::::!IIIH&FFF@::::!IIIH&M:
M7S,F),7S%"K^2<ET:ASN4;,E3<;0]NM</79*^VU<6X(UFHL9-XU<6*=5%VU!
M.*C$W3PXN$0*B/FEYV7KK:==8A3;ONA )BE,)>I-5Q 3% PE'VB@]PY ?"/U
M#@?KH.R7KTN"E.D8AA "G^X;D> $#_=$HC\C<\?7GC7M#T_2;_".OR?C@.2^
M+[Q> ]>_(=_T>H?4 T%/N9(T[">EVQTS%%N]7 /N]PX5.3@!X#U  [_'4;II
MMYK?D?$ "'A'N/Q].PC\A ?^0-3JW.PI6=PF!*4"@\21?$X_@CYZ13&#MWY\
M8'#C@0]>._.H5O2"HS5#L()\\]N.X" <AQZ>GQX]0XT$;[(3RSJ$^[Z'] X'
MD ^OISQS\_\ #K3KPH"8XG( #R)0#COR/Q ?B/''/PX_1K=MI1$ISG,)1'D_
M?D>0'N'/U[?3G\=:<=D!101Y$ (;D0[<#P'<. [CS\._P^&@]3$/"H !SQP(
M%[_'TX_;P/'Q_3K(P$2 )O"!1*'J/QX]!^?[/D(<ZQ]L4?&4Q/N@ CV-SSQ\
M>/\ I#7.";][Y-WY\(=@^8 /(]P_Z?T!H.%F[I7*N#0]CG6$.#XRH-?;U%$P
M<BAX!6!,"IJ>(4P4()N>./&''/?C[D)IE)LD7[%RDZ8/D$W+1VB8?)<-U@ R
M*J(B!1$BA1Y*(E*/<>P?").YM\L=Y6(X\8_:)LRR*Z,FL")HZ3(Z(TY(S525
M.<KAH9$Q7;=RFBJF4R:I2G14(H.ALJ73+\<CA]E!/MPE QN&+KKXK#@;&$'D
M^XV/,\6_JC;'=:GX64K]H1BZ#*P;BT2; TTG5*Y:)EHG'VBYUF-2:N5@D1N4
MV^U[<#6F+)>21K5WJX/STRVK(N'4<F@_437DJQ9VK--9ZM7I!TD1\V?1R*\C
M 2YEWJ+.0:/Y!H:LV+V6;FZS:(F1BJC5GAXB6:2K2::9&HP0'GL72;I)5P^5
MG6#YF*ADRF 563>22$05233=$3$NU:ON%WE5EQ;8:Z8PE+)$NK_E60C<AS>+
MLBR4ACRB,-S;_'D66;I]!5%6_P =&XT<Q]PIL'0CI3;^M(!*^]+1#I.IDN(0
M^Y+?$VLCYR_V_/%F5TO=!\F)M]=R(6%QS&/,)X/DYFH5AW4JY)2Q6TM>+/D=
M\K8K:5_'5V8KLC7)I\T>,7C9()A[>MM41A1_9[U,22T[DV[^]$G/%FGKE$TB
M%FE45)6&C;;:>9VWSLJ5JW:2MF<D;LVL416(B >D?R$DO)HA"E-R4H!R(<B
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M>,!\/(^'CGOS+BV)%#RT%@.0H"7PAVY /4?"' <<\=^>>_;UUC3RTB5,Z@J
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M*42E#G@#&X#Q 'H'KQQ^.@]6;'"K2K,X=#QE4<.!!4"B;DR(!_ ,'/<@F^'
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M]I;W;XR>3TP55HPO,;2XY9S$&6*4@.D'43>%J2BJ@ F.@XFVA6Y%!\Q1%;P
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M$F2"CI7A(B"?WCCQP %#GM\^>_'S[:"C.:V6NMI4!*3^1SN<F(6IG=)V<O\
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M8I8UPB<4GYS 1J94P\:RG+6X'!^!HYI+9HRUCS%T?("<(]Q>;9#5P) 4@$5
M8)23I!9[Y?'!_9DU?"(@4?O" :_G5T+9E@*Q=!7,.\^?JDC,;B*[N,:XUJ=T
M?6&:.A4:+79:OLR5NNU\CI.#9Q\J%DDW4N*C!=RL]]E<-%V0,T2!:9NCR_CC
M,1>D7B"R;-\8;Q=W=]V.8QL4'8MR^4YZA86905CII)>67L[-E,Q,//3* U*6
ME"34^LL=DLLNU9M7TB]2*(=RC&F5\99FK"%UQ+D"G9)J3E91LC8Z18HJS0YG
M2)2'6:'?1+IT@D\0*JD99HL9-RD51,5$B@<HCL#74+_<S!WD)N#ZH%);0U3I
M-=C+UC&11QUC.SN+9BJJS)Y;)\<];4*;6$"S,"W;,VT;$S8D]I?0S*-0757(
MS1,';TT#3330---- TTT$> $1] #D?CZ?0.X_HT%('[H'S!)TSIZ6S!-&7=&
MS-O;OV.MH.(8R,=I(RCR=RU:(]M9'":!CD5<,&=,93:$AY0@4GO)L14P)K#S
M:IMOPC5]MF L.8!IB*"-8P[C:G8YB!;HF;D<H5.#9Q*T@9$RBIB+2CQNYDW/
MB4.87#Q43',(\ZZ^=GM8]17]T*XYH, J:8P%TB<?6B[W!VF*AX>2W19$0;0;
M6- 5"&;G?U-VM$-D!\HCMC*X^M1$53H* L7L[ '  'KP !R/J/&@\Z:::!II
MIH&FFF@::::!IIIH&FFF@::::!IIIH&FFF@::::!IIIH&FFF@::::!IIIH&F
MFF@::::!IIIH&FFF@::::!IIIH&J.OW0[MSR]N<Z9N1*!@?'-LRME6*R7AJY
MU.D4B.)*V646@[PT;2B\>S47;D.$9"RDA).3F6(5)JU64,(E*(#>+K669<Q8
MQV_XPN>9<RVZ+H>+\>Q!I^YW":(\4BX"'3<-VIW[PC!J]>&2*X=-TN&[1=3Q
M*EX)QR(!RV-/>X8[HGO]DYCIS[&U7WS'O" F[8ROV?C@D6;HA3' CAJ]\]!<
MH',!54SE Q@ !'-]8'B[)U#S3CFCY;Q?8VEOQUDBKPMTI%H8(O&[*P5BPL4I
M&&EFK>1;,WZ"#YDNDNFD\:-G*93^%9%-0#%#/- U&/=;$C)XQ<+D #*Q,FQ>
M!V 1*14PH'^ CQR)!'T^OPU)S6L,PQ)9;&]R;>$#*FB%5T>>X@9F*;D! .?A
MY1A^GJ/;04*7E,1X "@!NXCVX'GN'/ >H^G'TU$#+F,FV180[(KM6.FF0J*Q
M;HJJP,U5"@)P92;4A_*<,E5  2K> SEDMX7"!N 516F=?VQTS<]P\/(#VY >
M.W/\OPYX_2&@GAP!0QC#ZF$ [\B)N1#N/';ZA\?D&@TMA[%9,<1)U7[D9"??
ME35?@5=8T:S 1(8\>P0$Q$CD$2E*\?F2*X>'(4I12;)I)C##('3&VMW>BY3K
M=S@'=IR%ERYV>_67<1/15*D\^Q5ALMD96$%*E=W-341K,57$8]E7JQ!1T62,
MC:X@=B9%=9RX<J68)''D XY'OZAV'GY\?+@?A\]8M-*<@H(<@81$O(? ?B'
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M<7:VW(S"1,S,W4IE0<0;Q=Y-1J:ZY)!LH\9Q[LR**R2S)$[U1B'9% H%$>
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M8<><"IFZ2"/'F>8)/O@8V0:!KB)U@$G$R3$P )73!ZWXY_A>>U52X'Y )C@
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M'(!2$[B8Q@\(< 4!$/3COV^'J'&K.=N.%D,<UM"6DFR0V:92*NNH;[RD<Q4
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M-':6M1E)R#-]*/XE1-)8KSV9RL'>!TU\<>[*^8,WQ0X*[:-G10#D>"N$$UP
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MT00!-TU7*F<6TE&.P**C"48*F!=F[2X,10!35*JW4604T%1XXSA5(2_OAE1
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M92/@G=EDF;(TI/R\M8)4BK"MU&JQ12O[%8'+=TFP*Y9)"A_GKS4M+1VZ;/\
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M^_)/)B/4ID1<X&0LY'U?!T:<9FA&KU20*YB"LG@R*(H>8S!JN*Y2 D?C<(B
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MF_IRW3=MUFRQ0,FLF9,X"'(" A\AY#L/ A]0U6AN*J[6.DW12-P RIE!$2@
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M?9XR4:-)'V)=9I[<W13="U54;BKY)S$$)G$ZZ'1\3!,";_MM) 2$YD@);E2
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M0%JXNOO_ *SMOZ_W$%O^%]4T$^MHO]2EME_]'S"W_%I6-2'U'C:+_4I;9?\
MT?,+?\6E8U(?0---- TTTT#3330---- TTTT#3330---- TTTT#3330----
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MY<MV;==V[71;-6J*KERY<*IH-V[= AE5EUUE3$21123*91550Y4TR%,<YBE
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MJS_?MSW^)NG]#]8&_CU=5G^_;GO\3=!?)YA?D?\ WM3_ )NGF%^1_P#>U/\
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MTW@M,@1-)C*U!K4..E?=OM@O7#A[-R,=*@P'R%$8E\4BJ)PG7K\F] _LB?\
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M- TTTT#3330---- TTTT'Y.0BA3$.4IR'*)3%, &*8I@$#%,40$#%, B!BB
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MR;R>H1B3:OD2KU*E7'?5N0R)/,K#C:DW1VZM+N_2E>6=I2%CAWSILW&*@XU
MK- Z;8IT#+@GYRRQS\+_ $4-UA?_  WXX_N"XF_Q9T']2W@/D';T^FHX[P9?
M)M>VH;E)["A+ ?,$+@G*TMBXE2ABV*T&R#'TB:=5 M<@!CY4)N<-.I,0BHGW
M9(>\'HHM/8G7F^2?^;!_10W6%_\ #?CC^X+B;_%G3^BANL*'IF_'']P7$_\
MBSH.Z;N6W ;C;OE!U9-ND]O&@(^.V]XO=8.I,+MCR!#4+)6YP<Z6N&NM7S,V
MR5@Y*0A*:K3$::E;)B9L5%AH6@R,S;Z[,C(L2R#:P#8]F2[Y!H,Y4,Q,LH-\
MSTO(.;$;8I>\17^B1!ZT3/\ E&,QHG6;;.4BLTBZQA,<,JD:'>U&4FUW%=-$
MRTJNHY?*NEOYV8_NHCK#" @.<,<B ]A <#8G$!#Y#_U-=_TZ#^ZB.L,/KG#'
M(\>G.!L3CQ__ ,UH/ZEG ?+T]--?RTOZ*&ZPO_AOQQ_<%Q-_BSI_10W6%_\
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7TTT#3330---- TTTT#3330----!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g667216.jpg
<DESCRIPTION>G667216.JPG
<TEXT>
begin 644 g667216.jpg
M_]C_X  02D9)1@ ! 0$!H@&B  #__@ _1$E32S$Q,CI;,35:0T@Q+C$U6D-(
M-# Q,#$N3U544%5473$X.# Q7S%?24Y&24Y)5%E?2U])0T].+D504__; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_   L(  < $ $!$0#_Q  4  $
M           '_\0 'Q   @,! 0 " P          !08$!P@# @$)"A06_]H
M" $!   _ &NN]$>9"-S.&+YT/\?D?3-(OV>YU=A'=MDT@1NP0ZD90#.3(H&S
M,?%GG%HVJ8RZ>8_*X5YV*.@=#;$D&IEV_K0)".AZ%33[YGHG*N_2/K[WNF\Z
MAH2]J\8G5OCU %&Q+("&]34 )4UT^5R%YR.#S1_;-U6^%N>4N8@3BI9TD5Z7
(7W/P.?\ _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g640635.jpg
<DESCRIPTION>G640635.JPG
<TEXT>
begin 644 g640635.jpg
M_]C_X  02D9)1@ ! 0$!A0&%  #__@ \1$E32S$Q,CI;,35:0T@Q+C$U6D-(
M-# Q,#$N3U544%5473$X.# Q7S%?345$24%.7TM?0D%2+D504__; $,  0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_   L( 4@":@$!$0#_Q  ?  $  00# 0$!
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M@SV<T\\F($XWL7&'M+I(;82BMZA.1Y3>9;BJ535E-GF,4TFB!P((QEV&B;8
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M/$Y 9\L>2'(&*."RQZ?N*$&2,U0./1Q&)H[,[ZP(3ATVQK$@D:203"+62O6
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M\-D$;N$)$;X0C3:)1++9JJ3Q_KE1"4MS4X$BESCK5(NL+N^HF1\4,6I;BO\
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M>>G#*_6_7&W2JM:FN;5JXB3+C@>;DK4[Z4+0LRC:V>+XW[&9I<-CGKQ]F_\
MT.&IQ6KVJ^N_CS;<MG_VE[6MC)AQ,,>N[>UZS(3=++FV[A?=NC[<ERU7LJVI
MN]6PUF.VV5O^C[ONKY6O_:Z=/!5M_;VF3_;X=_(ZG_S;3V]ID_V^'?R.I_\
M-M/;VF3_ &^'?R.I_P#-M9*#*67"(=9GW*1AE+D[-J5PR381K?;CHNIU6V=Z
MQV9&V&6=L.O2V5\;7OX^ENO2W#$W3>Y7>?70T'F;U _.3:W=W&]MWKJU).\>
MHGG'_P"-L>]X+N^;>YU?_+WJ_P -1=<ZNT,G7AO+0]&3:V1](&A\C]L-LWAT
M8G0?WIMK@_$++DW8(T+XY:MNK5BQX*,5.6_#9EFISUWU6QUXYYX5_P"G!Y#?
MDSBS_M!_XNG^G!Y#?DSBS_M!_P"+KB_;@\AK6RO[6<6>#'*__P!X/Q6O?_\
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MVS;BCVBZ4I5J0GW?S)YR"7V>#=75Z=?A_C>WS7ITM^?^-_\ OITM^?\ C?\
M[Z=+?G_C?_OKFE89<D_=8P^;E_2BJL=*4J1^,_)^'>;C5]%PJN:U6NV^]]4
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MUX886QQMT/\ ,AXQ_DVM_-1E_P"8*?YD/&/\FUOYJ,O_ #!52AW%"!0$F:#
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MT2,U-)R5"/(6&)'A5B@Y5+8U>S"'SA&SVU[I&8+&6Q#(+H/MB)S?G=L=$2\
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M F@;1<B.-4>\7)1+IQ2R]R&3'9>B"@T:$'8B:G*"=O&S$W(WUES'T,I:B,;
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M<1P2IU^V,#%0"+G$ZCI@?E1Y%(W)+XU$RR"2$G0*4LECPF\NRS4(;E0VW/\
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MKQO_ &$11]1F6L ).\I,A>?!9Z><*L#VG/:!<W^#'(\ 6:R[LRHMXB'P>7(
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M:ER%3;5OPU[+IUJ)0G6(]]L>]*DBC0IT9[-&[7LRWI^(_O5>-_["(H^HS+6
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M&=IW[Q'D7YJ,OUV%JTO,_N\OTLOGO7S2MCGL'?<OR8\Z8Q^KY14V+KY80?\
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MS>$$-F,<]D%E(^1Z5]_7A$T^MR7UC6Y>K.BS7G=9_:_L>I]'<[/_ )NO2JB
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M@FV(EZ!P0QN9I5J-:CW8X;4JI,IU;-._1LPQSU;<,L+V\%;9$S^3]5YQ1_\
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MF$=:UCV^.BW?TO;6E:VEO6N"O*ULL]:5+NV]Q>V%ZQDXP\TXOY3K"1F%1N3
M I'@V,I1U"$MB:40)"&'II2/RN));'T:%\(4JD./+"I.D2I%ZUM,QAW87)A/
MQ(1?-6MOW6+2=K'Q2R;#TE>,Y,&0@9CR1Y5 #Q[!-F8QR% HFDUEA@Z?8%R9
M'9Z>B[:VRH5!@6TL1 RAY&8*#</(0QH?PPA0$F?OO_:><:P6'3:6Y3TR/%*V
M-IJ8>.Q]$AH'Z-DM"\SE:4/=A,)5,PB]E@JX^R87/PXQ9RMB,W4$WBCWK=MQ
M2GLB=-"'+Z9\K9 "N]O^L@%CX?AQD06QO_SM?I^:KJV\7[\OGO7-*A=YT<]^
M(8U-"CC1R$X@FW)J-HR5\?G+D%*KC#L62A _&==R=-5,?P>N/6R1GBQ(YK"!
M[2V5.JF. PHWBS"I1.;GLRRV9HM$MX(  ,6BR -C0*$H]#&7#=K:1(&&F81&
M6K7?9EEMUMH^/(6YI0X9;+7RRLE1ZK9W_M9=UX+U'$Y]J3&S1,W*2/5+2%;A
MCB2CE-5(^:*< A1.SSA$$+!\Q%RP%XT;&].:$C'JQ-&P/3/V)$D0Y/\ I5[5
M/J5%AKSSI8I[61JBW?@(31QKE*/YB1'P\+/T7Z3"+'O?9D+@L<.Q=>$EBLF'
M6"3SY_;B/</,4'A-U\JE!L%R(T!S&2,8PF*'J1B$I>03@(KCY@9E: ,5EA6S
M KXJ5I5.H]%1EXWCZ60FC4FMU3#16Y-SJL$\]^S;M>1?6T$^K+%"_(]6OV96
M)1T>!R6S^^M#)=S'2-&W6=G%(W^KE=F-;GZE2>J]VKU0HOCTO;1J[O9EUM;'
M&][VM?W *U[ X=:]KVO85';7M?P7M>S,BM>U_P ]KU5E*4I2E*4I6!G:=^\1
MY%^:C+]=A:M+S/[O+]++Y[U\TK8Y[!WW+\F/.F,?J^45-BZ^6$'_ &>R1Z?C
M.KG4J"WMV'"9FB#HD=(ZYHS/P7 4<@O><QS)%7'Z8)P8\!SV,7V,;1*+OQ^>
M&N8(B#5;OJW:]<@CN:5JTNFY.V/[\/ZU*%7NP![#^2>)<135(8/"DW0[S<E3
MD#D")S64.'O%?F%O?&/6QW*G1?('+;DM/DQS*'ZV37@KT)6=$Z%PZ48/J_8D
M:1\@5.VA&EVS[7ZVM?I>W6UK]+^.W7\5_P ]OQUS2E6I"?=_,GG()?9X-U=:
ME*4I2E*4I2E*5QEXK_%?YJAXD[RDR%Y\%GIYPK#/D7VC01QYYV=HY$O/?F;(
MG"Z+%_'2(A3@M@U#3FV-[X)%<9JWB9.1\5$3>%EZ0ZGH0F=Q4 [4PKT^6P?;
MQ9I1)QMZT.CEM32H]E7*W(2<.SRXFRQRH;G)OG<XB9K>3G:]#>@.>G^UW)U2
M"QH]BJ7'6C''L^"DHV;O+(BTI438Y$"I*C1HTVO4ETR!TI5!2IY,9%\Q##ZN
MN55(._@!D_5#9]!3U[-*4I2E*4I6NERWXLSSR@Y;]HY#\;QK%N0SR$XI<"XA
M<9[D1T>F GA3)I..2I@N.HX2I -_U2,K#<]+:3LPLTEX6ZLDJ-8&ZJG5"@6Y
M$ YD]('9LR<=R7,ZL]E9EGX-G:.N1L<LLE3/L+M<Z\16>;XU+ ;0W0(-CBW;
MQW>QE(B)E NJ]:XP@^35(JL6[#24)34;%"%957'*!.98E)BZ>9)#X#;3]/"_
M#_B&D#&&63!S%%T4PK(IV43?-^A_QB%(YI2PG2R2Z*(CB98U^HM-A5K;S8Z9
M=A.N4CN'*GLM^4Q5&,=PD\O,0#K%PK@^28QXOG6@I('G;.I4\<B^/DWQD0RX
M*:P1'OB@=9Q7C<+ \@(&)Y.W-P*3<F(!W#<R"S1H)<EBSA)R'FR .>NPUT1I
M'4W<W)@B(^0 J0X># %C$3A@>@0#'F)V/D@&RN!&1OK'#[R4O*UN$\&M Z$[
M<+H\UJ-H4/ZR3Z9<;XQ^LM?I[I@/+P?!E(HOE;]_2]NOY_AJZUO%^_+Y[US2
MM.;MAVF&GOEWR96Z^-?..7QX="N#8QRT=.._: 7XO";[)TO&A"'\&0S""=K=
M=FEW=JDC >L]R._$;=>(][^E)V5D>5+2JU*)]^$L $#UPB985Y@PD?IU3L_F
MVPNB?E9R72<]C!6W7D!<_#B@RFMU170&NI1WAO>V-IS3[=8>DQ;F/'9LW-E]
MM_/E7L[5,W.SZ,29.KH[<?;+I<?8\C)DB\$%#Z.'F78'(N/JMI;9C9+Z,W./
MP,0-3!PCL>V@"$M2/#@SI3613H8%V<?PJP+X5': (Y#:9%Y'OYM,_)/$(8C*
M8Q\%0@60T! H@@CUO'XZ#M963Z1(B7B>\X<7$YUD2QSU2)(3X8,R!I:VL;$&
MGM\7>"K;Q@F689*'9"WKA>1M&]M88_;17$9UM;1L,G<L9M<@D&!.]8RB[1DT
M.22((5>+L 7E'$#L#!&UT9#Z@]?=F9A_CCD#&-\L<<KXBA)TO>UKWMU95V-^
MG6W@ZXWO:_3QVO>U_!>OH!]PP;YJ#GH9%56TI2E*4I2E8%]IY>V/ _D9E?KT
MQ$V:]^EKWOTL;"][]+6M>][^#P6M:][W\%K7O?I6K?%46QZFP(DLNN4>Z2MY
M61BWQ:TD$BE.L2==I@YD&IYR=RJ"M!IDQ.:74C8DN+:4[VNS5@Z*'%V2:-2?
M'9C6B/BFD%HO3G\O,Y^PZ\9. ;ESB.(=CH. 40/;H?,+MOWN29(Z8O)5O=AI
MN5*-R3!PL*#:YCV;F]U(B.[6EI.18'9+"2PTB1H="5G7:V]^U[\"/<J0#@VQ
MC*I27[!K,J:P<NDIO?"%&1N@VKL%IB-KC,$<#)[8TC2^('C=+[V#ON7Y,?C_
M /BF,?#;PV]SY1^/\=38NOEA!_V>R1Z?C.KG4J-[M$>T 5\'&J(4@IQ^,>24
MBS ^23ZS@(F;!<=7;@&$8K(IJF8U5E1UOULVQ4+1V,N*U@$\<-:TT?,DK"F7
MMN>^RJJ%[._M&2OF46&0-)'%QTXRONN#X#Y7Q%HVRB*RHADSC)R9V'2>*#1Y
MWB[*Q:P&1L5,>/:0WC95J?\ 0.[\D/K88$";9GOPE;I2E6I"?=_,GG()?9X-
MU=:E*4I2E*4I2E*5QEXK_%?YJAXD[RDR%Y\%GIYPK-KF9QS?N4,)JXP#I4=(
M-,LCR("YEEA@9-[T0CB./9=!9!)V1JUI7T96IM4B"XJZ1X\J4CZCQULY*LV+
M$[JCU;FE9_'@URO'^;_%R,>4 L)O0.Q2?<WS0"Y"N0.+PU6#I',(^48JUC9;
M%%N]5JQ-0O3]YMUUI%>C5MZ[M>R]9:4I5!2IY,9%\Q##ZNN55(._@!D_5#9]
M!3U[-*4I2E*4I3IX;W\/AZ?COT\'P6\5O'X>EO#^/Q6I2E*M5-'N 5^<8!]H
M0K5U+>+]^7SWKFE:U/*?A_Q\YS]I?REAMO8.6J<M >+/'&:9[*(NYFF7'B)2
M66F(J(E7"F-ED;";:NN2E"7(1-9 US"Z:U2>)'-@8]["B4OSGLVHY(>R%D,>
MD[@K&A(S;.0B=X2%DPB$C#?*"<WKDI,(-+H%*Y:%2J!O4X/F62B1F,4-V)X:
MPLD363H5PCK9]FA UY7VMB.36E*I(^]PQEYJ$?H9;0!]PP;YJ#GH9%56TI2E
M*4I2E8%]I[ECAP/Y%Y9Y8X8V%&7KEGE;#&W_ ,;BUO#EE>UK>'P>&]O#6GT#
M2Z<QE9VT@Q;@Q)WA6UN"])ZE''=%F[L&Q5M'R%,A(&YV1MQ0/;%RW-@*6W0C
M(F6ZQ59M<TV*C;CE1UB%=9N=VCUZO=N?W-O>7M-FLT;/75W:?7?UN<UJC9EF
MKW+TEW][SP4WWVV[-CHLV[\MNW9;/&O$DWR0B;G]I3'&>MO)FM"RNB?+0.[^
M]MK<+X@Z9.Q[U+=N5"F5PO'V(JU0GO8UKD-Y[6=R4JT6W9JRGL[!K9JS%N3-
MM>S5G;$IC"U[:MF&=L>H^4]+7[C*]L?!;P6OT\%O!4VCKY80?]GLD>GXSJYU
M*A[[::$^-Y3Q*+.2G(G+D#@W\0 V4Y''-/&Z9'>#CY^N<!&Z-"0(4&[/GJS1
MC!ZROEA,JR<-]F70..;OO>DSBUXJVY5B+V+,4,T"\CN3,+G\5R9'/(D(XV\1
MMFGV0<[R3GK'.GB^[N,P80H"@AB6B06]Q9MCTC:9!:%<9ZV+2*>M2EH)P94L
M'WG7ORV/J4I5J0GW?S)YR"7V>#=76I2E*4I2E*4I2E<9>*_Q7^:H>).\I,A>
M?!9Z><*BDYR\.'KGAV@O+7=QL[/3B/*SWQQ=X9#N1<P<L.67,:+'F8I*)8,C
MR16$*A8-X]E.H4$](A$Q !M#@6F36A;74A<K[;(]GK:XJU\Z'9.$4+%/9[<:
M7;CY"&[C;%N(N3,[9!&\E6F>45DPW(QF-R2':B]Q7.*PJ2-<FM)ABA)-RKJ^
M(MB=RP3HM:G!$GD3I2J"E3R8R+YB&'U=<JJ0=_ #)^J&SZ"GKV:4I2E*4I2E
M*4I5JIH]P"OSC /M"%:NI;Q?OR^>]<TK5Q_R@Y%Q;@ CA+E(7)N44=3/([%*
M,/O,F\0^63YQ%+) !8LBHUEP-AXO<VAD)4<K/YO(>#)'T8AV3,G(+[C)Z<T[
MNK;Q=..K)-^Q:?XP=^SXBAEB:#6OCN-QP93G$CM&K%(ZB9&!.>1;-AX%R,3L
MTP+M"5QE!(<&[4^%NXV<4B9:[N#LMQVX98)]6S.5>E*I(^]PQEYJ$?H9;0!]
MPP;YJ#GH9%56TI2E*4I2E>0_,#$4M*U@)F5I(F)RUXZ7%E?6U$[M*_5AMU[\
M-2UN<-"A&JUX;]6K=CAOT[,<=NO7LM:V>&.5K8_YNG'W\A<.?_3 (_H5/\W/
MC[^0N'/_ *8!']"I_FY\??R%PY_], C^A56HE'H" ZUVH%"! +U.FS1M<M8F
M,LHYK<-J7#9K2[%V#,A18J]B?7NVX:,U%MF6G#;LQUWQQSRM?P77RP@_[/9(
M]/QG5SJ5@3VHTM/<&=GGS#E0<& $S>1&!3Q4B%I2'%!C'K[DX-^+)N;BX-2I
MU6TR9=R9TW^JA"^GO)3?'!A4[="9PW;]>OCV&','AKQNY 2AP@ 9Q@63A29+
MPR2PE+L2<")3X=D4H3<3II+UR5$9<P6'GAD=FR,AT8%7P7*R1S&43#J-W -U
M[E[@C<,4>X':]KVM>WAM>UKVO^:_AM7-*5:D)]W\R><@E]G@W5UJ4I2E*4I2
ME*4I7&7BO\5_FJ'B3O*3(7GP6>GG"L6N:<;?Y/KERRE]_P"7O(F/8JY4%#B!
M+YC8,^T Y \>WO:Y-T=B+*#N)#'D<SL!#;<X>UNA$L4"_P!8DJE8SXH%N]1M
MOORWYY>=A,4C)IV4W$LE#005C45<F>5+L(<%.YT_C;:V(YYE1 F5-[W)9B?G
M+ML?<$GL@<'$B+WM8K<W5;OUJ-*/-,C32XTI5!2IY,9%\Q##ZNN55(._@!D_
M5#9]!3U[-*4I2E*4I2E*4JU4T>X!7YQ@'VA"M74MXOWY?/>N:5KF]LUR%E%?
M*W&SCJ 1GSP1@8A*S=+4Z3'QD[.W_.Q6M3:CC<Q71"NA\LD.*)2BM"8",LX#
MR@U5-#3:1!IK5:=HYNQRP==64D_9;M+0P<+XR86"_(FS$T.A^C:D_*3CN+<6
M)?1I;G+ZIR3/$*AL?QB/##392I4;AU8B#F[81M6[20+-R]8X[UN^0NE*I(^]
MPQEYJ$?H9;0!]PP;YJ#GH9%56TI2E*4I2K,\A9]C'BY#)_/LRO*X>C&,F7$@
M,'EM8'LI7H&K)Q0M??D@Z-H7-_>-]UCBEUZT#0WK7#??9W*9+NV=-=[4P_S?
M@66Q.5RE8\/\+[H(>DS+-@KR,&UL%%T5>NS.D)AE[-6D_P VQ.UBA@+."$B%
MBS!P4CSLBVJT6+CI?F9_9VK#Z9>U-2C;@9G$%@@O-G'" XDA>>.0TI)S5\8G
MG9&<Y26> #$L@H>P"')JD1P$V",3B4B3>^$(PR/(TA'V82<'):3XN[1?CEYR
M\D^&#@>BF"(B&9>DC*#)QY/%K69GCO'C.CB* EP*RO#&/.K0%FF;E)DB%$@L
M@Z#-[BF;AQMU)'U_)'3#0@0M;K8$1[4EPD$V"3(,AY(OXC$\Z<<^+ZR3EY:Z
M();0R]R>A:-9B!7S3&%Q+:.[8S8%LRQ=%Q6X;3S41V+2!_>FULVCHCA<DS"X
MV<HWJ?)2Y81T]1$3Q+LXU2N'1JCTF3R*.1 :("N( F5$AK="%/Q6Q,;([)S'
M5@.MVXC4D>;3IT+"AG%WI0I'F^^;KY80?]GLD>GXSJYU*Q#Y\"W(TVX:\D!3
MB0_*QOD<^103H8D=6PB;@][P*L]&K/6B'"]W2JVH1*79NUN#.+%3GJQ;ALB7
MMCTMWI$R':KT1A=CI O/Z%)8Y,H^8KYR[*A7$;!60 )^4?*$6GYI>GU-)TU/
M.:^'VT07=PP-><,.T)-TFK2IE;W51+#.6(QI6M#K-VA#/S2E*M2$^[^9/.02
M^SP;JZU*4I2E*4I2E*4KC+Q7^*_S5#Q)WE)D+SX+/3SA4JSK'8$^+][J\A0D
M[.:KO?JEP<QEB<%V_O.K#1J[\L6-^]3M[UIUZ]6OOFW+N-6&&O#IACCC:HVM
MJ;&1 F:V=O0M3:CPRUI&]M1ID"%-AELSVY8)TB35I3:,,MFS/9ECJU88WSSS
MSO:^665[^ ['X,P.^X??#(69GU.)/9[O9G4@:&YTT@XTJ0(2(QW(%BS2JU"S
M"M=6Q(\D&S5@T-:EP1:%JS1L4Z<<[8#W*OC&6#H>7C/(>$'T6D(OSCT"(6N5
M056S&Q[KOTS"!-PUOMTQ"7X_=>QEIV*WN^'<[,4-]>>O+.\#"4#91@Z;!M^:
M'[6R/KL,/&QG<4KCK;"-A4^HWQB79I-NW!*[,ZRV2-T;]M\52!5CFF5:M6_#
M/7C3\J>3&1?,0P^KKE51CM[>L#)X;?@AL_'_ /V*>O9ZV^&W\;4ZV^&W\;4Z
MV^&W\;4ZV^&W\;4ZV^&W\;4ZV^&W\;4ZV^&W\;4ZV^&W\;4ZV^&W\;4ZV^&W
M\;4ZV^&W\;4ZV^&W\;4ZV^&W\;4ZV^&W\;4ZV^&W\;4ZV^&W\;5:J:+VN J^
ME[7_ /B, _'_ /["%:NK;Q?OR^>]<TKCI\?\;_\ ?7-6A5\@8*0R@JA-;,D7
M))A0C6TR6Q:J/1=/("04TI-B_<1J1'<Z8/NAETM^K8X;G':AP3:F_#)?LV8(
MK=_JG&'ECQ=*1-C/!SD9!CV$DYQJC(;+FV60-4-D$CJ->O<F 61[UO\ ZW.I
MHKT;=*A&+H5&][5I=VA4F0[4V_3NV7C9"@;)=CWJ'7YG?-@T^K!@AP:7%(X9
M,A&WIT:I>Q.MDFW;Z@=T2=P0[E;<I[VK38*T]]VK#ON-K] ^]PQEYJ$?H9;7
M %>WL&#?#;W*#GX__P##(JJWK;X;?QM3K;X;?QM3K;X;?QM3K;X;?QM3K;X;
M?QM3K;X;?QM3K;X;?QM3K;X;?QM3K;X;?QM3K;X;?QM6!O:;0E(_(_@Y/D*1
M$D7+)%/V(7:1CUJ=6)F=4*M-(H8[JGIK<B50F84SD/MC8N?6^[ILS2;5;;I3
MYIU>6W%)OLCM[*6.I(*9(EWDG)!#*/(@XDV-Y+'I> F=-#NN*76%P!WC&*]P
M "6>)"&%J]H&B8P7D6Z2]<A,I*2E[RMU#+$S)!P?8?N4.S1(994O>LMY2F#J
MU33&T2P]R]]61J#(R#D* P;)A<? &;8XB*D1'8B,79E.".,Y-?AL.>V$O!7'
M9@P!H*1IFQ];ZUG'@K)TND2X^:>6!"%R4O'.24,W+L8F"';4W<8.2+J'O*^)
MVEE;W06TX&D6N((/.<4S$[K'ES1.MG3>="9X@<]K7JI4>[+L3##X-3!TMD3+
MQG%)@@GD5LX][!QO6K'";>.,.A4,1DZZY5]>4SFD ,6N,8S."H%WB3FY/\EA
MB-^2FK,QNS^+N6:D70(SQ?+?)&64! XNCAR/-8]-'II6)DFE&-J8]AP(AU&B
M:U&C*ZA9H<&T)2O"K:MMCMU+EJA/IM=-KU7JL76]KS"#]+__ -/9(]/QG5SJ
M4KCI:U[WM:UKW\=^GAOT\%NOP]+5X!46"X*.O!<:D;$(BH^AW.;\2DSL@8F%
ME;4_2ZAP=G=T4)6]O1:+98WVJE:C3IU];=UG:][6O0BR?8.;Y-4PNOF",44O
M(AO>8K(P5G8PF/DHHF2YKE!(I$M[IK?-#)H0Z\UVYQVHL$VI#AFOV;,46-U%
MN\(S3#Y^C#W(#E2.C9MD).0K -R#S4;)VXT1B6W5H*%@JO8W)>C?TH[OWIT[
MXH:]RK2TJ-^E.OS3[]NO7E<VK4A-[>S^8_#;W2"7V>#=75ZV^&W\;4ZV^&W\
M;4ZV^&W\;4ZV^&W\;4ZV^&W\;4ZV^&W\;4ZV^&W\;4ZV^&W\;4ZV^&W\;4ZV
M^&W\;4ZV^&W\;4ZV^&W\;4ZV^&W\;4ZV^&W\;4ZV^&W\;4ZV^&W\;5QE>W2_
MAMXK_CM\%0\R=Y29"\^"ST\X5,15!R:QG9($/;-&ARBC8U6X(\64T<0Y&?(V
M7/4X)=ZS/<)KWE@2.WJM!J5(=>.YV2V2[%."W'OV2?%/M@=Y$=GYSC/ICY*G
M*EXA.7-<X\1.3D1[22S44A3ZJ8UY1"[O!?''2B>9$<6$88%Z(/)[.3FV)L!)
M8\%4J$Q>IU.9>R:D-;/_  Z*>0N_E'R7=>/DEQ<=R;+0,D@V(2LO%QAX=Q;V
MO.,\<%3]R%' PP,P_5&V$F0L(2B]"P\3I#HA!X+'M"-T1[S%4,.V6?9^-_+$
M%>I@AN;@*S-$T:N.:&+3MQ0M"1Z.7E:<GNX@(_9"WR(;.DL;)#8;"TRG$D$P
MO$CGKE21S,63!F:5KR3#\@9L%)#EKR9G!X(FM!NUK$Z[2/NV35=R1KTFQ$J0
MK\\=&[+<EV:-NRW>\;Z\L<\KYXYVRZ7M2FJ),-&K5HTR+*NK3HUZ].K7@8WM
MCKU:L,=>O#'_ -VWOTPPQQQM>][WO:W6][WZWK^GM4W_ "D2O_.5_P"F4]JF
M_P"4B5_YRO\ TRGM4W_*1*_\Y7_IE/:IO^4B5_YRO_3*>U3?\I$K_P Y7_IE
M/:IO^4B5_P"<K_TRGM4W_*1*_P#.5_Z93VJ;_E(E?^<K_P!,I[5-_P I$K_S
ME?\ IE/:IO\ E(E?^<K_ -,I[5-_RD2O_.5_Z93VJ;_E(E?^<K_TRGM4W_*1
M*_\ .5_Z93VJ;_E(E?\ G*_],I[5-_RD2O\ SE?^F4]JF_Y2)7_G*_\ 3*_C
MNAYO6^I];J:R0\HM"]M<<VUS+<]Z!5O:7%*ZHL56G6ATY[=."U$FVYZ[;<+;
M.]]QE?N;Y6O=_P#]?QI2E4!*#$>$H*_,D9G*&-C9=I2X,9HY!R0^1,NS6N3;
ME>>\37/(^E=K*T.M2APQVNZ3U+L4XK<;[<T^.C9 -+O"OE&4&_*B.!P9D@E>
M)H(>7YEMD(T7Q9_FL*P6;^*)%&0*E!DV;EE*P=/V1^N&(\='_!&C=62+<))'
M'(L>(>4!HXMKQZX=E7(O7RDY$D?%J0HH(RG9%H?",!/!N)";T;)V>) Z*I(0
MS0WA)F5!:"#2E[:PID?]#(1I#YSC.!DCN-*VC4\-"-\RYX%-'+J.#R7X7F0*
MSPAP(6/RL,E!V:V-O=3\R?)%(W-Q,TY*VR89.LHK9?9%_MQR2]OP-$=H[D8G
M<8U86)\9F_2I:I%#(.3FC?BUJWHD:$F6*K6JP'7:[5FX)EB;-)O2+L[)]]]R
M;+5LSZ86[WEAG?N\<[96MTHU)#^A"E3(D<A2HF2(T^A(E3ZC&]M>A,FU8:-&
MG"UVV]^XU:=>&O'NKWRO;&U\LLLKWO?L>U3?\I$K_P Y7_IE/:IO^4B5_P"<
MK_TRGM4W_*1*_P#.5_Z93VJ;_E(E?^<K_P!,I[5-_P I$K_SE?\ IE/:IO\
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MJC63P4<'23F6T \MLXHVO<3S8IXAR5(+,3A<48M1H_R&Y'N4;BK<2MWLJ#!
M3D=W3EZ*+WQ^N-N*)#G1!W)1CF%NDW @!S:#S2&"5.,RK'DM;@C2^AN]Q#6"
M061WWD &9',?/(R]AQ*V.R,A'C!S;D^_6[LKIL;WMA=V])6L.SM%$]CZ\FB<
MT93!J:R$L&''-L6I]JE"ZAAF2@3Q@K18[<E2=)L(1)\UM"_;JP1OB!-K=6G<
MJ;U&E1G=O*_<VZ_GM:WXO#E>V-NM_#TMUO;K?I?I;\5ZB%OSBF;8X@DPN)9Q
M@C^"9/Y+O<'1A$$AXFC/*Q_'PA+^$)E,IX3?D4:(]%3U2^Z%QD%0NYQ>N;'L
M>VCH4Z2>V'!/FI&J7#.T'E8B=9S7*Y!@S7:*G/FPE10[KXT\DV\GR3\9B"91
MH8N[3ZOD;;$BK8NO';(1E6QM&$UEJ5:[#+$F;7?#0N2]*(>U%D:5C[LR8V3Q
MB)-Q3R;#S]XYDHMF]^RO A2%!4BCR03!O_;[^K5)-R$BN0F)FVD]UF>V.P9_
M<\=6;EM3K-4U]O#:U_AM:N:5BQRCEZ28Z2P\"0LS![G+W("7$D3A3E(6;MF!
MA*9"#',J'4@%36Q+&E[*4PK'T;DV]E"F=^'%QB6*A]AVDHPU*W0B:XZR;M%Y
M0$1/%EO+7%8I)&_ET,<?'29Q.-YB-1]*)D,*R?)?KD6<8A&0MLI!)^F*XU7
MFA$CDLL$7QIRQD1M<="+:XC0]<=A[0LJ&9LXI@<D.T7ED13E#W(HT-IU&H\D
MZ%D F8QP4:_:V;]8)*183D3&-O0H*R@TOZ@A4*%[J8M8PL'\V]G=\&]9D!V<
M?*P_YE<;],V22#,\<O[K)<JL[8(M%G2V3:!M!DNO%VY]]=EJU18M<XV6BKF7
M8Z<TZ#41JW+2WH$"37J2:<]*4I2E<=+=>O2W7ITZ]/#T^#KX^E+6M:W2UK6M
MUZ]+6M:W7KUZ]/AZ^'XZ=+6O>]K6M>_COT\-^G@MU^'I:N:C@YQ\N2GCI(L$
M C))T%PXTRF'SV4.Q[.4=2-)C9@OB7&)L6498V".9&CAPTK'G&1'5S7KUC@X
MXV1CV*-"@NL68[+8] _:KE0[%J60N1\!/X>\7BCC<8O8&*J!T<=1(CE6,Y2D
M8[UEY'.AY&0<(LR!ICC4X S 9/@U(;OO(&X'W#J\\P<FMKOYI[4.$E3<YG2"
M->0SG PS'#+(9SR.;(OP<(J ;D/'9!RG:18M1HR+=)Z)WSAMX'W5R(4D=+HW
M8"LH%HW?3I ?/Z%@O8_=VO0Z4$L4#</P5)DDF93*9)&!C!0XZ0<2S%H6[^.I
MIR C9T'"0>GQ3 :%G)F('(,GEQ+)90W&M[ ^"CZB9S'6@;EM\P#M08+E)\CF
MX$$S._QB>NL/!SE-U@QL;(_C>59X;/7&-HED%L=R5#(S<9+%*AC&R90R K^*
M A@6"XP8$;2YN*K!NRY,.1<, 4F L0EQ^/,1_(J$F<!=A<'!(GW*4PHD9EKG
M=9MV[\-37LVZ7YNLU:5]]&UXV9[M3;BHS3;[87LK#CDS,TL"Q["L'0?H!&H]
MF!/)Q>]R1)[:\$@7%T3PTV"V\Y)\ <=(P]YD O7OL@ @R+"N!@)-FK!X>2MY
M?-J,8L//\>[EVE\F8L<*-Z"4.*]U!E)O(D!(YJ$HRG.=09_10\'A1H(+&^&H
M^-V"2(F*R]E.4"LL$# K-$P3=!>Z!_)FHB&W93<=3VEKY%LOOHE,B8&(8E9.
MSV;N63=+82*',<K364FIQED@+([;(]/R B>!E$_12$MA" L3XX*B[-Y9C9(Y
MJ%=O6Q&CS-X'3E)W)#B7"\S30)C8'+1F.N6R1@L0S=-@X*F3"5D0J_L#7L>5
MKBY[-+4X,.Y)MV*UJC/-3JWYX[.]7UXXY=TKYRR[FW7X;XX_ORRMC;_G>W6H
MA!CG%-+X[P=*SP4<9 F&N1T\;8VB&#3769L,R$T2Y21HBQNE75-7LH6@%I/=
M')>RF"" ML6)T:YI?VR/4,H*3[/%9NMF#]HU-9< 3M(.DY@!2^1E'',<R985
MOQLY+,"_!RX]KY29Q!"^3VZR:JC-X;LUP4R+#!4Q#J%0\IEKLA%]#7O3ZEFF
MMHG[3,[EV>>STAICC<909<@X7D$\Y9[G#8^XKX0D4>$I';QF,@[+!=BF7.#C
M+\#<@F!SVD.A1MUC,:[%275@M7VWZ9DZ4I2E<=+=>O2W7ITZ]/#T\?3KX^G7
MP]*=+>#P6\%[WMX+>"]_'>WP7OUOUO\ GKFHB>=_.^2^.,LO4< QI H;O:>+
MC].8RSRS%\OR81R\=H3-\%FB,0[3%!^+N#)M<]K4W(,5.@8.WQ4ZDB"S0/N&
M:3)M6\D?:IM<,QU(LC<B(:,Q'2"E%TK^+CJ\"T.$;CH[Q0X[<B),0G9/)$A@
M8<_'X8]S*_";0!@SJN/9'P%E68 "/FYC)E"*[!AVFD.@^R5G][C#D%E#41HB
M=,^\A6Z.$+C$CB>!XR.$SW&3?N3E%S=L)+Y%;,*LY(9!0I%I#(63@ ,D@K"9
MI<$6K'Q5VQ8>M/6,?!('ER4,6P!Y$/\ ,4<QCLAN0I4BQW@7+C>5.;PO?Q:<
M5T*$@3G$T[ZR]-J 9#-S$Q>LF8&"6-Q/4K\()\K(R[0N'Y>E 5# 04DUVC>0
MR=;'L:\CKL3(GA8^DYLB75-SB ,FY02:Y%1K]<>6=5R$C((]9@=Y?1@G$6DF
M5DK5BW*\B57(F&44S)( 5'X]HE=<)J#).*;7%)@KR:$Y"T#'><MF6^VK6\[W
M5\;<4C%G>SLL2[[K4R78FU[-F-ZZP+Y(<@938Y=;(3B%\B^-=(Y"I=R+FZ;I
MA$R61!T CAB?<1099AF,Q,VCAS+R,K?$I,X/#NN.6-I"1@04[;-I,]$K.D08
M5O':42HHP@-'HD/B^"VD*%IH/"8]8HIY"\KP$C*HCG1GAC-.#)XG*X\)1%G<
M-"E82.[.<)'0B%GK=:.G!1O>A]U=5=5&O:<FD42)S# S8.$2/1"?%F()9@)]
M%VLK']LX3(7#PXB+(S6L#Z\NJX>NND.7>/K>$M>A0H?$S/(BY,]*G!P9LEN<
MC7$N5"^<>+_'F8I!:1]A/I.A>-CDZ8Q/-?M%F<S)1-K="IK&=KJH5N>X>0/J
MA>E9=SBJ4+MK;J3;%>[9ORV9WR$I7B$C^W"@\^$[OGLUM0ZSNCZY[-.K+?NU
MMS.A4.2[/5IPZY[MN"5+NRUZL/[6W.V.NW2^76T5L3\RY\<S'C"XRP2\6V!K
MY=B2Z0!/CJBS,V*9(T"2$%*CR*UB"4GDG<@F?2]7I84 ]) 2R1]%^UK6N+T^
M@3H4LX0HU%5@P3M*Y^+>'\I\BF KX^R;);%Q&0S:%0LS\;>3,3(D,H%"(3VB
MXR1R?($FO0V8BJ=\?]@NX>PY,V.SOGN1DK<XH&I.H2J<DHR[1=SF;F/Q]@F/
MQ!BVQ3(_$%5/4E%Z_:Y;2@-E8D]8W< B)'BG6:&G0O;!) =NT@IW! L7H]^T
M/TIMK;WY9J62KTI2E*5Q>UKVZ7^&U_WXWME;_G:L>=?&&+=7'\IXTX)7RT8F
M#'(8^\);O>_)YS;Y.?2,B*+)W?+5EGHW;'(I=<D.WO&=T6C/1HQQV:]&-LHX
M3/A!P%2SDXQ,5<I"<8DZ67">2@9X^X3A%(>5W<.3CXJD0[>A%M0A[9,1"^9R
M&+IY2CXD)BLN+11S ]3()N^N+VI["%-]WKLSX8.]"1V)IGY"F9@MQ.F*19/=
M9"#7,TE8-,C%E)2>-G]=JCRS!'0DC>Q9(A84_'MBA4A!$VPC0"+\P;RHLV/%
M*(^S5X=+9"/!UXDB1S307-?)DP9>/3]-*%6+10NY3ES\AGN5HI%V= U'HF\/
M1$^/HNS/ZHE>&.,%R]X;H[1"3X[ONYPS%AGB\"Q&P28UN;Z8S2^32]8/<P'$
MV*QLK)9)VI0YCCQN;"-"R"PH$:1YJ!QQI&DHVPAK*R;DVI>XN2%>_/C\[.?J
M\?>,,)<7AIX&(9 QL.1/Y*7%+XM:1T:9W5V6%IT7'^:)R7#[*S77- XY&CNU
M"#>JU[L!X=P1M*3/+'3MW;ZOUS9#>\*<)'U2O&NV/&MSV,KF=:CT3S#6YWTK
M]+7M:UQ5@\78D;EI<]^ANV(5#AJ5ZU^[2DRU8J=NO7E@\6<&N-;Y(.X"6SM+
M8^,2+).ODZBXD,<X,P_'3U(K >-$GNTD#@=I:K2GM%E<H-Z60"X":#79"#F9
MKW)]>0/->\+\U%RT?!40;UIXBU3;R,RCB1G><78EA??(0]NBW=?D*N/7>0F]
M(TY@5R%(W[G^1B1^8M6)3FI9G6Z#8F5;$Z#4EOVP#L_^-T:2F^3&),)"A.".
M38]EET6[2EP4H-I9&<&ET #G>&K9CZA0M6\2/#1]>VI'K3Z'R029[-EV6QX7
MJ+Y9M>"W2W[K?G\'_=:N:I,C/0@/<!EJ+# 6&',T=\1\/;B$A9V1<5/N6%MF
M+*-HW-:E4OSOEKO;9BV-.I8NRPO;.VB^-[7O8N>8\A3DFW+HJ(Y$VCYW$;^*
M2VTOL:R"TCDP0:7-J9RR%)%;=F&3IN&MBIE7O[3LUEP^X"!D(O)&,$;.0"SR
M[MBG&L4X#P(=,JF40_D1.YR9GDFALT[.2S!-@V1%;X7QT$2#$C"J&W-E%5<4
ML(NC!C\K$=X>!!+&&Z\<\U>AG2$'KDY+*GE'LV()G>.76.9W+9IF#0\BEPER
M+"^1[(SG>-ZY9$9F1(,",.8!3))FW% :VH$:Q(C3K<A-6\C:S>L;G53:LP8Q
MB@.B5"5-P6F5I$9@?F,D.^A2KR5:]9&<.5G5YQ087UZ\4#7AOMAK;FS3CWA
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MP?,A9\3#>.ZM]TNQ^T#%UMGW:RZU6-TV;KK09(,%%KZ<E%MEKXVQ(G./>/\
M,VUKY"(.1[C"1-!V)M'+AR"A>5HW8-C"P$2UFT'44R.XF+0=1BY,^1&V#+I=
MB.AU2]!I>W-CN+JQM\4J=RZD67LZXE'FJ/=L4S)R1C98'LDL-R0T#YDL^%9H
M@G>6]D\GBTS+9 '#UQ+%KS)BU:4(WG8IUK=%G)2@TJMC5GH2ZJO(.S]X^&AA
M&\AG&HU-#J,I:BB;VDK?2[?=U>I'AZ+]45#+P4^M2)K1O:-P;D3.3$K#=&F8
MGL]'!LIS;DZMA;M&C***(T%X:C,"B<*UKM0A' BPA0UJ<EVQR<-;(.-VAK;<
M%KAMQPVK56*5-KMO5;,,<]VRV6S+&V65[5<'Q^*NBYN;<RMK@\O"]$U-+2B5
M.3HZ.2K0A;FUN0Z,U*U>O7*MFE*C1)$VK8H5*U.W4G3Z->S=NV8:\,LK4'ME
MB(U@T*D>Z1H[4B$CKT; $ON9B+;APZ<WGO\ I0,PNZ9.F344KG;O"K2D;&=0
MX*'"VI1JTI]UM>W''!V/N#/'$7DR.PYLG:82M-Q??=<GPOQA>IR:W0.@)*^,
MI0(,62$):VMOD1[!V\8*R,4CIMF0D/F(&9=^MJCC(?U-K=9)5X9V?8,)1RJA
MIPG#DH=1#G&2")FR-3F2!]U&QT59<QSV-W8=C8 LCZC>!M&+MS:SN>YZ5[\6
M_8NUK<%VU5EOQK"'N!_'B"Y!>Y+CMF(FTG(9?G:;G'):5.3JWY&O(A**)#[!
M(@6VV:F\<3HPUG3B0NART,PGHNOP:4VO!>HM?,W_ -?^OXVI2E*4I7%_%?P=
M?!?P=>G7\W7\77X:UVN38#,>OEY)+7%L+<@B51*W*'B_*!#$Y]!@W+'"J9=<
M?I80'DW(QGY3,;",G?$N1HH#X[SWYL+Q)+KN:S>*&AX%XF,],@ZM)1CE)P1S
M(B02U D'#?.!ERBZ0.3\C I"WZ^44E*S@V<^T/E O>4>#..KV]B=_7GCKB,D
M28BY$EQ]$\ABY\L;H/BXQDWVP,G3*8,X_P#(MJS,8^C[3RC"PI^Y*RSF7D&9
MA)+65W&3WM;(VD5\=!(^-7507V&B7B"\$R_>0##OM2^L+D>9(UZ<XQ>]NB6K
MB"*G@-$KL&'N\W4[!>:>1+*#[Y$)GTT+,X@1SK(%H:LN+RET?"HF1ZHQR%]#
M(\D[T[$"QCU-V3LXJU>.S;>Z<W-WKQ#,M-/M?*Y9LZ1H=MUXL;R!.)N$DX+A
M9U2; %O*%:UL2#BXPU[LQY&^JG1L3-2EQU+M[D@U:<U>G7A$8B=&F7'>=7WB
M'+9UP\:^3P.<(HO7\3]H=(+,U?YD4N0PSCR/B2UC*%WD<7@$L=PZ/6J45P6J
M?B39(B]YQ=20*B%N+FWIP#Q8F "7<=8Z.>*IY:=<Y+[-"3!.9L$NXB&H1@SC
MY&#"V2U%Q).";0K91-UBUH8)5BG.-=3VF4RBNF_4H$T!(./YJ\,^>G(R#.1,
MD<G'@E;"+DBVQ\W27PE&QQOCN8C\ ",(L=7&2DG*[;9A#BAC0+\GH?<AQM+R
M%Q2JB(=U-P^[1\XBQ(B]?,XY74NGJ.)"B@2F*5N8K?*T=GG ($A5M&IC(,P/
M(!D[G 01Y)J+E,V(B7-*;G<GQPT(FMM632WO9<;QVVL"V"%JDO23BOU35\I7
M?G*WS3QJ2<9F6*7&+G(R)T\J[S9P.TV['3IA^7EJ347;!D-(4[*#XDJ0(S8W
M= N3O:T^R96%3HQ9EZG+=GGAW?<X]\[FV?<X]WW%[WQ[KI;NNYOE:U^Y[KKW
M/6W7ITO?P^"H..U3@R2I+-\<HJ "@I.9+XO2/! :_K^.3?/X*/%A'( L[,5A
M\TU2&)Y\4)!3.FQN-'&;9#8GV,50L$)%";9LDF/0X;),/)6XK2T5:))CT7XF
M'RJ6 ]=VCQ?/TDY,ZH<'N4473K,HT< ,5C4HJ=29NF)VG:.DHZQZ@G)\5:(T
M]K':)G.L5PL*IW;/H$"I0RXL=IV3\>(HD_C]OG UE8MXIAVD761+)R9SQXT1
M/&^R1!R.'=O97>*GHVF4-+RX:92!E:'A:IV)CAZ:="@IV:]M@YYAWE7Q_'^0
MDD0I(G(UJL!'_)U. O$E<ABLK"&" UG9_P"DW0$*B\W&[N VR;.5B)Y> ,WD
MB^[2(R#FB&EKTRPUI5CB7(CLURIT<[\V!>+BKD25A8$=Q8W0RU\S3V1S,Y&W
M<CXMQH;N[(0NYZX$TJ,3&XFQ%F0/#03[U1&C4O;HYCR# (<05/EE)PF=>9SJ
MPR7LY<M,<MJA/,$SH@3(35F.;UM&$,R'B,;PWI",4&T>8-J"] S[6[VFR5NQ
M$+Y(G5^MK7J-N>W.*E*4I2E*5'OVDP>J*H-#7!")S\^+0"=8IDI 7<8FH4,I
MGAUW#'%R<&"7!B(S(6-V6;4(P0;&MO*XOL($3JYB3\]$#$U*G@:1X5#DSQGR
MF;VA!R ;X)G_ &R<B5]I0IC0CC:/"OC!($U.TG05$5PZ<)S@A&X',?0U-!J4
M#<DMC,[%,?)-I>Z@@02-T?,\BG8N%Y>7IBCE>5-;HZX,7+T@)8ZD#F.@XWJ7
M=CY<L(ZUC$S=F=K01SCBV<B#(QD-W&MW)!@/FII>.0#I=W$3$C;1MP9(_8R<
M.'%<GT3Q5R68^4S%*9 _3ZO9"CD7RT8"]G)9%)G2+F7C_J"-&R!T33&REZV!
M#$U8&+$D<ADC;A[69YN#Z^(%K[FPN/K3HEKJ%#G+'9$:\EHTU1UQQD#9*26=
MN#ASC+26,$$@1Q,,5Q--&946"))-:AO<MO%&T!)LRR0;72.P<_RDO>6T>'4D
MA(RDG'M.!@]QC/$S-%:>W#*2D2+C4"0L-\U4F\$<<LN49.'\^HZE\C6!;7DW
M]WRK];&,1E'DIN>66Y2A(-4DZ !%N<)"*R4/0R)1S$TSX\##<8CH2E>"%$I<
MR'H[CP &%*V.92C/C=*7.UA*WU/J:T^"!9%&]XAAS-31U"T>*)V 6$I6CZI,
MV$*!:WH\59EC?D[QXC8I+&Z1N6+*";W3E-'LENCGR!*2,K:>.NCGO #!!R"&
MW"6C=Q;F><EG%EZEQE@LT3*]4KF"M^S2J2@AD/  ]09N]GN62$^P'R711B02
M":[ 3EE.\?0;JY:G4@$I*TAXDN#D+,(&Q8_>RJ5=#0.+-A V(T9K=WE!A3ZM
M+1(V%CA$2:=.0W AVY;/7'L07\Q6T5;9.WM^K+/%FR(M))NU^K'/%3L.6E[&
MAM*S/>-\4N"9&S:%*/-MMH4[=V&_;?7:['*X*WR1QAY$1\F;B]Y4&T(RF*Z6
M:/\ 8Q:CEXV/P0]MF#2'Y%#HR#&9,Y9*;(6302O3..JG#?H2O;JVMF]2MT0#
M"L*GS68IN04R<7""8^,N<H/6E/ T;<+"F&MZ5\RX2>T\CD1OX6/+_)1:G0.S
M]J<X(V&98KS6:,W[ DR1CT)M+06UZO'7BY,D?EW&N.3KC,<:.1#%._".8%W(
MS%&H(!((@>'N#@+$TFA+M/B1.L;L74:)AR3H6]J?%XTNIZKE#6?-S,XBK^5D
M;?FA-L <B9)Y3.Y+F4\FVZ-[\@^.8<A;@&:I#C\$U\>G" RN\\Y)6(+*&))B
MG?I'W,*$D++Z/9FR.C<U* A[&5EEB]7'PS'L_!<K<=!N<I8Y>))U#I5[,V*1
M!I8I><,8FSBN13+0T32P\EQQJ(;CA3,DB[V<O<7_ &RXSN$H$X8W1^1PNLV"
M3?,JW5-)RD=^<J"9^-"7C.RQ2Y1<Y%Y)HE7>;.!VFW6TZH>EU:DU%VT8#2%,
MR@^)*D"-C&[H%R=[7'^3*Q*=.+,O49;L],.[[G'OG<VS[G'N^XO>^/==+=UW
M-\K6OW/==>YZVZ].E[^'P5]4I2E*4J-;M+!Y\<0J""T?8N26#Q%<[ICYBE3B
MJ&BDO2C"9%MBZ3 1N-U<!%P-(:6: 1Z1&[O'I@/LPPXDPRG+T1TT8M]AU4_L
ML08_%/*$,%\9<0P7/8H=F,'3N')]<1"LT0XV+@LQ[1")C AF0T@*.5TBJ(*F
M*3X>(#.99%B2(DJ><RU+J+\(>O'TFJLD,<5=&,4\L'5[CXR=V7EH\2(*HN6,
M3"KT;M<_L[&DBO=SRX7RU%B-4S2J7&N>M.IXZYGFD5*I4)2&0GYM U(Z0$.R
M1036-#4E'$6*^0H3-8X8R,]SJ[-\@QYRZ62MKDB1RPL$T1@AY;#BWC@A9!%Z
M?7 6!,VN#7LK9Q;4#LC#Z\A;>EN7[7QY;4CAC*=?Q7Z6ZWZ7\'7IU_-U_%\=
M0(\N(>D:3.6H^D@R I! I11S(:$Q?*2J/$^Z.9-&"GA<4PV&<A-7*_4@WN<;
M/$-NCLWQ^T<?&LE;WHB<VI:Y.4>.@J0:2ZL;X\A')J+H4F#_ # Y7$.-T*-W
M"(/F^%MD,.JPC))3B3CUS# R*0QV"&]F5/\ -+5!9=,<'#.<@C[ 3Z3W-@S+
MP564LL8-KWCG/&_'^>4O!C@A!^YGEJ*->$M >N8 6/Y$>A4QCKCPM52J3)HG
M(#8+=FMZ9&@2&E\=QT3Z U[3;6GUM]:!MWTZ42)RUX=.X5RNA6%QG.5) Y?)
M J2@_AX+<C%EIJ-G295J];R?/@D_&H,<]Y7<N&9:)HK=(M&7QJ@U2S2H:@J=
MP7QYK>IZ4LSNX2(<(C*8RO@0^/D4/Y#()VWS%RP&(H=N41F1$A*K!@?E/*X<
M%-QX9,2<J('=V'@!B0LC5L[EW=;JFIL:RA7F\:GQ3CD_PG<>2[MQIB5QY9H!
M9NF58  "DBTCVQ_Q<\U:D!%][SN/&]^8!W%DD#(GV/V)0QLJ')B;%>.*=OWY
M=SMU:O'Y^@:F2>)$NB:08+#/?O2A[UB+!@:QR0\/F C(@>8;6]7&A"2"""3Q
M;=I8=ESJ+])(T/$D!&)"$CJKV1/K5JV0,EW&Z7LQ2:"^3N+)9/8]R"CCM"03
MCD' G&]VC73'$GSK?C@VQP_*8(?74O>N++++[U'QH88RG(3TD(@;6V;2J5W<
M,*SO8PVS!X\P/(0SR^BQO?./ID@E>,^2G,F89UY3*65P1A<G1!,$4*QN-DC9
M+"Q%I3R8XEST^1&T6BY,Y*W6/<./:IQ*&4>1,(+O?+L2;QPGB2N11:2.Y9RD
M;0DCY/'XAFB")[E2/@Q%QEMP :58YI8F,(,F% PMROENUIG347M*5(?8F]ES
M1I(TX<[/#$XX.Q3(\\MG*/C&T33)_*W'D-;D+Q>AXI&TTFN-N.V^&G+L]=LF
M&85(H"R/MP)9."J8$A9($FI7L>QG30\^QLG;5&GC;9FRV2]RD[\ZM',2&FN,
M&6)E7&-: R4I-US^XGNEQLYI'B"L$VPAWM8:XM;:7IT2Z0O:L:DCYJ:B1)8F
MV$F:7>U([Z<][]WUOTMAT_%UO?KT_/X*^Z4I2E<97O:W@MUOUM;^-[6Z_B\%
MNO6]NOAM;P5$*Q=J5@E"P@Q*(%DHC2&T?;>2+DY R8/;F.+^,99.+I%<6$!3
MO.C=C?"20%P_9A,WT3&&3)3N0["6S/KRWLB% \Y8'7,6/=^F30*#GH/DKD6)
M,TA:!F+G]V=0AE<C4$TN.MQ;"0X=V/!B86!I7H%.\@>M:E7?2UHEFYLU+U&2
M;7MC]5]H1R.QA8UDE(;<+,@0*E,W"F?ERJ:)7M \X[6..1-W#P& X=02.X2E
M*!X:R^^$T3)"*-9!D<849QV^/08T'1*OP FJ0KC)R%/Y8+), Y5C;9%YN'A_
M'^4= MGDH4*642GN-MCQ87('#;W&AQ+@*4PJ701[7-R9$A<$0^Q.F+>@4KU:
M35F'5*G#F0,886O(@-Z2\J:!E_=!H4W.J=ATDQ"WM"Q6RC^U[5:MZ5GUO3EH
M2->;JHT[M+=@JNLVZ\]>C+"\"()VG7)05#CYX.& <EB2F, A(Q(..;["DA\,
M>04.&4A3.#16=L&L2GPC2B\WP.,6-KIF6<P V5ZVTO;6QB>+%;8<MSVP9"S5
MVNHZ#.O)6/H]A$I/);@D,D Y:!:Q_!^-R1AB.8(YAR0UQ6R)97P,HF]3/$EL
M)&%-\CLH\\2,$[=A.*HM^&C>VX?)QS4A9E/F\X/N+SC-<DPVZS>ZN,UL<4P^
MQ.4!1 %<N3WC"INW/YQ);Z8*R!O>F+=DYM\>NFO;(C*SDINVL(QO6HP'"9/&
M]LK=;6Z6M?+'XKXY7POT_-UM?I^;X*^JXO:U_':U^GBZVM?IX;7_ !_GM:_Q
MVM\%1=]H-R4GV!R6-T(!??&<4/(3)9(8\B+\89:Y<C8S(@PL$-$>QQ(X#"KD
MW%L;1T7MKL5D1'+:O4K;T^@2N.(W 9<U>MSW6Z:.U'>&5I.G61(>'-K,.A/#
MEV%#P"FZ'M<*2,_<FXT,SQZ>QZ8Y(.@H<9XB9E(<J;P<Z/F\-<CN[@PMZ <V
M/Y&U-FS^(AVGS?-!2);F6,7\5@&00+BS)0N5FHV&EKK)H?R.C_E60/HAO'F.
M8-.0$O8<X%]1Y$CNVE;8KS;"9LTL+RT$(N4:LCN!4Y1-)(R\A<3\7W7BD/M(
M3$,X#@$H&(C$6Q[C?D>RD3\"&&L=B A>V<;)7/<%$R$P%GK6F?V5Q;4N2K>X
MZ%R??KD"I2E*4I2E*P<Y.<P-''DYUMJL=6/H< \:N0O*^8]C.UJ'8LV ,+X"
M+"Q!L?H-JYG9%AT;EAIDJ;<'EX3I/6P,=FZ^&E0]I'-M_B,\](K3-QCKG5A(
M^-I:$2:JC!X#)$S9"9=N=-L> <LM#@VNT4N!VP*4+F R4*+E6K<X)EK2\YNK
M&K3[,F[4N76<-^:4JH^2<+!L?X0031=,I1%R( CI.J,'[D=*L1EC'N<)4Y/-
M.ME<DS/$$2PDO5ZF]<DD\!6)CS8+$J%&="Q&0Q^/OO=:^9TX-H1,9W*<5@0'
M[1W.F/\ CT7B8^4O!^JO"<BM\$MS<=ZR=.V,"3,T:W">V,Y?D*=A]96\89'4
M4U67NNOV4;9/L;];=?Q^&U^GBZXWO:_3KT\'6U^E^GAI>UKWZWM:]_AO:W7P
M>+^%0^<_N8'(7CI*6Y&-KAN((?8(<9Y '9=D?CO,4Q09(\JYE9:D*8BG.8XE
M4;]7$$.'Q-B%G'"63 ?<6G9E(2HMLI6MD9/8@2_1]VKJ&&&"=RB78*(&5BBB
M>7F,!Y>ADV"VQD, X8XZ1;/[N8M9>92D/B[@]/;<>[T\9@NE8WF<C:-[!DVC
MK=NT&FX6\(A[24>)=$V+9(A=YMQQ#4<E;\A]X! J17_D-%#3P'!>9"K!$Q;I
M82H!!S5,)2K;<!0V%G?29:GL:&G#0).2<F<4.=_$F1!4G$S>-QJ UO&3= 9U
MC&KK#6U#&R!I&[/06(2R.K1K3$KP]!&IH?!*2&)R4HD&]*M:B':^-3@CSVH\
M7)QRPIX_'5OI8?3 4BZ1R>.@_3($@#@&8OP*!;G/0Q:#8R9QQR<!<1VO:C')
M.S:R9\3(&3-UWX9:F_%==5LQOAJO:H2HR[2B?V9C*[$S<PSJ<(G'B/H=(C=H
M3.N$/(F'7V?Y^&(4D!M)XBY$E"!OD*'1S,DT>U]-8"9.J3,R[D*)DY$UY;3E
M+=F2.V"%F5_FJ.HW@TR-I7BA:R+T0ID;PKAF]B&GDO'O&XT=2EO32EB21 ^M
MKT=H'T;#I0:1TI(QMR9GU.TXX:B-I8NVY\T8<12DP&!MQC<)<E2*W)Z8ROD@
MPQ/$0MOA2.23F;-W#T91M3J7R:3R(JVX&L>O&1(Q@3TM]?Q7!X/4S4U*G;"/
M=4R-KVO;K;\5[V^*^-[XWZ?OM?I^:N:4I2E*4K >?>:5X*D>6$+B!$!;'4#0
M'&DH'NL,;M+M(!.;3Y,3O%D.A (B>7<:&<U&.($<.9'9U>=5]EW<4QU*FS2G
M6Y+^R+]H#"V(PO<)FT.O'XM9)#D:+WL$.;H21P3%$99#:A_S;GR--AB/.K*H
M:S$4=VYQUK4V[;I>+)5*%*Y('!(GQ](^;'(_5R$4QS' AQ]E%,1#TF$\?P4.
ME!#JFIKC%AA]88Q)R,F:3=3JX1O$D:3/)Z1LCAJ"30&'2EN;2UE)V(C-GEF*
MPYJZ<'<\I=(WH;R-=T)RO%B[E,*\:LN07'H<.FZ*C-SD.*'=W2J8_P!A<8EU
MWG5%TZL:&(3,J9"(H"BS4:(7%J<!@L#3 )2R^8Y6RQQRMXLK6RMU\?2]NMNM
M.YQZ]>ENOP]+=?%T\?C\7@^*H9.8W-'D9 G(5X8K* F&(>&FN'G"/2N7X1ET
MI@7D"XE[TN1RB-21RWCK!T"^'CN(Z-;<QAZR21I4W;7=P;RUVN4C3K=B9OZ%
MW:^#,,1]F>S[!9J H]<V\GP':DR.(.3KDX+QYG17#F) S(7.6\+R-(#I?-*[
M*XGC)62F&*)F*G9$WW:;AEB_^)-S^;"1NE@?Y!\;79_CU ;<A8?TP+<'C*4G
MN9O:UY7<:>. 0^W<'27=X&@0OY!R!']3L"%0_GJV9:5Y1[*&-,.IF4DD'XG2
M8*23$FK6)Q2H@W1&Q>;PT\1%M2AJ5( $45D:P4=V%DO'JU>%JAO':DUK1U6/
M[M23>SK$E]Z!K7XJVU+DOXO%2]K7MTO:U[7\=K^&U_W59'DD9R='$ S$=PI'
M>N6);$(X+B&.(WR4736,S)L:%*IB'\;8;T>Y7L<%VO7AJ:TJYO5O.VV#0C<4
M"M=I6:(GH6[1B9,S(7 '/)DY%:R;D9 \2OCI[2A[PXG6$F:71"5WLCWSAQGG
MI[;"A(WMSG&5U,3G0&I*&N3&G(R%_6; GCG!Z.+@,?:Y#TDI7%)$<'%A*5C4
MX\,P4O9<I"@=ZTCT<<OII=8E8B]Y7B$NNR4</1E2+$B LAU]WII"#"%2-:2!
MEVL:]>YH.M$G-.%S*6(C-7;C,K+I0?4T(Q&8\PFB)(F ]#$]<@V=]=(U$VS6
M\26:3)87<<VZZ(G9&=])4 9M(&'>L4.Z)Q=-[/,MC>V6..=O%EC:]NOCZ96M
M?_NZU]4I2E*5QE;K;I^>U[>'IX<;VRM:]^E_!>]NE_!XNM8"1IV?\5C4;NL:
MG.I07M=@AW@Q@6(WDA95*?CNURT1R=%0&NUIE^.G%\!-#\E&5)*W63J'M&QH
MU&>*;6IV(-%5R)V?G%:3&^5D;Y'&QO6S0QG@](#^-%9@/D#JUR=FIR.]"=P1
MON6IML2ZUJY(XXH4FG5M;URUMQU8(%6]/G1[OV=,5/F\#='*6.42@GB]<;K(
M\,/\X8VU% ;JD(>'A8G;1QRU=Q@SMBED&D3>@3-Z9-FRHUKZB:-R- 0O*1;>
M^&($WQE(DS20]$[@5OLD^U:)LRQR6KG!R:HNAL&Q'PUE?'-PODI?B986D4G'
M)&09WUV7N!MZEMJOZW74JLDJH24$,?.L<';/+%V'VL7H1(F.0<"A;I;AQ0&O
M;2K:"1(^+=ZA)I3-:UH6JTBW9FIT=-&_/N=NO.^.5L$A_LNX&:VHL1ODC<F9
M(?7H";HM$3B5)]+I!-(ACQI.0V2$0K%3P0ZE*9ATY'$<1\0/+N]-Q*3E*H(&
M-!>]OJ%I3I:\,E[-#BR.MIBM(I(F44!R!CG,&2,CE-^]G  )DY5'C(9'K0((
MG5#BW-3@^3(D'#,;>7E2]%*<O3LH^G>%PM@B#ZK,GAW@4@)I2B@O/ )#(!A&
MYZ]2<"NTV-[4>91V42R7\DSLR7"6)&B?&%@W2$6E)<L(T;0WM+4VJ<FY+N1#
MZ%,ET2%)MZ=2GTJ4F[4H2J=>"E.HT;<-VC?I48VW:]VG=KRRU[=6W#.VS7LP
MRRPSPRQRPO?&]KU_>E86<@N*<2\C)(9GS*5YEB&900)S9'-_X[34^1.>.44'
M#VL5)1HWT,62NSH).9.*NR\3<ES9H>V-\:R/<%$+1O4D6*J@W/LR>-G? ?:#
M[Y.B:T6M,)M,6X1I(*YFPCK7 X-)T6"*X8R=T!!MP=G*+I>. (H=7;8[+75L
M<$SVFVMAJWIBK&CX:X@\&TI*HC6/92WR62P*, X 01YG/2(_*H[3 +[/JD ]
MG;:WKMYLUO[(@Y#2J(I59>IQ5/+(H;\7_6\D+ G?,<KH6!>/80\(%40O3"M=
M'^"(6%&FS8;XE'KO"<0V+6J*W=JU^NB[4O94V9P0I?9:BMNQ?MZU/BM<%6Q.
MC[G)&E*4I2E*4K$J=^*@[.4A#I2^*4UQQRAV:^/$OC.W%S3*#B(9A2C3QFC:
MGMI<$2QA(QHX!AY<U.>-MF&+$]F*/&VM8L0;]/MFO#[CS(ST6OYU'R<H<C4T
M32 ^9N3V28:<BE+'@5%NMP1:&YX0:T.&07'XLV[4>BUDFS<@V.%]-ERQ5OVT
M,*\$8= 9=43%'Q#,@&[N&<:X/8J*R\8-\?D+7$@HD"@0<?A+<J5IW069AY+D
MFUCBE5DT[%:]Y=<DUG5[=EBSWY6XJCIVUO ZQ*$["PRAR3BN?YVU+O7)W4FM
MXKPCI8D866VU9BG8=1"MA2*&1[UZ<,4&0PD*+ZD]W=YLHK+/&W2UK>._CO?I
MTZWO?K>_3\76][WZ?BZUS6 ,]\(>/O*:1C%\=I'F$6?%P>QQ#R"#(/G0GCIB
ME<"LD=7P> YO&!95?)7C<<.").WNJ#,6-MP88K6NQ'M8%#7J2=4][-3CT<ES
MB9ZG.5@5S<7!ZRMHC21%8.@:10OAJ+((/8\&]34V^J1@+.(_A.+$CQH8%;>0
MM*\-0K@LD$[+GE.Y4.X</>#$<1Y("B1Y*MJC<:'VF*9#>Y+G%K8AT*6;N,HG
MQ16X$S_ZJ&D8P9F<&YQ^S/5WI:E5+EUA<G:&]N=G2RISS9BY/#>TCD@RB\C'
M2)XEY6!RV9KA\M2DR5X3NT<C@+'Y8@P1N"Y$D'2,%CIIP8%S7W#,_P"#2O=4
M6U6HS7;[WGI5MY@98S)XM/Q.9?6+.*S 3>@T^3DKI=D9%XL7(M@T[-B]UP6M
MV]#K=$[K=MU*$BY(NP4JM%T"C4NNGSMA8-]F9"3.F)U3])7)63CQ[;HX8&26
MI;G,CD638\%HGE05FD,%X^(B%&H1,;6FDX)&"HBWJFAW?#=>R-6!P\$.AK;-
M2.T)SP%X-02SX;Y)GDUB$,?VHUB&-F^0N1[0'!@4WR-*0C/&H)BI,9ZTC;I?
MVB4([9#476J=I"<*+MVUH?G@E%4J5F17V=85X+M#[+D>/9@%H#!P#T<A2V(.
M$RZ4I>S@K!R D#E-K.G\>V$>M\&!71,$K&),J)-R! S7;W1.Q;E>+$A;TFJ0
M'#N;XVOC>U\<O[=KVO:]KVSOW76U[7O:]K]>MKVO>W3Q>"OJE*4I2E*Q%DKB
M>.2?,1&<D:RZL&DB(@:.9/"]>U>V*WMYA27,I<@\H;'IJW)]J/(:<R>1VPA1
M;K9Y/B)X'\,56E.S*T;CW2;A-QI-5+XK,(U2DN\@.3*15^;J^E%[XE)\WB38
M5+$ED+VALE3N:0(&\/4&'5(DS09;4>I/FJ5WW6EW=FM >6$T-:$GGME#>0&L
M_P!<IQXQ3J>-0,2^V0"I8V(,]K,G6=_T[$H6W-(^.9XN&60PV,S0A9+HT2#0
MFM["#A$UL*Z$V1MDB122-HLEUIF18.2><$9ZNR=P !?A.*A0.V+-R1K#PH:(
M'].;K&9 BLGVNX@-)D.C0DR78VSNM:V-K8V\6-K6M\5K=+5S>]K6O>]^EK>&
M][^*UOAO4=\M<#>-7)V0Y!-70]EN[,:JV@+Y'1'&4Z% [#4U. &VH&?0/3<
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MR%EL9#35%+/$4DS<V&YTBDB9=,DF)W/<MS"Z#@E(;MMW-XG'X??>5MC,W$)
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#7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g864922.jpg
<DESCRIPTION>G864922.JPG
<TEXT>
begin 644 g864922.jpg
M_]C_X  02D9)1@ ! 0$!60%9  #__@!"1$E32S$Q,CI;,35:0T@Q+C$U6D-(
M-# Q,#$N3U544%5473$X.# Q7S%?5%))1TQ90T52241%7TM?0D%2+D504__;
M $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_   L( 9 "=P$!$0#_Q  >  $  04
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M _. @(#\^1+;-"Z;N_G-9=<51^N<3B=\C%(QDD85/ZQADXGY"_$PCZ^87 B
M^H>N:]2W!+6Z#DTEKRV[ UI* K[5%6"GE7C5$WJ)0*FZ]C)B4ANA#J8*;H1+
MWZ]A:QU5S/H/G-2]VP&Q8](2^SC+XQ,F^6(0WH0'+YM*K=B3T,8+ W[#OH0'
MRB%1Y$\EJ()B[0XW/Y9F@ ^WF]>NUWK<J9.NUOD[4;,@ " ";I9ZR 0^8GJ
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MQ\HG @#UZJI&51[[\WL  2AG":B:I"J)'(HF<H&(HF8IR'*/J!BG*(E,40^
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M+*H[TH<%+6 D@@>+FHJU3AC.XXS0B1V[EM&.XUN@JT61\P+BFHL[!R85#A[
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ME5,BI))B)%"@8HBZ1*(@/TE.<IBB'J E, &*(" @ @(9]:#ILY PMG"#@""
M'%!9-4"B(=@!A3,;RB( (@ ]=A\,]^,8QC&,8QC&,8QC&,8QC&,8QC&,9Z5W
M"#5$[ARJF@@D &455,!$R (@4!,8P@  (B >H_$0#+8%B@A$ "7CQ$1   '*
M78B(]  ?A?$1] _+EYQC&,8QC&,8QC&4'X?I+_J&1/H[^Z^L?FF?^8IC.#'C
M ^(=+:OV_K7CGK"X;3T]L9C,NTEIN7\+78O."B[@>VFBQ=PAJKJ"=A[)58]2
MU5.$8S<K<&5:6F)(J)56[]NR3K[Q4TW^ &:H2_%3?E^K.Y;?NB;V?S:W_>=G
MRMEXY.N)T-4MKNV=$B;Q1:)HE[.V%S2ZW"/8ENXEB.'Y'DA?9"XO)1HWES2
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MF9,1+ 0*QTQ$0!X_[31^@!Z R:0"'QZ^4G$0_P ./=RQROX4Y.G02,'X3..
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M'=_()U&12+\$9 @^<P!\"^<X+B'H'78.$_T?'*!8[+'^DM6U%2%_K.(XQCE
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M&?%KQ51G(-(=J<S>*;M7QD8Y'^C9I&.H+@YB(A^" F7655,/SJ*&-\^?G?\
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MJEN(K4M==ZQD]F:MI\9!0U8ET)Y]=8.#'W?KS^:IL/7)U_#I+2(.G6UG+SF
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MLI%U!2P[(V]O.5@JS-.]PSH%:-+15)FOPS^LQ477D?N8P;NT6R?9_&,8R$M
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M@  !U#LHLP&, !WW,G_"$1$WSY4=];ZJHG"^\>I5V@D']-(TYZX?-R  _A*
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M9TSF$_8")1 2Y0UIYHNT3 GKC6L:8R@ 45Y1%58A , ]B3WL72.02CY1./\
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M@GY0ZZ]$P,("/F,/Q#(4.*N@VYA,37K(_8=>5Q+6)P0OJ ]E(K+F*4_IUYP
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MA(A7_K1K]7O9!LG@CR5J!/Z 5W#*(?2R)"K X$3)C*U:N ;_ -P/L2'53,H
M+&4]B5(HJW)AXR7%[M-*SU/>%+7$J/M@G*''K)(G41,J8!&-LCER8@"7R)F!
MH!EP,59)+V(*')+$!XJW!J=(03;E&%4/UVC/4F],#$[1!4?:+)5YVU*!3"+?
MS X,11R44DA4 2&--,!SAXAV;H(KD9J,1$IS 22N49!*^5-,BIQ%*=/&J%\I
M%"]]E#^D Z0=JIJ$+,\+MK5EE\ONYLF@S_F\WE^XMRK<IWY/9^?H&4FN(^3V
MJ7G_ .'VJ?FZ\Y>\^(JFH7S$,!R]B'F(/M [#XAV3S!V'P$._0?0<\_,'Q^
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M._B/JD'*=LWM13OVI3^TB*Q(GNTR"I $10/'5!&:6;J]AY1!V+<A#>BAR9J
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MO>X'4FPJ;=;/.RM.H\%L9@SCC.).(CVCF;FWH1CQRXCHF$4?($32D2QLM-G
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M1K;L6@T%C]T[Q=JE3HT4C+%?VBQP\ T.F4.Q.FO*O&I%"]"'0IB?OS !>Q$
MS1?8WBJ\,: )VS/8SW8LJ4YTB16MJ])3YEE2CY2D1F7Y(:MJ <_0%.E,*E,
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MK0MN2N]]1:<N^TU]GR&O'&OM:[0E&+XT]6]2Q%RNE6J%8K4HYBG2UFGYOLZ
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M\0,41Z Q1$?@ "'8_/\ 3]&>0" ^H#V'TAC'P^.,901 /B(!^<0#_7 " AV
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M=^4P#T/0]" ]#] ]? ?R#E<8[#T]?CZ!^4>A'H/T (_F <H(@'Q$ _./Z/\
M7TRN/_\ 7QQCL ^(]?-^GZ,IYB^;R^8OF$.P+V'FZ^GKX]94! ?@/?YL8QC&
M,8QD);DWM6=))UY6QP-QG L:LDDT]U(4DJ#88M-FHL+\ZSQDDW%8'J?R8A3J
M*+>S7-Y"D1,;-?Y+GIKXL>_-'4C9;>1!D[-'JSE=81\2#XC94[4'[L9LYTFP
MJE**PHI++BF!@1244Z#,*U;SLB&M+C&NPX&\62U(*OB/)6KP4:_;NFX.3':*
MNTR2,<+1V1%4J"B9&16YTTDEDU3J**D3DH>7-6V'!WB J->V97+ AKJ^SL=,
MS-=)&L6*\'6)!\DL:1:23PS)P18J2C-51,I#.2)I%4*L=(I^#/ASV3E3M.N^
M%7M#4KOQ1)2X6^L:DO'-K8O+'8]JL_#W86F[3Q\D)39DW48W9M]LB+NTV;:;
MVDRFD'.K*S%3""+E^YE#1M-&32'*D_&)W'Q0X2\7;S;8G36Y)QMPKHG(S8H[
MAY,S,%R0WJ5[8+9%6N)TUJ^EZQVQ:9&5K47559&5V1M\E!UI+S$S&P$+8'B$
M!?IRI]1B\X>1MGW1M935_&.JW/BEH'D,UXV[;V YVY(0>\_NQ%5VK3>V-OT?
M4[R@!39[4FFG=QCXZ=:.MH-=@W!I7[O*T^MN'<578&U\L[SXXTEOGCAR#/K9
M75E?<[1X'<O=XZ#FM [VF[[R#T58=5:*GMJTECR"K2>OZW5]=6VU5!%23A9Z
MCW^UPU.VE#*ZQ?O)9VM'6IUN5->*1R0TI83Z1Y!<5-<M.2>R=7:,V-Q=HNLN
M0LY;:A>W>[M_43C*TU]N>_6;2U0=ZNM.N]@;%JE@V!9*S4]CU)]1UI^2JJ\E
M/PB,!,;W\3>3&U]J7S?FA>0VJJAJ_>O'AUK*1G5=7; F-F:CV!KW<T!.SFN[
MU1[-:*3KJVLEU7M1NM4M%2LE2;/H.<JRCQC*34)-1;W-$?%7OE_C>67AT:L@
M%^8<U0=EQ7-&4O\ K3A9M-WJG9MT>Z]U]J:2I<K)3"&SM1(OJ]3'TW+/EV*]
MR2.9>33*WC)(RITB0-H7GER"X]\49YM>YR%D+?'\[=T<?*D/B0[YAM3;.T'J
MV+J\?L75%!Y%3])K&Q+QO7=UHK4E$2]%;Z6K^VE9K76P*=;;AL5PPKU@FW/N
ME_'2V&KJ/B]M-GQ]TOJJ(WAJS8E^F;?R>Y$732VCI6_:PW-:]-RG'?5F\G>@
M9&GMMK69Q4'=TKRN_P#[R46RJ\_50EFIG2EK4J4L;1\;2J4CD=<M90\3I)_3
M=2;\UQQYV)3)W=$TPY8V:>N2FN&]OO>GM+5[7%HJ]JIFL'6TH,RS*<V'!3^Q
MHBJ;+GJBDUBH&J+WB-:YSZNNAH[DML^XMMK;NM''[3WB<;4CJ>^W6I"Z^N,%
MJ;Q5=ZZ=HM&&MO:9/D86Z"KE)@Z=2MEJ2R[.MZ_$E."H+-"%E22WL;Q:=L\:
MF&YZ7RQTOHG6&ZJCL3BK1-=.(7D-/R7'YR/+B*VC*5>4VUM2R:DK5DHK'5[?
M2NR5KZO7M?W ]D^YL QHC5_*6=!LQW'X'<[F'+S5VXK;)1M,7F-%;%EJ%8I_
M0T_;MPZJV-'(T6L;(@;GJ&>=46JVNR(RE=M*,'-4\U75LE:V- V6F)FG@:Q4
MO+RSJ;FIJG<UTB:'5:'RN@IB992+YK([4X1\P-*TY!&,8'D7"<I?]N:3I=(A
M7BR!!2CV$M/LGLH^$D;&MW4@<C88/YH; Y+:_P"2/A^(T/8%&KG'S9G*2%U;
MMJI)5*?7VO<9.1TSR%N$8T;7H]M+48C7""U+@W<W7AH#VT3$RR9+-KA#Q2#J
M+DX!Y4:6O$WRYTAKG3',+F+4MF[JOQ]Z;$J\%O)D&JM1\8--3%/6VFYBM=.Z
ME(-VQ-E6"3J&D:-$22KEDG*[#M5T*J]3HCZ.5C+6]RY#(^(?4:M6.8>R^2^S
M#[DV^3FKHVDQ$#*<%N*/%]W [%DM)U09XNO8:4U_RFC'"6A6C:M.ME6;:=]>
M3FS[/:*6UU>YBYR&V4YS\]=]\<[]>*)HS0&L]J?>BX:['YO;.G]F;JL.L4!U
M]JRT.(.:UY2(FMZIV(XF=A6=BRDI"LR,X_K]28K1RC2P/FQ7C)<\&S_BG<DM
M<2CS6NR^+&JPWGMN+X@RO$JET7D%8YVJ6MUS*V!M>BUJL[QN<OIB#>:\>ZB9
MZBLUWV=/T*L;*AI*L-71*<@\DDD45[ZQYZ;QVK&[1X]['U]!\;.0FN^8>HN+
M=PL&J=M.=JU5:O&TA4>96X]J4"S3>MJ'--*\GQM;VM*NISU6;6".F9*)1FF3
M*7.G'J:9[:\13F'MQ#AAM1M0F/'?07*_3G.C>^BY*B;SG[!M"<H5-X);@V#J
M1IR HHZ]JM<JEHE D*/NFJ(4F\[%C:E-PYH*7=I3,5'S4OW-X%7"QWW@WPTO
M-TGY*T7*Y<4..MMMMDFWJDC-V&R6+3M,F9Z=EWRYC.'LG+RCUU(2#Q8QE73M
MRJNH83J"(Z';9YO;4U?;O$AWW 51]MNI\1;OQ1X?:BT0SOZ-#K]]W%MK[S-N
MV!;9N>7A;$E#S2C_ )0ZNIK.3D(A^VB837LFFP:MQLTL\4EW5GB"7*O+[VI'
M+C2L[7]IZ+W=7=2R+7AO0>2_,^G6!C<]%T'?%;M!1U_H%ML&H-4H2\'K4LI=
M:1#0JMCAQ1@YJ3-()-6^#>(#RFW;->'ENWD+PULDUI60US'61W;I'D3QFWOK
M+9AZM7F;,\VGJVH;5;:BG*W:7AY)H%7V38JE=:0G[*1!I!3#UH=:/BCQ*W_+
MDO(ZNR%)HW/6?XIZTXI7Z^; ?\'MLZ=U%87NS7&RXTXIO'>T[M6GE^GJ?J>H
MV61@-?4^,DIB6>6=L":I'2K%(=D^,O(XUOY3P56IM]MNT^._*?@?IKF9H&SV
MYRX6D8DE=DJYK&\D\DBT:2C!KL&H7K1=\7@W#6/+'7D^PY-1DG(V62*GU%QC
M&?%(ODHQFN]636530 @F(W)[14P'4*F'E*(E >A. F$3  % 1$?3,#E[PBK'
MKIQR4FT>&]E[%PJU2*FGTLF)_,)E%0#S)@<@=D-V8P!Z?$,.2MM@!5(5)-<R
M8*IBH4$6HB=,#E%0@=( /9B )0Z$!['T$/CDB!>XPP@4K&7$3"!2_P#4RCZF
M$ #L"KF,/J/J!0,/T (^F<3I.RS/*R_^(-M+;NT>9$#J3B!R&+Q&U#Q]X16G
M;5:V2UEH37.GK9:-[V.$T&+79.U;W9;;M9-_4*_/'F]:TK5=4CI=S2I%Q*VR
M4?::3/(+9NYMI< :B_VEXA/)RGRW$#G,K?"</%)_AEN2[;:XZ<L=(Z(2OVZ=
M8R^VM+EA)RBI&N=%O,>2:38/-@2SV;K-,C:[)MF<)F7);?\ N_BQNSPH[-0+
M1R[USHVIP/,O<G+'37*C93_8^U;=I9CN3BYI.QS&VI/[X6S&D^;33#?KS=6N
M /=)E.LU2NJ-6PQ .';-M-/#SD]OK>7C4<GBR.QK:MQ-?\=]PT[0&JUIAZ>D
M#,\1>2>LN/6T=R,H<C@89S*7'<SW<58C["T:@Y=5JIM&QWSMH#8J&9<Q;CR-
MT-RHT_ML-_<C9.N[3YK<==1UFKZZK-:=\%M(<<9ZU:KUCLJI\KG3ROR<\RV_
MM*?MMY5UY?\ [L(NVFS)[3E7C7E2J<99!DH8H_*/D=3*KH+Q!K)O:_7N$Y1\
MD.7>M;=Q6F751)IFC:DUMKOF-<=)P6KXR,JR%AK^T*$IQ<JJ&P;,ZLK][>7U
MPV8A9$S)M*>E5IYX17KD71ML\'";6Y*WKD,V\0/A;LWD;M"$NZU/-6-;;HI+
M3CA>FSSCZSK%6A5:IJ)U [YGJ(:DN)&88 RJ]"L:;PUF<VN5LF;<KO$CY'Z6
MVCR!@M1<7]7[.UMQ;L/$.N;(F[CR#G-=WN\2_,*R1%.J<7K2L,=.7"N,S46;
ML$&_MLK=K?&,9&#?G& ;.)1BY9#CR_B3\L6FPW'$ .-&AI7G0\Y"36HJ]#L>
M0M_:<8#:_K?&+7_*BQ[BLNT'.AE]IPC*%K6QJYKHU18Z@F7\CL&3C5&TJE77
M"[QMOEP5Y46'EYI::V3;]6):9M]4W9OS1=MU^A>&^Q4(BU\?MLV?45G5:VUI
M7JPUEF4A.U20>L%V\2DG\@5;&]H<YS 3DWSAM^Q[)XEFU]1I-/$OOE#JWA]Z
M!V'5*-X?.\6>JG50V)<MW\IZY.7.RQL]NC4=9F9RSQ=,J4+6U99"X, 5K*R<
MQ%(1Y/\ KN$?^MPW_P <."W$^\7ASQNW;MQ]Q'M>X]N3FV]YR&G]@[3OFGW\
MO WO2NLM*Z[TW>]GR^\(-[6INO;-LTYJ^BZ?KFQHT8)O)+N)-\UKFTJ7BUW&
M4Y<:HT.CJ?36O*3LHG&56LJ;YW[-:CV[NN%Y&4.HW.3N/%V(G-2CI?=$=II]
M;5JA:J4PW,RV=;;/2+W%5BJMI!"FLKG$FM?&SB.1%ZBJ;1&VF/<G>:'(2GZM
M0HV[)^Q\H]62NM-?;5L]-ON]]3MM;-JE2:S?BZLG$A"O;)G);5D_8-:Q%N%X
M[L<X:IX?QM\03=U=T[K,M*I=OY$\@-RVKPU>.J)-Z<CY.'U@VNV[O#;IO(NQ
M[?2%EJJUS]&@694)B9V= 1:%TL&P;*64M<8^CY230KY93N?C+6*BU75E*OM7
MXQ::Y&6[8/,:B7-SN?D);JQQFKP<,=SQNDK1(U;9$?J.2V-<7NS;/9:J\I,
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M+9=H6O5M_=W:BVYY/1;.S7F_E@MAD69;U;15YL49)[9ET311HN4@\,G1\;M
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MKY?K'),F?LQ*R0<HM"'.FW*89JD>).BW-'T;K6)IZ50H?'38U$V?JBJTYRK
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MGYR5CXF$@XU],3$M(O$&<=%Q48U5?2,E(/%SD0:,6#-!=T[=+G(DW;I**J&
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MP?+L1<)-%SIVA_RYXXDMFRM9U_=>IK?N75-5M-LN.EZYLJF2.T8:/J,6C*3
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M,O?-RNN*N\]S;JWZW)=:#<;QK"H-K-#;MD:)H:2LUGBW$K;:BWM%X9:\@95
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,#ER54APZ+XQC/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g612051.jpg
<DESCRIPTION>G612051.JPG
<TEXT>
begin 644 g612051.jpg
M_]C_X  02D9)1@ ! 0$!A0&%  #__@!!1$E32S$Q,CI;,35:0T@Q+C$U6D-(
M-# Q,#$N3U544%5473$X.# Q7S%?0D%315]44DE'3%E?2U]"05(N15!3_]L
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M<!=Z0Y#B]>W*[TAGA,1K&?3KIT%&L]S\ B)7,3!T1(?/HOLB=#',A3BQ@K(
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MYW'%;0Q$[N\NCF[.SZV)$SDYN3BN7+U"E4KW[=EY"4'"S-*S(2\1&"M$.D+
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MO3:U_LV^/[-<TI4;NMOJ#%G]MQM^U(*J1^/JO_.S_3RJ*_8_U%UGX3"__O\
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M3_+4W]5O_?9U3-*4I56"GTU=_1I_TMU5I2N,O5?[U_S5I4]H?7;]*?CG-_\
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MT6T&6;QJRTME\F[5LQSUH<KI,=-ZO_2E1NZV^H,6?VW&W[4@JI'X^J_\[/\
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MZ-/^ENJM*5QEZK_>O^:M*GM#Z[?I3\<YO_B&-1FI2E*VS?">^LHCO\)9/_:
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M:5/#:$$$.%\*MK=NE\;&6-[UD,4'@](3ZH*9:>$6BV46X=4.EH!BV"NCY8E
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MO@$3YJ6]!+D@MV$[S]*[)$9GN8H,>4*<;DMPVM>EN )-D!.W@P\F92%*2%K
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M/F/7H2-[6D)-:E-M(>QQSUXVRM[/&^.-_P#/M:][^CT7RM>WE[+[-_1;RO\
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M%CN\IY'<D:R^02,QTB%\C=N1&KO(.HSUB[%L&,P?AGPVG@;D<)CE/#T6P;=
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MBS;HSRPT/ T^M#T@SO;>WN*11CANPU /";Y+CLADGG.8XWX=C0=BZ,^@Y/T
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M:?\ 2W56E*XR]5_O7_-6E3VA]=OTI^.<W_Q#&HS4I2E;9OA/?641W^$LG_M
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M6ZJTI7&7JO\ >O\ FK2I[0^NWZ4_'.;_ .(8U&:E*4K;-\)[ZRB._P )9/\
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M]O3:]O1>WIM6V;X3WUE$=_A+)_[0'VLC^[Z5M_H\_P!&]0RC#ZFD>?@,)?X
MWUB8\>J106&"_C.:F _ZNC7JN+4_0[]%1IS(QPT4MX= [SIAL-Z9+YC'9[;7
MF/' $:-Q+$*=#IT,[L8[R5Q;L!]MW:-:]<V3O\(-JAT?Y,>AF*7^8"E_%NF.
MKAKH0AGO8/92R^=3LL]&B'H1\+-8;ED$)K/T@:ESX/IA#V+/J%W)EMNPQ>;N
MUJFM/?0(1SR-#KV6(2TC>3DS:8XC< CX:5EQ_(Y^](79W1"HBP)MB73O5Z6
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MWHI<!T;UN9 WJ&#6K<=S0E7#^S!>EW,3T\-V[2MSGI2E*C9%?U>NH?[=B/\
M96V5).E*4I2E*4I2E*4I2E*4I2E*59IQ^K^'_BDD+]<(YJ\M*4I44NWNKA?B
M/ER6.F2T9?3=''3:PIF0%&<TVI_/#P[+F".8T!&I0LMDF0J3*0BT9'+NF_2I
MT-&AQW.NY*JUH\DV[%LX>*CV((=QQ?SM+7#HK$W/YG-_._-9'T.3S,3KM#7.
MLY<LI9]S 0I@;(RVM,CH6XZ1ED&L9^P/'T#.!R/)T9(ZB*QZ1)+9]<;^RQQR
M]7GC:_V?LV\_LVM?Y;6O]NUJYI2HW=;?4&+/[;C;]J054C\?5?\ G9_IY5VI
M2E*4I2E*4I2E*4I2E*4I2OSW?2MO]'G^C>H91A]32//P&$O\ ;ZUU.N)YXL$
M_$K[N:M_B=R[X0DVCKOSZ'S+L&"X$, 'KM,Z\]A)>PRXABX_C,E1Q[(0.+D#
M5$JHS87;:K<$8TVK]R;4KV[+[L^'A<#/'PGQM'K7P]*>^=(/VO\ (CKG-CL3
M*C4NEN2G@Z?'*6) /3%<ULRHE."$\4O"DB<<FU&EP4XZT#8F3M2)#HU2NF4L
ME8.&TSS%0)')RK3K-^TFPDV7W*&6!@&DK<L6*W_Z(VZ*Y6NKS2;]&G%4B4M#
M6FTM^:IRS=;71V1J<62'Q;35QC4:-T7(3\Y/N/.\K=HR4)-DNH,/H5XZ SQT
M$P*5PQS(HY'%Q^:="CK(\R-#$5.H]'JE6*LSGI.BL(?+M+8ZW2P\6V"-Y+*#
M6C$S1P'0T//R($*FYQ!7/=+;U'CI&@TH$&0 :RE;* <ZG9A,4;B\0*I #A]!
M)J\C2;V/;J1N WN(LGXXM>7$?9%Y$SZ!XA5M#:I?F!*ZXOJ9C>MZ+1M=6=,]
MX(F[!XT-B_-0ATNN#>AP<M6C!;@C38;\=.%A8LO_ -?74/K_ /Z[$7V+_P"Z
MMM^*I)^=OC^2_P U/.WQ_)?YJ>=OC^2_S4\[?'\E_FIYV^/Y+_-3SM\?R7^:
MGG;X_DO\U/.WQ_)?YJ>=OC^2_P U/.WQ_)?YJ>=OC^2_S4\[?'\E_FIYV^/Y
M+_-3SM\?R7^:GG;X_DO\U/.WQ_)?YJ>=OC^2_P U/.WQ_)?YJ>=OC^2_S4\[
M?'\E_FIYV^/Y+_-3SM\?R7^:GG;X_DO\U/.WQ_)?YJ>=OC^2_P U/.WQ_)?Y
MJ>=OC^2_S4\[?'\E_FJS;AZ9_#[_ /\ J20OL>7K,(Z^W]Z]7EI2E*Q@>,X7
MPF">&5U>3=%QN\2O#2,0$T9J'#IAF $=]#W* *PLI6-F6#8]9#A)'1(Z,\B#
M[KBTN%TSP*H_)+MMG?&^'7D4E\-B7.M.9D<@^.A)GB1G$32)9UY$Y\E5_"]#
M(URW]#CZPL)\36!XS&W"8)2&6!:\V$"PR=M'O,N7.+KJT;ERG5[#;'Q]C[''
MV/IQ\K>Q\O._^;Y6\OMWOZ/_ .:QSRYV?,4(3G',9'< QSF#2$]2B^;CH7Z&
M?7DI!.?(=&EQ1(70QY'R[GQD:6D6%M&X+8'9A0R2YNNTRD(8'!Y20[-BE5IL
M,P>+DGP'1MSDCFPOCTAF:+X8FWF03VR;'R[9*,8SL?)X^$-YZ6/^06#0F;#S
M@\!SK(HR^D9,Q#[<=B#4.FAD;.6T133 YK[4$.J7@?TQB($&(XHA(6ELU?WY
M>QZ,P1XD)^<6N/8X4IF16_M)(0$#,+&AFI=APD6,",-2@A2VJWX>E,2=MEPN
MMK_]0Q9_;<;W]5_]Z05_\^7KJ1V-[>5_7_&S^Q?[O+XJ[>=OC^2_S4\[?'\E
M_FIYV^/Y+_-3SM\?R7^:GG;X_DO\U/.WQ_)?YJ>=OC^2_P U/.WQ_)?YJ>=O
MC^2_S4\[?'\E_FIYV^/Y+_-3SM\?R7^:GG;X_DO\U/.WQ_)?YJ>=OC^2_P U
M/.WQ_)?YJ>=OC^2_S4\[?'\E_FIYV^/Y+_-3SM\?R7^:GG;X_DO\U/.WQ_)?
MYJ>=OC^2_P U/.WQ_)?YJ>=OC^2_S4\[?'\E_FIYV^/Y+_-7Y[;V]JV^OZ7G
M]B_W-_BJ&<8?4UCS\!A+_ &^JE!>,X. YLZ8GQ(Q;R(ZZL+HW-)*P,-+"0LJ
M!VBR*1V'1K2'H5+#K4LB#8*#+?O=$ZI>Z[%;UM6+M.])HWXHM4F6EF:&%#K;
M&1K;F=NU9;<]2%J0I6U'JSW[,MN[/6E1:=&C7GMVYY;-N6&O'+9LRRSSO?*]
M[WA;TGQY>5(BG".8Q-BL'=.ER,$;IC?">296-V[.*=AXTJ)I%0 7)BDC'([5
MGL4*#D#0) 9I%&!-O)4JUP39:&A%CHLCUWQ7.L@GYN9\S%T3A^B;>,B3AR2&
MN1$A,C0QZ%+"4@>@26HQ;@YG<D9$31PAD"1VO3%[WD&#Y1[Z#6[,]'DX\I0.
M]22OP*H*&<,$(M)F"*FN.8%=A<;D)M9DFV4GZ=A*+_@BYHD ^=6]E:U9$-\]
M-#B1R +->1+9=A*:@2)&;%@W@;4K67=X_P"?)#B&$2R-YA?DROZ*3(P=6,.$
MI2EZ1V>*@5_:F5I2@(I,,J*&Z72339<W/AM=\><6=<P/9JXCXYJ3L0^S*-MT
MV?F.(V':Y*6M$;)E;SN2;W=;E+,K*%[GM0),4*'->N4FFU6KNB18XI$GM^[9
M9,GM[3IMAK_S:]OX!H]^Z.ORK2C^^%/@&CW[HZ_*M*/[X4^ :/?NCK\JTH_O
MA3X!H]^Z.ORK2C^^%/@&CW[HZ_*M*/[X4^ :/?NCK\JTH_OA3X!H]^Z.ORK2
MC^^%/@&CW[HZ_*M*/[X4^ :/?NCK\JTH_OA3X!H]^Z.ORK2C^^%/@&CW[HZ_
M*M*/[X4^ :/?NCK\JTH_OA3X!H]^Z.ORK2C^^%/@&CW[HZ_*M*/[X4^ :/?N
MCK\JTH_OA3X!H]^Z.ORK2C^^%/@&CW[HZ_*M*/[X4^ :/?NCK\JTH_OA3X!H
M]^Z.ORK2C^^%/@&CW[HZ_*M*/[X4^ :/?NCK\JTH_OA3X!H]^Z.ORK2C^^%/
M@&CW[HZ_*M*/[X4^ :/?NCK\JTH_OA3X!H]^Z.ORK2C^^%/@&CW[HZ_*M*/[
MX4^ :/?NCK\JTH_OA3X!H]^Z.ORK2C^^%>\+Q2%A[UD0LR5ZS>;MBAGQ7/9:
M6$VS0VJU25:J2I<2-[==:3!0J0I-V^Z;#5GMR3Z_9Y7MCY5<:E*4J./6O+L:
M]G\^R#S5+^TETQU)6 QK(]@BZ)&8@]@)F@V=MF"!R7-;RD3X['H6;=2W'<VJ
M<5#?FK38VU9[L=^J[:&.0!M7Z'1N"1%"Y)E&2I,O1C#$E6IU&7L_/=H5Z&_6
MIT[?+9GC[;KVX[/++*U\[^ROY^?)T7BDO"NX-,MA=J9-ZU"X;,PB1I$BQ]LH
M;MN6Y-;661<5!Q7H37SRO[J0Z'K6A7X>6I<G4ZL;86B[JY!4D\P]<'\GE"<B
M'9WA@%YHC-J0:U?O[&4&,X41:SMJN]N6&W?N)#^33LG*7IQ3;]^"]M88_3N6
MY0L8,?:H[\S<(S(/E L_=7.L'RDU0WQ6.<.QT&C38^NPM*8FV%0R3E<LRZU'
M8Q=$-D1_>-8P07C9B3'C &;&HE<M)F4^_3<WLU*MOA\='#\C0,=,LTLFE:B)
MAJ2)S<FLSE<(U,,CY2FE-924QC'XC9. 2L(2!#S>-<?C(K-J) DB*#0 -=!B
M[F\X/3$X9.Y%@Z.I75(U1T@('2R),F2ZT"(Y.&!FWZD;EB[I<E[$/$34S.:A
M,XX:E.E8X(%*K7GH3VPW8XZ-..O\+P1'V5[Y99'=\LKWRRO>5Y2O>][W\[WO
M?Z,?3>][WO>_V;UQ\ T>_='7Y5I1_?"GP#1[]T=?E6E']\*? -'OW1U^5:4?
MWPI\ T>_='7Y5I1_?"GP#1[]T=?E6E']\*? -'OW1U^5:4?WPI\ T>_='7Y5
MI1_?"GP#1[]T=?E6E']\*? -'OW1U^5:4?WPI\ T>_='7Y5I1_?"GP#1[]T=
M?E6E']\*? -'OW1U^5:4?WPI\ T>_='7Y5I1_?"GP#1[]T=?E6E']\*? -'O
MW1U^5:4?WPI\ T>_='7Y5I1_?"GP#1[]T=?E6E']\*? -'OW1U^5:4?WPI\
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M,;TPA+R[M.Z3G<('W- _*+?DOBZ\^#8JW/MHLZ:(R)&V]"$4K1D&Q*B*Y$@
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M3&],(2\N[3NDYW"!]S0/RBWY+XNO/@V*MS[:+.FB,B1MO0A%*T9!L2HBN1(
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M\)3U+[B(<@32D-X-C-MU$C/&O02WH!-*(?&4$GD_LR.;I!#M4#;RN)VY)(J
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MV@#!KSWI#*5%%LW09#T@"A' UEQ<]F+?+&!.[Y^Z.*&.9VHUYMA6!T,X<V0
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<KEL<!/0T*]NW;G*RE*4I2E*4I2E*4I2E*5__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g419181.jpg
<DESCRIPTION>G419181.JPG
<TEXT>
begin 644 g419181.jpg
M_]C_X  02D9)1@ ! 0$!N@&Z  #__@ \1$E32S$Q,CI;,35:0T@Q+C$U6D-(
M-# Q,#$N3U544%5473$X.# Q7S%?5%))04Q?2U],24Y%+D504__; $,  0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_   L( . "K $!$0#_Q  >  $  00# 0$
M        " $&!PD$!0H" __$ $X0   '  (! @,#"@,$" 0#"0$" P0%!@<
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M-]$OD %F+(?>1F=>EI&'9RL38_4-Z7M!@\IZ=9SF%7Z6V?H36:"[L-:@>O\
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M/X<>  1$  !'ZCX#R/CZ>1^H^.4$A!  $A1 !\@ E#P _B >/ #_ !X]I?\
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ME7O<KG!C0O:S?;79>C%Z^_XJFMU;--9^9-[-JJE@JH+=[%RC4/7#QS ES_\
M$'AW^Y6X?\<MYGOCCCCCCEDW6_U^@-6+N?+-&2D'*C5O]S5R=L*@*I)?&/\
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M_'+>9[XXXXXXX$//X_S$/^'.D9UJO1TF_FH^#B64O*  24HTCVK>0? !A/\
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M!Y$Y0#SX\B8 #S^'GSX\_P /KP!R&\>TY1\^0#P8!\B'S$ \#\_ ?,?PY4!
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M3:,DNHXC=!;W8OO=4PV$NTO:/LQ5>^,T2D777&N!8GO?IU95HDS56>5M^O\
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MJTH&3:1ZBG5RV7>EY,XT9@VU.T.,PK<A%P]>TB8SZ!TG7<:@]WH.<.=>?4"
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M''''''''''''''''''''''''''''''''''/A3YE#Y>?UT_X?10H^?H/T^O\
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M+6"U553.TL_K>>:U8H-C$UZ)%.YP]E<3D9'=MM_1/<=\ALH-0L5N&$RF*/\
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MKB;[J7\L'J@-S)K!G:QU&J79FU;6:"B; V:+*O8TT@T0=GCW;J.>19Y&+<F
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M>IK,6\G&2C99E-P[I!)RWD&3E$[=T0[98#(. 6;**(.&RI13=(G,D<!]P^=
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M%FD)C-<PTHQMNR!-$I_>2-CHJUNB76JM#"/P_B5^WD!!,0 C4Y2%*'[)[;W
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M;S3JZ^ 1*9E>DYS/'9# 82^U1"\1$ <AO/CR4W@P 8@B >\H#(>NZQEUO/\
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MF_V0(2-DW!S";Z@ %$1#Z!S(Q5"F*!BC[BC]!* F ?X@)?("'\0'GU[B_M$
M_P Q !_D/*\<<<<^% \E#Z?[:8_/Y?10H@'^8B'@/V"/@!$ ^?/+?Z..DO\
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M@0_O(85402,H78.7Y@ _B'G^?S_]^5XXXXXXXXXXXYQG3-H^1,W>M6[Q _\
MMH.D$G")@_ R2Q3D$!^@^2\CCHO3OK1JA5_RTQVER3A?SY>MXI*.>)G'_P#B
M)K,?@E*H'CY&^&(^0 ?V!XCJIZ:V>UTXKX[LO8#%U@ PHHTW3K $2@81'V@2
M(4?(LA2* ^!2,F8A@^1O(?+G-:]=^[5,=D6JG=.2N40T24 (+1L^ICUX^31;
MK%;(FG4H)1X5P98Y#JNEG/O<"D0BKA+W_:$8[==*YZG>7UJ\F694G1)"8O\
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MK[:Z1M&S^%LFBCN^ ?(?L_: ^/Q ? _C^T/F'D? _+R/UY7CCGYK&.1)0R1
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M!.9.E-46T-;C$P%/3RT_Y*3K.#E:5<5M+.I;8-*2J:\?%O%]GH?,/G]?H/\
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74X[FK?+27H[XXXXXXXXXXXXXXXY__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g197595.jpg
<DESCRIPTION>G197595.JPG
<TEXT>
begin 644 g197595.jpg
M_]C_X  02D9)1@ ! 0$!@P&#  #__@ ]1$E32S$Q,CI;,35:0T@Q+C$U6D-(
M-# Q,#$N3U544%5473$X.# Q7S%?2$5!3%1(65]+7T)!4BY%4%/_VP!#  $!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0'_P  +" %A F0! 1$ _\0 '@ !  (" P$! 0
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MKGJSC&>K/5UX\/X!]  %=+?]MOBS\J,V_<?98L6
M                        #5%SD]MQC^3YG^L$I&K+I.^0O'Q7S0LRA.1G
M)SI:)&H@E61BX(7Q6Z.VO9W (%#H*Z14C4^;V?9-'-CG:UENBV4,SRNW?I=)
M6.MH*0X(64B*87M*U]<+5="HRM5H5M$>4?'3D?TBR;CQ,6'N7,.+72"*'&VD
MY4L=X5#9@PS>@K;L5G:[+31!NWDBA/O)HU*9A4=H:J'$QG8VA<UD.97H   %
M=+?]MOBS\J,V_<?98L6
M    #5%SD]MQC^3YG^L$I$^\P^-7$SE$HKRL[X5$QFWGHN<>I]G\&GKA4G)&
M*N;;&]SIPLHVRXJO:9R@4)(TORNF,8;5;G&))'M#B9Q%)%&REJ360N(J3C_!
MZ6BW'7CG8K-8D*XBLD1XO+=VZ7,<U>8B[55!(JWHX;.G:/:$MJ>>-L651Q=(
M6ST(W*49CFGV/:VWM^B0NSP  KI;_MM\6?E1FW[C[+%BP
M  ?G;;737.VV<:ZZXSG.<^MC&,=><Y_%C&,9SG/K8QC.<^# _D2I(4%:'D&Z
M'DF8ZRS2=L'%F:^'^-IN5G?7?7P9QV6N<Z]?\7KZ_ /Z8,TSODK&^N3-=-3,
MZ=ECL\:;YVUUWSKU]EV.VVFV,;=78YSKMC&<YUSC'[
M       !JBYR>VXQ_)\S_6"4C49_=(4;NAP@B@FT.0/&>OZ%?W0A5QE:V'B[
MR,MCG1#K4@E;+)M9TQJ";4U/632-;-D5C<O>)/(W-(TP1KK+9:TSY4L3[EZJ
M=CW0-QIBK7AS**/:'_CL[+J&NI_JB3H./U#37CWLU2..02O<K5MMQ>?.;N^S
M.U)H2I33]7;*=P5,%AP^41%TCY^S82243NR  %=+?]MOBS\J,V_<?98L6
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M*F'1P^Q6R)K#]U2R+M\X-;=Y0BCJM4:8I4LB9U*;%"@S<XU+N9OOMM(
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MN/UHO7]L+_Z>O_[0O_\ 'K/\/7_]<;D"_P#LR_S-?_;@?L
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M+1%.\D7-R-,J?G0M&44D+<'8Y8LT2EED:G8*UQIB'+?]MOBS\J,V_<?98L6
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MB]1M9BQ#7-?U.PI&>N(:L7Q]J<#(?6L=73B2%JC7.P)TI?ID[X*6NFY6NPH
M 5TM_P!MOBS\J,V_<?98L6 T^\HT"\Z])L:2@7G%[8CW8F$H5AQ>W5&6?7/8
MF%$;Z;=6V,XSV.V>K.,XSU9QG K_ -RW3_);I_JQP^[!W+=/\ENG^K'#[L'<
MMT_R6Z?ZL</NP=RW3_);I_JQP^[!W+=/\ENG^K'#[L+ <7$"\F](2:<@7DEZ
MXD/9&'(5A)>O7&7C7'9&&D:::]>V<8QV6V.O.<8QUYSC W!  #AN'A0+<8QG
M.<I3^K&,=><_R6W@QC'ASGX!%O8;_P"+,_T>_P#RAV&_^+,_T>__ "AV&_\
MBS/]'O\ \H=AO_BS/]'O_P H=AO_ (LS_1[_ /*'8;_XLS_1[_\ *,[C&,X0
M&XSC;7/HK?P;8SKG_LBO#U9QC/5\(R,          5>D'LZ]?&KA^UFCJ
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MEK6\_;!*LDDWKTQD(           *O2#V=>OC5P_:S1U   "1:R]G5?Q4?\
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M@D0XGS&5N\[2R*0WD7-9X8G:'Z:(8Q-_1!C/7C&>K..O&,]6?7QU_@S\.!]
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M1>=GN6;/_-B?UVC@\[(   /09T?ON8H?\>3CZW.HNH  (^E?L@3^B:?K3AC
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M658X)DY+ZCCDET<8JY.K7LI;2I.Q2!DU4;K69=H5'5O^VWQ9^5&;?N/LL6+
M                       %7I![.O7QJX?M9HZ@  !(M9>SJOXJ/_:T0G,
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M+H<;D[51D\WK.*+V%R@                       !5Z0>SKU\:N'[6:.H
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MJ_%U?@ZO6#&NN,YSC7&,Y]?.,8QG/5ZW7GU\]7PBNMO^VWQ9^5&;?N/LL6+
M                       %7I![.O7QJX?M9HZ@  !(M9>SJOXJ/_:T0G,
M 5%YV>Y9L_\ -B?UVC@\[(   /09T?ON8H?\>3CZW.HNH  (^E?L@3^B:?K3
MAC   #DHOYZC_2TWZ\L2^ U1<Y/;<8_D^9_K!*1W')GH7NC&YAV_(;\Y*<4(
ME:5M2AOC[9()F[3"U&E6XH(HRI8^P$&M\8GK&R%X;69"E0E&)VPDXTL@LQ08
M<?C)N90X T1P.XT0BY:0X#1>'PF%U[?4C8KFAT/?YG(2XU?)<*@2F1M3ZJF[
MR^N*9_+A2F!'J42)?LV%HE" TG3"DY5G:^H  KI;_MM\6?E1FW[C[+%BP
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MXBC5IE69I 7J(N"\XAU<5[:@XEO^VWQ9^5&;?N/LL6+
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M.J_BH_\ :T0G,  5%YV>Y9L_\V)_7:.#SL@   ]!G1^^YBA_QY./K<ZBZ@
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M_)\S_6"4C7?TA_0Y<W.3]H](2=17([C)6](](=&^*;'9[39=661)[483N++
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MX\R!%J[';H=TB+:8  *Z6_[;?%GY49M^X^RQ8L
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M]9!T]656P2AJD,A3R25-22'16Y&2SH]6V6U>V[2&'(VZ4NL?;GMW<5;GNV
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MXDTC?-YP !72W_;;XL_*C-OW'V6+%@
M  *V7I<;PUQ^P:WX^/\ 2\KY<Z01<\5C4$_L)I9]SW57H40T2.71MN="IIO!
MVC*C+Z\[-J5$<[-K<>V-SLWJUQ"Y/JNI'F?S#N-KY1U/5]M<:;B?J"NJJ*\E
M/,=XJ.34+ :CALFA<MF=Y269<:9S;Y\CG"ZE](HUML3>6*S(W ;"WLIM/P]'
MDU)9)JZ-TW21<WUU+0V4UPS5G=A*NZ>2-<5]?T)XN\B9M5',\BJ'&M4=&1^L
MF>L)N[IJ%+Y&+959D50\E)M+YQQS8G6D7R7-BIVB,P9-$.T[BKRM9^0\MM'&
M9Y69*1<[F2&BZH0OC+Z;ZKC\Q93PPB^9A'L/RE\VAEP6(AE+Y5SXG8$4=6UE
MM!78IQ6N4F5$I+O    #31RHX6\E^0O->UY%6]TO7'FGK)X 0CC;.IFEKJ#6
M>GFQ3W=-YN<[C<<;9(_-2^&65%(5)V]7#YTJ1O\ $6W6;..7F&S)4F1)V;BJ
M>#"*CI]F5</:LY'\?IRT1JK:]?K2J>S^/C[%;\AM*0.-5S7B2X:?NN8KXU+-
MFV%1QOB^DH(8Z\M!*02>J;IFW&&X,-DB*=' [$7/%IRXWE)TG'2.\E9GSBB_
M$Q9!(ALLB?*&S6N3KI$I=KJ9WY0X2"M(_85@SNSF*ND# FR18CUJH53Y_AC0
MRQE/Q[QZ."U;?*)=6WF;+X38-E<6T?#SEK8"6F*V<G*_:@2/$F>27F,,:56P
MQNDK::S+"M!!&YFQMTLCC,VV Z:'0)S7L\9<&CG67T;4GLES75@OY1S,G@\^
MS*BIN]<4%\&9GUU:<T!BO%L7K6M+U6R$J25Y2,CD530233.!DQ%]?E#GK,2X
MK.XDBFB].DVI:XQKCJQ^/;/]>V<[9_VYS_0/H#5%SD]MQC^3YG^L$I&I3I)X
MD^\@.D"MVL.)?'?I!^5-R5E6=/2GDD35?2I._ /CC3I,XC"TNJ(NR(5I4@;G
MRQ9I&XR;(GEJ:&)N(SHN)?5[B?NJ=#D&QWH,$-!M_&F\$U/0+D?55BH^6EH,
MW+FM.5EHGW/<L+Y4QV*5TPS9M>;0/4J])VS+H8WU\]1F6I%)R5_9')(XZ^AS
M3C$A&ZL  5TM_P!MOBS\J,V_<?98L6
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M%L)&,+U"H[&Z;<S91OVSL=+E@ "NEO\ MM\6?E1FW[C[+%BP
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MYTW['7?L-\8SG.NW8;Z;]CMU9SKMKMU=CMKG-=K?]MOBS\J,V_<?98L6
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MDY&)$>IRC1 @6K-B\)DB@TOL>RUQC&<[8QC/5U9Z\=6>OUNK/X>O\'5ZX^@
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M<YH<V9>B8BWJ&I\5DK9.:SZ[.I<?2[FN^[;KE?JCRDQDX9X;+8L1)T<*.DC
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M'5Z_7G&.KP]7A\/@\/@\/X1]Z\8ZL9SC&<]?5CKQX>KPYZOQ]6/#GJ'T
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M)S549F#0US0%$-"/2+,;BU,.$N3237%QW. -%_*YXKABZ4V*.'*-PJ1KA.O
MYSQP)<.3"AA0\?DG+K2VI=B^<$+Y5N4VI;D55P;0.K=W$-UL RHB;*U@^=$>
M)G@W54LL^ 2CCA#F=AQP)K.$UCTZ#=&U4R6&SJ8='@\N\CX<S*QI5-H]$K*E
M\/0,E9/,PF[J@96N!26.5F^6:4?8,7.7G2IQ/=LFYBP;-]0?@?!>/]F\$IU=
M$?YS7A;%8NW1U-#5$*M:[TI'H\[XO:@FJ;M+79-DF;3Y[GU6M34Z*U[ZD+=(
M4Z-J0AGT*1&J54L\0[92<Q.F!X[=(<R;/A-=<E^+G-^J:";7OMR<YOH[C"JX
M1-;DHRWG:$;$*7KDO9_(S"@_9*68>C8&GJWW*UTSG9KR&K%H:NEAZ.ZV-'^?
MKWN517E]#%$:=[ E;M6[.UL]+QAQU6Q.M7!U-A45DCJI++Q(9.R,Z-]?TY"9
M&[N"I&G())T@M&IM2V))YQQ:MCB+ROY$\J[-Z6'"9JK[BNQPSG/Q@L3TON5=
MJQ^P][/D;GB^VI?6]A,D2X[SADMF*1ED4ESZO(] -42/N-I,]A'1EE\5T/+&
MIM>#1\ VK1ZZ*>M7[DIM4!D1.:'2X,V;"-*5DE]'0WL\+.1;LP*K_P /;O-3
M#9^\)$SYE_/4ZHB]BNMLZ><O+ Y*2/5DYN7=5<,>NE=]0,TUW7T0X^ZQN*T0
MX\(V^\WUV:5DNIV5299;AD^3*U,9L![?7-/%&Q?NWD1ARU3E'9K,Y<W.2Z)F
MFU>VGS]>^/VW&3C7SGL6H[CDC)Q]:Y/S,NKC]S;Y1<<8;'[%0RRN3(E.&RJJ
M]J"J<V-6=/M5>RNP);;[:_FKVXL]B2D^COA?8,PMGA[Q2M.PEV7.>V5QKHF?
MS=RV1HF[9PE\RJR*2.2KMD#<F1-Z'*MZ<ERC*-"C2(TV3.T)4Q!!996EEQ^=
M_P"]_KUZ_6_O>RQV77U^#JZNOLO@ZQXRWNPJ.@O1A78Y6XBX42OF]&K-Y*RW
MI!(!R7>I!'^7$PY!1&Q+"?ZY)J)?4YR2[66?*M&R#F<6)HP[)6F'U%I Y)6R
M]J8&3*E)/LAF\)<^;?.M_FEL]$C62B0.?$20;LG2&P]JG%B*4+IPFIA>K6PI
M]=[NK([O$)W./0D;&-+L6=(D\A7&NF<F[HR8>=;CG/$_F/THM_4RI<79=S=Y
M+OW &JRX^=JY,>>7AG#SAC.> LB)]"84HR69U36]?J0]S(P2A/:F9C,]%9*P
M3OML8Z+1FEO#WHNN1D+X[UF_7_,.-G*CI'*ZIVLT3PTH7JSWJL.5UJPN)-ZQ
M\D3NUMR360K6I,Z/[@J<RSBD)SD8BU4+<)$QVLAA;5LNJGI+*.Y&2NPN.2RR
MN;'1ORV\>1_-JIXA,*UE%HO\5XR2>3Q:?5W +<FL5AT,L)Z@Z%IA\'ED@8Z#
M@U3R"N*_F4Y0+5ZEM4294KM0;E;-+4QR;;.%\@X)5#S*YE5F;;4+IRFJ7X3<
MH[G0\3**G-13&U(#LM<J3=[/KQJEG(RI%3FW*7"+.-GU0>JCQ#1(V#5E8KU5
M7;UITQT <FMVH9B]QF6U_1?(!XXX3F1M;9*E;)6#1;]CH.,4A3-,G2+V:11U
M!2VM=*XLE=$JIN=XH6S8-R8F/T-$=NS]S IVYKOVTYY<C++CG%_I!.CMI./0
M6<QOC;EJM& <QG/BXFN:-V>XQRCHR\.6"]KLD!-4*HVXQ%17'H1LQL?(=,*-
MC,'X7<YK\LSD;T;!\AYG^F#*.:+CS'>^77#C#/3)K?QB>ZCK2;.T&JV--S#"
MFNWZI3U9*&?O$FB*R9-(Y%8LR8#7TQX2E)7EL<-LO2W^FW_!Q\LLTGWZ=^VM
M9X,78K?"G:Q#*T+D\=WNXF 808RZYG!U*:V$5$L,G8OW=[=#W"W+=_06^NLW
MTW>&\8YL]&>AX?MG1Z2^HY-*UE:46KXP29Y9[]KN"R:C+4<YNXRG2HU)-;+Z
M+7+XU&V8F V5KLD>;$4LD@+:S[!A21:V5PZ+N35P1QXX]I55T=$0;)3:+L-O
M00&&PI@;.D *E*JO[(3MS(9+3;N<EJFS$JK?KL#8JLDZ]W;2Y.B):6K=1Z)3
MZOL&2G/0O?P8WHB1YBOJ /X6+T7@]1EMSQ!]0YZHG$1PZ8SU=K_A./\ Z)X;
M_1N3N]?^0]#Y3>$>N'F"ZTI#^CW2VC=5"57R1/KVN*U.J>M;:@$5G['([WL!
MMB]44_'TJ24M3J0S*YK8<ZCL-6/C>44O1,[\Y;:&;$X-+WU&<I.#7'6AUG$6
MEWODQP@X_N]'<8.7]PN3-REXDP2=T]=EQVA.:@D]S6O'(Y,SZ]H]B(;91&#T
MCU$X:N.M:#5/+D3%!VA@BR@I_05BFT]K&U*-Y$6S>-;P&C^<+GQ?Z*N;]'14
M!C/$XW95(KI96\%>(%">$D;?"2)U%4FO+ ^RX[)V6"HD#H:A1MT7G"79(VE(
MB/3KR4WTL2X.+7'LO90H0O5BN'(>Q4)&Y.Y9E><:-VF1QPIQ),V[/1(NY"R:
MC<E8,TW+7$-#HF++VU+.,(TM=+0T,LNYC68U7>^<%D53P+HWBIQ5<>YZ,,PD
MC),9,JM"X-+Z;..QL;M.KS:VM4]DCM*-<OOB'J)C;M4)7*LMH)"S,R)4J6PV
MZR"CYO)[.LN>L;1#.D35](+T42SBC$K(>V5ZY85[0DSBG!9X9Z\K5PDJA18S
MA7!4,D/+)KNU0F_ZODZ]'R#=+$T,<4THV22-P]UI+'(3@$_191$,](0_\S^D
MD:><Q[,HB.]_N%;-C1RJ[\FKD9JT&;S'-91FQFSB^EJM),,ZL+*BQ3Q$0T(2
M+V7138KI,+CY81FVN4CA3/*NPJ.CO%SB[PFMR$P:&PNFWV.2VR[YY.WK5\R<
M;+43ZO95(I'%>\F",R!+"VM\CB##EIW8PN+5:9T,B>:7YR"JCDHOX16+SRM2
M!4$9S-<8:^\UK&-XYQZXXE&,<!:MY-P[C^78;I3C72K,OLRUI)-5K%)'^LLR
M4Z PM]K^/N&712A<DVT'HE;XLSDGPAA5L6Y92*X9DX6WRHB6+-;8W'XBWS:)
M5ARFN.LZ[D2&/Q9(C8D"-TK^(QE8GR@*W*6%':K\J%6565!E#[9?J[CO2/<Z
M5?)9XXPLMN&\<./6.CK7<W%C VTABG-XY,B^1R*%+GC<@_#CM<6CF?R$(AYN
MTP,B!E-;23MD2+8]"=;47L^N):P]&TH:5G1[4=6\,E?2\UK#S^3Z6:3[AX>S
MPZWJ@;68ZI6.W[$KJ415LE*?!CW3T3,D"9F@U:F*(W$(T5$TC.E;Y-Y@[(CK
M8Z,*^*<EW%RPY5PRI/I'N6C8X<'43?'N/DG44C<?"PZ[H!#&1FF<ZT2N<LXX
M32THI*FLV4N:]=-G719VI*<I0I"9WZ,60G6YTL7(3EN:M<U:+FIPB:KW@6'-
M.H;BRN/+)R^L:FN+1Z-I49[)K*E-$UI$[,6%9*+/V<K$7868W.)Z\5QL=OD,
M=YB$M_'1EXK6!RU*Z1GE9(->14+L=X5<^'B)/U1<A'UZH6SJ7D57-$C8:KIB
M.+*Y@NLD?K-=Z#=J^C5&/%7QLZ13&(&,$/.Y_'%DX[PAQX<O#8E*DG0\11[Z
M1QUHURCW?@N0G\I.$J:=RWDVX1$_NCB_-JP=N>>DD?)\HUGF$!-REJ3\&M3A
MJEWL='*GH9JY7=(<R\/"ZW1\34:OB4ICC7094.(X]ME\.583'-SE5\EKK32#
M(Y K@Q%#K["3,>NF^SJK;'!UT[JKE!IM&JSD?-&^; H4IVZ0KD?"&OE'CI2E
M4D9J_AW&-L15XT\,^3+?7]#M=6&O5#R!<QJRF%U*262^R%5+'&P4R+"<W#%L
MI-/UJQ;?27<K%O%NV[Q?^;9/&>ZJ%Z,7@[R!H"LDL:HS1LYAVQR*HG><6Y9C
M[!I["GR0SMLWL$A?4L$BM1N\;9JSED?>'I^;GHY8@;M?8:W&[GH$1QAG;=S4
MB4S<W^)_*;&)R]]M_P"3UUT_C[;9V_B:ZZ>'^+C&O5C'-      '\CR"5))R
M9044>G4%&$'D'%Z&DG$FZ;%FE&E&:[%F%F:;;:&%[Z[:;Z;9UVUSKG.,].]&
M1MGC3J;(-V9MB36R+C7HQV] I8^@CR! :8XF.7HO&C<F:$;:0=NKRIUU1$(B
MC,FXU(TVQB((7&^/5TL;->\;KZ R=)<D7KR:HYPZUHU)9%,8TC+:996;H]'2
M".II.=JS8)97V+II!IHMCJ@AO5HD[<K2D9)S]KJVM&)PFKNRU]!V=ULDW)UA
MN;7$H\W.$[/V)/39-F:U&VDJ94;LG5*$^=W\UQWV)4'DYSG0XS7>@\2Y<]&1
M(F.T:)A+M4CI#:DA%I6%+*Y9:4=RJX=8!7CRHC=PRFMV_-<I:]N6.Q)]5J&:
M?.-0FSE&VN:W"!Z,U4N!12B\ZFM*>F\0AK*K@E;RV!QWN ^P!K416*/\29.Y
MB33>+/,0;SFY8R->6]":5NP.+(0GRC2&:9;3BB-]>N3L8QCP8_\ GVYS^'/K
MYR   XJY"C<T2MN<4B9>@7ICT:U$L(*5)%B145N0I2JDQ^AA"E,H(,,)/3GE
MF$G%;[E&Z;Z;;:YPJ(536-?L6(O!*Z@L+C6O=7L8]$X?'(VQ:]W>T=VNQ9V5
ML0MV,N_H5-W4SA-_UCZ'(PL[?@DKL(ZG:;CG1+!B92R)U]$&UX>XI6R52W5^
MTG.;\_VG*V2 Q6&M[;'V!2[/*R72A^9F0AH3)5):K=3@U87HB3*5!$TFQ^/J
M35QIS(U''.9[:>XFG-2,S=<H8C"S&@]88:FSE4:U&DE&-AI^QFZ+<LLQ'L5M
MIIMB,[[*H9#6D@FO)!OK0^JZQ1JK&?WJUV6.O,3B!,72*%ATL.Q)4#@B;E;2
MFR?LG<4Q.K@7L;DA'ML<?J497>%<M.#/) ^$3MDD$3F#[#[G;Z<BRV=U3*HS
M8%6W'-(?WV,#&K8[3@D>L"J'.>18I$;%WUT:HTVS7#@P-K([.BQY9TJJ\QR-
M&J,1GJ$R90:@/RK0FG$%&F)%.Z8])LH2&&:;;)C]DBI2FR<1DLS*=0<3G;)1
MQFFT;67446LZN956JQ5)(:W2>*2*)%26L)&YUQ/8FEDQ':USG!9I%#6][B;V
M6?H0N(7-9^FABI.5W03+TN3DIT#<3.$U><2E%A/S#+YQ9,^M$J%-LNGT\15E
M'5F\7K=&^)8'"XY!J3KBHZDA45CBB52Y]PWQ"O690^2R82J629:\O[VI6XN6
M PZ<UY K.83(M9$*B4_C)RE,L.CLVC3)+&(Y6CVVW2*C6>0(7%M,4I=]]MTQ
M^Z;)Q&VVV2M],[;=?]%<"A"]FTCJZ'Q9:P%Y09+9%<=9E+1IEJ1$MK9V#8>B
M,0Z=SF].G0H.Q3X]!(R"4J;M2<HLO7\L< @L7QIWN0V)Q_!2W+IIW%C;(TX+
M<<H3FS*_7N>@3=@M[FJ#T&5>O4HRB..29,RG-W+VQ.O)G4DT=ILRUT:Q.2VD
MYDYU;*-V9DPG1168*F&,36011O<M&\A">I(;I+'%4E*85"A(C=S\M#P86_-B
M]"BE U$B4*$BTY(F.5(NW^@E)R<K=0D]%%X)4^ACC"\G)_1!6N"S\%;%]M+Q
MC0SLM<8P*-S/E)P+H'DKFO)/)ZU@O(VU%==L$D=VNNG39R5N=B.9S)4T=MRW
M8M"UD:B+O.W-!EOK9AM>;L+C*U6J,F+(E^RA#DZP]*J*2=6N9OM*,L09TJZR
MIZTV#B,1-##W!5:4/DKC$YUM,6XAJ:'%5*"'II4%J75Z3G*WA#L@>$BU<T.3
M<N52MW&:.V=N[EMW;>Z?=GMOH%)VSNOZ%] ]U.S[3V7='T%_T/T=U^B_0O\
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$ !__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g363356.jpg
<DESCRIPTION>G363356.JPG
<TEXT>
begin 644 g363356.jpg
M_]C_X  02D9)1@ ! 0$!< %P  #__@ _1$E32S$Q,CI;,35:0T@Q+C$U6D-(
M-# Q,#$N3U544%5473$X.# Q7S%?1T5-0T%"14Y%7TM?0D%2+D504__; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_   L( 94"20$!$0#_Q  >  $  @,! 0$!
M 0          " D&!PH!! 4" __$ %X0   %!  "  P0"P<" P8'   $!08'
M 0(#" D1$A,8(3$W5W>5M='2%!4V.%%24V%Q<G:1DI>RQQ89(D%6EK&TMM;7
M"A=5=8&3U=3P(R8R)"4G0I2A*$-%1U3!T__:  @! 0  /P#OX !!'B!2_),7
MQE%#8B1R8F(^]A-GM?-;TZ2;TQ#7#,:I$JOC$7>3T1$)SD%1MK#M3F4CN(DR
M"C@3E)#QO)203RLDK! GG2#U;IS9KB&D24@M2/5I.DU,U7V:V'AQXSDX&G#5
MQ5UX644@>4XGR;0YC;EAUO1;'*9#DJOY.F>6H4:]5VUSQN16TQJ-W(=Q-A\6
M$:;[<MJ>'3)"*ORDDWR2YEM2DICP'F*)Z:XXK@.U.:*?'Y95N+$K<RF]G(UU
MAG3-*K>4%M9<T5JTVMMEN$BWB&-O%SV_EW:F'&XY3+/5CC\Q.(L86"]$TK#L
MOJ-YZB 9Q%%@VD9DYC&BRVF$,Q@K3.K)&8ZF4L-D\M#=<1LM?E_QZJV(?:2I
M]04Z_P!.0ZJV(?:2I]04Z_TY#JK8A]I*GU!3K_3D.JMB'VDJ?4%.O].0ZJV(
M?:2I]04Z_P!.0ZJZ(/:2I]04Z_TY&'J6^.L*,>,IBP^5])4R=],9M.5(OE5/
M/E<EV.S+;C,DCC+PF2]]V+)CR6V9L5EU<=]E]*5MOMK7X?Q@FIW=)4/J[DO^
M4 _&":G=TE0^KN2_Y0#\8)J=W25#ZNY+_E /Q@FIW=)4/J[DO^4 _&":G=TE
M0^KN2_Y0#\8)J=W25#ZNY+_E /Q@FIW=)4/J[DO^4 _&":G=TI0^KN2_Y0&;
M%-N(6/E2QXCGDPZ2.8,1HH<)P3.!HH;+9[+<F R6,X(\R8#!?-CNMR8<V')?
MBRX[K;\=]UM:5K]'56Q#[25/J"G7^G(=5;$/M)4^H*=?Z<AU5L0^TE3Z@IU_
MIR'56Q#[25/J"G7^G(=5;$/M)4^H*=?Z<CXS>WT(I]Q*P^<D<C>I'\"4G6G(
M.FTI<H*AJS-E+)I&TQ'V.IQ0,8RYC)@)%J936;'@SWXL5UN+)6W[.JNB#VDJ
M?4%.O].0ZJV(?:2I]04Z_P!.0ZJV(?:2I]04Z_TY#JK8A]I*GU!3K_3D.JMB
M'VDJ?4%.O].0ZJV(?:2I]04Z_P!.1^8<W)@9.S4+J"L_B!BMEN6F ]"LT%,]
M<=];J69*8C# QY.EWUMNI;?T/0W5MNY5KRJ/DZM?7C](WE]3TP_R('5KZ\?I
M&\OJ>F'^1 ZM?7C](WE]3TP_R('5KZ\?I&\OJ>F'^1 ZM?7C](WE]3TP_P B
M!U:^O'Z1O+ZGIA_D0.K7UX_2-Y?4],/\B!U:^O'Z1O+ZGIA_D0?KE=N(6/8+
M#1+/)APKEZ+I1DI!,X&2^3H+JV7]+SX8\OQ7]#?;=9=T-U>AOMNMKRNI6E/]
M^JMB'VDJ?4%.O].0ZJV(?:2I]04Z_P!.0ZJV(?:2I]04Z_TY#JK8A]I*GU!3
MK_3D.JMB'VDJ?4%.O].1\2CM_""01,J:L=D9*326.F4XHJ4'38GD"F*[)9BM
MRFCIN/L)8OCNRY<>*E^;+9;7)DLQTK6^^VE?NKM;$-*UI6R5:5I6M*TK 4ZT
MK2M*\JTK3^[GK5I7K5I^:H\ZJV(?:2I]04Z_TY#JK8A]I*GU!3K_ $Y#JK8A
M]I*GU!3K_3D.JMB'VDJ?4%.O].0ZJV(?:2I]04Z_TY&(.O?#6%A^@/PZ?#@9
M7IIZ)]*_PPBZ56OZ9>@^D^B_2_T]91#T=Z$]$%_17H7IOH?T1@Z=T'3L?18?
M^,RTB[N:5^K3V_EL/QF6D7=S2OU:>W\MA^,RTB[N:5^K3V_EL/QF6D7=S2OU
M:>W\MA^,RTB[N:5^K3V_EL/QF6D7=S2OU:>W\MA^,RTB[N:5^K3V_EL/QF6D
M7=S2OU:>W\MC.&MO'K:^29E19#M=+S3R1JA$Z?:432VYB1,[7#C,T)FC:(QS
MQ<L;J7RXC%"V;)9GK@R8\U+.EWVW5R?JK8A]I*GU!3K_ $Y#JK8A]I*GU!3K
M_3D.JMB'VDJ?4%.O].0ZJV(?:2I]04Z_TY#JK8A]I*GU!3K_ $Y'^)C;6&BA
M<P;-7R@7*E"^<V:,9H&G/%A+EBV*_.8,9LM\=VV8L.##CR9<N2^ZVS'CLNOO
MNI;;6M/]>J\UR[J*-_\ 1+?_ !8DB #3<\P2PMBXZ.QM(6):QIEZXTG>A+[6
M7#S6>;*?4?N9+>C"?;*="7=8H-YUL]V(J6N(ZA@Z;@NS%;B*H34D<ZH)IO5+
M<TFA!NP&[-=?0SL761)3J6GK+ZJXW8H*SUF5S/!VDG=(:C)KIOLPFG%BD?,2
MHW7@E8<"<C&6+FO8B0G(K4PD4LG]S,TYA]B3^YMB4.YYWNMPWO,^4:ZF\5-3
MCAHN23;VI?*3P9;,,TN*(#FD>K(:]70=L-&2O1D#^=#((AASNW,O?MO7UTD#
M]GM5; _GK_BT+>6O_=*"2'*GO_/7RARI[_SU\H<J>_\ /7RARI[_ ,]?*'*G
MO_/7RCRZE.5>SV*_GK['PCG?W"NNILK+-*774IZ=I76I6OZ*-ZOLB-?1W^VN
M^E7RAT=_MKOI5\H='?[:[Z5?*'1W^VN^E7RAT=_MKOI5\H='?[:[Z5?*'1W^
MVN^E7RCRZ^_E7\J[L5_^:OL?".F""*<X2B*M:UY_W:,C\]?T;3??&UN5/?\
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M/X;31M<       $&MANV!B^3B7^]*0T8     L!A#M8MKX%3QRH#:X
M .>'CR=G5_XTP_8CH<\H    #IYX%_:!F/OU_=ZT!=^   Q-^^H=X_)5Q>)C
MHI;%Z    (W/7UTD#=ZK8'QM"HDB   \N[%?@K^P<[NX7KEI9_SM)_A-O"-0
M    \N[%?@K^P=,4#]I*(>]HR/X;31M<       $&MANV!B^3B7^]*0T8
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M"IXY4!M<       '/#QY.SJ_\:8?L1T.>4    !T\\"_M S'WZ_N]: N_
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MRTL_YVD_PFWA&H    >7=BOP5_8.F*!^TE$/>T9'\-IHVN       "#6PW;
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M3B7^]*0T8     L!A#M8MKX%3QRH#:X       .>'CR=G5_XTP_8CH<\H
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M+_>E(:,     6 PAVL6U\"IXY4!M<       '/#QY.SJ_P#&F'[$=#GE
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M[6+:^!4\<J VN       #GAX\G9U?^-,/V(Z'/*     Z>>!?V@9C[]?W>M
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M%0\@G:K<.X*$UHH1-9S"6:KF*&L5"Y['@RUREC&/H.CPY;;)9@
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M3H  (W/7UTD#=ZK8'QM"HDB                  (-;#=L#%\G$O]Z4AHP
M   !8#"':Q;7P*GCE0&UP       <\/'D[.K_P :8?L1T.>4    !T\\"_M
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M2_WI2&C     %@,(=K%M? J>.5 ;7       !SP\>3LZO_&F'[$=#GE
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M                  0:V&[8&+Y.)?[TI#1@    "P&$.UBVO@5/'*@-K@
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M,7R<2_WI2&C     %@,(=K%M? J>.5 ;7       !SP\>3LZO_&F'[$=#GE
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MY5K6E,I       !SP\>3LZO_ !IA^Q'0YY0    '3SP+^T#,??K^[UH"[\
M!B;]]0[Q^2KB\3'12V*SML'GK0P.+MNZ]^()PY-I-[FMBC/4=CZCJ[9TS7-K
MHFCIF%XM6'+-"0@$%V[$QDI969+<18^IJ)4DK*]IW$H%+#Z;=0^6SROX&&1B
MYMH^)@JZVZK;#Z=Z:O'#J&]8JAR;H0=D"H!28S;8F%O3\X(V8R]D.(B2GK5J
M!&_IR0:9_P!+"V0HFWW)B;CRD[,O2D  (W/7UTD#=ZK8'QM"HDB
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MDFSIZB;O]#HY9/+5IDMQUP]+P%[,4R@
M   '/#QY.SJ_\:8?L1T.>4    !T\\"_M S'WZ_N]: N_   8F_?4.\?DJXO
M$QT4MB]    $;GKZZ2!N]5L#XVA421
M   <\/'D[.K_ ,:8?L1T.>4    !T\\"_M S'WZ_N]: N_   8F_?4.\?DJX
MO$QT4MB]    $;GKZZ2!N]5L#XVA421
M    <\/'D[.K_P :8?L1T.>4    !T\\"_M S'WZ_N]: N_   8F_?4.\?DJ
MXO$QT4MB]    $;GKZZ2!N]5L#XVA421
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M?(0)G%"S%:<-%260T9O*%L^;)A*WF,]V#'CNS9*W:!>OKI(&[U6P/C:%1)$
M                               !57Q+]'Y6W(K#?]V:^PD/^[VK]JL_
MALHKJ?Z)_"BUJ43_ $M])6^N=-Z3Z1F_1?HGT+T'3"_2>G=%DZ75=^)!VJ_3
MZ!OUC?7\@!^)!VJ_3Z!OUC?7\@!^)!VJ_3Z!OUC?7\@!^)!VJ_3Z!OUC?7\@
M!^)!VJ_3Z!OUC?7\@!^)!VJ_3Z!OUC?7\@!^)!VJ_3Z!OUC?7\@!^)!VJ_3Z
M!OUC?7\@"XWAN:C2-I_&#^9<DK3-6E1TR'5V$,[+/+!\CA3OP6043I)O(LHJ
M)GL.>BTPQDZ7AP9L/H>_%=T_IEU^.RQ@  !B;]]0[Q^2KB\3'12V+T    1N
M>OKI(&[U6P/C:%1)$                                  !BKV-/0HU
M5TQ':2V%U[8$_+E;:0]7 L--J'U.VZSI1=<<J"UWHK)!"ZSIE<AM/:ZX9LNM
MLML(9*7W765?H6]^V:\J2TRVWINS)*>#0G]BZSL5T1G/+O4H/5)+-,YSOZ<%
M.5Y#7=?$AQ17&>O:"C(C<<[[2H_D*UVS Z2D,M9(R/%+5;2V"M+C$MY3OAI$
M=<'FF\]7H^G3&LB(*3,,>KQ)(=S2VK6-/%;' AY1QMI5VF2B4H(AES+6=BH"
M JM6+C*<O.5)(.U0)L8Q9;KQ-&2?V(:E!/;N-&8:\['3@B99M5LREDD6+T=3
MO1FS*E"^1)3+$=*D3*14G*T"&'.KT.,,XU''F4<9AP94I,WN     Q-^^H=X
M_)5Q>)CHI;%Z    (W/7UTD#=ZK8'QM"HDB
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MC8X     Q-^^H=X_)5Q>)CHI;%Z    (W/7UTD#=ZK8'QM"HDB
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MM-H9:A=Q9E\JV#><DK.BJ?1)2^@S',1BS$]X-PRL#Z!R]M1%UAYQ.4Q&17#
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MI961F S'X63#-]N0RG%WDVDMR82&>^S\B_,2QJ=I;)=;^3=?BK=3K5YC88
M      #7\H17'DTLP]'DIM-(?#)4U-L+"DV5[#D,I"@?9KI17HV\IXKCRX;3
M>-,<[>1E?&5,5R$S&<AAQG"YDK=E+Y-83CJ-KILA>:SS/%Z,\E VP%Z+KEOT
M>X6\Y2S%<CT8<CJ:$F.AIK*"X4BEK_C"/WHEJ26IDU= =+31EU 4$Q1+5,9-
M>7\/#37*NOIP&H-;ZB;D5!D)M.8@K+;S5VQ:DRZJHZ]+F-LLQ3<QIH,0[+2\
M@)"]*RPQ$-M+,E+I+&LO907%+)G,YMS.Z X'<<AY)O>\:L-7D(A$COAHP_G(
MD$3:D7AQW*)5PO-C&SJAT16C263R;A/+!(UCK@R66&+,F2PJ9.XL\04;A=\.
MUT(2(O)$/DW4G*; 8[=:CUMF2:7(LV1XUEEL/V(BK/?QB4#[B2T6-%9NH3A@
MTXW%TG6)K<RCDBPTV";E7\:MG1[AH:2J!$D4.PK9FRDD9YHV1:K(<MVNM9N?
M\HMZ:W&XW2\L3^L=KRD"^76HW))0I,=:TM2*TGPD$G(T70AJ>.N>[43ATWX6
M+ :.647FGQ0VF*Z'^Y%I3D9[["NXFUGM),@QHOZ\OXPYWDZ)8M27RZ93CS*J
MQ]*)=Q*:R>E2]&3KGY@<2^T44\CR_9$(ZSDS:<G,-GL*X_#4PN24"9)#-6G#
M;!F>26.LVN)RF2^)1,9DIT.I@2PJF<UBA;;0XWGK:H%2M"JB2,C!WYI9%DER
M=+SN>I$FX6+/4;18T)3C@Z3.%,:D](,=ZPY8CE=M.U%5TEQL]\-8JXCR;1;0
MC!9<PFFW&ZZWUIOJK+LRJ7XR[PXM,7(Q42.UB%21I"0E^1G-B4['I)9-^K:S
M,12J?+QA[2H0>A649#+RVF4+),J)K]>3D3)&1TY(1WB364Q%2"I'940:W($4
MRS-<MECI0RJRBG1*PFTB)*&7;K=C.%(/:I])CF+FXF%3)@M0BF.=W26\31TK
MB2RV8T];$HJD$R" 1KFDJ        /P'6U&R^FPX64]&^C.QH.U$5&TZ6NXT
MPFM(#B;RV2S)JPAK:0HX3!!4251/,F"2@GG<&8J;*YLN#/BOQWW6UAZU>')I
M:R5%,<!*%$M87&XTEUBMQR2$\)%E!P-"/G$SE]AK\?L]PR<\W:KLV.U)H.5;
M1SC%;1]):-V YZ)JD4.E21LK\4=:):4865?1@L,HX8TD2(E..<2=65I4?$>.
MB''\UL" 80TY&6Y%7FJ<:RRTKBQ!*,II.EN!)NPU0SA7%=9DKN+/J/K89>$E
MR!GAQE7O28W-!3RE!R^@,UBL^'/K*?2U2!EIPFK#5M3IV+CZ(E&FK?T-EA3*
M1P5,8S-MMUMV)S$Q(J=DA,+854DYGM:FKU);9TJ&EU1;QEFY8ME-BM\W)L;2
M=F4E4B0:F&AA'B63+3:]GLL3K&TEY%%+-(KBNRC3L::=\.!08JFR8Z:$4OED
M[%1DG)J9@Q2:MRA@=,-12X""@W$B(7 L/MTJ+5BN)W<XT999B+#RLWFA&3L4
MT1;;)5 7JI1RS82=HS$S9=.OF5D%_P %XZ@62Y5GNC*R7K+J6Y%V%D9KK++)
MRW(LCO)>7GB\G$AH3[DTV=47:><3B<+E<3<6C+A*8V81(G)L4I2E*4IUJ4IR
MI3V*4     !\*HEIJVFJ",LIY)62%8D;351+4BF ^G*2<?P9"IY/4")K'E*G
M2)TKEREC90SBRES)?+DP9\>3%DOLK#:/.'7IK%SG83Q:$)I5CBB<S;GB$\Y'
M3(+[LAK!0FN)MR/#!%]N]RIT0-C,FN-53#+2C<FV&P:3<A1.-)&8DE). C\C
M1X<6G#&2ZH#8B*Y/:U62Y8WHS<DBRXI,>UA.YI*C$7FAC9"M(!]I8F^;:2RH
MH>!,QHUI=-*9[:I5A$P7*Y\&Q3.F.K9Q>?[H,P@P\KAE--A%(D)9JF9:*+M3
M=<%@FOP>36#5IJW(8Q1NKIY \W*65QW8LQ$E0W<<Q%"^/%D,O042DU\0%):>
MM5;#XU_DXV^&\K6IF-4Q*[<=;.<4=R4PU0OD-$[Z)3N:3ES&"IO#GID1G@WF
M>XZEU'"BY4H]J%$X<NE: F2&B%(#:IM#DYD+$9N- 7E)VNAOI<<+SGS/=6CZ
M.D%S.-82(>8IMZ9,#OJT(C)L=OX'2F(3@+)^%6;R";3?G,:'1$GX(6:K'*U:
M<:QKL;=M2]F\;.NQZNZ9ID1T=1L9+HD63GH[EMYNA1;[RSM]]'5AVGW0O*ZC
M'[!1\:FG(*!0CFEH\6(TG^FI22\$?"MIR(ZV6^4PL8,',%A1U1XZ$IZLU9MO
M)F2V3)F0W.AI2O@PYK\A0QF)X\1XN:*W9<&3#W*S8:G<NV<CB3VG)!.*)93W
MBWKKCN)8*-.8(G53Y,BH\B1RI?&ZF&OWG;/0A^F?*A+Y>F3.4P*R?AO+85*V
MH6N<V+BVZ)'C-.674XDV(TI5=J<LNIIN[*5@63#DPPW>4=3-7F^OIA^.))4E
M1U-152U$FJIAQ65RN,[<F*J@1,:P2-'='2;IE\HFQ2QC*^^8\?+,DIH&7.X5
MA-0HQV$759Q2.A($>*#I.-^(FA-CG1EA?>A>/6\R4R2'"B&UA9JL*:-<8*9F
M0-:93&^(=V(1'# DEO>-5=^PQ"<LM]W,UVG6TXWVC$JR#&S.<R*LGBECD6T)
MIE_3IM%\^9:HG)1CD5PX,ASI^J;^%CH5GI?C.Z^HZL0_!62&$315QZ2@O-I&
MCF6\!_'($8-ML++Y/MUKQ2O&E&]>LBYN)B6P49W$D5ZH#>2G<WD!:3,Y1.'Y
MJ4@IR(1+1<;4#2#+S2G4HYW-),M/&0#TFL5BG8O:BVXI*=S\6Y"=J8CQFJ*T
M<86<ZG,M,C.P%A99AQMF6XKJ2::U[BX4^A6-+54:^"+39!9A]<U^-VJ4G30J
MF<$'+AIO*%L2)2@I2.;4$&/&LJM1O+<:-)#-)J-$J^F85^+RK16<A@]FD@@Z
MMP$VEHVY$>,D NX5 I*A-17<^154%E3Q3?='U\MY%144E(V=4CDAYHKC\RZU
M ]F,'U4XV$\YF,^BKC>8S^%+VK;%D;6B[69KWW1@UVZW8]38G/-@M;FK%BY#
M"NUW/"JXA$#>>EIK'';J8[04R::8.8Z'RB/5-S',-IJ\S9\.#2[7&Z9"VPRE
M&*,9F"QQEGZ96,"L\<+.OE#$S\;#OE4M%F=T&XTP2A1H6U:Q:3LC5,2-@;-,
M:+<Z\I:S\K3+GX:6M^&+9KC6&6J2A6^?V99$+[<:)F<;D.HT%+SP/KTCQ'%:
M<Y7,=2H@9SJ2G._2J2UHW+-IBMATNV]ZV,Y34$W 4RV!)J<12$\DE)A0N034
MTH6()Y$IBLP%21$GAQEB90M@QTMQX2Y4MBQ8,&*RVEN/%CLLMI2E*#[0
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:S+;<BHL>G=<"3=N                /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g395948.jpg
<DESCRIPTION>G395948.JPG
<TEXT>
begin 644 g395948.jpg
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ME[.T&B,V4E?7,U9HH=7P)"8G-4)5@I*4EK+1)31#1$5'2%1B9H>(D\'&_]H
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MA@<!M@8QPQL):UJJ(@X[-DV>\_L@596TIH@D>0\VJYZVY@.\@8$5@SD R4P
M<W8&&#?-H6\\KK2R^5E"PF>);RDWX%P0+9"]*?7&?LVJ<6W$1JL@-YC!R[IS
ML1Q^RA-25F[TPFW22+ !Y1/2H:0UH,'R)PJ&!M0$-% 2>.)A>&%'&"$$&O\
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MM1?B:XF-14]NL0O,6HNUFG,Q3.DXO-)!;A!M1%(3T=,C'$1;!"\SW"JX@N,
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MQ1>*;DT:>[Z!(D%P@Q]-%<7<^TR2YL]K)NX^DO4::(/,O@XON5+<_'N__/\
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M3?QAS;M?KW'6ZA1^FR6R:(^M66:LQ$X&=,$FN,LIJB3-*VCFR3R, 9.=N8.
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M3N5E-+4827XM5SK,.OMT^@64\\JJT4%-?+>0FD36R+53T)97BC'3!LB-RR(
MM$<%&%49\7A#;3<OG!DE_P R;UP3D@[6F\60D:]S@](.9$E)XT$E%.RJLHI!
M#,DG]GB=RLC!*)<87#%-,#I..5\#&6(E-T90[(['TOX+) V?;2<RM,HLBO?!
M)?RCL%HY+6ZD+Q-L*[]E99.M1:G76!EN]C+RI=YL4PW4R-7,N)ZFE(IXN;-@
MI:WAD+Y!W,2(]?(D1^);T?24Y3UI ]N1OD EI&CAWZ3R9"Y)"A-6A2+E1:(1
M!K$FRI/LJKVJA=Y$E.0TI&.YEUM3983U"4H^7B(AHPX^^JI)I-;3#D"D6&=2
M5%7XP)XY:=5Q];FY/$?[-)T#0W'">UG ?F3:Y3UXC!88$F/& TA]$6>6(QV>
ML39CB-&V^WEE"45)H7;>&!G3KNIOC3#[(:;3$A\21&F&]N,V?=8RS"T8=^J;
M)4!BKK-(DFR]K-JZME5U9C=O6CA:7D<TNM\X<7UV-%4RO.4T$F.PT6RLTG?/
MC^8O(0;G#??6U;?7&O*O&9#;)XUT7+4V673$["'\F"P?L1,>)V_']AH(FI6.
M!J"DW;+349K@:1=62E3)<:^ Z>/E&9F1(Y(2@3@!=O+-"TL+G'O%+<W;"DR.
MY%C20Y?1(<<#[7W><T^#V$B=I(*NX#WD,<G6TFLHBLLY:'0"(1Y!%($L,#R.
M7D#*#9C_ %4T&T@Y;]2-6]AH,B[0S?B4)#1HCFE>.&7ZKZ0;/."T<R6;9Z,>
M+$5J/8L>+C/(2]'D=+A<0NADW"ONL4R<*.05>4.A2+I SX9T$X2=B]I8&!EE
MT29R1H>Y&][IR@)4FU22V7M>FN:4WTWWRU6LS7LYSS)S1R,:(;E9PJ6KD%IS
M-A/ &33RIB0+5%?9R!K'MB>4"+MT%91:.V$^[HN5VZR*C:XIYLW!VRD2'+J3
M;.:^.G23:%N; 16Q(Q06DA$R2$.P#:@CAHX*:=3%]:73I8JWVEZ_(I'R3&NT
M^U>2^S[[.;+/MRZY!.'6G=;0&8 )XV(=+.9D:M\R^^/[=C4MZ/=Z,!IN@XC&
M%/!"#E6.K-PR746TL"OBZ?F95?Z,S).*:@SVJ?6D,ZV%@ZVT$VJMQ25;KJB@
M*1E))CGT4^M7RSNKG4DX(,GFU3PLKJ!@L(<OE>XU[W[/2E*4I2E*5C-W33#\
M?NMG,-]RK&[+>\B&<R4?LYV/IJMMU/HZ%G8,4FSFZM*Q%8<YH+/+'$0NADCP
MN&65L;X6RO;&_M"RW%8,D%X<&DI@!2X;0!'65BT1Y-O"1C+6"$R!%<I=CY*=
MG0,WPAL,P1%H)*R30Q,<L,S-KXY6MD*E*XO:U[VOV]G=TO>UNWV[6O:U_P!=
MK]/8I;&UNMNV_6][WZWO?MO[76]^EO:M;I:WL6M7%L+6_P!:_2W2W7+++]?;
M>_;^7O[^WMIX%OO>W+[WMM]_GV]?];[[[[WLNMK>Q3P;=,K=O3+KUZY7OW]_
M3K>_2WM6MTM;V+5"J N/_7/6>?\ 8/9*(DZ04&1-GW*O/282)Z6I%7H\<#P<
MBPGK*LZB,7K#@-,-!<@PZ64)!+J.AE50LC8B(A<V&E"B%<IKUXWPQO>]_OK7
MOW],LL;>_P!+7M;K^7IU_+V5!Z=^/'6W9'8N!]H):(22OR3K:OM1VQ&G%)CD
MQ%C-NNUF*ZRL(;L'B5*<9:.U9T!C+I\D=<2DWQUA21?)D,\='2B9<H'.&^-K
MVMCV]+=.G3*]N[V[XWM>]O;M?LO[-JYOC;+IUZ]E^MNF66/]?@WMUM[=K];7
M]FU<6PQM[??UZ>%EX/\ YO7P>SOM;ITM?MMVT\#&][W[>V_6]O"R\'_S>O@]
M+^S;ITO?K>]KWO>E\,;WO>_A=O3_ ,/.UK=.G=:V73&_9WXVM>_;U[[]5L+6
MO>_7+MM>W;GG?LOV]EKY=+7]J]NE[=UKVM7'@8]GX79UZ7\//KV]>R^7A=<K
M=M^ELKWM;V.E>5K6QMTMW?EO>][_ );WOUO>_MWO>][^S7%L;6\'MR^]Z].N
M>=^_O\+KE?POR>%UZ>QTKFUK6Z].O;?K?KEE?MO[76]^EOR6Z6M[%J6QM:][
MVZ]M^M^N65[?JM>][8V_)C:UJ=+=>O;UZ=.^_3_S>O@]?R].OY:X\&WMY?A>
M%^'GW^U^%^#_ /A_!_)2^-K^%VY??=_3/.W3I_J],OO/_)Z=?9I?#&_LY?JS
MSM['3V,K=O3V>_KTOWVM>G@6]B^79:UOP\K]EKVOV];WM>]^G2]^^]NMKWZ5
M!K5WCZA/528=C]@&LXI@DN:=HG*26)'DF<Y,59/<Y!M(9]:4&?%C(-J98F$T
M8L8V2\?*-)J$0!,D],#3$TRHG2:(C@D9S7QME;I?KV7M?LRRQOV?EQO:][>W
M:_9?V;7I?&U[];]>RU[=/"RM;M]O&U^E_?O:][>Q7'@6M>U^N79V_AYWM^NU
M\NE_>OUM[/?7-L;6O>]NO;?K?KEEE;]5KWO;&WY,>EOR4MC:W6_;]]?K?KEE
M?\G9:][VQM^3'I;KV]]<>!CTM;[[L[K^'GX7L]E\O"\*]NWNO>]N[L[+=(OS
M-J%#L[S=JWL _2CA'D/4!V2 \X=,)2^.F))5:DMFXL1SY.-+P+C8. L(A888
MD@!ABWD9K"P^&>>-\PLI/XAXXXVQMX72W3I>^>7A=ENEOONO7IT]CKT]CITI
MX&/2]NN?;:UK]1,[W[.[I>^76U_RVZ7O[-ZY\#'L_"[+=/P\[7O;\M_"ZWO^
M6_6]O;[;T\&W2UNWL[NF65K]O?UO:]KWZ]]^M[];]+W[;6O4'MXN/^%^09H,
M*-I^<\RAQ6T'N2>CGBN.Y.5V$PIK!3Q2)LFRIP1DLN**_6(64TTBLED+(XEC
M%5@J"H%%$N/C;*IN %2Y8N"4+ AEBI8(, N7+86+@@  X6#! !"!L'@$"$'C
MB&$%A;'# /''#'&V.-K6_6^&-^O?V]]K996M?V?P;7M;M]GL^^[K]:7PQOU_
M"[>G9;/*UNS\ELK6M^6UK=OL]>MZ\J4I2E*4I2E:NW).OZ5RALYMAJ>KOO5J
M&):F*+M?6AM!M3N5)4=IZE"L<8$E!Q1DQ-,(M=AQ->3OE<L4-GY."<1-;9<4
MQ5(;D;<A*#D>3\ LP@NL*QJ%Q92?,?FP$<7DI4.>^.W\UT;()O"['90@1EJ/
M7 E2,E8!@F'SEK*3XZ@7 @GW4'EBP0&L*Z&094 E8P?0Q;)^3EW\DT!Q9LOM
M5K3/NK#9AG7_ %S?LS81'*>L[YD%^.%2B=@N%Z.-,QDA%G1DI! NY[HX1-*S
MS9ANZ'XRXAG!2MCEC?I$5M/FTE&,8XDLKNUH,D%Y"8++?(*28T-E@V,EX/!L
M)3CLF"&P=N@@S>:?YI^1W-X E[&K@>4>3%O&>(#[[Z#'-Y[NK0#Y LN?S>T]
M!CF\]W5H!\@67/YO:>@QS>>[JT ^0++G\WM/08YO/=U: ?(%ES^;VGH,<WGN
MZM /D"RY_-[3T&.;SW=6@'R!9<_F]IZ#'-Y[NK0#Y LN?S>T]!CF\]W5H!\@
M67/YO:>@QS>>[JT ^0++G\WM/08YO/=U: ?(%ES^;VGH,<WGNZM /D"RY_-[
M3T&.;SW=6@'R!9<_F]IZ#'-Y[NK0#Y LN?S>T]!CF\]W5H!\@67/YO:>@QS>
M>[JT ^0++G\WM/08YO/=U: ?(%ES^;VGH,<WGNZM /D"RY_-[3T&.;SW=6@'
MR!9<_F]IZ#'-Y[NK0#Y LN?S>T]!CF\]W5H!\@67/YO:>@QS>>[JT ^0++G\
MWM/08YO/=U: ?(%ES^;VGH,<WGNZM /D"RY_-[3T&.;SW=6@'R!9<_F]IZ#'
M-Y[NK0#Y LN?S>T]!CF\]W5H!\@67/YO:>@QS>>[JT ^0++G\WM/08YO/=U:
M ?(%ES^;VGH,<WGNZM /D"RY_-[3T&.;SW=6@'R!9<_F]IZ#'-Y[NK0#Y LN
M?S>T]!CF\]W5H!\@67/YO:>@QS>>[JT ^0++G\WM/08YO/=U: ?(%ES^;VGH
M,<WGNZM /D"RY_-[3T&.;SW=6@'R!9<_F]IZ#'-Y[NK0#Y LN?S>T]!CF\]W
M5H!\@67/YO:>@QS>>[JT ^0++G\WM/08YO/=U: ?(%ES^;VGH,<WGNZM /D"
MRY_-[3T&.;SW=6@'R!9<_F]IZ#'-Y[NK0#Y LN?S>T]!CF\]W5H!\@67/YO:
MC[)TV\JFHD[Z=($];"Z?S5'&R$O25%"TAQMJG($4.A%%:FM$S34DK11RKVPT
M@$Q LEB-B*<<(70<,Q2AH:X9S#*]_ V!:4I2E*4KT#"4FFQ;C&D\B8&O:V-Q
M1R9883P<>S&WC!0L\^F/L6\+I;V.E?C=#1KK&#ANE)MUX-/S2 UJY$I=6P2L
MS%C>:9@I7!\NQ3LS6.)G(CB8L4R,8V'N#<6ULZ@1RX>M6\E'Q"]N?H%?E2$U
M%]2KK3\7^%OHR:U2(I2E*4I2E*4I2E*4I2E*4I2E=1=BH\$P,CDTFHGN@080
M?$]@?<P;<L2#PP#N (%GFE*?E=QL\A,,\+8@^)MA;*^6?A^#CB[T3I1\\WG1
M]"E$\VO,'SR>*]$<+R;S+\TO,KP_*O.KX/C_ "S[WQ'@?\'_ )SP_P#P:RBT
MU1X*89[)VM1/:X@(@&)' @Y@W'8Z'G@)<<07/!*3/)+@YXAX887Q&\=;.^5L
ML/ \'+MU*4I2E*4I2E4D<M_IX\4OQPYL_A^[9U=O2E*4I2E02V7W#=<!;%Z8
MP>2@=T.AI[5S28B-6G$RYV<CL)@J6$13%*))"*H@:X?D9S/=1 B<Q<,IYS$I
MC$D,V8/''W9<"(MP]&E0Y%II EU8=A*#&:9TH;&[3?X^U]^C/1U SW>75U[M
MV'1I@3F#BS1&&)"2)/[H3(C.$AGG9X'"0"Q) (Y8@GE&HJ?IS*[/ZULSCXY$
M86>.PD'-.8U_139@DA1,Y9:8"%):T==L'OLBU2:2Q%1P%'4I&G*=OY(WP":2
M,*M&?\PFXF1KVPO/C46U[:JZU6O:]KVU_A>U[7[+VO:,FMUM>WL7M4AZ4I2E
M*4I2E*4I2E*4I2E*4I2L-_\ U_\ _P"C_P#_ +BLR4I2E*4I2E*4JDCEO]/'
MBE^.'-G\/W;.KMZ4I2E*4J)NRVM9V?']IN]"CL*-H+5G:,'8<^0,HXZH(\28
M4"SI#5VL3, GR6*(:R,S 67_ #6,!*(%@$(=/N1N*?"-E85'>.V<1Y:6&<7G
M!E8:4.7>!%Y!EEF"M)U93X'*2*^&[,V4*D7E@YL6'>&%785LD9<-K0S;L[RR
M2948Q!31R9@L\27L<RNL&M;SX^.1&:7CKW!SLF- T4V8.H4LN6)6 NR6BG6E
M![[/-4XDOM4;YMU)IIM';>5M\<FK BHIG_/IN18:UL[3XU%O>^JNM5[WO>]]
M?X7O>]^V][WC)K=;WO[-[U(>E*4I2E*4I2E*4I2E*4I2E*C=L1,#EB4HU3#<
M)(IW-<.*Q<W98 .#XAX$"I,8&Y>Q,\2OCEEF8SL)<2XEKXVQMC;&]KWO%[[<
MN3O_ !&R?_0%K_IVNM_;1/WSW^?3S':?FKYV_.OXGR-6\A\@\UO-CQWB_-CQ
MWE?E/^;\/Q_B?$?>^)\9_G*[)]N7)W_B-D_^@+7_ $[4J=>);<<LI+E/N(DC
MDQD96)D"V*. < #$!,)^)O/(>QPZ=RR$L)>^.-\,@\;8=E\;W^^J1-*4I2E*
M4I2J2.6_T\>*7XX<V?P_=LZNWI2E*4I2E?/NK)=E3%#NHD;+.9'-3P2;FR]E
M+)-#,8%1%#$AXSRO(C@:$P+9G+ W*XF,\0,A;"Y8X7@'RX>M6\E'Q"]N?H%?
ME2$U%]2KK3\7^%OHR:U2(I2E*4I2E*4I2E*4I2E*4I2H,;L_][8[_I-Q_P"
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MZ?;W<U?N>.,+Y1>TW^XNGV]W-7[GCC"^47M-_N+KL#4W*YNG@Y$9KIFOO%N
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M$FZY(PP/N98-KB GAH!>;W'+!!LM@MFT$HF$U!3*6+.+7.!F1K)"S"@^.QG
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MOR<.18);/-2<X:&QE4\8*!"XM\FJF+A!96M:C6Z:K:U6M>U[6@"%[6O;NO\
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M5"68T9^;:?;Y&,0@[E]V+ZJIFT5?.-UGF#&#@/-.8/%&Z&L^H"=3S9,0Z&Q
MVU:3%@@&C:$*SD.,PRLMU(1T5P@RLAO+7G6QWLJ8$!4+"("XSW2P;+J4BDD/
M,Z:"Q,@DP;0+]W?T[;=MNGMV[.WKW]U_9Z7[.E^EZUGMWQXO-3.Q(KGS;'?Y
M7B9$AI+?\=2K">K\,[M,M[R(:G*9"[I(O5(0.-?8A*CR0&"0 ;+6:ZZ@+R81
M7V8V@4E?1D9XM4^NR!>=J/BTS< 1JX6D\I-DPDY&NEJ DH3;'>$6S/(-B@.2
M207Y.9EXQAPTB.4),(%$C!/.1LT1"20FIA8%&+%0P+B24KH<A26P8J1B;CDA
MU([+;IQ:3F_@ON(Y9+02ZJL9#!)99463%L$I'"4#(5B)8XM&R"<*HF"2=8WY
M<>)%S$ 61R*AO'>9;T^+QN@E2R6[)!8OE6,DW&FY%,QU&+9DT25WS N3)+W:
MFMS]"<@+1C"7\9"5,74[!FX4Q;H!=UEA$R=<S3''NO\ &3MF&5E@^@1\QR)9
M1<JPF-=V/,\1*&U(BD%Q"[88R$Y76K9YGU$H#D C(:@8#P$S,BA8%0# X6N'
MM%OU+DM2WLQ)<//O<5BZP:<1/K+*Y*5-=6E#*<S&<V99C(Y/3TF_8>'=BSS-
MEN?T@@QS*,E'->V@CHRNTH[;KW=)HL5D=R,00OFX[/.R)YT.C=0ALPX@6TV>
M6%F:)(^KQ,VQQX!6];UG8QAZG'Q#*99G"O0U.JVMNT[/R2_ 7S8R5Q 0F<4)
MX,2ZDE*7<N;G>AJQEI_OWK,?U[W/=JX[]'Y[22TL1UJG*KZUW1!7_##V3"IU
MV3@@I9AD-I*;>8V)I\J2H< *-$AX9U5%P"!%M:V34:W35;6JW6U^D 0O;K:_
M6U^D9M:W6U[=E[>U?V:@OS?6O?CPE7I;K_VWP]])[;K1WZ7]J_\ 5>G2_M7_
M *KTZ7]J_P#5>I.Z3VO]N1J?V7]4?#'L7_X_H=?T6;=WZ\OGO7-*4I7CG^!E
M^;E\UZT&.6+UQ+:/X8M?Z,6)5>%*5L!<8_J;#GZ4GI_@&Q5AU*5;;K'Z2++]
MY=_>17K/=*U\?LB/U-4%_I^M]&3XK45I2K/.&SUQ[7C\V5/H@?%;W>/=;WK?
M-7-*4I2E*4JJK;'TY5'X.-O^Y.5&RE<X]]O?M\]6\ZX^DHP?Z+-_ME3JK;EO
M]/'BE^.'-G\/W;.LBN]O;7:B[7[,3C#NJ9[<J,=O3T0O!:)QA*42Q?-$.O>)
M8D088%;)]$G9TL9D/R*G$C-E&=S?5$&1$MQ-%T*SZ(GF8J$E0BM9Y?T2B"=D
M-U;2[)[$,ELPP_\ ;&3V2\B\ M%Y$I$+1@U8RB=K1*VQWT^T=.2VX[IB>1-N
M9K+^56L$?;::FEV<SDI><835R6SMB EKWQM:UNOWX5_U6%PO>_ZK6O>_Y+5K
MF\>FFO*6U-5F<C(V\*;JPC82'L4J),#OW1%GOIUL9(<.RTP.)*P4W>X)=:JL
MN!N)-5BKL2SQIOI]\D=>3\0@QP< S0]]\1MZ1FG&S.;DN2.2EV24A% )O&2D
MYC$(U(O):#$%R'6BS$3%EPI[7",!YA!XI15:4@@;A7SL:SN)>V.1J@WOLO3$
M1BQG-R$58T6<KWE=FMYUMYH'(+QFAX1+C@JJ4GH4%(NR EX<<LA>89, \<1W
MD4/ELV$6>@Z45S<02+E;'6HL'OW7R'XKD269 +0\?28[.'-A(O4,6+E$*=UN
MM+!96(FRXH3<@UQH%C:>IOI%A9SI>M5W,*]A&C&A,BI)#B(61%S!8Z6!-%3
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MS<B 54RA$-2.)=PE8$L :N8)8%\Q<[8%31P/Q65C.'@9>-ME>]LO"PQZ6ZY
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MX0HF&%_I_:CZI=>GVM>OO7K;'TEXQ_"OW8_Z+=]_8MWW]BU8YPB;0$1W-!A
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MTLL&#%QHS,N&6!'  VMKEC6%K2ZPEA4:D:VCI18"TYDIADVJ;5LQ&.+V7#;
MWA5'3KJ9>\VYLWBC2-9I$?CBCZ19;\WM9X<@)+E%9:DN7\P!TYVMU\,Y?R=K
MX2D^/LGVL(_FP53AT[))*@]B8FEDWE-^S*X^(8G!0?8?)-)FU138QOL?6M$8
M8&ORFYG8:CC$_MB>++<_KJ(3A%0;VMJ]J\6322T8*$C2$!D@1< 1? NT#C;I
MCC;NZ6M;I>_6_9;V;^S[_LUS7SE<)0&2U %)- $504D;#33IHM<X6)J A<7
MB;,%+"!7,@%C>0(XP%A0KBAAY!^,#\+P\=/F^SS(AKB?B'6MJ#P&H[1P.ADD
M[;+C_FW7F3IDV$E7:IF2 VGN]I,LA1]+\2O1AHXTDICLV&4-HU-"?[/,HYQ
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MXL)A5]MH@=KL><CDM<W%'\<1XD1"XD2"EQ!446"I-8;P,N%!B&.VHSD >9V
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M<+9;;5?X"%)44R=#CD<$6R%FJ@,"8&(BRPTF@K/.)WYDBJY9NR"URR@@'QR
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2_?M:UK=+6Z6MV6M;NM;VJ__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g95314.jpg
<DESCRIPTION>G95314.JPG
<TEXT>
begin 644 g95314.jpg
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M_\0 %0$! 0                    '_Q  =$0$  00# 0
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M7B_V18?MUK_'=!L>CK7>UXO]D6'[=:_QW1[7B_V18?MUK_'=!L>CK7>UXO\
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MDY>%L49(0<@P,/IT)-DX:@4YTP[J'Q ?-$# (> @8![E,'@(&[]A P"'80$
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MBUVB9M)N(W!(#D-H-SNGO<Q2@['5J_EE/L43&2@)98^6NL]8J2G4Q(PLCQY
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M '1V#Z _ '6>CH,=@^@/P!T=@^@/P!UGHZ#'8/H#\ ='8/H#\ =9Z.@QV#Z
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MN_A^'5C/O0H7VQM/Q#[\U_Z/GZQ[T*%]L;7\0^_->@KG^P/Y6_XR#;/R"_\
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M_#]0??FO6?>A0OMC:?B'WYKT%<WV!_*[YO*0;7^07_\ +[^?T?/T?8'\KO\
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M^[\!'[G8/GZF)CX]Z)&]_P"^Y0/_ ,XN.H>?/][X_@[?3\/'X]_J^?J86/\
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M87L^G&J,3HW.$J#VKKL2%E6H/Y%*4.RC3%=$?+H&9N@2!%C0+K]K$M^)(/\
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M>2,H')0JH4SS@N:I3 X]R7Z5B18PH@Y H H(-6C9/*"N/-(CJ'#83/3HVB%
MW&SD8D#[("#!!(79X<_(HHQ=K:^UE_5\U7]++/1:I $HB"SL8[#6Q>4*?^KI
MQVF<-%UI5RSLD 1QQPY&,RO\?.XKJ4G=WJKGD0 0UL9)33E5MFCL#2;X[-%,
M9=J5P]6BX1J^5 I2MZOT;1N-_)C9\8S+:8^@ZIR:RN@UZTY,VTZ,E<NA+-MP
M5QDZ1VB?F,FGYEA$Z#2Z!FT_3Z\L5PH_>*M(N2>1<R(OD?@3O74N/H[7ALUN
M*CJ'TI[C:NCU^/T.R,8YG1;:OR+EZJ2%).UB[U^J1DA;$,1*S(B_@&24RX4:
MQ1E'D<&R2L?E"GHL?8^F<,WHV!:-L-4];XX\C8X)3*@3J9[+<9/UCD.I\G;/
M#C8W!8W/9 !DYT&*(EDXX5I$D/\ 9"<\H=)&03AM+X9O7-@6C9VCIN^.?(J+
M3GLU ]+"QVN95<\B13J=AARV=^:/HDB"\A.#&-2A(QX/9,T"PH>43X&.?4%%
M^:'$.;([F,ZMD@I*;G2J^2ZK2K+,5Z_N<\8L7YM(N4*E$R:D!DJ0IQ=A(T1"
M1>QI@<%AGJ#DGQ^#6J_Q_?;9A4UMF@/*%=87&9;3*]7;]LR#F/R6P0VU2%;&
M)2FZ/;HF"K\W/5+)F;3T=WB89*21%-B9PXA@[1;)Y0F2!F:O:;PTDAM*T7*9
M]Z]QPY'086*D)$JZESL$[ZQR&5&FS->3GGIH>JRI5G=I&/;$3?19G;T(C*=C
M\H5*)I#7=,X:22EF"/E<R(^XX<C(0MJJ:*-65MDQ8SNN0YS4.3@PGGP15=E2
M/7=C]G-?1+QYGCXL-%G5/*8\0*;CFM;%6=FRGE(QR57-;5IE2R*_5.0N&A(*
M7G%LW9ZO<639BV89.ZS2U.U"L*\=^A VL(55JXD&[XKAE%/"'-3B+(9?/; K
MR?XT7'*?EE"U:S:%(ZY5Z[2M2OM:99899U>K&QAG#')-$I2+59[6<O9F5>7V
M/;,)!%N5BY66B0<,EC\H=*HK*U72>&4L2=.Q<9J,GQTY&5\;5#M58PET?6('
MG(9=2B.Z\#QV:'C'Q9)6TBT1!!>.*Y6.SXC:/*$/TE%*OIO#67-8TD5\J+)<
M;N1T$6WHL&R"]M-9S.N0[DV>&A3'<EBDY(DFI9"HI"W*S47,BBW=RYG\1JA6
MX"SZ!R6XSN*YM5:KFCT6SWO8:QGD'R8IL'+4Z*'1QD1A!:4QAFT@9-G"H0!I
M)E<%FC<T@LP35<JL%)+\F>/);]6<>EMTPBR:MNT+5IVA9S9-*KM)N/*>+D(M
M :M,NJ\:"]J9TA%@P=GH*<,U>!J*46<T:1P!E2I!OU+/Y0AZHZ+5],X:RXS9
M3DS'VGQOY'P'RM=PCA="\HV4''(9V2A)0'JYS0SA\:6+;!\WU C4ADU#\W-E
M\H.\(\4K&G<-I<)M)PTRP)+C=R.K_P L;##-YY:T1=G*KR(=CGK"*-""2-FG
MP3"-@*L8S)LF?U)*05%8N55UQO.R>?VF@[A&62;LU,=/X:Q-D&&P6K*YZ7A+
M;2[L]@:M(M\BF,'EFCB&%F1922M$BS6:RS9JY\\IVNJG(>L:SR!Y(<:82$?V
M^]9I2,EF;+*V)!&J5OD='ZW6MLEJE2G2[* >2.7(9JWI#\J\^>-0-91]5!('
M@NE". 5CZQ>4,65?)5S3.&<N:40>Q^;^T../(R"^5EPKYK'\K8.Q"?D.\)1H
MF)) @,79GAY9M8C.#ECF1>S$9+F[L7E!EBOSU[3^&TJC))OX3.3O^-O(R%/:
MM"@RW,;!6; 0_(IX>D0+ ]33*RN;L95C,E>JF8L3>CBBSE=FF^5EJE:L?(]_
M8>*'(:X8=CO(FS</]IY&H&R-/-[#=*Q(.F2<1HM>B;.XU+-\CSKWBUI\748&
MERKR0:+'&P,"KBJW=SPQ_D+$<DIWE9 5ZLR;QYCW(#1.(%@=7(\5"I\B;A0J
M)<+NZS_];$3/)9OG%;C+]#MX'1W)DK)8U6$I[1B""LT+.@H5[)Y019!X> U#
MAM)JR!)&!HR3_C9R.ARV+2()"VJ6"K32JW(AT:I5YB>LE*QO#A.1CY@KM0S&
M/,<L8G,<G-B\H(!WAHK4>&[YNY*_K%45=<;.1K!2;UB*5M:4G391 W(MS\G:
MNW-6TO5]&5._BGP/%C-(U0J4::9:CE!RVA\/G<YS",S70.3VT<FW&ATO-L6R
MV/K$+;MAKV9MM#3T"KW5_?%*35\FQ_%QL5>0?;*I.K2=H=2"+=G&R!5'*KIP
M\/W1'DGGLCH#>@7JAR\O.7?$K'G>W5M.AZ0ZNE1E-8;O^,-RBX6)LU>@*A"M
MUXZ1K^[U2PV-E;XAZB^;N5E%Q1?!L%++Y00Z3A1CJ'#=RLN5W5X%);C9R.:)
MR6OQJ5@/)4I\H;D2I[(J;<\&4B&E*).HE\5P<[>+,8K).2Y*6;R@ JF]'J7#
MD[4X*5-HL/&CD:DHML*+AX@K256X<C!]7J91:@)=,,H>(4$YO,BQ3!)1?I<A
M]JCL$QNVZI.U:U:@R1?Q&0L*1G-<5F+IJ%HM-ILU$KW%R.CEX&,90U5B[!8X
ME-3='LFR:A&)24Q+NT(]HLL]AF_\I7'JQT"2&XU[!/[#.<A='X56;$G-IX^5
M6\TW0<PHLIKEEPFU6JQ7MIC!\@1S]U&3$#NU;TR4L4Z$O'M B$)(SAL 36^5
M'E Q.H4-0X;BF4@51(_V-7(XIU-E RP'HQRCR) 4ZB4I$C%T_P ]2).*AP]D
MAZ,IE.:-F\H$!T =ZCPX0;)E;U2762XT\C'*K#8'J\,@TI+1$>1:1I*IJC*J
M"II9%6T2V]7(*\6F0[I1@S^^\O*AQ9XS2_*CD!59NA5V%CJ;G]FI*KNGRE[A
M[!:9UK"CQ*4-'F4I$M 5E68&3F-OKUQEA7AHZ:?PQI?U1NB[7$9RRXPGURJ8
MHSY*<>RZ_+QM<J]=SR/TFOO= !A96=*LD%@5<IJ\ VF+!2KA6C>W8W7U6S>>
M/"K-Y=I&BQ*HZ9 IV]E\H("J)7NH<-VR2!&=6FU4>-?(UX:/U^15@R,*4R2-
MR*0]JU18DSYZVE)G;1+0R)2.8M,HO%&&$;)Y0=)-NK*:=PU9BQ195ZWE:\;^
M1LA[#U>8+40@Z;$@7D0@-EJ[U:T&3>:&W(RC(DC1-5Y%@!I,D,J+Q>8[(J/<
M-2M#=XVK>3U)>,L1:A6[!>+3 -85G3I=_P :*A4X6D+3.@1E@;-U48_2XUNI
M/&?NFK)FT!8W] P?S7RCM%F*7NLYH.*;KQWL'$>@8\]T+.;30VNDW^D4/=:?
M1;KEV3T>OXPTTI2Y5C3H"I6!G9+E8SP-WR>50!O;H>$;HB_BPEXSG_*$![/4
MGM.X:QB31*/K]W.PXW\C)8U=T^:5IZ4)4H5,G(ED-KK;P;0IZW?D/9D;%^I)
M"]CB$4DSPO!"R>4(;HM%+%IW#2*&'091FD%CN-W(V9^2EXG4*F>L5ZO&1Y#M
M#7F%DE;,*<C;&1(QK E:IJ/V F-))1$)X/RJ&.LJ?PWOC#--*B('?L7RO1F[
MN&3H,B\XRY-J.F<<,E@,VE8^Q2\"XUR%M&B7BOP$Y8<S0NE^K3!VK86<">/9
M(&2G9CNC(:%2(ZZPL1\@JQ4YJ3SR"ERF0L[2DQ#*>SBIQ\7FAF5><#J.8[<O
M$O92!T:9+'2\-6WT5-#&L4G*:40&J9V3RA*";$]GTWAI#DB4V<7IHQG&_D;/
MFJ-TG"U,]8@:V!.0[ ]\B)/Y3B$A:&01+2!]53]>:#YTE['&5B\H8BHR2L.E
M\,XI2'31;Z@5AQRY%SGR0FII*-/48^M'+R'9DOS.8-(D+*RC$T0G6P)YSUNN
M)7!6SMQ"+R#;PPKHQ=(^0R4/5WAHL'MG]QJ\^CD?HLQJX+T]N.I0E^\Y7VG>
M'A6CBI>L(^C32]75+$1SY"<D:9PZJ.=7S3XQK4*S&:QCN(2[R&FH=:,XO+;G
M-52N-Y7V_=(:MPF@Y[*^D4FM#LLA)-96CPA5U(6/D'K<&C<%8WM'E"62;92U
M:9PUAC0"?H]5+&<<.1]C"FOY5!BO46M8%'D,R'0T9D'Z995Y'$BB5OL/K2;H
MY%R('RH\H3'&;A9],X:1)H(PGT\(WCAR/G@J+28.]2I"]:]5Y#-RWY6>50:$
MF6S 8HU5!RLH].\(W(9RVC?FEQ&K>54[97')KC=1<E:34M1:YI$/JU=M5*RB
MUEBXUW.T;.YUU7VK3:9*QM6KZ0NB:_J\AFK$7+IZW0;,3'29W8O*!5C);A$T
MC)L(V'D3,4?&HODC:#\2F^=ZI7^-&,Z+(3S>IW:!MEYF*/ ;=-<B8Y*2E:S1
MH)[)SY(!G,3-:;.6[1LN["5XV?RA$>F!K-IG#6*4K23I]J9(WC?R-G"U")=M
MI9Q4W=:.UY#MQT)U-F8-"2L=%IQZ]<!VN*QGYVR"3[FYL?E"X@@C8],X9QP5
MY=](:+[/XY<C)L:Q3W*EF3I\Y "RY#%-=Y>>&$8>UZS'>I.:U[1<BJ]D2LF9
MI:!-D\IXQAK*UJF/\1>1.C_(SB73>:<HXSTV10K_ (VY1L!])C&\K'5+=[%F
M=ST'0)<\'(_+J@SD @XIZZCMK#!)@Q547Z]C\JC )LJ=+XWQ/W_3:T/#^N^4
M*5F<JD,2<N\ PW9)S8&;+08ZNZE<J9+Z=HUG9,'[RXYPW1?1=7(N])79:9*R
M,Z?!8 K8?*&19%PG],X91ZU9]I36CILN.7(N9+6:,=.XJ5:P0"K;D07Y;S,V
M6M,/:E3BBM7U?&3= 9W(F9QQ9T5LGE!(PT@6=U#ALP-6SRT[<09\;.1TN$/F
M_>U#5;5%"WY$@6S6&<)7V1I6CQ@A(UT9%P09"4%HQ&9V.3:M4MCQW/MLSMU'
M0- M6>M]WJ:Z1'DLYQNHZE7=;GH#6HENYJIU=#M5W;RC5&R9N\!1M3GJTJV:
M+R!&[4\XU?*'DVYXQO*G7XK%=6U+1;U8=4GJ3FV%PU=L,IG<; UK6[K<.1#B
MVZ.6DY^Y?6"MJHN'F;VFSH C.2I*S549Z4.DG( XCB>\H;'"X)*Z7PS:N(-:
M2L5N2;<<^1<@G#9456X%@KC%JM^1'F62S2B=:9'?9XP!*2B#23D@2;\&D<><
MXJ67R@C4SP)+4.&[48D\A:)CU?C7R.>>J9"F$\,/=6H(<BBED[9(^R$?7,U:
M":6C =*"$H^%)H60A+6O*C9QIC&A2^%X'N>IUF=H- Y&6EWEL)1K&]XNP7(>
MY;)6:3L-DJ<]/1%\TO5I0J<U:M%P_/:Y>8S/*;"6&R^TY2-28*SLD]SY>Y!Q
MNV[!,&TZ<94JZ<F[?I;_ "\S,S*8B:M)0E<OLTCR(E%W$,A(2=FT1ZZC:G!Y
M&PCIF-):YEI%>F BY7;P''5L7E"T#*(N=,X:)N&;MS8Y%-+CCR+6(VQPKF51
M9WE!=+D3YCZW.46""RV9(_TS;'<*)!-+%206><3V?R@93)D+J'#<P"<;6N)N
M-?(XIDL;\U;M>"#]D28%;<*A$BCF(')+%*H<_M;]3 JFJS'DEQ\W*?NU8Q+;
ML(T^>S:8E+Y=*UF.E05^?9\BO-6Q+[(]^2"@7SEW;'KD?0.\B,52#920N8Y.
M3672[.-+RLY#Q?%G(G>OSU3EK\#6VYP[K]&IZ\'&VBT6C6+Q%9O4-TA)*ZQ=
M:J+2[/)JR-U'F2V.P1%<BXE"1D7L@1)H * L4[%Y0M0Y44M,X:&<.7B5C8IG
MXX\BR$7QSUJ.1=7I=93D3Z-G;D$7JJR68J>=)N#HII>VTRJ+K-<)V7R@;H[0
M&&H<-W RAV5IBO3<;.1S3UG'SA"^U;LY!;D4)8^UL1E5 :9HZ$LM( W3$91F
M*CH&$5=SY^P/&+BE]D]O6#Z%37\A.FND!QX8V'*+UJ6@C&24=+K\DX2PYU-6
M?+B34)282:TB:SH+T2LUZH0K^6LKZ,2;"5/J3?E)\?KVUVK(+)4+F+6FQDQH
M;C1'ZM!9UB_7+,L=PS;+5>F==9/U],@-4AZEI=)C*7G\G28K+-&N$LE5H*XG
M?^JG,$N6T_Y0N0,@2.TWAFNO-+,;%4TU^./(MBG+Y3Y]2+-7&457Y$E)7;/&
MEL;PS//'P*R<J,>W+[39@ZD30GS8V+RALP5 8G2^&;GVXZCIZG YXX\C(P9K
M*C*U0D]<I;UKD,G\F;/%DL+T[#/'_II&8-'-R^U6 .WYX9V:T$S+L:\K(UYN
ME)6Q"JZ6[JDRZ!H^LQVB>-.)/9[-(Q=95C:M>Z$Y*\CRY3$.G$#87<:BHUD!
M9K"YB^=?:O)).-\UG%63Y2R%;T!'UE1[">\ME$N<C,MO\OYM10^1-LJH(+FC
M<E1 K*>.T9@LX:@LN:(!IV]@\H7*%;E@]-X9O5+,,;-9T5YQPY%Q066AD2IJ
MMGL4\JZY$C\B9N&^4S\(RH2OK#^?]F-?->1YGLD2!^+2R^4+E_-"O:7PSD!L
M2S*3SD'W''D;#_*>D-5*FE<+!/F>\A1"D3,$>P2 1-4DA>.[*$:U,B^CRO7Q
MH97W:Q6FO4*7M55S:5Y!V"7B(._5[,JL^@*=:.3BU>;8H7WA.).[-*A4LGM5
M/.FNI$465L,3#V)%@V%X[:F551B:I,[\L%3;;EVD[)<N)O(J$H$-I)\R:N+0
MIC+V?Y3<G*'K6,9"EF%?JF;VR?GZQMU;M"Y6]+K#1DQS2Z,X9X]DKHQ2:/58
M@+*@LWE"I I#5K3.&DH:S@Q?9>61XX\CH0+9 MFT*XN$C9/6N0R_R!>P0R+P
ML1$2H/7%F!DAZ)6-4=.$F'-2Q>4->*KI5_2N&<DI/^K.LN!_QTY&0P6Z+8)1
M2ER=V45N0[A//W$"9\Z)$1\@:45L_JB(H'8"Y6(R:'CCRAE^1UFO><6WC7NF
M0:='Q6?7>3IG(:KP]5CN1U5D&E9)#Z*SU#,6]]RJM2F<+0CY!WG];MBEE.^8
M,6EH@XDK\JK:6YFCN:<K%18P]P)>_9KYJ5ZX>P">[$K;2J%7L%I7;TU;W4NL
MU%%4L/$LQ<%NI6B K B991-J#1K6CRA+XBYZOIG#27"P%(3*_:7&_D=7OE@Z
MC&[I>WHV<%>0SL<^3A/4URQ#B2"4+9?-+ZL5F=5%-45M'E"'R;@U9TWAK+>W
MTO-RD)'C=R.@1N3^*:/'%L;6<5^0[DV>H0YV2J<6\D@E0L90 [5%LHH@@M V
M]>56R*DEU9YL&,[A6JP&3;/K=0MNEU:JT]MS9J'&J]Q^46J/AZS"R$M=\:DJ
M_<[56"Y*C<JS41U^(?1LJ=Q'-I-)->2W'?E;&\EDMMA[#E5URK1*%(5B!T_-
M-_7IU:L&HQT_ESW2J;,VZ;RX+_3\XIT#4%73^&FX.9=/IQQ7)F)FXUG)(>K/
M >)Q8O*%.2/U*QIG#282E4G,?FAI/CAR,@3VVVPORG^54+8RK<B'QZ'%17R=
M#V;8WGM9M8!<G]1:)]H\97@M9/*$."/%*]IO#24+,(.HW,_:'&_D;##;;K"(
M6M6T0%B!;D.[-0X>+5K0)QMJ?%E&L^1T=1BQ*8L:C+QII?E+>&>KX:?D!*[C
MD55H&J6N]9%#N][T:D9/(;=9LTE-(9/<WM18\L]$9M!5"%EJG=*Y<X24F'EB
MIMKKLK:&L(YE%(Y><R3LEQAEYF"=5_18G4(5Y&UZ7!RK&1O(5HRB-6=LZ)+O
M(^J.6N=U6GM%6B\!HD2H^"[LRBZ)ZPF[;A+@V3NQ^4$,X=$A-1X;R*,B60@:
M,J^XV<CHHUBTB!7MR5DJTTB;D2\+4J]'$K*9V%X=*2$=-G>JDCX\Q$HU69R[
ML/E!5!?'AM0X;2#=\1]7:,J\XV\C8H]CT^&-<R3=2FD!Y%.AJ5;9FJJ0-+\X
M-)1LH#Y8S./.5*+&<CI*<[ZU8N0^DX[6,=V#5:M5=%MG&W5.0\7"4R/R-71*
MI1-!U68PS1&/M(=0IF89#7+%%QUCY%5?/9VNI6UPG 3KTYG173^/D!Y8+)-$
MCWSXV';FTG-DS;-[5Q[KN@L,MITSS4R3:-HT+!L\I<9((VMY3\2I4%?K?7"O
M+IJ%AIMT&LRC">D(AT>6:,Y<+#'-E\H(*JY&&H<-W2*Y7M7@%5^-?(UD>3UZ
M,6L"<C2GZ8<B5PAZH@G"%.CI2JKJ)>G<&(UBU"@R5D>2]E\H$"C@&>H\-W#1
M4KFJPBZW&KD8V6D=?9.9UN]I3Q#[(M8T55$30Z8I:6=5U$N@<J"WBSI)LU)%
MK< Y<4GE<2.F,W@9QXQM67-%IA]9D82.,D_LMAUN)KO#JW?)]M8FD*=BC69R
M?1U^O.IMC*5IE&3R4H\CK77%YZ5S\CMTYD%R#'219122SA-\ND\9+6AXSDKX
M4W')^T+4%2P51B %-)#9DCJO9'LJH*2@'35? SREH\H&1,YD=0X;J*"4]31(
MIQJY'$*ILA05 *.8_P!D2J*51$Y *.G>8:([&\X(H_8H&^A++Y0$%2B?4>')
M6A2DJJZX<:>1IU4]A4=H-4Z21L/(P/2U(3+=S::"I8DG8!-% EYZR;J.2.E&
MRY"C&KF547S3T1TGB9'+T2N"AQJ44+3C"A3^X^C':P*9[YO<X(B/8#?8A71'
M:;CO'HE261S<9$J;LZS5X>4CRAQN39C3@*O45P[I&VD3@]2[@H"(=A53!HD[
M-Y0,J:!WNH<-VZJ)6U5FDT>-?(YR2/V%^G!FCJ2S.7D4G[4J:YY@2N-+(1M$
MLBH$.XBP$SPD?]&]C\H(*C0TGJ/#=DU;%95BT+-N-?(UZI#:U*+U9",ID8W+
MR+;C8*LX-8E17T=([&*8@S2%U&ID5D3Q#KH$=MFC1,1CHTT8:,S=1!!)X]3K
M3UZC0P+QO9*&J!!FZA-"*A5]G4*F]BRG2$J:8IJ Q[,81TQ7BUSC'P98(87.
MUWS1)W**T5Y(/\J*7CO%-5*D@6TU.P!Z4CG8EC(/(?SD#E21!-52+!G6EB\H
M7Z9HC+Z9PSCR,F\=7[BHSXX\C)(T%JLV%5/!TZ( O(=J%GK#Q*R>>\T-%6/C
MHHS8B;Z+(89+V5S:6+R@R(,3S^G\-8MO&IL(31%&/&WD9-*5;1)PM*]@5BOI
M$Y$M3W6 ?&MB@/;JT-%,(<&*1GS @JRP03LP[9Y'OXLRK:*KP5MG6\_<'9&>
MRYLX>2Q<G4# 88JM00"YU2W><HX>:TX40>UTZZ214$ 15")[$6F\B @UE?9U
M2"EH5ZEO'<<D\L"F-.YDF(E)B]:06J:(:/7+GW6(^TIWZJZK15FQB)H"BL$*
M#,-;+Y0INX9)6+3>&D46+1CXO1CL..'(Z<-5;O8U*N6HU^O$3Y#-27>&ERV(
MQI.UM%(II6Q:D+),A T@:*$;+Y0AF1HK9=.X:Q(0B*#74O9W&[D=._(^RS+:
MO+U:(K14>1#4= CI4T[YDG.1Y8I"O%0*9XT5/Z\C&NY&HO85_"F61BZ9\BT*
MY5W9XSUVRFQA>RK92*675LBU/1#28/2_U0TM>G:C5Q2!41!))($E31/!JD\@
MT8LRR472?D"SC()ZK& ]LXX*M/QV<^BI%536IZ8ZQ%W\3'"2L[P&J]2!PGZ-
M,HH*)1X-.2Q>4.8%CU;5I7#*'1BBBVTT\7QSY&3YZC+RQXHE-95I)MR':&OK
M6<]J$&7DF@0R59\S^C$G0%<BTV5%U_E#6M1JF?<BI7 +.A8J'JDQ98/(LOU"
MGNJQ.4>.JD]$MVMMO>J72#N\3/5RP. D6S*NQ*L5(&:H.) PD6;+N,DS>0*,
M(JM'Q%"^0Q C7;F+</;8?#U+,I4P0KE806IJ8:>STKTABS$R\!H>D^L@*!3@
MW,+5KW+1JSY X56IM%I6F<-GW(AG*4:.<N)"'S]G)5;.'SIE'7%:&AG-H3FV
MJREB<OCHJFAG#@T43T0(%!0)=8+>*UIF*91H=-K@U"IW;/JG::W5A;1K(:]"
M3<,TD(V&%I#_ -*FPQS5=-MZ"._H)+T?FM_U("].WTTN#1.;P6*Y3"X])%F<
MJBL_JD?G4L227F"2-,:0[5&NO22KHI7$B5S%D;J@\7*"K@# J< ,8>G:Z Z.
MCHZ Z.CHZ!-7-P_:5&T.HHRY)-M79Q>/.U3%5R1\C%/%69FZ0$4%1<KDB0I)
M@F?SU *7S#=_-&K.WVNZ2>"^2HMVE6J7KU]EMTQJ0N=HL,"12<3LTQQ>WM*8
M3EX%RP;%0D9R0=JPSQ-2/;&C%Y,[LJ+=1H426JV>55@JY/S2")'"T1"RTHBW
M4,<J:ZL?'N7B:)S$ 3E(J= J9C$ 3 4PB4!$ ZJG-R!J'-W/^(+_ "3DEQWS
MOE!!7.F;JCG$RN.G(^WRY%HE<NF?KU"*NE.M?IF,-?)Q<'PR!7D::'%=TR6+
MYXD"5!/20C=N*K:+H'R#:+F=>B=,;']CC[=BEO1*LA/&=M,]XWI0!<JOA62N
MS"0!*CYHX+Z2$*<RC:,H'R'4EUW*B+ME8OL>RV-)^JA),RGB_P#5(-JH+E=N
MFJW<*B,B=$OG U[#$:Z:5H>/VAK0K9S-X"9K<J:V;GJ59M=8U=*>IR5L9?JZ
M[Z+GN2P.K26R-G(KQ_RF(Z+'D5(>)%,2)G!3Z5*[C@1*JIHW*C@_D)5UK";*
MU;U1]A8%9.G1"*W0S+Y2<DB%NPN1F$EE$)OUI.NE>MBQ96Q ;^:$H3E4B 4(
MHRC*0-(";G'+=)ZRG@X_I3['301T)HH:-[Z*MI7I2%=5M;N2KE?N3!YP-507
M^3CTD/[4,HVC*-\C%[18G*B;ME/>X5&PM-0.CJ+8AXP?> XU#TI%7=37\XE3
M]?<E#T@-%07C2I,[E#Y=%[4SY3<'8;'HH7,Q1M(<4?87U)@).T2$_79.9&RO
M^21HZUHS<O8748TC9YPYC8Q\F@WB$FZZ;;U;&:2VZ:M%3$]B_*?@]<(B@24J
M]:RE1HNP7!CGUGLL=8GT_(S#@O)-RC,>U64\]?MX.R&4BX=N@B>(0;$3;';!
M)^9])$IOTSMHVF#4WL_<EVQ73*:+C#::7VH$MV;JJ1IOEN\OWI2$<Y^KYR=<
M&1>&#SQ9K"Z^\H8[$'H"2.KPU7V]=5P!=G(^YYM+MMI%/?D!/'#\M'=W\\HN
M,[5\Y*!];=^!@;K@ZAQGNDZ5K<^WIV.<R. EOLD:$[>JO7JA5=8MTO S+M2P
M&LUR.S2Y++N[!&J_+8Y#P4P5:NQ'=B+!NV$K,&G"7U71H6^ERMWS.X 0.CP]
MN.S@*,\JVJFM5>U2UC.-EW"L*[Y*@^G'\TK>"D8TR926AFAQ8%C&:0BT%J$O
MY@%&7M$AFD9 C"OYS05&WKC)^%#:/G^G&)R<34/&F^4#^P^<597*E/.1C#.'
M"8B<4%17^D@8Z1E"^BC6OLI9]H1R"X9*_(UH]/HOF\FTQ&--[;?S_G *F5G_
M %".%9< [^B4]/$[5;CKN+RD; ZERXX(99*OUI+0ZM$W:H:Y#/D[2\D+"C*7
MQJA,<E$'$U%G?33QL%6= >I,U6R:;9HD":!&VXN4SO%'HE=U&X\I>#U1SB>E
M(^T4J[SM#U^/J[R^6YC/RT=;8R;>\D$F,XWGHV5>/XVG+*K5<6C0JS%H5--,
M6P23$QTE'1!2C&(D5>Z)ZN#ADN#=H=R]$.4 J#&=U'Z_?SS92(BBF(F*/?L(
MC\42J'%NGZC%./Z8):/ZH+QFF4[,9(RH<I15)&D,#];_ %T.2E,5(IC"B!@$
M/.ZC?59?=[I09_4Z7RFX/6'-*U)V"V3]WA*+K\O58*^0;?VI8;A)SJ/)!1DU
M:P[-R5W(4U=5.JLFQRJJ-$T_-\W4Y=;==VJ1D(3)>6W!+2Y*$<H:%+1=*I^N
M3[V/M[F1%)&^O4HSDHX7;Q:\@86Z=25 *B*GZB5J)0 @!4QLGDH^7UFS_8N.
M.*[YB\+AFB;?JG-''- F;#OM Y%T6>UMW7)Z[:$+W&Y^MY[8:6E8)VRQ434K
M7%RLG#5.S.'*=6F[=$5N9BW>KODQ=I4YE'U^5TBBZ7B\_P F9GG%5H*6TC;*
MS<?;UDH5/I:^RL:%7';#'DG=5=RDDP2;S99";G\Z?J5:4K#Q^G&2+&>L'J>B
MSM\)ET/S/X S6B/[@X%W1V%7U1>T26OU]5H1>33AD.2AGS1W$JU9R1Y06:)*
MZ)DGI7C(_HUP5Y:!I6CY'8S4[6>9' .E645X70IBMVZKZQ6IA]:P6BG,'>S,
MG7)9%W&QBIJWW2JK0I*F^ 70+M%B N1<*JW/D<= F\):Y7&O..TG/VKR/:'!
M^O3 *VABPL]_4O6=7.3Y8@N:F^THVFU9&0;%4K+Q$NB6!['M@+'^@=@JC)&H
M\#>5U?V603JEMX<WK#MCV;"^5[A_I^-.+_O3^PY-@F"9"O>,W=SS5G1ZI$T&
MP0J5ES]U,NFMZA(*1L$!&QHKV4KIE.C3)C<\CCZ]+[+RGX.4B,M\VRL#>0N%
M&V"IM+M?:XQJ[R-L<4NOR3;I-$XQE!,7;FI0P_)M^B^54DF:Y3JF=?5*9W-Y
ME;G:W?*/@[)8T]=L;9:-(3H^Q-*1-VFNS56@HVTA:&G)((^ :1L[4FD2XKD0
MX1KS^0<.6DDV<*'=$>!2&CY'7EM<:)H,1):YQYL5SV_A[G6#U:R&L^S6"&UA
MWG/*/$]\D=EDJA;Z\VKF0T&(KT9(Q". YC$U>MQBWJL9#HSJ4HZG4'BO7DL^
M4&^6MSR*N6L8F[Y"W'DQC'(O/L]QVT[-B.&:M1L3X]16&DMAKA76S;6,IU&(
M)<75R+86#:0%!5@VJ4>PEH=^=XE:EFDUN6\)SZF<<J>#FMIQ;^MS&E*4>C;!
M(E=66-2B%*=,2!J]R24"H)H!3P6+ Q7JT1/E3>EE$'9!=^LIFC:AH>O6?Y!5
M#F;P"TNW6LZ<Q9*Q5*SJ[B>N,M3&<$LTFV4=!<E3.ZXC7VU70<R,77"(1;](
MSD\PDN4SHSH( TKR4ML94F&KT*IBMR).>3GY7\6XGUF:O[AIJ&L\CM?J>HRF
MEQ[N^-;+8*G1LB?N)U-Z$M(EMMJ621+"0K*/?^HLV\@O)+;B;3LAEE-2H.J9
M-8HO@K.6RLAJ>[9I*:;<>$N1YQ19.3S^#IIH.IH%JLG0FMJSN>T]9A+,'ZL@
MSD8N>BGWJ!;.[AJ-ZJMOG<XTSF=P C;Y(RE;;7ZJ35=UBKV.7GVA()S2R&B&
M_)=NZJ:Z")(A1*.@TVJ%B(Z2/)INBNU074&L639,D<HQ6[<L^"U)?Z(S%Y-M
M+G3-=I#F_H5KU*.8/8A(W)-HI7$(%?U)-X-6!NG)*J$+*BJ9<YE <7)8._)P
M-O9WRLX?/2^@Z'IDC!1F/(/J36.0E3CKQ87E95M99Z(2?431<X@SM'=^EVB:
MD;?[7[1<L'#EFJFJ,(- P7GC"\NN1.^<;+%P^U7.N7.?8KGCFL<@7>LU.Q:)
M)\>Z]L;":@XLV:UU2-J#>/&SNUCR+]XD,H6";$2/V=//22?L$YM;3-T]DNO*
M[@R3*=$)"(R^AO*5K\!3KP@=R[)1DHBP-.2C>.@19JE5005K2S=6S&0,$H*X
MB(!V:I+[IKM.N][K'*G@]H=**W?Q6MVVKT77U(!>,KT+)R:,<^DX'DD#2CJ5
MJ'F4Y-[(0:K!^_:((N)182*D.D%6]Y\G'S7M)^;V+5C2>*_V.7E!N8EWW*Y6
M9LGI9]_OM/;RK!_:>/U982L(TS:BRL$TS9\T]X4L[?M1&8>J-FLSZ)-,)!4;
MC-SFR':.8+O,7_#O0./'-_EGIVE3RECL^YTO<[I6)ZGS-$LN&5F3KU;&JT*V
MT2$H\O)5W05G";-:Q&164D5VB:X!*RAWO4^0$_8*YGW+[@7JD_.UY92\0E'J
M>MOY*9I+%>2;PY"LZ[R4]/6&T"ZLR"*MB@2,Y"75!FE).1%5($>H^U?196_3
M&6RW-#R?[W3+1,*Y=;J0G5M4C[5/'(YL\9&9XA L.2J+RMV"+>695G[1@$&=
MFD7+)!-ZJ*AD@:A&+2?)Y7RKW3 ]JXI[ YU?7L>C^1^-1).<^IZYLD1R#H^Y
M,)M#1N/LY?2OW&D9\YR0,UC'.?W1!W(5UZH\L*<A%+'=G<JJ#4N#NS\D:E1I
M7DAH?$O8MCA5M1KQ+/;>(M;T&F/+?*VVW24/QBR&,LMQJ%BSRF99$U,L1[R;
M<]M%@T&1>*S\[*MU(EJP5D7K&@ZQE4L[J>V<PN!5%G;56SISL+<*?K%/E+!G
M*A[4PAX]HT4Y)M',*A'+RSY(MM@_5IN46B@([=^>0!:[W0I[>*/5(_0].Y4\
M'*K3M&8-:LVMUAHFNUVOW"D2["R3L!4821/R0;,4' Q$ZY?M+="G2L\DR8D<
MJ.Q("8M B+=."6UTG#+HSX@\AST;DA;<Q;<::R]E+->ZAQ(@U$WLNRN^2Y;Q
M-AI&YYYC5FJU4KL@^I6G1+>81^7<M-3T@\73F)HKY@('R<FV0^$97G+W&/)F
MWBP9CL&NM%&FSP&P[Y7-6L.K5]S$6& N.CZ3!*Z>RY"#;$I":M.X*1<[#7B"
M-'5D%JPE#1CMK9M#36[7+,[#J\-RJX.6+*F$1.URWW^)H>NJU%MGU>3F"R56
M>6!ER2%G#*UPDT8S^Y(.4+.'JR8O'A>Y3-^GF5LVG;Y*;:Y+RUX*Z9+0T*UA
M;$WI-)UJP+QV;2#Y^G'5AZUBN2*Q6!EW'K#5"[BF2S.#-U !V)B=DPBO>^ U
M^EO);,^ T)K%;MFH0.5Y3A4?MFAC+!!SU]S71:WH \=I6'C6LC8(ZEBZKBD/
M#:&B[D).*@G$<V46?JQRAG#<R/D[=FL>MRXSUDXTQ>'WGG-E7+O0[0R@[Q+\
MD*9NM:-D5@?\1Z)9G+5C5'=$F;Y2XF%KNT.FT;(P&7R<Q6%ZXX<R K)S+JNJ
MZ#>KJWS^G<T_)_VB^RJ;VA,ZE!5C5)&PO*A#DD7,A06T.TY+*.5)*/2:R*KN
MW)(_*U%)HX,LY J B3[7;4]'R2W&IM_YH< :'=H*)BZ^2N6NJZI%3D5GLJ6(
M?M*JZB)/DHFJNK+M6"!VMT?(J6<4'8JMG8@8?3 H=GX]6+2K3&:=0MUU'!]=
MSZF+Y1FLK6M%L$GBM T":) EKV(Z5QT;.(K/-\B0D)_UES>K<W\Y1JUB&:3E
MBI&QKIC$/A_P6V3#7G,BZ:).8%G]JY*5"A9C*5+ $[XXRS-M?2K$%!6-24;:
M(D\EYZ\<B']VA?E59Z\T:UVE0U6@V+!S,/E#2B4P](GMUP@:T[U3E5P<S'VO
M'KU6F*WBB:]!$?46+&!7F*A'A,\D4TYIR!&[(SFXK$6M#$LB E=]C_JV23.[
MQN41FU-^4_!UGC\7"-8"MZ:K1-@<4F-H#B6K=<=UTUD=<DCQDR>6F:ZE#$M\
MJX<61E(/UV[-X#@IP<@Q>5\(I&I\*>(7&_2$\AE=7XVYWCV!3F_C#-96Q8 ]
M?L\=J6HT[ ))[5U;$PO^D5%[,QM*UIDK#N*=,2T9,.G:98MN@7I<-N+_ "<X
M[[1KUNU/>8T^-MHUM1,VS5A;KU?8[CDC8M&J-HI6;Q]0NK=2BU5K[K)NK8:Q
M)BK1K4_8]<87&7(E.+HI,Y!Y-.[KIL<YF<5Y3<'+S'YJR95,)*I477[>TIM3
M7;U^2=52:4)R1>(OG4NQJGIR6:?]8L;-!PZ59NNQ%?6DOE^F:5I$_"TK&N9?
M 2X6BOP#I&EP%5JNKVZ9@J0T1K"=F:*, Y*O'-H2=DAVHK62?!Y*PPR1A9N2
MG\X702^AA4A6\&*K>,H7R*;P]:<F;NF5B]P*T\EDGH\H8]XTOO%;Z+Z4?26]
M0"GK7K#?T7F^:@#>(7+/C?-\A:A@U+8IT2BLL+Y2<6=GML+9W2EAB\8KF9Z%
M2+M*Y_$*QL(Y6TJ7UMF@="+>222<- /5T4Y5=NQ+YQ/BXU'1*->HS+#<SN -
M:T6GR4?0*E296LZLZM-9&>&I(K4MW"R_)55[9I>RGCXXC-_8TG<ZR/,$"+4
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M?[A7L3DW:T/D=@L!8]%!A%9]%K25>>"956$FV#V19J.Q1=-T+3[8VHF:\R>
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M*@ %5_5 ['_3=$978"%2<H0\)$12+P0%TE&QC%@DY$I#)E%PFT;HD7$J9C$
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M%UD@057BXB.CEE$ ."@(J*LVR!SI H4IP3.82 <H& OG  ];[HZ!-I4ZIHR
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M5GUD2"HV^YPE4J+5A<DU":.I%FCGK^T,A1)*1QP=1ZJ(BV)%!)A5X"J#@II
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M.L?T)ZI1N4+81/(^R!G^*O*>3+&F,5?UP^A G6CC9FSPYA&II-?2C#)F;)J
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M2.5YU<7D!< OHK] 6<>66=@MF^KI"TB3"J4LJZ!2B%%O&&,@N4L@MYC,107
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M.=6'^G7C_2?PHO\ LMX#_2S_ %[X#^H> ]8'G9Q=*!Q-HSX 3DDX501SC5P
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M4T;Z #NRA&?'O*^5;2Y++WT[QGY(YSEF\:5K.8XKNE@DLRDLXT':L:&Y*2M
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M*GYB?M0Y1](!B"( 42I>9A1=WZ8_=RMW%%1F84G$AZJ,8#EZ!63/L[[>^<
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M"+C7L*R=L&%(D$X5)]4VK1PFJ@G NDZY %58>8*?>$BE""15B@H6>WN<HO\
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M5B8^0KQXADF]@H21)%S3IVOYA6H>VCN CV 0$0^(=P[_ ![?#[OA]WH[@(B
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M?0'X Z.P?0'X Z"JWW[^5%_P-\N_SEM_Y6]'OW\J+_@;Y=_G+;_RMZM2[!]
M?@#H[!] ?@#H*K??OY47_ WR[_.6W_E;T>_?RHO^!OEW^<MO_*WJU+L'T!^
M.CL'T!^ .@JM]^_E1?\  WR[_.6W_E;T>_?RHO\ @;Y=_G+;_P K>K4NP?0'
MX Z.P?0'X Z"JWW[^5%_P-\N_P Y;?\ E;T>_?RHO^!OEW^<MO\ RMZM2[!]
M ?@#H[!] ?@#H*K??OY47_ WR[_.6W_E;T>_?RHO^!OEW^<MO_*WJU+L'T!^
M .CL'T!^ .@JM]^_E1?\#?+O\Y;?^5O1[]_*B_X&^7?YRV_\K>K4NP?0'X Z
M.P?0'X Z"JWW[^5%_P #?+O\Y;?^5O1[]_*B_P"!OEW^<MO_ "MZM2[!] ?@
M#H[!] ?@#H*K??OY47_ WR[_ #EM_P"5O1[]_*B_X&^7?YRV_P#*WJU+L'T!
M^ .CL'T!^ .@JM]^_E1?\#?+O\Y;?^5O1[]_*B_X&^7?YRV_\K>K4NP?0'X
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M./S/Z!Z801$/K_YQ#L'WN_T?#M]_'S_-W'X@/T?N=^P=_B'C\_PZ!_/?P_\
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MVFX,/P[]^WJ7?L!0$1^H!'P !'H]_,A]K3+X?LFN/C]WU(.X=4+P,QJ>"66
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M$76H56+6?QHU4*?;9>KHO9\SF:#T'CN4P42E-4DBG.!A(47CPIC@7N!A3*+
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M._:7M)$?2_)F04:#:A;-#B0,H'Y<%]CGBO- ;6;SB>N FL;SQ[BJ&#/C. 7
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MAL6GLZ?4[0RO]LA;U'A;(RS0]3FL@KF+W1B>)G&,3'$N$!HE,W"J6*ORZ3*
M=PP)/X>=ADY5LX21<S6=3EJ#)YQ4*E23W_0]6G+!$U*O.;(WI4"UC:;6UK;<
M[7:K<[AK",- U^&(U2128U^9EIZ>F(:$C693NUW;1FD>(:\5::_I%9W2^0>M
ML9G7+!;-(=TC,+*ZO\GL$'F-8E1DZG(P3:J5UC5ZSD%"KE*CZPR8IQ</#&3D
M%):0>OI-TXMEXYUB4+49FH33S*]&IELF+U':-1Z[4Q>2EGMU8-4-#=6JHSD9
M)U"R1^A0:@H3\8\8IG9NF\7)5^0B9"'9.B@Y%(N4C/UB)E+K5'65VIT9\UEJ
M-:)V">O8Y[&RCN*4<14U'N$F%HK,N=J63JMG8-6:<_"/&+Q2-BW:CB.:MOR!
MW64PJ$7L:.46B^UZ!IUPT6^V%G8ZQ2JY2J71PB1DQ<3UO.1A.WJ="5$M$SIB
M=K*W \7+$0E(\S9N#M('X99#+!5W]W<VO1K?67#Z25O5R7J$Q9)Z>E;;(7B4
MF'ZK^E/FT.1:Q22ZL;6Z@E7*G6(M)E"UF#BFC-(QNQI/%*N72<IDK5+,3,(^
MFS-JMY*;&YKGEZHD[HMH?PCT-0FZE>H]_$N]"KOL<R-6L:R+E6!&6E9&.2:S
M*R,D@#7)<^Z>YO&R51E3XEVRQ^=6K+Q0^V9O%WZ6F#/Z-!L7TIE$VE&S.>44
MUBO;&*L6C72P-:Y0VL=)3EN]0BR(B:3>3;+"[(W]IU2#G20*-0I=BD9N1*S3
M;1D[>&B\TPHCA-HLZ3<3S&K#$VE_(L'3J#4AK-6EF3QT:63%--L^/Z!M8A]1
ML^BVZ[(U&9T>Q4.C3<)06->J$_K5?;U:].RS%=J\3;;1'/H$K^.C(.US,FSB
MT9AXHZ7FGC*!=0^J@N,D3#:'3],/H5[?V"N _?32*CEH@PN-DF'UTDIV8D0+
MZ1>)B[ ZNRI)ZG19Q@9)C4<VC2@T9T:.37#;ZUR0HF)7JF570#.XB"MF>ZYH
M;RZ)LIR8CJS%Y XSPLX::BZ[ S<@WBAC;XK-R5G=&90M:BZZ^<3"_HG2*B&N
MN_*S)ZI#7EW"OI/0+#3)%.KMZI5HJ63&VZ*[LM3I4;FM8N<Q%L<_?7!6WWRF
MPLNP1LCE2KA/(24V@@S;N?,4&N8'7=A=O'DW/V&'4>8=N^#J$A0C1(%<W]C3
MF%EF@%^U<&-.P2=+CU8 AQ&,.J[>>U&KLH-RIM)(\):%.3-VEY:ZW4#W",=-
M4E:ZQIU+FH:7+,4BQ52V.+'68!FXN]IR^?H$#*99,WR.GI.IF%\R?2%A8.O5
MTP^]^Y*:;F$17RW["H&I6BT[11LBK[F:WBNMLAE$KM3[G; M9-?5HZ/J)*RI
M29&NV.N2U)8OR2\A NXU\_AYMH\!N$^=4L^E8&KQ^:YFQLDA(<@XZ0EKER>J
M-/R1R/']UE#=^_H.NN*&_A[[&6T=:CDHYXC#PA(1_6+E'2P*+02Y^G@D^)T)
M<WL+,;#HELVJ9B=3HFFK#>JUGA:D_2SBJWNL5RD$S2(K3:AQE846T2PVJ<>-
MH=:SSMJ,S>/)D(R,AHB*ZM?X5XQ"7AC;G4+%62'A)O=YNK9M8Z10)/.:>;?I
M?*9VQ,:I6G-=580#&MRN6IO*JG%-60M5+E;A=^G4>(J%!Z,@UB V',<TTV,1
M6KB.FTFL7:.JU@>1R=FBF]FBV\HWC7[-%P/IW:)%_,37:)BVD&XHR#0#-G2/
M2>TS>:QF.BXKF3^)G)FP[1>6]1(O$I)#%9_$+P-KETKQ?7BPB,77WSVJ/*]
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M>NSC!J5!0'\J3PCC&3*8!\\O5BGZ)MQ)["(\<>2W;Y^_$><^YV_UOW^/AT$
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MN8_-\/\ L/KB;"ZV4IC#+S0 4HB(^<R\ * B/P:?,'?X?O\ 4'_T7+C_ /\
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MBZB@NF\POTG_ !BG^ET>C+])_P 8I_I=,_QXUE+>L#Q3;T8@U?3V#)\\TXL
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M^X@#74T2FP:L7/A-XP^RU: O%=V/*YZE6JT1](J]OA=$I\K5[)<Y9X$=%5*
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9O%N+!,JO92= ='1T= ='1T= ='1T=!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g684562.jpg
<DESCRIPTION>G684562.JPG
<TEXT>
begin 644 g684562.jpg
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M_$44 J3<V$QS$IL#>W6!U!,6AN=84$.@P>0+ W,E(4) VL=KFX^9"4P0I/M
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M?N3LIP@R$E.R1=5C(!YL9V8)*D"Y.JPY:?=3<_'?<R&EMM15"1"23N;Q3K%
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MV,2E1,1O DB0)N"".MOTPI0GEL2"9WFYZ$'V@6_$R<>)"4R 21,$'=)%YD1
MVGY&>A/2UYBHFQBP&\;'O/TL1U%I "8FIM]XVI:L;^&) ),#!].XMM06@))1
M,I<2%-N(4DI<:<200MMU!4VX@@A2%D'$3S;+4Y?4!5.'#0504_1+<!)")"7:
M92[A3M&X?!<,RI/A.D)#J1B5@#;I/0?IWP-VD&84JZ!92E;BBY0N+5RI9K "
ME(439#=4D"G>Z26'2)9!QY*]*]5DFBATYGP)G>D@"HQ+K/;-A'ZTU;5_J_I\
M%"!-.\$DD '%>#Z^V%C9E(N#%K "/2!^?7?TP0II25K;6"VXVM3:VW/*M"T*
M*5I4-PI"@4J$2"""!&%" 0(( .UC,Q;_ ,=>][EE<1\K>O=\L9L10[4P/!J$
M$PI-X[V*3N"09!!'8DD;"1@L7_MU_P ^PN>F%3:C$$7_ -T;P)@]E0>N]\!4
M2 2!AAL"@M-:7FGQ_MUP<D3:8,?(G]^^#DB!'[^7[WG $H,SM'S_ "Z?/!F*
MI$"8KXW!BL>&US&&,9@<H6TY3/LM55,\E2'J6H:0\RZ@@A25M.!2% R9!21L
M8)%@84-*)M8P  >H&P![CKO;\JT*J$C<>/2+?2/=[UX\P>8.XQ1FLN N59L7
M*_1E0WDE>HK6K**PNN92^I4J**-Q 6]EQ)LEL(>I@?\ TFDXUASK(<]TQ6JR
M_/\ +*C*ZHA7*W4I*6ZA"2)=I*A)+-4T"4D.T[BP@E)5RGRXZ,C8>W3^^_SW
MP1F>695G]"K+-09929M0K! 15LH6XR2#*Z=\CQJ=U) *'6EI<00"%" !HLYY
MUJ Y+K8 !D_Q!8=U2CW@!^E1G8*%!C%SG LKFM2V",J\08@$L+)@0I $MDG]
M:) W;),XXB\3]#G+:IS4.4M-_P .K'.:N82$I10U;I2 ZE*0 W2U:S8?=8JN
M9L$-O-8IHH@\RDI(&_6.^\S;L3],=@->?#J\NGJWM'.?QO+G6G$U&G,Q6@YB
MEE8Y5M4E2L(9KD<JCRMU'@U Y04//N<H',/7^A,RT;G53E532U5."IP4S=6T
MMBJ0F #353+B4K;JZ<K2EP%*0\VI#Z)2Y(5S;3+I.8RZI0O^8@44TLQ=!J$K
M)H?9U4!@@#V2<SF6"<GG$%+K8):>/>1F&DU(0XDZ%.-IN"=>B"I 4%'&S&DZ
M-=!HG1M$XV6EMZ>IZA;<$%*LQJ*FO5/0RE]L@B)$7MAU<0&T%4G81S)YC_[8
ML9-I)-B"9@'#T:3[ S2T92I::++LLHK0KE^RY?3-D':/.%$18WL"#A"X 3;[
MO0*.YZ&1?N1![8Z-M&AMM%>ZA*>5 D#IRQQ+CO:ONK,=]U:U5GO%4P+@0;;1
M (IAIY'%$F)V*PD[D?=1$S"9)4),FT]RE)G[T<Q!@*%Y!)-K  !5C$&T6PO<
M2$CE\R2;<PWN)@F1V^0L(P4I"P (2X#O:#RP>AWZ3(,GM.)*0?OO<'[[;DFM
MY"^]2 ;#]((@4FQ'SM:#AO4!!0/4JYHL"(FXL2"!U)F\FY3.,\J3R )41!!$
MH6$F.6#Y9/55C$ [86N(08*.8*)NE0)B+;;B+Q<@QL1<%):?*O\ I+WF5)\J
MB>LDQMO(WC BD@Q?PKR^XP<$$3.D5H3I-8L>HY3UC=I#,DE4(Y5>90DI*NB=
MCRI3,&)$P+SA"XD*62(2JZ0H;1.Y.QL !,W$V-L29=(\M)2E'AD@BZD\I]-Y
MDWG] ,%C)WEV6&6R/*?,I1,&"1"0-XO8D]<54VHV&\V\!Y7GK!H:D60XA$$J
MFT$D:HD20!,P #6X'F(L1!!CPP ;_P!*@+$$$P"HD@3(),S:,8HE(E \T@!
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MX:;=4D DU! '*!I[IFDT BIF*"F(^NF21S-P%)E7*1*28V*>H.T F!  $1A
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M4(Y@2#X7K2AY1$0E^G#@!O W";*003)'4@]1$$6PQOM$2E8*%"8)Z@'H3Y5
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MZ=!:'!31"^0 D*,">O>8[7FT^G<EU!2%%0/D0I?<$)!)N/;_ ,8<C[8S0J1
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M^$:V$7(02#%MQ-X/4>G_ (-\#6W'+RW!!O/K8F?<3[1A3R@F8$]^OU_3!:U
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M!>0D': 3YKP(L1TOA@=0?,5)!6 $@>\WD'I ,V/J ,*+14<OGT->GVWPVAR
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M6R4T)04/9N.T>4EI3>6:J#4&2YGJG,*K.M25==J/.:YPO5F;9_5U.>9I5O$
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M=A/Y6^F%A_I) D&#WB/H>UNA$X&6T*N1/L2/R,85(-P8/T,3SY7CRP^B!(@
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M;&2DJ^<SO.V$RV.7R@>6;!/E) $["-NL?WP0YA*H[L'F3Z@>N>%_\,<;&KM
MH") 29!!M4@FD01MM$8US5D]?4D!%!5J5_\ N'$IL.JE!*9@[R#L >A+&E<Y
M<YP:(H CPRZZRW/<&5R/6$[]3.+]J*<*.ZA.RMP?0B;Q'<*B+QAL<84D2I)"
M28YHF+VGK<=#$],3W5P0-JQ%>HY^B2*#$!"FQI"B>7(01<;<CT/.N*%J-'YH
M@@N&F:05))4'2H"")D(1UOS D;F";G"1[2JA9VI1M<(:)WW *E@$'L1MTMB\
MGV)(/*#8VBQ!'0&U_;K.(]69<#SK; $))"(^Z8L!.X)O!!B2(.+!II6U3O)
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M[RVDF((@GM:)$V@VQ<)5O(MUW GI'/E:DX#I3R'R^6"D@Q!(/K_?8?/ @F9
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M05<I\:G")$AQ2;BK5*,2F%7(5!DP)YA;<S8@];$3M<<-RZ@%-NN1L0I"A_X
MVN#6NV#J_$?$$GL\QE<N%Q!'9NH,BZA+I$S)"@"*=TFF.QS699+F"$N9=G.3
MUJ3<*H\TR^I2H&(NQ4KOL ")OUL,(LQREO,6B"@\Z0?#>0V7.6;D%2++;)$E
M/-:ZDP=^/00TM)4E"4*@RH)"52.BH )B-[&>ML>4^:9WEYC+\WS>B  /+1YI
MF%*GW 8J6AV@$ B+;8D</*2"AX@@[HV\=7TQ"N/AP%+V3!!BS][6!;F1M69
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M"DD]#8@Q<;LH"60VTVD)0VE*$"L!*0 D;DP!%_$S4*.E>8<6^ZM2W'%EQU=
M5+6H*42* 22::0 *!-,3?@AI[B(]FE9PSU'PES+BKPAXC5M#E^J]'9?J#2]!
MGN39M6J1E>4<0]%YBYG/V[(=7:7-5]J;6$-Y=GV7MNY/G:5TBVGJ?:CX_?AT
MTU\/^N'.,%$_JGB#J3BOFE?_  +(:C2K2-!\.CIK)=-96C4.>UU *E6>5[=*
MPU_ <DS%-#EM9G#]3F]>U49=DZ<KJN?*M7:MR5VEJ<LK%4Z\F(J\@I*-FFRW
M*LKS9IQNHI,Y7E>5LT5-FU?ES[2*O+/XPFNIV,P0Q5/M5(IT4Z[?U;QVUO\
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MEL'QZH ?R4&R0)_ZS@!2W!N4W<(D!(F<02JK:BN<"ZASFB2VR!#;0)F$)&Y
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M B"%)!GV&.DJU3UDDR>N(OJ'2FGM3,^%G>54U84SR50!8KV;$2U6,<E0 /\
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MPMML#M<RXRRZL*=;8:2D*+S#!6?"#I.NX(:[XY</?B0T=KG)N'=2YEN>4W_
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M#"$J5S!2D^''W@$I)@@Q, @2"-X/-N4!!2;^:0"">H([].W_ (&'QV%-J2X
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MXHY4.H9S+*%.M9AHN%;:@AK6ZTX N%H<; U"4K4#(ZK\19C*<=XB[Q?(9AI
MS_8NYC)YIQ.7>R;Z&&FW$%Q\-L/LE2"MIQAU:M"@%MMJ%=75.)0KF:)294J6
MU%*CS$FRT<HZ ?>WV];!X3:5XQ\4^(VF.'W!C)-<:YUYG-:U4Y5I'1]1F#^9
M5-'E[S51F.95H35T]!E>0Y93-+J<\U'GE3EVGLEHD.5F<9G14C:W1>V2H^!7
M3##M7J1OXM.-6:-*4JAR3*VN$'P\Z0?4E!4VWF^=+S/CGK3P5O "H5D]%EU5
MX"BFG?:?'BF$<2_BRUSFO#_,>#_"72NC/AOX.YQ3N,:ET3P;9SJCSWB.RL.
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M 5KY=W)._A;+-Y?BN0.:S&?S6<XLT[FD)SBEH(;RRE,F7W&D-ZG#I0L%UX*
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MH#*W:AD,YC2F!RJIJ]L)JFTD!)94EQ392 4\R#!UNU+P+6AQ=5I;,PZE*?\
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MS%4O.3NESEZ GD3$C>1,]00=QMB*/M)0^I*PM+1)Y'2>8@D!0'^WE))/*0%
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MI6BJ4UE6IQQM5=6.4&2TI5F&:4;2Y-P+^'/BY\2>?U>G>%^0TZ\LR0(J]?\
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M!&W2?><,=0Y*B02038;S>_+?S]X^\!.]L>.K*G%$DF]@HSM87GZ0>V^$-0N
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MD3S RD0""!/-N2#[&PB\R=MX4# H*WY6$#:U!),TW,SG,F'(420E*0E0!"@
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MHEM(0E2C E>E(E< F)D#'8/YEU_,/9AQU86^MQ:@A2@D!U?:E" 54;DT1)
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M)Y1(,BU9,>ZGA@"N%LGV5N)YR4J M8:4D[W5YXUY4E2#RK2I"O\ :M)0KZ*
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M?!;1.0\N7T2BA1/V:GA2U%Q7_32>92S=2S$J625+65*4222>(X>^KCG%'OQ
MH*'#LH7,AP-"PI(<%!GN(!"H,O*AE"@ >R"FUI#C4GZ]Q/+M_A7@;'X4;*#Q
M;/)8XK^)'$+2HMD0KAW"RM!(*<N"I]U!)3VJD.MJ+3P E^2Y;X3*)2  (-@3
MO(^1D #W[ XDBVH',.HDB-OT[?3OA?34R6V^0  )">;:_0;]K=">L]<8XV4W
MBQ[; ]!\_:VV.B"@57Y@#W?,^ACYZZDDS>DT'@(ZF!\A&&D@WG:#TDR3^FP$
M8"  8O?>1OZ3\^W>^%JV@;IW/<F!ZS)Z>G7VPD6"D@$Q"NLWW!BVW;8>V+X!
M@"A8P)OU$$1V)Z6@1A8RE/*DQ<6)FQ,#<2?<6'0X3D#WMZCY'O'TOA2P#!,V
M,0/U/;M&^]A&/8]AR:3"9!,'H8M['\#Z],+6 ()/TD;=3&X[>N$+))0=H!,>
MG6(WW/4S?"]@"";[QZ1;\1_;"[D]ZNXJ/$<N0OAYFX'@8OMSWM]<7SD+OVG3
MV5OP%*:2:9PBRN9*4Q/+>9;7,WFY%\.:1!/?<"3('8_4;XBNAWO$R>OI^M/5
M(? M9)Y.8^D)<<$]1UMB5@7F=_G(Z=H^781UQC.C0M:>JMST5SBLQ;ZXZK+J
M#C+2XDZ$@\I2"@P8DQIZ5CQ(P.@$VMT_<8] N+@SZ3VL>V\=8P''H)!M].\^
MG]NPQ"22GPIZ^&Q^@:$4)-C]4^=I]U,'0/*1T,[?/\3O_G"CP^8DA4];"(FX
M'4F1MT[$X*Y24I4)/-,@BX(,$=S[Q@YON2H*3Y>6+&U@1OV[;=<!Z<L&P<R@
M E!43$$"".TF9.]I%M^HPI(F#)&^QCKUZ]/U[8)0;BT$V(V]MC<"1:W:,*FV
MW'2H-H4OD3S+*1*4)ZJ<5]UM W*W"E(FY &/8]@'[_?7Z8-Y" E0F28$1-]H
M@R21L)]M\,=?J+(\L\5MVK%?5-@_\KE914 *M"7:\J%$WZE@UJDGRJ;!L(76
MZWS.IC^'!O*&D@IYZ4ERM5,^9RN>'B-GE($4J*9*8)@B^"H9<74"!_4J0*B:
M4DCJ 1UPN[FF&I"EZE#]".\KS,A*>H4H'IBS*NJH\M:4YF52S1@#F0V\L_:'
MB1LU2-A54X3,@^%X8DRX,0O,-;LH)3E5&'0 8J<Q20F3/F;HFG(Y0((\>H62
M;J:%TXKIQQ2U*=<6IQ:R2MQ:BM:R225*6HE2C)))))))VN<)W5VE,1<<UNUP
M9])]M^N&D95"3*B5FE+)IR%3XR8/+&<YQ!U5&P&AS]I?O( 'B$@]<..8YSF&
M9.(-=6/5*$F4M*6$TZ-P"W3-A#+:D7',EH+()"E7PF!V(]P<-A6 >X]/W'X_
MC;!C;Q',D;;CN#'Y$Q(]XC#(1I%$A*8H  !ML+7P@7-9E2BI1I*B23'4_#X8
M<>8V,[#Z^_><>A<>LR3/<]O3W_#"5+E@9 @$D=Y/I-^UAO?M@1=2$A0O)B-B
M/??'H!N <>DBQ(PI2O\ W?7^_P#C RH"Q)'I?][X3@@@$;$3CV9^5L5* >GA
MBVM7KUZ\<*/%F+D1-S\MSM^[],)J]G[6U;_J(!4W!L3%T[[+ &^R@#M,C20)
M[Q;T/[_+&<Q C\>HQ&F*IF0=S3QZWC;[V*]0*552H5 Z1&]+>-KC$7!6VI*T
M*4A:%!:%H44K0M)D*2I)"D+21(((4DB0>N+CTGKU%26<MU XE+_E;ILS7RI;
M>)D!NN/E2TYL$U(AMPP'@A1YU557L!"PZG[KAA0BP7O/_P"/>\>:>XPWXNMA
M#S>E0ZI4/:2J!\)N#0B-X('E\P[E7-2#T6@U2L7J.?)0@BNQ(.V"TB2D[3;U
M'0])!!WZ@R,('4%-AL4D]YG]1M:QWZXI_2VMWLJ#=!FI<J<M3RH9?\SC] @6
MY0 "M^F'_P!J?$:$EGF'\HW0TZQ5,(?8<;>9=;"VG6E!:%I4+%"A8]B+$$<J
M@""!D.,KRZ]*JI/LJ H>N\'FF^]1&.C9S+6:1K;HI(_B(,:DGP_4GDH""+P0
M0$2@>0"_2=^Q)GY_3"5QN9Y8YCO)N1,V!W/KV!F<.[R1 ) FP!]-H48BX[VG
M?8'"!2(DP.H^6^_4>G?OOBH,@'G@N&I3>Y3<3M8'Y0=OW."R"-\+%H <"4C>
M-]IW.^XB/RP!Q(! (A1)E.XZW2=P/>_UP0*.XGKO K?<>B<4* 9(H?A.$+B$
MJ$D29[;>O><(G&>9*^_3U CY=^F'):8%COMT(.X!_>W;!"DPDSO>(O/I[]1W
M_*Z3 B0:TYQX7^WAA=:2#.]S;:(CUMA@6DI-Q .W;VG;#9F#J6D"(\5<A-AY
M4_U*/4&\#N3/].'UPI0@N+^XV%$J/0 3M/R ZDVQ"JEY3[RW""!,)23/*D;#
MMZF+$DG!VDZE3L*GKT^_3Q&$\RX$II[2C3IS5]K5-) .&QVHJ&R$)??  /D+
MJU(%S!"5**2#<B4V,;P#AKJ2AQ4O4U&_S@SXM(P23W*D(;7(_P#=VGMAS>$K
M5,$6]Q(VG?U@6PWO-<Q\IN!U_P  S;VP\((@"%"LTYC>G]A?&4O5N932 3(I
MT--L-+F7Y:Z"#0MMD[%AUYF/8%;B=_3TMOA"YD]!!(<K&8!('\EX&.\I:,=X
M4?PP\D$&"(/K@M8E)!VZB)!]_P#.+I*M/M*D3O)IM!IX#[D874TVJ90B=H2$
M_P#B ;WWQ&UY2V3#=6D]@\RM&^TE)=&UR>D_/"4Y3428<9@G^E\ 'UA24D?3
M$@6V %*28 B4G<&0+>E[>D])P1BX6J+S:X'3E$R-ZWD;864RG9)$Q8GPD:M7
MGRKO@OQD0/,1>8['V[VZ7C:8,"*DNH6VI7,VXE3;B9@*0I)2H$>J2;^LXDZ@
MV1*VVR!N%MI,&VX()'2-K1.]_/LE"Y,TC,D6*4\GS\A3O$_[9G?$2+P=C0@Q
M;H)Z$1@X94:!Q-K*!$VB#4>,^-\:U9E3JH:NII5GS,NK2E6Y4B9;6+C[[920
M0>OI&&DF3-S[F3]<7?K#3V5+73UWV<H\1/V=PMO/"'&TE32H"U?>05),C^A/
M?%>.9#1JD(74-@R!YT+B?_<B3_\ G#&NSF&UH2>\*0212=R()WFFV.7S/#WF
MG5I!01,IA1DI,%-P-B*S<'$$?=(!![GJ"(!@;;_,3\L(%D&(/O\ A$XFM1I=
MNY16N01LME!([;+22"3ON(PU.:;J$SR5+*[6"D.(/SCG&^&0\VJ$I("8K(((
MWW'SN9QF'+/R902;T4D_6<1E:N5,Q/3#56.A*!?EYCU)M%R 3WG:9WCTE#V1
MYC=(%.L6(*7H%MX"T)OM8]^D'$<S#(\[YE%%(I:19/(XPN4D7@>(#<C[I$^N
M&$*1([Z: 14"NPVK]L(9EK,$3V+NFD'LU0)O4 WCG'QQ#JI\J4>91(FT ]MK
MSM>W?;#2XJ9[J,GIZ]3U/R'I;#M5Y5FS9/B9;7)&TBF<6D=_,VA8 )F)^4#9
MB=0ZU(<9?1"2HE;+J  "+2I  WV,3-NV)4H&LB+"OJN!(;*8U)*3N""*@<^A
MVH/EA'55"&P>=.W6TI)]!,?0@VZ8C]74 <Q2H@!))%P#S"TV!DB#()F>F#:^
MI <(#B04])&XBQ),@WV@IO;U97W06R 9)@'T%YV]O:+'"CCDD@>_Z4/OZR-\
M:+#00D&)) -3O0Q!D5(/O5%0,$./"" 2GE\WI,6D]C>")[$3(PV..J4?,00K
M<641%@9CVV(@D"!.,6Y 42("S!(O !W%R+[&#!@0,(JAT)25$JY1RB0+ 2!)
M&Z;3>X!-X&%5+BQL:^6V'FVP#SD7WDQ2D>,5\\>5;O+RBZ0D@F#-A<VO(/<=
M(F ,--4^E<D&T#>;0>HB]R+B_2^"*FH61R\W-*C (V)/<7/H1OUN("5Y8"%K
M/](YB28!Y1/FZ$3U/3MA5:[\J5\_@/73#C;=;28)'(162"-HMY8)?\-;#C3_
M ".-N!3;K;B0IM;2K*2XD@A:5@00JT7)VPWT_!M_+ -6.TY=RX\E32Y2X"XY
M1()2MNMJ4JN[1C>F:=27&4D.504@-D75H;17B(9SW/J=*0%(J,NR]Q)/-R\J
MVJZK23M,*IJ523,)=?2?Y;>+7<<D+)3SSN29,7F4FQF3,B0"1?#37#DO(#F8
M&DQ+0B2"8[RA-1(HF:@R8,'"#O&G<LXIC*+E)(3F"#W5)%T(56% &.T38@@:
MA.-3UU0)7SK*E*WYB5&9 L1Y2"._:PN"81G52E=:M !(0EIK8F3RA:HGL5B1
MZ^HQ?6K]$K0IW-<B9E$+559:C=D27''Z).ZD3)71H!6B2MB4@M)UHS*JYJUX
MJ((+SP\MP E7*D#J=KDB3WM?-S:5L=Q<S-#^E::208KUW$P9KC:X6M&:)<;(
M(" "@44VN02%#E ,&(56)FA#M0I+A2E4IY8Y4Q$DS8D @B\P+FVQLF\4@"0-
ME *-B8%CO<"_,+@^^"%*)6I1^Z28'7M(ZVB3Z3;LC6]*Q,@"#:1ZCK([\IB1
M<^N?57VV%K2=SCH0A* ";0 =C-),"L#F<*UK5S)45&$P(4 D>D_U [0 (5()
M.$]4:.N;73U;+-4RY95/4,AUE5YNEQ*D\W, 0H7!@@B,$NNI@K(*RD>5-Q!.
MX)%YF\&QN.D83A4WVBQ.WRZ"1]-L00+$23<1S\;TH1 ]V))*8* ("DZ2%'5$
M@$B"-)I,I)BIB20*WU#PLRJO4I_*7E90^0K^2I*JBA4J92"DJ-0Q,05-+<0@
M0KP9Q36=:1S[3MZ^A6:<+4D5M*O[52#I*G&4\S1)(M4-LF^QV&U;M020V8$"
M+2 (OYNL_/??'A7_ "R29"AYB18@V(4#8@W!!!GM$X4=R;+LD#LU10H *9$7
M0:1-X(Y;X=8SSS6X=02%.!=%D:0D=\ J) DB9WD22#I(Y A1$I,DJ29$!)-H
MF08'>9D3L4+K@D<J?Y)2/+8)*I,F(N9WB>_7&UF?</--9\E;B:<Y55E15X]
M AM2E6*G:0D4RTJW*FTLJDD\\G%*Y[PUU%D?BOM,HS>@96MS[1EZ2I]+921S
M/4!)J4@'[Q:#Z9OS<LD9;N3>:DZ0M _4FMCNGVA&^PB^-=&?:S  D-*41(<
MD&4BAD)*55,2"=Q88K9?,(-N4WB!YMA((M V(WN1$#!*V_$!,00%$P+J,2D$
M>G2TGOA6Z%@E*D*2$JA0(*5!8WYDJ(*""(4" =IO@DR3()BQ, =+[F";>41!
M'7:,)$A)A-(,@FL6.W2\S6D" 0T I<*),>S   )$"#,$B)V TTU09Q8/#+6[
MFB,_:JJ@K5DM>&Z;.F$2Y-.E0+=<TV+N55"I2G&P!+K*GZ?=:8W_ *1=/5-,
MU5(XVZQ4LL/-.-JYD.-/)#K;B"9E#K:T+382"#O..78*T)7*>97-*4]^8[@]
MQ?:_>8G&U7P_\1.98T+FSJ I(==TW4.NPI:O^H]D?F^\0HN567I"KC[12MI)
M#2<:_"LV4K.7=4="R>S5- X8E!F>ZJ930#7,>T2,CCG#TN-_G6&M"VD)+K0)
M)4U%'02)4I C7<A%5P4@8VQH7G*&JIZYLPNBJJ>M1?E/-3/H?2)@D26HDP+G
M'4.F7]J::J4)Y4U#350!O":EM#Z4R(D<K@$VMCEXE)<Y@8\[92>MMXM _J.Y
MZ=.O3#1%0JOTAI:L6J55&G<G6L[RM-"RVJ?=2"?KMCK\I36-H3\)^_GY8X#-
M)2XI"B8B=0FL'3%!)@P:\YZXD*$P ?2"( (-YB)@](VB^%#B+@<H@@W %IMO
MMM<=.^!! /2;CY>GL>QGTO,J$ME0'H;WZ&;]>H%A/7KATD"IP $" D6 %9 J
M0.?CSJ)K7 M.46B:G.T)XAYAJZ@TLS2UU15JT1EF39IJ2NJF6BK+\JHDZ@S"
M@R;+49C4GP:K.JXU[65,!52G*,S<Y*8[2Z?^.?.>!NFLRTC\(7!_1G 9&<IH
MV\_XCYY4JXL<8=4)H6UI:7G6H]09=ENFZ=!<>=J&<NH-,KRK+'7#_"J2E)6M
M>JBZ/Q/-!'>18D0-R-P#$Q?WP6G*VS=0DR#Y4G:>^_L>IMC/S62RF=*1FT',
MM#3_ )9QQ?Y4J2H*U.Y9)#;QF"G\PET(B6PDU.UPWBN?X4%*X>XG)OK!"LXR
MTV,\$J2$E#&<6E;V624R%'*K86N2'5+ 2 W:WUEQ+XRZG5K3BQK?4W$'4ZJ9
M%$C.=49BNOJ*6@;<=>:R[+F>5FARK+6WG7GD9=E=)1T2'W77@QXKBW#;^G<N
M13Y;0#E _P"48@=SX:8/XVM:(.("Q0)1$(@=)L>]P)/K:#/IBW<L;BAHA:33
M,@;?_;2/J?6)V[XC,!MMMIMIM+;:)2AIM*4-H2 .XA*0 E(V2!&P$'!<J\Z\
M^^^^XX^Z[5UUUQ3CKBB02I;BR5*4: E142*S,1ZIJ#RC8@@]Y%P9-^T0.D[8
M1*2""#<3!_>_S_+#NM%SO(Z6&WZV[_.,$.(D%)@$WGUG?"NHI,FQJ-B+5,<I
M \NN&5M@R=_J2+<OEY89EM1)3MVW,=3[">M^N$SC85Z*']6_]OQN+[;8=5H*
M#!^1Z=?[;83N-@I\H)(V]NHZ#U[VCTP=*^?2#]_G.$UMTV\;18?V'RV:U-*%
MP)  F_46/;??ZWP<T(3-Q)V(]C.PWZ$&X$8-@WMM8XP#H,$]# @DA0W%^5OL
M8\??A0Q]TV.\ST^7X?L8<J<6OL38?+?;U%[COA$C[B2=XOT].O[[6C"YBT&Q
MN(('0@2.]OQ]<+K,D^(^! PXR((,<Q-S$??[G%C: ?*,SJJ3F/+5T:QRVA2F
MSRR9'W@';=X/88L8>O[]L4[IBJ-)GN7NVY5O> N3 Y'O+]0KE($P2(ZXNA](
M0\ZD$0%DI[%*CS)CT"2!\NN,O- ]O(W ,C_2=)VO:G6:B3CI.'JU9>)/\-Q0
MCHH)4(Z3J\Y\B<#&P(&Q$Q,GY1U]XM[X]::<>5R-(4XO?E0E2U1WA(,#N3 '
M4X35>:Y)E"BG,LR3]H"9^PY:E&85G.-D.K;<31TIDB2_4E8!GPE;$,5TI!4H
MD$) )--/(6ZV$],/A24 J6I*$Q[2U!(F1221)Y 5-0 :X=V!*% F8-IC8V(L
M!%[W.#WVVZ)C[5F#U+EM&HPEZN=2P'3L/L[ 2JJJC,2*=AX@D \N^*VK>(-<
MD\N1T;&4)'-_SCA3F&9K!V(??;%-2D#_ /I:5"TW'C2 3!JFJJ:U]=55U#U5
M4N&5OU+JWWE'_N=<*EF.EX L !;!F\DXHRX0VGD(4OJ*'2FEC*ZW3S3=XFR@
M0TE3JN9E"!UJ-:N1&E$7"CBULPUSE-$OP\JI'<V<@_\ -9@'*&A2O:44;2_M
ME0D;@O5%*DD>9H@D8@N9:CSK-TANMKW5TP5SIHF0BFH$*(B4TE.EME1B!SN)
M<<( *EDWQ'R92#U&_P#D>MO3? D&T=OU_9PRG+MM@$)E0NI1!/B-A7^F+3'+
M/<SC[Q*5+TH4*(1W4Q D&*J%#[:E$&:X&#$$6C:,&)7!-MQ]2/[B=KR;&,%X
MPV!/;%\!P,+*4E)%NG_:>YVMWF8MTG!2ONG][VP%:P1;J+](C];7_P X*4L)
M3"C8VCZ[?E/U,8N$Q"B1<'R\>?J<44L5 Y7'/UOCPD $SM<Q<P#>WU]O<8Q"
MX@R#Z]+]#L9^0'SPD*C*H,R3U[[]?EZBQ!$ !!(V)Q;439,C?J*?'I7 K8=$
MJE5AN#/OW_S:9[@8]YP2?3K%OP_9^>&X.J&WMZ=[]Y,]H[X,2^/Z@0>XN/[C
M\<5[I)N+"NT4Z]!7^U@LCWSZ^?CYRXH=($ VV*>TW,3\]O7"E+@Y$DF\02>A
M'4^Y_=L-(<0=E >]OSP,N""2H"1W%]NQO(!^NUSB= V4/4??Y<\6"^8]5_88
M<RZD$">L&UHZG\8]#N(OC/&1,"3/I _&_P"&&M+Z.69VM?>/0"3%P-OR&!!X
M$ @Q>Q[Q,Q.W3>^*Z9L1>E?I]+XMK3'7EZBWCA:XI#K:VW$V4((GJ#,@]P0"
M/4=1B/N<S:U(-RFT]QT.YF1!OM<=\.A63U[& ;QMOV]=L)ZEL.(\1,<Z)V_J
M2#?_ /-DGK8'Y3"DB1O?PO?YQT@G:BB%6H1SBO2_JN&Z?\^IO?\ '$JTYJRN
MT^]R)!J<N<62_0J64@%4 OTRKAE\ "?_ $W19T'RJ1%)GKM;V_?]\9)Z&]_U
M[>N_SQ50"QI< 4DQ(/A<3;G(BM01?'FW5M+2XVLI4#((-ZV(L0;$&0;$8VDH
M,SHL[HT5F6U"7V5**5B"EQIQ(',T\@^9MQ,@P?*I)YFU+00HGJ0H(,@7)'J#
M^,BQ],:T9)G=?D=6*NA7X:S":AA=V:EH*YBV\D?>23)2M)#C9/,A0,S?^0ZC
MH-1TI53J#-6VE/VFB<(+K*K K0?_ %Z=1)Y'DA)%DN)0NV,MYA3)D EHF]RG
MHHB 140JT>(QT&4SS>:&E12A^)*!9<1);DSS)2>\ # (!(7\MX,=_I^7N=OP
MP0MOG,R9 MM8Q:#$@;SOO:,+5HN4@1 DD1WOZWZ]NI(O@LIA,D#H 1W]8,3[
MW[CI@6'<-;J%@W'<S:#W'N)M\^V"".A^8,?YP[*%B".:VW?MUB#[X:*]::9"
MUQ"E&&P"()5U((-DB3M<B#,R+@SW?<1<&0?=23BBQ0FE*S6W3USW.(MG3N],
MUW!=C91!"@@C;RV41WMTC$76!%A<#8[@S>]NE_?IB05 *E<RK\VY.Y-R23,R
M9],-50VG<2>BA!GI!.UA&XWF]L.-P GRD\SOC&>[REB"8F ; 4(BT>)\9F,-
M*T<T$&%#KZ=OW.$+J2-Q!&_L?;I[;8=%)Y?7"9UN05#>+@W_ %]=OIAE)L1Z
MZ824)D&F&-T'F)-P+>L=)^O]\%&X([X7+2""#(L;P;=_PPAP6RIF0JWC(^%:
M=/B#!"T""DW!Z[&W^?TPG+ FRB!V(G\9&%BDDW'TM^?]_P#R I(-@?I,>G[^
MF((4"=-!Y1MS];8@I!N,:;:.XN:CTWX-+4NJSO)VP0BBK'IJ&4E4S1U_*X\C
M[QY6G_M#%R ENQ&T6E]>Z?U8VA.65H;K@A+CV5U8#%<TJ!S<B50BJ;2J4^+2
MJ<20.924 D#GE3U-I!YDVZ7!!V-IN3?<['8X?*>J<0I#S2UH<20MMQM:VW$+
M292IM:"%H(Z*2H$'8W$[SN49?D@=FX:E2;$\RFQM,B#)J3CALKQ;-Y'2E2OS
M&7$ (<)D)$ !MPRI(BP.M V $D=%LR:^VT%13* 4LMEQHQ=+S8*FXC<R"GUY
MC8XJ\VD[1.]HCO:T=;?+%8:1XSYKEX;I=0H.<T:2A JPM#>:4[8@%97RAJN"
M4R>1[PWR0$_:#(Q8"\]R;.*A][),Q8JVG4"K4PD^%5TR'B>85%*Y_/:2EWG1
MXO*65$0AQ4843EWF)"Q*9$+%4DQ43 ()$456AB:G&N[Q#*YU"'6%D.#NN,K[
MKH!J"!,+2#(*D%0&I,Z9C'KJP22(GIZCV]+W]),X1+7$R#L23MW,VZ>T>V!.
M*W[Q%CMZ[_B+3[X2+43:".\]?S^LX.D0.I_:DX7 BGZC4FE!2?VO)J<%.*.X
MBYZ_X']X]<(U+42;B-NAM$;Q<P=]_;![BR-QUZWGU[_0S?<82DDR>OTQ<"3'
MH=<!>7!@&(%1,#:*S]ML9,=_E_C"-U96HW)3M!)^=B!;T.V!NKW$$="09!CV
MW]K$==XPD6XE) D7-SO ^74[#_Q@Z4[#YFG[80*MR>F"'Z:A<!#U+2.%6X<I
M6'"??G;5;OMB,5FE-,51*W,CRTJ4;J0R6B;R3_)4V!].ICMB1/+)DB\V D;=
M8VZ'KU.^$158CN?P_3;:UCVP4) @$ F),@'ES$$3XD>!P(K,R#$3!%#MO<>4
M=<0RHT!I)\F<L6UO!IZVL;%S> 7EI[P8-[F3M&Z_A1IM]!^S5>;4*I.U2U4H
M)BP\.H8F.LA<?GBSUKB(5!DB"/E/RW@F_I&$JW9GF*1RW))@@?6P_#%>P0KV
MD)-+!(%R)]D#I%;^.!*S:T2$N+D4!U2G;?5\"-H@3BEZO@S1D!3.HZD&-G\N
M84D#>5*;J6B9FY %A:,2[2OP^U33C6:9GFE#4AOD=H*)VAJ&D\Z2E3555 NN
M@A.[+'*4J,.N@^1&+TTYIR?"S+,6B+!=)2. 0H&"W4OI[1"F65"\AQS^E.)[
MA)U+"%I+;:2I"I*B5*3(V"22DUJ3!%HYXU<JC,.LJ.9<4E#J-*6T@-KT'2=9
M6E(<3,43(,$SL,48_H'4:%*2VBA?&Z%IK4I48)DE+R&RDJ$=X%B29PS/Z,U0
MVHA.5+<MR^(S44CH'6P#X-X$&+=<;#.*(-K2(FY,S:+]8-AW!.^$YB+&3-S<
M?OWWOM:Y/SCI$$(/D0?@KZ865PS+)/=4Z+@C4DC:THGZ\\:Q5^1Y[0MJ6_E.
M8IY$+5SIIG71*4E4!3 <)VL009DSM.I>MM"UE2Z]FE#05%+6E)>J:5ZE>916
MJDK6ZV74(2W5?[DPE#YDRETROJ/5**6'#, H@7())/+TZ7_>XC3ZE*!"I*23
M/,>8$1$<ID03'MOWQ1U(SB-#@  )((J0:5K8^!J)VD8/E5*X:[VK"RI2H!2H
M=TI%TJB)!\ 1,@A0G'&5]]3;BTN%+90LA:%E(6E0404J02E:2@S_ "U0H00H
M=,$N+*E6"C M">W4$6O8B3/;ICK/J+1F39RVJH7E64NUA3)%1EU$\BI@'RO^
M*P1XAB$/*YE?T+E,%-)UW#70[KKK=5HS)FWDJ(?Y:-5,M*U25 ?9W&I5:2I%
MAND]T3PA9'<?;)Y+2I)\HUS--X%:<M0_B1#:AVV6> D0IMQ*TJM0Z^STD5I4
MGK4JY]N.PDD">8A,P8B=AV,6,S $ 8)+JH3RDP4P3RB)VZB)%^G0S.V-YZG@
MMPXJ08R2HIH! %%FV8LICMRN/O)%K;0!ZP<1>N^'_1%2?^2S#4&6CF',E-73
M5R5IC8?;*7G2 9Y@%DJ%I%I YP?.#V2RH;0M22:@@C6A(H!N9KO@S7XDX:JB
MCF6J#VF@H)F)D-N.&E( 3"JDD1C3Q:P2=H@7C<"P%[#J-P#O>;8'5%(20 $D
M\I-C[&;F#%_PQM14?#=0+1S4>KJY!)(2BMR>E>YHO=5/64Y!@DB4"1Z89:CX
M;,Z0 JBU5E#ZH(Y*K+:^E))@A)6TY6!)MN4A.WN *X5GTS#&J0"2E;9BQH"N
M210DP3YX:;XYPA0KFTH,V<;?3J V_E&"2*DJI8;XUT\11N)DI ,V,]9D>X'2
MX,CH,*D<Y,$<IY02D@[@@B3??L+@@QBY*CX?^(S*5EAO(:HI*B@-YTVVI4&P
M J:9@))[+4(G>V&9W@IQ.:'.=+.O$$B:7,<IJ KEWY0FN"C,V)3<" )P Y/.
MI)G+9@4D?PW%#;=*8GQI6HWPPCB?#EB4Y_*$DD:59AM*@8]K2I0-R?4'%)Y]
MI33VI"E69T#:J@((36,*52UJ9,B'V8\029A]#HDW3>]+9]PAS:C2I_(:I&<M
M'F4JE=#=)7MM@;I!<%-5291#:V7"!);)QMY5<.-=T*2JMT9J-D-@2H934U"
M!>RZ5+S?*#))YR">Q$8CKM#6TP4BKH:^C6"935T-53&)F2'FF[6@&"?E?"CV
M10Y)>94VLSWM)0N@$^T!-H[P5%2-L:3'$5) [#,MN(I"$N)<1'=!"=*CIW/=
M(J!$[Z$UE'5T%46*JE>IJIHE#K%0VIEY*02E4(="24S8.(YDJ \JE G *=ZH
MIZEFH86NFK*5YNJI:EA0"Z=]E:767FEP/YK3B4+"3(*DR4G;&\N8Y7D^>TZJ
M#.:&DS!D J;%2E/BM0"GF8=0I#[*QS$I\%Q'+))!$8J'4/!1IWQJK3%>$JY2
M499F2O$02!'(QF*)6";%)J6' #93R0 <9KO#W$5:(6!%I2L0)L208-M-S^F,
M:K/$&W  YW>BH6@B@*9TF 9DS81)$1C9#A3KQO7NG&:QU2$9YEQ:H\]I@4 J
MJTMIY*]M"4I I<Q"5/MA*2EEWQZ8F6P#U0X-58K.'&F3,JHFJS+%3)@4=?4H
M0G:" RIH ]H@QM\^FE<PU3PEU-19IF.555.TKEI,QIG$I539OE+JDJJ&F*EL
MKIW'FRD5%&XA?B-5#: J$N.SW;^&7.://^'2JW+JE-5E[N;NU="\!!72YC04
M-6@E)\R%<Y=#C:AS-NI<;5YD*QTG!\V7DEMV4OMIAP$05>SI7!-) (5_J.P4
MD'D^-<.&5?0^T <J_5E2:A*[J9)J#I,E-9*2!*BA1&P@1<1U!%R=A'>;?YPH
M91>#VF1N(Z[&8Z@SUO? T() (O! .\_KT'XX5)0E-XO>_IC7*B?#EC#!*S$4
M-^M>?E'O/AB! *8B"1[]9]-\#Q@$FVYP<A%R"DD#;Y_A(B\DBUKQ-"H"_NWP
MRANW.HZ=.>P,\ZX&VV $K$D@@VM*28/4]][#IM<V=1M3E]$H':E:.UB.4Q$>
MQVF_OBO$(@1:( C?;8]O;?%HY:@*RG+U_P#[*TE6^XD C\!VPF^:"9()/B-_
MARH,:N23*EBQT ^<I%?5\)E@PE2H,C<=;R)Z C\?><%*$B/W^_KA<XV2/*/N
M*GM8P8]+SL#(@^R8IE6XF52# ((O%C?M-_<X7F/#>1M D^<S%]S?#Q$7PC4V
M#N >6_>)^DVZQ;?"-;923 D;C\3'<P >G0X=(^NWK_?!"D]P(Z?WWG%XB")(
M,2/J/KM7;%5)!Z=8K^_KS;"D$DD"2(V'K_CZ8 VWR3)F?3]GO/N,+76B+I%H
MF!^8[_7\L%-M..J"6T*<63 2A)4HGT"028_7%M1(N8W!VCQMA<M&12Y%+ST!
MFL_7 ,.#0\J9L !?H?GZ[_YPW5F89/DJBG.,Q9IG>612,@UE<H&X!I6"0U,0
M#4.- '?MB'5G$AQ*O"R++6J020C,,P**VK5RDPIJFY11TQ*8(YDU"T*  6<7
M0RZZ1H02F^M7=16(,GVASTA1$3!L1N9O+94GMG4I4)!;1"W9$4*$GNGEVA0#
ML:'%JLA5(&\QJ%LTE)3N(>55UCS=-3PT0YY7'2"Z822$LI=68(2A1MBU<SUM
MD=,&7:%MS/5OTS2TN@N4&7@\H2D\RD&KJ00D$!**=)$ JOC1ROS+,,U?-3F5
M94USYC^94NJ<Y8L VDGD:2!8):2A(Z#%V:?J556G<H=*BHM,JIE3%U-2V ?7
MF:5>/GTQ3,Y%*="W%%1"B"E/=2-8!JKVC!%"--S2E3<.XR75OM,-AM)0EQ*W
M"%K)2K283&A$A8E)[0T]JF)SF>JL[S5LT[U7]GHRJ10T*$TE-$GE#@;_ )KY
M )$U#KLS?$=!Y8 L!< 6%O3;'@,@'OCW PV@)A(":"P$;5CF8OUK.&UN+<5J
M<6I:N:B20.0FP&P%!L,'%S94;_>$]1M<;;S[[[#!Z5I4+']-M_;O?"+'H44[
M$CVQZ2DF9(Y_ 'SBQ-\4POQZE4*(C^F?Q_P/KZ80\ZH !B)][P;6M'2/7'OB
M*MZ0+6D#H??OB=0(,@Q3U<?VKCUL+^>-AUOZ_B8_P+D6P'G!L#=)[WZV.U_7
MK?UPE+R@3 $'8=K"#/6PFUL$E1N2=[D^W7'A%-*9K$VBG/S]0,3J-I]"/MZD
MX.4Z9Z&)2>RA>\]/E]8V)*B0$DV&P[8!S@D_,R>O[]L>%8&WKT-HZ'WO[6MC
MP@U4=^8@VY>5//?$8&3'[W]!ZX\!!._RVV]#?_Q@E:Q$DBWK8F)M<CO\K^@)
M4Z!RD7!-X)!$1O&VYL9VVQ[4:0)'[6Y".OAB"H#<;;\_VKA;(_"?EC,(P\!N
M#-[;VBQD2+0#WZ^PTO)O?>?K'U/S$]P.L@WE)$W-]AR^GWCVI/,>_"G&8*"X
M%R(Z3UGU_+]QYSD]>W;WQ4E%#',V'QG:NU)'3$X.QF"^?MVZ_/;ION;6Q[SC
M][@_D?0_ACT(Y\NG*-NH]3CV#0M0B#M8>GZ'YS@YMT"RCM)O>3,SU)MTZ]MS
MA+S F!VW]>G[[VWP+$D;IFE(J9VIS^5.F/83/H+:Y;,-*!4F=P>J"8%AS!2=
M['TPG+BDJF+Q<=%3[>YNF+P9PN<0'$E)ZBQ['I\NA':V&M0*24G<$@CUV./)
M(5RG>E_VYX$H:2(-S(Z'UZI@XN$W&PN-@01M/0^A [B,*F*ZIR]]FKHJARGJ
MV2E;3K9',A4;W!20192%!2%BRTE)(+=C,24)-P(@@@@$&:5F_GBH409!@BQ!
M@@B"""*@B!'+;&PVD=94N?-IHZXHI,W2 D"8:KN5 )<IS #;RB%%5(25=62M
M$I3-G&S(C8D6(W!(@^YZVD$#UQJ,A:VU)4A12I*@I*DDA04""""+@@B01!!O
M-A%RZ2XA!XLY9J!T(68;8S15DK,I2VU60 $K/2K/E4;/@$^+C.S&54DE;0E-
MU(%TVDIN5"YTWY8W\CQ(.:6<PH!4 (=,!*SL%F8"CLJRC[4$R;,6!S&+)3O-
MH'4WZ?OK>+9BLON$Q*+I;_\ :"3)[*5O/J!T)Q),P<"1X:#)4 5&=DG9(BQY
MA!F2"G:RAAA=9"P2)G<CH8MVL1O(F;@@S91!%"=['EZY_OC2>*J ;02.>X]Q
M%1>?"L=6G<1)$QTOT]I_\X:W4+$\P(F0#TGM/0]2/PC#[4)(4>J1:0-SU)]H
M@?YPWO@\OE )5N.X WG_ ' 6%Y()W C#*#!CGZ]4^X2<2/:&WUC<<J?MB/.
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M'?YDW'KB1Z/RJCKLQ?<JFR\*%MM]EI?*IE3JG>1*G4*2?$#?WD))">>"L*
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',QF"8#C_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
